<s> O None
Tricuspid I Disease
valve O Disease
regurgitation O Disease
and I None
lithium I Chemical
carbonate O Chemical
<eof> I None

<s> O None
toxicity I Disease
in I None
a I None
newborn I None
infant I None
. I None
<eof> I None

<s> O None
A I None
newborn I None
with I None
massive I None
tricuspid I Disease
regurgitation O Disease
, I None
atrial I Disease
flutter O Disease
, I None
congestive I Disease
heart O Disease
failure O Disease
, I None
and I None
a I None
high I None
serum I None
lithium I Chemical
level I None
is I None
described I None
. I None
<eof> I None

<s> O None
This I None
is I None
the I None
first I None
patient I None
to I None
initially I None
manifest I None
tricuspid I Disease
regurgitation O Disease
and I None
atrial I Disease
flutter O Disease
, I None
and I None
the I None
11th I None
described I None
patient I None
with I None
cardiac I Disease
disease O Disease
among I None
infants I None
exposed I None
to I None
lithium I Chemical
compounds I None
in I None
the I None
first I None
trimester I None
of I None
pregnancy I None
. I None
<eof> I None

<s> O None
Sixty I None
- I None
three I None
percent I None
of I None
these I None
infants I None
had I None
tricuspid I None
valve I None
involvement I None
. I None
<eof> I None

<s> O None
Lithium I Chemical
carbonate O Chemical
may I None
be I None
a I None
factor I None
in I None
the I None
increasing I None
incidence I None
of I None
congenital I Disease
heart O Disease
disease O Disease
when I None
taken I None
during I None
early I None
pregnancy I None
. I None
<eof> I None

<s> O None
It I None
also I None
causes I None
neurologic I Disease
depression O Disease
, I None
cyanosis I Disease
, I None
and I None
cardiac I Disease
arrhythmia O Disease
when I None
consumed I None
prior I None
to I None
delivery I None
. I None
<eof> I None

<s> O None
Phenobarbital I Chemical
-induced I None
dyskinesia I Disease
in I None
a I None
neurologically I Disease
- O Disease
impaired O Disease
child I None
. I None
<eof> I None

<s> O None
A I None
2-year I None
- I None
old I None
child I None
with I None
known I None
neurologic I Disease
impairment O Disease
developed I None
a I None
dyskinesia I Disease
soon I None
after I None
starting I None
phenobarbital I Chemical
therapy I None
for I None
seizures I Disease
. I None
<eof> I None

<s> O None
Known I None
causes I None
of I None
movement I Disease
disorders O Disease
were I None
eliminated I None
after I None
evaluation I None
. I None
<eof> I None

<s> O None
On I None
repeat I None
challenge I None
with I None
phenobarbital I Chemical
, I None
the I None
dyskinesia I Disease
recurred I None
. I None
<eof> I None

<s> O None
Phenobarbital I Chemical
should I None
be I None
added I None
to I None
the I None
list I None
of I None
anticonvulsant I None
drugs I None
that I None
can I None
cause I None
movement I Disease
disorders O Disease
. I None
<eof> I None

<s> O None
Acute I None
changes I None
of I None
blood I None
ammonia I Chemical
may I None
predict I None
short I None
- I None
term I None
adverse I None
effects I None
of I None
valproic I Chemical
acid O Chemical
. I None
<eof> I None

<s> O None
Valproic I Chemical
acid O Chemical
<eof> I None

<s> O None
( I None
VPA I Chemical
) I None
was I None
given I None
to I None
24 I None
epileptic I Disease
patients I None
who I None
were I None
already I None
being I None
treated I None
with I None
other I None
antiepileptic I None
drugs I None
. I None
<eof> I None

<s> O None
A I None
standardized I None
loading I None
dose I None
of I None
<eof> I None

<s> O None
VPA I Chemical
was I None
administered I None
, I None
and I None
venous I None
blood I None
was I None
sampled I None
at I None
0 I None
, I None
1 I None
, I None
2 I None
, I None
3 I None
, I None
and I None
4 I None
hours I None
. I None
<eof> I None

<s> O None
Ammonia I Chemical
<eof> I None

<s> O None
( I None
NH3 I Chemical
) I None
was I None
higher I None
in I None
patients I None
who I None
, I None
during I None
continuous I None
therapy I None
, I None
complained I None
of I None
drowsiness I Disease
<eof> I None

<s> O None
( I None
7 I None
patients I None
) I None
than I None
in I None
those I None
who I None
were I None
symptom I None
- I None
free I None
( I None
17 I None
patients I None
) I None
, I None
although I None
VPA I Chemical
plasma I None
levels I None
were I None
similar I None
in I None
both I None
groups I None
. I None
<eof> I None

<s> O None
By I None
measuring I None
VPA I Chemical
-induced I None
changes I None
of I None
blood I None
NH3 I Chemical
content I None
, I None
it I None
may I None
be I None
possible I None
to I None
identify I None
patients I None
at I None
higher I None
risk I None
of I None
obtundation I None
when I None
VPA I Chemical
is I None
given I None
chronically I None
. I None
<eof> I None

<s> O None
Effects I None
of I None
calcitonin I None
on I None
rat I None
extrapyramidal I None
motor I None
system I None
: I None
behavioral I None
and I None
biochemical I None
data I None
. I None
<eof> I None

<s> O None
The I None
effects I None
of I None
i.v.c I None
. I None
injection I None
of I None
human I None
and I None
salmon I None
calcitonin I None
on I None
biochemical I None
and I None
behavioral I None
parameters I None
related I None
to I None
the I None
extrapyramidal I None
motor I None
system I None
, I None
were I None
investigated I None
in I None
male I None
rats I None
. I None
<eof> I None

<s> O None
Calcitonin I None
injection I None
resulted I None
in I None
a I None
potentiation I None
of I None
haloperidol I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
catalepsy I Disease
and I None
a I None
partial I None
prevention I None
of I None
apomorphine I Chemical
-induced I None
hyperactivity I Disease
. I None
<eof> I None

<s> O None
Moreover I None
calcitonin I None
induced I None
a I None
significant I None
decrease I None
in I None
nigral I None
GAD I None
activity I None
but I None
no I None
change I None
in I None
striatal I None
DA I Chemical
and I None
DOPAC I Chemical
concentration I None
or I None
GAD I None
activity I None
. I None
<eof> I None

<s> O None
The I None
results I None
are I None
discussed I None
in I None
view I None
of I None
a I None
primary I None
action I None
of I None
calcitonin I None
on I None
the I None
striatonigral I None
GABAergic I None
pathway I None
mediating I None
the I None
DA I Chemical
-related I None
behavioral I None
messages I None
of I None
striatal I None
origin I None
. I None
<eof> I None

<s> O None
Development I None
of I None
isoproterenol I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
cardiac I Disease
hypertrophy O Disease
. I None
<eof> I None

<s> O None
The I None
development I None
of I None
cardiac I Disease
hypertrophy O Disease
was I None
studied I None
in I None
adult I None
female I None
Wistar I None
rats I None
following I None
daily I None
subcutaneous I None
injections I None
of I None
isoproterenol I Chemical
<eof> I None

<s> O None
( I None
ISO I Chemical
) I None
( I None
0.3 I None
mg I None
/ I None
kg I None
body I None
weight I None
) I None
. I None
<eof> I None

<s> O None
A I None
time I None
course I None
was I None
established I None
for I None
the I None
change I None
in I None
tissue I None
mass I None
, I None
RNA I None
and I None
DNA I None
content I None
, I None
as I None
well I None
as I None
hydroxyproline I Chemical
content I None
. I None
<eof> I None

<s> O None
Heart I None
weight I None
increased I None
44 I None
% I None
after I None
8 I None
days I None
of I None
treatment I None
with I None
a I None
half I None
time I None
of I None
3.4 I None
days I None
. I None
<eof> I None

<s> O None
Ventricular I None
RNA I None
content I None
was I None
elevated I None
26 I None
% I None
after I None
24 I None
h I None
of I None
a I None
single I None
injection I None
and I None
reached I None
a I None
maximal I None
level I None
following I None
8 I None
days I None
of I None
therapy I None
. I None
<eof> I None

<s> O None
The I None
half I None
time I None
for I None
RNA I None
accumulation I None
was I None
2.0 I None
days I None
. I None
<eof> I None

<s> O None
The I None
total I None
content I None
of I None
hydroxyproline I Chemical
remained I None
stable I None
during I None
the I None
first I None
2 I None
days I None
of I None
treatment I None
but I None
increased I None
46 I None
% I None
after I None
4 I None
days I None
of I None
therapy I None
. I None
<eof> I None

<s> O None
Ventricular I None
DNA I None
content I None
was I None
unchanged I None
during I None
the I None
early I None
stage I None
( I None
1 I None
- I None
4 I None
days I None
) I None
of I None
hypertrophic I Disease
growth I None
but I None
increased I None
to I None
a I None
new I None
steady I None
- I None
state I None
level I None
19 I None
% I None
above I None
the I None
controls I None
after I None
8 I None
days I None
of I None
treatment I None
. I None
<eof> I None

<s> O None
Intraventricular I None
pressures I None
and I None
coronary I None
flow I None
measures I None
were I None
similar I None
for I None
control I None
and I None
experimental I None
animals I None
following I None
4 I None
days I None
of I None
developed I None
hypertrophy I Disease
. I None
<eof> I None

<s> O None
However I None
, I None
dP I None
/ I None
dt I None
in I None
the I None
ISO I Chemical
<eof> I None

<s> O None
-treated I None
<eof> I None

<s> O None
hearts I None
was I None
slightly I None
but I None
significantly I None
( I None
P I None
less I None
than I None
0.05 I None
) I None
elevated I None
. I None
<eof> I None

<s> O None
These I None
data I None
indicate I None
that I None
the I None
adaptive I None
response I None
to I None
ISO I Chemical
shows I None
an I None
early I None
hypertrophic I Disease
phase I None
( I None
1 I None
- I None
4 I None
days I None
) I None
characterized I None
by I None
a I None
substantial I None
increase I None
in I None
RNA I None
content I None
and I None
cardiac I None
mass I None
in I None
the I None
absence I None
of I None
changes I None
in I None
DNA I None
. I None
<eof> I None

<s> O None
However I None
, I None
prolonged I None
stimulation I None
( I None
8 I None
- I None
12 I None
days I None
) I None
appears I None
to I None
represent I None
a I None
complex I None
integration I None
of I None
both I None
cellular I None
hypertrophy I Disease
and I None
hyperplasia I Disease
within I None
the I None
heart I None
. I None
<eof> I None

<s> O None
Co- I None
carcinogenic I Disease
effect I None
of I None
retinyl I Chemical
acetate O Chemical
on I None
forestomach I Disease
carcinogenesis O Disease
of I None
male I None
F344 I None
rats I None
induced I None
with I None
butylated I Chemical
hydroxyanisole O Chemical
. I None
<eof> I None

<s> O None
The I None
potential I None
modifying I None
effect I None
of I None
retinyl I Chemical
acetate O Chemical
<eof> I None

<s> O None
( I None
RA I Chemical
) I None
on I None
butylated I Chemical
hydroxyanisole O Chemical
<eof> I None

<s> O None
( I None
BHA I Chemical
) I None
-induced I None
<eof> I None

<s> O None
rat I None
forestomach I Disease
tumorigenesis O Disease
was I None
examined I None
. I None
<eof> I None

<s> O None
Male I None
F344 I None
rats I None
, I None
5 I None
weeks I None
of I None
age I None
, I None
were I None
maintained I None
on I None
diet I None
containing I None
1 I None
% I None
or I None
2 I None
% I None
BHA I Chemical
by I None
weight I None
and I None
simultaneously I None
on I None
drinking I None
water I None
supplemented I None
with I None
RA I Chemical
at I None
various I None
concentrations I None
( I None
w I None
/ I None
v I None
) I None
for I None
52 I None
weeks I None
. I None
<eof> I None

<s> O None
In I None
groups I None
given I None
2 I None
% I None
BHA I Chemical
, I None
although I None
marked I None
hyperplastic I None
changes I None
of I None
the I None
forestomach I None
epithelium I None
were I None
observed I None
in I None
all I None
animals I None
, I None
co I None
- I None
administration I None
of I None
0.25 I None
% I None
<eof> I None

<s> O None
RA I Chemical
significantly I None
( I None
P I None
less I None
than I None
0.05 I None
) I None
increased I None
the I None
incidence I None
of I None
forestomach I Disease
tumors O Disease
<eof> I None

<s> O None
( I None
squamous I Disease
cell O Disease
papilloma O Disease
and I None
carcinoma I Disease
) I None
to I None
60 I None
% I None
( I None
9/15 I None
, I None
2 I None
rats I None
with I None
carcinoma I Disease
) I None
from I None
15 I None
% I None
( I None
3/20 I None
, I None
one I None
rat I None
with I None
carcinoma I Disease
) I None
in I None
the I None
group I None
given I None
RA I Chemical
-free I None
water I None
. I None
<eof> I None

<s> O None
In I None
rats I None
given I None
1 I None
% I None
BHA I Chemical
, I None
<eof> I None

<s> O None
RA I Chemical
co I None
- I None
administered I None
at I None
a I None
dose I None
of I None
0.05 I None
, I None
0.1 I None
, I None
0.2 I None
or I None
0.25 I None
% I None
showed I None
a I None
dose I None
- I None
dependent I None
enhancing I None
effect I None
on I None
the I None
development I None
of I None
the I None
BHA I Chemical
-induced I None
epithelial I Disease
hyperplasia O Disease
. I None
<eof> I None

<s> O None
Tumors I Disease
, I None
all I None
papillomas I Disease
, I None
were I None
induced I None
in I None
3 I None
rats I None
( I None
17 I None
% I None
) I None
with I None
0.25 I None
% I None
RA I Chemical
and I None
in I None
one I None
rat I None
( I None
10 I None
% I None
) I None
with I None
0.05 I None
% I None
RA I Chemical
co I None
- I None
administration I None
. I None
<eof> I None

<s> O None
RA I Chemical
alone I None
did I None
not I None
induce I None
hyperplastic I None
changes I None
in I None
the I None
forestomach I None
. I None
<eof> I None

<s> O None
These I None
findings I None
indicate I None
that I None
RA I Chemical
acted I None
as I None
a I None
co I None
- I None
carcinogen I None
in I None
the I None
BHA I Chemical
forestomach I Disease
carcinogenesis O Disease
of I None
the I None
rat I None
. I None
<eof> I None

<s> O None
Ketanserin I Chemical
pretreatment I None
reverses I None
alfentanil I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
muscle I Disease
rigidity O Disease
. I None
<eof> I None

<s> O None
Systemic I None
pretreatment I None
with I None
ketanserin I Chemical
, I None
a I None
relatively I None
specific I None
type-2 I None
serotonin I Chemical
receptor I None
antagonist I None
, I None
significantly I None
attenuated I None
the I None
muscle I Disease
rigidity O Disease
produced I None
in I None
rats I None
by I None
the I None
potent I None
short I None
- I None
acting I None
opiate I None
agonist I None
alfentanil I Chemical
. I None
<eof> I None

<s> O None
Following I None
placement I None
of I None
subcutaneous I None
electrodes I None
in I None
each I None
animal I None
's I None
left I None
gastrocnemius I None
muscle I None
, I None
rigidity I Disease
was I None
assessed I None
by I None
analyzing I None
root I None
- I None
mean I None
- I None
square I None
electromyographic I None
activity I None
. I None
<eof> I None

<s> O None
Intraperitoneal I None
ketanserin I Chemical
administration I None
at I None
doses I None
of I None
0.63 I None
and I None
2.5 I None
<eof> I None

<s> O None
mg I None
/ I None
kg I None
prevented I None
<eof> I None

<s> O None
the I None
alfentanil I Chemical
-induced I None
increase I None
in I None
electromyographic I None
activity I None
compared I None
with I None
animals I None
pretreated I None
with I None
saline I None
. I None
<eof> I None

<s> O None
Chlordiazepoxide I Chemical
at I None
doses I None
up I None
to I None
10 I None
mg I None
/ I None
kg I None
failed I None
to I None
significantly I None
influence I None
the I None
rigidity I Disease
produced I None
by I None
alfentanil I Chemical
. I None
<eof> I None

<s> O None
Despite I None
the I None
absence I None
of I None
rigidity I Disease
, I None
animals I None
that I None
received I None
ketanserin I Chemical
<eof> I None

<s> O None
( I None
greater I None
than I None
0.31 I None
mg I None
/ I None
kg I None
i.p I None
. I None
) I None
<eof> I None

<s> O None
followed I None
by I None
<eof> I None

<s> O None
alfentanil I Chemical
were I None
motionless I None
, I None
flaccid I None
, I None
and I None
less I None
responsive I None
to I None
external I None
stimuli I None
than I None
were I None
animals I None
receiving I None
alfentanil I Chemical
alone I None
. I None
<eof> I None

<s> O None
Rats I None
that I None
received I None
ketanserin I Chemical
and I None
alfentanil I Chemical
exhibited I None
less I None
rearing I None
and I None
exploratory I None
behavior I None
at I None
the I None
end I None
of I None
the I None
60-min I None
recording I None
period I None
than I None
did I None
animals I None
that I None
received I None
ketanserin I Chemical
alone I None
. I None
<eof> I None

<s> O None
These I None
results I None
, I None
in I None
combination I None
with I None
previous I None
work I None
, I None
suggest I None
that I None
muscle I Disease
rigidity O Disease
, I None
a I None
clinically I None
relevant I None
side I None
- I None
effect I None
of I None
parenteral I None
narcotic I None
administration I None
, I None
may I None
be I None
partly I None
mediated I None
via I None
serotonergic I None
pathways I None
. I None
<eof> I None

<s> O None
Pretreatment I None
with I None
type-2 I None
serotonin I Chemical
antagonists I None
may I None
be I None
clinically I None
useful I None
in I None
attenuating I None
opiate I None
- I None
induced I None
rigidity I Disease
, I None
although I None
further I None
studies I None
will I None
be I None
necessary I None
to I None
assess I None
the I None
interaction I None
of I None
possibly I None
enhanced I None
CNS I None
, I None
cardiovascular I None
, I None
and I None
respiratory I None
depression I None
. I None
<eof> I None

<s> O None
Glycopyrronium I Chemical
requirements I None
for I None
antagonism I None
of I None
the I None
muscarinic I None
side I None
effects I None
of I None
edrophonium I Chemical
. I None
<eof> I None

<s> O None
We I None
have I None
compared I None
, I None
in I None
60 I None
adult I None
patients I None
, I None
the I None
cardiovascular I None
effects I None
of I None
glycopyrronium I Chemical
5 I None
micrograms I None
kg-1 I None
and I None
10 I None
micrograms I None
kg-1 I None
given I None
either I None
simultaneously I None
or I None
1 I None
min I None
before I None
edrophonium I Chemical
<eof> I None

<s> O None
1 I None
mg I None
kg-1 I None
. I None
<eof> I None

<s> O None
Significant I None
differences I None
between I None
the I None
four I None
groups I None
were I None
detected I None
( I None
P I None
less I None
than I None
0.001 I None
) I None
. I None
<eof> I None

<s> O None
Both I None
groups I None
receiving I None
10 I None
micrograms I None
kg-1 I None
showed I None
increases I None
in I None
heart I None
rate I None
of I None
up I None
to I None
30 I None
beat I None
min-1 I None
<eof> I None

<s> O None
( I None
95 I None
% I None
confidence I None
limits I None
28 I None
- I None
32 I None
beat I None
min-1 I None
) I None
. I None
<eof> I None

<s> O None
Use I None
of I None
glycopyrronium I Chemical
5 I None
micrograms I None
kg-1 I None
provided I None
greater I None
cardiovascular I None
stability I None
and I None
, I None
given I None
1 I None
min I None
before I None
the I None
edrophonium I Chemical
, I None
was I None
sufficient I None
to I None
minimize I None
early I None
, I None
edrophonium I Chemical
<eof> I None

<s> O None
-induced I None
bradycardias I Disease
. I None
<eof> I None

<s> O None
This I None
low I None
dose I None
of I None
glycopyrronium I Chemical
provided I None
good I None
control I None
of I None
oropharyngeal I None
secretions I None
. I None
<eof> I None

<s> O None
Involvement I None
of I None
locus I None
coeruleus I None
and I None
noradrenergic I None
neurotransmission I None
in I None
fentanyl I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
muscular I Disease
rigidity O Disease
in I None
the I None
rat I None
. I None
<eof> I None

<s> O None
Whereas I None
muscular I Disease
rigidity O Disease
is I None
a I None
well I None
- I None
known I None
side I None
effect I None
that I None
is I None
associated I None
with I None
high I None
- I None
dose I None
fentanyl I Chemical
anesthesia I None
, I None
a I None
paucity I None
of I None
information I None
exists I None
with I None
regard I None
to I None
its I None
underlying I None
mechanism(s I None
) I None
. I None
<eof> I None

<s> O None
We I None
investigated I None
in I None
this I None
study I None
the I None
possible I None
engagement I None
of I None
locus I None
coeruleus I None
of I None
the I None
pons I None
in I None
this I None
phenomenon I None
, I None
using I None
male I None
Sprague I None
- I None
Dawley I None
rats I None
anesthetized I None
with I None
ketamine I Chemical
. I None
<eof> I None

<s> O None
Under I None
proper I None
control I None
of I None
respiration I None
, I None
body I None
temperature I None
and I None
end I None
- I None
tidal I None
CO2 I Chemical
, I None
intravenous I None
administration I None
of I None
fentanyl I Chemical
<eof> I None

<s> O None
( I None
50 I None
or I None
100 I None
micrograms I None
/ I None
kg I None
) I None
consistently I None
promoted I None
an I None
increase I None
in I None
electromyographic I None
activity I None
recorded I None
from I None
the I None
gastrocnemius I None
and I None
abdominal I None
rectus I None
muscles I None
. I None
<eof> I None

<s> O None
Such I None
an I None
induced I None
muscular I Disease
rigidity O Disease
by I None
the I None
narcotic I None
agent I None
was I None
significantly I None
antagonized I None
or I None
even I None
reduced I None
by I None
prior I None
electrolytic I None
lesions I None
of I None
the I None
locus I None
coeruleus I None
or I None
pretreatment I None
with I None
the I None
alpha I None
- I None
adrenoceptor I None
blocker I None
, I None
prazosin I Chemical
. I None
<eof> I None

<s> O None
Microinjection I None
of I None
fentanyl I Chemical
( I None
2.5 I None
micrograms/50 I None
nl I None
) I None
directly I None
into I None
this I None
pontine I None
nucleus I None
, I None
on I None
the I None
other I None
hand I None
, I None
elicited I None
discernible I None
electromyographic I None
excitation I None
. I None
<eof> I None

<s> O None
It I None
is I None
speculated I None
that I None
the I None
induction I None
of I None
muscular I Disease
rigidity O Disease
by I None
fentanyl I Chemical
may I None
involve I None
the I None
coerulospinal I None
noradrenergic I None
fibers I None
to I None
the I None
spinal I None
motoneurons I None
. I None
<eof> I None

<s> O None
Cerebral I Disease
sinus O Disease
thrombosis O Disease
as I None
a I None
potential I None
hazard I None
of I None
antifibrinolytic I None
treatment I None
in I None
menorrhagia I Disease
. I None
<eof> I None

<s> O None
We I None
describe I None
a I None
42-year I None
- I None
old I None
woman I None
who I None
developed I None
superior I None
sagittal I None
and I None
left I None
transverse I None
sinus I None
thrombosis I None
associated I None
with I None
prolonged I None
epsilon I Chemical
- O Chemical
aminocaproic O Chemical
acid O Chemical
therapy I None
for I None
menorrhagia I Disease
. I None
<eof> I None

<s> O None
This I None
antifibrinolytic I None
agent I None
has I None
been I None
used I None
in I None
women I None
with I None
menorrhagia I Disease
to I None
promote I None
clotting I None
and I None
reduce I None
blood I Disease
loss O Disease
. I None
<eof> I None

<s> O None
Although I None
increased I None
risk I None
of I None
thromboembolic I Disease
disease O Disease
has I None
been I None
reported I None
during I None
treatment I None
with I None
epsilon I Chemical
- O Chemical
aminocaproic O Chemical
acid O Chemical
, I None
<eof> I None

<s> O None
cerebral I Disease
sinus O Disease
thrombosis O Disease
has I None
not I None
been I None
previously I None
described I None
. I None
<eof> I None

<s> O None
Careful I None
use I None
of I None
epsilon I Chemical
- O Chemical
aminocaproic O Chemical
acid O Chemical
<eof> I None

<s> O None
therapy I None
is I None
recommended I None
. I None
<eof> I None

<s> O None
Hemorrhagic I None
cystitis I None
complicating I None
bone I None
marrow I None
transplantation I None
. I None
<eof> I None

<s> O None
Hemorrhagic I None
cystitis I None
is I None
a I None
potentially I None
serious I None
complication I None
of I None
high I None
- I None
dose I None
cyclophosphamide I Chemical
therapy I None
administered I None
before I None
bone I None
marrow I None
transplantation I None
. I None
<eof> I None

<s> O None
As I None
standard I None
practice I None
at I None
our I None
institution I None
, I None
patients I None
who I None
are I None
scheduled I None
to I None
receive I None
a I None
bone I None
marrow I None
transplant I None
are I None
treated I None
prophylactically I None
with I None
forced I None
hydration I None
and I None
bladder I None
irrigation I None
. I None
<eof> I None

<s> O None
In I None
an I None
attempt I None
to I None
obviate I None
the I None
inconvenience I None
of I None
bladder I None
irrigation I None
, I None
we I None
conducted I None
a I None
feasibility I None
trial I None
of I None
uroprophylaxis I None
with I None
mesna I Chemical
, I None
which I None
neutralizes I None
the I None
hepatic I None
metabolite I None
of I None
cyclophosphamide I Chemical
that I None
causes I None
hemorrhagic I None
cystitis I None
. I None
<eof> I None

<s> O None
Of I None
97 I None
patients I None
who I None
received I None
standard I None
prophylaxis I None
, I None
4 I None
had I None
symptomatic I None
hemorrhagic I None
cystitis I None
. I None
<eof> I None

<s> O None
In I None
contrast I None
, I None
two I None
of I None
four I None
consecutive I None
patients I None
who I None
received I None
mesna I Chemical
uroprophylaxis I None
before I None
allogeneic I None
bone I None
marrow I None
transplantation I None
had I None
severe I None
hemorrhagic I None
cystitis I None
for I None
at I None
least I None
2 I None
weeks I None
. I None
<eof> I None

<s> O None
Because I None
of I None
this I None
suboptimal I None
result I None
, I None
we I None
resumed I None
the I None
use I None
of I None
bladder I None
irrigation I None
and I None
forced I None
hydration I None
to I None
minimize I None
the I None
risk I None
of I None
hemorrhagic I None
cystitis I None
. I None
<eof> I None

<s> O None
Reversal I None
of I None
central I None
benzodiazepine I Chemical
effects I None
by I None
flumazenil I Chemical
after I None
intravenous I None
conscious I None
sedation I None
with I None
diazepam I Chemical
and I None
opioids I None
: I None
report I None
of I None
a I None
double I None
- I None
blind I None
multicenter I None
study I None
. I None
<eof> I None

<s> O None
The I None
Flumazenil I Chemical
in I None
Intravenous I None
Conscious I None
Sedation I None
with I None
Diazepam I Chemical
<eof> I None

<s> O None
Multicenter I None
Study I None
Group I None
II I None
. I None
<eof> I None

<s> O None
The I None
efficacy I None
and I None
safety I None
of I None
a I None
new I None
benzodiazepine I Chemical
antagonist I None
, I None
flumazenil I Chemical
, I None
were I None
assessed I None
in I None
a I None
double I None
- I None
blind I None
multicenter I None
study I None
. I None
<eof> I None

<s> O None
Flumazenil I Chemical
<eof> I None

<s> O None
( I None
mean I None
dose I None
, I None
0.76 I None
mg I None
) I None
or I None
placebo I None
( I None
mean I None
dose I None
, I None
8.9 I None
ml I None
) I None
was I None
administered I None
intravenously I None
to I None
130 I None
and I None
67 I None
patients I None
, I None
respectively I None
, I None
who I None
had I None
been I None
given I None
diazepam I Chemical
in I None
conjunction I None
with I None
an I None
opioid I None
( I None
fentanyl I Chemical
, I None
meperidine I Chemical
, I None
or I None
morphine I Chemical
) I None
for I None
the I None
induction I None
and I None
maintenance I None
of I None
intravenous I None
conscious I None
sedation I None
for I None
diagnostic I None
or I None
therapeutic I None
surgical I None
procedures I None
. I None
<eof> I None

<s> O None
The I None
group I None
assessable I None
for I None
efficacy I None
comprised I None
122 I None
patients I None
treated I None
with I None
flumazenil I Chemical
and I None
64 I None
patients I None
given I None
placebo I None
. I None
<eof> I None

<s> O None
After I None
5 I None
minutes I None
, I None
80/115 I None
( I None
70 I None
% I None
) I None
<eof> I None

<s> O None
flumazenil I Chemical
<eof> I None

<s> O None
-treated I None
patients I None
, I None
compared I None
with I None
21/63 I None
( I None
33 I None
% I None
) I None
placebo I None
- I None
treated I None
patients I None
, I None
were I None
completely I None
awake I None
and I None
alert I None
, I None
as I None
indicated I None
by I None
a I None
score I None
of I None
5 I None
on I None
the I None
Observer I None
's I None
Assessment I None
of I None
Alertness I None
/ I None
Sedation I None
Scale I None
. I None
<eof> I None

<s> O None
Ninety I None
- I None
five I None
percent I None
of I None
patients I None
in I None
each I None
group I None
who I None
attained I None
a I None
score I None
of I None
5 I None
at I None
the I None
5-minute I None
assessment I None
showed I None
no I None
loss I None
of I None
alertness I None
throughout I None
the I None
180-minute I None
assessment I None
period I None
. I None
<eof> I None

<s> O None
Flumazenil I Chemical
<eof> I None

<s> O None
-treated I None
patients I None
also I None
performed I None
significantly I None
better I None
on I None
the I None
Finger I None
- I None
to I None
- I None
Nose I None
Test I None
and I None
the I None
recall I None
of I None
pictures I None
shown I None
at I None
the I None
5-minute I None
assessment I None
. I None
<eof> I None

<s> O None
Flumazenil I Chemical
was I None
well I None
tolerated I None
, I None
with I None
no I None
serious I None
adverse I None
effects I None
reported I None
. I None
<eof> I None

<s> O None
Thirty I None
- I None
nine I None
( I None
30 I None
% I None
) I None
of I None
<eof> I None

<s> O None
flumazenil I Chemical
<eof> I None

<s> O None
-treated I None
patients I None
, I None
compared I None
with I None
17 I None
( I None
25 I None
% I None
) I None
of I None
placebo I None
- I None
treated I None
patients I None
had I None
one I None
or I None
more I None
drug I None
- I None
related I None
adverse I None
experiences I None
. I None
<eof> I None

<s> O None
The I None
most I None
common I None
adverse I None
effects I None
were I None
nausea I Disease
and I None
vomiting I Disease
in I None
the I None
flumazenil I Chemical
group I None
and I None
nausea I Disease
and I None
injection I None
- I None
site I None
pain I Disease
in I None
the I None
placebo I None
group I None
. I None
<eof> I None

<s> O None
Flumazenil I Chemical
was I None
found I None
to I None
promptly I None
reverse I None
sedation I None
induced I None
by I None
diazepam I Chemical
in I None
the I None
presence I None
of I None
opioids I None
. I None
<eof> I None

<s> O None
Hepatic I None
adenomas I Disease
and I None
focal I Disease
nodular O Disease
hyperplasia O Disease
of I None
the I None
liver I None
in I None
young I None
women I None
on I None
oral I Chemical
contraceptives O Chemical
: I None
case I None
reports I None
. I None
<eof> I None

<s> O None
Two I None
cases I None
of I None
hepatic I None
adenoma I Disease
and I None
one I None
of I None
focal I Disease
nodular O Disease
hyperplasia O Disease
presumably I None
associated I None
with I None
the I None
use I None
of I None
oral I Chemical
contraceptives O Chemical
, I None
are I None
reported I None
. I None
<eof> I None

<s> O None
Special I None
reference I None
is I None
made I None
to I None
their I None
clinical I None
presentation I None
, I None
which I None
may I None
be I None
totally I None
asymptomatic I None
. I None
<eof> I None

<s> O None
Liver I None
- I None
function I None
tests I None
are I None
of I None
little I None
diagnostic I None
value I None
, I None
but I None
valuable I None
information I None
may I None
be I None
obtained I None
from I None
both I None
liver I None
scanning I None
and I None
hepatic I None
angiography I None
. I None
<eof> I None

<s> O None
Histologic I None
differences I None
and I None
clinical I None
similarities I None
between I None
hepatic I None
adenoma I Disease
and I None
focal I Disease
nodular O Disease
hyperplasia O Disease
of I None
the I None
liver I None
are I None
discussed I None
. I None
<eof> I None

<s> O None
Arterial I None
thromboembolism I Disease
in I None
patients I None
receiving I None
systemic I None
heparin I Chemical
therapy I None
: I None
a I None
complication I None
associated I None
with I None
<eof> I None

<s> O None
heparin I Chemical
-induced I None
<eof> I None

<s> O None
thrombocytopenia I Disease
. I None
<eof> I None

<s> O None
Arterial I None
<eof> I None

<s> O None
thromboembolism I Disease
is I None
a I None
recognized I None
complication I None
of I None
systemic I None
heparin I Chemical
therapy I None
. I None
<eof> I None

<s> O None
Characteristic I None
of I None
the I None
entity I None
is I None
arterial I Disease
occlusion O Disease
by I None
platelet I None
- I None
fibrin I None
thrombi I Disease
with I None
distal I None
ischemia I Disease
occurring I None
four I None
to I None
twenty I None
days I None
after I None
the I None
initiation I None
of I None
heparin I Chemical
therapy I None
, I None
preceded I None
by I None
profound I None
thrombocytopenia I Disease
with I None
platelet I None
counts I None
in I None
the I None
range I None
of I None
30,000 I None
to I None
40,000 I None
per I None
cubic I None
millimeter I None
. I None
<eof> I None

<s> O None
The I None
clinically I None
apparent I None
occlusion I None
may I None
be I None
preceded I None
by I None
gastrointestinal I None
and I None
musculoskeletal I None
symptoms I None
that I None
appear I None
to I None
be I None
ischemic I Disease
in I None
origin I None
, I None
and I None
might I None
serve I None
to I None
warn I None
the I None
clinician I None
of I None
these I None
complications I None
. I None
<eof> I None

<s> O None
Previous I None
reports I None
of I None
these I None
phenomena I None
as I None
well I None
as I None
recent I None
studies I None
of I None
the I None
effect I None
of I None
heparin I Chemical
are I None
reviewed I None
. I None
<eof> I None

<s> O None
The I None
common I None
factor I None
relating I None
thromboembolism I Disease
and I None
thrombocytopenia I Disease
is I None
heparin I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
platelet I Disease
aggregation O Disease
. I None
<eof> I None

<s> O None
Appropriate I None
treatment I None
consists I None
of I None
discontinuation I None
of I None
heparin I Chemical
, I None
and I None
anticoagulation I None
with I None
sodium I Chemical
warfarin O Chemical
if I None
necessary I None
. I None
<eof> I None

<s> O None
Vascular I None
procedures I None
are I None
performed I None
as I None
indicated I None
. I None
<eof> I None

<s> O None
Long I None
- I None
term I None
prognosis I None
for I None
transplant I None
- I None
free I None
survivors I None
of I None
paracetamol I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
acute I Disease
liver O Disease
failure O Disease
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
<eof> I None

<s> O None
The I None
prognosis I None
for I None
transplant I None
- I None
free I None
survivors I None
of I None
paracetamol I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
acute I Disease
liver O Disease
failure O Disease
remains I None
unknown I None
. I None
<eof> I None

<s> O None
AIM I None
: I None
To I None
examine I None
whether I None
paracetamol I Chemical
-induced I None
acute I Disease
liver O Disease
failure O Disease
increases I None
long I None
- I None
term I None
mortality I None
. I None
<eof> I None

<s> O None
METHODS I None
: I None
We I None
followed I None
up I None
all I None
transplant I None
- I None
free I None
survivors I None
of I None
paracetamol I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
acute I Disease
liver O Disease
injury O Disease
, I None
hospitalized I None
in I None
a I None
Danish I None
national I None
referral I None
centre I None
during I None
1984 I None
- I None
2004 I None
. I None
<eof> I None

<s> O None
We I None
compared I None
age I None
- I None
specific I None
mortality I None
rates I None
from I None
1 I None
year I None
post I None
- I None
discharge I None
through I None
2008 I None
between I None
those I None
in I None
whom I None
the I None
liver I Disease
injury O Disease
led I None
to I None
an I None
acute I Disease
liver O Disease
failure O Disease
and I None
those I None
in I None
whom I None
it I None
did I None
not I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
We I None
included I None
641 I None
patients I None
. I None
<eof> I None

<s> O None
On I None
average I None
, I None
age I None
- I None
specific I None
mortality I None
rates I None
were I None
slightly I None
higher I None
for I None
the I None
101 I None
patients I None
whose I None
paracetamol I Chemical
-induced I None
liver I Disease
injury O Disease
had I None
caused I None
an I None
acute I Disease
liver O Disease
failure O Disease
( I None
adjusted I None
mortality I None
rate I None
ratio I None
= I None
1.70 I None
, I None
95 I None
% I None
CI I None
1.02 I None
- I None
2.85 I None
) I None
, I None
but I None
the I None
association I None
was I None
age I None
- I None
dependent I None
, I None
and I None
no I None
survivors I None
of I None
acute I Disease
liver O Disease
failure O Disease
died I None
of I None
liver I Disease
disease O Disease
, I None
whereas I None
suicides I None
were I None
frequent I None
in I None
both I None
groups I None
. I None
<eof> I None

<s> O None
These I None
observations I None
speak I None
against I None
long I None
- I None
term I None
effects I None
of I None
acute I Disease
liver O Disease
failure O Disease
. I None
<eof> I None

<s> O None
More I None
likely I None
, I None
the I None
elevated I None
mortality I None
rate I None
ratio I None
resulted I None
from I None
incomplete I None
adjustment I None
for I None
the I None
greater I None
prevalence I None
of I None
substance I Disease
abuse O Disease
among I None
survivors I None
of I None
acute I Disease
liver O Disease
failure O Disease
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
Paracetamol I Chemical
-induced I None
<eof> I None

<s> O None
acute I Disease
liver O Disease
failure O Disease
did I None
not I None
affect I None
long I None
- I None
term I None
mortality I None
. I None
<eof> I None

<s> O None
Clinical I None
follow I None
- I None
up I None
may I None
be I None
justified I None
by I None
the I None
cause I None
of I None
the I None
liver I Disease
failure O Disease
, I None
but I None
not I None
by I None
the I None
liver I Disease
failure O Disease
itself I None
. I None
<eof> I None

<s> O None
Serotonin I Chemical
6 I None
receptor I None
gene I None
is I None
associated I None
with I None
methamphetamine I Chemical
-induced I None
psychosis I Disease
in I None
a I None
Japanese I None
population I None
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
<eof> I None

<s> O None
Altered I None
serotonergic I None
neural I None
transmission I None
is I None
hypothesized I None
to I None
be I None
a I None
susceptibility I None
factor I None
for I None
psychotic I Disease
disorders O Disease
such I None
as I None
schizophrenia I Disease
. I None
<eof> I None

<s> O None
The I None
serotonin I Chemical
6 I None
( I None
5-HT I Chemical
6 I None
) I None
receptor I None
is I None
therapeutically I None
targeted I None
by I None
several I None
second I None
generation I None
antipsychotics I None
, I None
such I None
as I None
clozapine I Chemical
and I None
olanzapine I Chemical
, I None
and I None
d I Chemical
- O Chemical
amphetamine O Chemical
-induced I None
<eof> I None

<s> O None
hyperactivity I Disease
in I None
rats I None
is I None
corrected I None
with I None
the I None
use I None
of I None
a I None
selective I None
5-HT I Chemical
6 I None
receptor I None
antagonist I None
. I None
<eof> I None

<s> O None
In I None
addition I None
, I None
the I None
disrupted I None
prepulse I None
inhibition I None
induced I None
by I None
d I Chemical
- O Chemical
amphetamine O Chemical
or I None
phencyclidine I Chemical
was I None
restored I None
by I None
5-HT I Chemical
6 I None
receptor I None
antagonist I None
in I None
an I None
animal I None
study I None
using I None
rats I None
. I None
<eof> I None

<s> O None
These I None
animal I None
models I None
were I None
considered I None
to I None
reflect I None
the I None
positive I None
symptoms I None
of I None
schizophrenia I Disease
, I None
and I None
the I None
above I None
evidence I None
suggests I None
that I None
altered I None
5-HT I Chemical
6 I None
receptors I None
are I None
involved I None
in I None
the I None
pathophysiology I None
of I None
psychotic I Disease
disorders O Disease
. I None
<eof> I None

<s> O None
The I None
symptoms I None
of I None
methamphetamine I Chemical
<eof> I None

<s> O None
( I None
METH I Chemical
) I None
-induced I None
<eof> I None

<s> O None
psychosis I Disease
are I None
similar I None
to I None
those I None
of I None
paranoid I Disease
type O Disease
schizophrenia O Disease
. I None
<eof> I None

<s> O None
Therefore I None
, I None
we I None
conducted I None
an I None
analysis I None
of I None
the I None
association I None
of I None
the I None
5-HT I Chemical
6 I None
gene I None
( I None
HTR6 I None
) I None
with I None
<eof> I None

<s> O None
METH I Chemical
-induced I None
<eof> I None

<s> O None
psychosis I Disease
. I None
<eof> I None

<s> O None
METHOD I None
: I None
<eof> I None

<s> O None
Using I None
five I None
tagging I None
SNPs I None
( I None
rs6693503 I None
, I None
rs1805054 I None
, I None
rs4912138 I None
, I None
rs3790757 I None
and I None
rs9659997 I None
) I None
, I None
we I None
conducted I None
a I None
genetic I None
association I None
analysis I None
of I None
case I None
- I None
control I None
samples I None
( I None
197 I None
METH I Chemical
-induced I None
psychosis I Disease
patients I None
and I None
337 I None
controls I None
) I None
in I None
the I None
Japanese I None
population I None
. I None
<eof> I None

<s> O None
The I None
age I None
and I None
sex I None
of I None
the I None
control I None
subjects I None
did I None
not I None
differ I None
from I None
those I None
of I None
the I None
methamphetamine I Chemical
dependence I None
patients I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
rs6693503 I None
was I None
associated I None
with I None
<eof> I None

<s> O None
METH I Chemical
-induced I None
<eof> I None

<s> O None
psychosis I Disease
patients I None
in I None
the I None
allele I None
/ I None
genotype I None
- I None
wise I None
analysis I None
. I None
<eof> I None

<s> O None
Moreover I None
, I None
this I None
association I None
remained I None
significant I None
after I None
Bonferroni I None
correction I None
. I None
<eof> I None

<s> O None
In I None
the I None
haplotype I None
- I None
wise I None
analysis I None
, I None
we I None
detected I None
an I None
association I None
between I None
two I None
markers I None
( I None
rs6693503 I None
and I None
rs1805054 I None
) I None
and I None
three I None
markers I None
( I None
rs6693503 I None
, I None
rs1805054 I None
and I None
rs4912138 I None
) I None
in I None
HTR6 I None
and I None
<eof> I None

<s> O None
METH I Chemical
-induced I None
<eof> I None

<s> O None
psychosis I Disease
patients I None
, I None
respectively I None
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
<eof> I None

<s> O None
HTR6 I None
may I None
play I None
an I None
important I None
role I None
in I None
the I None
pathophysiology I None
of I None
METH I Chemical
-induced I None
<eof> I None

<s> O None
psychosis I Disease
in I None
the I None
Japanese I None
population I None
. I None
<eof> I None

<s> O None
Effect I None
of I None
increasing I None
intraperitoneal I None
infusion I None
rates I None
on I None
bupropion I Chemical
hydrochloride O Chemical
-induced I None
<eof> I None

<s> O None
seizures I Disease
in I None
mice I None
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
<eof> I None

<s> O None
It I None
is I None
not I None
known I None
if I None
there I None
is I None
a I None
relationship I None
between I None
input I None
rate I None
and I None
incidence I None
of I None
bupropion I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
seizures I Disease
. I None
<eof> I None

<s> O None
This I None
is I None
important I None
, I None
since I None
different I None
controlled I None
release I None
formulations I None
of I None
bupropion I Chemical
release I None
the I None
active I None
drug I None
at I None
different I None
rates I None
. I None
<eof> I None

<s> O None
METHODS I None
: I None
We I None
investigated I None
the I None
effect I None
of I None
varying I None
the I None
intraperitoneal I None
infusion I None
rates I None
of I None
bupropion I Chemical
HCl O Chemical
120 I None
mg I None
/ I None
kg I None
, I None
a I None
known I None
convulsive I Disease
dose I None
50 I None
( I None
CD50 I None
) I None
, I None
on I None
the I None
incidence I None
and I None
severity I None
of I None
bupropion I Chemical
-induced I None
convulsions I Disease
in I None
the I None
Swiss I None
albino I None
mice I None
. I None
<eof> I None

<s> O None
A I None
total I None
of I None
69 I None
mice I None
, I None
approximately I None
7 I None
weeks I None
of I None
age I None
, I None
and I None
weighing I None
21.0 I None
to I None
29.1 I None
g I None
were I None
randomly I None
assigned I None
to I None
bupropion I Chemical
HCl O Chemical
120 I None
mg I None
/ I None
kg I None
treatment I None
by I None
intraperitoneal I None
( I None
IP I None
) I None
administration I None
in I None
7 I None
groups I None
( I None
9 I None
to I None
10 I None
animals I None
per I None
group I None
) I None
. I None
<eof> I None

<s> O None
Bupropion I Chemical
HCl O Chemical
was I None
infused I None
through I None
a I None
surgically I None
implanted I None
IP I None
dosing I None
catheter I None
with I None
infusions I None
in I None
each I None
group I None
of I None
0 I None
min I None
, I None
15 I None
min I None
, I None
30 I None
min I None
, I None
60 I None
min I None
, I None
90 I None
min I None
, I None
120 I None
min I None
, I None
and I None
240 I None
min I None
. I None
<eof> I None

<s> O None
The I None
number I None
, I None
time I None
of I None
onset I None
, I None
duration I None
and I None
the I None
intensity I None
of I None
the I None
convulsions I Disease
or I None
absence I None
of I None
convulsions I Disease
were I None
recorded I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
The I None
results I None
showed I None
that I None
IP I None
administration I None
of I None
bupropion I Chemical
HCl O Chemical
120 I None
mg I None
/ I None
kg I None
by I None
bolus I None
injection I None
induced I None
convulsions I Disease
in I None
6 I None
out I None
of I None
10 I None
mice I None
( I None
60 I None
% I None
of I None
convulsing I None
mice I None
) I None
in I None
group I None
1 I None
. I None
<eof> I None

<s> O None
Logistic I None
regression I None
analysis I None
revealed I None
that I None
infusion I None
time I None
was I None
significant I None
( I None
p I None
= I None
0.0004 I None
; I None
odds I None
ratio I None
= I None
0.974 I None
) I None
and I None
increasing I None
the I None
IP I None
infusion I None
time I None
of I None
bupropion I Chemical
HCl O Chemical
120 I None
mg I None
/ I None
kg I None
was I None
associated I None
with I None
a I None
91 I None
% I None
reduced I None
odds I None
of I None
convulsions I Disease
at I None
infusion I None
times I None
of I None
15 I None
to I None
90 I None
min I None
compared I None
to I None
bolus I None
injection I None
. I None
<eof> I None

<s> O None
Further I None
increase I None
in I None
infusion I None
time I None
resulted I None
in I None
further I None
reduction I None
in I None
the I None
odds I None
of I None
convulsions I Disease
to I None
99.8 I None
% I None
reduction I None
at I None
240 I None
min I None
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
<eof> I None

<s> O None
In I None
conclusion I None
, I None
the I None
demonstration I None
of I None
an I None
inverse I None
relationship I None
between I None
infusion I None
time I None
of I None
a I None
fixed I None
and I None
convulsive I Disease
dose I None
of I None
bupropion I Chemical
and I None
the I None
risk I None
of I None
convulsions I Disease
in I None
a I None
prospective I None
study I None
is I None
novel I None
. I None
<eof> I None

<s> O None
Detailed I None
spectral I None
profile I None
analysis I None
of I None
penicillin I Chemical
-induced I None
epileptiform I Disease
activity O Disease
in I None
anesthetized I None
rats I None
. I None
<eof> I None

<s> O None
Penicillin I Chemical
model I None
is I None
a I None
widely I None
used I None
experimental I None
model I None
for I None
epilepsy I Disease
research I None
. I None
<eof> I None

<s> O None
In I None
the I None
present I None
study I None
we I None
aimed I None
to I None
portray I None
a I None
detailed I None
spectral I None
analysis I None
of I None
penicillin I Chemical
-induced I None
<eof> I None

<s> O None
epileptiform I Disease
activity O Disease
in I None
comparison I None
with I None
basal I None
brain I None
activity I None
in I None
anesthetized I None
Wistar I None
rats I None
. I None
<eof> I None

<s> O None
Male I None
Wistar I None
rats I None
were I None
anesthetized I None
with I None
i.p I None
. I None
<eof> I None

<s> O None
urethane I Chemical
and I None
connected I None
to I None
an I None
electrocorticogram I None
setup I None
. I None
<eof> I None

<s> O None
After I None
a I None
short I None
period I None
of I None
basal I None
activity I None
recording I None
, I None
epileptic I Disease
focus I None
was I None
induced I None
by I None
injecting I None
400IU/2 I None
microl I None
<eof> I None

<s> O None
penicillin I Chemical
- O Chemical
G O Chemical
potassium O Chemical
into I None
the I None
left I None
lateral I None
ventricle I None
while I None
the I None
cortical I None
activity I None
was I None
continuously I None
recorded I None
. I None
<eof> I None

<s> O None
Basal I None
activity I None
, I None
latent I None
period I None
and I None
the I None
penicillin I Chemical
-induced I None
<eof> I None

<s> O None
epileptiform I Disease
activity O Disease
periods I None
were I None
then I None
analyzed I None
using I None
both I None
conventional I None
methods I None
and I None
spectral I None
analysis I None
. I None
<eof> I None

<s> O None
Spectral I None
analyses I None
were I None
conducted I None
by I None
dividing I None
the I None
whole I None
spectrum I None
into I None
different I None
frequency I None
bands I None
including I None
delta I None
, I None
theta I None
( I None
slow I None
and I None
fast I None
) I None
, I None
alpha I None
- I None
sigma I None
, I None
beta I None
( I None
1 I None
and I None
2 I None
) I None
and I None
gamma I None
( I None
1 I None
and I None
2 I None
) I None
bands I None
. I None
<eof> I None

<s> O None
Our I None
results I None
show I None
that I None
the I None
most I None
affected I None
frequency I None
bands I None
were I None
delta I None
, I None
theta I None
, I None
beta-2 I None
and I None
gamma-2 I None
bands I None
during I None
the I None
epileptiform I Disease
activity O Disease
and I None
there I None
were I None
marked I None
differences I None
in I None
terms I None
of I None
spectral I None
densities I None
between I None
three I None
investigated I None
episodes I None
( I None
basal I None
activity I None
, I None
latent I None
period I None
and I None
epileptiform I Disease
activity O Disease
) I None
. I None
<eof> I None

<s> O None
Our I None
results I None
may I None
help I None
to I None
analyze I None
novel I None
data I None
obtained I None
using I None
similar I None
experimental I None
models I None
and I None
the I None
simple I None
analysis I None
method I None
described I None
here I None
can I None
be I None
used I None
in I None
similar I None
studies I None
to I None
investigate I None
the I None
basic I None
neuronal I None
mechanism I None
of I None
this I None
or I None
other I None
types I None
of I None
experimental I None
epilepsies I Disease
. I None
<eof> I None

<s> O None
High I None
dose I None
<eof> I None

<s> O None
dexmedetomidine I Chemical
as I None
the I None
sole I None
sedative I None
for I None
pediatric I None
MRI I None
. I None
<eof> I None

<s> O None
OBJECTIVE I None
: I None
<eof> I None

<s> O None
This I None
large I None
- I None
scale I None
retrospective I None
review I None
evaluates I None
the I None
sedation I None
profile I None
of I None
dexmedetomidine I Chemical
. I None
<eof> I None

<s> O None
AIM I None
: I None
To I None
determine I None
the I None
hemodynamic I None
responses I None
, I None
efficacy I None
and I None
adverse I None
events I None
associated I None
with I None
the I None
use I None
of I None
high I None
dose I None
dexmedetomidine I Chemical
as I None
the I None
sole I None
sedative I None
for I None
magnetic I None
resonance I None
imaging I None
( I None
MRI I None
) I None
studies I None
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
<eof> I None

<s> O None
Dexmedetomidine I Chemical
has I None
been I None
used I None
at I None
our I None
institution I None
since I None
2005 I None
to I None
provide I None
sedation I None
for I None
pediatric I None
radiological I None
imaging I None
studies I None
. I None
<eof> I None

<s> O None
Over I None
time I None
, I None
an I None
effective I None
protocol I None
utilizing I None
high I None
dose I None
dexmedetomidine I Chemical
as I None
the I None
sole I None
sedative I None
agent I None
has I None
evolved I None
. I None
<eof> I None

<s> O None
METHODS I None
/ I None
MATERIALS I None
: I None
<eof> I None

<s> O None
As I None
part I None
of I None
the I None
ongoing I None
Quality I None
Assurance I None
process I None
, I None
data I None
on I None
all I None
sedations I None
are I None
reviewed I None
monthly I None
and I None
protocols I None
modified I None
as I None
needed I None
. I None
<eof> I None

<s> O None
Data I None
were I None
analyzed I None
from I None
all I None
747 I None
consecutive I None
patients I None
who I None
received I None
dexmedetomidine I Chemical
for I None
MRI I None
sedation I None
from I None
April I None
2005 I None
to I None
April I None
2007 I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
Since I None
2005 I None
, I None
the I None
10-min I None
loading I None
dose I None
of I None
our I None
dexmedetomidine I Chemical
protocol I None
increased I None
from I None
2 I None
to I None
3 I None
microg.kg(-1 I None
) I None
, I None
and I None
the I None
infusion I None
rate I None
increased I None
from I None
1 I None
to I None
1.5 I None
to I None
2 I None
microg.kg(-1).h(-1 I None
) I None
. I None
<eof> I None

<s> O None
The I None
current I None
sedation I None
protocol I None
progressively I None
increased I None
the I None
rate I None
of I None
successful I None
sedation I None
( I None
able I None
to I None
complete I None
the I None
imaging I None
study I None
) I None
when I None
using I None
dexmedetomidine I Chemical
alone I None
from I None
91.8 I None
% I None
to I None
97.6 I None
% I None
( I None
P I None
= I None
0.009 I None
) I None
, I None
reducing I None
the I None
requirement I None
for I None
adjuvant I None
pentobarbital I Chemical
in I None
the I None
event I None
of I None
sedation I None
failure I None
with I None
dexmedetomidine I Chemical
alone I None
and I None
decreased I None
the I None
mean I None
recovery I None
time I None
by I None
10 I None
min I None
( I None
P I None
< I None
0.001 I None
) I None
. I None
<eof> I None

<s> O None
Although I None
dexmedetomidine I Chemical
sedation I None
was I None
associated I None
with I None
a I None
16 I None
% I None
incidence I None
of I None
bradycardia I Disease
, I None
all I None
concomitant I None
mean I None
arterial I None
blood I None
pressures I None
were I None
within I None
20 I None
% I None
of I None
age I None
- I None
adjusted I None
normal I None
range I None
and I None
oxygen I Chemical
saturations I None
were I None
95 I None
% I None
or I None
higher I None
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
<eof> I None

<s> O None
Dexmedetomidine I Chemical
in I None
high I None
doses I None
provides I None
adequate I None
sedation I None
for I None
pediatric I None
MRI I None
studies I None
. I None
<eof> I None

<s> O None
While I None
use I None
of I None
high I None
dose I None
<eof> I None

<s> O None
dexmedetomidine I Chemical
is I None
associated I None
with I None
decreases I None
in I None
heart I None
rate I None
and I None
blood I None
pressure I None
outside I None
the I None
established I None
' I None
awake I None
' I None
norms I None
, I None
this I None
deviation I None
is I None
generally I None
within I None
20 I None
% I None
of I None
norms I None
, I None
and I None
is I None
not I None
associated I None
with I None
adverse I None
sequelae I None
. I None
<eof> I None

<s> O None
Dexmedetomidine I Chemical
is I None
useful I None
as I None
the I None
sole I None
sedative I None
for I None
pediatric I None
MRI I None
. I None
<eof> I None

<s> O None
Methamphetamine I Chemical
causes I None
alterations I None
in I None
the I None
MAP I None
kinase I None
- I None
related I None
pathways I None
in I None
the I None
brains I None
of I None
mice I None
that I None
display I None
increased I None
<eof> I None

<s> O None
aggressiveness I Disease
. I None
<eof> I None

<s> O None
Aggressive I Disease
behaviors O Disease
have I None
been I None
reported I None
in I None
patients I None
who I None
suffer I None
from I None
some I None
psychiatric I Disease
disorders O Disease
, I None
and I None
are I None
common I None
in I None
methamphetamine I Chemical
<eof> I None

<s> O None
( I None
METH I Chemical
) I None
abusers I None
. I None
<eof> I None

<s> O None
Herein I None
, I None
we I None
report I None
that I None
multiple I None
( I None
but I None
not I None
single I None
) I None
injections I None
of I None
METH I Chemical
significantly I None
increased I None
aggressiveness I Disease
in I None
male I None
CD-1 I None
mice I None
. I None
<eof> I None

<s> O None
This I None
increase I None
in I None
aggressiveness I Disease
was I None
not I None
secondary I None
to I None
METH I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
hyperactivity I Disease
. I None
<eof> I None

<s> O None
Analysis I None
of I None
protein I None
expression I None
using I None
antibody I None
microarrays I None
and I None
Western I None
blotting I None
revealed I None
differential I None
changes I None
in I None
MAP I None
kinase I None
- I None
related I None
pathways I None
after I None
multiple I None
and I None
single I None
METH I Chemical
injections I None
. I None
<eof> I None

<s> O None
There I None
were I None
statistically I None
significant I None
( I None
p<0.05 I None
) I None
decreases I None
in I None
MEK1 I None
, I None
Erk2p I None
, I None
GSK3alpha I None
, I None
14 I None
- I None
3 I None
- I None
3e I None
, I None
and I None
MEK7 I None
in I None
the I None
striata I None
of I None
mice I None
after I None
multiple I None
injections I None
of I None
METH I Chemical
. I None
<eof> I None

<s> O None
MEK1 I None
was I None
significantly I None
decreased I None
also I None
after I None
a I None
single I None
injection I None
of I None
METH I Chemical
, I None
but I None
to I None
a I None
much I None
lesser I None
degree I None
than I None
after I None
multiple I None
injections I None
of I None
METH I Chemical
. I None
<eof> I None

<s> O None
In I None
the I None
frontal I None
cortex I None
, I None
there I None
was I None
a I None
statistically I None
significant I None
decrease I None
in I None
GSK3alpha I None
after I None
multiple I None
( I None
but I None
not I None
single I None
) I None
injections I None
of I None
METH I Chemical
. I None
<eof> I None

<s> O None
These I None
findings I None
suggest I None
that I None
alterations I None
in I None
MAP I None
kinase I None
- I None
related I None
pathways I None
in I None
the I None
prefronto I None
- I None
striatal I None
circuitries I None
might I None
be I None
involved I None
in I None
the I None
manifestation I None
of I None
aggressive I Disease
behaviors O Disease
in I None
mice I None
. I None
<eof> I None

<s> O None
Lamotrigine I Chemical
associated I None
with I None
exacerbation I None
or I None
de I None
novo I None
myoclonus I Disease
in I None
idiopathic I Disease
generalized O Disease
epilepsies O Disease
. I None
<eof> I None

<s> O None
Five I None
patients I None
with I None
idiopathic I Disease
generalized O Disease
epilepsies O Disease
<eof> I None

<s> O None
( I None
IGE I Disease
) I None
treated I None
with I None
lamotrigine I Chemical
<eof> I None

<s> O None
( I None
LTG I Chemical
) I None
experienced I None
exacerbation I None
or I None
de I None
novo I None
appearance I None
of I None
myoclonic I Disease
jerks O Disease
<eof> I None

<s> O None
( I None
MJ I Disease
) I None
. I None
<eof> I None

<s> O None
In I None
three I None
patients I None
, I None
LTG I Chemical
exacerbated I None
<eof> I None

<s> O None
MJ I Disease
in I None
a I None
dose I None
- I None
dependent I None
manner I None
with I None
early I None
aggravation I None
during I None
titration I None
. I None
<eof> I None

<s> O None
MJ I Disease
disappeared I None
when I None
LTG I Chemical
dose I None
was I None
decreased I None
by I None
25 I None
to I None
50 I None
% I None
. I None
<eof> I None

<s> O None
In I None
two I None
patients I None
, I None
LTG I Chemical
exacerbated I None
<eof> I None

<s> O None
MJ I Disease
in I None
a I None
delayed I None
but I None
more I None
severe I None
manner I None
, I None
with I None
myoclonic I Disease
status O Disease
that I None
only I None
ceased I None
after I None
LTG I Chemical
withdrawal I None
. I None
<eof> I None

<s> O None
rTMS I None
of I None
supplementary I None
motor I None
area I None
modulates I None
therapy I None
- I None
induced I None
dyskinesias I Disease
in I None
Parkinson I Disease
disease O Disease
. I None
<eof> I None

<s> O None
The I None
neural I None
mechanisms I None
and I None
circuitry I None
involved I None
in I None
levodopa I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
dyskinesia I Disease
are I None
unclear I None
. I None
<eof> I None

<s> O None
Using I None
repetitive I None
transcranial I None
magnetic I None
stimulation I None
( I None
rTMS I None
) I None
over I None
the I None
supplementary I None
motor I None
area I None
( I None
SMA I None
) I None
in I None
a I None
group I None
of I None
patients I None
with I None
advanced I None
Parkinson I Disease
disease O Disease
, I None
the I None
authors I None
investigated I None
whether I None
modulation I None
of I None
SMA I None
excitability I None
may I None
result I None
in I None
a I None
modification I None
of I None
a I None
dyskinetic I Disease
state I None
induced I None
by I None
continuous I None
apomorphine I Chemical
infusion I None
. I None
<eof> I None

<s> O None
rTMS I None
at I None
1 I None
<eof> I None

<s> O None
Hz I None
was I None
observed I None
to I None
markedly I None
reduce I None
drug I Disease
- O Disease
induced O Disease
dyskinesias O Disease
, I None
whereas I None
5-Hz I None
rTMS I None
induced I None
a I None
slight I None
but I None
not I None
significant I None
increase I None
. I None
<eof> I None

<s> O None
Assessment I None
of I None
the I None
onset I None
and I None
persistence I None
of I None
amnesia I Disease
during I None
procedural I None
sedation I None
with I None
propofol I Chemical
. I None
<eof> I None

<s> O None
OBJECTIVES I None
: I None
<eof> I None

<s> O None
To I None
assess I None
patients I None
' I None
ability I None
to I None
repeat I None
and I None
recall I None
words I None
presented I None
to I None
them I None
while I None
undergoing I None
procedural I None
sedation I None
with I None
propofol I Chemical
, I None
and I None
correlate I None
their I None
recall I None
with I None
their I None
level I None
of I None
awareness I None
as I None
measured I None
by I None
bispectral I None
index I None
( I None
BIS I None
) I None
monitoring I None
. I None
<eof> I None

<s> O None
METHODS I None
: I None
<eof> I None

<s> O None
This I None
was I None
a I None
prospective I None
, I None
single I None
- I None
intervention I None
study I None
of I None
consenting I None
adult I None
patients I None
undergoing I None
procedural I None
sedation I None
with I None
propofol I Chemical
between I None
December I None
28 I None
, I None
2002 I None
, I None
and I None
October I None
31 I None
, I None
2003 I None
. I None
<eof> I None

<s> O None
BIS I None
monitoring I None
was I None
initiated I None
starting I None
3 I None
minutes I None
before I None
the I None
procedure I None
and I None
continuing I None
until I None
the I None
patient I None
had I None
regained I None
baseline I None
mental I None
status I None
. I None
<eof> I None

<s> O None
At I None
1-minute I None
intervals I None
during I None
the I None
procedural I None
sedation I None
, I None
until I None
the I None
patient I None
regained I None
baseline I None
mental I None
status I None
at I None
the I None
end I None
of I None
the I None
procedure I None
, I None
a I None
word I None
from I None
a I None
standardized I None
list I None
was I None
read I None
aloud I None
, I None
and I None
the I None
patient I None
was I None
asked I None
to I None
immediately I None
repeat I None
the I None
word I None
to I None
the I None
investigator I None
. I None
<eof> I None

<s> O None
The I None
BIS I None
score I None
at I None
the I None
time I None
the I None
word I None
was I None
read I None
and I None
the I None
patient I None
's I None
ability I None
to I None
repeat I None
the I None
word I None
were I None
recorded I None
. I None
<eof> I None

<s> O None
After I None
the I None
procedure I None
, I None
the I None
patient I None
was I None
asked I None
to I None
state I None
all I None
of I None
the I None
words I None
from I None
the I None
list I None
that I None
he I None
or I None
she I None
could I None
recall I None
, I None
and I None
to I None
identify I None
the I None
last I None
word I None
recalled I None
from I None
prior I None
to I None
the I None
start I None
of I None
the I None
procedure I None
and I None
the I None
first I None
word I None
recalled I None
from I None
after I None
the I None
procedure I None
was I None
completed I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
Seventy I None
- I None
five I None
consenting I None
patients I None
were I None
enrolled I None
; I None
one I None
patient I None
was I None
excluded I None
from I None
data I None
analysis I None
for I None
a I None
protocol I None
violation I None
. I None
<eof> I None

<s> O None
No I None
serious I None
adverse I None
events I None
were I None
noted I None
during I None
the I None
procedural I None
sedations I None
. I None
<eof> I None

<s> O None
The I None
mean I None
( I None
+ I None
/-standard I None
deviation I None
) I None
time I None
of I None
data I None
collection I None
was I None
16.4 I None
minutes I None
( I None
+ I None
/-7.1 I None
; I None
range I None
5 I None
to I None
34 I None
minutes I None
) I None
. I None
<eof> I None

<s> O None
The I None
mean I None
initial I None
( I None
preprocedure I None
) I None
<eof> I None

<s> O None
BIS I None
score I None
was I None
97.1 I None
( I None
+ I None
/-2.3 I None
; I None
range I None
92 I None
to I None
99 I None
) I None
. I None
<eof> I None

<s> O None
The I None
mean I None
lowest I None
BIS I None
score I None
occurring I None
during I None
these I None
procedural I None
sedations I None
was I None
66.9 I None
( I None
+ I None
/-14.4 I None
; I None
range I None
33 I None
to I None
91 I None
) I None
. I None
<eof> I None

<s> O None
The I None
mean I None
lowest I None
BIS I None
score I None
corresponding I None
to I None
the I None
ability I None
of I None
the I None
patient I None
to I None
immediately I None
repeat I None
words I None
read I None
from I None
the I None
list I None
was I None
77.1 I None
( I None
95 I None
% I None
CI I None
= I None
74.3 I None
to I None
80.0 I None
) I None
. I None
<eof> I None

<s> O None
The I None
mean I None
highest I None
BIS I None
score I None
corresponding I None
to I None
the I None
inability I Disease
to O Disease
repeat O Disease
words O Disease
was I None
81.5 I None
( I None
95 I None
% I None
CI I None
= I None
78.1 I None
to I None
84.8 I None
) I None
. I None
<eof> I None

<s> O None
The I None
mean I None
BIS I None
score I None
corresponding I None
to I None
the I None
last I None
word I None
recalled I None
from I None
prior I None
to I None
the I None
initiation I None
of I None
the I None
sedation I None
was I None
96.7 I None
( I None
+ I None
/-2.4 I None
; I None
range I None
84 I None
to I None
98 I None
) I None
. I None
<eof> I None

<s> O None
The I None
mean I None
BIS I None
score I None
corresponding I None
to I None
the I None
first I None
word I None
recalled I None
after I None
the I None
procedure I None
was I None
completed I None
was I None
91.2 I None
( I None
95 I None
% I None
CI I None
= I None
88.1 I None
to I None
94.3 I None
) I None
. I None
<eof> I None

<s> O None
All I None
patients I None
recalled I None
at I None
least I None
one I None
word I None
that I None
had I None
been I None
read I None
to I None
them I None
during I None
the I None
protocol I None
. I None
<eof> I None

<s> O None
The I None
mean I None
lowest I None
BIS I None
score I None
for I None
any I None
recalled I None
word I None
was I None
91.5 I None
( I None
+ I None
/-11.1 I None
; I None
range I None
79 I None
to I None
98 I None
) I None
, I None
and I None
no I None
words I None
were I None
recalled I None
when I None
the I None
corresponding I None
BIS I None
score I None
was I None
less I None
than I None
90 I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
There I None
is I None
a I None
range I None
of I None
BIS I None
scores I None
during I None
which I None
sedated I None
patients I None
are I None
able I None
to I None
repeat I None
words I None
read I None
to I None
them I None
but I None
are I None
not I None
able I None
to I None
subsequently I None
recall I None
these I None
words I None
. I None
<eof> I None

<s> O None
Furthermore I None
, I None
patients I None
had I None
no I None
recall I None
of I None
words I None
repeated I None
prior I None
to I None
procedural I None
sedation I None
in I None
BIS I None
ranges I None
associated I None
with I None
recall I None
after I None
procedural I None
sedation I None
, I None
suggestive I None
of I None
retrograde I Disease
amnesia O Disease
. I None
<eof> I None

<s> O None
Assessment I None
of I None
perinatal I None
hepatitis I Disease
B O Disease
and I None
rubella I Disease
prevention I None
in I None
New I None
Hampshire I None
delivery I None
hospitals I None
. I None
<eof> I None

<s> O None
OBJECTIVE I None
: I None
<eof> I None

<s> O None
To I None
evaluate I None
current I None
performance I None
on I None
recommended I None
perinatal I None
hepatitis I Disease
B O Disease
and I None
rubella I Disease
prevention I None
practices I None
in I None
New I None
Hampshire I None
. I None
<eof> I None

<s> O None
METHODS I None
: I None
Data I None
were I None
extracted I None
from I None
2021 I None
paired I None
mother I None
- I None
infant I None
records I None
for I None
the I None
year I None
2000 I None
birth I None
cohort I None
in I None
New I None
Hampshire I None
's I None
25 I None
delivery I None
hospitals I None
. I None
<eof> I None

<s> O None
Assessment I None
was I None
done I None
on I None
the I None
following I None
: I None
prenatal I None
screening I None
for I None
hepatitis I Disease
B O Disease
and I None
rubella I Disease
, I None
administration I None
of I None
the I None
hepatitis I Disease
B O Disease
vaccine I None
birth I None
dose I None
to I None
all I None
infants I None
, I None
administration I None
of I None
hepatitis I Disease
B O Disease
immune I None
globulin I None
to I None
infants I None
who I None
were I None
born I None
to I None
hepatitis I Chemical
B O Chemical
surface O Chemical
antigen O Chemical
-positive I None
mothers I None
, I None
rubella I Disease
immunity I None
, I None
and I None
administration I None
of I None
in I None
- I None
hospital I None
postpartum I None
rubella I Disease
vaccine I None
to I None
rubella I Disease
nonimmune I None
women I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
Prenatal I None
screening I None
rates I None
for I None
hepatitis I Disease
B O Disease
( I None
98.8 I None
% I None
) I None
and I None
rubella I Disease
( I None
99.4 I None
% I None
) I None
were I None
high I None
. I None
<eof> I None

<s> O None
Hepatitis I Disease
B O Disease
vaccine I None
birth I None
dose I None
was I None
administered I None
to I None
76.2 I None
% I None
of I None
all I None
infants I None
. I None
<eof> I None

<s> O None
All I None
infants I None
who I None
were I None
born I None
to I None
hepatitis I Chemical
B O Chemical
surface O Chemical
antigen O Chemical
-positive I None
mothers I None
also I None
received I None
hepatitis I Disease
B O Disease
immune I None
globulin I None
. I None
<eof> I None

<s> O None
Multivariate I None
logistic I None
regression I None
showed I None
that I None
the I None
month I None
of I None
delivery I None
and I None
infant I None
birth I None
weight I None
were I None
independent I None
predictors I None
of I None
hepatitis I Disease
B O Disease
vaccination I None
. I None
<eof> I None

<s> O None
The I None
proportion I None
of I None
infants I None
who I None
were I None
vaccinated I None
in I None
January I None
and I None
February I None
2000 I None
( I None
48.5 I None
% I None
and I None
67.5 I None
% I None
, I None
respectively I None
) I None
was I None
less I None
than I None
any I None
other I None
months I None
, I None
whereas I None
the I None
proportion I None
who I None
were I None
vaccinated I None
in I None
December I None
2000 I None
( I None
88.2 I None
% I None
) I None
was I None
the I None
highest I None
. I None
<eof> I None

<s> O None
Women I None
who I None
were I None
born I None
between I None
1971 I None
and I None
1975 I None
had I None
the I None
highest I None
rate I None
of I None
rubella I Disease
nonimmunity I None
( I None
9.5 I None
% I None
) I None
. I None
<eof> I None

<s> O None
In I None
- I None
hospital I None
postpartum I None
rubella I Disease
<eof> I None

<s> O None
vaccine I None
administration I None
was I None
documented I None
for I None
75.6 I None
% I None
of I None
nonimmune I None
women I None
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
<eof> I None

<s> O None
This I None
study I None
documents I None
good I None
compliance I None
in I None
New I None
Hampshire I None
's I None
birthing I None
hospitals I None
with I None
national I None
guidelines I None
for I None
perinatal I None
hepatitis I Disease
B O Disease
and I None
rubella I Disease
prevention I None
and I None
highlights I None
potential I None
areas I None
for I None
improvement I None
. I None
<eof> I None

<s> O None
Expression I None
of I None
p300 I None
protects I None
cardiac I None
myocytes I None
from I None
apoptosis I None
in I None
vivo I None
. I None
<eof> I None

<s> O None
Doxorubicin I Chemical
is I None
an I None
anti- I None
tumor I Disease
agent I None
that I None
represses I None
cardiac I None
- I None
specific I None
gene I None
expression I None
and I None
induces I None
myocardial I None
cell I None
apoptosis I None
. I None
<eof> I None

<s> O None
Doxorubicin I Chemical
depletes I None
cardiac I None
p300 I None
, I None
a I None
transcriptional I None
coactivator I None
that I None
is I None
required I None
for I None
the I None
maintenance I None
of I None
the I None
differentiated I None
phenotype I None
of I None
cardiac I None
myocytes I None
. I None
<eof> I None

<s> O None
However I None
, I None
the I None
role I None
of I None
p300 I None
in I None
protection I None
against I None
doxorubicin I Chemical
-induced I None
apoptosis I None
is I None
unknown I None
. I None
<eof> I None

<s> O None
Transgenic I None
mice I None
overexpressing I None
p300 I None
in I None
the I None
heart I None
and I None
wild I None
- I None
type I None
mice I None
were I None
subjected I None
to I None
doxorubicin I Chemical
treatment I None
. I None
<eof> I None

<s> O None
Compared I None
with I None
wild I None
- I None
type I None
mice I None
, I None
transgenic I None
mice I None
exhibited I None
higher I None
survival I None
rate I None
as I None
well I None
as I None
more I None
preserved I None
left I None
ventricular I None
function I None
and I None
cardiac I None
expression I None
of I None
alpha I None
- I None
sarcomeric I None
actin I None
. I None
<eof> I None

<s> O None
Doxorubicin I Chemical
induced I None
myocardial I None
cell I None
apoptosis I None
in I None
wild I None
- I None
type I None
mice I None
but I None
not I None
in I None
transgenic I None
mice I None
. I None
<eof> I None

<s> O None
Expression I None
of I None
p300 I None
increased I None
the I None
cardiac I None
level I None
of I None
bcl-2 I None
and I None
mdm-2 I None
, I None
but I None
not I None
that I None
of I None
p53 I None
or I None
other I None
members I None
of I None
the I None
bcl-2 I None
family I None
. I None
<eof> I None

<s> O None
These I None
findings I None
demonstrate I None
that I None
overexpression I None
of I None
p300 I None
protects I None
cardiac I None
myocytes I None
from I None
<eof> I None

<s> O None
doxorubicin I Chemical
-induced I None
apoptosis I None
and I None
reduces I None
the I None
extent I None
of I None
acute I None
heart I Disease
failure O Disease
in I None
adult I None
mice I None
in I None
vivo I None
. I None
<eof> I None

<s> O None
Mitochondrial I None
DNA I None
and I None
its I None
respiratory I None
chain I None
products I None
are I None
defective I None
in I None
doxorubicin I Chemical
nephrosis I Disease
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
<eof> I None

<s> O None
Doxorubicin I Chemical
induces I None
a I None
self I None
- I None
perpetuating I None
nephropathy I Disease
characterized I None
by I None
early I None
glomerular I Disease
and O Disease
late O Disease
- O Disease
onset O Disease
tubular O Disease
lesions O Disease
in I None
rats I None
. I None
<eof> I None

<s> O None
We I None
investigated I None
the I None
potential I None
role I None
of I None
mitochondrial I Disease
injury O Disease
in I None
the I None
onset I None
of I None
these I None
lesions I None
. I None
<eof> I None

<s> O None
METHODS I None
: I None
Rats I None
were I None
treated I None
with I None
intravenous I None
doxorubicin I Chemical
<eof> I None

<s> O None
( I None
1 I None
mg I None
kg(-1 I None
) I None
week(-1 I None
) I None
) I None
for I None
7 I None
weeks I None
and I None
were I None
sacrificed I None
either I None
1 I None
week I None
( I None
' I None
short I None
- I None
term I None
' I None
) I None
or I None
30 I None
weeks I None
( I None
' I None
long I None
- I None
term I None
' I None
) I None
following I None
the I None
last I None
dose I None
. I None
<eof> I None

<s> O None
Additional I None
rats I None
received I None
a I None
single I None
dose I None
either I None
6 I None
days I None
or I None
2 I None
h I None
prior I None
to I None
euthanasia I None
. I None
<eof> I None

<s> O None
All I None
rats I None
were I None
killed I None
at I None
48 I None
weeks I None
of I None
age I None
. I None
<eof> I None

<s> O None
Glomerular I Disease
and O Disease
tubular O Disease
injury O Disease
was I None
monitored I None
and I None
correlated I None
to I None
the I None
activity I None
or I None
expression I None
of I None
respiratory I None
chain I None
components I None
. I None
<eof> I None

<s> O None
Finally I None
, I None
we I None
quantified I None
both I None
nuclear I None
and I None
mitochondrial I None
DNA I None
( I None
mtDNA I None
) I None
as I None
well I None
as I None
superoxide I Chemical
production I None
and I None
the I None
4834 I None
base I None
pair I None
' I None
common I None
' I None
mtDNA I None
deletion I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
The I None
' I None
long I None
- I None
term I None
' I None
group I None
had I None
significant I None
glomerular I Disease
and O Disease
tubular O Disease
lesions O Disease
, I None
depressed I None
activities I None
of I None
mtDNA I None
- I None
encoded I None
NADH I None
dehydrogenase I None
and I None
cytochrome I None
- I None
c I None
oxidase I None
( I None
COX I None
) I None
and I None
increased I None
citrate I Chemical
synthase I None
activity I None
. I None
<eof> I None

<s> O None
In I None
addition I None
, I None
expression I None
of I None
the I None
mtDNA I None
- I None
encoded I None
COX I None
subunit I None
I I None
was I None
reduced I None
and I None
mtDNA I None
levels I None
were I None
decreased I None
. I None
<eof> I None

<s> O None
In I None
' I None
short I None
- I None
term I None
' I None
rats I None
, I None
there I None
were I None
fewer I None
tubular I Disease
lesions O Disease
, I None
but I None
similar I None
numbers I None
of I None
glomerular I Disease
lesions O Disease
activity I None
. I None
<eof> I None

<s> O None
Among I None
all I None
animals I None
, I None
glomerular I Disease
and O Disease
tubular O Disease
injury O Disease
were I None
inversely I None
correlated I None
with I None
mtDNA I None
levels I None
, I None
mtDNA I None
- I None
encoded I None
respiratory I None
chain I None
activities I None
and I None
with I None
the I None
expression I None
of I None
the I None
mtDNA I None
- I None
encoded I None
respiratory I None
chain I None
subunit I None
COX I None
- I None
I. I None
Injury I None
was I None
positively I None
correlated I None
with I None
superoxide I Chemical
production I None
and I None
the I None
activities I None
of I None
nucleus I None
- I None
encoded I None
mitochondrial I None
or I None
cytoplasmic I None
enzymes I None
. I None
<eof> I None

<s> O None
Kidneys I None
from I None
the I None
' I None
long I None
- I None
term I None
' I None
group I None
showed I None
more I None
mtDNA I None
deletions I None
than I None
in I None
' I None
short I None
- I None
term I None
' I None
animals I None
and I None
these I None
were I None
not I None
observed I None
in I None
the I None
other I None
groups I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
These I None
results I None
suggest I None
an I None
important I None
role I None
for I None
quantitative I None
and I None
qualitative I None
mtDNA I None
alterations I None
through I None
the I None
reduction I None
of I None
mtDNA I None
- I None
encoded I None
respiratory I None
chain I None
function I None
and I None
induction I None
of I None
superoxide I Chemical
in I None
doxorubicin I Chemical
-induced I None
<eof> I None

<s> O None
renal I Disease
lesions O Disease
. I None
<eof> I None

<s> O None
Amphotericin I Chemical
B O Chemical
-induced I None
seizures I Disease
in I None
a I None
patient I None
with I None
AIDS I Disease
. I None
<eof> I None

<s> O None
OBJECTIVE I None
: I None
<eof> I None

<s> O None
To I None
report I None
a I None
case I None
of I None
multiple I None
episodes I None
of I None
seizure I Disease
activity I None
in I None
an I None
AIDS I Disease
patent I None
following I None
amphotericin I Chemical
B O Chemical
infusion I None
. I None
<eof> I None

<s> O None
CASE I None
SUMMARY I None
: I None
<eof> I None

<s> O None
A I None
46-year I None
- I None
old I None
African I None
- I None
American I None
man I None
experienced I None
recurrent I None
grand I Disease
mal O Disease
seizures O Disease
during I None
intravenous I None
infusion I None
of I None
amphotericin I Chemical
B O Chemical
, I None
then I None
petit I None
mal I None
seizures I Disease
as I None
the I None
infusion I None
was I None
stopped I None
and I None
the I None
drug I None
concentrations I None
decreased I None
with I None
time I None
. I None
<eof> I None

<s> O None
The I None
patients I None
concurrent I None
medications I None
included I None
didanosine I Chemical
, I None
hydroxyzine I Chemical
, I None
promethazine I Chemical
, I None
hydrocortisone I Chemical
, I None
and I None
prochlorperazine I Chemical
. I None
<eof> I None

<s> O None
Despite I None
administration I None
of I None
phenytoin I Chemical
and I None
lorazepam I Chemical
, I None
the I None
seizures I Disease
persisted I None
and I None
occurred I None
only I None
during I None
amphotercin I Chemical
B O Chemical
administration I None
. I None
<eof> I None

<s> O None
DISCUSSION I None
: I None
<eof> I None

<s> O None
AIDS I Disease
and I None
cryptococcal I Disease
meningitis O Disease
, I None
both I None
of I None
which I None
the I None
patient I None
had I None
, I None
can I None
potentially I None
cause I None
seizures I Disease
. I None
<eof> I None

<s> O None
The I None
patient I None
had I None
a I None
history I None
of I None
alcohol I Disease
abuse O Disease
; I None
alcohol I Chemical
intake I None
as I None
well I None
as I None
withdrawal I None
can I None
also I None
cause I None
seizures I Disease
. I None
<eof> I None

<s> O None
Didanosine I Chemical
also I None
has I None
a I None
potential I None
for I None
inducing I None
seizures I Disease
. I None
<eof> I None

<s> O None
However I None
, I None
these I None
other I None
potential I None
causes I None
of I None
seizure I Disease
were I None
ruled I None
out I None
. I None
<eof> I None

<s> O None
The I None
time I None
course I None
of I None
events I None
suggested I None
that I None
amphotericin I Chemical
B O Chemical
was I None
the I None
cause I None
of I None
the I None
seizures I Disease
in I None
this I None
AIDS I Disease
patient I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
Amphotericin I Chemical
B O Chemical
seems I None
to I None
be I None
the I None
probable I None
cause I None
of I None
the I None
seizures I Disease
. I None
<eof> I None

<s> O None
To I None
date I None
, I None
only I None
three I None
cases I None
of I None
seizures I Disease
associated I None
with I None
amphotericin I Chemical
B O Chemical
have I None
been I None
reported I None
in I None
the I None
literature I None
, I None
but I None
healthcare I None
providers I None
should I None
be I None
aware I None
of I None
the I None
potential I None
for I None
this I None
rare I None
adverse I None
effect I None
. I None
<eof> I None

<s> O None
Therapeutic I None
drug I None
monitoring I None
of I None
tobramycin I Chemical
: I None
<eof> I None

<s> O None
once I None
- I None
daily I None
versus I None
twice I None
- I None
daily I None
dosage I None
schedules I None
. I None
<eof> I None

<s> O None
OBJECTIVE I None
: I None
<eof> I None

<s> O None
To I None
evaluate I None
the I None
effect I None
of I None
dosage I None
regimen I None
( I None
once I None
- I None
daily I None
vs. I None
twice I None
- I None
daily I None
) I None
of I None
<eof> I None

<s> O None
tobramicyn I Chemical
on I None
steady I None
- I None
state I None
serum I None
concentrations I None
and I None
toxicity I Disease
. I None
<eof> I None

<s> O None
MATERIALS I None
AND I None
METHODS I None
: I None
<eof> I None

<s> O None
Patients I None
undergoing I None
treatment I None
with I None
i.v I None
. I None
<eof> I None

<s> O None
tobramycin I Chemical
( I None
4 I None
mg I None
/ I None
kg I None
/ I None
day I None
) I None
were I None
randomised I None
to I None
two I None
groups I None
. I None
<eof> I None

<s> O None
Group I None
OD I None
( I None
n I None
= I None
22 I None
) I None
received I None
a I None
once I None
- I None
daily I None
dose I None
of I None
tobramycin I Chemical
and I None
group I None
TD I None
<eof> I None

<s> O None
( I None
n I None
= I None
21 I None
) I None
received I None
the I None
same I None
dose I None
divided I None
into I None
two I None
doses I None
daily I None
. I None
<eof> I None

<s> O None
Tobramycin I Chemical
serum I None
concentrations I None
( I None
peak I None
and I None
trough I None
) I None
were I None
measured I None
by I None
enzyme I None
multiplied I None
immunoassay I None
. I None
<eof> I None

<s> O None
The I None
renal I None
and I None
auditory I None
functions I None
of I None
the I None
patients I None
were I None
monitored I None
before I None
, I None
during I None
and I None
immediately I None
after I None
treatment I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
The I None
two I None
groups I None
were I None
comparable I None
with I None
respect I None
to I None
sex I None
, I None
age I None
, I None
body I None
weight I None
and I None
renal I None
function I None
. I None
<eof> I None

<s> O None
No I None
statistically I None
significant I None
differences I None
were I None
found I None
in I None
mean I None
daily I None
dose I None
, I None
duration I None
of I None
treatment I None
, I None
or I None
cumulative I None
dose I None
. I None
<eof> I None

<s> O None
Trough I None
concentrations I None
were I None
< I None
2 I None
g I None
/ I None
ml I None
in I None
the I None
two I None
groups I None
( I None
100 I None
% I None
) I None
. I None
<eof> I None

<s> O None
Peak I None
concentrations I None
were I None
> I None
6 I None
microg I None
/ I None
ml I None
in I None
100 I None
% I None
of I None
the I None
OD I None
group I None
and I None
in I None
67 I None
% I None
of I None
the I None
TD I None
group I None
( I None
P I None
< I None
0.01 I None
) I None
. I None
<eof> I None

<s> O None
Mean I None
peak I None
concentrations I None
were I None
markedly I None
different I None
: I None
<eof> I None

<s> O None
11.00+/-2.89 I None
microg I None
/ I None
ml I None
in I None
OD I None
vs. I None
6.53+/-1.45 I None
microg I None
/ I None
ml I None
in I None
TD I None
( I None
P I None
< I None
0.01 I None
) I None
. I None
<eof> I None

<s> O None
The I None
pharmacokinetics I None
parameters I None
were I None
: I None
Ke I None
, I None
( I None
0.15+/-0.03/h I None
in I None
OD I None
vs. I None
0.24+/-0.06/h I None
in I None
TD I None
) I None
, I None
t1/2 I None
, I None
( I None
4.95+/-1.41 I None
h I None
in I None
OD I None
vs. I None
3.07+/-0.71 I None
h I None
in I None
TD I None
) I None
, I None
Vd I None
( I None
0.35+/-0.11 I None
l I None
/ I None
kg I None
in I None
OD I None
vs. I None
0.33+/-0.09 I None
l I None
/ I None
kg I None
in I None
TD I None
) I None
, I None
Cl I None
<eof> I None

<s> O None
( I None
0.86+/-0.29 I None
ml I None
/ I None
min I None
/ I None
kg I None
in I None
OD I None
vs. I None
1.28+/-0.33 I None
ml I None
/ I None
min I None
/ I None
kg I None
in I None
TD I None
) I None
. I None
<eof> I None

<s> O None
Increased I None
serum I None
<eof> I None

<s> O None
creatinine I Chemical
was I None
observed I None
in I None
73 I None
% I None
of I None
patients I None
in I None
OD I None
versus I None
57 I None
% I None
of I None
patients I None
in I None
TD I None
, I None
without I None
evidence I None
of I None
nephrotoxicity I Disease
. I None
<eof> I None

<s> O None
In I None
TD I None
group I None
, I None
three I None
patients I None
developed I None
decreased I Disease
auditory O Disease
function O Disease
, I None
of I None
which I None
one I None
presented I None
with I None
an I None
auditory I Disease
loss O Disease
of I None
-30 I None
dB I None
, I None
whereas I None
in I None
the I None
OD I None
group I None
only I None
one I None
patient I None
presented I None
decreased I Disease
auditory O Disease
function O Disease
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
<eof> I None

<s> O None
This I None
small I None
study I None
suggests I None
that I None
a I None
once I None
- I None
daily I None
dosing I None
regimen I None
of I None
tobramycin I Chemical
is I None
at I None
least I None
as I None
effective I None
as I None
and I None
is I None
no I None
more I None
and I None
possibly I None
less I None
toxic I None
than I None
the I None
twice I None
- I None
daily I None
regimen I None
. I None
<eof> I None

<s> O None
Using I None
a I None
single I None
- I None
dose I None
therapy I None
, I None
peak I None
concentration I None
determination I None
is I None
not I None
necessary I None
, I None
only I None
trough I None
samples I None
should I None
be I None
monitored I None
to I None
ensure I None
levels I None
below I None
2 I None
microg I None
/ I None
ml I None
. I None
<eof> I None

<s> O None
Chronic I None
effects I None
of I None
a I None
novel I None
synthetic I None
anthracycline I Chemical
derivative I None
( I None
SM-5887 I Chemical
) I None
on I None
normal I None
heart I None
and I None
<eof> I None

<s> O None
doxorubicin I Chemical
-induced I None
<eof> I None

<s> O None
cardiomyopathy I Disease
in I None
beagle I None
dogs I None
. I None
<eof> I None

<s> O None
This I None
study I None
was I None
designed I None
to I None
investigate I None
the I None
chronic I None
cardiotoxic I Disease
potential I None
of I None
SM-5887 I Chemical
and I None
a I None
possible I None
deteriorating I None
effect I None
of I None
SM-5887 I Chemical
on I None
low I None
- I None
grade I None
cardiotoxicity I Disease
pre I None
- I None
induced I None
by I None
doxorubicin I Chemical
in I None
beagle I None
dogs I None
. I None
<eof> I None

<s> O None
In I None
the I None
chronic I None
treatment I None
, I None
beagle I None
dogs I None
of I None
each I None
sex I None
were I None
given I None
intravenously I None
once I None
every I None
3 I None
weeks I None
, I None
either I None
a I None
sublethal I None
dose I None
of I None
doxorubicin I Chemical
<eof> I None

<s> O None
( I None
1.5 I None
mg I None
/ I None
kg I None
) I None
or I None
SM-5887 I Chemical
( I None
2.5 I None
mg I None
/ I None
kg I None
) I None
. I None
<eof> I None

<s> O None
The I None
experiment I None
was I None
terminated I None
3 I None
weeks I None
after I None
the I None
ninth I None
dosing I None
. I None
<eof> I None

<s> O None
Animals I None
which I None
received I None
over I None
six I None
courses I None
of I None
doxorubicin I Chemical
demonstrated I None
the I None
electrocardiogram I None
( I None
ECG I None
) I None
changes I None
, I None
decrease I None
of I None
blood I None
pressure I None
and I None
high I None
- I None
grade I None
histopathological I None
cardiomyopathy I Disease
, I None
while I None
animals I None
which I None
were I None
terminally I None
sacrificed I None
after I None
the I None
SM-5887 I Chemical
administration I None
did I None
not I None
show I None
any I None
changes I None
in I None
ECG I None
, I None
blood I None
pressure I None
and I None
histopathological I None
examinations I None
. I None
<eof> I None

<s> O None
To I None
examine I None
a I None
possibly I None
deteriorating I None
cardiotoxic I Disease
effect I None
of I None
SM-5887 I Chemical
, I None
low I None
- I None
grade I None
<eof> I None

<s> O None
cardiomyopathy I Disease
was I None
induced I None
in I None
dogs I None
by I None
four I None
courses I None
of I None
doxorubicin I Chemical
<eof> I None

<s> O None
( I None
1.5 I None
mg I None
/ I None
kg I None
) I None
. I None
<eof> I None

<s> O None
Nine I None
weeks I None
after I None
pre I None
- I None
treatment I None
, I None
dogs I None
were I None
given I None
four I None
courses I None
of I None
either I None
doxorubicin I Chemical
<eof> I None

<s> O None
( I None
1.5 I None
mg I None
/ I None
kg I None
) I None
or I None
SM-5887 I Chemical
( I None
2.5 I None
mg I None
/ I None
kg I None
) I None
once I None
every I None
3 I None
weeks I None
. I None
<eof> I None

<s> O None
The I None
low I None
- I None
grade I None
cardiotoxic I Disease
changes I None
were I None
enhanced I None
by I None
the I None
additional I None
doxorubicin I Chemical
treatment I None
. I None
<eof> I None

<s> O None
On I None
the I None
contrary I None
, I None
the I None
SM-5887 I Chemical
treatment I None
did I None
not I None
progress I None
the I None
grade I None
of I None
cardiomyopathy I Disease
. I None
<eof> I None

<s> O None
In I None
conclusion I None
, I None
SM-5887 I Chemical
does I None
not I None
have I None
any I None
potential I None
of I None
chronic I None
cardiotoxicity I Disease
and I None
deteriorating I None
effect I None
on I None
doxorubicin I Chemical
-induced I None
<eof> I None

<s> O None
cardiotoxicity I Disease
in I None
dogs I None
. I None
<eof> I None

<s> O None
Posteroventral I None
medial I None
pallidotomy I None
in I None
advanced I None
Parkinson I Disease
's O Disease
disease O Disease
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
<eof> I None

<s> O None
Posteroventral I None
medial I None
pallidotomy I None
sometimes I None
produces I None
striking I None
improvement I None
in I None
patients I None
with I None
advanced I None
Parkinson I Disease
's O Disease
disease O Disease
, I None
but I None
the I None
studies I None
to I None
date I None
have I None
involved I None
small I None
numbers I None
of I None
patients I None
and I None
short I None
- I None
term I None
follow I None
- I None
up I None
. I None
<eof> I None

<s> O None
METHODS I None
: I None
<eof> I None

<s> O None
Forty I None
patients I None
with I None
Parkinson I Disease
's O Disease
disease O Disease
<eof> I None

<s> O None
underwent I None
serial I None
, I None
detailed I None
assessments I None
both I None
after I None
drug I None
withdrawal I None
( I None
" I None
off I None
" I None
period I None
) I None
and I None
while I None
taking I None
their I None
optimal I None
medical I None
regimens I None
( I None
" I None
on I None
" I None
period I None
) I None
. I None
<eof> I None

<s> O None
All I None
patients I None
were I None
examined I None
preoperatively I None
and I None
39 I None
were I None
examined I None
at I None
six I None
months I None
; I None
27 I None
of I None
the I None
patients I None
were I None
also I None
examined I None
at I None
one I None
year I None
, I None
and I None
11 I None
at I None
two I None
years I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
The I None
percent I None
improvements I None
at I None
six I None
months I None
were I None
as I None
follows I None
: I None
off I None
- I None
period I None
score I None
for I None
overall I None
motor I None
function I None
, I None
28 I None
percent I None
( I None
95 I None
percent I None
confidence I None
interval I None
, I None
19 I None
to I None
38 I None
percent I None
) I None
, I None
with I None
most I None
of I None
the I None
improvement I None
in I None
the I None
contralateral I None
limbs I None
; I None
off I None
- I None
period I None
score I None
for I None
activities I None
of I None
daily I None
living I None
, I None
29 I None
percent I None
( I None
95 I None
percent I None
confidence I None
interval I None
, I None
19 I None
to I None
39 I None
percent I None
) I None
; I None
on I None
- I None
period I None
score I None
for I None
contralateral I None
dyskinesias I Disease
, I None
82 I None
percent I None
( I None
95 I None
percent I None
confidence I None
interval I None
, I None
72 I None
to I None
91 I None
percent I None
) I None
; I None
and I None
on I None
- I None
period I None
score I None
for I None
ipsilateral I None
dyskinesias I Disease
, I None
44 I None
percent I None
( I None
95 I None
percent I None
confidence I None
interval I None
, I None
29 I None
to I None
59 I None
percent I None
) I None
. I None
<eof> I None

<s> O None
The I None
improvements I None
in I None
dyskinesias I Disease
and I None
the I None
total I None
scores I None
for I None
off I None
- I None
period I None
parkinsonism I Disease
, I None
contralateral I None
bradykinesia I Disease
, I None
and I None
rigidity I Disease
were I None
sustained I None
in I None
the I None
11 I None
patients I None
examined I None
at I None
two I None
years I None
. I None
<eof> I None

<s> O None
The I None
improvement I None
in I None
ipsilateral I None
dyskinesias I Disease
was I None
lost I None
after I None
one I None
year I None
, I None
and I None
the I None
improvements I None
in I None
postural I None
stability I None
and I None
gait I None
lasted I None
only I None
three I None
to I None
six I None
months I None
. I None
<eof> I None

<s> O None
Approximately I None
half I None
the I None
patients I None
who I None
had I None
been I None
dependent I None
on I None
assistance I None
in I None
activities I None
of I None
daily I None
living I None
in I None
the I None
off I None
period I None
before I None
surgery I None
became I None
independent I None
after I None
surgery I None
. I None
<eof> I None

<s> O None
The I None
complications I None
of I None
surgery I None
were I None
generally I None
well I None
tolerated I None
, I None
and I None
there I None
were I None
no I None
significant I None
changes I None
in I None
the I None
use I None
of I None
medication I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
In I None
late I None
- I None
stage I None
Parkinson I Disease
's O Disease
disease O Disease
, I None
pallidotomy I None
significantly I None
reduces I None
levodopa I Chemical
-induced I None
dyskinesias I Disease
and I None
off I None
- I None
period I None
disability I None
. I None
<eof> I None

<s> O None
Much I None
of I None
the I None
benefit I None
is I None
sustained I None
at I None
two I None
years I None
, I None
although I None
some I None
improvements I None
, I None
such I None
as I None
those I None
on I None
the I None
ipsilateral I None
side I None
and I None
in I None
axial I None
symptoms I None
, I None
wane I None
within I None
the I None
first I None
year I None
. I None
<eof> I None

<s> O None
The I None
on I None
- I None
period I None
symptoms I None
that I None
are I None
resistant I None
to I None
dopaminergic I None
therapy I None
do I None
not I None
respond I None
to I None
pallidotomy I None
. I None
<eof> I None

<s> O None
Neuropeptide I None
- I None
Y I None
immunoreactivity I None
in I None
the I None
pilocarpine I Chemical
model I None
of I None
temporal I Disease
lobe O Disease
epilepsy O Disease
. I None
<eof> I None

<s> O None
Neuropeptide I None
- I None
Y I None
( I None
NPY I None
) I None
is I None
expressed I None
by I None
granule I None
cells I None
and I None
mossy I None
fibres I None
of I None
the I None
hippocampal I None
dentate I None
gyrus I None
during I None
experimental I None
temporal I Disease
lobe O Disease
epilepsy O Disease
<eof> I None

<s> O None
( I None
TLE I Disease
) I None
. I None
<eof> I None

<s> O None
This I None
expression I None
may I None
represent I None
an I None
endogenous I None
damping I None
mechanism I None
since I None
NPY I None
has I None
been I None
shown I None
to I None
block I None
seizure I Disease
-like I None
events I None
following I None
high I None
- I None
frequency I None
stimulation I None
in I None
hippocampal I None
slices I None
. I None
<eof> I None

<s> O None
The I None
pilocarpine I Chemical
<eof> I None

<s> O None
( I None
PILO I Chemical
) I None
model I None
of I None
epilepsy I Disease
is I None
characterized I None
by I None
an I None
acute I None
period I None
of I None
status I Disease
epilepticus O Disease
followed I None
by I None
spontaneous I None
recurrent I None
seizures I Disease
and I None
related I None
brain I Disease
damage O Disease
. I None
<eof> I None

<s> O None
We I None
report I None
peroxidase I None
- I None
antiperoxidase I None
immunostaining I None
for I None
NPY I None
in I None
several I None
brain I None
regions I None
in I None
this I None
model I None
. I None
<eof> I None

<s> O None
PILO I Chemical
-injected I None
animals I None
exhibited I None
NPY I None
immunoreactivity I None
in I None
the I None
region I None
of I None
the I None
mossy I None
fibre I None
terminals I None
, I None
in I None
the I None
dentate I None
gyrus I None
inner I None
molecular I None
layer I None
and I None
, I None
in I None
a I None
few I None
cases I None
, I None
within I None
presumed I None
granule I None
cells I None
. I None
<eof> I None

<s> O None
NPY I None
immunoreactivity I None
was I None
also I None
dramatically I None
changed I None
in I None
the I None
entorhinal I None
cortex I None
, I None
amygdala I None
and I None
sensorimotor I None
areas I None
. I None
<eof> I None

<s> O None
In I None
addition I None
, I None
PILO I Chemical
injected I None
animals I None
exhibited I None
a I None
reduction I None
in I None
the I None
number I None
of I None
NPY I None
- I None
immunoreactive I None
interneurons I None
compared I None
with I None
controls I None
. I None
<eof> I None

<s> O None
The I None
results I None
demonstrate I None
that I None
changes I None
in I None
NPY I None
expression I None
, I None
including I None
expression I None
in I None
the I None
granule I None
cells I None
and I None
mossy I None
fibres I None
and I None
the I None
loss I None
of I None
vulnerable I None
NPY I None
neurons I None
, I None
are I None
present I None
in I None
the I None
PILO I Chemical
model I None
of I None
TLE I Disease
. I None
<eof> I None

<s> O None
However I None
, I None
the I None
significance I None
of I None
this I None
changed I None
synthesis I None
of I None
NPY I None
remains I None
to I None
be I None
determined I None
. I None
<eof> I None

<s> O None
Effect I None
of I None
myopic I None
excimer I None
laser I None
photorefractive I None
keratectomy I None
on I None
the I None
electrophysiologic I None
function I None
of I None
the I None
retina I None
and I None
optic I None
nerve I None
. I None
<eof> I None

<s> O None
PURPOSE I None
: I None
<eof> I None

<s> O None
To I None
assess I None
by I None
electrophysiologic I None
testing I None
the I None
effect I None
of I None
photorefractive I None
keratectomy I None
( I None
PRK I None
) I None
on I None
the I None
retina I None
and I None
optic I None
nerve I None
. I None
<eof> I None

<s> O None
SETTING I None
: I None
<eof> I None

<s> O None
Eye I None
Clinic I None
, I None
S. I None
Salvatore I None
Hospital I None
, I None
L'Aquila I None
University I None
, I None
Italy I None
. I None
<eof> I None

<s> O None
METHODS I None
: I None
<eof> I None

<s> O None
Standard I None
pattern I None
electroretinograms I None
( I None
P I None
- I None
ERGs I None
) I None
and I None
standard I None
pattern I None
visual I None
evoked I None
potentials I None
( I None
P I None
- I None
VEPs I None
) I None
were I None
done I None
in I None
25 I None
eyes I None
of I None
25 I None
patients I None
who I None
had I None
myopic I None
PRK I None
for I None
an I None
attempted I None
correction I None
between I None
5.00 I None
and I None
15.00 I None
diopters I None
( I None
D I None
) I None
<eof> I None

<s> O None
( I None
mean I None
8.00 I None
D I None
) I None
. I None
<eof> I None

<s> O None
Testing I None
was I None
done I None
preoperatively I None
and I None
3 I None
, I None
6 I None
, I None
12 I None
, I None
and I None
18 I None
months I None
postoperatively I None
. I None
<eof> I None

<s> O None
The I None
contralateral I None
eyes I None
served I None
as I None
controls I None
. I None
<eof> I None

<s> O None
During I None
the I None
follow I None
- I None
up I None
, I None
3 I None
patients I None
( I None
12 I None
% I None
) I None
developed I None
<eof> I None

<s> O None
steroid I Chemical
-induced I None
<eof> I None

<s> O None
elevated I Disease
intraocular O Disease
pressure O Disease
<eof> I None

<s> O None
( I None
IOP I None
) I None
that I None
resolved I None
after I None
corticosteroid I Chemical
<eof> I None

<s> O None
therapy I None
was I None
discontinued I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
No I None
statistically I None
significant I None
differences I None
were I None
seen I None
between I None
treated I None
and I None
control I None
eyes I None
nor I None
between I None
treated I None
eyes I None
preoperatively I None
and I None
postoperatively I None
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
<eof> I None

<s> O None
Myopic I None
excimer I None
laser I None
PRK I None
did I None
not I None
seem I None
to I None
affect I None
the I None
posterior I None
segment I None
. I None
<eof> I None

<s> O None
The I None
transient I None
steroid I Chemical
-induced I None
IOP I Disease
rise O Disease
did I None
not I None
seem I None
to I None
cause I None
functional I None
impairment I None
. I None
<eof> I None

<s> O None
Liposomal I None
daunorubicin I Chemical
in I None
advanced I None
Kaposi I Disease
's O Disease
sarcoma O Disease
: I None
a I None
phase I None
II I None
study I None
. I None
<eof> I None

<s> O None
We I None
report I None
a I None
non I None
- I None
randomized I None
Phase I None
II I None
clinical I None
trial I None
to I None
assess I None
the I None
efficacy I None
and I None
safety I None
of I None
liposomal I None
daunorubicin I Chemical
<eof> I None

<s> O None
( I None
DaunoXome I None
) I None
in I None
the I None
treatment I None
of I None
<eof> I None

<s> O None
AIDS I Disease
related I None
Kaposi I Disease
's O Disease
sarcoma O Disease
. I None
<eof> I None

<s> O None
Eleven I None
homosexual I None
men I None
with I None
advanced I None
Kaposi I Disease
's O Disease
sarcoma O Disease
were I None
entered I None
in I None
the I None
trial I None
. I None
<eof> I None

<s> O None
Changes I None
in I None
size I None
, I None
colour I None
and I None
associated I None
oedema I Disease
of I None
selected I None
' I None
target I None
' I None
lesions I None
were I None
measured I None
. I None
<eof> I None

<s> O None
Clinical I None
, I None
biochemical I None
and I None
haematological I None
toxicities I Disease
were I None
assessed I None
. I None
<eof> I None

<s> O None
Ten I None
subjects I None
were I None
evaluated I None
. I None
<eof> I None

<s> O None
A I None
partial I None
response I None
was I None
achieved I None
in I None
four I None
, I None
of I None
whom I None
two I None
subsequently I None
relapsed I None
. I None
<eof> I None

<s> O None
Stabilization I None
of I None
Kaposi I Disease
's O Disease
sarcoma O Disease
occurred I None
in I None
the I None
remaining I None
six I None
, I None
maintained I None
until I None
the I None
end I None
of I None
the I None
trial I None
period I None
in I None
four I None
. I None
<eof> I None

<s> O None
The I None
drug I None
was I None
generally I None
well I None
tolerated I None
, I None
with I None
few I None
mild I None
symptoms I None
of I None
toxicity I Disease
. I None
<eof> I None

<s> O None
The I None
main I None
problem I None
encountered I None
was I None
haematological I None
toxicity I Disease
, I None
with I None
three I None
subjects I None
experiencing I None
severe I None
neutropenia I Disease
<eof> I None

<s> O None
( I None
neutrophil I None
count I None
< I None
0.5 I None
x I None
10(9)/l I None
) I None
. I None
<eof> I None

<s> O None
There I None
was I None
no I None
evidence I None
of I None
cardiotoxicity I Disease
. I None
<eof> I None

<s> O None
In I None
this I None
small I None
patient I None
sample I None
, I None
liposomal I None
daunorubicin I Chemical
was I None
an I None
effective I None
and I None
well I None
tolerated I None
agent I None
in I None
the I None
treatment I None
of I None
Kaposi I Disease
's O Disease
sarcoma O Disease
. I None
<eof> I None

<s> O None
Failure I None
of I None
ancrod I None
in I None
the I None
treatment I None
of I None
heparin I Chemical
-induced I None
arterial I None
thrombosis I Disease
. I None
<eof> I None

<s> O None
The I None
morbidity I None
and I None
mortality I None
associated I None
with I None
<eof> I None

<s> O None
heparin I Chemical
-induced I None
<eof> I None

<s> O None
thrombosis I Disease
remain I None
high I None
despite I None
numerous I None
empirical I None
therapies I None
. I None
<eof> I None

<s> O None
Ancrod I None
has I None
been I None
used I None
successfully I None
for I None
prophylaxis I None
against I None
development I None
of I None
thrombosis I Disease
in I None
patients I None
with I None
heparin I Chemical
induced I None
platelet I Disease
aggregation O Disease
who I None
require I None
brief I None
reexposure I None
to I None
heparin I Chemical
, I None
but I None
its I None
success I None
in I None
patients I None
who I None
have I None
developed I None
the I None
thrombosis I Disease
syndrome I None
is I None
not I None
well I None
defined I None
. I None
<eof> I None

<s> O None
The I None
authors I None
present I None
a I None
case I None
of I None
failure I None
of I None
ancrod I None
treatment I None
in I None
a I None
patient I None
with I None
heparin I Chemical
-induced I None
thrombosis I Disease
. I None
<eof> I None

<s> O None
Seizure I Disease
after I None
flumazenil I Chemical
administration I None
in I None
a I None
pediatric I None
patient I None
. I None
<eof> I None

<s> O None
Flumazenil I Chemical
is I None
a I None
benzodiazepine I Chemical
receptor I None
antagonist I None
used I None
to I None
reverse I None
sedation I None
and I None
respiratory I Disease
depression O Disease
induced I None
by I None
benzodiazepines I Chemical
. I None
<eof> I None

<s> O None
Seizures I Disease
and I None
cardiac I Disease
arrhythmias O Disease
have I None
complicated I None
its I None
use I None
in I None
adult I None
patients I None
. I None
<eof> I None

<s> O None
Overdose I Disease
patients I None
who I None
have I None
coingested I None
tricyclic I None
antidepressants I None
have I None
a I None
higher I None
risk I None
of I None
these I None
complications I None
. I None
<eof> I None

<s> O None
Little I None
information I None
exists I None
concerning I None
adverse I None
effects I None
of I None
flumazenil I Chemical
in I None
children I None
. I None
<eof> I None

<s> O None
We I None
report I None
the I None
occurrence I None
of I None
a I None
generalized I None
tonic I Disease
- O Disease
clonic O Disease
seizure O Disease
in I None
a I None
pediatric I None
patient I None
following I None
the I None
administration I None
of I None
flumazenil I Chemical
. I None
<eof> I None

<s> O None
Remodelling I None
of I None
nerve I None
structure I None
in I None
experimental I None
isoniazid I Chemical
neuropathy I Disease
in I None
the I None
rat I None
. I None
<eof> I None

<s> O None
The I None
neuropathy I Disease
<eof> I None

<s> O None
caused I None
by I None
a I None
single I None
dose I None
of I None
isoniazid I Chemical
in I None
rats I None
was I None
studied I None
with I None
a I None
computer I None
- I None
assisted I None
morphometric I None
method I None
. I None
<eof> I None

<s> O None
Scatter I None
diagrams I None
of I None
the I None
g I None
ratio I None
( I None
quotient I None
fibre I None
diameter I None
/ I None
axon I None
diameter I None
) I None
define I None
regenerating I None
fibres I None
as I None
a I None
distinct I None
population I None
, I None
distinguishable I None
from I None
the I None
surviving I None
fibres I None
by I None
reduced I None
sheath I None
thickness I None
and I None
reduced I None
axon I None
calibre I None
. I None
<eof> I None

<s> O None
There I None
was I None
also I None
evidence I None
of I None
a I None
subtle I None
direct I None
toxic I None
effect I None
on I None
the I None
entire I None
fibre I None
population I None
, I None
causing I None
axon I None
shrinkage I None
masked I None
by I None
readjustment I None
of I None
the I None
myelin I None
sheath I None
. I None
<eof> I None

<s> O None
Selective I None
injection I None
of I None
iopentol I Chemical
, I None
iohexol I Chemical
and I None
metrizoate I Chemical
into I None
the I None
left I None
coronary I None
artery I None
of I None
the I None
dog I None
. I None
<eof> I None

<s> O None
Induction I None
of I None
ventricular I Disease
fibrillation O Disease
and I None
decrease I None
of I None
aortic I None
pressure I None
. I None
<eof> I None

<s> O None
In I None
twenty I None
beagle I None
dogs I None
selective I None
injections I None
were I None
made I None
into I None
the I None
left I None
coronary I None
artery I None
with I None
iopentol I Chemical
, I None
<eof> I None

<s> O None
iohexol I Chemical
and I None
metrizoate I Chemical
in I None
doses I None
of I None
4 I None
ml I None
, I None
8 I None
ml I None
and I None
16 I None
ml I None
. I None
<eof> I None

<s> O None
Thirty I None
- I None
six I None
<eof> I None

<s> O None
iopentol I Chemical
injections I None
, I None
35 I None
iohexol I Chemical
injections I None
and I None
37 I None
metrizoate I Chemical
injections I None
were I None
made I None
. I None
<eof> I None

<s> O None
Frequencies I None
of I None
ventricular I Disease
fibrillation O Disease
were I None
significantly I None
lower I None
( I None
p I None
less I None
than I None
0.05 I None
) I None
after I None
iopentol I Chemical
( I None
0 I None
% I None
) I None
and I None
iohexol I Chemical
( I None
3 I None
% I None
) I None
than I None
after I None
metrizoate I Chemical
( I None
22 I None
% I None
) I None
. I None
<eof> I None

<s> O None
Iopentol I Chemical
and I None
iohexol I Chemical
also I None
produced I None
significantly I None
less I None
decrease I None
in I None
aortic I None
blood I None
pressure I None
than I None
metrizoate I Chemical
at I None
the I None
different I None
doses I None
. I None
<eof> I None

<s> O None
Magnetic I None
resonance I None
imaging I None
of I None
cerebral I None
venous I Disease
thrombosis O Disease
secondary I None
to I None
" I None
low I None
- I None
dose I None
" I None
birth I None
control I None
pills I None
. I None
<eof> I None

<s> O None
The I None
clinical I None
and I None
radiographic I None
features I None
of I None
cerebral I None
deep I Disease
venous O Disease
thrombosis O Disease
in I None
a I None
21-year I None
- I None
old I None
white I None
woman I None
are I None
presented I None
. I None
<eof> I None

<s> O None
This I None
nulliparous I None
patient I None
presented I None
with I None
relatively I None
mild I None
clinical I None
symptoms I None
and I None
progressing I None
mental I None
status I None
changes I None
. I None
<eof> I None

<s> O None
The I None
only I None
known I None
risk I None
factor I None
was I None
" I None
low I None
- I None
dose I None
" I None
oral I Chemical
contraceptive O Chemical
pills I None
. I None
<eof> I None

<s> O None
The I None
magnetic I None
resonance I None
image I None
( I None
MRI I None
) I None
showed I None
increased I None
signal I None
intensity I None
from I None
the I None
internal I None
cerebral I None
veins I None
, I None
vein I None
of I None
Galen I None
, I None
and I None
straight I None
sinus I None
. I None
<eof> I None

<s> O None
The I None
diagnosis I None
was I None
confirmed I None
by I None
arterial I None
angiography I None
. I None
<eof> I None

<s> O None
Relation I None
of I None
perfusion I None
defects I None
observed I None
with I None
myocardial I None
contrast I None
echocardiography I None
to I None
the I None
severity I None
of I None
coronary I Disease
stenosis O Disease
: I None
correlation I None
with I None
thallium I Chemical
-201 I None
single I None
- I None
photon I None
emission I None
tomography I None
. I None
<eof> I None

<s> O None
It I None
has I None
been I None
previously I None
shown I None
that I None
myocardial I None
contrast I None
echocardiography I None
is I None
a I None
valuable I None
technique I None
for I None
delineating I None
regions I None
of I None
myocardial I None
underperfusion I None
secondary I None
to I None
coronary I Disease
occlusion O Disease
and I None
to I None
critical I None
coronary I Disease
stenoses O Disease
in I None
the I None
presence I None
of I None
hyperemic I Disease
stimulation I None
. I None
<eof> I None

<s> O None
The I None
aim I None
of I None
this I None
study I None
was I None
to I None
determine I None
whether I None
myocardial I None
contrast I None
echocardiography I None
performed I None
with I None
a I None
stable I None
solution I None
of I None
sonicated I None
albumin I None
could I None
detect I None
regions I None
of I None
myocardial I None
underperfusion I None
resulting I None
from I None
various I None
degrees I None
of I None
coronary I Disease
stenosis O Disease
. I None
<eof> I None

<s> O None
The I None
perfusion I None
defect I None
produced I None
in I None
16 I None
open I None
chest I None
dogs I None
was I None
compared I None
with I None
the I None
anatomic I None
area I None
at I None
risk I None
measured I None
by I None
the I None
postmortem I None
dual I None
- I None
perfusion I None
technique I None
and I None
with I None
thallium I Chemical
-201 I None
single I None
- I None
photon I None
emission I None
tomography I None
( I None
SPECT I None
) I None
. I None
<eof> I None

<s> O None
During I None
a I None
transient I None
( I None
20-s I None
) I None
coronary I Disease
occlusion O Disease
, I None
a I None
perfusion I None
defect I None
was I None
observed I None
with I None
contrast I None
echocardiography I None
in I None
14 I None
of I None
the I None
15 I None
dogs I None
in I None
which I None
the I None
occlusion I None
was I None
produced I None
. I None
<eof> I None

<s> O None
The I None
perfusion I None
defect I None
correlated I None
significantly I None
with I None
the I None
anatomic I None
area I None
at I None
risk I None
( I None
r I None
= I None
0.74 I None
; I None
p I None
less I None
than I None
0.002 I None
) I None
. I None
<eof> I None

<s> O None
During I None
dipyridamole I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
hyperemia I Disease
, I None
12 I None
of I None
the I None
16 I None
dogs I None
with I None
a I None
partial I None
coronary I Disease
stenosis O Disease
had I None
a I None
visible I None
area I None
of I None
hypoperfusion I None
by I None
contrast I None
echocardiography I None
. I None
<eof> I None

<s> O None
The I None
four I None
dogs I None
without I None
a I None
perfusion I None
defect I None
had I None
a I None
stenosis I None
that I None
resulted I None
in I None
a I None
mild I None
( I None
0 I None
% I None
to I None
50 I None
% I None
) I None
reduction I None
in I None
dipyridamole I Chemical
-induced I None
hyperemia I Disease
. I None
<eof> I None

<s> O None
The I None
size I None
of I None
the I None
perfusion I None
defect I None
during I None
stenosis I None
correlated I None
significantly I None
with I None
the I None
anatomic I None
area I None
at I None
risk I None
( I None
r I None
= I None
0.61 I None
; I None
p I None
= I None
0.02 I None
) I None
. I None
<eof> I None

<s> O None
Thallium I Chemical
-201 I None
SPECT I None
demonstrated I None
a I None
perfusion I None
defect I None
in I None
all I None
14 I None
dogs I None
analyzed I None
during I None
dipyridamole I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
hyperemia I Disease
; I None
the I None
size I None
of I None
the I None
perfusion I None
defect I None
correlated I None
with I None
the I None
anatomic I None
area I None
at I None
risk I None
( I None
r I None
= I None
0.58 I None
; I None
p I None
less I None
than I None
0.03 I None
) I None
and I None
with I None
the I None
perfusion I None
defect I None
by I None
contrast I None
echocardiography I None
( I None
r I None
= I None
0.58 I None
; I None
p I None
less I None
than I None
0.03 I None
) I None
. I None
<eof> I None

<s> O None
Thus I None
, I None
myocardial I None
contrast I None
echocardiography I None
can I None
be I None
used I None
to I None
visualize I None
and I None
quantitate I None
the I None
amount I None
of I None
jeopardized I None
myocardium I None
during I None
moderate I None
to I None
severe I None
degrees I None
of I None
coronary I Disease
stenosis O Disease
. I None
<eof> I None

<s> O None
The I None
results I None
obtained I None
show I None
a I None
correlation I None
with I None
the I None
anatomic I None
area I None
at I None
risk I None
similar I None
to I None
that I None
obtained I None
with I None
<eof> I None

<s> O None
thallium I Chemical
-201 I None
SPECT I None
. I None
<eof> I None

<s> O None
Potential I None
deleterious I None
effect I None
of I None
furosemide I Chemical
in I None
radiocontrast I None
nephropathy I Disease
. I None
<eof> I None

<s> O None
The I None
purpose I None
of I None
the I None
study I None
was I None
to I None
determine I None
the I None
efficacy I None
of I None
furosemide I Chemical
in I None
addition I None
to I None
intravenous I None
fluids I None
in I None
the I None
prevention I None
of I None
radiocontrast I None
nephropathy I Disease
. I None
<eof> I None

<s> O None
18 I None
patients I None
, I None
referred I None
to I None
a I None
radiocontrast I None
study I None
, I None
considered I None
at I None
risk I None
because I None
of I None
preexisting I None
renal I Disease
insufficiency O Disease
, I None
were I None
enrolled I None
in I None
a I None
prospective I None
, I None
randomized I None
, I None
controlled I None
trial I None
, I None
performed I None
at I None
the I None
secondary I None
care I None
center I None
of I None
a I None
1,100-bed I None
private I None
university I None
hospital I None
. I None
<eof> I None

<s> O None
In I None
addition I None
to I None
fluids I None
, I None
the I None
treatment I None
group I None
received I None
furosemide I Chemical
<eof> I None

<s> O None
( I None
mean I None
dose I None
110 I None
mg I None
) I None
<eof> I None

<s> O None
intravenously I None
30 I None
min I None
prior I None
to I None
the I None
injection I None
of I None
contrast I None
material I None
. I None
<eof> I None

<s> O None
The I None
control I None
group I None
received I None
fluids I None
( I None
mean I None
3 I None
liters I None
) I None
. I None
<eof> I None

<s> O None
Radiological I None
studies I None
were I None
mostly I None
angiographies I None
performed I None
with I None
both I None
ionic I None
and I None
non I None
- I None
ionic I None
contrast I None
material I None
, I None
at I None
an I None
average I None
dose I None
of I None
245 I None
ml I None
. I None
<eof> I None

<s> O None
Renal I Disease
function O Disease
significantly O Disease
deteriorated O Disease
in I None
the I None
group I None
pretreated I None
with I None
furosemide I Chemical
<eof> I None

<s> O None
( I None
p I None
< I None
0.005 I None
by I None
ANOVA I None
) I None
, I None
with I None
a I None
rise I None
in I None
serum I None
creatinine I Chemical
from I None
145 I None
+ I None
/- I None
13 I None
to I None
182 I None
+ I None
/- I None
<eof> I None

<s> O None
16 I None
mumol I None
/ I None
l I None
at I None
24 I None
h I None
, I None
while I None
no I None
change I None
occurred I None
in I None
the I None
control I None
group I None
( I None
from I None
141 I None
+ I None
/- I None
6 I None
to I None
142 I None
+ I None
/- I None
7 I None
mumol I None
/ I None
l I None
) I None
. I None
<eof> I None

<s> O None
Renal I Disease
failure O Disease
was I None
associated I None
with I None
weight I Disease
loss O Disease
in I None
the I None
furosemide I Chemical
-treated I None
group I None
. I None
<eof> I None

<s> O None
Furosemide I Chemical
may I None
be I None
deleterious I None
in I None
the I None
prevention I None
of I None
radiocontrast I None
nephropathy I Disease
. I None
<eof> I None

<s> O None
The I None
renal I None
pathology I None
in I None
a I None
case I None
of I None
lithium I Chemical
-induced I None
diabetes I Disease
insipidus O Disease
. I None
<eof> I None

<s> O None
A I None
case I None
of I None
lithium I Chemical
-induced I None
diabetes I Disease
insipidus O Disease
is I None
reported I None
. I None
<eof> I None

<s> O None
At I None
necropsy I None
microscopy I None
shoed I None
unique I None
and I None
extensive I None
damage I None
to I None
cells I None
lining I None
the I None
distal I None
nephron I None
. I None
<eof> I None

<s> O None
It I None
is I None
suggested I None
that I None
these I None
changes I None
represent I None
a I None
specific I None
toxic I None
effect I None
of I None
lithium I Chemical
, I None
reported I None
here I None
for I None
the I None
first I None
time I None
in I None
man I None
. I None
<eof> I None

<s> O None
Etiologic I None
factors I None
in I None
the I None
pathogenesis I None
of I None
liver I Disease
tumors O Disease
associated I None
with I None
oral I Chemical
contraceptives O Chemical
. I None
<eof> I None

<s> O None
Within I None
the I None
last I None
several I None
years I None
, I None
previously I None
rare I None
liver I Disease
tumors O Disease
have I None
been I None
seen I None
in I None
young I None
women I None
using I None
oral I Chemical
contraceptive O Chemical
steroids I Chemical
. I None
<eof> I None

<s> O None
The I None
Registry I None
for I None
Liver I Disease
Tumors O Disease
<eof> I None

<s> O None
Associated I None
with I None
Oral I Chemical
Contraceptives O Chemical
at I None
the I None
University I None
of I None
California I None
, I None
Irvine I None
, I None
has I None
clearly I None
identified I None
27 I None
cases I None
. I None
<eof> I None

<s> O None
The I None
recent I None
literature I None
contains I None
44 I None
case I None
reports I None
. I None
<eof> I None

<s> O None
Common I None
to I None
these I None
71 I None
cases I None
has I None
been I None
a I None
histopathologic I None
diagnosis I None
of I None
focal I Disease
nodular O Disease
hyperplasia O Disease
, I None
adenoma I Disease
, I None
hamartoma I Disease
, I None
and I None
hepatoma I Disease
. I None
<eof> I None

<s> O None
Significant I None
statistical I None
etiologic I None
factors I None
include I None
prolonged I None
uninterrupted I None
usage I None
of I None
oral I Chemical
contraceptive O Chemical
steroids I Chemical
. I None
<eof> I None

<s> O None
Eight I None
deaths I None
and I None
liver I None
rupture I Disease
in I None
18 I None
patients I None
attest I None
to I None
the I None
seriousness I None
of I None
this I None
new I None
potentially I None
lethal I None
adverse I None
phenomenon I None
. I None
<eof> I None

<s> O None
Graft I Disease
- O Disease
versus O Disease
- O Disease
host O Disease
disease O Disease
prophylaxis I None
with I None
everolimus I Chemical
and I None
tacrolimus I Chemical
is I None
associated I None
with I None
a I None
high I None
incidence I None
of I None
sinusoidal I Disease
obstruction O Disease
syndrome O Disease
and I None
microangiopathy I Disease
: I None
results I None
of I None
the I None
EVTAC I None
trial I None
. I None
<eof> I None

<s> O None
A I None
calcineurin I None
inhibitor I None
combined I None
with I None
methotrexate I Chemical
is I None
the I None
standard I None
prophylaxis I None
for I None
graft I Disease
- O Disease
versus O Disease
- O Disease
host O Disease
disease O Disease
<eof> I None

<s> O None
( I None
GVHD I Disease
) I None
after I None
allogeneic I None
hematopoietic I None
stem I None
cell I None
transplantation I None
( I None
HSCT I None
) I None
. I None
<eof> I None

<s> O None
Everolimus I Chemical
, I None
a I None
derivative I None
of I None
sirolimus I Chemical
, I None
seems I None
to I None
mediate I None
antileukemia I None
effects I None
. I None
<eof> I None

<s> O None
We I None
report I None
on I None
a I None
combination I None
of I None
everolimus I Chemical
and I None
tacrolimus I Chemical
in I None
24 I None
patients I None
( I None
median I None
age I None
, I None
62 I None
years I None
) I None
with I None
either I None
myelodysplastic I Disease
syndrome O Disease
<eof> I None

<s> O None
( I None
MDS I Disease
; I None
n I None
= I None
17 I None
) I None
or I None
acute I Disease
myeloid O Disease
leukemia O Disease
( I None
AML I Disease
; I None
n I None
= I None
7 I None
) I None
undergoing I None
intensive I None
conditioning I None
followed I None
by I None
HSCT I None
from I None
related I None
( I None
n I None
= I None
4 I None
) I None
or I None
unrelated I None
( I None
n I None
= I None
20 I None
) I None
donors I None
. I None
<eof> I None

<s> O None
All I None
patients I None
engrafted I None
, I None
and I None
only I None
1 I None
patient I None
experienced I None
grade I None
IV I None
mucositis I Disease
. I None
<eof> I None

<s> O None
Nine I None
patients I None
( I None
37 I None
% I None
) I None
developed I None
acute I None
grade I None
II I None
- I None
IV I None
GVHD I Disease
, I None
and I None
11 I None
of I None
17 I None
evaluable I None
patients I None
( I None
64 I None
% I None
) I None
developed I None
chronic I None
extensive I None
GVHD I Disease
. I None
<eof> I None

<s> O None
Transplantation I Disease
- O Disease
associated O Disease
microangiopathy O Disease
<eof> I None

<s> O None
( I None
TMA I Disease
) I None
occurred I None
in I None
7 I None
patients I None
( I None
29 I None
% I None
) I None
, I None
with I None
2 I None
cases I None
of I None
acute I Disease
renal O Disease
failure O Disease
. I None
<eof> I None

<s> O None
The I None
study I None
was I None
terminated I None
prematurely I None
because I None
an I None
additional I None
6 I None
patients I None
( I None
25 I None
% I None
) I None
developed I None
sinusoidal I Disease
obstruction O Disease
syndrome O Disease
<eof> I None

<s> O None
( I None
SOS I Disease
) I None
, I None
which I None
was I None
fatal I None
in I None
2 I None
cases I None
. I None
<eof> I None

<s> O None
With I None
a I None
median I None
follow I None
- I None
up I None
of I None
26 I None
months I None
, I None
the I None
2-year I None
overall I None
survival I None
rate I None
was I None
47 I None
% I None
. I None
<eof> I None

<s> O None
Although I None
this I None
new I None
combination I None
appears I None
to I None
be I None
effective I None
as I None
a I None
prophylactic I None
regimen I None
for I None
acute I None
GVHD I Disease
, I None
the I None
incidence I None
of I None
TMA I Disease
and I None
SOS I Disease
is I None
considerably I None
higher I None
than I None
seen I None
with I None
other I None
regimens I None
. I None
<eof> I None

<s> O None
Effect I None
of I None
some I None
convulsants I None
on I None
the I None
protective I None
activity I None
of I None
loreclezole I Chemical
and I None
its I None
combinations I None
with I None
valproate I Chemical
or I None
clonazepam I Chemical
in I None
amygdala I None
- I None
kindled I None
rats I None
. I None
<eof> I None

<s> O None
Loreclezole I Chemical
( I None
5 I None
mg I None
/ I None
kg I None
) I None
exerted I None
a I None
significant I None
protective I None
action I None
in I None
amygdala I None
- I None
kindled I None
rats I None
, I None
reducing I None
both I None
seizure I Disease
and I None
afterdischarge I None
durations I None
. I None
<eof> I None

<s> O None
The I None
combinations I None
of I None
loreclezole I Chemical
( I None
2.5 I None
mg I None
/ I None
kg I None
) I None
with I None
valproate I Chemical
, I None
clonazepam I Chemical
, I None
or I None
carbamazepine I Chemical
( I None
applied I None
at I None
their I None
subprotective I None
doses I None
) I None
also I None
exhibited I None
antiseizure I None
effect I None
in I None
this I None
test I None
. I None
<eof> I None

<s> O None
However I None
, I None
only I None
two I None
first I None
combinations I None
occurred I None
to I None
be I None
of I None
pharmacodynamic I None
nature I None
. I None
<eof> I None

<s> O None
Among I None
several I None
chemoconvulsants I None
, I None
bicuculline I Chemical
, I None
<eof> I None

<s> O None
N I Chemical
- O Chemical
methyl O Chemical
- O Chemical
D O Chemical
- O Chemical
aspartic O Chemical
acid O Chemical
and I None
BAY I Chemical
k-8644 O Chemical
( I None
the I None
opener I None
of I None
L I None
- I None
type I None
calcium I Chemical
channels I None
) I None
reversed I None
the I None
protective I None
activity I None
of I None
loreclezole I Chemical
alone I None
and I None
its I None
combination I None
with I None
valproate I Chemical
. I None
<eof> I None

<s> O None
On I None
the I None
other I None
hand I None
, I None
bicuculline I Chemical
, I None
aminophylline I Chemical
and I None
BAY I Chemical
k-8644 O Chemical
inhibited I None
the I None
anticonvulsive I None
action I None
of I None
loreclezole I Chemical
combined I None
with I None
clonazepam I Chemical
. I None
<eof> I None

<s> O None
The I None
results I None
support I None
the I None
hypothesis I None
that I None
the I None
protective I None
activity I None
of I None
loreclezole I Chemical
and I None
its I None
combinations I None
with I None
other I None
antiepileptics I None
may I None
involve I None
potentiation I None
of I None
GABAergic I None
neurotransmission I None
and I None
blockade I None
of I None
L I None
- I None
type I None
of I None
calcium I Chemical
channels I None
. I None
<eof> I None

<s> O None
Acute I Disease
liver O Disease
failure O Disease
with I None
concurrent I None
bupropion I Chemical
and I None
carbimazole I Chemical
therapy I None
. I None
<eof> I None

<s> O None
OBJECTIVE I None
: I None
<eof> I None

<s> O None
To I None
report I None
a I None
case I None
of I None
fatal I None
liver I Disease
failure O Disease
possibly I None
associated I None
with I None
concurrent I None
use I None
of I None
bupropion I Chemical
and I None
carbimazole I Chemical
. I None
<eof> I None

<s> O None
CASE I None
SUMMARY I None
: I None
<eof> I None

<s> O None
A I None
41-year I None
- I None
old I None
Chinese I None
man I None
with I None
a I None
history I None
of I None
hyperthyroidism I Disease
had I None
been I None
treated I None
with I None
carbimazole I Chemical
and I None
propranolol I Chemical
for I None
the I None
past I None
5 I None
years I None
. I None
<eof> I None

<s> O None
He I None
received I None
a I None
10-day I None
course I None
of I None
bupropion I Chemical
as I None
an I None
aid I None
for I None
smoking I None
cessation I None
10 I None
weeks I None
prior I None
to I None
presentation I None
. I None
<eof> I None

<s> O None
He I None
developed I None
acute I Disease
liver O Disease
failure O Disease
with I None
rapid I None
deterioration I None
of I None
renal I None
function I None
. I None
<eof> I None

<s> O None
Liver I None
biopsy I None
showed I None
evidence I None
of I None
nonspecific I None
drug I Disease
- O Disease
induced O Disease
acute O Disease
liver O Disease
injury O Disease
. I None
<eof> I None

<s> O None
His I None
condition I None
was I None
further I None
complicated I None
by I None
sepsis I Disease
and I None
coagulopathy I Disease
. I None
<eof> I None

<s> O None
Death I None
resulted I None
19 I None
days I None
after I None
the I None
onset I None
of I None
symptoms I None
. I None
<eof> I None

<s> O None
The I None
likelihood I None
that I None
bupropion I Chemical
induced I None
hepatotoxicity I Disease
in I None
our I None
patient I None
was I None
possible I None
, I None
based I None
on I None
the I None
Naranjo I None
probability I None
scale I None
. I None
<eof> I None

<s> O None
DISCUSSION I None
: I None
<eof> I None

<s> O None
Although I None
there I None
is I None
increasing I None
evidence I None
of I None
hepatotoxicity I Disease
induced I None
by I None
bupropion I Chemical
, I None
this I None
is I None
the I None
first I None
case I None
of I None
fatality I None
that I None
could I None
have I None
resulted I None
from I None
acute I Disease
liver O Disease
failure O Disease
in I None
a I None
patient I None
receiving I None
bupropion I Chemical
while I None
on I None
concomitant I None
treatment I None
with I None
carbimazole I Chemical
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
Clinicians I None
should I None
be I None
aware I None
of I None
the I None
possibility I None
of I None
acute I Disease
liver O Disease
insult O Disease
induced I None
by I None
bupropion I Chemical
given I None
concurrently I None
with I None
other I None
hepatotoxic I Disease
drugs I None
. I None
<eof> I None

<s> O None
Long I None
term I None
hormone I None
therapy I None
for I None
perimenopausal I None
and I None
postmenopausal I None
women I None
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
<eof> I None

<s> O None
Hormone I None
therapy I None
( I None
HT I None
) I None
is I None
widely I None
used I None
for I None
controlling I None
menopausal I None
symptoms I None
and I None
has I None
also I None
been I None
used I None
for I None
the I None
management I None
and I None
prevention I None
of I None
cardiovascular I Disease
disease O Disease
, I None
osteoporosis I Disease
and I None
dementia I Disease
in I None
older I None
women I None
. I None
<eof> I None

<s> O None
This I None
is I None
an I None
updated I None
version I None
of I None
the I None
original I None
Cochrane I None
review I None
first I None
published I None
in I None
2005 I None
. I None
<eof> I None

<s> O None
OBJECTIVES I None
: I None
<eof> I None

<s> O None
To I None
assess I None
the I None
effect I None
of I None
long I None
- I None
term I None
HT I None
on I None
mortality I None
, I None
cardiovascular I None
outcomes I None
, I None
cancer I Disease
, I None
gallbladder I Disease
disease O Disease
, I None
cognition I None
, I None
fractures I Disease
and I None
quality I None
of I None
life I None
. I None
<eof> I None

<s> O None
SEARCH I None
STRATEGY I None
: I None
<eof> I None

<s> O None
We I None
searched I None
the I None
following I None
databases I None
to I None
November I None
2007 I None
: I None
Trials I None
Register I None
of I None
the I None
Cochrane I None
Menstrual I Disease
Disorders O Disease
and I None
Subfertility I None
Group I None
, I None
Cochrane I None
Central I None
Register I None
of I None
Controlled I None
Trials I None
, I None
MEDLINE I None
, I None
EMBASE I None
, I None
Biological I None
Abstracts I None
. I None
<eof> I None

<s> O None
Also I None
relevant I None
non I None
- I None
indexed I None
journals I None
and I None
conference I None
abstracts I None
. I None
<eof> I None

<s> O None
SELECTION I None
CRITERIA I None
: I None
<eof> I None

<s> O None
Randomised I None
double I None
- I None
blind I None
trials I None
of I None
HT I None
versus I None
placebo I None
, I None
taken I None
for I None
at I None
least I None
one I None
year I None
by I None
perimenopausal I None
or I None
postmenopausal I None
women I None
. I None
<eof> I None

<s> O None
HT I None
included I None
oestrogens I Chemical
, I None
with I None
or I None
without I None
progestogens I Chemical
, I None
via I None
oral I None
, I None
transdermal I None
, I None
subcutaneous I None
or I None
transnasal I None
routes I None
. I None
<eof> I None

<s> O None
DATA I None
COLLECTION I None
AND I None
ANALYSIS I None
: I None
<eof> I None

<s> O None
Two I None
authors I None
independently I None
assessed I None
trial I None
quality I None
and I None
extracted I None
data I None
. I None
<eof> I None

<s> O None
MAIN I None
RESULTS I None
: I None
<eof> I None

<s> O None
Nineteen I None
trials I None
involving I None
41,904 I None
women I None
were I None
included I None
. I None
<eof> I None

<s> O None
In I None
relatively I None
healthy I None
women I None
, I None
combined I None
continuous I None
HT I None
significantly I None
increased I None
the I None
risk I None
of I None
venous I Disease
thrombo O Disease
- O Disease
embolism O Disease
or I None
coronary I None
event I None
( I None
after I None
one I None
year I None
's I None
use I None
) I None
, I None
stroke I Disease
<eof> I None

<s> O None
( I None
after I None
three I None
years I None
) I None
, I None
<eof> I None

<s> O None
breast I Disease
cancer O Disease
and I None
gallbladder I Disease
disease O Disease
. I None
<eof> I None

<s> O None
Long I None
- I None
term I None
<eof> I None

<s> O None
oestrogen I Chemical
<eof> I None

<s> O None
-only I None
<eof> I None

<s> O None
HT I None
significantly I None
increased I None
the I None
risk I None
of I None
venous I Disease
thrombo O Disease
- O Disease
embolism O Disease
, I None
stroke I Disease
and I None
gallbladder I Disease
disease O Disease
( I None
after I None
one I None
to I None
two I None
years I None
, I None
three I None
years I None
and I None
seven I None
years I None
' I None
use I None
respectively I None
) I None
, I None
but I None
did I None
not I None
significantly I None
increase I None
the I None
risk I None
of I None
breast I Disease
cancer O Disease
. I None
<eof> I None

<s> O None
The I None
only I None
statistically I None
significant I None
benefits I None
of I None
HT I None
were I None
a I None
decreased I None
incidence I None
of I None
fractures I Disease
and I None
( I None
for I None
combined I None
HT I None
) I None
<eof> I None

<s> O None
colon I Disease
cancer O Disease
, I None
with I None
long I None
- I None
term I None
use I None
. I None
<eof> I None

<s> O None
Among I None
women I None
aged I None
over I None
65 I None
who I None
were I None
relatively I None
healthy I None
( I None
i.e. I None
generally I None
fit I None
, I None
without I None
overt I None
disease I None
) I None
and I None
taking I None
continuous I None
combined I None
HT I None
, I None
there I None
was I None
a I None
statistically I None
significant I None
increase I None
in I None
the I None
incidence I None
of I None
dementia I Disease
. I None
<eof> I None

<s> O None
Among I None
women I None
with I None
cardiovascular I Disease
disease O Disease
, I None
long I None
- I None
term I None
use I None
of I None
combined I None
continuous I None
HT I None
significantly I None
increased I None
the I None
risk I None
of I None
venous I Disease
thrombo O Disease
- O Disease
embolism O Disease
<eof> I None

<s> O None
.One I None
<eof> I None

<s> O None
trial I None
analysed I None
subgroups I None
of I None
2839 I None
relatively I None
healthy I None
50 I None
to I None
59 I None
year I None
old I None
women I None
taking I None
combined I None
continuous I None
HT I None
and I None
1637 I None
taking I None
oestrogen I Chemical
<eof> I None

<s> O None
-only I None
<eof> I None

<s> O None
HT I None
, I None
versus I None
similar I None
- I None
sized I None
placebo I None
groups I None
. I None
<eof> I None

<s> O None
The I None
only I None
significantly I None
increased I None
risk I None
reported I None
was I None
for I None
venous I Disease
thrombo O Disease
- O Disease
embolism O Disease
in I None
women I None
taking I None
combined I None
continuous I None
HT I None
: I None
their I None
absolute I None
risk I None
remained I None
low I None
, I None
at I None
less I None
than I None
1/500 I None
. I None
<eof> I None

<s> O None
However I None
, I None
this I None
study I None
was I None
not I None
powered I None
to I None
detect I None
differences I None
between I None
groups I None
of I None
younger I None
women I None
. I None
<eof> I None

<s> O None
AUTHORS I None
' I None
CONCLUSIONS I None
: I None
HT I None
is I None
not I None
indicated I None
for I None
the I None
routine I None
management I None
of I None
chronic I None
disease I None
. I None
<eof> I None

<s> O None
We I None
need I None
more I None
evidence I None
on I None
the I None
safety I None
of I None
HT I None
for I None
menopausal I None
symptom I None
control I None
, I None
though I None
short I None
- I None
term I None
use I None
appears I None
to I None
be I None
relatively I None
safe I None
for I None
healthy I None
younger I None
women I None
. I None
<eof> I None

<s> O None
Passage I None
of I None
mannitol I Chemical
into I None
the I None
brain I None
around I None
gliomas I Disease
: I None
a I None
potential I None
cause I None
of I None
rebound I None
phenomenon I None
. I None
<eof> I None

<s> O None
A I None
study I None
on I None
21 I None
patients I None
. I None
<eof> I None

<s> O None
AIM I None
: I None
Widespread I None
use I None
of I None
mannitol I Chemical
to I None
reduce I None
brain I Disease
edema O Disease
and I None
lower I None
elevated I Disease
ICP O Disease
in I None
<eof> I None

<s> O None
brain I Disease
tumor O Disease
patients I None
continues I None
to I None
be I None
afflicted I None
by I None
the I None
so I None
- I None
called I None
rebound I None
phenomenon I None
. I None
<eof> I None

<s> O None
Leakage I None
of I None
mannitol I Chemical
into I None
the I None
brain I None
parenchyma I None
through I None
an I None
altered I None
BBB I None
and I None
secondary I None
reversal I None
of I None
osmotic I None
gradient I None
is I None
considered I None
the I None
major I None
cause I None
of I None
rebound I None
. I None
<eof> I None

<s> O None
This I None
has I None
only I None
been I None
demonstrated I None
experimentally I None
in I None
animals I None
. I None
<eof> I None

<s> O None
As I None
a I None
contribution I None
to I None
this I None
issue I None
we I None
decided I None
to I None
research I None
the I None
possible I None
passage I None
of I None
mannitol I Chemical
into I None
the I None
brain I None
after I None
administration I None
to I None
21 I None
<eof> I None

<s> O None
brain I Disease
tumor O Disease
patients I None
. I None
<eof> I None

<s> O None
METHODS I None
: I None
Mannitol I Chemical
<eof> I None

<s> O None
( I None
18 I None
% I None
solution I None
; I None
1 I None
g I None
/ I None
kg I None
) I None
was I None
administered I None
as I None
a I None
bolus I None
to I None
patients I None
( I None
ten I None
had I None
malignant I Disease
glioma O Disease
, I None
seven I None
brain I None
metastases I Disease
and I None
four I None
meningioma I Disease
) I None
about I None
30 I None
minutes I None
before I None
craniotomy I None
. I None
<eof> I None

<s> O None
During I None
resection I None
, I None
a I None
sample I None
of I None
the I None
surrounding I None
edematous I Disease
<eof> I None

<s> O None
white I None
matter I None
was I None
taken I None
at I None
the I None
same I None
time I None
as I None
a I None
10 I None
ml I None
venous I None
blood I None
sample I None
. I None
<eof> I None

<s> O None
Mannitol I Chemical
concentrations I None
were I None
measured I None
in I None
plasma I None
and I None
white I None
matter I None
by I None
a I None
modified I None
version I None
of I None
the I None
enzyme I None
assay I None
of I None
Blonquist I None
et I None
al I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
In I None
most I None
glioma I Disease
patients I None
, I None
mannitol I Chemical
concentrations I None
in I None
white I None
matter I None
were I None
2 I None
to I None
6 I None
times I None
higher I None
than I None
in I None
plasma I None
( I None
mean I None
3.5 I None
times I None
) I None
. I None
<eof> I None

<s> O None
In I None
meningioma I Disease
and I None
metastases I Disease
patients I None
plasma I None
concentrations I None
of I None
mannitol I Chemical
were I None
higher I None
than I None
white I None
matter I None
concentrations I None
except I None
in I None
three I None
cases I None
with I None
infiltration I None
by I None
neoplastic I None
cells I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
The I None
results I None
of I None
our I None
study I None
show I None
that I None
even I None
after I None
a I None
single I None
bolus I None
, I None
mannitol I Chemical
may I None
leak I None
through I None
the I None
altered I None
BBB I None
near I None
gliomas I Disease
, I None
reversing I None
the I None
initial I None
plasma I None
- I None
to I None
- I None
blood I None
osmotic I None
gradient I None
, I None
aggravating I None
peritumoral I None
edema I Disease
and I None
promoting I None
rebound I None
of I None
ICP I None
. I None
<eof> I None

<s> O None
Can I None
lidocaine I Chemical
reduce I None
<eof> I None

<s> O None
succinylcholine I Chemical
induced I None
<eof> I None

<s> O None
postoperative I Disease
myalgia O Disease
? I None
<eof> I None

<s> O None
This I None
study I None
was I None
undertaken I None
to I None
determine I None
the I None
effect I None
of I None
lidocaine I Chemical
pretreatment I None
on I None
reduction I None
of I None
succinylcholine I Chemical
-induced I None
<eof> I None

<s> O None
myalgia I Disease
in I None
patients I None
undergoing I None
general I None
anesthesia I None
for I None
gynecological I None
surgery I None
. I None
<eof> I None

<s> O None
One I None
hundred I None
and I None
thirty I None
- I None
five I None
patients I None
were I None
assigned I None
to I None
one I None
of I None
three I None
groups I None
in I None
a I None
prospective I None
, I None
double I None
blind I None
, I None
randomized I None
manner I None
. I None
<eof> I None

<s> O None
Group I None
PS I None
, I None
the I None
control I None
group I None
, I None
received I None
normal I None
saline I None
and I None
succinylcholine I Chemical
1.5 I None
mg I None
x I None
kg(-1 I None
) I None
; I None
Group I None
LS I None
, I None
lidocaine I Chemical
1.5 I None
mg I None
x I None
kg(-1 I None
) I None
and I None
succinylcholine I Chemical
1.5 I None
mg I None
x I None
kg(-1 I None
) I None
; I None
Group I None
PR I None
, I None
normal I None
saline I None
and I None
rocuronium I Chemical
0.6 I None
mg I None
x I None
kg(-1 I None
) I None
. I None
<eof> I None

<s> O None
Morphine I Chemical
0.1 I None
mg I None
x I None
kg(-1 I None
<eof> I None

<s> O None
) I None
iv I None
was I None
given I None
for I None
premedication I None
and I None
all I None
patients I None
were I None
monitored I None
with I None
a I None
noninvasive I None
blood I None
pressure I None
monitor I None
, I None
ECG I None
and I None
pulse I None
oximetry I None
. I None
<eof> I None

<s> O None
Anesthesia I None
was I None
induced I None
with I None
5 I None
mg.kg(-1 I None
) I None
<eof> I None

<s> O None
thiopental I Chemical
iv I None
. I None
followed I None
by I None
succinylcholine I Chemical
<eof> I None

<s> O None
( I None
Group I None
PS I None
, I None
LS I None
) I None
or I None
rocuronium I Chemical
( I None
Group I None
PR I None
) I None
for I None
tracheal I None
intubation I None
. I None
<eof> I None

<s> O None
Following I None
administration I None
of I None
these I None
agents I None
, I None
the I None
presence I None
, I None
and I None
degree I None
of I None
fasciculation I Disease
were I None
assessed I None
visually I None
on I None
a I None
four I None
point I None
scale I None
by I None
one I None
investigator I None
who I None
was I None
blinded I None
to I None
the I None
drug I None
administered I None
. I None
<eof> I None

<s> O None
The I None
blood I None
pressure I None
and I None
heart I None
rate I None
of I None
each I None
patient I None
were I None
monitored I None
on I None
nine I None
occasions I None
. I None
<eof> I None

<s> O None
Twenty I None
- I None
four I None
hours I None
later I None
, I None
any I None
myalgia I Disease
experienced I None
was I None
assessed I None
according I None
to I None
a I None
structured I None
questionaire I None
and I None
graded I None
by I None
a I None
four I None
point I None
scale I None
by I None
one I None
investigator I None
blinded I None
to I None
the I None
intraoperative I None
management I None
. I None
<eof> I None

<s> O None
The I None
results I None
indicate I None
that I None
muscle I Disease
fasciculation O Disease
was I None
not I None
found I None
in I None
Group I None
PR I None
while I None
the I None
patients I None
in I None
Group I None
LS I None
had I None
a I None
lower I None
incidence I None
of I None
muscle I Disease
fasciculation O Disease
than I None
those I None
in I None
Group I None
PS I None
( I None
p I None
< I None
0.001 I None
) I None
. I None
<eof> I None

<s> O None
At I None
24 I None
h I None
, I None
the I None
incidence I None
of I None
myalgia I Disease
was I None
higher I None
in I None
Group I None
PS I None
than I None
in I None
Group I None
LS I None
and I None
PR I None
( I None
p I None
< I None
0.05 I None
) I None
. I None
<eof> I None

<s> O None
A I None
correlation I None
was I None
not I None
found I None
between I None
the I None
incidence I None
of I None
myalgia I Disease
and I None
the I None
occurrence I None
of I None
muscle I Disease
fasciculation O Disease
. I None
<eof> I None

<s> O None
The I None
changes I None
in I None
systolic I None
and I None
diastolic I None
blood I None
pressure I None
and I None
heart I None
rate I None
were I None
not I None
significant I None
among I None
the I None
three I None
groups I None
. I None
<eof> I None

<s> O None
In I None
conclusion I None
, I None
where I None
succinylcholine I Chemical
is I None
used I None
, I None
lidocaine I Chemical
is I None
proven I None
to I None
be I None
the I None
useful I None
pretreatment I None
agent I None
for I None
the I None
reduction I None
of I None
postoperative I Disease
myalgia O Disease
. I None
<eof> I None

<s> O None
Open I None
- I None
label I None
assessment I None
of I None
levofloxacin I Chemical
for I None
the I None
treatment I None
of I None
acute I None
bacterial I None
sinusitis I Disease
in I None
adults I None
. I None
<eof> I None

<s> O None
PURPOSE I None
: I None
To I None
evaluate I None
the I None
efficacy I None
and I None
safety I None
of I None
levofloxacin I Chemical
<eof> I None

<s> O None
( I None
500 I None
mg I None
orally I None
once I None
daily I None
for I None
10 I None
to I None
14 I None
days I None
) I None
in I None
treating I None
adult I None
outpatients I None
with I None
acute I None
bacterial I None
sinusitis I Disease
. I None
<eof> I None

<s> O None
PATIENTS I None
AND I None
METHODS I None
: I None
<eof> I None

<s> O None
A I None
total I None
of I None
329 I None
patients I None
enrolled I None
in I None
the I None
study I None
at I None
24 I None
centers I None
. I None
<eof> I None

<s> O None
All I None
patients I None
had I None
a I None
pre I None
- I None
therapy I None
Gram I None
's I None
stain I None
and I None
culture I None
of I None
sinus I None
exudate I None
obtained I None
by I None
antral I None
puncture I None
or I None
nasal I None
endoscopy I None
. I None
<eof> I None

<s> O None
Clinical I None
response I None
was I None
assessed I None
on I None
the I None
basis I None
of I None
signs I None
and I None
symptoms I None
and I None
sinus I None
radiograph I None
or I None
computed I None
tomography I None
results I None
. I None
<eof> I None

<s> O None
Microbiologic I None
cure I None
rates I None
were I None
determined I None
on I None
the I None
basis I None
of I None
presumed I None
plus I None
documented I None
eradication I None
of I None
the I None
pre I None
- I None
therapy I None
pathogen(s I None
) I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
The I None
most I None
common I None
pathogens I None
were I None
Haemophilus I None
influenzae I None
, I None
Streptococcus I None
pneumoniae I None
, I None
Staphylococcus I None
aureus I None
, I None
and I None
Moraxella I None
catarrhalis I None
. I None
<eof> I None

<s> O None
Of I None
300 I None
clinically I None
evaluable I None
patients I None
, I None
175 I None
( I None
58 I None
% I None
) I None
were I None
cured I None
and I None
90 I None
( I None
30 I None
% I None
) I None
were I None
improved I None
at I None
the I None
post I None
- I None
therapy I None
evaluation I None
, I None
resulting I None
in I None
a I None
clinical I None
success I None
rate I None
of I None
88 I None
% I None
. I None
<eof> I None

<s> O None
Thirty I None
- I None
five I None
patients I None
( I None
12 I None
% I None
) I None
clinically I None
failed I None
treatment I None
. I None
<eof> I None

<s> O None
The I None
microbiologic I None
eradication I None
rate I None
( I None
presumed I None
plus I None
documented I None
) I None
among I None
138 I None
microbiologically I None
evaluable I None
patients I None
was I None
92 I None
% I None
. I None
<eof> I None

<s> O None
Microbiologic I None
eradication I None
rates I None
( I None
presumed I None
plus I None
documented I None
) I None
of I None
the I None
most I None
common I None
pathogens I None
ranged I None
from I None
93 I None
% I None
( I None
M. I None
catarrhalis I None
) I None
to I None
100 I None
% I None
( I None
S. I None
pneumoniae I None
) I None
at I None
the I None
post I None
- I None
therapy I None
visit I None
. I None
<eof> I None

<s> O None
All I None
but I None
one I None
of I None
the I None
265 I None
patients I None
who I None
were I None
cured I None
or I None
improved I None
at I None
post I None
- I None
therapy I None
returned I None
for I None
a I None
long I None
- I None
term I None
follow I None
- I None
up I None
visit I None
; I None
243 I None
( I None
92 I None
% I None
) I None
remained I None
well I None
4 I None
to I None
6 I None
weeks I None
after I None
therapy I None
; I None
and I None
21 I None
( I None
8 I None
% I None
) I None
had I None
a I None
relapse I None
of I None
symptoms I None
. I None
<eof> I None

<s> O None
Adverse I None
events I None
considered I None
to I None
be I None
related I None
to I None
levofloxacin I Chemical
administration I None
were I None
reported I None
by I None
29 I None
patients I None
( I None
9 I None
% I None
) I None
. I None
<eof> I None

<s> O None
The I None
most I None
common I None
drug I None
- I None
related I None
adverse I None
events I None
were I None
diarrhea I Disease
, I None
flatulence I Disease
, I None
and I None
nausea I Disease
; I None
most I None
adverse I None
events I None
were I None
mild I None
to I None
moderate I None
in I None
severity I None
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
<eof> I None

<s> O None
The I None
results I None
of I None
this I None
study I None
indicate I None
that I None
levofloxacin I Chemical
500 I None
mg I None
once I None
daily I None
is I None
an I None
effective I None
and I None
safe I None
treatment I None
for I None
acute I None
bacterial I None
sinusitis I Disease
. I None
<eof> I None

<s> O None
Clinical I None
evaluation I None
on I None
combined I None
administration I None
of I None
oral I None
prostacyclin I Chemical
analogue I None
<eof> I None

<s> O None
beraprost I Chemical
and I None
phosphodiesterase I None
inhibitor I None
cilostazol I Chemical
. I None
<eof> I None

<s> O None
Among I None
various I None
oral I None
antiplatelets I None
, I None
a I None
combination I None
of I None
a I None
novel I None
prostacyclin I Chemical
analogue I None
beraprost I Chemical
<eof> I None

<s> O None
( I None
BPT I Chemical
) I None
and I None
a I None
potent I None
phosphodiesterase I None
inhibitor I None
cilostazol I Chemical
<eof> I None

<s> O None
( I None
CLZ I Chemical
) I None
may I None
result I None
in I None
untoward I None
clinical I None
effects I None
due I None
to I None
possible I None
synergistic I None
elevation I None
of I None
intracellular I None
cAMP I Chemical
<eof> I None

<s> O None
( I None
cyclic I Chemical
adenosine O Chemical
3',5'-monophosphate O Chemical
) I None
. I None
<eof> I None

<s> O None
Thereby I None
, I None
a I None
clinical I None
study I None
of I None
the I None
combined I None
administration I None
of I None
the I None
two I None
agents I None
was I None
attempted I None
. I None
<eof> I None

<s> O None
Twelve I None
healthy I None
volunteers I None
were I None
assigned I None
to I None
take I None
BPT I Chemical
/ I None
CLZ I Chemical
in I None
the I None
following I None
schedule I None
; I None
BPT I Chemical
: I None
40 I None
micrograms I None
at I None
day I None
1 I None
and I None
120 I None
micrograms I None
t.i.d I None
. I None
<eof> I None

<s> O None
from I None
day I None
7 I None
to I None
14 I None
, I None
CLZ I Chemical
: I None
200 I None
mg I None
t.i.d I None
. I None
<eof> I None

<s> O None
from I None
day I None
3 I None
to I None
14 I None
. I None
<eof> I None

<s> O None
At I None
various I None
time I None
intervals I None
, I None
physical I None
examination I None
and I None
blood I None
collection I None
for I None
ex I None
vivo I None
platelet I Disease
aggregation O Disease
and I None
determination I None
of I None
intraplatelet I None
cAMP I Chemical
were I None
performed I None
. I None
<eof> I None

<s> O None
Throughout I None
the I None
observation I None
period I None
, I None
no I None
significant I None
alteration I None
in I None
vital I None
signs I None
was I None
observed I None
. I None
<eof> I None

<s> O None
Seven I None
out I None
of I None
12 I None
subjects I None
experienced I None
headache I Disease
of I None
a I None
short I None
duration I None
accompanying I None
facial I Disease
flush O Disease
in I None
one I None
and I None
nausea I Disease
in I None
one I None
, I None
especially I None
after I None
ingestion I None
of I None
CLZ I Chemical
. I None
<eof> I None

<s> O None
All I None
of I None
these I None
symptoms I None
, I None
probably I None
caused I None
by I None
the I None
vasodilating I None
effect I None
of I None
the I None
two I None
agents I None
, I None
were I None
of I None
mild I None
degree I None
and I None
no I None
special I None
treatment I None
was I None
required I None
. I None
<eof> I None

<s> O None
Intraplatelet I None
cAMP I Chemical
content I None
was I None
gradually I None
but I None
significantly I None
increased I None
to I None
9.84 I None
+ I None
/- I None
<eof> I None

<s> O None
4.59 I None
pmol I None
per I None
10(9 I None
) I None
platelets I None
at I None
day I None
14 I None
in I None
comparison I None
with I None
the I None
initial I None
value I None
( I None
6.87 I None
+ I None
/- I None
<eof> I None

<s> O None
2.25 I None
pmol I None
) I None
. I None
<eof> I None

<s> O None
The I None
platelet I None
aggregability I None
was I None
significantly I None
suppressed I None
at I None
various I None
time I None
intervals I None
but I None
no I None
additive I None
or I None
synergistic I None
inhibitory I None
effect I None
by I None
the I None
combined I None
administration I None
was I None
noted I None
. I None
<eof> I None

<s> O None
In I None
conclusion I None
, I None
the I None
combined I None
administration I None
of I None
BPT I Chemical
/ I None
CLZ I Chemical
is I None
safe I None
at I None
doses I None
used I None
in I None
the I None
study I None
, I None
though I None
the I None
beneficial I None
clinical I None
effect I None
of I None
the I None
combined I None
administration I None
has I None
yet I None
to I None
be I None
elucidated I None
. I None
<eof> I None

<s> O None
Gastrointestinal I None
tolerability I None
of I None
etoricoxib I Chemical
in I None
rheumatoid I Disease
arthritis O Disease
patients I None
: I None
results I None
of I None
the I None
etoricoxib I Chemical
vs I None
diclofenac I Chemical
sodium O Chemical
gastrointestinal I None
tolerability I None
and I None
effectiveness I None
trial I None
( I None
EDGE I None
- I None
II I None
) I None
. I None
<eof> I None

<s> O None
OBJECTIVE I None
: I None
<eof> I None

<s> O None
A I None
randomised I None
, I None
double I None
- I None
blind I None
study I None
to I None
compare I None
the I None
gastrointestinal I None
( I None
GI I None
) I None
tolerability I None
, I None
safety I None
and I None
efficacy I None
of I None
etoricoxib I Chemical
and I None
diclofenac I Chemical
in I None
patients I None
with I None
rheumatoid I Disease
arthritis O Disease
<eof> I None

<s> O None
( I None
RA I Disease
) I None
. I None
<eof> I None

<s> O None
PATIENTS I None
AND I None
METHODS I None
: I None
<eof> I None

<s> O None
A I None
total I None
of I None
4086 I None
patients I None
( I None
mean I None
age I None
60.8 I None
years I None
) I None
diagnosed I None
with I None
RA I Disease
were I None
enrolled I None
and I None
received I None
etoricoxib I Chemical
<eof> I None

<s> O None
90 I None
mg I None
daily I None
( I None
n I None
= I None
2032 I None
) I None
or I None
diclofenac I Chemical
75 I None
mg I None
twice I None
daily I None
( I None
n I None
= I None
2054 I None
) I None
. I None
<eof> I None

<s> O None
Use I None
of I None
gastroprotective I None
agents I None
and I None
low I None
- I None
dose I None
<eof> I None

<s> O None
aspirin I Chemical
was I None
allowed I None
. I None
<eof> I None

<s> O None
The I None
prespecified I None
primary I None
end I None
point I None
consisted I None
of I None
the I None
cumulative I None
rate I None
of I None
patient I None
discontinuations I None
due I None
to I None
clinical I None
and I None
laboratory I None
GI I None
adverse I None
experiences I None
( I None
AEs I None
) I None
. I None
<eof> I None

<s> O None
General I None
safety I None
was I None
also I None
assessed I None
, I None
including I None
adjudicated I None
thrombotic I Disease
cardiovascular O Disease
event I None
data I None
. I None
<eof> I None

<s> O None
Efficacy I None
was I None
evaluated I None
using I None
the I None
Patient I None
Global I None
Assessment I None
of I None
Disease I None
Status I None
( I None
PGADS I None
; I None
0 I None
- I None
4 I None
point I None
scale I None
) I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
Mean I None
( I None
SD I None
; I None
maximum I None
) I None
duration I None
of I None
treatment I None
was I None
19.3 I None
( I None
10.3 I None
; I None
32.9 I None
) I None
and I None
19.1 I None
( I None
10.4 I None
; I None
33.1 I None
) I None
months I None
in I None
the I None
etoricoxib I Chemical
and I None
diclofenac I Chemical
groups I None
, I None
respectively I None
. I None
<eof> I None

<s> O None
The I None
cumulative I None
discontinuation I None
rate I None
due I None
to I None
GI I Disease
AEs O Disease
was I None
significantly I None
lower I None
with I None
etoricoxib I Chemical
than I None
diclofenac I Chemical
( I None
5.2 I None
vs I None
8.5 I None
events I None
per I None
100 I None
patient I None
- I None
years I None
, I None
respectively I None
; I None
hazard I None
ratio I None
0.62 I None
( I None
95 I None
% I None
CI I None
: I None
0.47 I None
, I None
0.81 I None
; I None
p I None
< I None
or=0.001 I None
) I None
) I None
. I None
<eof> I None

<s> O None
The I None
incidence I None
of I None
discontinuations I None
for I None
hypertension I Disease
-related I None
and I None
oedema I Disease
-related I None
AEs I None
were I None
significantly I None
higher I None
with I None
etoricoxib I Chemical
<eof> I None

<s> O None
( I None
2.5 I None
% I None
and I None
1.1 I None
% I None
respectively I None
) I None
compared I None
with I None
diclofenac I Chemical
( I None
1.5 I None
% I None
and I None
0.4 I None
% I None
respectively I None
; I None
p<0.001 I None
for I None
hypertension I Disease
and I None
p<0.01 I None
for I None
oedema I Disease
) I None
. I None
<eof> I None

<s> O None
Etoricoxib I Chemical
and I None
diclofenac I Chemical
treatment I None
resulted I None
in I None
similar I None
efficacy I None
( I None
PGADS I None
mean I None
changes I None
from I None
baseline I None
-0.62 I None
vs I None
-0.58 I None
, I None
respectively I None
) I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
Etoricoxib I Chemical
<eof> I None

<s> O None
90 I None
mg I None
demonstrated I None
a I None
significantly I None
lower I None
risk I None
for I None
discontinuing I None
treatment I None
due I None
to I None
GI I Disease
AEs O Disease
compared I None
with I None
diclofenac I Chemical
150 I None
mg I None
. I None
<eof> I None

<s> O None
Discontinuations I None
from I None
renovascular I None
AEs I None
, I None
although I None
less I None
common I None
than I None
discontinuations I None
from I None
GI I Disease
AEs O Disease
, I None
were I None
significantly I None
higher I None
with I None
etoricoxib I Chemical
. I None
<eof> I None

<s> O None
Placebo I None
- I None
level I None
incidence I None
of I None
extrapyramidal I Disease
symptoms O Disease
<eof> I None

<s> O None
( I None
EPS I Disease
) I None
with I None
<eof> I None

<s> O None
quetiapine I Chemical
in I None
controlled I None
studies I None
of I None
patients I None
with I None
bipolar I Disease
mania O Disease
. I None
<eof> I None

<s> O None
OBJECTIVES I None
: I None
<eof> I None

<s> O None
To I None
evaluate I None
extrapyramidal I Disease
symptoms O Disease
<eof> I None

<s> O None
( I None
EPS I Disease
) I None
, I None
including I None
akathisia I Disease
, I None
with I None
quetiapine I Chemical
in I None
patients I None
with I None
bipolar I Disease
mania O Disease
. I None
<eof> I None

<s> O None
METHODS I None
: I None
<eof> I None

<s> O None
Data I None
were I None
analyzed I None
from I None
four I None
similarly I None
designed I None
, I None
randomized I None
, I None
double I None
- I None
blind I None
, I None
<eof> I None

<s> O None
3- I None
to I None
12-week I None
studies I None
. I None
<eof> I None

<s> O None
Two I None
studies I None
evaluated I None
quetiapine I Chemical
monotherapy I None
( I None
up I None
to I None
800 I None
mg I None
/ I None
day I None
) I None
<eof> I None

<s> O None
( I None
n I None
= I None
209 I None
) I None
versus I None
placebo I None
( I None
n I None
= I None
198 I None
) I None
, I None
with I None
lithium I Chemical
or I None
haloperidol I Chemical
monotherapy I None
as I None
respective I None
active I None
controls I None
. I None
<eof> I None

<s> O None
Two I None
studies I None
evaluated I None
<eof> I None

<s> O None
quetiapine I Chemical
( I None
up I None
to I None
800 I None
mg I None
/ I None
day I None
) I None
in I None
combination I None
with I None
a I None
mood I None
stabilizer I None
( I None
lithium I Chemical
or I None
divalproex I Chemical
, I None
QTP I Chemical
+ I None
Li I Chemical
/ I None
DVP I Chemical
) I None
( I None
n I None
= I None
196 I None
) I None
compared I None
to I None
placebo I None
and I None
mood I None
stabilizer I None
( I None
PBO I None
+ I None
Li I Chemical
/ I None
DVP I Chemical
) I None
<eof> I None

<s> O None
( I None
n I None
= I None
203 I None
) I None
. I None
<eof> I None

<s> O None
Extrapyramidal I Disease
symptoms O Disease
were I None
evaluated I None
using I None
the I None
Simpson I None
- I None
Angus I None
Scale I None
( I None
SAS I None
) I None
, I None
the I None
Barnes I None
Akathisia I None
Rating I None
Scale I None
( I None
BARS I None
) I None
, I None
adverse I None
event I None
reports I None
and I None
anticholinergic I None
drug I None
usage I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
The I None
incidence I None
of I None
EPS I Disease
-related I None
adverse I None
events I None
, I None
including I None
akathisia I Disease
, I None
was I None
no I None
different I None
with I None
quetiapine I Chemical
monotherapy I None
( I None
12.9 I None
% I None
) I None
than I None
with I None
placebo I None
( I None
13.1 I None
% I None
) I None
. I None
<eof> I None

<s> O None
Similarly I None
, I None
EPS I Disease
-related I None
adverse I None
events I None
with I None
QTP I Chemical
+ I None
Li I Chemical
/ I None
DVP I Chemical
<eof> I None

<s> O None
( I None
21.4 I None
% I None
) I None
were I None
no I None
different I None
than I None
with I None
PBO I None
+ I None
Li I Chemical
/ I None
DVP I Chemical
( I None
19.2 I None
% I None
) I None
. I None
<eof> I None

<s> O None
Adverse I None
events I None
related I None
to I None
EPS I Disease
occurred I None
in I None
59.6 I None
% I None
of I None
patients I None
treated I None
with I None
haloperidol I Chemical
<eof> I None

<s> O None
( I None
n I None
= I None
99 I None
) I None
monotherapy I None
, I None
whereas I None
26.5 I None
% I None
of I None
patients I None
treated I None
with I None
lithium I Chemical
<eof> I None

<s> O None
( I None
n I None
= I None
98 I None
) I None
monotherapy I None
experienced I None
adverse I None
events I None
related I None
to I None
EPS I Disease
. I None
<eof> I None

<s> O None
The I None
incidence I None
of I None
akathisia I Disease
was I None
low I None
and I None
similar I None
with I None
quetiapine I Chemical
monotherapy I None
( I None
3.3 I None
% I None
) I None
and I None
placebo I None
( I None
6.1 I None
% I None
) I None
, I None
and I None
with I None
QTP I Chemical
+ I None
Li I Chemical
/ I None
DVP I Chemical
<eof> I None

<s> O None
( I None
3.6 I None
% I None
) I None
and I None
PBO I None
+ I None
Li I Chemical
/ I None
DVP I Chemical
( I None
4.9 I None
% I None
) I None
. I None
<eof> I None

<s> O None
Lithium I Chemical
was I None
associated I None
with I None
a I None
significantly I None
higher I None
incidence I None
( I None
p I None
< I None
0.05 I None
) I None
of I None
tremor I Disease
( I None
18.4 I None
% I None
) I None
than I None
quetiapine I Chemical
( I None
5.6 I None
% I None
) I None
; I None
cerebellar I None
tremor I Disease
, I None
which I None
is I None
a I None
known I None
adverse I None
effect I None
of I None
lithium I Chemical
, I None
may I None
have I None
contributed I None
to I None
the I None
elevated I None
rate I None
of I None
tremor I Disease
in I None
patients I None
receiving I None
lithium I Chemical
therapy I None
. I None
<eof> I None

<s> O None
Haloperidol I Chemical
induced I None
a I None
significantly I None
higher I None
incidence I None
( I None
p I None
< I None
0.001 I None
) I None
of I None
<eof> I None

<s> O None
akathisia I Disease
( I None
33.3 I None
% I None
versus I None
5.9 I None
% I None
) I None
, I None
tremor I Disease
<eof> I None

<s> O None
( I None
30.3 I None
% I None
versus I None
7.8 I None
% I None
) I None
, I None
and I None
extrapyramidal I Disease
syndrome O Disease
( I None
35.4 I None
% I None
versus I None
5.9 I None
% I None
) I None
than I None
quetiapine I Chemical
. I None
<eof> I None

<s> O None
No I None
significant I None
differences I None
were I None
observed I None
between I None
quetiapine I Chemical
and I None
placebo I None
on I None
SAS I None
and I None
BARS I None
scores I None
. I None
<eof> I None

<s> O None
Anticholinergic I None
use I None
was I None
low I None
and I None
similar I None
with I None
quetiapine I Chemical
or I None
placebo I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
In I None
bipolar I Disease
mania O Disease
, I None
the I None
incidence I None
of I None
EPS I Disease
, I None
including I None
akathisia I Disease
, I None
with I None
quetiapine I Chemical
therapy I None
is I None
similar I None
to I None
that I None
with I None
placebo I None
. I None
<eof> I None

<s> O None
Contribution I None
of I None
the I None
sympathetic I None
nervous I None
system I None
to I None
salt I None
- I None
sensitivity I None
in I None
lifetime I None
captopril I Chemical
-treated I None
spontaneously I None
hypertensive I Disease
rats I None
. I None
<eof> I None

<s> O None
OBJECTIVE I None
: I None
<eof> I None

<s> O None
To I None
test I None
the I None
hypothesis I None
that I None
, I None
in I None
lifetime I None
captopril I Chemical
-treated I None
spontaneously I None
hypertensive I Disease
rats I None
( I None
SHR I None
) I None
, I None
the I None
sympathetic I None
nervous I None
system I None
contributes I None
importantly I None
to I None
the I None
hypertensive I Disease
effect I None
of I None
dietary I Chemical
sodium O Chemical
chloride O Chemical
supplementation I None
. I None
<eof> I None

<s> O None
METHODS I None
: I None
Male I None
SHR I None
( I None
aged I None
6 I None
weeks I None
) I None
that I None
had I None
been I None
treated I None
from I None
conception I None
onward I None
with I None
either I None
captopril I Chemical
or I None
vehicle I None
remained I None
on I None
a I None
basal I None
sodium I Chemical
chloride O Chemical
diet I None
or I None
were I None
fed I None
a I None
high I None
sodium I Chemical
chloride O Chemical
diet I None
. I None
<eof> I None

<s> O None
After I None
2 I None
weeks I None
, I None
the I None
rats I None
were I None
subjected I None
to I None
ganglionic I None
blockade I None
and I None
2 I None
days I None
later I None
, I None
an I None
infusion I None
of I None
clonidine I Chemical
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
Lifetime I None
captopril I Chemical
treatment I None
significantly I None
lowered I None
mean I None
arterial I None
pressure I None
in I None
both I None
groups I None
. I None
<eof> I None

<s> O None
Intravenous I None
infusion I None
of I None
the I None
ganglionic I None
blocker I None
hexamethonium I Chemical
resulted I None
in I None
a I None
rapid I None
decline I None
in I None
MAP I None
that I None
eliminated I None
the I None
dietary I Chemical
sodium O Chemical
chloride O Chemical
-induced I None
increase I Disease
in O Disease
MAP O Disease
in I None
both I None
groups I None
. I None
<eof> I None

<s> O None
Infusion I None
of I None
the I None
central I None
nervous I None
system I None
alpha2-adrenergic I Chemical
receptor O Chemical
agonist O Chemical
<eof> I None

<s> O None
clonidine I Chemical
also I None
resulted I None
in I None
a I None
greater I None
reduction I None
in I None
MAP I None
in I None
both I None
groups I None
of I None
SHR I None
that I None
were I None
fed I None
the I None
high I None
( I None
compared I None
with I None
the I None
basal I None
) I None
<eof> I None

<s> O None
sodium I Chemical
chloride O Chemical
diet I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
In I None
both I None
lifetime I None
captopril I Chemical
-treated I None
and I None
control I None
SHR I None
, I None
the I None
sympathetic I None
nervous I None
system I None
contributes I None
to I None
the I None
pressor I None
effects I None
of I None
a I None
high I None
sodium I Chemical
chloride O Chemical
diet I None
. I None
<eof> I None

<s> O None
Dose I None
- I None
related I None
beneficial I None
and I None
adverse I None
effects I None
of I None
dietary I None
corticosterone I Chemical
on I None
<eof> I None

<s> O None
organophosphorus I Chemical
-induced I None
delayed I None
<eof> I None

<s> O None
neuropathy I Disease
in I None
chickens I None
. I None
<eof> I None

<s> O None
Tri I Chemical
- O Chemical
ortho O Chemical
- O Chemical
tolyl O Chemical
phosphate O Chemical
( I None
TOTP I Chemical
) I None
, I None
360 I None
mg I None
/ I None
kg I None
, I None
po I None
, I None
and I None
0,0'-diisopropyl I Chemical
phosphorofluoridate O Chemical
<eof> I None

<s> O None
( I None
DFP I Chemical
) I None
, I None
1 I None
mg I None
/ I None
kg I None
sc I None
, I None
were I None
administered I None
to I None
adult I None
White I None
Leghorn I None
chickens I None
24 I None
hr I None
after I None
they I None
were I None
placed I None
on I None
diets I None
containing I None
0 I None
to I None
300 I None
ppm I None
corticosterone I Chemical
. I None
<eof> I None

<s> O None
Supplemented I None
diets I None
were I None
continued I None
until I None
clinical I None
signs I None
and I None
lesions I None
of I None
delayed I None
neuropathy I Disease
appeared I None
. I None
<eof> I None

<s> O None
Although I None
low I None
concentrations I None
( I None
less I None
than I None
or I None
equal I None
to I None
50 I None
ppm I None
) I None
of I None
corticosterone I Chemical
had I None
beneficial I None
effects I None
on I None
TOTP I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
neuropathy I Disease
, I None
greater I None
than I None
or I None
equal I None
to I None
200 I None
ppm I None
exacerbated I None
clinical I None
signs I None
in I None
chickens I None
given I None
either I None
TOTP I Chemical
or I None
DFP I Chemical
. I None
<eof> I None

<s> O None
Neurotoxic I Disease
esterase I None
activities I None
24 I None
hr I None
after I None
TOTP I Chemical
or I None
DFP I Chemical
were I None
less I None
than I None
20 I None
% I None
of I None
values I None
measured I None
in I None
chickens I None
not I None
given I None
organophosphorous I Chemical
compounds I None
. I None
<eof> I None

<s> O None
Chickens I None
given I None
200 I None
ppm I None
corticosterone I Chemical
without I None
TOTP I Chemical
or I None
DFP I Chemical
had I None
significantly I None
elevated I None
activity I None
of I None
plasma I None
cholinesterase I None
and I None
significantly I None
inhibited I None
activity I None
of I None
liver I None
carboxylesterase I None
. I None
<eof> I None

<s> O None
Degenerating I Disease
myelinated O Disease
fibers O Disease
were I None
also I None
evident I None
in I None
distal I None
levels I None
of I None
the I None
peripheral I None
nerves I None
of I None
chickens I None
given I None
TOTP I Chemical
or I None
DFP I Chemical
. I None
<eof> I None

<s> O None
In I None
vivo I None
characterization I None
of I None
a I None
dual I None
adenosine I Chemical
A2A O Chemical
/ O Chemical
A1 O Chemical
receptor O Chemical
antagonist O Chemical
in I None
animal I None
models I None
of I None
Parkinson I Disease
's O Disease
disease O Disease
. I None
<eof> I None

<s> O None
The I None
in I None
vivo I None
characterization I None
of I None
a I None
dual I None
adenosine I Chemical
A(2A)/A(1 O Chemical
) O Chemical
receptor O Chemical
antagonist O Chemical
in I None
several I None
animal I None
models I None
of I None
Parkinson I Disease
's O Disease
disease O Disease
is I None
described I None
. I None
<eof> I None

<s> O None
Discovery I None
and I None
scale I None
- I None
up I None
syntheses I None
of I None
compound I None
1 I None
are I None
described I None
in I None
detail I None
, I None
highlighting I None
optimization I None
steps I None
that I None
increased I None
the I None
overall I None
yield I None
of I None
1 I None
from I None
10.0 I None
% I None
to I None
30.5 I None
% I None
. I None
<eof> I None

<s> O None
Compound I None
1 I None
is I None
a I None
potent I None
A(2A)/A(1 I None
) I None
receptor I None
antagonist I None
in I None
vitro I None
( I None
A(2A I None
) I None
K(i I None
) I None
<eof> I None

<s> O None
= I None
4.1 I None
nM I None
; I None
A(1 I None
) I None
K(i I None
) I None
<eof> I None

<s> O None
= I None
17.0 I None
nM I None
) I None
that I None
has I None
excellent I None
activity I None
, I None
after I None
oral I None
administration I None
, I None
across I None
a I None
number I None
of I None
animal I None
models I None
of I None
Parkinson I Disease
's O Disease
disease O Disease
including I None
mouse I None
and I None
rat I None
models I None
of I None
haloperidol I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
catalepsy I Disease
, I None
mouse I None
model I None
of I None
reserpine I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
akinesia I Disease
, I None
rat I None
6-hydroxydopamine I Chemical
<eof> I None

<s> O None
( I None
6-OHDA I Chemical
) I None
lesion I None
model I None
of I None
drug I None
- I None
induced I None
rotation I None
, I None
and I None
MPTP I Chemical
-treated I None
non I None
- I None
human I None
primate I None
model I None
. I None
<eof> I None

<s> O None
An I None
extremely I None
rare I None
case I None
of I None
delusional I Disease
parasitosis O Disease
in I None
a I None
chronic I Disease
hepatitis O Disease
C O Disease
patient I None
during I None
pegylated I Chemical
interferon O Chemical
alpha-2b O Chemical
and I None
ribavirin I Chemical
treatment I None
. I None
<eof> I None

<s> O None
During I None
treatment I None
of I None
chronic I Disease
hepatitis O Disease
C O Disease
patients I None
with I None
interferon I None
and I None
ribavirin I Chemical
, I None
a I None
lot I None
of I None
side I None
effects I None
are I None
described I None
. I None
<eof> I None

<s> O None
Twenty I None
- I None
three I None
percent I None
to I None
44 I None
% I None
of I None
patients I None
develop I None
depression I Disease
. I None
<eof> I None

<s> O None
A I None
minority I None
of I None
patients I None
evolve I None
to I None
psychosis I Disease
. I None
<eof> I None

<s> O None
To I None
the I None
best I None
of I None
our I None
knowledge I None
, I None
no I None
cases I None
of I None
psychogenic I Disease
parasitosis O Disease
occurring I None
during I None
interferon I None
therapy I None
have I None
been I None
described I None
in I None
the I None
literature I None
. I None
<eof> I None

<s> O None
We I None
present I None
a I None
49-year I None
- I None
old I None
woman I None
who I None
developed I None
a I None
delusional I Disease
parasitosis O Disease
during I None
treatment I None
with I None
pegylated I Chemical
interferon O Chemical
alpha-2b O Chemical
<eof> I None

<s> O None
weekly I None
and I None
ribavirin I Chemical
. I None
<eof> I None

<s> O None
She I None
complained I None
of I None
seeing I None
parasites I None
and I None
the I None
larvae I None
of I None
fleas I None
in I None
her I None
stools I None
. I None
<eof> I None

<s> O None
This I None
could I None
not I None
be I None
confirmed I None
by I None
any I None
technical I None
examination I None
. I None
<eof> I None

<s> O None
All I None
the I None
complaints I None
disappeared I None
after I None
stopping I None
pegylated I Chemical
interferon O Chemical
alpha-2b O Chemical
and I None
reappeared I None
after I None
restarting I None
it I None
. I None
<eof> I None

<s> O None
She I None
had I None
a I None
complete I None
sustained I None
viral I None
response I None
. I None
<eof> I None

<s> O None
Possible I None
neuroleptic I Disease
malignant O Disease
syndrome O Disease
related I None
to I None
concomitant I None
treatment I None
with I None
paroxetine I Chemical
and I None
alprazolam I Chemical
. I None
<eof> I None

<s> O None
A I None
74-year I None
- I None
old I None
man I None
with I None
depressive I Disease
symptoms O Disease
was I None
admitted I None
to I None
a I None
psychiatric I Disease
hospital I None
due I None
to I None
insomnia I Disease
, I None
loss I Disease
of O Disease
appetite O Disease
, I None
exhaustion I None
, I None
and I None
agitation I Disease
. I None
<eof> I None

<s> O None
Medical I None
treatment I None
was I None
initiated I None
at I None
a I None
daily I None
dose I None
of I None
20 I None
mg I None
paroxetine I Chemical
and I None
1.2 I None
mg I None
alprazolam I Chemical
. I None
<eof> I None

<s> O None
On I None
the I None
10th I None
day I None
of I None
paroxetine I Chemical
and I None
alprazolam I Chemical
treatment I None
, I None
the I None
patient I None
exhibited I None
marked I None
psychomotor I Disease
retardation O Disease
, I None
disorientation I None
, I None
and I None
severe I None
muscle I Disease
rigidity O Disease
with I None
tremors I Disease
. I None
<eof> I None

<s> O None
The I None
patient I None
had I None
a I None
fever I Disease
( I None
38.2 I None
degrees I None
C I None
) I None
, I None
fluctuating I None
blood I None
pressure I None
( I None
between I None
165/90 I None
and I None
130/70 I None
mg I None
mm I None
Hg I None
) I None
, I None
and I None
severe I None
extrapyramidal I Disease
symptoms O Disease
. I None
<eof> I None

<s> O None
Laboratory I None
tests I None
showed I None
an I None
elevation I None
of I None
creatine I Chemical
phosphokinase I None
<eof> I None

<s> O None
( I None
2218 I None
IU I None
/ I None
L I None
) I None
, I None
aspartate I Chemical
aminotransferase I None
( I None
134 I None
IU I None
/ I None
L I None
) I None
, I None
alanine I Chemical
aminotransferase I None
( I None
78 I None
IU I None
/ I None
L I None
) I None
, I None
and I None
BUN I None
( I None
27.9 I None
mg I None
/ I None
ml I None
) I None
levels I None
. I None
<eof> I None

<s> O None
The I None
patient I None
received I None
bromocriptine I Chemical
and I None
diazepam I Chemical
to I None
treat I None
his I None
symptoms I None
. I None
<eof> I None

<s> O None
7 I None
days I None
later I None
, I None
the I None
fever I Disease
disappeared I None
and I None
the I None
patient I None
's I None
serum I None
<eof> I None

<s> O None
CPK I None
levels I None
were I None
normalized I None
( I None
175 I None
IU I None
/ I None
L I None
) I None
. I None
<eof> I None

<s> O None
This I None
patient I None
presented I None
with I None
symptoms I None
of I None
neuroleptic I Disease
malignant O Disease
syndrome O Disease
<eof> I None

<s> O None
( I None
NMS I Disease
) I None
, I None
thus I None
demonstrating I None
that I None
NMS I Disease
-like I None
symptoms I None
can I None
occur I None
after I None
combined I None
paroxetine I Chemical
and I None
alprazolam I Chemical
treatment I None
. I None
<eof> I None

<s> O None
The I None
adverse I None
drug I None
reaction I None
score I None
obtained I None
by I None
the I None
Naranjo I None
algorithm I None
was I None
6 I None
in I None
our I None
case I None
, I None
indicating I None
a I None
probable I None
relationship I None
between I None
the I None
patient I None
's I None
NMS I Disease
-like I None
adverse I None
symptoms I None
and I None
the I None
combined I None
treatment I None
used I None
in I None
this I None
case I None
. I None
<eof> I None

<s> O None
The I None
involvement I None
of I None
physiologic I None
and I None
environmental I None
aspects I None
specific I None
to I None
this I None
patient I None
was I None
suspected I None
. I None
<eof> I None

<s> O None
Several I None
risk I None
factors I None
for I None
NMS I Disease
should I None
be I None
noted I None
in I None
elderly I None
depressive I Disease
patients I None
whose I None
symptoms I None
often I None
include I None
dehydration I Disease
, I None
agitation I Disease
, I None
malnutrition I Disease
, I None
and I None
exhaustion I None
. I None
<eof> I None

<s> O None
Careful I None
therapeutic I None
intervention I None
is I None
necessary I None
in I None
cases I None
involving I None
elderly I None
patients I None
who I None
suffer I None
from I None
depression I Disease
. I None
<eof> I None

<s> O None
Pilocarpine I Chemical
seizures I Disease
cause I None
age I None
- I None
dependent I None
impairment I Disease
in O Disease
auditory O Disease
location O Disease
discrimination O Disease
. I None
<eof> I None

<s> O None
Children I None
who I None
have I None
status I Disease
epilepticus O Disease
have I None
continuous I None
or I None
rapidly I None
repeating I None
seizures I Disease
that I None
may I None
be I None
life I None
- I None
threatening I None
and I None
may I None
cause I None
life I None
- I None
long I None
changes I None
in I None
brain I None
and I None
behavior I None
. I None
<eof> I None

<s> O None
The I None
extent I None
to I None
which I None
status I Disease
epilepticus O Disease
causes I None
deficits I Disease
in O Disease
auditory O Disease
discrimination O Disease
is I None
unknown I None
. I None
<eof> I None

<s> O None
A I None
naturalistic I None
auditory I None
location I None
discrimination I None
method I None
was I None
used I None
to I None
evaluate I None
this I None
question I None
using I None
an I None
animal I None
model I None
of I None
status I Disease
epilepticus O Disease
. I None
<eof> I None

<s> O None
Male I None
Sprague I None
- I None
Dawley I None
rats I None
were I None
injected I None
with I None
saline I None
on I None
postnatal I None
day I None
( I None
P I None
) I None
20 I None
, I None
or I None
a I None
convulsant I None
dose I None
of I None
<eof> I None

<s> O None
pilocarpine I Chemical
on I None
P20 I None
or I None
P45 I None
. I None
<eof> I None

<s> O None
Pilocarpine I Chemical
on I None
either I None
day I None
induced I None
status I Disease
epilepticus O Disease
; I None
status I Disease
epilepticus O Disease
at I None
P45 I None
resulted I None
in I None
CA3 I None
cell I None
loss I None
and I None
spontaneous I None
seizures I Disease
, I None
whereas I None
P20 I None
rats I None
had I None
no I None
cell I None
loss I None
or I None
spontaneous I None
seizures I Disease
. I None
<eof> I None

<s> O None
Mature I None
rats I None
were I None
trained I None
with I None
sound I None
- I None
source I None
location I None
and I None
sound I None
- I None
silence I None
discriminations I None
. I None
<eof> I None

<s> O None
Control I None
( I None
saline I None
P20 I None
) I None
rats I None
acquired I None
both I None
discriminations I None
immediately I None
. I None
<eof> I None

<s> O None
In I None
status I Disease
epilepticus O Disease
( I None
P20 I None
) I None
rats I None
, I None
acquisition I None
of I None
the I None
sound I None
- I None
source I None
location I None
discrimination I None
was I None
moderately I None
impaired I None
. I None
<eof> I None

<s> O None
Status I Disease
epilepticus O Disease
( I None
P45 I None
) I None
rats I None
failed I None
to I None
acquire I None
either I None
sound I None
- I None
source I None
location I None
or I None
sound I None
- I None
silence I None
discriminations I None
. I None
<eof> I None

<s> O None
Status I Disease
epilepticus O Disease
in I None
rat I None
causes I None
an I None
age I None
- I None
dependent I None
, I None
long I None
- I None
term I None
impairment I Disease
in O Disease
auditory O Disease
discrimination O Disease
. I None
<eof> I None

<s> O None
This I None
impairment I None
may I None
explain I None
one I None
cause I None
of I None
impaired I Disease
auditory O Disease
location O Disease
discrimination O Disease
in I None
humans I None
. I None
<eof> I None

<s> O None
Cardiovascular I None
risk I None
with I None
cyclooxygenase I Chemical
inhibitors O Chemical
: I None
general I None
problem I None
with I None
substance I None
specific I None
differences I None
? I None
<eof> I None

<s> O None
Randomised I None
clinical I None
trials I None
and I None
observational I None
studies I None
have I None
shown I None
an I None
increased I None
risk I None
of I None
myocardial I Disease
infarction O Disease
, I None
stroke I Disease
, I None
<eof> I None

<s> O None
hypertension I Disease
and I None
heart I Disease
failure O Disease
during I None
treatment I None
with I None
cyclooxygenase I Chemical
inhibitors O Chemical
. I None
<eof> I None

<s> O None
Adverse I None
cardiovascular I None
effects I None
occurred I None
mainly I None
, I None
but I None
not I None
exclusively I None
, I None
in I None
patients I None
with I None
concomitant I None
risk I None
factors I None
. I None
<eof> I None

<s> O None
Cyclooxygenase I Chemical
inhibitors O Chemical
cause I None
complex I None
changes I None
in I None
renal I None
, I None
vascular I None
and I None
cardiac I None
prostanoid I None
profiles I None
thereby I None
increasing I None
vascular I None
resistance I None
and I None
fluid I None
retention I None
. I None
<eof> I None

<s> O None
The I None
incidence I None
of I None
cardiovascular I None
adverse I None
events I None
tends I None
to I None
increase I None
with I None
the I None
daily I None
dose I None
and I None
total I None
exposure I None
time I None
. I None
<eof> I None

<s> O None
A I None
comparison I None
of I None
individual I None
selective I None
and I None
unselective I None
cyclooxygenase I Chemical
inhibitors O Chemical
suggests I None
substance I None
- I None
specific I None
differences I None
, I None
which I None
may I None
depend I None
on I None
differences I None
in I None
pharmacokinetic I None
parameters I None
or I None
inhibitory I None
potency I None
and I None
may I None
be I None
contributed I None
by I None
prostaglandin I Chemical
-independent I None
effects I None
. I None
<eof> I None

<s> O None
Diagnostic I None
markers I None
such I None
as I None
N I Chemical
- O Chemical
terminal O Chemical
pro O Chemical
brain O Chemical
natriuretic O Chemical
peptide O Chemical
<eof> I None

<s> O None
( I None
NT I Chemical
- O Chemical
proBNP O Chemical
) I None
or I None
high I None
- I None
sensitive I None
C I None
- I None
reactive I None
protein I None
might I None
help I None
in I None
the I None
early I None
identification I None
of I None
patients I None
at I None
risk I None
, I None
thus I None
avoiding I None
the I None
occurrence I None
of I None
serious I None
cardiovascular I Disease
toxicity O Disease
. I None
<eof> I None

<s> O None
Predictors I None
of I None
decreased I Disease
renal O Disease
function O Disease
in I None
patients I None
with I None
heart I Disease
failure O Disease
during I None
angiotensin I Chemical
-converting I None
enzyme I None
inhibitor I None
therapy I None
: I None
results I None
from I None
the I None
studies I None
of I None
left I Disease
ventricular O Disease
dysfunction O Disease
<eof> I None

<s> O None
( I None
SOLVD I None
) I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
<eof> I None

<s> O None
Although I None
angiotensin I Chemical
-converting I None
enzyme I None
inhibitor I None
therapy I None
reduces I None
mortality I None
rates I None
in I None
patients I None
with I None
congestive I Disease
heart O Disease
failure O Disease
<eof> I None

<s> O None
( I None
CHF I Disease
) I None
, I None
it I None
may I None
also I None
cause I None
decreased I Disease
renal O Disease
function O Disease
. I None
<eof> I None

<s> O None
Little I None
information I None
is I None
available I None
to I None
predict I None
which I None
patients I None
are I None
at I None
highest I None
risk I None
for I None
this I None
complication I None
. I None
<eof> I None

<s> O None
OBJECTIVE I None
: I None
<eof> I None

<s> O None
To I None
quantify I None
specific I None
clinical I None
predictors I None
of I None
reduction I Disease
in O Disease
renal O Disease
function O Disease
in I None
patients I None
with I None
CHF I Disease
who I None
are I None
prescribed I None
angiotensin I Chemical
-converting I None
enzyme I None
inhibitor I None
therapy I None
. I None
<eof> I None

<s> O None
METHOD I None
: I None
<eof> I None

<s> O None
We I None
analyzed I None
data I None
from I None
the I None
Studies I None
of I None
Left I Disease
Ventricular O Disease
Dysfunction O Disease
<eof> I None

<s> O None
( I None
SOLVD I None
) I None
, I None
a I None
randomized I None
, I None
double I None
- I None
blind I None
, I None
placebo I None
- I None
controlled I None
trial I None
of I None
enalapril I Chemical
for I None
the I None
treatment I None
of I None
CHF I Disease
. I None
<eof> I None

<s> O None
There I None
were I None
3379 I None
patients I None
randomly I None
assigned I None
to I None
enalapril I Chemical
with I None
a I None
median I None
follow I None
- I None
up I None
of I None
974 I None
days I None
and I None
3379 I None
patients I None
randomly I None
assigned I None
to I None
placebo I None
with I None
a I None
mean I None
follow I None
- I None
up I None
of I None
967 I None
days I None
. I None
<eof> I None

<s> O None
Decreased I Disease
renal O Disease
function O Disease
was I None
defined I None
as I None
a I None
rise I None
in I None
serum I None
creatinine I Chemical
<eof> I None

<s> O None
> I None
/=0.5 I None
mg I None
/ I None
dL I None
( I None
44 I None
micromol I None
/ I None
L I None
) I None
from I None
baseline I None
. I None
<eof> I None

<s> O None
We I None
used I None
time I None
- I None
to I None
- I None
event I None
analysis I None
to I None
identify I None
potential I None
predictors I None
of I None
decrease I None
in I None
renal I None
function I None
including I None
age I None
, I None
baseline I None
ejection I None
fraction I None
, I None
baseline I None
creatinine I Chemical
, I None
low I None
systolic I None
blood I None
pressure I None
( I None
< I None
100 I None
mm I None
Hg I None
) I None
, I None
history I None
of I None
hypertension I Disease
, I None
diabetes I Disease
, I None
and I None
use I None
of I None
antiplatelet I None
, I None
diuretic I Chemical
, I None
and I None
beta I None
- I None
blocker I None
therapy I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
Patients I None
randomly I None
assigned I None
to I None
enalapril I Chemical
had I None
a I None
33 I None
% I None
greater I None
likelihood I None
of I None
decreased I Disease
renal O Disease
function O Disease
than I None
controls I None
( I None
P I None
= I None
.003 I None
) I None
. I None
<eof> I None

<s> O None
By I None
multivariate I None
analysis I None
, I None
in I None
both I None
the I None
placebo I None
and I None
enalapril I Chemical
groups I None
older I None
age I None
, I None
diuretic I Chemical
therapy I None
, I None
and I None
diabetes I Disease
were I None
associated I None
with I None
decreased I Disease
renal O Disease
function O Disease
, I None
whereas I None
beta I None
- I None
blocker I None
therapy I None
and I None
higher I None
ejection I None
fraction I None
were I None
renoprotective I None
. I None
<eof> I None

<s> O None
Older I None
age I None
was I None
associated I None
with I None
a I None
greater I None
risk I None
of I None
developing I None
decreased I Disease
renal O Disease
function O Disease
in I None
both I None
groups I None
, I None
but I None
significantly I None
more I None
so I None
in I None
the I None
enalapril I Chemical
group I None
( I None
enalapril I Chemical
: I None
risk I None
ratio I None
[ I None
RR I None
] I None
1.42 I None
per I None
10 I None
years I None
, I None
95 I None
% I None
confidence I None
interval I None
[ I None
CI I None
] I None
1.32 I None
- I None
1.52 I None
with I None
enalapril I Chemical
; I None
placebo I None
: I None
RR I None
1.18 I None
, I None
95 I None
% I None
CI I None
1.12 I None
- I None
1.25 I None
) I None
. I None
<eof> I None

<s> O None
Diuretic I Chemical
therapy I None
was I None
likewise I None
associated I None
with I None
a I None
greater I None
risk I None
of I None
decreased I Disease
renal O Disease
function O Disease
in I None
the I None
enalapril I Chemical
group I None
( I None
RR I None
1.89 I None
, I None
95 I None
% I None
CI I None
1.70 I None
- I None
2.08 I None
) I None
than I None
in I None
the I None
placebo I None
group I None
( I None
RR I None
1.35 I None
, I None
95 I None
% I None
CI I None
1.09 I None
- I None
1.66 I None
) I None
. I None
<eof> I None

<s> O None
Conversely I None
, I None
enalapril I Chemical
had I None
a I None
relative I None
renoprotective I None
effect I None
( I None
RR I None
1.33 I None
, I None
95 I None
% I None
CI I None
1.13 I None
- I None
1.53 I None
) I None
compared I None
with I None
placebo I None
( I None
RR I None
1.96 I None
, I None
95 I None
% I None
CI I None
1.57 I None
- I None
2.44 I None
) I None
in I None
patients I None
with I None
diabetes I Disease
. I None
<eof> I None

<s> O None
A I None
lower I None
risk I None
of I None
renal I Disease
impairment O Disease
was I None
seen I None
in I None
both I None
groups I None
with I None
beta I None
- I None
blocker I None
therapy I None
( I None
RR I None
0.70 I None
, I None
95 I None
% I None
CI I None
0.57 I None
- I None
0.85 I None
) I None
and I None
higher I None
baseline I None
ejection I None
fraction I None
( I None
RR I None
0.93 I None
per I None
5 I None
% I None
increment I None
, I None
95 I None
% I None
CI I None
0.91 I None
- I None
0 I None
. I None
<eof> I None

<s> O None
96 I None
) I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
Enalapril I Chemical
use I None
caused I None
a I None
33 I None
% I None
increase I None
in I None
the I None
risk I None
of I None
decreased I Disease
renal O Disease
function O Disease
in I None
patients I None
with I None
CHF I Disease
. I None
<eof> I None

<s> O None
Diuretic I Chemical
use I None
and I None
advanced I None
age I None
increased I None
this I None
risk I None
. I None
<eof> I None

<s> O None
Diabetes I Disease
was I None
associated I None
with I None
an I None
increased I None
risk I None
of I None
renal I Disease
impairment O Disease
in I None
all I None
patients I None
with I None
CHF I Disease
, I None
but I None
this I None
risk I None
was I None
reduced I None
in I None
the I None
enalapril I Chemical
group I None
compared I None
with I None
the I None
placebo I None
group I None
. I None
<eof> I None

<s> O None
beta I None
- I None
Blocker I None
therapy I None
and I None
higher I None
ejection I None
fraction I None
were I None
renoprotective I None
in I None
all I None
patients I None
regardless I None
of I None
therapy I None
. I None
<eof> I None

<s> O None
Pemoline I Chemical
induced I None
acute I None
choreoathetosis I Disease
: I None
case I None
report I None
and I None
review I None
of I None
the I None
literature I None
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
<eof> I None

<s> O None
Pemoline I Chemical
is I None
an I None
oxazolidine I Chemical
derivative I None
that I None
is I None
structurally I None
different I None
from I None
amphetamines I Chemical
and I None
used I None
in I None
the I None
treatment I None
of I None
attention I Disease
deficit O Disease
disorder O Disease
. I None
<eof> I None

<s> O None
Pemoline I Chemical
has I None
not I None
been I None
commonly I None
associated I None
in I None
the I None
literature I None
as I None
a I None
cause I None
of I None
acute I None
movement I Disease
disorders O Disease
. I None
<eof> I None

<s> O None
The I None
following I None
case I None
describes I None
two I None
children I None
acutely I None
poisoned I None
with I None
pemoline I Chemical
who I None
experienced I None
profound I None
choreoathetosis I Disease
. I None
<eof> I None

<s> O None
CASE I None
REPORT I None
: I None
<eof> I None

<s> O None
Two I None
, I None
3-year I None
- I None
old I None
male I None
, I None
identical I None
twin I None
siblings I None
presented I None
to I None
the I None
emergency I None
department I None
after I None
found I None
playing I None
with I None
a I None
an I None
empty I None
bottle I None
of I None
pemoline I Chemical
originally I None
containing I None
59 I None
tablets I None
. I None
<eof> I None

<s> O None
The I None
children I None
had I None
a I None
medical I None
history I None
significant I None
for I None
attention I Disease
deficit O Disease
disorder O Disease
previously I None
treated I None
with I None
methylphenidate I Chemical
without I None
success I None
. I None
<eof> I None

<s> O None
This I None
was I None
their I None
first I None
day I None
of I None
pemoline I Chemical
therapy I None
. I None
<eof> I None

<s> O None
The I None
choreoathetoid I Disease
movements I None
began I None
45 I None
min I None
to I None
1 I None
h I None
after I None
ingestion I None
. I None
<eof> I None

<s> O None
The I None
children I None
gave I None
no I None
history I None
of I None
prior I None
movement I Disease
disorders O Disease
<eof> I None

<s> O None
and I None
there I None
was I None
no I None
family I None
history I None
of I None
movement I Disease
disorders O Disease
. I None
<eof> I None

<s> O None
The I None
children I None
received I None
gastrointestinal I None
decontamination I None
and I None
high I None
doses I None
of I None
intravenous I None
benzodiazepines I Chemical
in I None
an I None
attempt I None
to I None
control I None
the I None
choreoathetoid I Disease
movements I None
. I None
<eof> I None

<s> O None
Despite I None
treatment I None
, I None
the I None
children I None
continued I None
to I None
have I None
choreoathetosis I Disease
for I None
approximately I None
24 I None
hours I None
. I None
<eof> I None

<s> O None
Forty I None
- I None
eight I None
hours I None
after I None
admission I None
, I None
the I None
children I None
appeared I None
to I None
be I None
at I None
their I None
baseline I None
and I None
were I None
discharged I None
home I None
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
<eof> I None

<s> O None
Pemoline I Chemical
associated I None
<eof> I None

<s> O None
movement I Disease
disorder O Disease
has I None
been I None
rarely I None
reported I None
in I None
the I None
acute I None
toxicology I None
literature I None
. I None
<eof> I None

<s> O None
The I None
possibility I None
of I None
choreoathetoid I Disease
movements I None
should I None
be I None
considered I None
in I None
patients I None
presenting I None
after I None
pemoline I Chemical
overdose I Disease
. I None
<eof> I None

<s> O None
Continuous I None
subcutaneous I None
administration I None
of I None
mesna I Chemical
to I None
prevent I None
ifosfamide I Chemical
-induced I None
hemorrhagic I None
cystitis I None
. I None
<eof> I None

<s> O None
Hemorrhagic I None
cystitis I None
is I None
a I None
major I None
potential I None
<eof> I None

<s> O None
toxicity I Disease
of I None
ifosfamide I Chemical
that I None
can I None
be I None
prevented I None
by I None
administering I None
mesna I Chemical
along I None
with I None
the I None
cytotoxic I None
agent I None
. I None
<eof> I None

<s> O None
Mesna I Chemical
is I None
generally I None
administered I None
by I None
the I None
intravenous I None
route I None
, I None
although I None
experience I None
with I None
oral I None
delivery I None
of I None
the I None
drug I None
has I None
increased I None
. I None
<eof> I None

<s> O None
The I None
continuous I None
subcutaneous I None
administration I None
of I None
mesna I Chemical
has I None
the I None
advantage I None
of I None
not I None
requiring I None
intravenous I None
access I None
. I None
<eof> I None

<s> O None
In I None
addition I None
, I None
subcutaneous I None
delivery I None
of I None
the I None
neutralizing I None
agent I None
will I None
not I None
be I None
associated I None
with I None
the I None
risk I None
of I None
inadequate I None
urinary I None
mesna I Chemical
concentrations I None
, I None
such I None
as I None
in I None
a I None
patient I None
taking I None
oral I None
mesna I Chemical
who I None
experiences I None
severe I None
ifosfamide I Chemical
-induced I None
emesis I Disease
and I None
is I None
unable I None
to I None
absorb I None
the I None
drug I None
. I None
<eof> I None

<s> O None
Limited I None
clinical I None
experience I None
with I None
continuous I None
subcutaneous I None
mesna I Chemical
administration I None
suggests I None
it I None
is I None
a I None
safe I None
, I None
practical I None
, I None
and I None
economic I None
method I None
of I None
drug I None
delivery I None
that I None
permits I None
ifosfamide I Chemical
to I None
be I None
administered I None
successfully I None
in I None
the I None
outpatient I None
setting I None
. I None
<eof> I None

<s> O None
Modification I None
of I None
drug I None
action I None
by I None
hyperammonemia I Disease
. I None
<eof> I None

<s> O None
Pretreatment I None
with I None
ammonium I Chemical
acetate O Chemical
<eof> I None

<s> O None
( I None
NH4Ac I Chemical
) I None
( I None
6 I None
mmol I None
/ I None
kg I None
s.c I None
. I None
) I None
approximately I None
doubled I None
the I None
time I None
<eof> I None

<s> O None
morphine I Chemical
<eof> I None

<s> O None
-treated I None
mice I None
remained I None
on I None
a I None
hot I None
surface I None
and I None
similarly I None
increased I None
muscular I None
incoordination I Disease
by I None
diazepam I Chemical
, I None
but I None
NH4Ac I Chemical
treatment I None
alone I None
had I None
no I None
effect I None
. I None
<eof> I None

<s> O None
Thus I None
, I None
hyperammonemia I Disease
is I None
capable I None
of I None
altering I None
drug I None
action I None
and I None
must I None
be I None
considered I None
along I None
with I None
impaired I None
drug I None
metabolism I None
in I None
enhanced I None
drug I None
responses I None
associated I None
with I None
liver I Disease
disease O Disease
. I None
<eof> I None

<s> O None
Experiments I None
in I None
vitro I None
showed I None
that I None
acetylcholine I Chemical
-induced I None
catecholamine I Chemical
release I None
from I None
bovine I None
adrenal I None
medulla I None
is I None
depressed I None
as I None
much I None
as I None
50 I None
% I None
by I None
0.3 I None
mM I None
NH4Ac I Chemical
and I None
KCl I Chemical
-induced I None
contractions I None
of I None
guinea I None
- I None
pig I None
ileum I None
were I None
inhibited I None
20 I None
% I None
by I None
5 I None
mM I None
NH4Ac I Chemical
. I None
<eof> I None

<s> O None
Addition I None
of I None
excess I None
calcium I Chemical
reversed I None
the I None
depression I Disease
in I None
both I None
tissues I None
, I None
but I None
calcium I Chemical
-independent I None
<eof> I None

<s> O None
catecholamine I Chemical
release I None
by I None
acetaldehyde I Chemical
was I None
not I None
blocked I None
by I None
NH4Ac I Chemical
. I None
<eof> I None

<s> O None
These I None
results I None
suggested I None
that I None
ammonia I Chemical
blocks I None
calcium I Chemical
channels I None
. I None
<eof> I None

<s> O None
Parallels I None
in I None
the I None
actions I None
of I None
NH4Ac I Chemical
and I None
the I None
calcium I Chemical
channel I None
blocker I None
verapamil I Chemical
support I None
this I None
concept I None
. I None
<eof> I None

<s> O None
Both I None
verapamil I Chemical
<eof> I None

<s> O None
( I None
10 I None
mg I None
/ I None
kg I None
i.p I None
. I None
) I None
and I None
NH4Ac I Chemical
pretreatment I None
enhanced I None
morphine I Chemical
analgesia I Disease
- I None
and I None
diazepam I Chemical
-induced I None
muscular I None
incoordination I Disease
and I None
antagonized I None
amphetamine I Chemical
-induced I None
motor I None
activity I None
, I None
and I None
neither I None
verapamil I Chemical
nor I None
NH4Ac I Chemical
affected I None
the I None
convulsant I None
action I None
of I None
metrazol I Chemical
. I None
<eof> I None

<s> O None
The I None
data I None
suggest I None
that I None
hyperammonemia I Disease
exerts I None
a I None
calcium I Chemical
channel I None
blocking I None
action I None
which I None
enhances I None
the I None
effects I None
of I None
central I None
nervous I None
system I None
depressants I None
and I None
certain I None
opioid I None
analgesics I None
. I None
<eof> I None

<s> O None
Risk I None
of I None
nephropathy I Disease
after I None
consumption I None
of I None
nonionic I None
contrast I Chemical
media O Chemical
by I None
children I None
undergoing I None
cardiac I None
angiography I None
: I None
a I None
prospective I None
study I None
. I None
<eof> I None

<s> O None
Despite I None
increasing I None
reports I None
on I None
nonionic I None
contrast I Chemical
media O Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
nephropathy I Disease
<eof> I None

<s> O None
( I None
CIN I Disease
) I None
in I None
hospitalized I None
adult I None
patients I None
during I None
cardiac I None
procedures I None
, I None
the I None
studies I None
in I None
pediatrics I None
are I None
limited I None
, I None
with I None
even I None
less I None
focus I None
on I None
possible I None
predisposing I None
factors I None
and I None
preventive I None
measures I None
for I None
patients I None
undergoing I None
cardiac I None
angiography I None
. I None
<eof> I None

<s> O None
This I None
prospective I None
study I None
determined I None
the I None
incidence I None
of I None
CIN I Disease
for I None
two I None
nonionic I None
contrast I Chemical
media O Chemical
<eof> I None

<s> O None
( I None
CM I Chemical
) I None
, I None
<eof> I None

<s> O None
iopromide I Chemical
and I None
iohexol I Chemical
, I None
among I None
80 I None
patients I None
younger I None
than I None
18 I None
years I None
and I None
compared I None
the I None
rates I None
for I None
this I None
complication I None
in I None
relation I None
to I None
the I None
type I None
and I None
dosage I None
of I None
CM I Chemical
and I None
the I None
presence I None
of I None
cyanosis I Disease
. I None
<eof> I None

<s> O None
The I None
80 I None
patients I None
in I None
the I None
study I None
consecutively I None
received I None
either I None
iopromide I Chemical
<eof> I None

<s> O None
( I None
group I None
A I None
, I None
n I None
= I None
40 I None
) I None
or I None
iohexol I Chemical
( I None
group I None
B I None
, I None
n I None
= I None
40 I None
) I None
. I None
<eof> I None

<s> O None
Serum I None
sodium I Chemical
<eof> I None

<s> O None
( I None
Na I Chemical
) I None
, I None
potassium I Chemical
<eof> I None

<s> O None
( I None
K I Chemical
) I None
, I None
and I None
creatinine I Chemical
<eof> I None

<s> O None
( I None
Cr I Chemical
) I None
were I None
measured I None
24 I None
h I None
before I None
angiography I None
as I None
baseline I None
values I None
, I None
then I None
measured I None
again I None
at I None
12- I None
, I None
24- I None
, I None
and I None
48-h I None
intervals I None
after I None
CM I Chemical
use I None
. I None
<eof> I None

<s> O None
Urine I None
samples I None
for I None
Na I Chemical
and I None
Cr I Chemical
also I None
were I None
checked I None
at I None
the I None
same I None
intervals I None
. I None
<eof> I None

<s> O None
Risk I None
of I None
renal I Disease
failure O Disease
, I None
Injury I Disease
to O Disease
the O Disease
kidney O Disease
, I None
Failure I Disease
of O Disease
kidney O Disease
function O Disease
, I None
Loss I Disease
of O Disease
kidney O Disease
function O Disease
, I None
and I None
End I None
- I None
stage I None
<eof> I None

<s> O None
renal I Disease
damage O Disease
( I None
RIFLE I None
criteria I None
) I None
were I None
used I None
to I None
define I None
CIN I Disease
and I None
its I None
incidence I None
in I None
the I None
study I None
population I None
. I None
<eof> I None

<s> O None
Accordingly I None
, I None
among I None
the I None
15 I None
CIN I Disease
patients I None
( I None
18.75 I None
% I None
) I None
, I None
7.5 I None
% I None
of I None
the I None
patients I None
in I None
group I None
A I None
had I None
increased I None
risk I None
and I None
3.75 I None
% I None
had I None
renal I Disease
injury O Disease
, I None
whereas I None
5 I None
% I None
of I None
group I None
B I None
had I None
increased I None
risk I None
and I None
2.5 I None
% I None
had I None
<eof> I None

<s> O None
renal I Disease
injury O Disease
. I None
<eof> I None

<s> O None
Whereas I None
33.3 I None
% I None
of I None
the I None
patients I None
with I None
CIN I Disease
were I None
among I None
those I None
who I None
received I None
the I None
proper I None
dosage I None
of I None
CM I Chemical
, I None
the I None
percentage I None
increased I None
to I None
66.6 I None
% I None
among I None
those I None
who I None
received I None
larger I None
doses I None
, I None
with I None
a I None
significant I None
difference I None
in I None
the I None
incidence I None
of I None
CIN I Disease
related I None
to I None
the I None
different I None
dosages I None
of I None
CM I Chemical
<eof> I None

<s> O None
( I None
p I None
= I None
0.014 I None
) I None
. I None
<eof> I None

<s> O None
Among I None
the I None
15 I None
patients I None
with I None
CIN I Disease
, I None
6 I None
had I None
cyanotic I None
congenital I Disease
heart O Disease
diseases O Disease
, I None
but I None
the I None
incidence I None
did I None
not I None
differ I None
significantly I None
from I None
that I None
for I None
the I None
noncyanotic I None
patients I None
( I None
p I None
= I None
0.243 I None
) I None
. I None
<eof> I None

<s> O None
Although I None
clinically I None
silent I None
, I None
CIN I Disease
is I None
not I None
rare I None
in I None
pediatrics I None
. I None
<eof> I None

<s> O None
The I None
incidence I None
depends I None
on I None
dosage I None
but I None
not I None
on I None
the I None
type I None
of I None
consumed I None
nonionic I None
CM I Chemical
, I None
nor I None
on I None
the I None
presence I None
of I None
cyanosis I Disease
, I None
and I None
although I None
CIN I Disease
usually I None
is I None
reversible I None
, I None
more I None
concern I None
is I None
needed I None
for I None
the I None
prevention I None
of I None
such I None
a I None
complication I None
in I None
children I None
. I None
<eof> I None

<s> O None
A I None
case I None
of I None
ventricular I Disease
tachycardia O Disease
related I None
to I None
caffeine I Chemical
pretreatment I None
. I None
<eof> I None

<s> O None
Suboptimal I None
seizure I Disease
duration I None
is I None
commonly I None
encountered I None
in I None
electroconvulsive I None
therapy I None
practice I None
, I None
especially I None
in I None
older I None
patients I None
with I None
higher I None
seizure I Disease
thresholds I None
. I None
<eof> I None

<s> O None
Intravenous I None
caffeine I Chemical
is I None
commonly I None
used I None
to I None
improve I None
seizure I Disease
duration I None
and I None
quality I None
in I None
such I None
patients I None
and I None
is I None
generally I None
well I None
tolerated I None
aside I None
from I None
occasional I None
reports I None
of I None
relatively I None
benign I None
ventricular I Disease
ectopy O Disease
. I None
<eof> I None

<s> O None
We I None
describe I None
a I None
patient I None
with I None
no I None
previous I None
history I None
of I None
cardiac I Disease
disease O Disease
or I None
arrhythmia I Disease
who I None
developed I None
sustained I None
bigeminy I None
and I None
2 I None
brief I None
runs I None
of I None
ventricular I Disease
tachycardia O Disease
after I None
caffeine I Chemical
administration I None
. I None
<eof> I None

<s> O None
Although I None
intravenous I None
caffeine I Chemical
is I None
generally I None
well I None
tolerated I None
, I None
the I None
clinician I None
should I None
be I None
aware I None
of I None
the I None
potential I None
for I None
unpredictable I None
and I None
serious I None
ventricular I Disease
arrhythmias O Disease
. I None
<eof> I None

<s> O None
Optical I None
coherence I None
tomography I None
can I None
measure I None
axonal I None
loss I None
in I None
patients I None
with I None
ethambutol I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
optic I Disease
neuropathy O Disease
. I None
<eof> I None

<s> O None
PURPOSE I None
: I None
<eof> I None

<s> O None
To I None
map I None
and I None
identify I None
the I None
pattern I None
, I None
in I None
vivo I None
, I None
of I None
axonal I Disease
degeneration O Disease
in I None
ethambutol I Chemical
-induced I None
optic I Disease
neuropathy O Disease
using I None
optical I None
coherence I None
tomography I None
( I None
OCT I None
) I None
. I None
<eof> I None

<s> O None
Ethambutol I Chemical
is I None
an I None
antimycobacterial I None
agent I None
often I None
used I None
to I None
treat I None
tuberculosis I Disease
. I None
<eof> I None

<s> O None
A I None
serious I None
complication I None
of I None
ethambutol I Chemical
is I None
an I None
optic I Disease
neuropathy O Disease
<eof> I None

<s> O None
that I None
impairs I None
visual I None
acuity I None
, I None
contrast I None
sensitivity I None
, I None
and I None
color I None
vision I None
. I None
<eof> I None

<s> O None
However I None
, I None
early I None
on I None
, I None
when I None
the I None
toxic I None
optic I Disease
neuropathy O Disease
is I None
mild I None
and I None
partly I None
reversible I None
, I None
the I None
funduscopic I None
findings I None
are I None
often I None
subtle I None
and I None
easy I None
to I None
miss I None
. I None
<eof> I None

<s> O None
METHODS I None
: I None
<eof> I None

<s> O None
Three I None
subjects I None
with I None
a I None
history I None
of I None
ethambutol I Chemical
<eof> I None

<s> O None
( I None
EMB I Chemical
) I None
-induced I None
<eof> I None

<s> O None
optic I Disease
neuropathy O Disease
of I None
short- I None
, I None
intermediate- I None
, I None
and I None
long I None
- I None
term I None
<eof> I None

<s> O None
visual I Disease
deficits O Disease
were I None
administered I None
a I None
full I None
neuro I None
- I None
ophthalmologic I None
examination I None
including I None
visual I None
acuity I None
, I None
color I None
vision I None
, I None
contrast I None
sensitivity I None
, I None
and I None
fundus I None
examination I None
. I None
<eof> I None

<s> O None
In I None
addition I None
, I None
OCT I None
( I None
OCT I None
3000 I None
, I None
Humphrey I None
- I None
Zeiss I None
, I None
Dublin I None
, I None
CA I None
) I None
was I None
performed I None
on I None
both I None
eyes I None
of I None
each I None
subject I None
using I None
the I None
retinal I None
nerve I None
fiber I None
layer I None
( I None
RNFL I None
) I None
analysis I None
protocol I None
. I None
<eof> I None

<s> O None
OCT I None
interpolates I None
data I None
from I None
100 I None
points I None
around I None
the I None
optic I None
nerve I None
to I None
effectively I None
map I None
out I None
the I None
RNFL I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
The I None
results I None
were I None
compared I None
to I None
the I None
calculated I None
average I None
RNFL I None
of I None
normal I None
eyes I None
accumulated I None
from I None
four I None
prior I None
studies I None
using I None
OCT I None
, I None
n=661 I None
. I None
<eof> I None

<s> O None
In I None
all I None
subjects I None
with I None
history I None
of I None
EMB I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
optic I Disease
neuropathy O Disease
, I None
there I None
was I None
a I None
mean I None
loss I None
of I None
72 I None
% I None
nerve I None
fiber I None
layer I None
thickness I None
in I None
the I None
temporal I None
quadrant I None
( I None
patient I None
A I None
, I None
with I None
eventual I None
recovery I None
of I None
visual I None
acuity I None
and I None
fields I None
, I None
58 I None
% I None
loss I None
; I None
patient I None
B I None
, I None
with I None
intermediate I None
visual I Disease
deficits O Disease
, I None
68 I None
% I None
loss I None
; I None
patient I None
C I None
, I None
with I None
chronic I None
visual I Disease
deficits O Disease
, I None
90 I None
% I None
loss I None
) I None
, I None
with I None
an I None
average I None
mean I None
optic I None
nerve I None
thickness I None
of I None
26+/-16 I None
microm I None
. I None
<eof> I None

<s> O None
There I None
was I None
a I None
combined I None
mean I None
loss I None
of I None
46 I None
% I None
of I None
fibers I None
from I None
the I None
superior I None
, I None
inferior I None
, I None
and I None
nasal I None
quadrants I None
in I None
the I None
( I None
six I None
) I None
eyes I None
of I None
all I None
three I None
subjects I None
( I None
mean I None
average I None
thickness I None
of I None
55+/-29 I None
microm I None
) I None
. I None
<eof> I None

<s> O None
In I None
both I None
sets I None
( I None
four I None
) I None
of I None
eyes I None
of I None
the I None
subjects I None
with I None
persistent I None
visual I Disease
deficits O Disease
<eof> I None

<s> O None
( I None
patients I None
B I None
and I None
C I None
) I None
, I None
there I None
was I None
an I None
average I None
loss I None
of I None
79 I None
% I None
of I None
nerve I None
fiber I None
thickness I None
in I None
the I None
temporal I None
quadrant I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
The I None
OCT I None
results I None
in I None
these I None
patients I None
with I None
<eof> I None

<s> O None
EMB I Chemical
-induced I None
<eof> I None

<s> O None
optic I Disease
neuropathy O Disease
show I None
considerable I None
loss I None
especially I None
of I None
the I None
temporal I None
fibers I None
. I None
<eof> I None

<s> O None
This I None
is I None
consistent I None
with I None
prior I None
histopathological I None
studies I None
that I None
show I None
predominant I None
loss I None
of I None
parvo I None
- I None
cellular I None
axons I None
( I None
or I None
small I None
- I None
caliber I None
axons I None
) I None
within I None
the I None
papillo I None
- I None
macular I None
bundle I None
in I None
toxic I None
or I None
hereditary I None
optic I Disease
neuropathies O Disease
. I None
<eof> I None

<s> O None
OCT I None
can I None
be I None
a I None
valuable I None
tool I None
in I None
the I None
quantitative I None
analysis I None
of I None
optic I Disease
neuropathies O Disease
. I None
<eof> I None

<s> O None
Additionally I None
, I None
in I None
terms I None
of I None
management I None
of I None
EMB I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
optic I Disease
neuropathy O Disease
, I None
it I None
is I None
important I None
to I None
properly I None
manage I None
ethambutol I Chemical
dosing I None
in I None
patients I None
with I None
renal I Disease
impairment O Disease
and I None
to I None
achieve I None
proper I None
transition I None
to I None
a I None
maintenance I None
dose I None
once I None
an I None
appropriate I None
loading I None
dose I None
has I None
been I None
reached I None
. I None
<eof> I None

<s> O None
Effects I None
of I None
the I None
cyclooxygenase-2 I None
specific I None
inhibitor I None
valdecoxib I Chemical
versus I None
nonsteroidal I None
antiinflammatory I None
agents I None
and I None
placebo I None
on I None
cardiovascular I None
thrombotic I Disease
events I None
in I None
patients I None
with I None
arthritis I Disease
. I None
<eof> I None

<s> O None
There I None
have I None
been I None
concerns I None
that I None
the I None
risk I None
of I None
cardiovascular I None
thrombotic I Disease
events I None
may I None
be I None
higher I None
with I None
cyclooxygenase I None
( I None
COX)-2-specific I None
inhibitors I None
than I None
nonselective I None
nonsteroidal I None
antiinflammatory I None
drugs I None
( I None
NSAIDs I None
) I None
. I None
<eof> I None

<s> O None
We I None
evaluated I None
cardiovascular I None
event I None
data I None
for I None
valdecoxib I Chemical
, I None
a I None
new I None
COX-2-specific I None
inhibitor I None
in I None
approximately I None
8000 I None
patients I None
with I None
osteoarthritis I Disease
and I None
rheumatoid I Disease
arthritis O Disease
treated I None
with I None
this I None
agent I None
in I None
randomized I None
clinical I None
trials I None
. I None
<eof> I None

<s> O None
The I None
incidence I None
of I None
cardiovascular I None
thrombotic I Disease
events I None
( I None
cardiac I None
, I None
cerebrovascular I None
and I None
peripheral I None
vascular I None
, I None
or I None
arterial I None
thrombotic I Disease
) I None
was I None
determined I None
by I None
analyzing I None
pooled I None
valdecoxib I Chemical
<eof> I None

<s> O None
( I None
10 I None
- I None
80 I None
mg I None
daily I None
) I None
, I None
<eof> I None

<s> O None
nonselective I None
NSAID I None
( I None
diclofenac I Chemical
75 I None
mg I None
bid I None
, I None
ibuprofen I Chemical
800 I None
mg I None
tid I None
, I None
or I None
naproxen I Chemical
500 I None
mg I None
bid I None
) I None
and I None
placebo I None
data I None
from I None
10 I None
randomized I None
osteoarthritis I Disease
and I None
rheumatoid I Disease
arthritis O Disease
trials I None
that I None
were I None
6 I None
- I None
52 I None
weeks I None
in I None
duration I None
. I None
<eof> I None

<s> O None
The I None
incidence I None
rates I None
of I None
events I None
were I None
determined I None
in I None
all I None
patients I None
( I None
n I None
= I None
7934 I None
) I None
and I None
in I None
users I None
of I None
low I None
- I None
dose I None
( I None
< I None
or I None
= I None
325 I None
mg I None
daily I None
) I None
<eof> I None

<s> O None
aspirin I Chemical
( I None
n I None
= I None
1051 I None
) I None
and I None
nonusers I None
of I None
aspirin I Chemical
<eof> I None

<s> O None
( I None
n I None
= I None
6883 I None
) I None
. I None
<eof> I None

<s> O None
Crude I None
and I None
exposure I None
- I None
adjusted I None
incidences I None
of I None
thrombotic I Disease
events I None
were I None
similar I None
for I None
valdecoxib I Chemical
, I None
NSAIDs I None
, I None
and I None
placebo I None
. I None
<eof> I None

<s> O None
The I None
risk I None
of I None
serious I None
thrombotic I Disease
events I None
was I None
also I None
similar I None
for I None
each I None
valdecoxib I Chemical
dose I None
. I None
<eof> I None

<s> O None
Thrombotic I Disease
risk I None
was I None
consistently I None
higher I None
for I None
users I None
of I None
aspirin I Chemical
users I None
than I None
nonusers I None
of I None
aspirin I Chemical
<eof> I None

<s> O None
( I None
placebo I None
, I None
1.4 I None
% I None
vs. I None
0 I None
% I None
; I None
valdecoxib I Chemical
, I None
1.7 I None
% I None
vs. I None
0.2 I None
% I None
; I None
NSAIDs I None
, I None
1.9 I None
% I None
vs. I None
0.5 I None
% I None
) I None
. I None
<eof> I None

<s> O None
The I None
rates I None
of I None
events I None
in I None
users I None
of I None
aspirin I Chemical
were I None
similar I None
for I None
all I None
3 I None
treatment I None
groups I None
and I None
across I None
valdecoxib I Chemical
doses I None
. I None
<eof> I None

<s> O None
Short- I None
and I None
intermediate I None
- I None
term I None
treatment I None
with I None
therapeutic I None
( I None
10 I None
or I None
20 I None
mg I None
daily I None
) I None
and I None
supratherapeutic I None
( I None
40 I None
or I None
80 I None
mg I None
daily I None
) I None
<eof> I None

<s> O None
valdecoxib I Chemical
doses I None
was I None
not I None
associated I None
with I None
an I None
increased I None
incidence I None
of I None
thrombotic I Disease
events I None
relative I None
to I None
nonselective I None
NSAIDs I None
or I None
placebo I None
in I None
osteoarthritis I Disease
and I None
rheumatoid I Disease
arthritis O Disease
patients I None
in I None
controlled I None
clinical I None
trials I None
. I None
<eof> I None

<s> O None
A I None
randomized I None
, I None
placebo I None
- I None
controlled I None
, I None
crossover I None
study I None
of I None
ephedrine I Chemical
for I None
SSRI I None
- I None
induced I None
female I None
sexual I Disease
dysfunction O Disease
. I None
<eof> I None

<s> O None
The I None
objective I None
of I None
this I None
study I None
was I None
to I None
determine I None
whether I None
ephedrine I Chemical
, I None
an I None
alpha- I None
and I None
beta I None
- I None
adrenergic I None
agonist I None
previously I None
shown I None
to I None
enhance I None
genital I None
blood I None
flow I None
in I None
women I None
, I None
has I None
beneficial I None
effects I None
in I None
reversing I None
antidepressant I None
- I None
induced I None
sexual I Disease
dysfunction O Disease
. I None
<eof> I None

<s> O None
Nineteen I None
sexually I Disease
dysfunctional O Disease
<eof> I None

<s> O None
women I None
receiving I None
either I None
fluoxetine I Chemical
, I None
sertraline I Chemical
, I None
or I None
paroxetine I Chemical
participated I None
in I None
an I None
eight I None
- I None
week I None
, I None
double I None
- I None
blind I None
, I None
placebo I None
- I None
controlled I None
, I None
cross I None
- I None
over I None
study I None
of I None
the I None
effects I None
of I None
ephedrine I Chemical
<eof> I None

<s> O None
( I None
50 I None
mg I None
) I None
on I None
self I None
- I None
report I None
measures I None
of I None
sexual I None
desire I None
, I None
arousal I None
, I None
orgasm I None
, I None
and I None
sexual I None
satisfaction I None
. I None
<eof> I None

<s> O None
Although I None
there I None
were I None
significant I None
improvements I None
relative I None
to I None
baseline I None
in I None
sexual I None
desire I None
and I None
orgasm I None
intensity I None
/ I None
pleasure I None
on I None
50 I None
mg I None
<eof> I None

<s> O None
ephedrine I Chemical
1-hr I None
prior I None
to I None
sexual I None
activity I None
, I None
significant I None
improvements I None
in I None
these I None
measures I None
, I None
as I None
well I None
as I None
in I None
sexual I None
arousal I None
and I None
orgasmic I None
ability I None
also I None
were I None
noted I None
with I None
placebo I None
. I None
<eof> I None

<s> O None
These I None
findings I None
highlight I None
the I None
importance I None
of I None
conducting I None
placebo I None
- I None
controlled I None
trials I None
for I None
this I None
condition I None
. I None
<eof> I None

<s> O None
Erectile I Disease
dysfunction O Disease
occurs I None
following I None
substantia I None
nigra I None
lesions I None
in I None
the I None
rat I None
. I None
<eof> I None

<s> O None
Erectile I None
function I None
was I None
assessed I None
6 I None
weeks I None
following I None
uni- I None
and I None
bilateral I None
injections I None
of I None
6-hydroxydopamine I Chemical
in I None
the I None
substantia I None
nigra I None
nucleus I None
of I None
the I None
brain I None
. I None
<eof> I None

<s> O None
Behavioral I None
apomorphine I Chemical
<eof> I None

<s> O None
-induced I None
penile I None
erections I None
were I None
reduced I None
( I None
5/8 I None
) I None
and I None
increased I None
( I None
3/8 I None
) I None
in I None
uni- I None
and I None
bilateral I None
lesioned I None
animals I None
. I None
<eof> I None

<s> O None
Intracavernous I None
pressures I None
, I None
following I None
electrical I None
stimulation I None
of I None
the I None
cavernous I None
nerve I None
, I None
decreased I None
in I None
lesioned I None
animals I None
. I None
<eof> I None

<s> O None
Lesions I None
of I None
the I None
substantia I None
nigra I None
were I None
confirmed I None
by I None
histology I None
. I None
<eof> I None

<s> O None
Concentration I None
of I None
dopamine I Chemical
and I None
its I None
metabolites I None
were I None
decreased I None
in I None
the I None
striatum I None
of I None
substantia I None
nigra I None
lesioned I None
rats I None
. I None
<eof> I None

<s> O None
Lesions I None
of I None
the I None
substantia I None
nigra I None
are I None
therefore I None
associated I None
with I None
erectile I Disease
dysfunction O Disease
in I None
rats I None
and I None
may I None
serve I None
as I None
a I None
model I None
to I None
study I None
erectile I Disease
dysfunction O Disease
in I None
Parkinson I Disease
's O Disease
disease O Disease
. I None
<eof> I None

<s> O None
Potential I None
therapeutic I None
use I None
of I None
the I None
selective I None
dopamine I Chemical
D1 I None
receptor I None
agonist I None
, I None
A-86929 I Chemical
: I None
an I None
acute I None
study I None
in I None
parkinsonian I Disease
levodopa I Chemical
<eof> I None

<s> O None
-primed I None
monkeys I None
. I None
<eof> I None

<s> O None
The I None
clinical I None
utility I None
of I None
dopamine I Chemical
<eof> I None

<s> O None
( I None
DA I Chemical
) I None
D1 I None
receptor I None
agonists I None
in I None
the I None
treatment I None
of I None
Parkinson I Disease
's O Disease
disease O Disease
<eof> I None

<s> O None
( I None
PD I Disease
) I None
is I None
still I None
unclear I None
. I None
<eof> I None

<s> O None
The I None
therapeutic I None
use I None
of I None
selective I None
DA I Chemical
D1 I None
receptor I None
agonists I None
such I None
as I None
SKF-82958 I Chemical
<eof> I None

<s> O None
( I None
6-chloro-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzaze I Chemical
pine O Chemical
hydrobromide O Chemical
) I None
and I None
A-77636 I Chemical
<eof> I None

<s> O None
( I None
[ I Chemical
1R O Chemical
, O Chemical
3S O Chemical
] O Chemical
3-[1'-admantyl]-1-aminomethyl-3,4-dihydro-5,6-dihydroxy-1H-2-benzo O Chemical
pyran O Chemical
hydrochloride O Chemical
) I None
seems I None
limited I None
because I None
of I None
their I None
duration I None
of I None
action I None
, I None
which I None
is I None
too I None
short I None
for I None
SKF-82958 I Chemical
<eof> I None

<s> O None
( I None
< I None
1 I None
hr I None
) I None
and I None
too I None
long I None
for I None
A-77636 I Chemical
<eof> I None

<s> O None
( I None
> I None
20 I None
hr I None
, I None
leading I None
to I None
behavioral I None
tolerance I None
) I None
. I None
<eof> I None

<s> O None
We I None
therefore I None
conducted I None
the I None
present I None
acute I None
dose I None
- I None
response I None
study I None
in I None
four I None
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine I Chemical
<eof> I None

<s> O None
( I None
MPTP I Chemical
) I None
-exposed I None
<eof> I None

<s> O None
cynomolgus I None
monkeys I None
primed I None
to I None
exhibit I None
<eof> I None

<s> O None
levodopa I Chemical
-induced I None
<eof> I None

<s> O None
dyskinesias I Disease
to I None
evaluate I None
the I None
locomotor I None
and I None
dyskinetic I Disease
effects I None
on I None
challenge I None
with I None
four I None
doses I None
( I None
from I None
0.03 I None
to I None
1.0 I None
mg I None
/ I None
kg I None
) I None
of I None
A-86929 I Chemical
<eof> I None

<s> O None
( I None
[ I Chemical
-]-[5aR,11bS]-4,5,5a,6,7,11b O Chemical
- O Chemical
hexahydro-2-propyl-3-thia-5-+ O Chemical
+ O Chemical
+ O Chemical
azacyclopent-1- O Chemical
ena[c]phenathrene-9 O Chemical
- O Chemical
10-diol O Chemical
) I None
, I None
a I None
selective I None
and I None
full I None
DA I Chemical
D1-like I None
receptor I None
agonist I None
with I None
an I None
intermediate I None
duration I None
of I None
action I None
. I None
<eof> I None

<s> O None
Levodopa I Chemical
and I None
the I None
<eof> I None

<s> O None
DA I Chemical
D2-like I None
receptor I None
agonist I None
, I None
LY-171555 I Chemical
<eof> I None

<s> O None
( I None
[ I Chemical
4aR O Chemical
- O Chemical
trans]-4,4a,5,6,7,8,8a,9-o O Chemical
- O Chemical
dihydro-5n O Chemical
- O Chemical
propyl-2H O Chemical
- O Chemical
pyrazo O Chemical
lo-3 O Chemical
- O Chemical
4-quinoline O Chemical
hydrochloride O Chemical
) I None
were I None
also I None
used I None
for I None
comparison I None
. I None
<eof> I None

<s> O None
Acute I None
administration I None
of I None
A-86929 I Chemical
was I None
as I None
efficacious I None
in I None
alleviating I None
MPTP I Chemical
-induced I None
<eof> I None

<s> O None
parkinsonism I Disease
as I None
levodopa I Chemical
and I None
LY-171555 I Chemical
, I None
but I None
was I None
less I None
likely I None
to I None
reproduce I None
the I None
levodopa I Chemical
-induced I None
dyskinesias I Disease
in I None
these I None
animals I None
than I None
with I None
either I None
LY-171555 I Chemical
or I None
subsequent I None
challenge I None
of I None
levodopa I Chemical
. I None
<eof> I None

<s> O None
Selective I None
stimulation I None
of I None
the I None
DA I Chemical
D1 I None
receptor I None
may I None
provide I None
better I None
integration I None
of I None
neural I None
inputs I None
transmitted I None
to I None
the I None
internal I None
segment I None
of I None
the I None
globus I None
pallidus I None
( I None
referred I None
to I None
as I None
the I None
basal I None
ganglia I None
output I None
) I None
compared I None
with I None
levodopa I Chemical
and I None
selective I None
DA I Chemical
D2 I None
receptor I None
agonist I None
. I None
<eof> I None

<s> O None
Potent I None
DA I Chemical
<eof> I None

<s> O None
D1 I None
receptor I None
agents I None
with I None
an I None
intermediate I None
duration I None
of I None
efficacy I None
such I None
as I None
A-86929 I Chemical
<eof> I None

<s> O None
( I None
approximately I None
4 I None
hr I None
at I None
higher I None
doses I None
tested I None
) I None
are I None
potential I None
therapeutic I None
tools I None
in I None
PD I Disease
and I None
merit I None
further I None
attention I None
. I None
<eof> I None

<s> O None
Deaths I None
from I None
local I None
anesthetic I None
- I None
induced I None
convulsions I Disease
in I None
mice I None
. I None
<eof> I None

<s> O None
Median I None
convulsant I None
( I None
CD50 I None
) I None
and I None
median I None
lethal I None
<eof> I None

<s> O None
( I None
LD50 I None
) I None
doses I None
of I None
three I None
representative I None
local I None
anesthetics I None
were I None
determined I None
in I None
adult I None
mice I None
to I None
evaluate I None
the I None
threat I None
to I None
life I None
of I None
local I None
anesthetic I None
- I None
induced I None
convulsions I Disease
. I None
<eof> I None

<s> O None
The I None
CD50 I None
and I None
LD50 I None
, I None
respectively I None
, I None
were I None
57.7 I None
and I None
58.7 I None
mg I None
/ I None
kg I None
for I None
<eof> I None

<s> O None
bupivacaine I Chemical
, I None
111.0 I None
and I None
133.1 I None
mg I None
/ I None
kg I None
for I None
lidocaine I Chemical
, I None
and I None
243.4 I None
and I None
266.5 I None
mg I None
/ I None
kg I None
for I None
<eof> I None

<s> O None
chloroprocaine I Chemical
. I None
<eof> I None

<s> O None
When I None
given I None
intraperitoneally I None
, I None
bupivacaine I Chemical
thus I None
was I None
only I None
about I None
twice I None
as I None
toxic I None
as I None
lidocaine I Chemical
and I None
four I None
times I None
as I None
toxic I None
as I None
chloroprocaine I Chemical
. I None
<eof> I None

<s> O None
Convulsions I Disease
always I None
preceded I None
death I None
, I None
except I None
after I None
precipitous I None
cardiopulmonary I Disease
arrest O Disease
from I None
extreme I None
doses I None
. I None
<eof> I None

<s> O None
A I None
CD50 I None
dose I None
of I None
local I None
anesthetic I None
( I None
causing I None
convulsions I Disease
in I None
50 I None
% I None
of I None
mice I None
) I None
was I None
fatal I None
in I None
90 I None
% I None
of I None
bupivacaine I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
seizures I Disease
, I None
in I None
57 I None
% I None
of I None
the I None
chloroprocaine I Chemical
group I None
, I None
and I None
in I None
6 I None
% I None
of I None
the I None
lidocaine I Chemical
group I None
. I None
<eof> I None

<s> O None
The I None
narrow I None
gap I None
between I None
convulsant I None
and I None
lethal I None
doses I None
of I None
local I None
anesthetics I None
indicates I None
that I None
untreated I None
convulsions I Disease
present I None
<eof> I None

<s> O None
much I None
more I None
of I None
a I None
threat I None
to I None
life I None
than I None
heretofore I None
appreciated I None
. I None
<eof> I None

<s> O None
Myoclonic I None
, I None
atonic I None
, I None
and I None
absence I None
seizures I None
following I None
institution I None
of I None
carbamazepine I Chemical
therapy I None
in I None
children I None
. I None
<eof> I None

<s> O None
Five I None
children I None
, I None
aged I None
3 I None
to I None
11 I None
years I None
, I None
treated I None
with I None
carbamazepine I Chemical
for I None
epilepsy I Disease
, I None
had I None
an I None
acute I None
aberrant I None
reaction I None
characterized I None
by I None
the I None
onset I None
of I None
myoclonic I None
, I None
atypical I None
absence I None
and/or I None
atonic I None
( I None
minor I None
motor I None
) I None
seizures I None
within I None
a I None
few I None
days I None
. I None
<eof> I None

<s> O None
When I None
the I None
carbamazepine I Chemical
was I None
discontinued I None
, I None
two I None
of I None
the I None
children I None
returned I None
to I None
their I None
former I None
state I None
very I None
quickly I None
, I None
two I None
had I None
the I None
minor I None
motor I None
seizures I Disease
resolve I None
in I None
3 I None
and I None
6 I None
months I None
, I None
and I None
one I None
had I None
the I None
seizures I Disease
persist I None
. I None
<eof> I None

<s> O None
The I None
child I None
in I None
whom I None
the I None
seizures I Disease
persisted I None
was I None
later I None
found I None
to I None
have I None
ceroid I Disease
lipofuscinosis O Disease
. I None
<eof> I None

<s> O None
The I None
other I None
children I None
are I None
doing I None
well I None
on I None
other I None
anticonvulsants I None
. I None
<eof> I None

<s> O None
Naloxone I Chemical
reversal I None
of I None
hypotension I Disease
due I None
to I None
captopril I Chemical
overdose I Disease
. I None
<eof> I None

<s> O None
The I None
hemodynamic I None
effects I None
of I None
captopril I Chemical
and I None
other I None
angiotensin I Chemical
- O Chemical
converting O Chemical
enzyme O Chemical
inhibitors O Chemical
may I None
be I None
mediated I None
by I None
the I None
endogenous I None
opioid I None
system I None
. I None
<eof> I None

<s> O None
The I None
opioid I None
antagonist I None
naloxone I Chemical
has I None
been I None
shown I None
to I None
block I None
or I None
reverse I None
the I None
hypotensive I Disease
actions I None
of I None
captopril I Chemical
. I None
<eof> I None

<s> O None
We I None
report I None
a I None
case I None
of I None
an I None
intentional I None
captopril I Chemical
overdose I Disease
, I None
manifested I None
by I None
marked I None
hypotension I Disease
, I None
that I None
resolved I None
promptly I None
with I None
the I None
administration I None
of I None
naloxone I Chemical
. I None
<eof> I None

<s> O None
To I None
our I None
knowledge I None
, I None
this I None
is I None
the I None
first I None
reported I None
case I None
of I None
captopril I Chemical
-induced I None
<eof> I None

<s> O None
hypotension I Disease
treated I None
with I None
naloxone I Chemical
. I None
<eof> I None

<s> O None
Our I None
experience I None
demonstrates I None
a I None
possible I None
role I None
of I None
naloxone I Chemical
in I None
the I None
reversal I None
of I None
hypotension I Disease
resulting I None
from I None
captopril I Chemical
. I None
<eof> I None

<s> O None
Carbamazepine I Chemical
-induced I None
cardiac I Disease
dysfunction O Disease
. I None
<eof> I None

<s> O None
Characterization I None
of I None
two I None
distinct I None
clinical I None
syndromes I None
. I None
<eof> I None

<s> O None
A I None
patient I None
with I None
sinus I None
bradycardia I Disease
and I None
atrioventricular I Disease
block O Disease
, I None
induced I None
by I None
carbamazepine I Chemical
, I None
prompted I None
an I None
extensive I None
literature I None
review I None
of I None
all I None
previously I None
reported I None
cases I None
. I None
<eof> I None

<s> O None
From I None
the I None
analysis I None
of I None
these I None
cases I None
, I None
two I None
distinct I None
forms I None
of I None
carbamazepine I Chemical
-associated I None
cardiac I Disease
dysfunction O Disease
emerged I None
. I None
<eof> I None

<s> O None
One I None
patient I None
group I None
developed I None
sinus I Disease
tachycardias O Disease
in I None
the I None
setting I None
of I None
a I None
massive I None
carbamazepine I Chemical
overdose I Disease
. I None
<eof> I None

<s> O None
The I None
second I None
group I None
consisted I None
almost I None
exclusively I None
of I None
elderly I None
women I None
who I None
developed I None
potentially I None
life I None
- I None
threatening I None
bradyarrhythmias I Disease
or I None
atrioventricular I Disease
conduction O Disease
delay O Disease
, I None
associated I None
with I None
either I None
therapeutic I None
or I None
modestly I None
elevated I None
carbamazepine I Chemical
serum I None
levels I None
. I None
<eof> I None

<s> O None
Because I None
carbamazepine I Chemical
is I None
widely I None
used I None
in I None
the I None
treatment I None
of I None
many I None
neurologic I None
and I None
psychiatric I Disease
conditions I None
, I None
the I None
recognition I None
of I None
the I None
latter I None
syndrome I None
has I None
important I None
implications I None
for I None
the I None
use I None
of I None
this I None
drug I None
in I None
elderly I None
patients I None
. I None
<eof> I None

<s> O None
Glutamatergic I None
neurotransmission I None
mediated I None
by I None
NMDA I Chemical
receptors I None
in I None
the I None
inferior I None
colliculus I None
can I None
modulate I None
haloperidol I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
catalepsy I Disease
. I None
<eof> I None

<s> O None
The I None
inferior I None
colliculus I None
( I None
IC I None
) I None
is I None
primarily I None
involved I None
in I None
the I None
processing I None
of I None
auditory I None
information I None
, I None
but I None
it I None
is I None
distinguished I None
from I None
other I None
auditory I None
nuclei I None
in I None
the I None
brainstem I None
by I None
its I None
connections I None
with I None
structures I None
of I None
the I None
motor I None
system I None
. I None
<eof> I None

<s> O None
Functional I None
evidence I None
relating I None
the I None
IC I None
to I None
motor I None
behavior I None
derives I None
from I None
experiments I None
showing I None
that I None
activation I None
of I None
the I None
IC I None
by I None
electrical I None
stimulation I None
or I None
excitatory I None
amino I Chemical
acid O Chemical
microinjection I None
causes I None
freezing I None
, I None
escape I None
- I None
like I None
behavior I None
, I None
and I None
immobility I None
. I None
<eof> I None

<s> O None
However I None
, I None
the I None
nature I None
of I None
this I None
immobility I None
is I None
still I None
unclear I None
. I None
<eof> I None

<s> O None
The I None
present I None
study I None
examined I None
the I None
influence I None
of I None
excitatory I None
amino I Chemical
acid O Chemical
-mediated I None
mechanisms I None
in I None
the I None
IC I None
on I None
the I None
catalepsy I Disease
induced I None
by I None
the I None
dopamine I Chemical
receptor I None
blocker I None
haloperidol I Chemical
administered I None
systemically I None
( I None
1 I None
or I None
0.5 I None
mg I None
/ I None
kg I None
) I None
in I None
rats I None
. I None
<eof> I None

<s> O None
Haloperidol I Chemical
-induced I None
<eof> I None

<s> O None
catalepsy I Disease
was I None
challenged I None
with I None
prior I None
intracollicular I None
microinjections I None
of I None
glutamate I Chemical
NMDA I Chemical
receptor I None
antagonists I None
, I None
MK-801 I Chemical
( I None
15 I None
or I None
30 I None
mmol/0.5 I None
microl I None
) I None
and I None
AP7 I Chemical
( I None
10 I None
or I None
20 I None
nmol/0.5 I None
microl I None
) I None
, I None
or I None
of I None
the I None
NMDA I Chemical
receptor I None
agonist I None
N I Chemical
- O Chemical
methyl O Chemical
- O Chemical
d O Chemical
- O Chemical
aspartate O Chemical
<eof> I None

<s> O None
( I None
NMDA I Chemical
, I None
20 I None
or I None
30 I None
nmol/0.5 I None
microl I None
) I None
. I None
<eof> I None

<s> O None
The I None
results I None
showed I None
that I None
intracollicular I None
microinjection I None
of I None
MK-801 I Chemical
and I None
AP7 I Chemical
previous I None
to I None
systemic I None
injections I None
of I None
haloperidol I Chemical
significantly I None
attenuated I None
the I None
catalepsy I Disease
, I None
as I None
indicated I None
by I None
a I None
reduced I None
latency I None
to I None
step I None
down I None
from I None
a I None
horizontal I None
bar I None
. I None
<eof> I None

<s> O None
Accordingly I None
, I None
intracollicular I None
microinjection I None
of I None
NMDA I Chemical
increased I None
the I None
latency I None
to I None
step I None
down I None
the I None
bar I None
. I None
<eof> I None

<s> O None
These I None
findings I None
suggest I None
that I None
glutamate I Chemical
-mediated I None
mechanisms I None
in I None
the I None
neural I None
circuits I None
at I None
the I None
IC I None
level I None
influence I None
<eof> I None

<s> O None
haloperidol I Chemical
-induced I None
<eof> I None

<s> O None
catalepsy I Disease
and I None
participate I None
in I None
the I None
regulation I None
of I None
motor I None
activity I None
. I None
<eof> I None

<s> O None
Metabotropic I None
glutamate I Chemical
7 I None
receptor I None
subtype I None
modulates I None
motor I None
symptoms I None
in I None
rodent I None
models I None
of I None
Parkinson I Disease
's O Disease
disease O Disease
. I None
<eof> I None

<s> O None
Metabotropic I None
glutamate I Chemical
<eof> I None

<s> O None
( I None
mGlu I None
) I None
receptors I None
modulate I None
synaptic I None
transmission I None
in I None
the I None
central I None
nervous I None
system I None
and I None
represent I None
promising I None
therapeutic I None
targets I None
for I None
symptomatic I None
treatment I None
of I None
Parkinson I Disease
's O Disease
disease O Disease
<eof> I None

<s> O None
( I None
PD I Disease
) I None
. I None
<eof> I None

<s> O None
Among I None
the I None
eight I None
mGlu I None
receptor I None
subtypes I None
, I None
mGlu7 I None
receptor I None
is I None
prominently I None
expressed I None
in I None
the I None
basal I None
ganglia I None
, I None
but I None
its I None
role I None
in I None
restoring I None
motor I None
function I None
in I None
animal I None
models I None
of I None
PD I Disease
is I None
not I None
known I None
. I None
<eof> I None

<s> O None
The I None
effects I None
of I None
N I Chemical
, O Chemical
N'-dibenzhydrylethane-1,2-diamine O Chemical
dihydrochloride O Chemical
<eof> I None

<s> O None
( I None
AMN082 I Chemical
) I None
, I None
the I None
first I None
selective I None
allosteric I None
activator I None
of I None
mGlu7 I None
receptors I None
, I None
were I None
thus I None
tested I None
in I None
different I None
rodent I None
models I None
of I None
PD I Disease
. I None
<eof> I None

<s> O None
Here I None
, I None
we I None
show I None
that I None
oral I None
( I None
5 I None
mg I None
/ I None
kg I None
) I None
or I None
intrastriatal I None
administration I None
( I None
0.1 I None
and I None
0.5 I None
nmol I None
) I None
of I None
AMN082 I Chemical
reverses I None
<eof> I None

<s> O None
haloperidol I Chemical
-induced I None
<eof> I None

<s> O None
catalepsy I Disease
in I None
rats I None
. I None
<eof> I None

<s> O None
AMN082 I Chemical
( I None
2.5 I None
and I None
5 I None
mg I None
/ I None
kg I None
) I None
reduces I None
apomorphine I Chemical
-induced I None
rotations I None
in I None
unilateral I None
6-hydroxydopamine I Chemical
<eof> I None

<s> O None
( I None
6-OHDA I Chemical
) I None
-lesioned I None
rats I None
. I None
<eof> I None

<s> O None
In I None
a I None
more I None
complex I None
task I None
commonly I None
used I None
to I None
evaluate I None
major I None
akinetic I Disease
symptoms I None
of I None
PD I Disease
patients I None
, I None
5 I None
mg I None
/ I None
kg I None
AMN082 I Chemical
reverses I None
the I None
increased I None
reaction I None
time I None
to I None
respond I None
to I None
a I None
cue I None
of I None
bilateral I None
6-OHDA I Chemical
-lesioned I None
rats I None
. I None
<eof> I None

<s> O None
In I None
addition I None
, I None
AMN082 I Chemical
reduces I None
the I None
duration I None
of I None
haloperidol I Chemical
-induced I None
<eof> I None

<s> O None
catalepsy I Disease
in I None
a I None
mGlu7 I None
receptor I None
- I None
dependent I None
manner I None
in I None
wild I None
- I None
type I None
but I None
not I None
mGlu7 I None
receptor I None
knockout I None
mice I None
. I None
<eof> I None

<s> O None
Higher I None
doses I None
of I None
AMN082 I Chemical
<eof> I None

<s> O None
( I None
10 I None
and I None
20 I None
mg I None
/ I None
kg I None
p.o I None
. I None
) I None
<eof> I None

<s> O None
have I None
no I None
effect I None
on I None
the I None
same I None
models I None
of I None
PD I Disease
. I None
<eof> I None

<s> O None
Overall I None
these I None
findings I None
suggest I None
that I None
mGlu7 I None
receptor I None
activation I None
can I None
reverse I None
motor I None
dysfunction I None
associated I None
with I None
reduced I None
dopamine I Chemical
activity I None
. I None
<eof> I None

<s> O None
Selective I None
ligands I None
of I None
mGlu7 I None
receptor I None
subtypes I None
may I None
thus I None
be I None
considered I None
as I None
promising I None
compounds I None
for I None
the I None
development I None
of I None
antiparkinsonian I None
therapeutic I None
strategies I None
. I None
<eof> I None

<s> O None
Nimodipine I Chemical
prevents I None
memory I Disease
impairment O Disease
caused I None
by I None
<eof> I None

<s> O None
nitroglycerin I Chemical
-induced I None
<eof> I None

<s> O None
hypotension I Disease
in I None
adult I None
mice I None
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
<eof> I None

<s> O None
Hypotension I Disease
and I None
a I None
resultant I None
decrease I None
in I None
cerebral I None
blood I None
flow I None
have I None
been I None
implicated I None
in I None
the I None
development I None
of I None
cognitive I Disease
dysfunction O Disease
. I None
<eof> I None

<s> O None
We I None
tested I None
the I None
hypothesis I None
that I None
nimodipine I Chemical
<eof> I None

<s> O None
( I None
NIMO I Chemical
) I None
administered I None
at I None
the I None
onset I None
of I None
nitroglycerin I Chemical
<eof> I None

<s> O None
( I None
NTG I Chemical
) I None
-induced I None
<eof> I None

<s> O None
hypotension I Disease
would I None
preserve I None
long I None
- I None
term I None
associative I None
memory I None
. I None
<eof> I None

<s> O None
METHODS I None
: I None
<eof> I None

<s> O None
The I None
passive I None
avoidance I None
( I None
PA I None
) I None
paradigm I None
was I None
used I None
to I None
assess I None
memory I None
retention I None
. I None
<eof> I None

<s> O None
For I None
PA I None
training I None
, I None
latencies I None
( I None
seconds I None
) I None
were I None
recorded I None
for I None
entry I None
from I None
a I None
suspended I None
platform I None
into I None
a I None
Plexiglas I None
tube I None
where I None
a I None
shock I None
was I None
automatically I None
delivered I None
. I None
<eof> I None

<s> O None
Latencies I None
were I None
recorded I None
48 I None
h I None
later I None
for I None
a I None
testing I None
trial I None
. I None
<eof> I None

<s> O None
Ninety I None
- I None
six I None
Swiss I None
- I None
Webster I None
mice I None
( I None
30 I None
- I None
35 I None
g I None
, I None
6 I None
- I None
8 I None
wk I None
) I None
, I None
were I None
randomized I None
into I None
6 I None
groups I None
1 I None
) I None
saline I None
( I None
control I None
) I None
, I None
2 I None
) I None
NTG I Chemical
immediately I None
after I None
learning I None
, I None
3 I None
) I None
NTG I Chemical
3 I None
h I None
after I None
learning I None
, I None
4 I None
) I None
NTG I Chemical
and I None
NIMO I Chemical
, I None
5 I None
) I None
vehicle I None
, I None
and I None
6 I None
) I None
NIMO I Chemical
alone I None
. I None
<eof> I None

<s> O None
The I None
extent I None
of I None
hypotension I Disease
and I None
changes I None
in I None
brain I None
tissue I None
oxygenation I None
( I None
PbtO(2 I None
) I None
) I None
and I None
in I None
cerebral I None
blood I None
flow I None
were I None
studied I None
in I None
a I None
separate I None
group I None
of I None
animals I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
All I None
groups I None
exhibited I None
similar I None
training I None
latencies I None
( I None
17.0 I None
+ I None
/- I None
4.6 I None
s I None
) I None
. I None
<eof> I None

<s> O None
Mice I None
subjected I None
to I None
hypotensive I Disease
episodes I None
showed I None
a I None
significant I None
decrease I None
in I None
latency I None
time I None
( I None
178 I None
+ I None
/- I None
<eof> I None

<s> O None
156 I None
s I None
) I None
compared I None
with I None
those I None
injected I None
with I None
saline I None
, I None
NTG I Chemical
+ I None
NIMO I Chemical
, I None
or I None
delayed I None
NTG I Chemical
<eof> I None

<s> O None
( I None
580 I None
+ I None
/- I None
<eof> I None

<s> O None
81 I None
s I None
, I None
557 I None
+ I None
/- I None
<eof> I None

<s> O None
67 I None
s I None
, I None
and I None
493 I None
+ I None
/- I None
<eof> I None

<s> O None
146 I None
s I None
, I None
respectively I None
) I None
. I None
<eof> I None

<s> O None
A I None
Kruskal I None
- I None
Wallis I None
1-way I None
analysis I None
of I None
variance I None
indicated I None
a I None
significant I None
difference I None
among I None
the I None
4 I None
treatment I None
groups I None
( I None
H I None
= I None
15.34 I None
; I None
P I None
< I None
0.001 I None
) I None
. I None
<eof> I None

<s> O None
In I None
a I None
separate I None
group I None
of I None
mice I None
not I None
subjected I None
to I None
behavioral I None
studies I None
, I None
the I None
same I None
dose I None
of I None
NTG I Chemical
<eof> I None

<s> O None
( I None
n I None
= I None
3 I None
) I None
and I None
NTG I Chemical
+ I None
NIMO I Chemical
( I None
n I None
= I None
3 I None
) I None
caused I None
mean I None
arterial I None
blood I None
pressure I None
to I None
decrease I None
from I None
85.9 I None
+ I None
/- I None
<eof> I None

<s> O None
3.8 I None
mm I None
Hg I None
sem I None
to I None
31.6 I None
+ I None
/- I None
0.8 I None
mm I None
Hg I None
sem I None
and I None
from I None
86.2 I None
+ I None
/- I None
<eof> I None

<s> O None
3.7 I None
mm I None
Hg I None
sem I None
to I None
32.6 I None
+ I None
/- I None
<eof> I None

<s> O None
0.2 I None
mm I None
Hg I None
sem I None
, I None
respectively I None
. I None
<eof> I None

<s> O None
Mean I None
arterial I None
blood I None
pressure I None
in I None
mice I None
treated I None
with I None
NIMO I Chemical
alone I None
decreased I None
from I None
88.1 I None
+ I None
/- I None
<eof> I None

<s> O None
3.8 I None
mm I None
Hg I None
to I None
80.0 I None
+ I None
/- I None
<eof> I None

<s> O None
2.9 I None
mm I None
Hg I None
. I None
<eof> I None

<s> O None
The I None
intergroup I None
difference I None
was I None
statistically I None
significant I None
( I None
P I None
< I None
0.05 I None
) I None
. I None
<eof> I None

<s> O None
PbtO(2 I None
) I None
decreased I None
from I None
51.7 I None
+ I None
/- I None
<eof> I None

<s> O None
4.5 I None
mm I None
Hg I None
sem I None
to I None
33.8 I None
+ I None
/- I None
<eof> I None

<s> O None
5.2 I None
mm I None
Hg I None
sem I None
in I None
the I None
NTG I Chemical
group I None
and I None
from I None
38.6 I None
+ I None
/- I None
6.1 I None
mm I None
Hg I None
sem I None
to I None
25.4 I None
+ I None
/- I None
2.0 I None
mm I None
Hg I None
sem I None
in I None
the I None
NTG I Chemical
+ I None
NIMO I Chemical
groups I None
, I None
respectively I None
. I None
<eof> I None

<s> O None
There I None
were I None
no I None
significant I None
differences I None
among I None
groups I None
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
<eof> I None

<s> O None
In I None
a I None
PA I None
retention I None
paradigm I None
, I None
the I None
injection I None
of I None
NTG I Chemical
immediately I None
after I None
learning I None
produced I None
a I None
significant I None
impairment I None
of I None
long I None
- I None
term I None
associative I None
memory I None
in I None
mice I None
, I None
whereas I None
delayed I None
induced I None
hypotension I Disease
had I None
no I None
effect I None
. I None
<eof> I None

<s> O None
NIMO I Chemical
attenuated I None
the I None
disruption I None
in I None
consolidation I None
of I None
long I None
- I None
term I None
memory I None
caused I None
by I None
NTG I Chemical
but I None
did I None
not I None
improve I None
latency I None
in I None
the I None
absence I None
of I None
hypotension I Disease
. I None
<eof> I None

<s> O None
The I None
observed I None
effect I None
of I None
NIMO I Chemical
may I None
have I None
been I None
attributable I None
to I None
the I None
preservation I None
of I None
calcium I Chemical
homeostasis I None
during I None
hypotension I Disease
, I None
because I None
there I None
were I None
no I None
differences I None
in I None
the I None
PbtO(2 I None
) I None
indices I None
among I None
groups I None
. I None
<eof> I None

<s> O None
Fatal I None
haemopericardium I Disease
and I None
gastrointestinal I Disease
haemorrhage O Disease
due I None
to I None
possible I None
interaction I None
of I None
cranberry I None
juice I None
with I None
warfarin I Chemical
. I None
<eof> I None

<s> O None
We I None
report I None
a I None
case I None
of I None
fatal I None
internal I None
haemorrhage I Disease
in I None
an I None
elderly I None
man I None
who I None
consumed I None
only I None
cranberry I None
juice I None
for I None
two I None
weeks I None
while I None
maintaining I None
his I None
usual I None
dosage I None
of I None
warfarin I Chemical
. I None
<eof> I None

<s> O None
We I None
propose I None
that I None
naturally I None
occurring I None
compounds I None
such I None
as I None
flavonoids I Chemical
, I None
which I None
are I None
present I None
in I None
fruit I None
juices I None
, I None
may I None
increase I None
the I None
potency I None
of I None
warfarin I Chemical
by I None
competing I None
for I None
the I None
enzymes I None
that I None
normally I None
inactivate I None
warfarin I Chemical
. I None
<eof> I None

<s> O None
While I None
traditionally I None
regarded I None
as I None
foodstuffs I None
, I None
consumption I None
of I None
fruit I None
juices I None
should I None
be I None
considered I None
when I None
patients I None
develop I None
adverse I None
drug I None
reactions I None
. I None
<eof> I None

<s> O None
Isoproterenol I Chemical
induces I None
primary I None
loss I None
of I None
dystrophin I None
in I None
rat I None
hearts I None
: I None
correlation I None
with I None
myocardial I Disease
injury O Disease
. I None
<eof> I None

<s> O None
The I None
mechanism I None
of I None
<eof> I None

<s> O None
isoproterenol I Chemical
-induced I None
<eof> I None

<s> O None
myocardial I Disease
damage O Disease
is I None
unknown I None
, I None
but I None
a I None
mismatch I None
of I None
oxygen I Chemical
supply I None
vs. I None
demand I None
following I None
coronary I None
hypotension I Disease
and I None
myocardial I Disease
hyperactivity O Disease
is I None
the I None
best I None
explanation I None
for I None
the I None
complex I None
morphological I None
alterations I None
observed I None
. I None
<eof> I None

<s> O None
Severe I None
alterations I None
in I None
the I None
structural I None
integrity I None
of I None
the I None
sarcolemma I None
of I None
cardiomyocytes I None
have I None
been I None
demonstrated I None
to I None
be I None
caused I None
by I None
isoproterenol I Chemical
. I None
<eof> I None

<s> O None
Taking I None
into I None
account I None
that I None
the I None
sarcolemmal I None
integrity I None
is I None
stabilized I None
by I None
the I None
dystrophin I None
- I None
glycoprotein I None
complex I None
( I None
DGC I None
) I None
that I None
connects I None
actin I None
and I None
laminin I None
in I None
contractile I None
machinery I None
and I None
extracellular I None
matrix I None
and I None
by I None
integrins I None
, I None
this I None
study I None
tests I None
the I None
hypothesis I None
that I None
isoproterenol I Chemical
affects I None
sarcolemmal I None
stability I None
through I None
changes I None
in I None
the I None
DGC I None
and I None
integrins I None
. I None
<eof> I None

<s> O None
We I None
found I None
different I None
sensitivity I None
of I None
the I None
DGC I None
and I None
integrin I None
to I None
isoproterenol I Chemical
subcutaneous I None
administration I None
. I None
<eof> I None

<s> O None
Immunofluorescent I None
staining I None
revealed I None
that I None
dystrophin I None
is I None
the I None
most I None
sensitive I None
among I None
the I None
structures I None
connecting I None
the I None
actin I None
in I None
the I None
cardiomyocyte I None
cytoskeleton I None
and I None
the I None
extracellular I None
matrix I None
. I None
<eof> I None

<s> O None
The I None
sarcomeric I None
actin I None
dissolution I None
occurred I None
after I None
the I None
reduction I None
or I None
loss I None
of I None
dystrophin I None
. I None
<eof> I None

<s> O None
Subsequently I None
, I None
after I None
lysis I None
of I None
myofilaments I None
, I None
gamma I None
- I None
sarcoglycan I None
, I None
beta I None
- I None
dystroglycan I None
, I None
beta1-integrin I None
, I None
and I None
laminin I None
alpha-2 I None
expressions I None
were I None
reduced I None
followed I None
by I None
their I None
breakdown I None
, I None
as I None
epiphenomena I None
of I None
the I None
myocytolytic I None
process I None
. I None
<eof> I None

<s> O None
In I None
conclusion I None
, I None
administration I None
of I None
isoproterenol I Chemical
to I None
rats I None
results I None
in I None
primary I None
loss I None
of I None
dystrophin I None
, I None
the I None
most I None
sensitive I None
among I None
the I None
structural I None
proteins I None
that I None
form I None
the I None
DGC I None
that I None
connects I None
the I None
extracellular I None
matrix I None
and I None
the I None
cytoskeleton I None
in I None
cardiomyocyte I None
. I None
<eof> I None

<s> O None
These I None
changes I None
, I None
related I None
to I None
ischaemic I Disease
injury O Disease
, I None
explain I None
the I None
severe I None
alterations I None
in I None
the I None
structural I None
integrity I None
of I None
the I None
sarcolemma I None
of I None
cardiomyocytes I None
and I None
hence I None
severe I None
and I None
irreversible I None
injury I None
induced I None
by I None
isoproterenol I Chemical
. I None
<eof> I None

<s> O None
High I None
fat I Chemical
diet I None
- I None
fed I None
obese I Disease
rats I None
are I None
highly I None
sensitive I None
to I None
doxorubicin I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
cardiotoxicity I Disease
. I None
<eof> I None

<s> O None
Often I None
, I None
chemotherapy I None
by I None
doxorubicin I Chemical
<eof> I None

<s> O None
( I None
Adriamycin I Chemical
) I None
is I None
limited I None
due I None
to I None
life I None
threatening I None
cardiotoxicity I Disease
in I None
patients I None
during I None
and I None
posttherapy I None
. I None
<eof> I None

<s> O None
Recently I None
, I None
we I None
have I None
shown I None
that I None
moderate I None
diet I None
restriction I None
remarkably I None
protects I None
against I None
doxorubicin I Chemical
-induced I None
cardiotoxicity I Disease
. I None
<eof> I None

<s> O None
This I None
cardioprotection I None
is I None
accompanied I None
by I None
decreased I None
cardiac I None
oxidative I None
stress I None
and I None
triglycerides I Chemical
and I None
increased I None
cardiac I None
fatty I None
- I None
acid I None
oxidation I None
, I None
ATP I Chemical
synthesis I None
, I None
and I None
upregulated I None
JAK I None
/ I None
STAT3 I None
pathway I None
. I None
<eof> I None

<s> O None
In I None
the I None
current I None
study I None
, I None
we I None
investigated I None
whether I None
a I None
physiological I None
intervention I None
by I None
feeding I None
40 I None
% I None
high I None
fat I Chemical
diet I None
( I None
HFD I None
) I None
, I None
which I None
induces I None
obesity I Disease
in I None
male I None
Sprague I None
- I None
Dawley I None
rats I None
( I None
250 I None
- I None
275 I None
g I None
) I None
, I None
sensitizes I None
to I None
doxorubicin I Chemical
-induced I None
cardiotoxicity I Disease
. I None
<eof> I None

<s> O None
A I None
LD(10 I None
) I None
dose I None
( I None
8 I None
mg I None
doxorubicin I Chemical
/kg I None
, I None
ip I None
) I None
administered I None
on I None
day I None
43 I None
of I None
the I None
HFD I None
feeding I None
regimen I None
led I None
to I None
higher I None
cardiotoxicity I Disease
, I None
cardiac I Disease
dysfunction O Disease
, I None
lipid I None
peroxidation I None
, I None
and I None
80 I None
% I None
mortality I None
in I None
the I None
obese I Disease
<eof> I None

<s> O None
( I None
OB I Disease
) I None
rats I None
in I None
the I None
absence I None
of I None
any I None
significant I None
renal I None
or I None
hepatic I None
toxicity I None
. I None
<eof> I None

<s> O None
Doxorubicin I Chemical
toxicokinetics I None
studies I None
revealed I None
no I None
change I None
in I None
accumulation I None
of I None
doxorubicin I Chemical
and I None
doxorubicinol I Chemical
<eof> I None

<s> O None
( I None
toxic I None
metabolite I None
) I None
in I None
the I None
normal I None
diet I None
- I None
fed I None
( I None
ND I None
) I None
and I None
OB I Disease
hearts I None
. I None
<eof> I None

<s> O None
Mechanistic I None
studies I None
revealed I None
that I None
OB I Disease
rats I None
are I None
sensitized I None
due I None
to I None
: I None
( I None
1 I None
) I None
higher I None
oxyradical I None
stress I None
leading I None
to I None
upregulation I None
of I None
uncoupling I None
proteins I None
2 I None
and I None
3 I None
, I None
( I None
2 I None
) I None
downregulation I None
of I None
cardiac I None
peroxisome I None
proliferators I None
activated I None
receptor I None
- I None
alpha I None
, I None
( I None
3 I None
) I None
decreased I None
plasma I None
adiponectin I None
levels I None
, I None
( I None
4 I None
) I None
decreased I None
cardiac I None
fatty I None
- I None
acid I None
oxidation I None
( I None
666.9+/-14.0 I None
nmol I None
/ I None
min I None
/ I None
<eof> I None

<s> O None
g I None
heart I None
in I None
ND I None
versus I None
400.2+/-11.8 I None
nmol I None
/ I None
min I None
/ I None
<eof> I None

<s> O None
g I None
heart I None
in I None
OB I Disease
) I None
, I None
( I None
5 I None
) I None
decreased I None
mitochondrial I None
<eof> I None

<s> O None
AMP I Chemical
-alpha2 I None
protein I None
kinase I None
, I None
and I None
( I None
6 I None
) I None
86 I None
% I None
drop I None
in I None
cardiac I None
ATP I Chemical
levels I None
accompanied I None
by I None
decreased I None
ATP I Chemical
/ I None
ADP I Chemical
ratio I None
after I None
doxorubicin I Chemical
administration I None
. I None
<eof> I None

<s> O None
Decreased I None
cardiac I None
erythropoietin I None
and I None
increased I None
SOCS3 I None
further I None
downregulated I None
the I None
cardioprotective I None
JAK I None
/ I None
STAT3 I None
pathway I None
. I None
<eof> I None

<s> O None
In I None
conclusion I None
, I None
HFD I None
- I None
induced I None
obese I Disease
rats I None
are I None
highly I None
sensitized I None
to I None
doxorubicin I Chemical
-induced I None
cardiotoxicity I Disease
by I None
substantially I None
downregulating I None
cardiac I None
mitochondrial I None
ATP I Chemical
generation I None
, I None
increasing I None
oxidative I None
stress I None
and I None
downregulating I None
the I None
JAK I None
/ I None
STAT3 I None
pathway I None
. I None
<eof> I None

<s> O None
Complete I None
atrioventricular I Disease
block O Disease
secondary I None
to I None
lithium I Chemical
therapy I None
. I None
<eof> I None

<s> O None
Sinus I Disease
node O Disease
dysfunction O Disease
has I None
been I None
reported I None
most I None
frequently I None
among I None
the I None
adverse I None
cardiovascular I None
effects I None
of I None
lithium I Chemical
. I None
<eof> I None

<s> O None
In I None
the I None
present I None
case I None
, I None
complete I None
atrioventricular I Disease
( O Disease
AV O Disease
) O Disease
block O Disease
with I None
syncopal I Disease
attacks O Disease
developed I None
secondary I None
to I None
lithium I Chemical
therapy I None
, I None
necessitating I None
permanent I None
pacemaker I None
implantation I None
. I None
<eof> I None

<s> O None
Serum I None
lithium I Chemical
levels I None
remained I None
under I None
or I None
within I None
the I None
therapeutic I None
range I None
during I None
the I None
syncopal I Disease
attacks O Disease
. I None
<eof> I None

<s> O None
Lithium I Chemical
should I None
be I None
used I None
with I None
extreme I None
caution I None
, I None
especially I None
in I None
patients I None
with I None
mild I None
disturbance I None
of I None
AV I None
conduction I None
. I None
<eof> I None

<s> O None
Neuroleptic I Disease
malignant O Disease
syndrome O Disease
induced I None
by I None
ziprasidone I Chemical
on I None
the I None
second I None
day I None
of I None
treatment I None
. I None
<eof> I None

<s> O None
Neuroleptic I Disease
malignant O Disease
syndrome O Disease
<eof> I None

<s> O None
( I None
NMS I Disease
) I None
is I None
the I None
rarest I None
and I None
most I None
serious I None
of I None
the I None
neuroleptic I None
- I None
induced I None
movement I Disease
disorders O Disease
. I None
<eof> I None

<s> O None
We I None
describe I None
a I None
case I None
of I None
neuroleptic I Disease
malignant O Disease
syndrome O Disease
<eof> I None

<s> O None
( I None
NMS I Disease
) I None
associated I None
with I None
the I None
use I None
of I None
ziprasidone I Chemical
. I None
<eof> I None

<s> O None
Although I None
conventional I None
neuroleptics I None
are I None
more I None
frequently I None
associated I None
with I None
NMS I Disease
, I None
atypical I None
antipsychotic I None
drugs I None
like I None
ziprasidone I Chemical
may I None
also I None
be I None
a I None
cause I None
. I None
<eof> I None

<s> O None
The I None
patient I None
is I None
a I None
24-year I None
- I None
old I None
male I None
with I None
a I None
history I None
of I None
schizophrenia I Disease
who I None
developed I None
signs I None
and I None
symptoms I None
of I None
NMS I Disease
after I None
2 I None
days I None
of I None
treatment I None
with I None
an I None
80-mg I None
/ I None
day I None
dose I None
of I None
orally I None
administrated I None
ziprasidone I Chemical
. I None
<eof> I None

<s> O None
This I None
case I None
is I None
the I None
earliest I None
( I None
second I None
day I None
of I None
treatment I None
) I None
<eof> I None

<s> O None
NMS I Disease
due I None
to I None
ziprasidone I Chemical
reported I None
in I None
the I None
literature I None
. I None
<eof> I None

<s> O None
Role I None
of I None
mangiferin I Chemical
on I None
biochemical I None
alterations I None
and I None
antioxidant I None
status I None
in I None
isoproterenol I Chemical
-induced I None
<eof> I None

<s> O None
myocardial I Disease
infarction O Disease
in I None
rats I None
. I None
<eof> I None

<s> O None
The I None
current I None
study I None
dealt I None
with I None
the I None
protective I None
role I None
of I None
mangiferin I Chemical
, I None
a I None
polyphenol I Chemical
from I None
Mangifera I None
indica I None
Linn I None
. I None
<eof> I None

<s> O None
( I None
Anacardiaceae I None
) I None
, I None
on I None
isoproterenol I Chemical
<eof> I None

<s> O None
( I None
ISPH I Chemical
) I None
-induced I None
<eof> I None

<s> O None
myocardial I Disease
infarction O Disease
<eof> I None

<s> O None
( I None
MI I Disease
) I None
in I None
rats I None
through I None
its I None
antioxidative I None
mechanism I None
. I None
<eof> I None

<s> O None
Subcutaneous I None
injection I None
of I None
ISPH I Chemical
<eof> I None

<s> O None
( I None
200 I None
mg I None
/ I None
kg I None
body I None
weight I None
in I None
1 I None
ml I None
saline I None
) I None
to I None
rats I None
for I None
2 I None
consecutive I None
days I None
caused I None
myocardial I Disease
damage O Disease
in I None
rat I None
heart I None
, I None
which I None
was I None
determined I None
by I None
the I None
increased I None
activity I None
of I None
serum I None
lactate I Chemical
dehydrogenase I None
( I None
LDH I None
) I None
and I None
creatine I Chemical
<eof> I None

<s> O None
phosphokinase I None
isoenzymes I None
( I None
CK I None
- I None
MB I None
) I None
, I None
increased I None
uric I Chemical
acid O Chemical
level I None
and I None
reduced I None
plasma I None
<eof> I None

<s> O None
iron I Chemical
binding I None
capacity I None
. I None
<eof> I None

<s> O None
The I None
protective I None
role I None
of I None
mangiferin I Chemical
was I None
analyzed I None
by I None
triphenyl I Chemical
tetrazolium O Chemical
chloride O Chemical
<eof> I None

<s> O None
( I None
TTC I Chemical
) I None
test I None
used I None
for I None
macroscopic I None
enzyme I None
mapping I None
assay I None
of I None
the I None
ischemic I Disease
myocardium O Disease
. I None
<eof> I None

<s> O None
The I None
heart I None
tissue I None
antioxidant I None
enzymes I None
such I None
as I None
superoxide I Chemical
dismutase I None
, I None
catalase I None
, I None
glutathione I Chemical
peroxidase I None
, I None
glutathione I Chemical
transferase I None
and I None
glutathione I Chemical
reductase I None
activities I None
, I None
non I None
- I None
enzymic I None
antioxidants I None
such I None
as I None
cerruloplasmin I None
, I None
Vitamin I Chemical
C O Chemical
, I None
<eof> I None

<s> O None
Vitamin I Chemical
E O Chemical
and I None
glutathione I Chemical
levels I None
were I None
altered I None
in I None
MI I Disease
rats I None
. I None
<eof> I None

<s> O None
Upon I None
pretreatment I None
with I None
mangiferin I Chemical
<eof> I None

<s> O None
( I None
100 I None
mg I None
/ I None
kg I None
body I None
weight I None
suspended I None
in I None
2 I None
ml I None
of I None
dimethyl I Chemical
sulphoxide O Chemical
) I None
given I None
intraperitoneally I None
for I None
28 I None
days I None
to I None
MI I Disease
rats I None
protected I None
the I None
above I None
- I None
mentioned I None
parameters I None
to I None
fall I None
from I None
the I None
normal I None
levels I None
. I None
<eof> I None

<s> O None
Activities I None
of I None
heart I None
tissue I None
enzymic I None
antioxidants I None
and I None
serum I None
non I None
- I None
enzymic I None
antioxidants I None
levels I None
rose I None
significantly I None
upon I None
mangiferin I Chemical
administration I None
as I None
compared I None
to I None
ISPH I Chemical
-induced I None
MI I Disease
rats I None
. I None
<eof> I None

<s> O None
From I None
the I None
present I None
study I None
it I None
is I None
concluded I None
that I None
mangiferin I Chemical
exerts I None
a I None
beneficial I None
effect I None
against I None
ISPH I Chemical
-induced I None
MI I Disease
due I None
to I None
its I None
antioxidant I None
potential I None
, I None
which I None
regulated I None
the I None
tissues I None
defense I None
system I None
against I None
cardiac I Disease
damage O Disease
. I None
<eof> I None

<s> O None
Remifentanil I Chemical
pretreatment I None
reduces I None
<eof> I None

<s> O None
myoclonus I Disease
after I None
etomidate I Chemical
. I None
<eof> I None

<s> O None
STUDY I None
OBJECTIVE I None
: I None
<eof> I None

<s> O None
The I None
aim I None
of I None
the I None
study I None
was I None
to I None
compare I None
the I None
effect I None
of I None
pretreatment I None
with I None
remifentanil I Chemical
<eof> I None

<s> O None
1 I None
microg I None
/ I None
kg I None
and I None
the I None
effect I None
of I None
gender I None
on I None
the I None
incidence I None
of I None
myoclonus I Disease
after I None
anesthesia I None
induction I None
with I None
etomidate I Chemical
. I None
<eof> I None

<s> O None
DESIGN I None
: I None
<eof> I None

<s> O None
This I None
was I None
a I None
randomized I None
, I None
double I None
- I None
blind I None
study I None
. I None
<eof> I None

<s> O None
SETTING I None
: I None
<eof> I None

<s> O None
The I None
study I None
was I None
conducted I None
at I None
a I None
university I None
hospital I None
. I None
<eof> I None

<s> O None
PATIENTS I None
: I None
<eof> I None

<s> O None
Sixty I None
patients I None
were I None
pretreated I None
in I None
a I None
randomized I None
double I None
- I None
blinded I None
fashion I None
with I None
remifentanil I Chemical
<eof> I None

<s> O None
1 I None
microg I None
/ I None
kg I None
or I None
placebo I None
. I None
<eof> I None

<s> O None
Two I None
minutes I None
after I None
remifentanil I Chemical
or I None
placebo I None
injection I None
, I None
etomidate I Chemical
0.3 I None
mg I None
/ I None
kg I None
was I None
given I None
. I None
<eof> I None

<s> O None
MEASUREMENTS I None
: I None
Myoclonus I Disease
was I None
recorded I None
with I None
a I None
scale I None
of I None
0 I None
to I None
3 I None
. I None
<eof> I None

<s> O None
The I None
grade I None
of I None
sedation I None
( I None
none I None
, I None
mild I None
, I None
moderate I None
, I None
severe I None
) I None
, I None
nausea I Disease
, I None
pruritus I Disease
, I None
and I None
apnea I Disease
were I None
recorded I None
after I None
injection I None
of I None
both I None
drugs I None
. I None
<eof> I None

<s> O None
MAIN I None
RESULTS I None
: I None
<eof> I None

<s> O None
The I None
incidence I None
of I None
myoclonus I Disease
was I None
significantly I None
lower I None
in I None
the I None
remifentanil I Chemical
group I None
( I None
6.7 I None
% I None
) I None
than I None
in I None
the I None
placebo I None
group I None
( I None
70 I None
% I None
) I None
( I None
P I None
< I None
0.001 I None
) I None
. I None
<eof> I None

<s> O None
None I None
of I None
the I None
patients I None
experienced I None
sedation I None
, I None
apnea I Disease
, I None
nausea I Disease
, I None
or I None
pruritus I Disease
after I None
injection I None
of I None
both I None
drugs I None
. I None
<eof> I None

<s> O None
In I None
the I None
placebo I None
group I None
, I None
male I None
patients I None
were I None
associated I None
with I None
significantly I None
increased I None
incidence I None
of I None
myoclonus I Disease
after I None
etomidate I Chemical
administration I None
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
<eof> I None

<s> O None
Pretreatment I None
with I None
remifentanil I Chemical
<eof> I None

<s> O None
1 I None
microg I None
/ I None
kg I None
reduced I None
<eof> I None

<s> O None
myoclonus I Disease
after I None
etomidate I Chemical
induction I None
without I None
side I None
effects I None
such I None
as I None
sedation I None
, I None
apnea I Disease
, I None
nausea I Disease
, I None
or I None
pruritus I Disease
. I None
<eof> I None

<s> O None
Men I None
experience I None
increased I None
incidence I None
of I None
myoclonus I Disease
than I None
women I None
after I None
etomidate I Chemical
administration I None
. I None
<eof> I None

<s> O None
Daidzein I Chemical
activates I None
<eof> I None

<s> O None
choline I Chemical
acetyltransferase I None
from I None
MC I None
- I None
IXC I None
cells I None
and I None
improves I None
drug I None
- I None
induced I None
amnesia I Disease
. I None
<eof> I None

<s> O None
The I None
choline I Chemical
acetyltransferase I None
( I None
ChAT I None
) I None
activator I None
, I None
which I None
enhances I None
cholinergic I None
transmission I None
via I None
an I None
augmentation I None
of I None
the I None
enzymatic I None
production I None
of I None
acetylcholine I Chemical
<eof> I None

<s> O None
( I None
ACh I Chemical
) I None
, I None
is I None
an I None
important I None
factor I None
in I None
the I None
treatment I None
of I None
Alzheimer I Disease
's O Disease
disease O Disease
<eof> I None

<s> O None
( I None
AD I Disease
) I None
. I None
<eof> I None

<s> O None
Methanolic I None
extracts I None
from I None
Pueraria I None
thunbergiana I None
exhibited I None
an I None
activation I None
effect I None
( I None
46 I None
% I None
) I None
on I None
ChAT I None
in I None
vitro I None
. I None
<eof> I None

<s> O None
Via I None
the I None
sequential I None
isolation I None
of I None
Pueraria I None
thunbergiana I None
, I None
the I None
active I None
component I None
was I None
ultimately I None
identified I None
as I None
daidzein I Chemical
<eof> I None

<s> O None
( I None
4',7-dihydroxy I Chemical
- O Chemical
isoflavone O Chemical
) I None
. I None
<eof> I None

<s> O None
In I None
order I None
to I None
investigate I None
the I None
effects I None
of I None
daidzein I Chemical
from I None
Pueraria I None
thunbergiana I None
on I None
scopolamine I Chemical
-induced I None
impairments I None
of I None
learning I None
and I None
memory I None
, I None
we I None
conducted I None
a I None
series I None
of I None
in I None
vivo I None
tests I None
. I None
<eof> I None

<s> O None
Administration I None
of I None
daidzein I Chemical
<eof> I None

<s> O None
( I None
4.5 I None
mg I None
/ I None
kg I None
body I None
weight I None
) I None
to I None
mice I None
was I None
shown I None
significantly I None
to I None
reverse I None
<eof> I None

<s> O None
scopolamine I Chemical
-induced I None
<eof> I None

<s> O None
amnesia I Disease
, I None
according I None
to I None
the I None
results I None
of I None
a I None
Y I None
- I None
maze I None
test I None
. I None
<eof> I None

<s> O None
Injections I None
of I None
scopolamine I Chemical
into I None
mice I None
resulted I None
in I None
impaired I None
performance I None
on I None
Y I None
- I None
maze I None
tests I None
( I None
a I None
37 I None
% I None
decreases I None
in I None
alternation I None
behavior I None
) I None
. I None
<eof> I None

<s> O None
By I None
way I None
of I None
contrast I None
, I None
mice I None
treated I None
with I None
daidzein I Chemical
prior I None
to I None
the I None
scopolamine I Chemical
injections I None
were I None
noticeably I None
protected I None
from I None
this I None
performance I None
impairment I None
( I None
an I None
approximately I None
12%-21 I None
% I None
decrease I None
in I None
alternation I None
behavior I None
) I None
. I None
<eof> I None

<s> O None
These I None
results I None
indicate I None
that I None
daidzein I Chemical
might I None
play I None
a I None
role I None
in I None
acetylcholine I Chemical
biosynthesis I None
as I None
a I None
ChAT I None
activator I None
, I None
and I None
that I None
it I None
also I None
ameliorates I None
scopolamine I Chemical
<eof> I None

<s> O None
-induced I None
amnesia I Disease
. I None
<eof> I None

<s> O None
Possible I None
azithromycin I Chemical
-associated I None
hiccups I Disease
. I None
<eof> I None

<s> O None
OBJECTIVE I None
: I None
<eof> I None

<s> O None
To I None
report I None
a I None
case I None
of I None
persistent I None
hiccups I Disease
associated I None
by I None
azithromycin I Chemical
therapy I None
. I None
<eof> I None

<s> O None
CASE I None
SUMMARY I None
: I None
<eof> I None

<s> O None
A I None
76-year I None
- I None
old I None
man I None
presented I None
with I None
persistent I None
hiccups I Disease
after I None
beginning I None
azithromycin I Chemical
for I None
the I None
treatment I None
of I None
pharyngitis I Disease
. I None
<eof> I None

<s> O None
Hiccups I Disease
were I None
persistent I None
and I None
exhausting I None
. I None
<eof> I None

<s> O None
Discontinuation I None
of I None
azithromycin I Chemical
and I None
therapy I None
with I None
baclofen I Chemical
finally I None
resolved I None
hiccups I Disease
. I None
<eof> I None

<s> O None
No I None
organic I None
cause I None
of I None
hiccups I Disease
was I None
identified I None
despite I None
extensive I None
investigation I None
. I None
<eof> I None

<s> O None
DISCUSSION I None
: I None
Pharmacotherapeutic I None
agents I None
have I None
been I None
uncommonly I None
associated I None
with I None
hiccups I Disease
. I None
<eof> I None

<s> O None
Corticosteroids I None
( I None
dexamethasone I Chemical
and I None
methylprednisolone I Chemical
) I None
, I None
benzodiazepines I Chemical
<eof> I None

<s> O None
( I None
midazolam I Chemical
) I None
and I None
general I None
anaesthesia I None
have I None
been I None
the I None
specific I None
agents I None
mentioned I None
most I None
frequently I None
in I None
the I None
literature I None
as I None
being I None
associated I None
with I None
the I None
development I None
of I None
hiccups I Disease
. I None
<eof> I None

<s> O None
Few I None
cases I None
of I None
drug I None
- I None
induced I None
hiccups I Disease
have I None
been I None
reported I None
related I None
to I None
macrolide I Chemical
antimicrobials I None
. I None
<eof> I None

<s> O None
Using I None
the I None
Naranjo I None
adverse I None
effect I None
reaction I None
probability I None
scale I None
this I None
event I None
could I None
be I None
classified I None
as I None
possible I None
( I None
score I None
5 I None
points I None
) I None
, I None
mostly I None
because I None
of I None
the I None
close I None
temporal I None
sequence I None
, I None
previous I None
reports I None
on I None
this I None
reaction I None
with I None
other I None
macrolides I Chemical
and I None
the I None
absence I None
of I None
any I None
alternative I None
explanation I None
for I None
hiccups I Disease
. I None
<eof> I None

<s> O None
Our I None
hypothesis I None
is I None
that I None
a I None
vagal I None
mechanism I None
mediated I None
by I None
azithromycin I Chemical
could I None
be I None
the I None
pathogenesis I None
of I None
hiccups I Disease
in I None
our I None
patient I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
Diagnosis I None
of I None
drug I None
- I None
induced I None
hiccups I Disease
is I None
difficult I None
and I None
often I None
achieved I None
only I None
by I None
a I None
process I None
of I None
elimination I None
. I None
<eof> I None

<s> O None
However I None
, I None
macrolide I Chemical
antimicrobials I None
have I None
been I None
reported I None
to I None
be I None
associated I None
with I None
hiccups I Disease
and I None
vagal I None
mechanism I None
could I None
explain I None
the I None
development I None
of I None
this I None
side I None
- I None
effect I None
. I None
<eof> I None

<s> O None
Time I None
trends I None
in I None
warfarin I Chemical
<eof> I None

<s> O None
-associated I None
<eof> I None

<s> O None
hemorrhage I Disease
. I None
<eof> I None

<s> O None
The I None
annual I None
incidence I None
of I None
warfarin I Chemical
-related I None
bleeding I Disease
at I None
Brigham I None
and I None
Women I None
's I None
Hospital I None
increased I None
from I None
0.97/1,000 I None
patient I None
admissions I None
in I None
the I None
first I None
time I None
period I None
( I None
January I None
1995 I None
to I None
October I None
1998 I None
) I None
to I None
1.19/1,000 I None
patient I None
admissions I None
in I None
the I None
second I None
time I None
period I None
( I None
November I None
1998 I None
to I None
August I None
2002 I None
) I None
of I None
this I None
study I None
. I None
<eof> I None

<s> O None
The I None
proportion I None
of I None
patients I None
with I None
major I None
and I None
intracranial I Disease
bleeding O Disease
increased I None
from I None
20.2 I None
% I None
and I None
1.9 I None
% I None
, I None
respectively I None
, I None
in I None
the I None
first I None
time I None
period I None
, I None
to I None
33.3 I None
% I None
and I None
7.8 I None
% I None
, I None
respectively I None
, I None
in I None
the I None
second I None
. I None
<eof> I None

<s> O None
Fatal I None
haemorrhagic I None
myocarditis I None
secondary I None
to I None
cyclophosphamide I Chemical
therapy I None
. I None
<eof> I None

<s> O None
Haemorrhagic I None
myocarditis I None
is I None
a I None
rare I None
but I None
important I None
complication I None
of I None
cyclophosphamide I Chemical
therapy I None
. I None
<eof> I None

<s> O None
Echocardiographic I None
identification I None
of I None
the I None
disorder I None
can I None
be I None
made I None
. I None
<eof> I None

<s> O None
We I None
believe I None
that I None
the I None
ultrasound I None
features I None
of I None
this I None
disorder I None
have I None
not I None
been I None
previously I None
reported I None
. I None
<eof> I None

<s> O None
Glyceryl I Chemical
trinitrate O Chemical
induces I None
attacks I None
of I None
migraine I Disease
without O Disease
aura O Disease
in I None
sufferers I None
of I None
migraine I Disease
with O Disease
aura O Disease
. I None
<eof> I None

<s> O None
Migraine I Disease
with O Disease
aura O Disease
and I None
migraine I Disease
without O Disease
aura O Disease
have I None
the I None
same I None
pain I Disease
phase I None
, I None
thus I None
indicating I None
that I None
migraine I Disease
with O Disease
aura O Disease
and I None
migraine I Disease
without O Disease
aura O Disease
share I None
a I None
common I None
pathway I None
of I None
nociception I None
. I None
<eof> I None

<s> O None
In I None
recent I None
years I None
, I None
increasing I None
evidence I None
has I None
suggested I None
that I None
the I None
messenger I None
molecule I None
nitric I Chemical
oxide O Chemical
<eof> I None

<s> O None
( I None
NO I Chemical
) I None
is I None
involved I None
in I None
pain I Disease
mechanisms I None
of I None
migraine I Disease
without O Disease
aura O Disease
. I None
<eof> I None

<s> O None
In I None
order I None
to I None
clarify I None
whether I None
the I None
same I None
is I None
true I None
for I None
migraine I Disease
with O Disease
aura O Disease
, I None
in I None
the I None
present I None
study I None
we I None
examined I None
the I None
headache I Disease
response I None
to I None
intravenous I None
infusion I None
of I None
glyceryl I Chemical
trinitrate O Chemical
<eof> I None

<s> O None
( I None
GTN I Chemical
) I None
( I None
0.5 I None
microg I None
/ I None
kg I None
/ I None
min I None
for I None
20 I None
min I None
) I None
in I None
12 I None
sufferers I None
of I None
migraine I Disease
with O Disease
aura O Disease
. I None
<eof> I None

<s> O None
The I None
specific I None
aim I None
was I None
to I None
elucidate I None
whether I None
an I None
aura I None
and/or I None
an I None
attack I None
of I None
migraine I Disease
without O Disease
aura O Disease
could I None
be I None
induced I None
. I None
<eof> I None

<s> O None
Fourteen I None
healthy I None
subjects I None
served I None
as I None
controls I None
. I None
<eof> I None

<s> O None
Aura I None
symptoms I None
were I None
not I None
elicited I None
in I None
any I None
subject I None
. I None
<eof> I None

<s> O None
Headache I Disease
was I None
more I None
severe I None
in I None
<eof> I None

<s> O None
migraineurs I Disease
than I None
in I None
the I None
controls I None
during I None
and I None
immediately I None
after I None
GTN I Chemical
infusion I None
( I None
p=0.037 I None
) I None
as I None
well I None
as I None
during I None
the I None
following I None
11 I None
h I None
( I None
p I None
= I None
0.008 I None
) I None
. I None
<eof> I None

<s> O None
In I None
the I None
controls I None
, I None
the I None
GTN I Chemical
-induced I None
headache I Disease
gradually I None
disappeared I None
, I None
whereas I None
in I None
migraineurs I Disease
peak I None
headache I Disease
intensity I None
occurred I None
at I None
a I None
mean I None
time I None
of I None
240 I None
min I None
post I None
- I None
infusion I None
. I None
<eof> I None

<s> O None
At I None
this I None
time I None
the I None
induced I None
headache I Disease
in I None
6 I None
of I None
12 I None
migraineurs I Disease
fulfilled I None
the I None
diagnostic I None
criteria I None
for I None
migraine I Disease
without O Disease
aura O Disease
of I None
the I None
International I None
Headache I Disease
Society I None
. I None
<eof> I None

<s> O None
The I None
results I None
therefore I None
suggest I None
that I None
NO I Chemical
is I None
involved I None
in I None
the I None
pain I Disease
mechanisms I None
of I None
migraine I Disease
with O Disease
aura O Disease
. I None
<eof> I None

<s> O None
Since I None
cortical I None
spreading I None
depression I Disease
has I None
been I None
shown I None
to I None
liberate I None
NO I Chemical
in I None
animals I None
, I None
this I None
finding I None
may I None
help I None
our I None
understanding I None
of I None
the I None
coupling I None
between I None
cortical I None
spreading I None
depression I Disease
and I None
headache I Disease
in I None
migraine I Disease
with O Disease
aura O Disease
. I None
<eof> I None

<s> O None
Stroke I Disease
and I None
cocaine I Chemical
or I None
amphetamine I Chemical
use I None
. I None
<eof> I None

<s> O None
The I None
association I None
of I None
cocaine I Chemical
and I None
amphetamine I Chemical
use I None
with I None
hemorrhagic I None
and I None
ischemic I Disease
stroke I Disease
is I None
based I None
almost I None
solely I None
on I None
data I None
from I None
case I None
series I None
. I None
<eof> I None

<s> O None
The I None
limited I None
number I None
of I None
epidemiologic I None
studies I None
of I None
stroke I Disease
and I None
use I None
of I None
cocaine I Chemical
and/or I None
amphetamine I Chemical
have I None
been I None
done I None
in I None
settings I None
that I None
serve I None
mostly I None
the I None
poor I None
and/or I None
minorities I None
. I None
<eof> I None

<s> O None
This I None
case I None
- I None
control I None
study I None
was I None
conducted I None
in I None
the I None
defined I None
population I None
comprising I None
members I None
of I None
Kaiser I None
Permanente I None
of I None
Northern I None
and I None
Southern I None
California I None
. I None
<eof> I None

<s> O None
We I None
attempted I None
to I None
identify I None
all I None
incident I None
<eof> I None

<s> O None
strokes I Disease
in I None
women I None
ages I None
15 I None
- I None
44 I None
years I None
during I None
a I None
3-year I None
period I None
using I None
hospital I None
admission I None
and I None
discharge I None
records I None
, I None
emergency I None
department I None
logs I None
, I None
and I None
payment I None
requests I None
for I None
out I None
- I None
of I None
- I None
plan I None
hospitalizations I None
. I None
<eof> I None

<s> O None
We I None
selected I None
controls I None
, I None
matched I None
on I None
age I None
and I None
facility I None
of I None
usual I None
care I None
, I None
at I None
random I None
from I None
healthy I None
members I None
of I None
the I None
health I None
plan I None
. I None
<eof> I None

<s> O None
We I None
obtained I None
information I None
in I None
face I None
- I None
to I None
- I None
face I None
interviews I None
. I None
<eof> I None

<s> O None
There I None
were I None
347 I None
confirmed I None
stroke I Disease
cases I None
and I None
1,021 I None
controls I None
. I None
<eof> I None

<s> O None
The I None
univariate I None
matched I None
odds I None
ratio I None
for I None
stroke I Disease
in I None
women I None
who I None
admitted I None
to I None
using I None
cocaine I Chemical
and/or I None
amphetamine I Chemical
was I None
8.5 I None
( I None
95 I None
% I None
confidence I None
interval I None
= I None
3.6 I None
- I None
20.0 I None
) I None
. I None
<eof> I None

<s> O None
After I None
further I None
adjustment I None
for I None
potential I None
confounders I None
, I None
the I None
odds I None
ratio I None
in I None
women I None
who I None
reported I None
using I None
cocaine I Chemical
and/or I None
amphetamine I Chemical
was I None
7.0 I None
( I None
95 I None
% I None
confidence I None
interval I None
= I None
2.8 I None
- I None
17.9 I None
) I None
. I None
<eof> I None

<s> O None
The I None
use I None
of I None
cocaine I Chemical
and/or I None
amphetamine I Chemical
is I None
a I None
strong I None
risk I None
factor I None
for I None
stroke I Disease
in I None
this I None
socioeconomically I None
heterogeneous I None
, I None
insured I None
urban I None
population I None
. I None
<eof> I None

<s> O None
Prevention I None
of I None
breast I Disease
cancer O Disease
with I None
tamoxifen I Chemical
: I None
preliminary I None
findings I None
from I None
the I None
Italian I None
randomised I None
trial I None
among I None
hysterectomised I None
women I None
. I None
<eof> I None

<s> O None
Italian I None
Tamoxifen I Chemical
<eof> I None

<s> O None
Prevention I None
Study I None
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
<eof> I None

<s> O None
Tamoxifen I Chemical
is I None
a I None
candidate I None
chemopreventive I None
agent I None
in I None
breast I Disease
cancer O Disease
, I None
although I None
the I None
drug I None
may I None
be I None
associated I None
with I None
the I None
development I None
of I None
endometrial I Disease
cancer O Disease
. I None
<eof> I None

<s> O None
Therefore I None
we I None
did I None
a I None
trial I None
in I None
hysterectomised I None
women I None
of I None
tamoxifen I Chemical
as I None
a I None
chemopreventive I None
. I None
<eof> I None

<s> O None
METHODS I None
: I None
<eof> I None

<s> O None
In I None
October I None
, I None
1992 I None
, I None
we I None
started I None
a I None
double I None
- I None
blind I None
placebo I None
- I None
controlled I None
, I None
randomised I None
trial I None
of I None
tamoxifen I Chemical
in I None
women I None
( I None
mainly I None
in I None
Italy I None
) I None
who I None
did I None
not I None
have I None
breast I Disease
cancer O Disease
and I None
who I None
had I None
had I None
a I None
hysterectomy I None
. I None
<eof> I None

<s> O None
Women I None
were I None
randomised I None
to I None
receive I None
tamoxifen I Chemical
20 I None
mg I None
per I None
day I None
or I None
placebo I None
, I None
both I None
orally I None
for I None
5 I None
years I None
. I None
<eof> I None

<s> O None
The I None
original I None
plan I None
was I None
to I None
follow I None
the I None
intervention I None
phase I None
by I None
5 I None
years I None
' I None
follow I None
- I None
up I None
. I None
<eof> I None

<s> O None
In I None
June I None
, I None
1997 I None
, I None
the I None
trialists I None
and I None
the I None
data I None
- I None
monitoring I None
committee I None
decided I None
to I None
end I None
recruitment I None
primarily I None
because I None
of I None
the I None
number I None
of I None
women I None
dropping I None
out I None
of I None
the I None
study I None
. I None
<eof> I None

<s> O None
Recruitment I None
ended I None
on I None
July I None
11 I None
, I None
1997 I None
, I None
and I None
the I None
study I None
will I None
continue I None
as I None
planned I None
. I None
<eof> I None

<s> O None
The I None
primary I None
endpoints I None
are I None
the I None
occurrence I None
of I None
and I None
deaths I None
from I None
breast I Disease
cancer O Disease
. I None
<eof> I None

<s> O None
This I None
preliminary I None
interim I None
analysis I None
is I None
based I None
on I None
intention I None
- I None
to I None
- I None
treat I None
. I None
<eof> I None

<s> O None
FINDINGS I None
: I None
5408 I None
<eof> I None

<s> O None
women I None
were I None
randomised I None
; I None
participating I None
women I None
have I None
a I None
median I None
follow I None
- I None
up I None
of I None
46 I None
months I None
for I None
major I None
endpoints I None
. I None
<eof> I None

<s> O None
41 I None
cases I None
of I None
breast I Disease
cancer O Disease
occurred I None
so I None
far I None
; I None
there I None
have I None
been I None
no I None
deaths I None
from I None
breast I Disease
cancer O Disease
. I None
<eof> I None

<s> O None
There I None
is I None
no I None
difference I None
in I None
breast I Disease
- O Disease
cancer O Disease
frequency I None
between I None
the I None
placebo I None
( I None
22 I None
cases I None
) I None
and I None
tamoxifen I Chemical
( I None
19 I None
) I None
arms I None
. I None
<eof> I None

<s> O None
There I None
is I None
a I None
statistically I None
significant I None
reduction I None
of I None
breast I Disease
cancer O Disease
among I None
women I None
receiving I None
tamoxifen I Chemical
who I None
also I None
used I None
hormone I None
- I None
replacement I None
therapy I None
during I None
the I None
trial I None
: I None
among I None
390 I None
women I None
on I None
such I None
therapy I None
and I None
allocated I None
to I None
placebo I None
, I None
we I None
found I None
eight I None
cases I None
of I None
breast I Disease
cancer O Disease
compared I None
with I None
one I None
case I None
among I None
362 I None
women I None
allocated I None
to I None
tamoxifen I Chemical
. I None
<eof> I None

<s> O None
Compared I None
with I None
the I None
placebo I None
group I None
, I None
there I None
was I None
a I None
significantly I None
increased I None
risk I None
of I None
vascular I Disease
events O Disease
and I None
hypertriglyceridaemia I Disease
among I None
women I None
on I None
tamoxifen I Chemical
. I None
<eof> I None

<s> O None
INTERPRETATION I None
: I None
<eof> I None

<s> O None
Although I None
this I None
preliminary I None
analysis I None
has I None
low I None
power I None
, I None
in I None
this I None
cohort I None
of I None
women I None
at I None
low I None
- I None
to I None
- I None
normal I None
risk I None
of I None
breast I Disease
cancer O Disease
, I None
the I None
postulated I None
protective I None
effects I None
of I None
tamoxifen I Chemical
are I None
not I None
yet I None
apparent I None
. I None
<eof> I None

<s> O None
Women I None
using I None
hormone I None
- I None
replacement I None
therapy I None
appear I None
to I None
have I None
benefited I None
from I None
use I None
of I None
tamoxifen I Chemical
. I None
<eof> I None

<s> O None
There I None
were I None
no I None
deaths I None
from I None
breast I Disease
cancer O Disease
recorded I None
in I None
women I None
in I None
the I None
study I None
. I None
<eof> I None

<s> O None
It I None
is I None
essential I None
to I None
continue I None
follow I None
- I None
up I None
to I None
quantify I None
the I None
long I None
- I None
term I None
risks I None
and I None
benefits I None
of I None
tamoxifen I Chemical
therapy I None
. I None
<eof> I None

<s> O None
A I None
measure I None
of I None
pupillary I Disease
oscillation O Disease
as I None
a I None
marker I None
of I None
cocaine I Chemical
-induced I None
paranoia I Disease
. I None
<eof> I None

<s> O None
Cocaine I Chemical
-induced I None
<eof> I None

<s> O None
paranoia I Disease
<eof> I None

<s> O None
( I None
CIP I Disease
) I None
remains I None
an I None
important I None
drug I None
- I None
induced I None
model I None
of I None
idiopathic I None
paranoia I Disease
for I None
which I None
no I None
psychophysiologic I None
marker I None
has I None
yet I None
emerged I None
. I None
<eof> I None

<s> O None
Measures I None
of I None
pupillary I Disease
oscillation O Disease
were I None
able I None
to I None
significantly I None
distinguish I None
a I None
group I None
of I None
abstinent I None
crack I Chemical
cocaine O Chemical
abusers I None
endorsing I None
past I None
CIP I Disease
<eof> I None

<s> O None
( I None
n I None
= I None
32 I None
) I None
from I None
another I None
group I None
of I None
crack I Chemical
<eof> I None

<s> O None
addicts I None
who I None
denied I None
past I None
CIP I Disease
<eof> I None

<s> O None
( I None
n I None
= I None
29 I None
) I None
. I None
<eof> I None

<s> O None
Seizures I Disease
induced I None
by I None
combined I None
levomepromazine I Chemical
- I None
fluvoxamine I Chemical
treatment I None
. I None
<eof> I None

<s> O None
We I None
report I None
a I None
case I None
of I None
combined I None
levomepromazine I Chemical
- I None
fluvoxamine I Chemical
treatment I None
- I None
induced I None
seizures I Disease
. I None
<eof> I None

<s> O None
It I None
seems I None
that I None
combined I None
treatment I None
of I None
fluvoxamine I Chemical
with I None
phenothiazines I Chemical
may I None
possess I None
proconvulsive I None
activity I None
. I None
<eof> I None

<s> O None
Why I None
may I None
epsilon I Chemical
- O Chemical
aminocaproic O Chemical
acid O Chemical
<eof> I None

<s> O None
( I None
EACA I Chemical
) I None
induce I None
myopathy I Disease
in I None
man I None
? I None
<eof> I None

<s> O None
Report I None
of I None
a I None
case I None
and I None
literature I None
review I None
. I None
<eof> I None

<s> O None
A I None
case I None
of I None
necrotizing I None
myopathy I None
due I None
to I None
a I None
short I None
epsilon I Chemical
- O Chemical
aminocaproic O Chemical
acid O Chemical
( I None
EACA I Chemical
) I None
treatment I None
in I None
a I None
72 I None
year I None
- I None
old I None
patient I None
with I None
subarachnoid I Disease
haemorrhage O Disease
<eof> I None

<s> O None
( I None
SAH I Disease
) I None
is I None
described I None
. I None
<eof> I None

<s> O None
Pathogenetic I None
hypotheses I None
are I None
discussed I None
. I None
<eof> I None

<s> O None
Comparison I None
of I None
the I None
effectiveness I None
of I None
ranitidine I Chemical
and I None
cimetidine I Chemical
in I None
inhibiting I None
acid I None
secretion I None
in I None
patients I None
with I None
gastric I None
hypersecretory I None
states I None
. I None
<eof> I None

<s> O None
The I None
H2- I None
histamine I Chemical
receptor I None
antagonists I None
ranitidine I Chemical
and I None
cimetidine I Chemical
were I None
compared I None
for I None
their I None
abilities I None
to I None
control I None
gastric I None
acid I None
hypersecretion I None
on I None
a I None
short- I None
and I None
long I None
- I None
term I None
basis I None
in I None
22 I None
patients I None
with I None
gastric I None
acid I None
hypersecretory I None
states I None
. I None
<eof> I None

<s> O None
Nineteen I None
patients I None
had I None
<eof> I None

<s> O None
Zollinger I Disease
- O Disease
Ellison O Disease
syndrome O Disease
, I None
one I None
patient I None
had I None
systemic I Disease
mastocytosis O Disease
, I None
and I None
two I None
patients I None
had I None
idiopathic I None
hypersecretion I None
. I None
<eof> I None

<s> O None
The I None
rates I None
of I None
onset I None
of I None
the I None
action I None
of I None
cimetidine I Chemical
and I None
ranitidine I Chemical
were I None
the I None
same I None
. I None
<eof> I None

<s> O None
The I None
actions I None
of I None
both I None
drugs I None
were I None
increased I None
by I None
anticholinergic I None
agents I None
, I None
and I None
there I None
was I None
a I None
close I None
correlation I None
between I None
the I None
daily I None
maintenance I None
dose I None
of I None
each I None
drug I None
needed I None
to I None
control I None
acid I None
secretion I None
. I None
<eof> I None

<s> O None
However I None
, I None
ranitidine I Chemical
was I None
threefold I None
more I None
potent I None
than I None
cimetidine I Chemical
both I None
in I None
acute I None
inhibition I None
studies I None
and I None
in I None
the I None
median I None
maintenance I None
dose I None
needed I None
( I None
1.2 I None
g I None
per I None
day I None
for I None
ranitidine I Chemical
and I None
3.6 I None
g I None
per I None
day I None
for I None
cimetidine I Chemical
) I None
. I None
<eof> I None

<s> O None
Sixty I None
percent I None
of I None
the I None
males I None
developed I None
breast I None
changes I None
or I None
impotence I Disease
while I None
taking I None
cimetidine I Chemical
and I None
in I None
all I None
cases I None
these I None
changes I None
disappeared I None
when I None
cimetidine I Chemical
was I None
replaced I None
by I None
ranitidine I Chemical
. I None
<eof> I None

<s> O None
Treatment I None
with I None
high I None
doses I None
of I None
cimetidine I Chemical
<eof> I None

<s> O None
( I None
one I None
to I None
60 I None
months I None
; I None
median I None
, I None
11 I None
months I None
) I None
or I None
ranitidine I Chemical
<eof> I None

<s> O None
( I None
two I None
to I None
31 I None
months I None
; I None
median I None
, I None
14 I None
months I None
) I None
was I None
not I None
associated I None
with I None
hepatic I None
or I None
hematologic I None
toxicity I None
or I None
alterations I None
of I None
serum I None
gastrin I None
concentrations I None
, I None
but I None
ranitidine I Chemical
therapy I None
was I None
associated I None
with I None
a I None
significantly I None
lower I None
serum I None
creatinine I Chemical
level I None
than I None
seen I None
with I None
cimetidine I Chemical
therapy I None
. I None
<eof> I None

<s> O None
The I None
results I None
show I None
that I None
both I None
drugs I None
can I None
adequately I None
inhibit I None
acid I None
secretion I None
in I None
patients I None
with I None
gastric I None
hypersecretory I None
states I None
. I None
<eof> I None

<s> O None
Both I None
are I None
safe I None
at I None
high I None
doses I None
, I None
but I None
ranitidine I Chemical
is I None
threefold I None
more I None
potent I None
and I None
does I None
not I None
cause I None
the I None
antiandrogen I None
side I None
effects I None
frequently I None
seen I None
with I None
high I None
doses I None
of I None
cimetidine I Chemical
. I None
<eof> I None

<s> O None
A I None
catch I None
in I None
the I None
Reye I Disease
. I None
<eof> I None

<s> O None
Twenty I None
- I None
six I None
cases I None
of I None
Reye I Disease
syndrome O Disease
from I None
The I None
Children I None
's I None
Hospital I None
, I None
Camperdown I None
, I None
Australia I None
, I None
occurring I None
between I None
1973 I None
and I None
1982 I None
were I None
reviewed I None
. I None
<eof> I None

<s> O None
Of I None
these I None
, I None
20 I None
cases I None
met I None
the I None
US I None
Public I None
Health I None
Service I None
Centers I None
for I None
Disease I None
Control I None
criteria I None
for I None
the I None
diagnosis I None
of I None
Reye I Disease
syndrome O Disease
. I None
<eof> I None

<s> O None
Aspirin I Chemical
or I None
salicylate I Chemical
ingestion I None
had I None
occurred I None
in I None
only I None
one I None
of I None
the I None
20 I None
cases I None
( I None
5 I None
% I None
) I None
, I None
and I None
paracetamol I Chemical
<eof> I None

<s> O None
( I None
acetaminophen I Chemical
) I None
had I None
been I None
administered I None
in I None
only I None
six I None
of I None
the I None
cases I None
( I None
30 I None
% I None
) I None
. I None
<eof> I None

<s> O None
Pathologic I None
confirmation I None
of I None
the I None
diagnosis I None
of I None
Reye I Disease
syndrome O Disease
was I None
accomplished I None
in I None
90 I None
% I None
of I None
the I None
cases I None
. I None
<eof> I None

<s> O None
The I None
incidence I None
of I None
Reye I Disease
syndrome O Disease
in I None
New I None
South I None
Wales I None
, I None
Australia I None
, I None
is I None
estimated I None
from I None
this I None
study I None
to I None
be I None
approximately I None
nine I None
cases I None
per I None
1 I None
million I None
children I None
compared I None
with I None
recent I None
US I None
data I None
of I None
ten I None
to I None
20 I None
cases I None
per I None
1 I None
million I None
children I None
and I None
three I None
to I None
seven I None
cases I None
per I None
1 I None
million I None
children I None
in I None
Great I None
Britain I None
. I None
<eof> I None

<s> O None
The I None
mortality I None
for I None
these I None
Reye I Disease
syndrome O Disease
cases I None
in I None
Australia I None
was I None
45 I None
% I None
as I None
compared I None
with I None
a I None
32 I None
% I None
case I None
- I None
fatality I None
rate I None
in I None
the I None
United I None
States I None
. I None
<eof> I None

<s> O None
In I None
Australia I None
, I None
the I None
pediatric I None
usage I None
of I None
aspirin I Chemical
has I None
been I None
extremely I None
low I None
for I None
the I None
past I None
25 I None
years I None
( I None
less I None
than I None
1 I None
% I None
of I None
total I None
dosage I None
units I None
sold I None
) I None
, I None
with I None
paracetamol I Chemical
<eof> I None

<s> O None
( I None
acetaminophen I Chemical
) I None
dominating I None
the I None
pediatric I None
analgesic I None
and I None
antipyretic I None
market I None
. I None
<eof> I None

<s> O None
Reye I Disease
syndrome O Disease
may I None
be I None
disappearing I None
from I None
Australia I None
despite I None
a I None
total I None
lack I None
of I None
association I None
with I None
salicylates I Chemical
or I None
aspirin I Chemical
ingestion I None
, I None
since I None
there I None
were I None
no I None
cases I None
found I None
at I None
The I None
Children I None
's I None
Hospital I None
in I None
1983 I None
, I None
1984 I None
, I None
or I None
1985 I None
. I None
<eof> I None

<s> O None
St. I Disease
Anthony O Disease
's O Disease
fire O Disease
, I None
then I None
and I None
now I None
: I None
a I None
case I None
report I None
and I None
historical I None
review I None
. I None
<eof> I None

<s> O None
A I None
rare I None
case I None
of I None
morbid I None
vasospasm I Disease
, I None
together I None
with I None
striking I None
angiographic I None
findings I None
, I None
is I None
described I None
secondary I None
to I None
the I None
ingestion I None
of I None
methysergide I Chemical
by I None
a I None
48-year I None
- I None
old I None
woman I None
. I None
<eof> I None

<s> O None
A I None
brief I None
review I None
of I None
the I None
literature I None
on I None
similar I None
cases I None
is I None
presented I None
. I None
<eof> I None

<s> O None
A I None
discussion I None
of I None
the I None
history I None
of I None
ergot I Chemical
includes I None
its I None
original I None
discovery I None
, I None
the I None
epidemics I None
of I None
gangrene I Disease
that I None
it I None
has I None
caused I None
through I None
the I None
ages I None
and I None
its I None
past I None
and I None
present I None
role I None
in I None
the I None
management I None
of I None
migraine I Disease
headache O Disease
. I None
<eof> I None

<s> O None
Despite I None
the I None
advent I None
of I None
calcium I Chemical
channel I None
blockers I None
and I None
beta I None
- I None
adrenergic I None
antagonists I None
, I None
ergot I Chemical
preparations I None
continue I None
to I None
play I None
a I None
major I None
role I None
in I None
migraine I Disease
therapy I None
, I None
so I None
that I None
the I None
danger I None
of I None
St. I Disease
Anthony O Disease
's O Disease
fire O Disease
persists I None
. I None
<eof> I None

<s> O None
Beta-2-adrenoceptor I None
- I None
mediated I None
hypokalemia I Disease
and I None
its I None
abolishment I None
by I None
oxprenolol I Chemical
. I None
<eof> I None

<s> O None
The I None
time I None
course I None
and I None
concentration I None
- I None
effect I None
relationship I None
of I None
<eof> I None

<s> O None
terbutaline I Chemical
-induced I None
<eof> I None

<s> O None
hypokalemia I Disease
was I None
studied I None
, I None
using I None
computer I None
- I None
aided I None
pharmacokinetic I None
- I None
dynamic I None
modeling I None
. I None
<eof> I None

<s> O None
Subsequently I None
we I None
investigated I None
the I None
efficacy I None
of I None
oxprenolol I Chemical
in I None
antagonizing I None
such I None
hypokalemia I Disease
, I None
together I None
with I None
the I None
pharmacokinetic I None
interaction I None
between I None
both I None
drugs I None
. I None
<eof> I None

<s> O None
Six I None
healthy I None
subjects I None
were I None
given I None
a I None
0.5 I None
mg I None
subcutaneous I None
dose I None
of I None
terbutaline I Chemical
on I None
two I None
occasions I None
: I None
1 I None
hour I None
after I None
oral I None
administration I None
of I None
a I None
placebo I None
and I None
1 I None
hour I None
after I None
80 I None
mg I None
oxprenolol I Chemical
orally I None
. I None
<eof> I None

<s> O None
In I None
the I None
7-hour I None
period I None
after I None
terbutaline I Chemical
administration I None
, I None
plasma I None
samples I None
were I None
taken I None
for I None
determination I None
of I None
plasma I None
potassium I Chemical
levels I None
and I None
drug I None
concentrations I None
. I None
<eof> I None

<s> O None
The I None
sigmoid I None
Emax I None
model I None
offered I None
a I None
good I None
description I None
of I None
the I None
relation I None
between I None
terbutaline I Chemical
concentrations I None
and I None
potassium I Chemical
effects I None
. I None
<eof> I None

<s> O None
Oxprenolol I Chemical
caused I None
decreases I None
of I None
65 I None
% I None
and I None
56 I None
% I None
of I None
terbutaline I Chemical
volume I None
of I None
distribution I None
and I None
clearance I None
, I None
respectively I None
, I None
and I None
an I None
increase I None
of I None
130 I None
% I None
of I None
its I None
AUC I None
. I None
<eof> I None

<s> O None
In I None
spite I None
of I None
higher I None
terbutaline I Chemical
concentrations I None
after I None
oxprenolol I Chemical
pretreatment I None
, I None
the I None
hypokalemia I Disease
was I None
almost I None
completely I None
antagonized I None
by I None
the I None
beta I None
2-blocking I None
action I None
. I None
<eof> I None

<s> O None
Midline I None
B3 I None
<eof> I None

<s> O None
serotonin I Chemical
nerves I None
in I None
rat I None
medulla I None
are I None
involved I None
in I None
hypotensive I Disease
effect I None
of I None
methyldopa I Chemical
. I None
<eof> I None

<s> O None
Previous I None
experiments I None
in I None
this I None
laboratory I None
have I None
shown I None
that I None
microinjection I None
of I None
methyldopa I Chemical
onto I None
the I None
ventrolateral I None
cells I None
of I None
the I None
B3 I None
serotonin I Chemical
neurons I None
in I None
the I None
medulla I None
elicits I None
a I None
hypotensive I Disease
response I None
mediated I None
by I None
a I None
projection I None
descending I None
into I None
the I None
spinal I None
cord I None
. I None
<eof> I None

<s> O None
The I None
present I None
experiments I None
were I None
designed I None
to I None
investigate I None
the I None
role I None
of I None
the I None
midline I None
cells I None
of I None
the I None
B3 I None
serotonin I Chemical
neurons I None
in I None
the I None
medulla I None
, I None
coinciding I None
with I None
the I None
raphe I None
magnus I None
. I None
<eof> I None

<s> O None
In I None
spontaneously I None
hypertensive I Disease
, I None
stroke I Disease
-prone I None
rats I None
, I None
microinjection I None
of I None
methyldopa I Chemical
into I None
the I None
area I None
of I None
the I None
midline I None
B3 I None
serotonin I Chemical
cell I None
group I None
in I None
the I None
ventral I None
medulla I None
caused I None
a I None
potent I None
hypotension I Disease
of I None
30 I None
- I None
40 I None
mm I None
Hg I None
, I None
which I None
was I None
maximal I None
2 I None
- I None
3 I None
h I None
after I None
administration I None
and I None
was I None
abolished I None
by I None
the I None
serotonin I Chemical
neurotoxin I None
5,7-dihydroxytryptamine I Chemical
<eof> I None

<s> O None
( I None
5,7-DHT I Chemical
) I None
injected I None
intracerebroventricularly I None
. I None
<eof> I None

<s> O None
However I None
, I None
intraspinal I None
injection I None
of I None
5,7-DHT I Chemical
to I None
produce I None
a I None
more I None
selective I None
lesion I None
of I None
only I None
descending I None
<eof> I None

<s> O None
serotonin I Chemical
projections I None
in I None
the I None
spinal I None
cord I None
did I None
not I None
affect I None
this I None
hypotension I Disease
. I None
<eof> I None

<s> O None
Further I None
, I None
5,7-DHT I Chemical
lesion I None
of I None
serotonin I Chemical
nerves I None
travelling I None
in I None
the I None
median I None
forebrain I None
bundle I None
, I None
one I None
of I None
the I None
main I None
ascending I None
pathways I None
from I None
the I None
B3 I None
serotonin I Chemical
cells I None
, I None
did I None
not I None
affect I None
the I None
fall I None
in I None
blood I None
pressure I None
associated I None
with I None
a I None
midline I None
B3 I None
serotonin I Chemical
methyldopa I Chemical
injection I None
. I None
<eof> I None

<s> O None
It I None
is I None
concluded I None
therefore I None
that I None
, I None
unlike I None
the I None
ventrolateral I None
B3 I None
cells I None
which I None
mediate I None
a I None
methyldopa I Chemical
-induced I None
hypotension I Disease
via I None
descending I None
projections I None
, I None
the I None
midline I None
serotonin I Chemical
B3 I None
cells I None
in I None
the I None
medulla I None
contribute I None
to I None
the I None
hypotensive I Disease
action I None
of I None
methyldopa I Chemical
, I None
either I None
by I None
way I None
of I None
an I None
ascending I None
projection I None
which I None
does I None
not I None
pass I None
through I None
the I None
median I None
forebrain I None
bundle I None
, I None
or I None
through I None
a I None
projection I None
restricted I None
to I None
the I None
caudal I None
brainstem I None
. I None
<eof> I None

<s> O None
Yohimbine I Chemical
treatment I None
of I None
sexual I Disease
side O Disease
effects O Disease
induced I None
by I None
serotonin I Chemical
reuptake I None
blockers I None
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
<eof> I None

<s> O None
Preclinical I None
and I None
clinical I None
studies I None
suggest I None
that I None
yohimbine I Chemical
facilitates I None
sexual I None
behavior I None
and I None
may I None
be I None
helpful I None
in I None
the I None
treatment I None
of I None
male I Disease
impotence O Disease
. I None
<eof> I None

<s> O None
A I None
single I None
case I None
report I None
suggests I None
that I None
yohimbine I Chemical
may I None
be I None
used I None
to I None
treat I None
the I None
sexual I Disease
side O Disease
effects O Disease
of I None
clomipramine I Chemical
. I None
<eof> I None

<s> O None
This I None
study I None
evaluated I None
yohimbine I Chemical
as I None
a I None
treatment I None
for I None
the I None
sexual I Disease
side O Disease
effects O Disease
caused I None
by I None
serotonin I Chemical
reuptake I None
blockers I None
. I None
<eof> I None

<s> O None
METHOD I None
: I None
<eof> I None

<s> O None
Six I None
patients I None
with I None
either I None
obsessive I Disease
compulsive O Disease
disorder O Disease
, I None
trichotillomania I Disease
, I None
anxiety I Disease
, I None
or I None
affective I Disease
disorders O Disease
who I None
suffered I None
sexual I Disease
side O Disease
effects O Disease
after I None
treatment I None
with I None
serotonin I Chemical
reuptake I None
blockers I None
were I None
given I None
yohimbine I Chemical
on I None
a I None
p.r.n I None
. I None
basis I None
in I None
an I None
open I None
clinical I None
trial I None
. I None
<eof> I None

<s> O None
Various I None
doses I None
of I None
yohimbine I Chemical
were I None
used I None
to I None
determine I None
the I None
ideal I None
dose I None
for I None
each I None
patient I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
Five I None
of I None
the I None
six I None
patients I None
experienced I None
improved I None
sexual I None
functioning I None
after I None
taking I None
yohimbine I Chemical
. I None
<eof> I None

<s> O None
One I None
patient I None
who I None
failed I None
to I None
comply I None
with I None
yohimbine I Chemical
treatment I None
had I None
no I None
therapeutic I None
effects I None
. I None
<eof> I None

<s> O None
Side I None
effects I None
of I None
yohimbine I Chemical
included I None
excessive I None
sweating I None
, I None
increased I None
anxiety I Disease
, I None
and I None
a I None
wound I None
- I None
up I None
feeling I None
in I None
some I None
patients I None
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
<eof> I None

<s> O None
The I None
results I None
of I None
this I None
study I None
indicate I None
that I None
yohimbine I Chemical
may I None
be I None
an I None
effective I None
treatment I None
for I None
the I None
sexual I Disease
side O Disease
effects O Disease
caused I None
by I None
serotonin I Chemical
reuptake I None
blockers I None
. I None
<eof> I None

<s> O None
Future I None
controlled I None
studies I None
are I None
needed I None
to I None
further I None
investigate I None
the I None
effectiveness I None
and I None
safety I None
of I None
yohimbine I Chemical
for I None
this I None
indication I None
. I None
<eof> I None

<s> O None
Hypersensitivity I Disease
immune I None
reaction I None
as I None
a I None
mechanism I None
for I None
dilevalol I Chemical
<eof> I None

<s> O None
-associated I None
<eof> I None

<s> O None
hepatitis I Disease
. I None
<eof> I None

<s> O None
OBJECTIVE I None
: I None
<eof> I None

<s> O None
To I None
assess I None
lymphocyte I None
reactivity I None
to I None
dilevalol I Chemical
and I None
to I None
serum I None
containing I None
putative I None
ex I None
vivo I None
dilevalol I Chemical
antigens I None
or I None
metabolites I None
in I None
a I None
case I None
of I None
dilevalol I Chemical
-induced I None
liver I Disease
injury O Disease
. I None
<eof> I None

<s> O None
PATIENT I None
: I None
<eof> I None

<s> O None
A I None
58-year I None
- I None
old I None
woman I None
with I None
a I None
clinical I None
diagnosis I None
of I None
dilevalol I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
liver I Disease
injury O Disease
. I None
<eof> I None

<s> O None
METHODS I None
: I None
Peripheral I None
blood I None
mononuclear I None
cells I None
collected I None
from I None
the I None
patient I None
were I None
cultured I None
in I None
the I None
presence I None
of I None
a I None
solution I None
of I None
dilevalol I Chemical
and I None
also I None
with I None
sera I None
collected I None
from I None
a I None
volunteer I None
before I None
and I None
after I None
dilevalol I Chemical
intake I None
. I None
<eof> I None

<s> O None
A I None
similar I None
protocol I None
was I None
performed I None
with I None
lymphocytes I None
from I None
a I None
healthy I None
subject I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
No I None
lymphocyte I None
proliferation I None
was I None
observed I None
either I None
in I None
the I None
patient I None
or I None
in I None
the I None
healthy I None
volunteer I None
in I None
the I None
presence I None
of I None
dilevalol I Chemical
solutions I None
. I None
<eof> I None

<s> O None
A I None
significant I None
proliferative I None
response I None
to I None
serum I None
collected I None
after I None
dilevalol I Chemical
intake I None
was I None
observed I None
in I None
the I None
case I None
of I None
the I None
patient I None
compared I None
with I None
the I None
proliferative I None
response I None
to I None
the I None
serum I None
collected I None
before I None
the I None
drug I None
intake I None
. I None
<eof> I None

<s> O None
No I None
reactivity I None
was I None
found I None
when I None
lymphocytes I None
from I None
the I None
healthy I None
subject I None
were I None
tested I None
under I None
similar I None
conditions I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
The I None
methodology I None
used I None
allowed I None
the I None
detection I None
of I None
lymphocyte I None
sensitization I None
to I None
sera I None
containing I None
ex I None
vivo I None
- I None
prepared I None
<eof> I None

<s> O None
dilevalol I Chemical
antigens I None
, I None
suggesting I None
the I None
involvement I None
of I None
an I None
immunologic I None
mechanism I None
in I None
dilevalol I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
liver I Disease
injury O Disease
. I None
<eof> I None

<s> O None
Reversible I None
myocardial I Disease
hypertrophy O Disease
induced I None
by I None
tacrolimus I Chemical
in I None
a I None
pediatric I None
heart I None
transplant I None
recipient I None
: I None
case I None
report I None
. I None
<eof> I None

<s> O None
Tacrolimus I Chemical
is I None
a I None
potent I None
immunosuppressant I None
that I None
is I None
frequently I None
used I None
in I None
organ I None
transplantation I None
. I None
<eof> I None

<s> O None
However I None
, I None
adverse I None
effects I None
include I None
cardiac I Disease
toxicity O Disease
. I None
<eof> I None

<s> O None
Herein I None
we I None
describe I None
transient I None
myocardial I Disease
hypertrophy O Disease
induced I None
by I None
tacrolimus I Chemical
after I None
heart I None
transplantation I None
. I None
<eof> I None

<s> O None
The I None
hypertrophy I Disease
caused I None
no I None
clinical I None
symptoms I None
but I None
was I None
noted I None
because I None
of I None
elevation I None
of I None
plasma I None
brain I None
natriuretic I None
peptide I None
concentration I None
and I None
confirmed I None
at I None
echocardiography I None
. I None
<eof> I None

<s> O None
Initially I None
, I None
allograft I None
rejection I None
was I None
feared I None
; I None
however I None
, I None
myocardial I None
biopsy I None
samples I None
revealed I None
only I None
interstitial I None
edema I Disease
and I None
mild I None
myocardial I Disease
hypertrophy O Disease
; I None
neither I None
cellular I None
nor I None
humoral I None
rejection I None
was I None
detected I None
. I None
<eof> I None

<s> O None
The I None
blood I None
tacrolimus I Chemical
concentration I None
was I None
higher I None
than I None
usual I None
at I None
that I None
time I None
; I None
thus I None
, I None
tacrolimus I Chemical
dosage I None
was I None
reduced I None
. I None
<eof> I None

<s> O None
Myocardial I Disease
hypertrophy O Disease
completely I None
resolved I None
upon I None
reducing I None
the I None
target I None
concentration I None
of I None
tacrolimus I Chemical
and I None
did I None
not I None
recur I None
, I None
as I None
confirmed I None
at I None
echocardiography I None
and I None
myocardial I None
biopsy I None
. I None
<eof> I None

<s> O None
Thus I None
, I None
we I None
conclude I None
that I None
tacrolimus I Chemical
induces I None
reversible I None
myocardial I Disease
hypertrophy O Disease
. I None
<eof> I None

<s> O None
In I None
patients I None
receiving I None
tacrolimus I Chemical
therapy I None
, I None
blood I None
concentration I None
should I None
be I None
carefully I None
controlled I None
and I None
extreme I None
attention I None
paid I None
to I None
cardiac I None
involvement I None
. I None
<eof> I None

<s> O None
Comparison I None
of I None
unilateral I None
pallidotomy I None
and I None
subthalamotomy I None
findings I None
in I None
advanced I None
idiopathic I Disease
Parkinson O Disease
's O Disease
disease O Disease
. I None
<eof> I None

<s> O None
A I None
prospective I None
, I None
randomized I None
, I None
double I None
- I None
blind I None
pilot I None
study I None
to I None
compare I None
the I None
results I None
of I None
stereotactic I None
unilateral I None
pallidotomy I None
and I None
subthalamotomy I None
in I None
advanced I None
idiopathic I Disease
Parkinson O Disease
's O Disease
disease O Disease
<eof> I None

<s> O None
( I None
PD I Disease
) I None
refractory I None
to I None
medical I None
treatment I None
was I None
designed I None
. I None
<eof> I None

<s> O None
Ten I None
consecutive I None
patients I None
( I None
mean I None
age I None
, I None
58.4 I None
+ I None
/- I None
6.8 I None
years I None
; I None
7 I None
men I None
, I None
3 I None
women I None
) I None
with I None
similar I None
characteristics I None
at I None
the I None
duration I None
of I None
disease I None
( I None
mean I None
disease I None
time I None
, I None
8.4 I None
+ I None
/- I None
<eof> I None

<s> O None
3.5 I None
years I None
) I None
, I None
disabling I None
motor I None
fluctuations I None
( I None
Hoehn I None
_ I None
Yahr I None
stage I None
3 I None
- I None
5 I None
in I None
off I None
- I None
drug I None
phases I None
) I None
and I None
levodopa I Chemical
-induced I None
<eof> I None

<s> O None
dyskinesias I Disease
were I None
selected I None
. I None
<eof> I None

<s> O None
All I None
patients I None
had I None
bilateral I None
symptoms I None
and I None
their I None
levodopa I Chemical
equivalent I None
dosing I None
were I None
analysed I None
. I None
<eof> I None

<s> O None
Six I None
patients I None
were I None
operated I None
on I None
in I None
the I None
globus I None
pallidus I None
interna I None
( I None
GPi I None
) I None
and I None
four I None
in I None
the I None
subthalamic I None
nucleus I None
( I None
STN I None
) I None
. I None
<eof> I None

<s> O None
Clinical I None
evaluation I None
included I None
the I None
use I None
of I None
the I None
Unified I None
Parkinson I Disease
's O Disease
Disease O Disease
Rating I None
Scale I None
( I None
UPDRS I None
) I None
, I None
Hoehn_Yahr I None
score I None
and I None
Schwab I None
England I None
activities I None
of I None
daily I None
living I None
( I None
ADL I None
) I None
score I None
in I None
' I None
on'- I None
and I None
' I None
off'-drug I None
conditions I None
before I None
surgery I None
and I None
6 I None
months I None
after I None
surgery I None
. I None
<eof> I None

<s> O None
There I None
was I None
statistically I None
significant I None
improvement I None
in I None
all I None
contralateral I None
major I None
parkinsonian I Disease
<eof> I None

<s> O None
motor I None
signs I None
in I None
all I None
patients I None
followed I None
for I None
6 I None
months I None
. I None
<eof> I None

<s> O None
Levodopa I Chemical
equivalent I None
daily I None
intake I None
was I None
significantly I None
reduced I None
in I None
the I None
STN I None
group I None
. I None
<eof> I None

<s> O None
Changes I None
in I None
UPDRS I None
, I None
Hoehn I None
_ I None
Yahr I None
and I None
Schwab I None
England I None
ADL I None
scores I None
were I None
similar I None
in I None
both I None
groups I None
. I None
<eof> I None

<s> O None
Cognitive I None
functions I None
were I None
unchanged I None
in I None
both I None
groups I None
. I None
<eof> I None

<s> O None
Complications I None
were I None
observed I None
in I None
two I None
patients I None
: I None
one I None
had I None
a I None
left I None
homonymous I Disease
hemianopsia O Disease
after I None
pallidotomy I None
and I None
another I None
one I None
developed I None
left I None
hemiballistic I None
movements I None
3 I None
days I None
after I None
subthalamotomy I None
which I None
partly I None
improved I None
within I None
1 I None
month I None
with I None
Valproate I Chemical
<eof> I None

<s> O None
1000 I None
mg I None
/ I None
day I None
. I None
<eof> I None

<s> O None
The I None
findings I None
of I None
this I None
study I None
suggest I None
that I None
lesions I None
of I None
the I None
unilateral I None
STN I None
and I None
GPi I None
are I None
equally I None
effective I None
treatment I None
for I None
patients I None
with I None
advanced I None
PD I Disease
refractory I None
to I None
medical I None
treatment I None
. I None
<eof> I None

<s> O None
Protective I None
effects I None
of I None
antithrombin I None
on I None
puromycin I Chemical
aminonucleoside O Chemical
<eof> I None

<s> O None
nephrosis I Disease
in I None
rats I None
. I None
<eof> I None

<s> O None
We I None
investigated I None
the I None
effects I None
of I None
antithrombin I None
, I None
a I None
plasma I None
inhibitor I None
of I None
coagulation I None
factors I None
, I None
in I None
rats I None
with I None
puromycin I Chemical
aminonucleoside O Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
nephrosis I Disease
, I None
which I None
is I None
an I None
experimental I None
model I None
of I None
human I None
nephrotic I Disease
syndrome O Disease
. I None
<eof> I None

<s> O None
Antithrombin I None
( I None
50 I None
or I None
500 I None
IU I None
/ I None
kg I None
/ I None
i.v I None
. I None
) I None
was I None
administered I None
to I None
rats I None
once I None
a I None
day I None
for I None
10 I None
days I None
immediately I None
after I None
the I None
injection I None
of I None
puromycin I Chemical
aminonucleoside O Chemical
<eof> I None

<s> O None
( I None
50 I None
mg I None
/ I None
kg I None
/ I None
i.v I None
. I None
) I None
. I None
<eof> I None

<s> O None
Treatment I None
with I None
antithrombin I None
attenuated I None
the I None
puromycin I Chemical
aminonucleoside O Chemical
-induced I None
hematological I Disease
abnormalities O Disease
. I None
<eof> I None

<s> O None
Puromycin I Chemical
aminonucleoside O Chemical
-induced I None
<eof> I None

<s> O None
renal I Disease
dysfunction O Disease
and I None
hyperlipidemia I Disease
were I None
also I None
suppressed I None
. I None
<eof> I None

<s> O None
Histopathological I None
examination I None
revealed I None
severe I None
renal I Disease
damage O Disease
such I None
as I None
proteinaceous I None
casts I None
in I None
tubuli I None
and I None
tubular I None
expansion I None
in I None
the I None
kidney I None
of I None
control I None
rats I None
, I None
while I None
an I None
improvement I None
of I None
the I None
damage I None
was I None
seen I None
in I None
antithrombin I None
- I None
treated I None
rats I None
. I None
<eof> I None

<s> O None
In I None
addition I None
, I None
antithrombin I None
treatment I None
markedly I None
suppressed I None
puromycin I Chemical
aminonucleoside O Chemical
-induced I None
apoptosis I None
of I None
renal I None
tubular I None
epithelial I None
cells I None
. I None
<eof> I None

<s> O None
Furthermore I None
, I None
puromycin I Chemical
aminonucleoside O Chemical
-induced I None
increases I None
in I None
renal I None
cytokine I None
content I None
were I None
also I None
decreased I None
. I None
<eof> I None

<s> O None
These I None
findings I None
suggest I None
that I None
thrombin I None
plays I None
an I None
important I None
role I None
in I None
the I None
pathogenesis I None
of I None
puromycin I Chemical
aminonucleoside O Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
nephrotic I Disease
syndrome O Disease
. I None
<eof> I None

<s> O None
Treatment I None
with I None
antithrombin I None
may I None
be I None
clinically I None
effective I None
in I None
patients I None
with I None
nephrotic I Disease
syndrome O Disease
. I None
<eof> I None

<s> O None
Reverse I None
or I None
inverted I None
left I Disease
ventricular O Disease
apical O Disease
ballooning O Disease
syndrome O Disease
<eof> I None

<s> O None
( I None
reverse I None
Takotsubo I Disease
cardiomyopathy O Disease
) I None
in I None
a I None
young I None
woman I None
in I None
the I None
setting I None
of I None
amphetamine I Chemical
use I None
. I None
<eof> I None

<s> O None
Transient I None
left I Disease
ventricular O Disease
apical O Disease
ballooning O Disease
syndrome O Disease
was I None
first I None
described I None
in I None
Japan I None
as I None
" I None
Takotsubo I Disease
cardiomyopathy O Disease
. I None
<eof> I None

<s> O None
" I None
<eof> I None

<s> O None
This I None
syndrome I None
has I None
been I None
identified I None
in I None
many I None
other I None
countries I None
. I None
<eof> I None

<s> O None
Many I None
variations I None
of I None
this I None
syndrome I None
have I None
been I None
recently I None
described I None
in I None
the I None
literature I None
. I None
<eof> I None

<s> O None
One I None
of I None
the I None
rarest I None
is I None
the I None
reverse I None
type I None
of I None
this I None
syndrome I None
, I None
with I None
hyperdynamic I None
apex I None
and I None
complete I None
<eof> I None

<s> O None
akinesia I Disease
of I None
the I None
base I None
( I None
as I None
opposed I None
to I None
the I None
classic I None
apical I Disease
ballooning O Disease
) I None
. I None
<eof> I None

<s> O None
In I None
this I None
article I None
, I None
we I None
report I None
an I None
interesting I None
case I None
of I None
a I None
young I None
woman I None
who I None
presented I None
with I None
this I None
rare I None
type I None
of I None
reverse I None
apical I Disease
ballooning O Disease
syndrome O Disease
occurring I None
after I None
amphetamine I Chemical
use I None
. I None
<eof> I None

<s> O None
This I None
report I None
is I None
followed I None
by I None
review I None
of I None
the I None
literature I None
. I None
<eof> I None

<s> O None
Attenuated I None
disruption I None
of I None
prepulse I None
inhibition I None
by I None
dopaminergic I None
stimulation I None
after I None
maternal I None
deprivation I None
and I None
adolescent I None
corticosterone I Chemical
treatment I None
in I None
rats I None
. I None
<eof> I None

<s> O None
The I None
development I None
of I None
schizophrenia I Disease
may I None
include I None
an I None
early I None
neurodevelopmental I None
stress I None
component I None
which I None
increases I None
vulnerability I None
to I None
later I None
stressful I None
life I None
events I None
, I None
in I None
combination I None
leading I None
to I None
overt I None
disease I None
. I None
<eof> I None

<s> O None
We I None
investigated I None
the I None
effect I None
of I None
an I None
early I None
stress I None
, I None
in I None
the I None
form I None
of I None
maternal I None
deprivation I None
, I None
combined I None
with I None
a I None
later I None
stress I None
, I None
simulated I None
by I None
chronic I None
periadolescent I None
<eof> I None

<s> O None
corticosterone I Chemical
treatment I None
, I None
on I None
behaviour I None
in I None
rats I None
. I None
<eof> I None

<s> O None
Acute I None
treatment I None
with I None
apomorphine I Chemical
caused I None
disruption I None
of I None
prepulse I None
inhibition I None
( I None
PPI I None
) I None
in I None
controls I None
and I None
in I None
rats I None
that I None
had I None
undergone I None
either I None
maternal I None
deprivation I None
or I None
corticosterone I Chemical
treatment I None
, I None
but I None
was I None
surprisingly I None
absent I None
in I None
rats I None
that I None
had I None
undergone I None
the I None
combined I None
early I None
and I None
late I None
stress I None
. I None
<eof> I None

<s> O None
Amphetamine I Chemical
treatment I None
significantly I None
disrupted I None
PPI I None
in I None
both I None
non I None
- I None
deprived I None
groups I None
, I None
but I None
was I None
absent I None
in I None
both I None
maternally I None
deprived I None
groups I None
. I None
<eof> I None

<s> O None
The I None
serotonin I Chemical
-1A I None
receptor I None
agonist I None
, I None
8-OH I Chemical
- O Chemical
DPAT O Chemical
, I None
induced I None
a I None
significant I None
disruption I None
of I None
PPI I None
in I None
all I None
groups I None
. I None
<eof> I None

<s> O None
Amphetamine I Chemical
-induced I None
<eof> I None

<s> O None
locomotor I Disease
hyperactivity O Disease
was I None
similar I None
in I None
all I None
groups I None
. I None
<eof> I None

<s> O None
These I None
results I None
show I None
an I None
inhibitory I None
interaction I None
of I None
early I None
stress I None
, I None
caused I None
by I None
maternal I None
deprivation I None
, I None
combined I None
with I None
' I None
adolescent I None
' I None
stress I None
, I None
simulated I None
by I None
corticosterone I Chemical
treatment I None
, I None
on I None
dopaminergic I None
regulation I None
of I None
PPI I None
. I None
<eof> I None

<s> O None
The I None
altered I None
effects I None
of I None
apomorphine I Chemical
and I None
amphetamine I Chemical
could I None
indicate I None
differential I None
changes I None
in I None
dopamine I Chemical
receptor I None
signalling I None
leading I None
to I None
functional I None
desensitisation I None
, I None
or I None
altered I None
modulation I None
of I None
sensory I None
gating I None
in I None
the I None
nucleus I None
accumbens I None
by I None
limbic I None
structures I None
such I None
as I None
the I None
hippocampus I None
. I None
<eof> I None

<s> O None
Peripheral I None
iron I Chemical
dextran O Chemical
induced I None
<eof> I None

<s> O None
degeneration I Disease
of O Disease
dopaminergic O Disease
neurons O Disease
in I None
rat I None
substantia I None
nigra I None
. I None
<eof> I None

<s> O None
Iron I Chemical
accumulation I None
is I None
considered I None
to I None
be I None
involved I None
in I None
the I None
pathogenesis I None
of I None
Parkinson I Disease
's O Disease
disease O Disease
. I None
<eof> I None

<s> O None
To I None
demonstrate I None
the I None
relationship I None
between I None
peripheral I None
iron I Chemical
overload I None
and I None
dopaminergic I None
neuron I None
loss I None
in I None
rat I None
substantia I None
nigra I None
( I None
SN I None
) I None
, I None
in I None
the I None
present I None
study I None
we I None
used I None
fast I None
cyclic I None
voltammetry I None
, I None
tyrosine I Chemical
hydroxylase I None
( I None
TH I None
) I None
immunohistochemistry I None
, I None
Perls I None
' I None
iron I Chemical
staining I None
, I None
and I None
high I None
performance I None
liquid I None
chromatography I None
- I None
electrochemical I None
detection I None
to I None
study I None
the I None
degeneration I Disease
of O Disease
dopaminergic O Disease
neurons O Disease
and I None
increased I None
iron I Chemical
content I None
in I None
the I None
SN I None
of I None
iron I Chemical
dextran O Chemical
overloaded I None
animals I None
. I None
<eof> I None

<s> O None
The I None
findings I None
showed I None
that I None
peripheral I None
iron I Chemical
dextran O Chemical
overload I None
increased I None
the I None
iron I Chemical
staining I None
positive I None
cells I None
and I None
reduced I None
the I None
number I None
of I None
TH I None
- I None
immunoreactive I None
neurons I None
in I None
the I None
SN I None
. I None
<eof> I None

<s> O None
As I None
a I None
result I None
, I None
dopamine I Chemical
release I None
and I None
content I None
, I None
as I None
well I None
as I None
its I None
metabolites I None
contents I None
were I None
decreased I None
in I None
caudate I None
putamen I None
. I None
<eof> I None

<s> O None
Even I None
more I None
dramatic I None
changes I None
were I None
found I None
in I None
chronic I None
overload I None
group I None
. I None
<eof> I None

<s> O None
These I None
results I None
suggest I None
that I None
peripheral I None
iron I Chemical
dextran O Chemical
can I None
increase I None
the I None
iron I Chemical
level I None
in I None
the I None
SN I None
, I None
where I None
excessive I None
iron I Chemical
causes I None
the I None
degeneration I Disease
of O Disease
dopaminergic O Disease
neurons O Disease
. I None
<eof> I None

<s> O None
The I None
chronic I None
iron I Chemical
overload I None
may I None
be I None
more I None
destructive I None
to I None
dopaminergic I None
neurons I None
than I None
the I None
acute I None
iron I Chemical
overload I None
. I None
<eof> I None

<s> O None
Warfarin I Chemical
-induced I None
leukocytoclastic I Disease
vasculitis O Disease
. I None
<eof> I None

<s> O None
Skin I None
reactions I None
associated I None
with I None
oral I None
coumarin I Chemical
<eof> I None

<s> O None
-derived I None
<eof> I None

<s> O None
anticoagulants I None
are I None
an I None
uncommon I None
occurrence I None
. I None
<eof> I None

<s> O None
Leukocytoclastic I Disease
vasculitis O Disease
<eof> I None

<s> O None
( I None
LV I Disease
) I None
is I None
primarily I None
a I None
cutaneous I Disease
small O Disease
vessel O Disease
vasculitis O Disease
, I None
though I None
systemic I None
involvement I None
may I None
be I None
encountered I None
. I None
<eof> I None

<s> O None
We I None
report I None
4 I None
patients I None
with I None
late I None
- I None
onset I None
LV I Disease
probably I None
due I None
to I None
warfarin I Chemical
. I None
<eof> I None

<s> O None
All I None
4 I None
patients I None
presented I None
with I None
skin I Disease
eruptions O Disease
that I None
developed I None
after I None
receiving I None
warfarin I Chemical
for I None
several I None
years I None
. I None
<eof> I None

<s> O None
The I None
results I None
of I None
skin I Disease
lesion O Disease
biopsies I None
were I None
available I None
in I None
3 I None
patients I None
, I None
confirming I None
LV I Disease
Cutaneous O Disease
lesions O Disease
resolved I None
in I None
all I None
patients I None
after I None
warfarin I Chemical
was I None
discontinued I None
. I None
<eof> I None

<s> O None
In I None
2 I None
of I None
the I None
4 I None
patients I None
, I None
rechallenge I None
with I None
warfarin I Chemical
led I None
to I None
recurrence I None
of I None
the I None
lesions I None
. I None
<eof> I None

<s> O None
LV I Disease
may I None
be I None
a I None
late I None
- I None
onset I None
adverse I None
reaction I None
associated I None
with I None
warfarin I Chemical
therapy I None
. I None
<eof> I None

<s> O None
The I None
activation I None
of I None
spinal I None
N I Chemical
- O Chemical
methyl O Chemical
- O Chemical
D O Chemical
- O Chemical
aspartate O Chemical
receptors I None
may I None
contribute I None
to I None
degeneration I None
of I None
spinal I None
motor I None
neurons I None
induced I None
by I None
neuraxial I None
morphine I Chemical
after I None
a I None
noninjurious I None
interval I None
of I None
spinal I Disease
cord O Disease
ischemia O Disease
. I None
<eof> I None

<s> O None
We I None
investigated I None
the I None
relationship I None
between I None
the I None
degeneration I None
of I None
spinal I None
motor I None
neurons I None
and I None
activation I None
of I None
N I Chemical
- O Chemical
methyl O Chemical
- O Chemical
d O Chemical
- O Chemical
aspartate O Chemical
<eof> I None

<s> O None
( I None
NMDA I Chemical
) I None
receptors I None
after I None
neuraxial I None
morphine I Chemical
following I None
a I None
noninjurious I None
interval I None
of I None
aortic I Disease
occlusion O Disease
in I None
rats I None
. I None
<eof> I None

<s> O None
Spinal I Disease
cord O Disease
ischemia O Disease
was I None
induced I None
by I None
aortic I Disease
occlusion O Disease
for I None
6 I None
min I None
with I None
a I None
balloon I None
catheter I None
. I None
<eof> I None

<s> O None
In I None
a I None
microdialysis I None
study I None
, I None
10 I None
muL I None
of I None
saline I None
( I None
group I None
C I None
; I None
n I None
= I None
8) I None
or I None
30 I None
mug I None
of I None
morphine I Chemical
<eof> I None

<s> O None
( I None
group I None
M I None
; I None
n I None
= I None
8) I None
was I None
injected I None
intrathecally I None
( I None
IT I None
) I None
0.5 I None
h I None
after I None
reflow I None
, I None
and I None
30 I None
mug I None
of I None
morphine I Chemical
<eof> I None

<s> O None
( I None
group I None
SM I None
; I None
n I None
= I None
8) I None
or I None
10 I None
muL I None
of I None
saline I None
( I None
group I None
SC I None
; I None
n I None
= I None
8) I None
was I None
injected I None
IT I None
0.5 I None
h I None
after I None
sham I None
operation I None
. I None
<eof> I None

<s> O None
Microdialysis I None
samples I None
were I None
collected I None
preischemia I None
, I None
before I None
IT I None
injection I None
, I None
and I None
at I None
2 I None
, I None
4 I None
, I None
8 I None
, I None
24 I None
, I None
and I None
48 I None
h I None
of I None
reperfusion I None
( I None
after I None
IT I None
injection I None
) I None
. I None
<eof> I None

<s> O None
Second I None
, I None
we I None
investigated I None
the I None
effect I None
of I None
IT I None
MK-801 I Chemical
( I None
30 I None
mug I None
) I None
on I None
the I None
histopathologic I None
changes I None
in I None
the I None
spinal I None
cord I None
after I None
morphine I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
spastic I Disease
paraparesis O Disease
. I None
<eof> I None

<s> O None
After I None
IT I None
morphine I Chemical
, I None
the I None
cerebrospinal I None
fluid I None
( I None
CSF I None
) I None
<eof> I None

<s> O None
glutamate I Chemical
concentration I None
was I None
increased I None
in I None
group I None
M I None
relative I None
to I None
both I None
baseline I None
and I None
group I None
C I None
( I None
P I None
< I None
0.05 I None
) I None
. I None
<eof> I None

<s> O None
This I None
increase I None
persisted I None
for I None
8 I None
hrs I None
. I None
<eof> I None

<s> O None
IT I None
<eof> I None

<s> O None
MK-801 I Chemical
significantly I None
reduced I None
the I None
number I None
of I None
dark I None
- I None
stained I None
alpha I None
- I None
motoneurons I None
after I None
<eof> I None

<s> O None
morphine I Chemical
-induced I None
spastic I Disease
paraparesis O Disease
compared I None
with I None
the I None
saline I None
group I None
. I None
<eof> I None

<s> O None
These I None
data I None
indicate I None
that I None
IT I None
morphine I Chemical
induces I None
spastic I Disease
paraparesis O Disease
with I None
a I None
concomitant I None
increase I None
in I None
CSF I None
glutamate I Chemical
, I None
which I None
is I None
involved I None
in I None
NMDA I Chemical
receptor I None
activation I None
. I None
<eof> I None

<s> O None
We I None
suggest I None
that I None
opioids I None
may I None
be I None
neurotoxic I Disease
in I None
the I None
setting I None
of I None
spinal I Disease
cord O Disease
ischemia O Disease
via I None
NMDA I Chemical
receptor I None
activation I None
. I None
<eof> I None

<s> O None
Reduced I None
sodium I Chemical
channel I None
density I None
, I None
altered I None
voltage I None
dependence I None
of I None
inactivation I None
, I None
and I None
increased I None
susceptibility I None
to I None
seizures I Disease
in I None
mice I None
lacking I None
sodium I Chemical
channel I None
beta I None
2-subunits I None
. I None
<eof> I None

<s> O None
Sodium I Chemical
channel I None
beta I None
- I None
subunits I None
modulate I None
channel I None
gating I None
, I None
assembly I None
, I None
and I None
cell I None
surface I None
expression I None
in I None
heterologous I None
cell I None
systems I None
. I None
<eof> I None

<s> O None
We I None
generated I None
beta2(-/- I None
) I None
mice I None
to I None
investigate I None
the I None
role I None
of I None
beta2 I None
in I None
control I None
of I None
sodium I Chemical
channel I None
density I None
, I None
localization I None
, I None
and I None
function I None
in I None
neurons I None
in I None
vivo I None
. I None
<eof> I None

<s> O None
Measurements I None
of I None
[ I None
( I None
3)H I None
] I None
saxitoxin I Chemical
<eof> I None

<s> O None
( I None
STX I Chemical
) I None
binding I None
showed I None
a I None
significant I None
reduction I None
in I None
the I None
level I None
of I None
plasma I None
membrane I None
sodium I Chemical
channels I None
in I None
beta2(-/- I None
) I None
neurons I None
. I None
<eof> I None

<s> O None
The I None
loss I None
of I None
beta2 I None
resulted I None
in I None
negative I None
shifts I None
in I None
the I None
voltage I None
dependence I None
of I None
inactivation I None
as I None
well I None
as I None
significant I None
decreases I None
in I None
sodium I Chemical
current I None
density I None
in I None
acutely I None
dissociated I None
hippocampal I None
neurons I None
. I None
<eof> I None

<s> O None
The I None
integral I None
of I None
the I None
compound I None
action I None
potential I None
in I None
optic I None
nerve I None
was I None
significantly I None
reduced I None
, I None
and I None
the I None
threshold I None
for I None
action I None
potential I None
generation I None
was I None
increased I None
, I None
indicating I None
a I None
reduction I None
in I None
the I None
level I None
of I None
functional I None
plasma I None
membrane I None
sodium I Chemical
channels I None
. I None
<eof> I None

<s> O None
In I None
contrast I None
, I None
the I None
conduction I None
velocity I None
, I None
the I None
number I None
and I None
size I None
of I None
axons I None
in I None
the I None
optic I None
nerve I None
, I None
and I None
the I None
specific I None
localization I None
of I None
Na I Chemical
( I None
v)1.6 I None
channels I None
in I None
the I None
nodes I None
of I None
Ranvier I None
were I None
unchanged I None
. I None
<eof> I None

<s> O None
beta2(-/- I None
) I None
mice I None
displayed I None
increased I None
susceptibility I None
to I None
seizures I Disease
, I None
as I None
indicated I None
by I None
reduced I None
latency I None
and I None
threshold I None
for I None
pilocarpine I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
seizures I Disease
, I None
but I None
seemed I None
normal I None
in I None
other I None
neurological I None
tests I None
. I None
<eof> I None

<s> O None
Our I None
observations I None
show I None
that I None
beta2-subunits I None
play I None
an I None
important I None
role I None
in I None
the I None
regulation I None
of I None
sodium I Chemical
channel I None
density I None
and I None
function I None
in I None
neurons I None
in I None
vivo I None
and I None
are I None
required I None
for I None
normal I None
action I None
potential I None
generation I None
and I None
control I None
of I None
excitability I None
. I None
<eof> I None

<s> O None
Screening I None
for I None
stimulant I None
use I None
in I None
adult I None
emergency I None
department I None
seizure I Disease
patients I None
. I None
<eof> I None

<s> O None
OBJECTIVE I None
: I None
<eof> I None

<s> O None
The I None
objective I None
of I None
this I None
study I None
was I None
to I None
determine I None
the I None
prevalence I None
of I None
positive I None
plasma I None
drug I None
screening I None
for I None
cocaine I Chemical
or I None
amphetamine I Chemical
in I None
adult I None
emergency I None
department I None
seizure I Disease
patients I None
. I None
<eof> I None

<s> O None
METHODS I None
: I None
<eof> I None

<s> O None
This I None
prospective I None
study I None
evaluated I None
consecutive I None
eligible I None
seizure I Disease
patients I None
who I None
had I None
a I None
plasma I None
sample I None
collected I None
as I None
part I None
of I None
their I None
clinical I None
evaluation I None
. I None
<eof> I None

<s> O None
Plasma I None
was I None
tested I None
for I None
amphetamine I Chemical
and I None
the I None
cocaine I Chemical
metabolite I None
benzoylecgonine I Chemical
using I None
enzyme I None
- I None
mediated I None
immunoassay I None
methodology I None
. I None
<eof> I None

<s> O None
Plasma I None
samples I None
with I None
benzoylecgonine I Chemical
<eof> I None

<s> O None
greater I None
than I None
150 I None
ng I None
/ I None
mL I None
or I None
an I None
amphetamine I Chemical
greater I None
than I None
500 I None
ng I None
/ I None
mL I None
were I None
defined I None
as I None
positive I None
. I None
<eof> I None

<s> O None
Patient I None
demographics I None
, I None
history I None
of I None
underlying I None
drug I None
or I None
alcohol I Chemical
-related I None
seizure I Disease
disorder I None
, I None
estimated I None
time I None
from I None
seizure I Disease
to I None
sample I None
collection I None
, I None
history I None
or I None
suspicion I None
of I None
cocaine I None
or I None
amphetamine I None
abuse I None
, I None
results I None
of I None
clinical I None
urine I None
testing I None
for I None
drugs I None
of I None
abuse I None
, I None
and I None
assay I None
results I None
were I None
recorded I None
without I None
patient I None
identifiers I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
Fourteen I None
of I None
248 I None
( I None
5.6 I None
% I None
, I None
95 I None
% I None
CI I None
<eof> I None

<s> O None
2.7%-8.5 I None
% I None
) I None
plasma I None
samples I None
were I None
positive I None
by I None
immunoassay I None
testing I None
for I None
benzoylecgonine I Chemical
and I None
no I None
samples I None
( I None
0 I None
% I None
, I None
95 I None
% I None
CI I None
0 I None
- I None
1.2 I None
% I None
) I None
were I None
positive I None
for I None
amphetamine I Chemical
. I None
<eof> I None

<s> O None
Positive I None
test I None
results I None
were I None
more I None
common I None
in I None
patient I None
visits I None
where I None
there I None
was I None
a I None
history I None
or I None
suspicion I None
of I None
cocaine I None
or I None
amphetamine I None
abuse I None
( I None
p I None
< I None
0.0005 I None
) I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
During I None
this I None
study I None
period I None
, I None
routine I None
plasma I None
screening I None
for I None
cocaine I Chemical
and I None
amphetamines I Chemical
in I None
adult I None
seizure I Disease
patients I None
had I None
a I None
low I None
yield I None
. I None
<eof> I None

<s> O None
As I None
a I None
result I None
, I None
routine I None
plasma I None
screening I None
would I None
yield I None
few I None
cases I None
of I None
stimulant I None
drug I None
in I None
which I None
there I None
was I None
neither I None
a I None
history I None
nor I None
suspicion I None
of I None
drug I Disease
abuse O Disease
in I None
this I None
population I None
. I None
<eof> I None

<s> O None
Evidence I None
of I None
functional I None
somatotopy I None
in I None
GPi I None
from I None
results I None
of I None
pallidotomy I None
. I None
<eof> I None

<s> O None
The I None
objective I None
of I None
this I None
study I None
was I None
to I None
explore I None
the I None
functional I None
anatomy I None
of I None
the I None
globus I None
pallidus I None
internus I None
( I None
GPi I None
) I None
by I None
studying I None
the I None
effects I None
of I None
unilateral I None
pallidotomy I None
on I None
parkinsonian I Disease
' I None
off I None
' I None
signs I None
and I None
levodopa I Chemical
-induced I None
dyskinesias I Disease
( I None
LID I Disease
) I None
. I None
<eof> I None

<s> O None
We I None
found I None
significant I None
positive I None
correlations I None
between I None
the I None
preoperative I None
levodopa I Chemical
responsiveness I None
of I None
motor I None
signs I None
and I None
the I None
levodopa I Chemical
responsiveness I None
of I None
scores I None
in I None
timed I None
tests I None
( I None
Core I None
Assessment I None
Program I None
for I None
Intracerebral I None
Transplantations I None
) I None
in I None
the I None
contralateral I None
limbs I None
and I None
the I None
improvement I None
in I None
these I None
scores I None
after I None
surgery I None
, I None
whereas I None
there I None
was I None
no I None
correlation I None
with I None
the I None
improvement I None
in I None
LID I Disease
. I None
<eof> I None

<s> O None
We I None
also I None
found I None
a I None
highly I None
significant I None
correlation I None
( I None
P I None
: I None
< I None
0.0001 I None
, I None
r I None
= I None
0.8 I None
) I None
between I None
the I None
volume I None
of I None
the I None
ventral I None
lesion I None
in I None
the I None
GPi I None
and I None
the I None
improvement I None
in I None
LID I Disease
in I None
the I None
contralateral I None
limbs I None
, I None
whereas I None
there I None
was I None
no I None
correlation I None
between I None
the I None
ventral I None
volume I None
and I None
the I None
improvement I None
in I None
parkinsonian I Disease
' I None
off I None
' I None
signs I None
. I None
<eof> I None

<s> O None
The I None
volumes I None
of I None
the I None
total I None
lesion I None
cylinder I None
and I None
the I None
dorsal I None
lesion I None
did I None
not I None
correlate I None
with I None
the I None
outcome I None
of I None
either I None
dyskinesias I Disease
or I None
parkinsonian I Disease
' I None
off I None
' I None
signs I None
. I None
<eof> I None

<s> O None
The I None
differential I None
predictive I None
value I None
of I None
levodopa I Chemical
responsiveness I None
for I None
the I None
outcome I None
of I None
parkinsonian I Disease
' I None
off I None
' I None
signs I None
and I None
LID I Disease
and I None
the I None
different I None
correlations I None
of I None
ventral I None
lesion I None
volume I None
with I None
dyskinesias I Disease
and I None
parkinsonian I Disease
' I None
off I None
' I None
signs I None
indicate I None
that I None
different I None
anatomical I None
or I None
pathophysiological I None
substrates I None
may I None
be I None
responsible I None
for I None
the I None
generation I None
of I None
parkinsonian I Disease
' I None
off I None
' I None
signs I None
and I None
dyskinesias I Disease
. I None
<eof> I None

<s> O None
Whereas I None
cells I None
in I None
a I None
wider I None
area I None
of I None
the I None
GPi I None
may I None
be I None
implicated I None
in I None
parkinsonism I Disease
, I None
the I None
ventral I None
GPi I None
seems I None
to I None
be I None
crucial I None
for I None
the I None
manifestation I None
of I None
LID I Disease
. I None
<eof> I None

<s> O None
We I None
suggest I None
that I None
our I None
observations I None
are I None
additional I None
proof I None
of I None
the I None
functional I None
somatotopy I None
of I None
the I None
systems I None
within I None
the I None
GPi I None
that I None
mediate I None
parkinsonism I Disease
and I None
dyskinesias I Disease
, I None
especially I None
along I None
the I None
dorsoventral I None
trajectory I None
used I None
in I None
pallidotomy I None
. I None
<eof> I None

<s> O None
The I None
outcome I None
of I None
pallidotomy I None
in I None
which I None
the I None
lesion I None
involves I None
the I None
ventral I None
and I None
dorsal I None
GPi I None
could I None
be I None
the I None
net I None
effect I None
of I None
alteration I None
in I None
the I None
activity I None
of I None
pathways I None
which I None
mediate I None
different I None
symptoms I None
, I None
and I None
hence I None
could I None
be I None
variable I None
. I None
<eof> I None

<s> O None
Pain I Disease
responses I None
in I None
methadone I Chemical
<eof> I None

<s> O None
-maintained I None
opioid I None
abusers I None
. I None
<eof> I None

<s> O None
Providing I None
pain I Disease
management I None
for I None
known I None
opioid I None
abusers I None
is I None
a I None
challenging I None
clinical I None
task I None
, I None
in I None
part I None
because I None
little I None
is I None
known I None
about I None
their I None
pain I Disease
experience I None
and I None
analgesic I None
requirements I None
. I None
<eof> I None

<s> O None
This I None
study I None
was I None
designed I None
to I None
describe I None
pain I Disease
tolerance I None
and I None
analgesic I None
response I None
in I None
a I None
sample I None
of I None
opioid I Disease
addicts O Disease
stabilized I None
in I None
<eof> I None

<s> O None
methadone I Chemical
-maintenance I None
<eof> I None

<s> O None
( I None
MM I None
) I None
treatment I None
( I None
n I None
= I None
60 I None
) I None
in I None
comparison I None
to I None
matched I None
nondependent I None
control I None
subjects I None
( I None
n I None
= I None
60 I None
) I None
. I None
<eof> I None

<s> O None
By I None
using I None
a I None
placebo I None
- I None
controlled I None
, I None
two I None
- I None
way I None
factorial I None
design I None
, I None
tolerance I None
to I None
cold I None
- I None
pressor I None
( I None
CP I None
) I None
pain I Disease
was I None
examined I None
, I None
both I None
before I None
and I None
after I None
oral I None
administration I None
of I None
therapeutic I None
doses I None
of I None
common I None
opioid I None
( I None
hydromorphone I Chemical
2 I None
mg I None
) I None
and I None
nonsteroidal I None
anti I None
- I None
inflammatory I None
( I None
ketorolac I Chemical
10 I None
mg I None
) I None
analgesic I None
agents I None
. I None
<eof> I None

<s> O None
Results I None
showed I None
that I None
MM I None
individuals I None
were I None
significantly I None
less I None
tolerant I None
of I None
CP I None
pain I Disease
than I None
control I None
subjects I None
, I None
replicating I None
previous I None
work I None
. I None
<eof> I None

<s> O None
Analgesic I None
effects I None
were I None
significant I None
neither I None
for I None
medication I None
nor I None
group I None
. I None
<eof> I None

<s> O None
These I None
data I None
indicate I None
that I None
MM I None
opioid I None
abusers I None
represent I None
a I None
pain I Disease
- O Disease
intolerant O Disease
subset I None
of I None
clinical I None
patients I None
. I None
<eof> I None

<s> O None
Their I None
complaints I None
of I None
pain I Disease
should I None
be I None
evaluated I None
seriously I None
and I None
managed I None
aggressively I None
. I None
<eof> I None

<s> O None
Urine I None
N I None
- I None
acetyl I None
- I None
beta I None
- I None
D I None
- I None
glucosaminidase I None
-- I None
a I None
marker I None
of I None
tubular I None
damage I None
? I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
<eof> I None

<s> O None
Although I None
an I None
indicator I None
of I None
renal I Disease
tubular O Disease
dysfunction O Disease
, I None
an I None
increased I None
urinary I None
N I None
- I None
acetyl I None
- I None
beta I None
- I None
D I None
- I None
glucosaminidase I None
( I None
NAG I None
) I None
activity I None
might I None
reflect I None
increased I None
lysosomal I None
activity I None
in I None
renal I None
tubular I None
cells I None
. I None
<eof> I None

<s> O None
METHODS I None
: I None
Puromycin I Chemical
aminonucleoside O Chemical
<eof> I None

<s> O None
( I None
PAN I Chemical
) I None
was I None
administered I None
to I None
Sprague I None
Dawley I None
rats I None
to I None
induce I None
proteinuria I Disease
. I None
<eof> I None

<s> O None
Total I None
protein I None
, I None
albumin I None
, I None
NAG I None
activity I None
and I None
protein I None
electrophoretic I None
pattern I None
were I None
assessed I None
in I None
daily I None
urine I None
samples I None
for I None
33 I None
days I None
. I None
<eof> I None

<s> O None
The I None
morphological I None
appearance I None
of I None
the I None
kidneys I None
was I None
examined I None
on I None
days I None
three I None
, I None
four I None
, I None
six I None
, I None
eight I None
and I None
thirty I None
three I None
and I None
the I None
NAG I None
isoenzyme I None
patterns I None
on I None
days I None
zero I None
, I None
four I None
, I None
eight I None
and I None
thirty I None
three I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
Following I None
intravenous I None
PAN I Chemical
urine I None
volume I None
and I None
urine I None
NAG I None
activity I None
increased I None
significantly I None
by I None
day I None
two I None
, I None
but I None
returned I None
to I None
normal I None
by I None
day I None
four I None
. I None
<eof> I None

<s> O None
After I None
day I None
four I None
all I None
treated I None
animals I None
exhibited I None
a I None
marked I None
rise I None
in I None
urine I None
albumin I None
, I None
total I None
protein I None
excretion I None
and I None
NAG I None
activity I None
. I None
<eof> I None

<s> O None
Electrophoresis I None
showed I None
a I None
generalised I None
increase I None
in I None
middle I None
and I None
high I None
molecular I None
weight I None
urine I None
proteins I None
from I None
day I None
four I None
onwards I None
. I None
<eof> I None

<s> O None
Protein I None
droplets I None
first I None
appeared I None
prominent I None
in I None
tubular I None
cells I None
on I None
day I None
four I None
. I None
<eof> I None

<s> O None
Peak I None
urine I None
NAG I None
activity I None
and I None
a I None
change I None
in I None
NAG I None
isoenzyme I None
pattern I None
coincided I None
with I None
both I None
the I None
peak I None
proteinuria I Disease
and I None
the I None
reduction I None
in I None
intracellular I None
protein I None
and I None
NAG I None
droplets I None
( I None
day I None
six I None
onwards I None
) I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
This I None
animal I None
model I None
demonstrates I None
that I None
an I None
increase I None
in I None
lysosomal I None
turnover I None
and I None
hence I None
urine I None
NAG I None
activity I None
, I None
occurs I None
when I None
increased I None
protein I None
is I None
presented I None
to I None
the I None
tubular I None
cells I None
. I None
<eof> I None

<s> O None
Urine I None
NAG I None
activity I None
is I None
thus I None
a I None
measure I None
of I None
altered I None
function I None
in I None
the I None
renal I None
tubules I None
and I None
not I None
simply I None
an I None
indicator I None
of I None
damage I None
. I None
<eof> I None

<s> O None
Over I None
expression I None
of I None
vascular I None
endothelial I None
growth I None
factor I None
and I None
its I None
receptor I None
during I None
the I None
development I None
of I None
estrogen I Chemical
-induced I None
rat I None
<eof> I None

<s> O None
pituitary I Disease
tumors O Disease
may I None
mediate I None
estrogen I Chemical
-initiated I None
<eof> I None

<s> O None
tumor I Disease
angiogenesis I None
. I None
<eof> I None

<s> O None
Estrogens I Chemical
, I None
which I None
have I None
been I None
associated I None
with I None
several I None
types I None
of I None
human I None
and I None
animal I None
cancers I Disease
, I None
can I None
induce I None
tumor I Disease
angiogenesis I None
in I None
the I None
pituitary I None
of I None
Fischer I None
344 I None
rats I None
. I None
<eof> I None

<s> O None
The I None
mechanistic I None
details I None
of I None
tumor I Disease
angiogenesis I None
induction I None
, I None
during I None
estrogen I Chemical
carcinogenesis I Disease
, I None
are I None
still I None
unknown I None
. I None
<eof> I None

<s> O None
To I None
elucidate I None
the I None
role I None
of I None
estrogen I Chemical
in I None
the I None
regulation I None
of I None
tumor I Disease
angiogenesis I None
in I None
the I None
pituitary I None
of I None
female I None
rats I None
, I None
the I None
density I None
of I None
blood I None
vessels I None
was I None
analysed I None
using I None
factor I None
VIII I None
related I None
antigen I None
( I None
FVIIIRAg I None
) I None
immunohistochemistry I None
and I None
the I None
expression I None
of I None
vascular I None
endothelial I None
growth I None
factor I None
/ I None
vascular I None
permeability I None
factor I None
( I None
VEGF I None
/ I None
VPF I None
) I None
was I None
examined I None
by I None
Western I None
blot I None
and I None
immunohistochemical I None
analysis I None
. I None
<eof> I None

<s> O None
The I None
expression I None
of I None
VEGF I None
receptor I None
( I None
VEGFR-2/Flk-1/KDR I None
) I None
was I None
also I None
examined I None
by I None
immunohistochemistry I None
. I None
<eof> I None

<s> O None
The I None
results I None
demonstrated I None
that I None
17beta I Chemical
- O Chemical
estradiol O Chemical
<eof> I None

<s> O None
( I None
E2 I Chemical
) I None
induces I None
neovascularization I None
, I None
as I None
well I None
as I None
the I None
growth I None
and I None
enlargement I None
of I None
blood I None
vessels I None
after I None
7 I None
days I None
of I None
exposure I None
. I None
<eof> I None

<s> O None
The I None
high I None
tumor I Disease
angiogenic I None
potential I None
was I None
associated I None
with I None
an I None
elevated I None
VEGF I None
/ I None
VPF I None
protein I None
expression I None
in I None
the I None
E2 I Chemical
<eof> I None

<s> O None
exposed I None
pituitary I None
of I None
ovariectomized I None
( I None
OVEX I None
) I None
rats I None
. I None
<eof> I None

<s> O None
VEGF I None
/ I None
VPF I None
and I None
FVIIIRAg I None
immunohistochemistry I None
and I None
endothelial I None
specific I None
lectin I None
( I None
UEA1 I None
) I None
binding I None
studies I None
, I None
indicate I None
that I None
the I None
elevation I None
of I None
VEGF I None
protein I None
expression I None
initially I None
occurred I None
in I None
both I None
blood I None
vessels I None
and I None
non I None
- I None
endothelial I None
cells I None
. I None
<eof> I None

<s> O None
After I None
15 I None
days I None
of I None
E2 I Chemical
exposure I None
, I None
VEGF I None
/ I None
VPF I None
protein I None
expression I None
, I None
in I None
the I None
non I None
- I None
endothelial I None
cell I None
population I None
, I None
sharply I None
declined I None
and I None
was I None
restricted I None
to I None
the I None
blood I None
vessels I None
. I None
<eof> I None

<s> O None
The I None
function I None
of I None
non I None
- I None
endothelial I None
- I None
derived I None
VEGF I None
is I None
not I None
clear I None
. I None
<eof> I None

<s> O None
Furthermore I None
, I None
immunohistochemical I None
studies I None
demonstrated I None
that I None
VEGFR-2 I None
( I None
flk-1/KDR I None
) I None
, I None
expression I None
was I None
elevated I None
significantly I None
in I None
the I None
endothelial I None
cells I None
of I None
microblood I None
vessels I None
after I None
7 I None
days I None
of I None
E2 I Chemical
exposure I None
. I None
<eof> I None

<s> O None
These I None
findings I None
suggest I None
that I None
over I None
expression I None
of I None
VEGF I None
and I None
its I None
receptor I None
( I None
VEGFR-2 I None
) I None
may I None
play I None
an I None
important I None
role I None
in I None
the I None
initial I None
step I None
of I None
the I None
regulation I None
of I None
estrogen I Chemical
induced I None
tumor I Disease
angiogenesis I None
in I None
the I None
rat I None
pituitary I None
. I None
<eof> I None

<s> O None
Pravastatin I Chemical
-associated I None
myopathy I Disease
. I None
<eof> I None

<s> O None
Report I None
of I None
a I None
case I None
. I None
<eof> I None

<s> O None
A I None
case I None
of I None
acute I None
inflammatory I Disease
myopathy O Disease
associated I None
with I None
the I None
use I None
of I None
pravastatin I Chemical
, I None
a I None
new I None
hydrophilic I None
3-hydroxy-3 I None
methylglutaril I None
coenzyme I None
A I None
reductase I None
inhibitor I None
, I None
is I None
reported I None
. I None
<eof> I None

<s> O None
The I None
patient I None
, I None
a I None
69-year I None
- I None
old I None
man I None
was I None
affected I None
by I None
non I Disease
- O Disease
insulin O Disease
- O Disease
dependent O Disease
diabetes O Disease
mellitus O Disease
and I None
hypertension I Disease
. I None
<eof> I None

<s> O None
He I None
assumed I None
pravastatin I Chemical
<eof> I None

<s> O None
( I None
20 I None
mg I None
/ I None
day I None
) I None
because I None
of I None
hypercholesterolemia I Disease
. I None
<eof> I None

<s> O None
He I None
was I None
admitted I None
with I None
acute I None
myopathy I Disease
of I None
the I None
lower I None
limbs I None
which I None
resolved I None
in I None
a I None
few I None
days I None
after I None
pravastatin I Chemical
discontinuation I None
. I None
<eof> I None

<s> O None
A I None
previously I None
unknown I None
hypothyroidism I Disease
, I None
probably I None
due I None
to I None
chronic I None
autoimmune I Disease
thyroiditis O Disease
, I None
was I None
evidenced I None
. I None
<eof> I None

<s> O None
Muscle I None
biopsy I None
( I None
left I None
gastrocnemius I None
) I None
revealed I None
a I None
perimysial I None
and I None
endomysial I None
inflammatory I None
infiltrate I None
with I None
a I None
prevalence I None
of I None
CD4 I None
+ I None
lymphocytes I None
. I None
<eof> I None

<s> O None
While I None
lovastatin I Chemical
and I None
simvastatin I Chemical
have I None
been I None
associated I None
with I None
toxic I None
myopathy I Disease
, I None
pravastatin I Chemical
-associated I None
<eof> I None

<s> O None
myopathy I Disease
could I None
represent I None
a I None
distinct I None
, I None
inflammatory I None
entity I None
. I None
<eof> I None

<s> O None
Dose I None
- I None
effect I None
and I None
structure I None
- I None
function I None
relationships I None
in I None
doxorubicin I Chemical
cardiomyopathy I Disease
. I None
<eof> I None

<s> O None
The I None
cardiomyopathy I Disease
<eof> I None

<s> O None
( I None
CM I Disease
) I None
produced I None
by I None
the I None
anticancer I None
drug I None
doxorubicin I Chemical
<eof> I None

<s> O None
( I None
DXR I Chemical
) I None
( I None
Adriamycin I Chemical
) I None
provides I None
a I None
unique I None
opportunity I None
to I None
analyze I None
dose I None
- I None
effect I None
and I None
structure I None
- I None
function I None
relationships I None
during I None
development I None
of I None
myocardial I Disease
disease O Disease
. I None
<eof> I None

<s> O None
We I None
measured I None
the I None
degree I None
of I None
morphologic I None
damage I None
by I None
ultrastructural I None
examination I None
of I None
endomyocardial I None
biopsy I None
and I None
the I None
degree I None
of I None
performance I None
abnormally I None
by I None
right I None
heart I None
catheterization I None
in I None
patients I None
receiving I None
DXR I Chemical
. I None
<eof> I None

<s> O None
Morphologic I None
damage I None
was I None
variable I None
but I None
was I None
proportional I None
to I None
the I None
total I None
cumulative I None
DXR I Chemical
dose I None
between I None
100 I None
and I None
600 I None
mg I None
/ I None
m2 I None
. I None
<eof> I None

<s> O None
Performance I None
abnormalities I None
correlated I None
weakly I None
with I None
dose I None
, I None
exhibited I None
a I None
curvilinear I None
relationship I None
, I None
and I None
had I None
a I None
" I None
threshold I None
" I None
for I None
expression I None
. I None
<eof> I None

<s> O None
Catheterization I None
abnormalities I None
correlated I None
well I None
with I None
morphologic I None
damage I None
( I None
r I None
= I None
0.57 I None
to I None
0.78 I None
) I None
in I None
a I None
subgroup I None
of I None
patients I None
in I None
whom I None
exercise I None
hemodynamics I None
were I None
measured I None
, I None
and I None
this I None
relationship I None
also I None
exhibited I None
a I None
curvilinear I None
, I None
threshold I None
configuration I None
. I None
<eof> I None

<s> O None
In I None
DXR I Chemical
- I None
CM I Disease
myocardial I Disease
damage O Disease
is I None
proportional I None
to I None
the I None
degree I None
of I None
cytotoxic I None
insult I None
( I None
DXR I Chemical
dose I None
) I None
while I None
myocardial I None
function I None
is I None
preserved I None
until I None
a I None
critical I None
dose I None
or I None
degree I None
of I None
damage I None
is I None
reached I None
, I None
after I None
which I None
myocardial I None
performance I None
deteriorates I None
rapidly I None
. I None
<eof> I None

<s> O None
Fatal I None
aplastic I Disease
anemia O Disease
<eof> I None

<s> O None
following I None
topical I None
administration I None
of I None
ophthalmic I None
chloramphenicol I Chemical
. I None
<eof> I None

<s> O None
A I None
73-year I None
- I None
old I None
woman I None
died I None
of I None
aplastic I Disease
anemia O Disease
less I None
than I None
two I None
months I None
after I None
undergoing I None
cataract I Disease
extraction I None
and I None
beginning I None
topical I None
therapy I None
with I None
chloramphenicol I Chemical
. I None
<eof> I None

<s> O None
The I None
first I None
signs I None
of I None
pancytopenia I Disease
began I None
within I None
one I None
month I None
of I None
the I None
surgery I None
. I None
<eof> I None

<s> O None
The I None
pattern I None
of I None
the I None
aplastic I Disease
anemia O Disease
was I None
associated I None
with I None
an I None
idiosyncratic I None
response I None
to I None
chloramphenicol I Chemical
. I None
<eof> I None

<s> O None
This I None
was I None
the I None
second I None
report I None
of I None
fatal I None
aplastic I Disease
anemia O Disease
after I None
topical I None
treatment I None
with I None
chloramphenicol I Chemical
for I None
ocular I None
conditions I None
, I None
although I None
two I None
cases I None
of I None
reversible I None
bone I Disease
marrow O Disease
hypoplasia O Disease
have I None
also I None
been I None
reported I None
. I None
<eof> I None

<s> O None
Any I None
other I None
suspected I None
cases I None
of I None
ocular I Disease
toxicity O Disease
associated I None
with I None
topically I None
applied I None
<eof> I None

<s> O None
chloramphenicol I Chemical
should I None
be I None
reported I None
to I None
the I None
National I None
Registry I None
of I None
Drug I None
- I None
Induced I None
Ocular I None
Side I None
Effects I None
, I None
Oregon I None
Health I None
Sciences I None
University I None
, I None
Portland I None
, I None
OR I None
97201 I None
. I None
<eof> I None

<s> O None
Bradycardia I Disease
due I None
to I None
trihexyphenidyl I Chemical
hydrochloride O Chemical
. I None
<eof> I None

<s> O None
A I None
chronic I None
schizophrenic I Disease
patient I None
was I None
treated I None
with I None
an I None
anticholinergic I None
drug I None
, I None
trihexyphenidyl I Chemical
hydrochloride O Chemical
. I None
<eof> I None

<s> O None
The I None
patient I None
developed I None
, I None
paradoxically I None
, I None
sinus I None
bradycardia I Disease
. I None
<eof> I None

<s> O None
The I None
reaction I None
was I None
specific I None
to I None
trihexyphenidyl I Chemical
and I None
not I None
to I None
other I None
anticholinergic I None
drugs I None
. I None
<eof> I None

<s> O None
This I None
antidyskinetic I None
drug I None
is I None
widely I None
used I None
in I None
clinical I None
psychiatric I Disease
practice I None
and I None
physicians I None
should I None
be I None
aware I None
of I None
this I None
side I None
effect I None
. I None
<eof> I None

<s> O None
Experimental I None
cyclosporine I Chemical
<eof> I None

<s> O None
nephrotoxicity I Disease
: I None
risk I None
of I None
concomitant I None
chemotherapy I None
. I None
<eof> I None

<s> O None
The I None
role I None
of I None
cyclosporine I Chemical
<eof> I None

<s> O None
( I None
CSA I Chemical
) I None
alone I None
or I None
in I None
combination I None
with I None
various I None
chemotherapeutics I None
in I None
the I None
development I None
of I None
renal I Disease
toxicity O Disease
was I None
evaluated I None
in I None
rats I None
. I None
<eof> I None

<s> O None
Administration I None
of I None
20 I None
mg I None
/ I None
kg I None
/ I None
day I None
CSA I Chemical
for I None
4 I None
weeks I None
caused I None
renal I None
functional I None
and I None
structural I None
changes I None
similar I None
to I None
those I None
reported I None
in I None
man I None
. I None
<eof> I None

<s> O None
The I None
combined I None
administration I None
of I None
CSA I Chemical
and I None
various I None
chemotherapeutic I None
drugs I None
with I None
a I None
nephrotoxic I Disease
potential I None
, I None
such I None
as I None
gentamicin I Chemical
( I None
at I None
therapeutic I None
doses I None
) I None
, I None
<eof> I None

<s> O None
amphothericin I Chemical
B O Chemical
and I None
ketoconazole I Chemical
, I None
which I None
are I None
frequently I None
used I None
in I None
immunosuppressed I None
patients I None
, I None
did I None
not I None
aggravate I None
the I None
CSA I Chemical
induced I None
<eof> I None

<s> O None
toxicity I Disease
in I None
the I None
rat I None
model I None
. I None
<eof> I None

<s> O None
Gentamicin I Chemical
at I None
toxic I None
doses I None
, I None
however I None
, I None
increased I None
<eof> I None

<s> O None
CSA I Chemical
<eof> I None

<s> O None
nephrotoxicity I Disease
. I None
<eof> I None

<s> O None
Thus I None
, I None
the I None
nephrotoxicity I Disease
induced I None
by I None
CSA I Chemical
has I None
a I None
different I None
pathogenetic I None
mechanism I None
. I None
<eof> I None

<s> O None
Receptor I None
mechanisms I None
of I None
nicotine I Chemical
-induced I None
<eof> I None

<s> O None
locomotor I Disease
hyperactivity O Disease
in I None
chronic I None
nicotine I Chemical
-treated I None
rats I None
. I None
<eof> I None

<s> O None
Rats I None
were I None
pretreated I None
with I None
saline I None
or I None
nicotine I Chemical
( I None
1.5 I None
mg I None
/ I None
kg I None
per I None
day I None
) I None
by I None
subcutaneously I None
implanting I None
each I None
animal I None
with I None
an I None
Alzet I None
osmotic I None
mini I None
- I None
pump I None
which I None
continuously I None
released I None
saline I None
or I None
nicotine I Chemical
for I None
1 I None
, I None
5 I None
and I None
14 I None
days I None
. I None
<eof> I None

<s> O None
At I None
the I None
end I None
of I None
each I None
pretreatment I None
period I None
, I None
animals I None
were I None
used I None
for I None
( I None
i I None
) I None
determining I None
their I None
locomotor I None
response I None
to I None
acutely I None
injected I None
nicotine I Chemical
( I None
0.2 I None
mg I None
/ I None
kg I None
, I None
s.c I None
. I None
) I None
<eof> I None

<s> O None
and I None
( I None
ii I None
) I None
measuring I None
the I None
density I None
of I None
L-[3H I None
] I None
nicotine I Chemical
and I None
[ I None
3H I None
] I None
spiperone I Chemical
binding I None
sites I None
in I None
the I None
striatum I None
. I None
<eof> I None

<s> O None
We I None
observed I None
no I None
changes I None
in I None
nicotine I Chemical
<eof> I None

<s> O None
-induced I None
locomotor I None
response I None
, I None
striatal I None
L-[3H I None
] I None
nicotine I Chemical
and I None
[ I None
3H I None
] I None
spiperone I Chemical
binding I None
in I None
the I None
animals I None
pretreated I None
with I None
nicotine I Chemical
for I None
1 I None
day I None
. I None
<eof> I None

<s> O None
In I None
rats I None
which I None
were I None
pretreated I None
with I None
nicotine I Chemical
for I None
5 I None
days I None
, I None
there I None
was I None
a I None
significant I None
increase I None
in I None
the I None
nicotine I Chemical
-stimulated I None
locomotor I None
response I None
which I None
was I None
associated I None
with I None
an I None
increase I None
in I None
the I None
number I None
of I None
L-[3H I None
] I None
nicotine I Chemical
binding I None
sites I None
and I None
also I None
with I None
an I None
elevated I None
dopamine I Chemical
<eof> I None

<s> O None
( I None
DA I Chemical
) I None
level I None
in I None
the I None
striatum I None
. I None
<eof> I None

<s> O None
The I None
number I None
of I None
striatal I None
[ I None
3H I None
] I None
spiperone I Chemical
binding I None
sites I None
was I None
not I None
affected I None
. I None
<eof> I None

<s> O None
In I None
animals I None
pretreated I None
with I None
nicotine I Chemical
for I None
14 I None
days I None
, I None
the I None
nicotine I Chemical
-induced I None
locomotor I None
response I None
remained I None
to I None
be I None
potentiated I None
. I None
<eof> I None

<s> O None
However I None
, I None
this I None
response I None
was I None
correlated I None
with I None
an I None
elevated I None
number I None
of I None
striatal I None
[ I None
3H I None
] I None
spiperone I Chemical
binding I None
sites I None
, I None
whereas I None
the I None
number I None
of I None
striatal I None
L-[3H I None
] I None
nicotine I Chemical
binding I None
sites I None
and I None
the I None
striatal I None
DA I Chemical
level I None
were I None
normal I None
. I None
<eof> I None

<s> O None
These I None
results I None
suggest I None
that I None
chronic I None
nicotine I Chemical
<eof> I None

<s> O None
-treated I None
rats I None
develop I None
<eof> I None

<s> O None
locomotor I Disease
hyperactivity O Disease
in I None
response I None
to I None
nicotine I Chemical
initially I None
due I None
to I None
increases I None
of I None
both I None
the I None
density I None
of I None
nicotinic I None
receptors I None
and I None
DA I Chemical
concentration I None
, I None
followed I None
by I None
inducing I None
DA I Chemical
receptor I None
supersensitivity I None
in I None
the I None
striatum I None
. I None
<eof> I None

<s> O None
Hydrocortisone I Chemical
-induced I None
hypertension I Disease
in I None
humans I None
: I None
pressor I None
responsiveness I None
and I None
sympathetic I None
function I None
. I None
<eof> I None

<s> O None
Oral I None
hydrocortisone I Chemical
increases I None
blood I None
pressure I None
and I None
enhances I None
pressor I None
responsiveness I None
in I None
normal I None
human I None
subjects I None
. I None
<eof> I None

<s> O None
We I None
studied I None
the I None
effects I None
of I None
1 I None
week I None
of I None
oral I None
hydrocortisone I Chemical
( I None
200 I None
mg I None
/ I None
day I None
) I None
on I None
blood I None
pressure I None
, I None
cardiac I None
output I None
, I None
total I None
peripheral I None
resistance I None
, I None
forearm I None
vascular I None
resistance I None
, I None
and I None
norepinephrine I Chemical
spillover I None
to I None
plasma I None
in I None
eight I None
healthy I None
male I None
volunteers I None
. I None
<eof> I None

<s> O None
Although I None
diastolic I None
blood I None
pressure I None
remained I None
unchanged I None
, I None
systolic I None
blood I None
pressure I None
increased I None
from I None
119 I None
to I None
135 I None
mm I None
Hg I None
( I None
SED I None
+ I None
/- I None
3.4 I None
, I None
p I None
less I None
than I None
0.01 I None
) I None
, I None
associated I None
with I None
an I None
increased I Disease
cardiac O Disease
output O Disease
<eof> I None

<s> O None
( I None
5.85 I None
- I None
7.73 I None
l I None
/ I None
min I None
, I None
SED I None
+ I None
/- I None
0.46 I None
, I None
p I None
less I None
than I None
0.01 I None
) I None
. I None
<eof> I None

<s> O None
Total I None
peripheral I None
vascular I None
resistance I None
fell I None
from I None
15.1 I None
to I None
12.2 I None
mm I None
Hg I None
/ I None
l I None
/ I None
min I None
( I None
SED I None
+ I None
/- I None
1.03 I None
, I None
p I None
less I None
than I None
0.05 I None
) I None
. I None
<eof> I None

<s> O None
Resting I None
forearm I None
vascular I None
resistance I None
remained I None
unchanged I None
, I None
but I None
the I None
reflex I None
response I None
to I None
the I None
cold I None
pressor I None
test I None
was I None
accentuated I None
, I None
the I None
rise I None
in I None
resistance I None
increasing I None
from I None
10.5 I None
mm I None
Hg I None
/ I None
ml/100 I None
ml I None
/ I None
min I None
( I None
R I None
units I None
) I None
before I None
treatment I None
to I None
32.6 I None
R I None
units I None
after I None
treatment I None
( I None
SED I None
+ I None
/- I None
6.4 I None
, I None
p I None
less I None
than I None
0.025 I None
) I None
. I None
<eof> I None

<s> O None
The I None
rise I None
in I None
forearm I None
vascular I None
resistance I None
accompanying I None
intra I None
- I None
arterial I None
norepinephrine I Chemical
( I None
25 I None
, I None
50 I None
, I None
and I None
100 I None
ng I None
/ I None
min I None
) I None
was I None
also I None
significantly I None
greater I None
after I None
hydrocortisone I Chemical
, I None
increasing I None
from I None
an I None
average I None
of I None
14.9 I None
+ I None
/- I None
<eof> I None

<s> O None
2.4 I None
R I None
units I None
before I None
treatment I None
to I None
35.1 I None
+ I None
/- I None
5.5 I None
R I None
units I None
after I None
hydrocortisone I Chemical
<eof> I None

<s> O None
( I None
SED I None
+ I None
/- I None
6.0 I None
, I None
p I None
less I None
than I None
0.05 I None
) I None
. I None
<eof> I None

<s> O None
A I None
shift I None
to I None
the I None
left I None
in I None
the I None
dose I None
- I None
response I None
relation I None
and I None
fall I None
in I None
threshold I None
suggested I None
increased I None
sensitivity I None
to I None
norepinephrine I Chemical
after I None
treatment I None
. I None
<eof> I None

<s> O None
Measurement I None
of I None
resting I None
norepinephrine I Chemical
spillover I None
rate I None
to I None
plasma I None
and I None
norepinephrine I Chemical
uptake I None
indicated I None
that I None
overall I None
resting I None
sympathetic I None
nervous I None
system I None
activity I None
was I None
not I None
increased I None
. I None
<eof> I None

<s> O None
The I None
rise I Disease
in O Disease
resting O Disease
blood O Disease
pressure O Disease
with I None
hydrocortisone I Chemical
is I None
associated I None
with I None
an I None
increased I Disease
cardiac O Disease
output O Disease
( I None
presumably I None
due I None
to I None
increased I None
blood I None
volume).(ABSTRACT I None
TRUNCATED I None
AT I None
250 I None
WORDS I None
) I None
<eof> I None

<s> O None
Effects I None
of I None
suprofen I Chemical
on I None
the I None
isolated I None
perfused I None
rat I None
kidney I None
. I None
<eof> I None

<s> O None
Although I None
suprofen I Chemical
has I None
been I None
associated I None
with I None
the I None
development I None
of I None
acute I Disease
renal O Disease
failure O Disease
in I None
greater I None
than I None
100 I None
subjects I None
, I None
the I None
mechanism I None
of I None
damage I None
remains I None
unclear I None
. I None
<eof> I None

<s> O None
The I None
direct I None
nephrotoxic I Disease
effects I None
of I None
a I None
single I None
dose I None
of I None
15 I None
mg I None
of I None
suprofen I Chemical
were I None
compared I None
in I None
the I None
recirculating I None
isolated I None
rat I None
kidney I None
perfused I None
with I None
cell I None
- I None
free I None
buffer I None
with I None
or I None
without I None
the I None
addition I None
of I None
5 I None
mg I None
/ I None
dL I None
of I None
uric I Chemical
acid O Chemical
. I None
<eof> I None

<s> O None
There I None
were I None
no I None
significant I None
differences I None
in I None
renal I None
sodium I Chemical
excretion I None
, I None
oxygen I Chemical
consumption I None
, I None
or I None
urinary I None
flow I None
rates I None
in I None
kidneys I None
perfused I None
with I None
suprofen I Chemical
compared I None
with I None
the I None
drug I None
- I None
free I None
control I None
groups I None
. I None
<eof> I None

<s> O None
In I None
contrast I None
, I None
a I None
significant I None
decline I None
in I None
glomerular I None
filtration I None
rate I None
was I None
found I None
after I None
the I None
introduction I None
of I None
suprofen I Chemical
to I None
the I None
kidney I None
perfused I None
with I None
uric I Chemical
acid O Chemical
; I None
no I None
changes I None
were I None
found I None
with I None
suprofen I Chemical
in I None
the I None
absence I None
of I None
uric I Chemical
acid O Chemical
. I None
<eof> I None

<s> O None
A I None
significant I None
decrease I None
in I None
the I None
baseline I None
excretion I None
rate I None
of I None
uric I Chemical
acid O Chemical
was I None
found I None
in I None
rats I None
given I None
suprofen I Chemical
, I None
compared I None
with I None
drug I None
- I None
free I None
controls I None
. I None
<eof> I None

<s> O None
However I None
, I None
the I None
fractional I None
excretion I None
of I None
uric I Chemical
acid O Chemical
was I None
unchanged I None
between I None
the I None
groups I None
over I None
the I None
experimental I None
period I None
. I None
<eof> I None

<s> O None
In I None
summary I None
, I None
suprofen I Chemical
causes I None
<eof> I None

<s> O None
acute I Disease
declines O Disease
in O Disease
renal O Disease
function O Disease
, I None
most I None
likely I None
by I None
directly I None
altering I None
the I None
intrarenal I None
distribution I None
of I None
uric I Chemical
acid O Chemical
. I None
<eof> I None

<s> O None
Cocaine I Chemical
-induced I None
brainstem I None
seizures I Disease
and I None
behavior I None
. I None
<eof> I None

<s> O None
A I None
variety I None
of I None
abnormal I None
sensory I None
/ I None
motor I None
behaviors I None
associated I None
with I None
electrical I None
discharges I None
recorded I None
from I None
the I None
bilateral I None
brainstem I None
were I None
induced I None
in I None
adult I None
WKY I None
rats I None
by I None
mechanical I None
( I None
electrode I None
implants I None
) I None
and I None
DC I None
electrical I None
current I None
stimulations I None
and I None
by I None
acute I None
and I None
chronic I None
administration I None
of I None
cocaine I Chemical
. I None
<eof> I None

<s> O None
The I None
electrode I None
implant I None
implicated I None
one I None
side I None
or I None
the I None
other I None
of I None
the I None
reticular I None
system I None
of I None
the I None
brainstem I None
but I None
subjects I None
were I None
not I None
incapacitated I None
by I None
the I None
stimulations I None
. I None
<eof> I None

<s> O None
Cocaine I Chemical
<eof> I None

<s> O None
( I None
40 I None
mg I None
/ I None
kg I None
) I None
was I None
injected I None
subcutaneously I None
for I None
an I None
acute I None
experiment I None
and I None
subsequent I None
20 I None
mg I None
/ I None
kg I None
doses I None
twice I None
daily I None
for I None
3 I None
days I None
in I None
a I None
chronic I None
study I None
. I None
<eof> I None

<s> O None
Cocaine I Chemical
generated I None
more I None
abnormal I None
behaviors I None
in I None
the I None
brainstem I None
perturbation I None
group I None
, I None
especially I None
the I None
electrically I None
perturbated I None
subjects I None
. I None
<eof> I None

<s> O None
The I None
abnormal I None
behaviors I None
were I None
yawning I None
, I None
retrocollis I None
, I None
hyperactivity I Disease
, I None
hypersensitivity I Disease
, I None
" I None
beating I None
drum I None
" I None
behavior I None
, I None
squealing I None
, I None
head I None
bobbing I None
, I None
circling I None
, I None
sniffing I None
, I None
abnormal I None
posturing I None
, I None
and I None
facial I None
twitching I None
. I None
<eof> I None

<s> O None
Shifts I None
in I None
the I None
power I None
frequency I None
spectra I None
of I None
the I None
discharge I None
patterns I None
were I None
noted I None
between I None
quiet I None
and I None
pacing I None
behavioral I None
states I None
. I None
<eof> I None

<s> O None
Hypersensitivity I Disease
to I None
various I None
auditory I None
, I None
tactile I None
, I None
and I None
visual I None
stimulation I None
was I None
present I None
and I None
shifts I None
in I None
the I None
brainstem I None
ambient I None
power I None
spectral I None
frequency I None
occurred I None
in I None
response I None
to I None
tactile I None
stimulation I None
. I None
<eof> I None

<s> O None
These I None
findings I None
suggest I None
that I None
the I None
brainstem I None
generates I None
and I None
propagates I None
pathological I None
discharges I None
that I None
can I None
be I None
elicited I None
by I None
mechanical I None
and I None
DC I None
electrical I None
perturbation I None
. I None
<eof> I None

<s> O None
Cocaine I Chemical
was I None
found I None
to I None
activate I None
the I None
discharge I None
system I None
and I None
thus I None
induce I None
abnormal I None
behaviors I None
that I None
are I None
generated I None
at I None
the I None
discharge I None
site I None
and I None
at I None
distant I None
sites I None
to I None
which I None
the I None
discharge I None
propagates I None
. I None
<eof> I None

<s> O None
Cognitive I None
functions I None
may I None
also I None
be I None
involved I None
since I None
dopaminergic I None
and I None
serotonergic I None
cellular I None
elements I None
at I None
the I None
brainstem I None
level I None
are I None
also I None
implicated I None
. I None
<eof> I None

<s> O None
Increased I None
sulfation I None
and I None
decreased I None
7alpha I None
- I None
hydroxylation I None
of I None
deoxycholic I Chemical
acid O Chemical
in I None
<eof> I None

<s> O None
ethinyl I Chemical
estradiol O Chemical
-induced I None
<eof> I None

<s> O None
cholestasis I Disease
in I None
rats I None
. I None
<eof> I None

<s> O None
Deoxycholic I Chemical
acid O Chemical
conjugation I None
, I None
transport I None
capacity I None
, I None
and I None
metabolism I None
were I None
compared I None
in I None
control I None
and I None
ethinyl I Chemical
estradiol O Chemical
-treated I None
rats I None
. I None
<eof> I None

<s> O None
Control I None
rats I None
were I None
found I None
to I None
have I None
a I None
lower I None
capacity I None
to I None
transport I None
deoxycholic I Chemical
acid O Chemical
than I None
taurodeoxycholic I Chemical
acid O Chemical
, I None
and I None
both I None
were I None
decreased I None
by I None
ethinyl I Chemical
estradiol O Chemical
treatment I None
. I None
<eof> I None

<s> O None
During I None
[ I None
24 I None
- I None
14C I None
] I None
sodium I Chemical
deoxycholate O Chemical
infusion I None
, I None
[ I None
14C]biliary I None
bile I Chemical
acid O Chemical
secretion I None
increased I None
, I None
but I None
bile I None
flow I None
did I None
not I None
change I None
significantly I None
in I None
either I None
control I None
or I None
ethinyl I Chemical
estradiol O Chemical
-treated I None
rats I None
. I None
<eof> I None

<s> O None
Ethinyl I Chemical
estradiol O Chemical
<eof> I None

<s> O None
-treated I None
animals I None
excreted I None
significantly I None
less I None
14C I None
as I None
taurocholic I Chemical
acid O Chemical
than I None
did I None
control I None
animals I None
, I None
consistent I None
with I None
an I None
impairment I None
of I None
7alpha I None
- I None
hydroxylation I None
of I None
taurodeoxycholic I Chemical
acid O Chemical
. I None
<eof> I None

<s> O None
Ethinyl I Chemical
estradiol O Chemical
treatment I None
did I None
not I None
impair I None
conjugation I None
of I None
deoxycholic I Chemical
acid O Chemical
, I None
but I None
did I None
result I None
in I None
an I None
increase I None
in I None
sulfation I None
of I None
taurodeoxycholic I Chemical
acid O Chemical
from I None
1.5 I None
% I None
in I None
controls I None
to I None
nearly I None
4.0 I None
% I None
( I None
P I None
less I None
than I None
0.01 I None
) I None
. I None
<eof> I None

<s> O None
These I None
results I None
are I None
consistent I None
with I None
the I None
hypothesis I None
that I None
the I None
rat I None
has I None
a I None
poorer I None
tolerance I None
for I None
deoxycholic I Chemical
acid O Chemical
than I None
do I None
certain I None
other I None
species I None
. I None
<eof> I None

<s> O None
Furthermore I None
, I None
the I None
rat I None
converts I None
<eof> I None

<s> O None
deoxycholic I Chemical
acid O Chemical
, I None
a I None
poor I None
choleretic I None
, I None
to I None
taurocholic I Chemical
acid O Chemical
, I None
a I None
good I None
choleretic I None
. I None
<eof> I None

<s> O None
When I None
this I None
conversion I None
is I None
impaired I None
with I None
ethinyl I Chemical
estradiol O Chemical
treatment I None
, I None
sulfation I None
may I None
be I None
an I None
important I None
alternate I None
pathway I None
for I None
excretion I None
of I None
this I None
potentially I None
harmful I None
bile I Chemical
acid O Chemical
. I None
<eof> I None

<s> O None
Effects I None
of I None
ouabain I Chemical
on I None
myocardial I None
oxygen I Chemical
supply I None
and I None
demand I None
in I None
patients I None
with I None
chronic I None
coronary I Disease
artery O Disease
disease O Disease
. I None
<eof> I None

<s> O None
A I None
hemodynamic I None
, I None
volumetric I None
, I None
and I None
metabolic I None
study I None
in I None
patients I None
without I None
heart I Disease
failure O Disease
. I None
<eof> I None

<s> O None
The I None
effects I None
of I None
digitalis I Chemical
glycosides O Chemical
on I None
myocardial I None
oxygen I Chemical
supply I None
and I None
demand I None
are I None
of I None
particular I None
interest I None
in I None
the I None
presence I None
of I None
obstructive I None
coronary I Disease
artery O Disease
disease O Disease
, I None
but I None
have I None
not I None
been I None
measured I None
previously I None
in I None
man I None
. I None
<eof> I None

<s> O None
We I None
assessed I None
the I None
effects I None
of I None
ouabain I Chemical
<eof> I None

<s> O None
( I None
0.015 I None
mg I None
/ I None
kg I None
body I None
weight I None
) I None
on I None
hemodynamic I None
, I None
volumetric I None
, I None
and I None
metabolic I None
parameters I None
in I None
11 I None
patients I None
with I None
severe I None
chronic I None
coronary I Disease
artery O Disease
disease O Disease
without I None
clinical I None
congestive I Disease
heart O Disease
failure O Disease
. I None
<eof> I None

<s> O None
Because I None
the I None
protocol I None
was I None
long I None
and I None
involved I None
interventions I None
which I None
might I None
affect I None
the I None
determinations I None
, I None
we I None
also I None
studied I None
in I None
nine I None
patients I None
using I None
an I None
identical I None
protocol I None
except I None
that I None
ouabain I Chemical
administration I None
was I None
omitted I None
. I None
<eof> I None

<s> O None
Left I None
ventricular I None
end I None
- I None
diastolic I None
pressure I None
and I None
left I None
ventricular I None
end I None
- I None
diastolic I None
volume I None
fell I None
in I None
each I None
patient I None
given I None
ouabain I Chemical
, I None
even I None
though I None
they I None
were I None
initially I None
elevated I None
in I None
only I None
two I None
patients I None
. I None
<eof> I None

<s> O None
Left I None
ventricular I None
end I None
- I None
diastolic I None
pressure I None
fell I None
from I None
11.5+/-1.4 I None
<eof> I None

<s> O None
( I None
mean+/-SE I None
) I None
to I None
5.6+/-0.9 I None
mm I None
Hg I None
( I None
P I None
less I None
than I None
0.001 I None
) I None
and I None
left I None
ventricular I None
end I None
- I None
diastolic I None
volume I None
fell I None
from I None
100+/-17 I None
to I None
82+/-12 I None
ml I None
/ I None
m2 I None
( I None
P I None
less I None
than I None
0.01 I None
) I None
1 I None
h I None
after I None
ouabain I Chemical
infusion I None
was I None
completed I None
. I None
<eof> I None

<s> O None
The I None
maximum I None
velocity I None
of I None
contractile I None
element I None
shortening I None
increased I None
from I None
1.68+/-0.11 I None
ml I None
/ I None
s I None
to I None
2.18+/-0.21 I None
muscle I None
- I None
lengths I None
/ I None
s I None
( I None
P I None
less I None
than I None
0.05 I None
) I None
and I None
is I None
consistent I None
with I None
an I None
increase I None
in I None
contractility I None
. I None
<eof> I None

<s> O None
No I None
significant I None
change I None
in I None
these I None
parameters I None
occurred I None
in I None
the I None
control I None
patients I None
. I None
<eof> I None

<s> O None
No I None
significant I None
change I None
in I None
myocardial I None
oxygen I Chemical
consumption I None
occurred I None
after I None
ouabain I Chemical
administration I None
but I None
this I None
may I None
be I None
related I None
to I None
a I None
greater I None
decrease I None
in I None
mean I None
arterial I None
pressure I None
in I None
the I None
ouabain I Chemical
patients I None
than I None
in I None
the I None
control I None
patients I None
. I None
<eof> I None

<s> O None
We I None
conclude I None
that I None
in I None
patients I None
with I None
chronic I None
coronary I Disease
artery O Disease
disease O Disease
who I None
are I None
not I None
in I None
clinical I None
congestive I Disease
heart O Disease
failure O Disease
left I Disease
ventricular O Disease
end O Disease
- O Disease
diastolic O Disease
volume O Disease
falls O Disease
after I None
ouabain I Chemical
administration I None
even I None
when I None
it I None
is I None
initially I None
normal I None
. I None
<eof> I None

<s> O None
Though I None
this I None
fall I None
would I None
be I None
associated I None
with I None
a I None
decrease I None
in I None
wall I None
tension I None
, I None
and I None
, I None
therefore I None
, I None
of I None
myocardial I None
oxygen I Chemical
consumption I None
, I None
it I None
may I None
not I None
be I None
of I None
sufficient I None
magnitude I None
to I None
prevent I None
a I None
net I None
increase I None
in I None
myocardial I None
oxygen I Chemical
consumption I None
. I None
<eof> I None

<s> O None
Nevertheless I None
, I None
compensatory I None
mechanisms I None
prevent I None
a I None
deterioration I None
of I None
resting I None
myocardial I None
metabolism I None
. I None
<eof> I None

<s> O None
Prolongation I Disease
of O Disease
the O Disease
QT O Disease
interval O Disease
related I None
to I None
cisapride I Chemical
- I None
diltiazem I Chemical
interaction I None
. I None
<eof> I None

<s> O None
Cisapride I Chemical
, I None
a I None
cytochrome I None
P450 I None
3A4 I None
( I None
CYP3A4 I None
) I None
substrate I None
, I None
is I None
widely I None
prescribed I None
for I None
the I None
treatment I None
of I None
gastrointestinal I Disease
motility O Disease
disorders O Disease
. I None
<eof> I None

<s> O None
Prolongation I Disease
of O Disease
QT O Disease
interval O Disease
, I None
torsades I Disease
de O Disease
pointes O Disease
, I None
and I None
sudden I Disease
cardiac O Disease
death O Disease
have I None
been I None
reported I None
after I None
concomitant I None
administration I None
with I None
erythromycin I Chemical
or I None
azole I Chemical
antifungal I None
agents I None
, I None
but I None
not I None
with I None
other I None
CYP3A4 I None
inhibitors I None
. I None
<eof> I None

<s> O None
A I None
possible I None
drug I None
interaction I None
occurred I None
in I None
a I None
45-year I None
- I None
old I None
woman I None
who I None
was I None
taking I None
cisapride I Chemical
for I None
gastroesophageal I Disease
reflux O Disease
disorder O Disease
and I None
diltiazem I Chemical
, I None
an I None
agent I None
that I None
has I None
inhibitory I None
effect I None
on I None
CYP3A4 I None
, I None
for I None
hypertension I Disease
. I None
<eof> I None

<s> O None
The I None
patient I None
was I None
in I None
near I None
syncope I Disease
and I None
had I None
QT I Disease
- O Disease
interval O Disease
prolongation O Disease
. I None
<eof> I None

<s> O None
After I None
discontinuing I None
cisapride I Chemical
, I None
the I None
QT I None
interval I None
returned I None
to I None
normal I None
and I None
symptoms I None
did I None
not I None
recur I None
. I None
<eof> I None

<s> O None
We I None
suggest I None
that I None
caution I None
be I None
taken I None
when I None
cisapride I Chemical
is I None
prescribed I None
with I None
any I None
potent I None
inhibitor I None
of I None
CYP3A4 I None
, I None
including I None
diltiazem I Chemical
. I None
<eof> I None

<s> O None
Paclitaxel I Chemical
combined I None
with I None
carboplatin I Chemical
in I None
the I None
first I None
- I None
line I None
treatment I None
of I None
advanced I None
ovarian I Disease
cancer O Disease
. I None
<eof> I None

<s> O None
In I None
a I None
phase I None
I I None
study I None
to I None
determine I None
the I None
maximum I None
tolerated I None
dose I None
of I None
paclitaxel I Chemical
<eof> I None

<s> O None
( I None
Taxol I Chemical
; I None
Bristol I None
- I None
Myers I None
Squibb I None
Company I None
, I None
Princeton I None
, I None
NJ I None
) I None
given I None
as I None
a I None
3-hour I None
infusion I None
in I None
combination I None
with I None
carboplatin I Chemical
administered I None
every I None
21 I None
days I None
to I None
women I None
with I None
advanced I None
ovarian I Disease
cancer O Disease
, I None
paclitaxel I Chemical
doses I None
were I None
escalated I None
as I None
follows I None
: I None
level I None
1 I None
, I None
135 I None
mg I None
/ I None
m2 I None
; I None
level I None
2 I None
, I None
160 I None
mg I None
/ I None
m2 I None
; I None
level I None
3 I None
, I None
185 I None
mg I None
/ I None
m2 I None
; I None
and I None
level I None
4,210 I None
mg I None
/ I None
m2 I None
. I None
<eof> I None

<s> O None
The I None
fixed I None
dose I None
of I None
carboplatin I Chemical
at I None
levels I None
1 I None
through I None
4 I None
was I None
given I None
to I None
achieve I None
an I None
area I None
under I None
the I None
concentration I None
- I None
time I None
curve I None
( I None
AUC I None
) I None
of I None
5 I None
using I None
the I None
Calvert I None
formula I None
. I None
<eof> I None

<s> O None
In I None
levels I None
5 I None
and I None
6 I None
the I None
carboplatin I Chemical
dose I None
was I None
targeted I None
at I None
AUCs I None
of I None
6 I None
and I None
7.5 I None
, I None
respectively I None
, I None
combined I None
with I None
a I None
fixed I None
paclitaxel I Chemical
dose I None
of I None
185 I None
mg I None
/ I None
m2 I None
. I None
<eof> I None

<s> O None
To I None
date I None
, I None
30 I None
previously I None
untreated I None
patients I None
, I None
all I None
with I None
a I None
good I None
performance I None
status I None
( I None
Eastern I None
Cooperative I None
Oncology I None
Group I None
0 I None
to I None
2 I None
) I None
have I None
been I None
entered I None
into I None
this I None
ongoing I None
study I None
. I None
<eof> I None

<s> O None
The I None
dose I None
- I None
limiting I None
toxicity I Disease
of I None
the I None
combination I None
was I None
myelosuppression I Disease
<eof> I None

<s> O None
( I None
leukopenia I Disease
, I None
granulocytopenia I Disease
, I None
and I None
thrombocytopenia I Disease
) I None
. I None
<eof> I None

<s> O None
Neurotoxicity I Disease
was I None
largely I None
moderate I None
. I None
<eof> I None

<s> O None
So I None
far I None
, I None
14 I None
patients I None
are I None
evaluable I None
for I None
response I None
; I None
of I None
these I None
, I None
eight I None
( I None
57 I None
% I None
) I None
showed I None
objective I None
( I None
complete I None
or I None
partial I None
) I None
response I None
and I None
disease I None
stabilized I None
in I None
six I None
patients I None
. I None
<eof> I None

<s> O None
No I None
patient I None
had I None
disease I None
progression I None
. I None
<eof> I None

<s> O None
We I None
conclude I None
that I None
the I None
combination I None
of I None
paclitaxel I Chemical
<eof> I None

<s> O None
185 I None
mg I None
/ I None
m2 I None
administered I None
as I None
a I None
3-hour I None
infusion I None
followed I None
immediately I None
by I None
a I None
1-hour I None
infusion I None
of I None
carboplatin I Chemical
at I None
an I None
AUC I None
of I None
6 I None
can I None
be I None
administered I None
safely I None
in I None
a I None
21-day I None
schedule I None
in I None
the I None
outpatient I None
setting I None
. I None
<eof> I None

<s> O None
The I None
recommended I None
dose I None
for I None
phase I None
III I None
studies I None
is I None
paclitaxel I Chemical
<eof> I None

<s> O None
185 I None
mg I None
/ I None
m2 I None
and I None
carboplatin I Chemical
AUC I None
6 I None
. I None
<eof> I None

<s> O None
Treatment I None
of I None
tacrolimus I Chemical
-related I None
adverse I None
effects I None
by I None
conversion I None
to I None
cyclosporine I Chemical
in I None
liver I None
transplant I None
recipients I None
. I None
<eof> I None

<s> O None
When I None
tacrolimus I Chemical
side I None
effects I None
persist I None
despite I None
dose I None
reduction I None
, I None
conversion I None
to I None
cyclosporine I Chemical
-based I None
immunosuppression I None
( I None
CyA I None
) I None
is I None
necessary I None
. I None
<eof> I None

<s> O None
We I None
characterized I None
tacrolimus I Chemical
side I None
effects I None
that I None
warranted I None
discontinuation I None
of I None
the I None
drug I None
, I None
and I None
outcomes I None
after I None
conversion I None
. I None
<eof> I None

<s> O None
Of I None
388 I None
liver I None
recipients I None
who I None
received I None
tacrolimus I Chemical
as I None
primary I None
immunosuppression I None
, I None
70 I None
required I None
conversion I None
to I None
CyA. I None
<eof> I None

<s> O None
We I None
recorded I None
indication I None
for I None
conversion I None
, I None
whether I None
conversion I None
was I None
early I None
or I None
late I None
after I None
transplantation I None
, I None
tacrolimus I Chemical
dose I None
and I None
trough I None
blood I None
level I None
at I None
conversion I None
, I None
and I None
incidence I None
of I None
rejection I None
after I None
conversion I None
. I None
<eof> I None

<s> O None
Conversion I None
was I None
early I None
in I None
29 I None
patients I None
( I None
41.4 I None
% I None
) I None
and I None
late I None
in I None
41 I None
( I None
58.6 I None
% I None
) I None
. I None
<eof> I None

<s> O None
Indications I None
for I None
early I None
conversion I None
were I None
neurotoxicity I Disease
( I None
20 I None
) I None
, I None
( I Disease
insulin O Disease
- O Disease
dependent O Disease
) O Disease
diabetes O Disease
mellitus O Disease
<eof> I None

<s> O None
( I None
IDDM I Disease
) I None
( I None
5 I None
) I None
, I None
nephrotoxicity I Disease
( I None
3 I None
) I None
, I None
gastrointestinal I Disease
( O Disease
GI O Disease
) O Disease
toxicity O Disease
( I None
6 I None
) I None
, I None
and I None
cardiomyopathy I Disease
( I None
1 I None
) I None
, I None
and I None
for I None
late I None
conversion I None
were I None
neurotoxicity I Disease
( I None
15 I None
) I None
, I None
IDDM I Disease
( I None
12 I None
) I None
, I None
nephrotoxicity I Disease
( I None
3 I None
) I None
, I None
GI I Disease
toxicity O Disease
<eof> I None

<s> O None
( I None
5 I None
) I None
, I None
<eof> I None

<s> O None
hepatotoxicity I Disease
( I None
6 I None
) I None
, I None
post I Disease
- O Disease
transplant O Disease
lmphoproliferate O Disease
disease O Disease
<eof> I None

<s> O None
( I None
PTLD I Disease
) I None
( I None
2 I None
) I None
, I None
cardiomyopathy I Disease
( I None
1 I None
) I None
, I None
hemolytic I Disease
anemia O Disease
( I None
1 I None
) I None
, I None
and I None
pruritus I Disease
( I None
1 I None
) I None
. I None
<eof> I None

<s> O None
All I None
early I None
- I None
conversion I None
patients I None
showed I None
improvement I None
/ I None
resolution I None
of I None
symptoms I None
. I None
<eof> I None

<s> O None
Among I None
late I None
- I None
conversion I None
patients I None
, I None
37 I None
( I None
90.2 I None
% I None
) I None
had I None
improvement I None
/ I None
resolution I None
; I None
in I None
4 I None
( I None
9.8 I None
% I None
) I None
, I None
adverse I None
effects I None
persisted I None
. I None
<eof> I None

<s> O None
The I None
overall I None
rejection I None
rate I None
was I None
30 I None
% I None
. I None
<eof> I None

<s> O None
Sixty I None
- I None
two I None
patients I None
( I None
88.6 I None
% I None
) I None
are I None
alive I None
with I None
functioning I None
grafts I None
686 I None
+ I None
/- I None
<eof> I None

<s> O None
362 I None
days I None
( I None
range I None
, I None
154 I None
- I None
1433 I None
days I None
) I None
after I None
conversion I None
. I None
<eof> I None

<s> O None
When I None
tacrolimus I Chemical
side I None
effects I None
are I None
unresponsive I None
to I None
dose I None
reduction I None
, I None
conversion I None
to I None
CyA I None
can I None
be I None
accomplished I None
safely I None
, I None
with I None
no I None
increased I None
risk I None
of I None
rejection I None
and I None
excellent I None
long I None
- I None
term I None
outcome I None
. I None
<eof> I None

<s> O None
Relative I None
efficacy I None
and I None
toxicity I Disease
of I None
netilmicin I Chemical
and I None
tobramycin I Chemical
in I None
oncology I None
patients I None
. I None
<eof> I None

<s> O None
We I None
prospectively I None
compared I None
the I None
efficacy I None
and I None
safety I None
of I None
netilmicin I Chemical
sulfate O Chemical
or I None
tobramycin I Chemical
sulfate O Chemical
in I None
conjunction I None
with I None
piperacillin I Chemical
sodium O Chemical
in I None
118 I None
immunocompromised I None
patients I None
with I None
presumed I None
severe I None
infections I Disease
. I None
<eof> I None

<s> O None
The I None
two I None
treatment I None
regimens I None
were I None
equally I None
efficacious I None
. I None
<eof> I None

<s> O None
Nephrotoxicity I Disease
occurred I None
in I None
a I None
similar I None
proportion I None
in I None
patients I None
treated I None
with I None
netilmicin I Chemical
and I None
tobramycin I Chemical
<eof> I None

<s> O None
( I None
17 I None
% I None
vs I None
11 I None
% I None
) I None
. I None
<eof> I None

<s> O None
Ototoxicity I Disease
occurred I None
in I None
four I None
( I None
9.5 I None
% I None
) I None
of I None
42 I None
<eof> I None

<s> O None
netilmicin I Chemical
and I None
piperacillin I Chemical
and I None
in I None
12 I None
( I None
22 I None
% I None
) I None
of I None
54 I None
tobramycin I Chemical
and I None
piperacillin I Chemical
<eof> I None

<s> O None
-treated I None
patients I None
. I None
<eof> I None

<s> O None
Of I None
those I None
evaluated I None
with I None
posttherapy I None
audiograms I None
, I None
three I None
of I None
four I None
netilmicin I Chemical
and I None
piperacillin I Chemical
<eof> I None

<s> O None
-treated I None
patients I None
had I None
auditory I None
thresholds I None
return I None
to I None
baseline I None
compared I None
with I None
one I None
of I None
nine I None
tobramycin I Chemical
and I None
piperacillin I Chemical
-treated I None
patients I None
. I None
<eof> I None

<s> O None
The I None
number I None
of I None
greater I None
than I None
or I None
equal I None
to I None
15-dB I None
increases I None
in I None
auditory I None
threshold I None
as I None
a I None
proportion I None
of I None
total I None
greater I None
than I None
or I None
equal I None
to I None
15-dB I None
changes I None
( I None
increases I None
and I None
decreases I None
) I None
was I None
significantly I None
lower I None
in I None
<eof> I None

<s> O None
netilmicin I Chemical
and I None
piperacillin I Chemical
- I None
vs I None
tobramycin I Chemical
and I None
piperacillin I Chemical
<eof> I None

<s> O None
-treated I None
patients I None
( I None
18 I None
of I None
78 I None
vs I None
67 I None
of I None
115 I None
) I None
. I None
<eof> I None

<s> O None
We I None
conclude I None
that I None
aminoglycoside I Chemical
-associated I None
ototoxicity I Disease
was I None
less I None
severe I None
and I None
more I None
often I None
reversible I None
with I None
netilmicin I Chemical
than I None
with I None
tobramycin I Chemical
. I None
<eof> I None

<s> O None
Effect I None
of I None
prostaglandin I Chemical
synthetase I None
inhibitors I None
on I None
experimentally I None
induced I None
convulsions I Disease
in I None
rats I None
. I None
<eof> I None

<s> O None
To I None
investigate I None
the I None
relationship I None
of I None
prostaglandins I Chemical
<eof> I None

<s> O None
( I None
PGs I Chemical
) I None
to I None
seizure I Disease
induction I None
, I None
the I None
effects I None
of I None
six I None
PG I None
synthetase I None
inhibitors I None
on I None
convulsions I Disease
induced I None
by I None
flurothyl I Chemical
, I None
picrotoxin I Chemical
, I None
pentetrazol I Chemical
<eof> I None

<s> O None
( I None
PTZ I Chemical
) I None
, I None
electroshock I None
or I None
bicuculline I Chemical
were I None
evaluated I None
. I None
<eof> I None

<s> O None
Ibuprofen I Chemical
, I None
sulindac I Chemical
, I None
mefenamic I Chemical
acid O Chemical
, I None
and I None
low I None
dose I None
meclofenamic I Chemical
acid O Chemical
increased I None
the I None
latency I None
- I None
to I None
- I None
onset I None
in I None
the I None
flurothyl I Chemical
and/or I None
PTZ I Chemical
models I None
; I None
the I None
electroshock I None
, I None
picrotoxin I Chemical
and I None
bicuculline I Chemical
models I None
were I None
not I None
significantly I None
affected I None
by I None
any I None
of I None
the I None
pretreatment I None
agents I None
. I None
<eof> I None

<s> O None
These I None
results I None
suggest I None
that I None
PGs I Chemical
are I None
involved I None
in I None
the I None
mechanism(s I None
) I None
underlying I None
<eof> I None

<s> O None
fluorthyl I Chemical
- I None
and I None
PTZ I Chemical
-induced I None
convulsions I Disease
, I None
but I None
not I None
<eof> I None

<s> O None
picrotoxin I Chemical
- I None
, I None
electroshock- I None
, I None
or I None
bicuculline I Chemical
-induced I None
convulsions I Disease
. I None
<eof> I None

<s> O None
Angiotensin I None
- I None
converting I None
enzyme I None
( I None
ACE I None
) I None
inhibitor I None
- I None
associated I None
angioedema I Disease
of I None
the I None
stomach I None
and I None
small I None
intestine I None
: I None
a I None
case I None
report I None
. I None
<eof> I None

<s> O None
This I None
is I None
a I None
case I None
report I None
on I None
a I None
45-year I None
old I None
African I None
- I None
American I None
female I None
with I None
newly I None
diagnosed I None
hypertension I Disease
, I None
who I None
was I None
started I None
on I None
a I None
combination I None
pill I None
of I None
amlodipine I Chemical
/ I None
benazapril I Chemical
<eof> I None

<s> O None
10/5 I None
mg I None
. I None
<eof> I None

<s> O None
The I None
very I None
next I None
day I None
, I None
she I None
presented I None
at I None
the I None
emergency I None
room I None
( I None
ER I None
) I None
with I None
abdominal I Disease
pain O Disease
, I None
nausea I Disease
and I None
vomiting I Disease
. I None
<eof> I None

<s> O None
Physical I None
exam I None
, I None
complete I None
metabolic I None
panel I None
, I None
and I None
hemogram I None
were I None
in I None
the I None
normal I None
range I None
. I None
<eof> I None

<s> O None
She I None
was I None
discharged I None
from I None
the I None
ER I None
after I None
a I None
few I None
hours I None
of I None
treatment I None
with I None
fluid I None
and I None
analgesics I None
. I None
<eof> I None

<s> O None
However I None
, I None
she I None
returned I None
to I None
the I None
ER I None
the I None
next I None
day I None
with I None
the I None
same I None
complaints I None
. I None
<eof> I None

<s> O None
This I None
time I None
the I None
physical I None
exam I None
was I None
significant I None
for I None
a I None
distended I None
abdomen I None
with I None
dullness I None
to I None
percussion I None
. I None
<eof> I None

<s> O None
CT I None
scan I None
of I None
the I None
abdomen I None
revealed I None
markedly I None
thickened I None
antrum I None
of I None
the I None
stomach I None
, I None
duodenum I None
and I None
jejunum I None
, I None
along I None
with I None
fluid I None
in I None
the I None
abdominal I None
and I None
pelvic I None
cavity I None
. I None
<eof> I None

<s> O None
Angiotensin I None
- I None
converting I None
enzyme I None
inhibitor I None
( I None
ACEI)-induced I None
angioedema I Disease
was I None
suspected I None
, I None
and I None
anti- I None
hypertensive I Disease
medications I None
were I None
discontinued I None
. I None
<eof> I None

<s> O None
Her I None
symptoms I None
improved I None
within I None
the I None
next I None
24 I None
hours I None
, I None
and I None
repeat I None
CT I None
after I None
72 I None
hours I None
revealed I None
marked I None
improvement I None
in I None
stomach I None
and I None
small I None
bowel I None
thickening I None
and I None
resolution I None
of I None
ascites I Disease
. I None
<eof> I None

<s> O None
The I None
recognition I None
of I None
angiotensin I Chemical
-converting I None
enzyme I None
( I None
ACE I None
) I None
and I None
angiotensin I Chemical
receptor I None
blocker I None
( I None
ARB I None
) I None
intestinal I None
angioedema I None
constitutes I None
a I None
challenge I None
to I None
primary I None
care I None
physicians I None
, I None
internists I None
, I None
emergency I None
room I None
personal I None
and I None
surgeons I None
. I None
<eof> I None

<s> O None
Valproic I Chemical
acid O Chemical
<eof> I None

<s> O None
I I None
: I None
time I None
course I None
of I None
lipid I None
peroxidation I None
biomarkers I None
, I None
liver I Disease
toxicity O Disease
, I None
and I None
valproic I Chemical
acid O Chemical
metabolite I None
levels I None
in I None
rats I None
. I None
<eof> I None

<s> O None
A I None
single I None
dose I None
of I None
valproic I Chemical
acid O Chemical
<eof> I None

<s> O None
( I None
VPA I Chemical
) I None
, I None
which I None
is I None
a I None
widely I None
used I None
antiepileptic I None
drug I None
, I None
is I None
associated I None
with I None
oxidative I None
stress I None
in I None
rats I None
, I None
as I None
recently I None
demonstrated I None
by I None
elevated I None
levels I None
of I None
15-F(2t)-isoprostane I Chemical
<eof> I None

<s> O None
( I None
15-F(2t)-IsoP I Chemical
) I None
. I None
<eof> I None

<s> O None
To I None
determine I None
whether I None
there I None
was I None
a I None
temporal I None
relationship I None
between I None
VPA I Chemical
<eof> I None

<s> O None
-associated I None
oxidative I None
stress I None
and I None
hepatotoxicity I Disease
, I None
adult I None
male I None
Sprague I None
- I None
Dawley I None
rats I None
were I None
treated I None
ip I None
with I None
VPA I Chemical
<eof> I None

<s> O None
( I None
500 I None
mg I None
/ I None
kg I None
) I None
or I None
0.9 I None
% I None
saline I None
( I None
vehicle I None
) I None
once I None
daily I None
for I None
2 I None
, I None
4 I None
, I None
7 I None
, I None
10 I None
, I None
or I None
14 I None
days I None
. I None
<eof> I None

<s> O None
Oxidative I None
stress I None
was I None
assessed I None
by I None
determining I None
plasma I None
and I None
liver I None
levels I None
of I None
15-F(2t)-IsoP I Chemical
, I None
lipid I Chemical
hydroperoxides O Chemical
<eof> I None

<s> O None
( I None
LPO I Chemical
) I None
, I None
and I None
thiobarbituric I Chemical
acid O Chemical
reactive O Chemical
substances O Chemical
( I None
TBARs I Chemical
) I None
. I None
<eof> I None

<s> O None
Plasma I None
and I None
liver I None
15-F(2t)-IsoP I Chemical
were I None
elevated I None
and I None
reached I None
a I None
plateau I None
after I None
day I None
2 I None
of I None
VPA I Chemical
treatment I None
compared I None
to I None
control I None
. I None
<eof> I None

<s> O None
Liver I None
LPO I Chemical
levels I None
were I None
not I None
elevated I None
until I None
day I None
7 I None
of I None
treatment I None
( I None
1.8-fold I None
versus I None
control I None
, I None
p I None
< I None
0.05 I None
) I None
. I None
<eof> I None

<s> O None
Liver I None
and I None
plasma I None
TBARs I Chemical
were I None
not I None
increased I None
until I None
14 I None
days I None
( I None
2-fold I None
vs. I None
control I None
, I None
p I None
< I None
0.05 I None
) I None
. I None
<eof> I None

<s> O None
Liver I Disease
toxicity O Disease
was I None
evaluated I None
based I None
on I None
serum I None
levels I None
of I None
alpha- I None
glutathione I Chemical
S I None
- I None
transferase I None
( I None
alpha I None
- I None
GST I None
) I None
and I None
by I None
histology I None
. I None
<eof> I None

<s> O None
Serum I None
alpha I None
- I None
GST I None
levels I None
were I None
significantly I None
elevated I None
by I None
day I None
4 I None
, I None
which I None
corresponded I None
to I None
hepatotoxicity I Disease
as I None
shown I None
by I None
the I None
increasing I None
incidence I None
of I None
inflammation I Disease
of I None
the I None
liver I None
capsule I None
, I None
necrosis I Disease
, I None
and I None
steatosis I Disease
throughout I None
the I None
study I None
. I None
<eof> I None

<s> O None
The I None
liver I None
levels I None
of I None
beta I None
- I None
oxidation I None
metabolites I None
of I None
VPA I Chemical
were I None
decreased I None
by I None
day I None
14 I None
, I None
while I None
the I None
levels I None
of I None
4-ene I Chemical
- O Chemical
VPA O Chemical
and I None
( I None
E)- I None
2,4-diene I Chemical
- O Chemical
VPA O Chemical
were I None
not I None
elevated I None
throughout I None
the I None
study I None
. I None
<eof> I None

<s> O None
Overall I None
, I None
these I None
findings I None
indicate I None
that I None
VPA I Chemical
treatment I None
results I None
in I None
oxidative I None
stress I None
, I None
as I None
measured I None
by I None
levels I None
of I None
15-F(2t)-IsoP I Chemical
, I None
which I None
precedes I None
the I None
onset I None
of I None
necrosis I Disease
, I None
steatosis I Disease
, I None
and I None
elevated I None
levels I None
of I None
serum I None
alpha I None
- I None
GST I None
. I None
<eof> I None

<s> O None
Pheochromocytoma I Disease
unmasked I None
by I None
amisulpride I Chemical
and I None
tiapride I Chemical
. I None
<eof> I None

<s> O None
OBJECTIVE I None
: I None
<eof> I None

<s> O None
To I None
describe I None
the I None
unmasking I None
of I None
pheochromocytoma I Disease
in I None
a I None
patient I None
treated I None
with I None
amisulpride I Chemical
and I None
tiapride I Chemical
. I None
<eof> I None

<s> O None
CASE I None
SUMMARY I None
: I None
<eof> I None

<s> O None
A I None
42-year I None
- I None
old I None
white I None
man I None
developed I None
acute I None
hypertension I Disease
with I None
severe I None
headache I Disease
and I None
vomiting I Disease
2 I None
hours I None
after I None
the I None
first I None
doses I None
of I None
amisulpride I Chemical
<eof> I None

<s> O None
100 I None
mg I None
and I None
tiapride I Chemical
100 I None
mg I None
. I None
<eof> I None

<s> O None
Both I None
drugs I None
were I None
immediately I None
discontinued I None
, I None
and I None
the I None
patient I None
recovered I None
after I None
subsequent I None
nicardipine I Chemical
and I None
verapamil I Chemical
treatment I None
. I None
<eof> I None

<s> O None
Abdominal I None
ultrasound I None
showed I None
an I None
adrenal I None
mass I None
, I None
and I None
postoperative I None
histologic I None
examination I None
confirmed I None
the I None
diagnosis I None
of I None
pheochromocytoma I Disease
. I None
<eof> I None

<s> O None
DISCUSSION I None
: I None
<eof> I None

<s> O None
Drug I None
- I None
induced I None
symptoms I None
of I None
pheochromocytoma I Disease
are I None
often I None
associated I None
with I None
the I None
use I None
of I None
substituted I None
benzamide I Chemical
drugs I None
, I None
but I None
the I None
underlying I None
mechanism I None
is I None
unknown I None
. I None
<eof> I None

<s> O None
In I None
our I None
case I None
, I None
use I None
of I None
the I None
Naranjo I None
probability I None
scale I None
indicated I None
a I None
possible I None
relationship I None
between I None
the I None
hypertensive I Disease
crisis I None
and I None
amisulpride I Chemical
and I None
tiapride I Chemical
therapy I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
As I None
of I None
March I None
24 I None
, I None
2005 I None
, I None
this I None
is I None
the I None
first I None
reported I None
case I None
of I None
amisulpride I Chemical
- I None
and I None
tiapride I Chemical
-induced I None
hypertensive I Disease
crisis I None
in I None
a I None
patient I None
with I None
pheochromocytoma I Disease
. I None
<eof> I None

<s> O None
Physicians I None
and I None
other I None
healthcare I None
professionals I None
should I None
be I None
aware I None
of I None
this I None
potential I None
adverse I None
effect I None
of I None
tiapride I Chemical
and I None
amisulpride I Chemical
. I None
<eof> I None

<s> O None
Quantitative I None
drug I None
levels I None
in I None
stimulant I None
psychosis I Disease
: I None
relationship I None
to I None
symptom I None
severity I None
, I None
catecholamines I Chemical
and I None
hyperkinesia I Disease
. I None
<eof> I None

<s> O None
To I None
examine I None
the I None
relationship I None
between I None
quantitative I None
stimulant I None
drug I None
levels I None
, I None
catecholamines I Chemical
, I None
and I None
psychotic I Disease
symptoms O Disease
, I None
nineteen I None
patients I None
in I None
a I None
psychiatric I Disease
emergency I None
service I None
with I None
a I None
diagnosis I None
of I None
amphetamine I Chemical
- I None
or I None
cocaine I Chemical
-induced I None
<eof> I None

<s> O None
psychosis I Disease
were I None
interviewed I None
, I None
and I None
plasma I None
and I None
urine I None
were I None
collected I None
for I None
quantitative I None
assays I None
of I None
stimulant I None
drug I None
and I None
catecholamine I Chemical
metabolite I None
levels I None
. I None
<eof> I None

<s> O None
Methamphetamine I Chemical
or I None
amphetamine I Chemical
levels I None
were I None
related I None
to I None
several I None
psychopathology I None
scores I None
and I None
the I None
global I None
hyperkinesia I Disease
rating I None
. I None
<eof> I None

<s> O None
HVA I None
levels I None
were I None
related I None
to I None
global I None
hyperkinesia I Disease
but I None
not I None
to I None
psychopathology I None
ratings I None
. I None
<eof> I None

<s> O None
Although I None
many I None
other I None
factors I None
such I None
as I None
sensitization I None
may I None
play I None
a I None
role I None
, I None
intensity I None
of I None
stimulant I None
- I None
induced I None
psychotic I Disease
symptoms O Disease
and I None
stereotypies I Disease
appears I None
to I None
be I None
at I None
least I None
in I None
part I None
dose I None
- I None
related I None
. I None
<eof> I None

<s> O None
Delayed I None
asystolic I Disease
<eof> I None

<s> O None
cardiac I Disease
arrest O Disease
after I None
diltiazem I Chemical
overdose I Disease
; I None
resuscitation I None
with I None
high I None
dose I None
intravenous I None
calcium I Chemical
. I None
<eof> I None

<s> O None
A I None
51 I None
year I None
old I None
man I None
took I None
a I None
mixed I None
overdose I Disease
including I None
1.8 I None
- I None
3.6 I None
g I None
of I None
diltiazem I Chemical
, I None
paracetamol I Chemical
, I None
aspirin I Chemical
, I None
isosorbide I Chemical
nitrate I Chemical
, I None
and I None
alcohol I Chemical
. I None
<eof> I None

<s> O None
He I None
initially I None
presented I None
to I None
hospital I None
after I None
six I None
hours I None
with I None
mild I None
hypotension I Disease
and I None
was I None
treated I None
with I None
activated I None
charcoal I None
and I None
intravenous I None
fluids I None
. I None
<eof> I None

<s> O None
Eighteen I None
hours I None
after I None
the I None
overdose I Disease
<eof> I None

<s> O None
he I None
had I None
two I None
generalised I None
tonic I Disease
- O Disease
clonic O Disease
seizures O Disease
. I None
<eof> I None

<s> O None
The I None
patient I None
remained I None
unresponsive I None
with I None
junctional I None
bradycardia I Disease
, I None
unrecordable I None
blood I None
pressure I None
, I None
and I None
then I None
became I None
asystolic I Disease
. I None
<eof> I None

<s> O None
He I None
was I None
resuscitated I None
with I None
high I None
dose I None
( I None
13.5 I None
g I None
) I None
intravenous I None
calcium I Chemical
and I None
adrenaline I Chemical
<eof> I None

<s> O None
( I None
epinephrine I Chemical
) I None
. I None
<eof> I None

<s> O None
He I None
required I None
inotropic I None
support I None
and I None
temporary I None
pacing I None
over I None
the I None
next I None
48 I None
hours I None
. I None
<eof> I None

<s> O None
This I None
case I None
suggests I None
there I None
is I None
a I None
role I None
for I None
aggressive I None
high I None
dose I None
intravenous I None
calcium I Chemical
therapy I None
in I None
severe I None
diltiazem I Chemical
<eof> I None

<s> O None
overdose I Disease
, I None
particularly I None
with I None
the I None
onset I None
of I None
asystole I Disease
. I None
<eof> I None

<s> O None
It I None
should I None
be I None
considered I None
early I None
in I None
cases I None
of I None
cardiac I Disease
arrest O Disease
after I None
diltiazem I Chemical
overdose I Disease
. I None
<eof> I None

<s> O None
The I None
case I None
also I None
highlights I None
the I None
problems I None
with I None
delayed I None
toxicity I Disease
<eof> I None

<s> O None
when I None
whole I None
bowel I None
irrigation I None
is I None
not I None
administered I None
. I None
<eof> I None

<s> O None
Renal I Disease
papillary O Disease
necrosis O Disease
due I None
to I None
naproxen I Chemical
. I None
<eof> I None

<s> O None
A I None
31-year I None
- I None
old I None
man I None
with I None
rheumatoid I Disease
arthritis O Disease
, I None
who I None
had I None
previously I None
been I None
treated I None
with I None
sulindac I Chemical
, I None
fenoprofen I Chemical
calcium O Chemical
, I None
high I None
dose I None
salicylates I Chemical
and I None
gold I Chemical
salts I None
, I None
developed I None
renal I Disease
papillary O Disease
necrosis O Disease
<eof> I None

<s> O None
( I None
RPN I Disease
) I None
4 I None
months I None
after I None
institution I None
of I None
naproxen I Chemical
therapy I None
. I None
<eof> I None

<s> O None
No I None
other I None
factor I None
predisposing I None
to I None
RPN I Disease
could I None
be I None
discovered I None
. I None
<eof> I None

<s> O None
Sulindac I Chemical
was I None
substituted I None
for I None
naproxen I Chemical
and I None
no I None
further I None
adverse I None
renal I None
effects I None
occurred I None
over I None
the I None
next I None
12 I None
months I None
. I None
<eof> I None

<s> O None
We I None
review I None
previous I None
reports I None
linking I None
RPN I Disease
to I None
antiinflammatory I None
drug I None
use I None
and I None
discuss I None
possible I None
advantages I None
of I None
sulindac I Chemical
in I None
patients I None
who I None
have I None
experienced I None
renal I Disease
toxicity O Disease
from I None
other I None
antiinflammatory I None
agents I None
. I None
<eof> I None

<s> O None
Adverse I None
interaction I None
between I None
beta I Chemical
- O Chemical
adrenergic O Chemical
blocking O Chemical
drugs O Chemical
and I None
verapamil I Chemical
--report I None
of I None
three I None
cases I None
. I None
<eof> I None

<s> O None
Three I None
patients I None
with I None
ischaemic I Disease
heart O Disease
disease O Disease
developed I None
profound I None
cardiac I Disease
failure O Disease
, I None
hypotension I Disease
and I None
bradycardia I Disease
during I None
combined I None
therapy I None
with I None
verapamil I Chemical
and I None
beta I Chemical
- O Chemical
adrenergic O Chemical
blocking O Chemical
drugs O Chemical
. I None
<eof> I None

<s> O None
This I None
clinical I None
picture I None
resolved I None
completely I None
with I None
cessation I None
of I None
the I None
combined I None
therapy I None
. I None
<eof> I None

<s> O None
Baseline I None
left I None
ventricular I None
function I None
, I None
assessed I None
by I None
cardiac I None
catheterisation I None
or I None
nuclear I None
angiography I None
, I None
was I None
normal I None
in I None
two I None
patients I None
and I None
only I None
mildly I None
reduced I None
in I None
the I None
other I None
. I None
<eof> I None

<s> O None
Simultaneously I None
administration I None
of I None
beta I Chemical
- O Chemical
adrenergic O Chemical
blocking O Chemical
drugs O Chemical
and I None
verapamil I Chemical
may I None
result I None
in I None
profound I None
adverse I None
interactions I None
and I None
should I None
only I None
be I None
administered I None
with I None
great I None
caution I None
. I None
<eof> I None

<s> O None
Adverse I None
reactions I None
to I None
bendrofluazide I Chemical
and I None
propranolol I Chemical
for I None
the I None
treatment I None
of I None
mild I None
hypertension I Disease
. I None
<eof> I None

<s> O None
Report I None
of I None
Medical I None
Research I None
Council I None
Working I None
Party I None
on I None
Mild I None
to I None
Moderate I None
Hypertension I Disease
. I None
<eof> I None

<s> O None
Participants I None
in I None
the I None
Medical I None
Research I None
Council I None
treatment I None
trial I None
for I None
mild I None
hypertension I Disease
are I None
randomly I None
allocated I None
to I None
one I None
of I None
four I None
treatment I None
groups I None
: I None
bendrofluazide I Chemical
, I None
propranolol I Chemical
, I None
or I None
a I None
placebo I None
for I None
either I None
of I None
these I None
drugs I None
. I None
<eof> I None

<s> O None
The I None
trial I None
is I None
single I None
- I None
blind I None
. I None
<eof> I None

<s> O None
23 I None
582 I None
patient I None
- I None
years I None
of I None
observation I None
have I None
been I None
completed I None
so I None
far I None
, I None
10 I None
684 I None
on I None
active I None
drugs I None
and I None
12 I None
898 I None
on I None
placebos I None
. I None
<eof> I None

<s> O None
The I None
results I None
show I None
an I None
association I None
between I None
bendrofluazide I Chemical
treatment I None
and I None
impotence I Disease
, I None
and I None
impotence I Disease
also I None
occurred I None
more I None
frequently I None
in I None
patients I None
taking I None
propranolol I Chemical
than I None
in I None
those I None
taking I None
placebos I None
. I None
<eof> I None

<s> O None
Other I None
adverse I None
reactions I None
significantly I None
linked I None
with I None
active I None
drugs I None
include I None
impaired I Disease
glucose O Disease
tolerance O Disease
in I None
men I None
and I None
women I None
and I None
gout I Disease
in I None
men I None
, I None
associated I None
with I None
bendrofluazide I Chemical
treatment I None
, I None
and I None
Raynaud I Disease
's O Disease
phenomenon O Disease
and I None
dyspnoea I Disease
in I None
men I None
and I None
women I None
taking I None
propranolol I Chemical
. I None
<eof> I None

<s> O None
No I None
corneal I Disease
disease O Disease
is I None
known I None
to I None
have I None
occurred I None
in I None
the I None
propranolol I Chemical
group I None
. I None
<eof> I None

<s> O None
Mean I None
serum I None
potassium I Chemical
level I None
fell I None
, I None
and I None
urea I Chemical
and I None
uric I Chemical
acid O Chemical
levels I None
rose I None
, I None
in I None
men I None
and I None
women I None
taking I None
bendrofluazide I Chemical
. I None
<eof> I None

<s> O None
In I None
the I None
propranolol I Chemical
group I None
, I None
serum I None
<eof> I None

<s> O None
potassium I Chemical
and I None
uric I Chemical
acid O Chemical
levels I None
rose I None
in I None
both I None
sexes I None
, I None
but I None
the I None
urea I Chemical
level I None
rose I None
significantly I None
in I None
women I None
only I None
. I None
<eof> I None

<s> O None
Dexmedetomidine I Chemical
and I None
cardiac I None
protection I None
for I None
non I None
- I None
cardiac I None
surgery I None
: I None
a I None
meta I None
- I None
analysis I None
of I None
randomised I None
controlled I None
trials I None
. I None
<eof> I None

<s> O None
We I None
conducted I None
a I None
systematic I None
review I None
of I None
the I None
effects I None
of I None
dexmedetomidine I Chemical
on I None
cardiac I None
outcomes I None
following I None
non I None
- I None
cardiac I None
surgery I None
. I None
<eof> I None

<s> O None
We I None
included I None
prospective I None
, I None
randomised I None
peri I None
- I None
operative I None
studies I None
of I None
dexmedetomidine I Chemical
<eof> I None

<s> O None
that I None
reported I None
mortality I None
, I None
cardiac I None
morbidity I None
or I None
adverse I None
drug I None
events I None
. I None
<eof> I None

<s> O None
A I None
PubMed I None
Central I None
and I None
EMBASE I None
search I None
was I None
conducted I None
up I None
to I None
July I None
2007 I None
. I None
<eof> I None

<s> O None
The I None
reference I None
lists I None
of I None
identified I None
papers I None
were I None
examined I None
for I None
further I None
trials I None
. I None
<eof> I None

<s> O None
Of I None
425 I None
studies I None
identified I None
, I None
20 I None
were I None
included I None
in I None
the I None
meta I None
- I None
analysis I None
( I None
840 I None
patients I None
) I None
. I None
<eof> I None

<s> O None
Dexmedetomidine I Chemical
was I None
associated I None
with I None
a I None
trend I None
towards I None
improved I None
cardiac I None
outcomes I None
; I None
all I None
- I None
cause I None
mortality I None
( I None
OR I None
0.27 I None
, I None
95 I None
% I None
CI I None
0.01 I None
- I None
7.13 I None
, I None
p I None
= I None
0.44 I None
) I None
, I None
non I None
- I None
fatal I None
myocardial I Disease
infarction O Disease
( I None
OR I None
0.26 I None
, I None
95 I None
% I None
CI I None
0.04 I None
- I None
1.60 I None
, I None
p I None
= I None
0.14 I None
) I None
, I None
and I None
myocardial I Disease
ischaemia O Disease
( I None
OR I None
0.65 I None
, I None
95 I None
% I None
CI I None
0.26 I None
- I None
1.63 I None
, I None
p I None
= I None
0.36 I None
) I None
. I None
<eof> I None

<s> O None
Peri I None
- I None
operative I None
hypotension I Disease
<eof> I None

<s> O None
( I None
26 I None
% I None
, I None
OR I None
3.80 I None
, I None
95 I None
% I None
CI I None
1.91 I None
- I None
7.54 I None
, I None
p I None
= I None
0.0001 I None
) I None
and I None
bradycardia I Disease
<eof> I None

<s> O None
( I None
17 I None
% I None
, I None
OR I None
5.45 I None
, I None
95 I None
% I None
CI I None
2.98 I None
- I None
9.95 I None
, I None
p I None
< I None
0.00001 I None
) I None
were I None
significantly I None
increased I None
. I None
<eof> I None

<s> O None
An I None
anticholinergic I None
did I None
not I None
reduce I None
the I None
incidence I None
of I None
bradycardia I Disease
<eof> I None

<s> O None
( I None
p I None
= I None
0.43 I None
) I None
. I None
<eof> I None

<s> O None
A I None
randomised I None
placebo I None
- I None
controlled I None
trial I None
of I None
dexmedetomidine I Chemical
is I None
warranted I None
. I None
<eof> I None

<s> O None
Differential I None
diagnosis I None
of I None
high I None
serum I None
creatine I Chemical
kinase I None
levels I None
in I None
systemic I Disease
lupus O Disease
erythematosus O Disease
. I None
<eof> I None

<s> O None
We I None
report I None
the I None
clinical I None
and I None
bioptic I None
findings I None
for I None
a I None
57-year I None
- I None
old I None
woman I None
with I None
severe I None
chloroquine I Chemical
-induced I None
myopathy I Disease
. I None
<eof> I None

<s> O None
Since I None
1989 I None
, I None
she I None
had I None
been I None
suffering I None
from I None
systemic I Disease
lupus O Disease
erythematosus O Disease
<eof> I None

<s> O None
( I None
SLE I Disease
) I None
with I None
renal I Disease
involvement O Disease
and I None
undergone I None
periods I None
of I None
treatment I None
with I None
azathioprine I Chemical
and I None
cyclophosphamide I Chemical
. I None
<eof> I None

<s> O None
Additional I None
therapy I None
with I None
chloroquine I Chemical
<eof> I None

<s> O None
( I None
CQ I Chemical
) I None
was I None
started I None
because I None
of I None
arthralgia I Disease
. I None
<eof> I None

<s> O None
At I None
the I None
same I None
time I None
, I None
slightly I None
increased I None
<eof> I None

<s> O None
creatine I Chemical
kinase I None
( I None
CK I None
) I None
levels I None
were I None
noted I None
. I None
<eof> I None

<s> O None
Myositis I Disease
was I None
suspected I None
, I None
and I None
the I None
patient I None
was I None
treated I None
with I None
steroids I Chemical
. I None
<eof> I None

<s> O None
The I None
CK I None
increase I None
persisted I None
, I None
however I None
, I None
and I None
she I None
developed I None
progressive I None
muscular I Disease
weakness O Disease
and I None
muscular I Disease
atrophy O Disease
. I None
<eof> I None

<s> O None
Routine I None
controls I None
revealed I None
markedly I None
elevated I None
CK I None
levels I None
of I None
1,700 I None
U I None
/ I None
l I None
. I None
<eof> I None

<s> O None
The I None
neurological I None
and I None
electrophysiological I None
findings I None
were I None
not I None
typical I None
of I None
myositis I Disease
. I None
<eof> I None

<s> O None
Thus I None
, I None
muscle I None
biopsy I None
of I None
the I None
deltoid I None
muscle I None
was I None
performed I None
in I None
order I None
to I None
exclude I None
polymyositis I Disease
or I None
toxic I None
myopathy I Disease
. I None
<eof> I None

<s> O None
As I None
it I None
revealed I None
chloroquine I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
myopathy I Disease
, I None
medication I None
was I None
stopped I None
. I None
<eof> I None

<s> O None
Discriminating I None
between I None
primary I None
SLE I Disease
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
affection I Disease
of O Disease
the O Disease
musculoskeletal O Disease
system O Disease
and I None
drug I None
- I None
induced I None
side I None
effects I None
is I None
important I None
for I None
appropriate I None
treatment I None
of I None
SLE I Disease
patients I None
. I None
<eof> I None

<s> O None
Intravenous I None
ribavirin I Chemical
treatment I None
for I None
severe I None
adenovirus I Disease
disease O Disease
in I None
immunocompromised I None
children I None
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
<eof> I None

<s> O None
Adenovirus I None
is I None
an I None
important I None
cause I None
of I None
morbidity I None
and I None
mortality I None
in I None
the I None
immunocompromised I None
host I None
. I None
<eof> I None

<s> O None
The I None
incidence I None
of I None
severe I None
adenovirus I Disease
disease O Disease
in I None
pediatrics I None
is I None
increasing I None
in I None
association I None
with I None
growing I None
numbers I None
of I None
immunocompromised I None
children I None
, I None
where I None
case I None
fatality I None
rates I None
as I None
high I None
as I None
50 I None
% I None
to I None
80 I None
% I None
have I None
been I None
reported I None
. I None
<eof> I None

<s> O None
There I None
are I None
no I None
approved I None
antiviral I None
agents I None
with I None
proven I None
efficacy I None
for I None
the I None
treatment I None
of I None
severe I None
adenovirus I Disease
disease O Disease
, I None
nor I None
are I None
there I None
any I None
prospective I None
randomized I None
, I None
controlled I None
trials I None
of I None
potentially I None
useful I None
anti I None
- I None
adenovirus I None
therapies I None
. I None
<eof> I None

<s> O None
Apparent I None
clinical I None
success I None
in I None
the I None
treatment I None
of I None
severe I None
adenovirus I Disease
disease O Disease
is I None
limited I None
to I None
a I None
few I None
case I None
reports I None
and I None
small I None
series I None
. I None
<eof> I None

<s> O None
Experience I None
is I None
greatest I None
with I None
intravenous I None
ribavirin I Chemical
and I None
cidofovir I Chemical
. I None
<eof> I None

<s> O None
Ribavirin I Chemical
, I None
a I None
guanosine I Chemical
analogue I None
, I None
has I None
broad I None
antiviral I None
activity I None
against I None
both I None
RNA I None
and I None
DNA I None
viruses I None
, I None
including I None
documented I None
activity I None
against I None
adenovirus I None
in I None
vitro I None
. I None
<eof> I None

<s> O None
Ribavirin I Chemical
is I None
licensed I None
in I None
aerosol I None
form I None
for I None
the I None
treatment I None
of I None
respiratory I Disease
syncytial O Disease
virus O Disease
infection O Disease
, I None
and I None
orally I None
in I None
combination I None
with I None
interferon I None
to I None
treat I None
hepatitis I Disease
C O Disease
. I None
<eof> I None

<s> O None
Intravenous I None
ribavirin I Chemical
is I None
the I None
treatment I None
of I None
choice I None
for I None
infection I Disease
with O Disease
hemorrhagic O Disease
fever O Disease
viruses O Disease
. I None
<eof> I None

<s> O None
The I None
most I None
common I None
adverse I None
effect I None
of I None
intravenous I None
ribavirin I Chemical
is I None
reversible I None
mild I None
anemia I Disease
. I None
<eof> I None

<s> O None
The I None
use I None
of I None
cidofovir I Chemical
in I None
severe I None
adenovirus I Disease
infection O Disease
has I None
been I None
limited I None
by I None
adverse I None
effects I None
, I None
the I None
most I None
significant I None
of I None
which I None
is I None
nephrotoxicity I Disease
. I None
<eof> I None

<s> O None
OBJECTIVE I None
: I None
<eof> I None

<s> O None
We I None
report I None
our I None
experience I None
with I None
intravenous I None
ribavirin I Chemical
therapy I None
for I None
severe I None
adenovirus I Disease
disease O Disease
in I None
a I None
series I None
of I None
immunocompromised I None
children I None
and I None
review I None
the I None
literature I None
. I None
<eof> I None

<s> O None
DESIGN I None
/ I None
METHODS I None
: I None
We I None
retrospectively I None
reviewed I None
the I None
medical I None
records I None
of I None
5 I None
children I None
treated I None
with I None
intravenous I None
ribavirin I Chemical
for I None
documented I None
severe I None
adenovirus I Disease
disease O Disease
. I None
<eof> I None

<s> O None
Two I None
patients I None
developed I None
adenovirus I None
hemorrhagic I None
cystitis I None
after I None
cardiac I None
and I None
bone I None
marrow I None
transplants I None
, I None
respectively I None
. I None
<eof> I None

<s> O None
The I None
bone I None
marrow I None
transplant I None
patient I None
also I None
received I None
intravenous I None
cidofovir I Chemical
for I None
progressive I None
disseminated I None
disease I None
. I None
<eof> I None

<s> O None
An I None
additional I None
3 I None
children I None
developed I None
adenovirus I None
pneumonia I None
; I None
2 I None
were I None
neonates I None
, I None
1 I None
of I None
whom I None
had I None
partial I None
DiGeorge I Disease
syndrome O Disease
. I None
<eof> I None

<s> O None
The I None
remaining I None
infant I None
had I None
recently I None
undergone I None
a I None
cardiac I None
transplant I None
. I None
<eof> I None

<s> O None
Intravenous I None
ribavirin I Chemical
was I None
administered I None
on I None
a I None
compassionate I None
- I None
use I None
protocol I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
Complete I None
clinical I None
recovery I None
followed I None
later I None
by I None
viral I None
clearance I None
was I None
observed I None
in I None
2 I None
children I None
: I None
the I None
cardiac I None
transplant I None
recipient I None
with I None
adenovirus I None
hemorrhagic I None
cystitis I None
and I None
the I None
immunocompetent I None
neonate I None
with I None
adenovirus I None
pneumonia I None
. I None
<eof> I None

<s> O None
The I None
remaining I None
3 I None
children I None
died I None
of I None
adenovirus I Disease
disease O Disease
. I None
<eof> I None

<s> O None
Intravenous I None
ribavirin I Chemical
<eof> I None

<s> O None
therapy I None
was I None
well I None
tolerated I None
. I None
<eof> I None

<s> O None
Use I None
of I None
cidofovir I Chemical
in I None
1 I None
child I None
was I None
associated I None
with I None
progressive I Disease
renal O Disease
failure O Disease
and I None
neutropenia I Disease
. I None
<eof> I None

<s> O None
DISCUSSION I None
: I None
<eof> I None

<s> O None
Our I None
series I None
of I None
patients I None
is I None
representative I None
of I None
the I None
spectrum I None
of I None
immunocompromised I None
children I None
at I None
greatest I None
risk I None
for I None
severe I None
adenovirus I Disease
disease O Disease
, I None
namely I None
solid I None
- I None
organ I None
and I None
bone I None
marrow I None
transplant I None
recipients I None
, I None
neonates I None
, I None
and I None
children I None
with I None
immunodeficiency I Disease
. I None
<eof> I None

<s> O None
Although I None
intravenous I None
ribavirin I Chemical
was I None
not I None
effective I None
for I None
all I None
children I None
with I None
severe I None
adenovirus I Disease
disease O Disease
in I None
this I None
series I None
or I None
in I None
the I None
literature I None
, I None
therapy I None
is I None
unlikely I None
to I None
be I None
of I None
benefit I None
if I None
begun I None
late I None
in I None
the I None
course I None
of I None
the I None
infection I Disease
. I None
<eof> I None

<s> O None
Early I None
identification I None
, I None
eg I None
by I None
polymerase I None
chain I None
reaction I None
of I None
those I None
patients I None
at I None
risk I None
of I None
disseminated I None
<eof> I None

<s> O None
adenovirus I Disease
disease O Disease
may I None
permit I None
earlier I None
antiviral I None
treatment I None
and I None
better I None
evaluation I None
of I None
therapeutic I None
response I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
Two I None
of I None
5 I None
children I None
with I None
severe I None
adenovirus I Disease
disease O Disease
treated I None
with I None
intravenous I None
ribavirin I Chemical
recovered I None
. I None
<eof> I None

<s> O None
The I None
availability I None
of I None
newer I None
rapid I None
diagnostic I None
techniques I None
, I None
such I None
as I None
polymerase I None
chain I None
reaction I None
, I None
may I None
make I None
earlier I None
, I None
more I None
effective I None
treatment I None
of I None
adenovirus I Disease
infection O Disease
possible I None
. I None
<eof> I None

<s> O None
Given I None
the I None
seriousness I None
and I None
increasing I None
prevalence I None
of I None
adenovirus I Disease
disease O Disease
in I None
certain I None
hosts I None
, I None
especially I None
children I None
, I None
a I None
large I None
, I None
multicenter I None
clinical I None
trial I None
of I None
potentially I None
useful I None
anti I None
- I None
adenoviral I None
therapies I None
, I None
such I None
as I None
intravenous I None
ribavirin I Chemical
, I None
is I None
clearly I None
required I None
to I None
demonstrate I None
the I None
most I None
effective I None
and I None
least I None
toxic I None
therapy I None
. I None
<eof> I None

<s> O None
Hepatotoxicity I Disease
of I None
amiodarone I Chemical
. I None
<eof> I None

<s> O None
Amiodarone I Chemical
has I None
proved I None
very I None
effective I None
in I None
the I None
treatment I None
of I None
otherwise I None
resistant I None
cardiac I None
tachyarrhythmias I Disease
. I None
<eof> I None

<s> O None
The I None
use I None
of I None
amiodarone I Chemical
has I None
, I None
however I None
, I None
been I None
limited I None
due I None
to I None
its I None
serious I None
side I None
- I None
effects I None
. I None
<eof> I None

<s> O None
A I None
patient I None
with I None
cholestatic I None
hepatitis I None
due I None
to I None
amiodarone I Chemical
treatment I None
is I None
presented I None
below I None
and I None
a I None
review I None
of I None
the I None
hepatotoxicity I Disease
of I None
amiodarone I Chemical
is I None
given I None
. I None
<eof> I None

<s> O None
It I None
is I None
concluded I None
that I None
solid I None
evidence I None
exists I None
of I None
hepatic I Disease
injury O Disease
due I None
to I None
amiodarone I Chemical
treatment I None
, I None
including I None
steatosis I Disease
, I None
alterations I None
resembling I None
alcoholic I Disease
hepatitis O Disease
, I None
cholestatic I None
hepatitis I None
and I None
micronodular I None
cirrhosis I Disease
of O Disease
the O Disease
liver O Disease
. I None
<eof> I None

<s> O None
Patients I None
receiving I None
amiodarone I Chemical
should I None
be I None
regularly I None
screened I None
with I None
respect I None
to I None
hepatic I None
enzyme I None
levels I None
. I None
<eof> I None

<s> O None
Therapy I None
should I None
be I None
discontinued I None
on I None
the I None
suspicion I None
of I None
cholestatic I Disease
injury O Disease
or I None
hepatomegaly I Disease
. I None
<eof> I None

<s> O None
Catalepsy I Disease
induced I None
by I None
combinations I None
of I None
ketamine I Chemical
and I None
morphine I Chemical
: I None
potentiation I None
, I None
antagonism I None
, I None
tolerance I None
and I None
cross I None
- I None
tolerance I None
in I None
the I None
rat I None
. I None
<eof> I None

<s> O None
Previous I None
studies I None
demonstrated I None
that I None
both I None
ketamine I Chemical
and I None
morphine I Chemical
induced I None
analgesia I Disease
and I None
catalepsy I Disease
in I None
the I None
rat I None
. I None
<eof> I None

<s> O None
Pre I None
- I None
treatment I None
with I None
ketamine I Chemical
produced I None
cross I None
- I None
tolerance I None
to I None
morphine I Chemical
, I None
whereas I None
pretreatment I None
with I None
morphine I Chemical
did I None
not I None
induce I None
cross I None
- I None
tolerance I None
to I None
ketamine I Chemical
but I None
rather I None
augmented I None
the I None
cataleptic I Disease
response I None
; I None
this I None
augmentation I None
was I None
attributed I None
to I None
residual I None
morphine I Chemical
in I None
the I None
brain I None
. I None
<eof> I None

<s> O None
The I None
present I None
studies I None
explored I None
the I None
duration I None
of I None
the I None
loss I None
of I None
righting I None
reflex I None
induced I None
by I None
sub I None
- I None
effective I None
doses I None
of I None
ketamine I Chemical
and I None
morphine I Chemical
, I None
administered I None
simultaneously I None
. I None
<eof> I None

<s> O None
There I None
was I None
mutual I None
potentiation I None
between I None
sub I None
- I None
effective I None
doses I None
of I None
ketamine I Chemical
and I None
morphine I Chemical
, I None
but I None
sub I None
- I None
effective I None
doses I None
of I None
ketamine I Chemical
partly I None
antagonized I None
fully I None
- I None
effective I None
doses I None
of I None
morphine I Chemical
. I None
<eof> I None

<s> O None
Latency I None
to I None
the I None
loss I None
of I None
righting I None
reflex I None
, I None
rigidity I Disease
and I None
behavior I None
on I None
recovery I None
, I None
reflected I None
the I None
relative I None
predominance I None
of I None
ketamine I Chemical
or I None
morphine I Chemical
in I None
each I None
combination I None
. I None
<eof> I None

<s> O None
Naloxone I Chemical
inhibited I None
the I None
induced I None
cataleptic I Disease
effects I None
. I None
<eof> I None

<s> O None
The I None
degree I None
and I None
time I None
course I None
of I None
development I None
of I None
tolerance I None
to I None
daily I None
administration I None
of I None
sub I None
- I None
effective I None
dose I None
combinations I None
of I None
ketamine I Chemical
and I None
morphine I Chemical
were I None
similar I None
. I None
<eof> I None

<s> O None
Rats I None
, I None
tolerant I None
to I None
ketamine I Chemical
-dominant I None
combinations I None
, I None
were I None
cross I None
- I None
tolerant I None
to I None
both I None
drugs I None
, I None
while I None
those I None
tolerant I None
to I None
<eof> I None

<s> O None
morphine I Chemical
-dominant I None
combinations I None
were I None
cross I None
- I None
tolerant I None
to I None
morphine I Chemical
but I None
showed I None
either I None
no I None
cross I None
- I None
tolerance I None
or I None
an I None
augmented I None
response I None
to I None
ketamine I Chemical
. I None
<eof> I None

<s> O None
While I None
the I None
mutual I None
potentiation I None
, I None
antagonism I None
and I None
tolerance I None
suggest I None
common I None
mechanisms I None
for I None
the I None
induced I None
catalepsy I Disease
, I None
differences I None
in I None
latency I None
, I None
rigidity I Disease
and I None
behavior I None
, I None
asymmetry I None
of I None
cross I None
- I None
tolerance I None
and I None
a I None
widely I None
- I None
different I None
ID50 I None
for I None
<eof> I None

<s> O None
naloxone I Chemical
would I None
argue I None
against I None
an I None
action I None
at I None
a I None
single I None
opioid I None
site I None
. I None
<eof> I None

<s> O None
Acute I Disease
renal O Disease
failure O Disease
in I None
patients I None
with I None
AIDS I Disease
on I None
tenofovir I Chemical
while I None
receiving I None
prolonged I None
vancomycin I Chemical
course I None
for I None
osteomyelitis I Disease
. I None
<eof> I None

<s> O None
Renal I Disease
failure O Disease
developed I None
after I None
a I None
prolonged I None
course I None
of I None
vancomycin I Chemical
therapy I None
in I None
2 I None
patients I None
who I None
were I None
receiving I None
tenofovir I Chemical
disoproxil O Chemical
fumarate O Chemical
as I None
part I None
of I None
an I None
antiretroviral I None
regimen I None
. I None
<eof> I None

<s> O None
Tenofovir I Chemical
has I None
been I None
implicated I None
in I None
the I None
development I None
of I None
Fanconi I Disease
syndrome O Disease
and I None
renal I Disease
insufficiency O Disease
because I None
of I None
its I None
effects I None
on I None
the I None
proximal I None
renal I None
tubule I None
. I None
<eof> I None

<s> O None
Vancomycin I Chemical
<eof> I None

<s> O None
nephrotoxicity I Disease
is I None
infrequent I None
but I None
may I None
result I None
from I None
coadministration I None
with I None
a I None
nephrotoxic I Disease
agent I None
. I None
<eof> I None

<s> O None
Clinicians I None
should I None
be I None
aware I None
that I None
tenofovir I Chemical
may I None
raise I None
the I None
risk I None
of I None
renal I Disease
failure O Disease
during I None
prolonged I None
administration I None
of I None
vancomycin I Chemical
. I None
<eof> I None

<s> O None
Delayed I None
leukoencephalopathy I Disease
with I None
<eof> I None

<s> O None
stroke I Disease
-like I None
presentation I None
in I None
chemotherapy I None
recipients I None
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
<eof> I None

<s> O None
A I None
transient I None
leukoencephalopathy I Disease
mimicking I None
<eof> I None

<s> O None
cerebrovascular I Disease
accident O Disease
has I None
been I None
described I None
as I None
a I None
complication I None
of I None
chemotherapy I None
, I None
most I None
commonly I None
in I None
recipients I None
of I None
intrathecal I None
methotrexate I Chemical
for I None
childhood I None
leukaemia I Disease
. I None
<eof> I None

<s> O None
Recently I None
published I None
neuroimaging I None
data I None
suggest I None
a I None
common I None
pathophysiology I None
associated I None
with I None
a I None
variety I None
of I None
chemotherapy I None
agents I None
and I None
modes I None
of I None
administration I None
. I None
<eof> I None

<s> O None
METHODS I None
: I None
<eof> I None

<s> O None
We I None
reviewed I None
the I None
medical I None
literature I None
for I None
single I None
reports I None
and I None
case I None
series I None
of I None
patients I None
presenting I None
with I None
<eof> I None

<s> O None
stroke I Disease
-like I None
episodes I None
while I None
receiving I None
systemic I None
or I None
intrathecal I None
chemotherapy I None
. I None
<eof> I None

<s> O None
We I None
only I None
included I None
studies I None
providing I None
detailed I None
neuroimaging I None
data I None
. I None
<eof> I None

<s> O None
Patients I None
with I None
cerebrovascular I Disease
accidents O Disease
were I None
excluded I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
We I None
identified I None
27 I None
reports I None
of I None
toxic I None
leukoencephalopathy I Disease
in I None
patients I None
treated I None
with I None
methotrexate I Chemical
( I None
intrathecal I None
, I None
systemic I None
) I None
, I None
5-fluorouracil I Chemical
and I None
its I None
derivative I None
carmofur I Chemical
, I None
and I None
capecitabine I Chemical
. I None
<eof> I None

<s> O None
Diffusion I None
weighted I None
imaging I None
( I None
DWI I None
) I None
of I None
all I None
patients I None
revealed I None
well I None
demarcated I None
hyperintense I None
lesions I Disease
within O Disease
the O Disease
subcortical O Disease
white O Disease
matter O Disease
of I None
the I None
cerebral I None
hemispheres I None
and I None
the I None
corpus I None
callosum I None
, I None
corresponding I None
to I None
areas I None
of I None
decreased I None
proton I None
diffusion I None
on I None
apparent I None
diffusion I None
coefficient I None
( I None
ADC I None
) I None
maps I None
( I None
available I None
in I None
21/27 I None
patients I None
) I None
. I None
<eof> I None

<s> O None
Lesions I None
exceeded I None
the I None
confines I None
of I None
adjacent I None
vascular I None
territories I None
. I None
<eof> I None

<s> O None
Complete I None
resolution I None
of I None
symptoms I None
within I None
1 I None
- I None
4 I None
days I None
was I None
accompanied I None
by I None
normalisation I None
of I None
ADC I None
abnormalities I None
. I None
<eof> I None

<s> O None
However I None
, I None
fluid I None
attenuated I None
inversion I None
recovery I None
( I None
FLAIR I None
) I None
sequences I None
frequently I None
revealed I None
persistent I None
white I Disease
matter O Disease
abnormalities O Disease
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
Several I None
pathophysiological I None
models I None
of I None
delayed I None
leukoencephalopathy I Disease
after I None
exposure I None
to I None
intrathecal I None
or I None
systemic I None
chemotherapy I None
have I None
been I None
proposed I None
. I None
<eof> I None

<s> O None
DWI I None
findings I None
in I None
this I None
cohort I None
are I None
indicative I None
of I None
cytotoxic I Disease
oedema O Disease
within O Disease
cerebral O Disease
white O Disease
matter O Disease
and I None
lend I None
support I None
to I None
an I None
at I None
least I None
partially I None
reversible I None
metabolic I None
derangement I None
as I None
the I None
basis I None
for I None
this I None
syndrome I None
. I None
<eof> I None

<s> O None
Down I None
- I None
regulation I None
of I None
norepinephrine I Chemical
transporter I None
function I None
induced I None
by I None
chronic I None
administration I None
of I None
desipramine I Chemical
linking I None
to I None
the I None
alteration I None
of I None
sensitivity I None
of I None
local I None
- I None
anesthetics I None
- I None
induced I None
convulsions I Disease
and I None
the I None
counteraction I None
by I None
co I None
- I None
administration I None
with I None
local I None
anesthetics I None
. I None
<eof> I None

<s> O None
Alterations I None
of I None
norepinephrine I Chemical
transporter I None
( I None
NET I None
) I None
function I None
by I None
chronic I None
inhibition I None
of I None
NET I None
in I None
relation I None
to I None
sensitization I None
to I None
<eof> I None

<s> O None
seizures I Disease
induce I None
by I None
cocaine I Chemical
and I None
local I None
anesthetics I None
were I None
studied I None
in I None
mice I None
. I None
<eof> I None

<s> O None
Daily I None
administration I None
of I None
desipramine I Chemical
, I None
an I None
inhibitor I None
of I None
the I None
NET I None
, I None
for I None
5 I None
days I None
decreased I None
[ I None
( I None
3)H I None
] I None
norepinephrine I Chemical
uptake I None
in I None
the I None
P2 I None
fractions I None
of I None
hippocampus I None
but I None
not I None
cortex I None
, I None
striatum I None
or I None
amygdalae I None
. I None
<eof> I None

<s> O None
Co I None
- I None
administration I None
of I None
lidocaine I Chemical
, I None
bupivacaine I Chemical
or I None
tricaine I Chemical
with I None
desipramine I Chemical
reversed I None
this I None
effect I None
. I None
<eof> I None

<s> O None
Daily I None
treatment I None
of I None
cocaine I Chemical
increased I None
[ I None
( I None
3)H I None
] I None
norepinephrine I Chemical
uptake I None
into I None
the I None
hippocampus I None
. I None
<eof> I None

<s> O None
Daily I None
administration I None
of I None
desipramine I Chemical
increased I None
the I None
incidence I None
of I None
appearance I None
of I None
lidocaine I Chemical
-induced I None
<eof> I None

<s> O None
convulsions I Disease
and I None
decreased I None
that I None
of I None
cocaine I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
convulsions I Disease
<eof> I None

<s> O None
. I None
Co I None
- I None
administration I None
of I None
lidocaine I Chemical
with I None
desipramine I Chemical
reversed I None
the I None
changes I None
of I None
convulsive I Disease
activity I None
of I None
lidocaine I Chemical
and I None
cocaine I Chemical
induced I None
by I None
repeated I None
administration I None
of I None
desipramine I Chemical
. I None
<eof> I None

<s> O None
These I None
results I None
suggest I None
that I None
down I None
- I None
regulation I None
of I None
hippocampal I None
NET I None
induced I None
by I None
chronic I None
administration I None
of I None
desipramine I Chemical
may I None
be I None
relevant I None
to I None
desipramine I Chemical
-induced I None
sensitization I None
of I None
lidocaine I Chemical
convulsions I Disease
. I None
<eof> I None

<s> O None
Inhibition I None
of I None
Na I Chemical
( I None
+ I None
) I None
channels I None
by I None
local I None
anesthetics I None
may I None
regulate I None
desipramine I Chemical
-induced I None
down I None
- I None
regulation I None
of I None
NET I None
function I None
. I None
<eof> I None

<s> O None
Repeated I None
administration I None
of I None
cocaine I Chemical
induces I None
up I None
- I None
regulation I None
of I None
hippocampal I None
NET I None
function I None
. I None
<eof> I None

<s> O None
Desipramine I Chemical
<eof> I None

<s> O None
-induced I None
sensitization I None
of I None
lidocaine I Chemical
<eof> I None

<s> O None
seizures I Disease
may I None
have I None
a I None
mechanism I None
distinct I None
from I None
kindling I None
resulting I None
from I None
repeated I None
administration I None
of I None
cocaine I Chemical
. I None
<eof> I None

<s> O None
Definition I None
and I None
management I None
of I None
anemia I Disease
in I None
patients I None
infected I Disease
with O Disease
hepatitis O Disease
C O Disease
virus O Disease
. I None
<eof> I None

<s> O None
Chronic I Disease
infection O Disease
with O Disease
hepatitis O Disease
C O Disease
virus O Disease
( I None
HCV I None
) I None
can I None
progress I None
to I None
cirrhosis I Disease
, I None
hepatocellular I Disease
carcinoma O Disease
, I None
and I None
end I Disease
- O Disease
stage O Disease
liver O Disease
disease O Disease
. I None
<eof> I None

<s> O None
The I None
current I None
best I None
treatment I None
for I None
HCV I Disease
infection O Disease
is I None
combination I None
therapy I None
with I None
pegylated I None
interferon I Chemical
and I None
ribavirin I Chemical
. I None
<eof> I None

<s> O None
Although I None
this I None
regimen I None
produces I None
sustained I None
virologic I None
responses I None
( I None
SVRs I None
) I None
in I None
approximately I None
50 I None
% I None
of I None
patients I None
, I None
it I None
can I None
be I None
associated I None
with I None
a I None
potentially I None
dose I None
- I None
limiting I None
hemolytic I Disease
anemia O Disease
. I None
<eof> I None

<s> O None
Hemoglobin I None
concentrations I None
decrease I None
mainly I None
as I None
a I None
result I None
of I None
ribavirin I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
hemolysis I Disease
, I None
and I None
this I None
anemia I Disease
can I None
be I None
problematic I None
in I None
patients I None
with I None
HCV I Disease
infection O Disease
, I None
especially I None
those I None
who I None
have I None
comorbid I None
renal I None
or I None
cardiovascular I None
disorders I None
. I None
<eof> I None

<s> O None
In I None
general I None
, I None
anemia I Disease
can I None
increase I None
the I None
risk I None
of I None
morbidity I None
and I None
mortality I None
, I None
and I None
may I None
have I None
negative I None
effects I None
on I None
cerebral I None
function I None
and I None
quality I None
of I None
life I None
. I None
<eof> I None

<s> O None
Although I None
ribavirin I Chemical
-associated I None
anemia I Disease
can I None
be I None
reversed I None
by I None
dose I None
reduction I None
or I None
discontinuation I None
, I None
this I None
approach I None
compromises I None
outcomes I None
by I None
significantly I None
decreasing I None
SVR I None
rates I None
. I None
<eof> I None

<s> O None
Recombinant I None
human I None
erythropoietin I None
has I None
been I None
used I None
to I None
manage I None
ribavirin I Chemical
<eof> I None

<s> O None
-associated I None
<eof> I None

<s> O None
anemia I Disease
but I None
has I None
other I None
potential I None
disadvantages I None
. I None
<eof> I None

<s> O None
Viramidine I Chemical
, I None
a I None
liver I None
- I None
targeting I None
prodrug I None
of I None
ribavirin I Chemical
, I None
has I None
the I None
potential I None
to I None
maintain I None
the I None
virologic I None
efficacy I None
of I None
ribavirin I Chemical
while I None
decreasing I None
the I None
risk I None
of I None
hemolytic I Disease
anemia O Disease
in I None
patients I None
with I None
chronic I Disease
hepatitis O Disease
C O Disease
. I None
<eof> I None

<s> O None
Calcium I Chemical
carbonate O Chemical
<eof> I None

<s> O None
toxicity I Disease
: I None
the I None
updated I None
milk I Disease
- O Disease
alkali O Disease
syndrome O Disease
; I None
report I None
of I None
3 I None
cases I None
and I None
review I None
of I None
the I None
literature I None
. I None
<eof> I None

<s> O None
OBJECTIVE I None
: I None
<eof> I None

<s> O None
To I None
describe I None
3 I None
patients I None
with I None
calcium I Chemical
carbonate O Chemical
-induced I None
hypercalcemia I Disease
and I None
gain I None
insights I None
into I None
the I None
cause I None
and I None
management I None
of I None
the I None
milk I Disease
- O Disease
alkali O Disease
syndrome O Disease
. I None
<eof> I None

<s> O None
METHODS I None
: I None
<eof> I None

<s> O None
We I None
report I None
the I None
clinical I None
and I None
laboratory I None
data I None
in I None
3 I None
patients I None
who I None
presented I None
with I None
severe I None
hypercalcemia I Disease
( I None
corrected I None
serum I None
calcium I Chemical
> I None
or I None
= I None
14 I None
mg I None
/ I None
dL I None
) I None
and I None
review I None
the I None
pertinent I None
literature I None
on I None
milk I Disease
- O Disease
alkali O Disease
syndrome O Disease
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
The I None
3 I None
patients I None
had I None
acute I Disease
renal O Disease
insufficiency O Disease
, I None
relative I None
metabolic I Disease
alkalosis O Disease
, I None
and I None
low I None
parathyroid I None
hormone I None
( I None
PTH I None
) I None
, I None
PTH I None
- I None
related I None
peptide I None
, I None
and I None
1,25-dihydroxyvitamin I Chemical
D O Chemical
concentrations I None
. I None
<eof> I None

<s> O None
No I None
malignant I None
lesion I None
was I None
found I None
. I None
<eof> I None

<s> O None
Treatment I None
included I None
aggressive I None
hydration I None
and I None
varied I None
amounts I None
of I None
furosemide I Chemical
. I None
<eof> I None

<s> O None
The I None
2 I None
patients I None
with I None
the I None
higher I None
serum I None
<eof> I None

<s> O None
calcium I Chemical
concentrations I None
received I None
pamidronate I Chemical
intravenously I None
( I None
60 I None
and I None
30 I None
mg I None
, I None
respectively I None
) I None
, I None
which I None
caused I None
severe I None
hypocalcemia I Disease
. I None
<eof> I None

<s> O None
Of I None
the I None
3 I None
patients I None
, I None
2 I None
were I None
ingesting I None
acceptable I None
doses I None
of I None
elemental I None
calcium I Chemical
( I None
1 I None
g I None
and I None
2 I None
g I None
daily I None
, I None
respectively I None
) I None
in I None
the I None
form I None
of I None
calcium I Chemical
carbonate O Chemical
. I None
<eof> I None

<s> O None
In I None
addition I None
to I None
our I None
highlighted I None
cases I None
, I None
we I None
review I None
the I None
history I None
, I None
classification I None
, I None
pathophysiologic I None
features I None
, I None
and I None
treatment I None
of I None
milk I Disease
- O Disease
alkali O Disease
syndrome O Disease
and I None
summarize I None
the I None
cases I None
reported I None
from I None
early I None
1995 I None
to I None
November I None
2003 I None
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
<eof> I None

<s> O None
Milk I Disease
- O Disease
alkali O Disease
syndrome O Disease
may I None
be I None
a I None
common I None
cause I None
of I None
unexplained I None
hypercalcemia I Disease
and I None
can I None
be I None
precipitated I None
by I None
small I None
amounts I None
of I None
orally I None
ingested I None
calcium I Chemical
carbonate O Chemical
in I None
susceptible I None
persons I None
. I None
<eof> I None

<s> O None
Treatment I None
with I None
hydration I None
, I None
furosemide I Chemical
, I None
and I None
discontinuation I None
of I None
the I None
calcium I Chemical
and I None
vitamin I Chemical
D O Chemical
source I None
is I None
adequate I None
. I None
<eof> I None

<s> O None
Pamidronate I Chemical
treatment I None
is I None
associated I None
with I None
considerable I None
risk I None
for I None
hypocalcemia I Disease
, I None
even I None
in I None
cases I None
of I None
initially I None
severe I None
hypercalcemia I Disease
. I None
<eof> I None

<s> O None
Management I None
strategies I None
for I None
ribavirin I Chemical
-induced I None
hemolytic I Disease
anemia O Disease
in I None
the I None
treatment I None
of I None
hepatitis I Disease
C O Disease
: I None
clinical I None
and I None
economic I None
implications I None
. I None
<eof> I None

<s> O None
OBJECTIVES I None
: I None
<eof> I None

<s> O None
Recently I None
published I None
studies I None
have I None
demonstrated I None
increased I None
efficacy I None
and I None
cost I None
- I None
effectiveness I None
of I None
combination I None
therapy I None
with I None
interferon I None
and I None
alpha-2b/ I None
ribavirin I Chemical
compared I None
with I None
interferon I Chemical
- O Chemical
alpha O Chemical
monotherapy I None
in I None
the I None
treatment I None
of I None
chronic I Disease
hepatitis O Disease
C O Disease
<eof> I None

<s> O None
( I None
CHC I Disease
) I None
. I None
<eof> I None

<s> O None
Combination I None
therapy I None
is I None
associated I None
with I None
a I None
clinically I None
important I None
adverse I None
effect I None
: I None
ribavirin I Chemical
-induced I None
hemolytic I Disease
anemia O Disease
<eof> I None

<s> O None
( I None
RIHA I Disease
) I None
. I None
<eof> I None

<s> O None
The I None
objective I None
of I None
this I None
study I None
was I None
to I None
evaluate I None
the I None
direct I None
health I None
- I None
care I None
costs I None
and I None
management I None
of I None
RIHA I Disease
during I None
treatment I None
of I None
CHC I Disease
in I None
a I None
clinical I None
trial I None
setting I None
. I None
<eof> I None

<s> O None
METHODS I None
: I None
<eof> I None

<s> O None
A I None
systematic I None
literature I None
review I None
was I None
conducted I None
to I None
synthesize I None
information I None
on I None
the I None
incidence I None
and I None
management I None
of I None
RIHA I Disease
. I None
<eof> I None

<s> O None
Decision I None
- I None
analytic I None
techniques I None
were I None
used I None
to I None
estimate I None
the I None
cost I None
of I None
treating I None
RIHA I Disease
. I None
<eof> I None

<s> O None
Uncertainty I None
was I None
evaluated I None
using I None
sensitivity I None
analyses I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
RIHA I Disease
, I None
defined I None
as I None
a I None
reduction I None
in I None
hemoglobin I None
to I None
less I None
than I None
100 I None
g I None
/ I None
L I None
, I None
occurs I None
in I None
approximately I None
7 I None
% I None
to I None
9 I None
% I None
of I None
patients I None
treated I None
with I None
combination I None
therapy I None
. I None
<eof> I None

<s> O None
The I None
standard I None
of I None
care I None
for I None
management I None
of I None
RIHA I Disease
is I None
reduction I None
or I None
discontinuation I None
of I None
the I None
ribavirin I Chemical
dosage I None
. I None
<eof> I None

<s> O None
We I None
estimated I None
the I None
direct I None
cost I None
of I None
treating I None
clinically I None
significant I None
RIHA I Disease
to I None
be I None
170 I None
per I None
patient I None
receiving I None
combination I None
therapy I None
per I None
48-week I None
treatment I None
course I None
( I None
range I None
68- I None
692 I None
) I None
. I None
<eof> I None

<s> O None
The I None
results I None
of I None
the I None
one I None
- I None
way I None
sensitivity I None
analyses I None
ranged I None
from I None
57 I None
to I None
317 I None
. I None
<eof> I None

<s> O None
In I None
comparison I None
, I None
the I None
cost I None
of I None
48 I None
weeks I None
of I None
combination I None
therapy I None
is I None
16,459 I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
The I None
direct I None
cost I None
of I None
treating I None
clinically I None
significant I None
RIHA I Disease
is I None
1 I None
% I None
( I None
170/ I None
16,459 I None
) I None
of I None
drug I None
treatment I None
costs I None
. I None
<eof> I None

<s> O None
Questions I None
remain I None
about I None
the I None
optimal I None
dose I None
of I None
ribavirin I Chemical
and I None
the I None
incidence I None
of I None
RIHA I Disease
in I None
a I None
real I None
- I None
world I None
population I None
. I None
<eof> I None

<s> O None
Despite I None
these I None
uncertainties I None
, I None
this I None
initial I None
evaluation I None
of I None
the I None
direct I None
cost I None
of I None
treating I None
RIHA I Disease
provides I None
an I None
estimate I None
of I None
the I None
cost I None
and I None
management I None
implications I None
of I None
this I None
clinically I None
important I None
adverse I None
effect I None
. I None
<eof> I None

<s> O None
Effects I None
of I None
amine I Chemical
pretreatment I None
on I None
ketamine I Chemical
catatonia I Disease
in I None
pinealectomized I None
or I None
hypophysectomized I None
animals I None
. I None
<eof> I None

<s> O None
The I None
present I None
studies I None
were I None
designed I None
to I None
clarify I None
the I None
role I None
of I None
catecholamines I Chemical
and I None
pineal I None
idolamines I None
on I None
ketamine I Chemical
-induced I None
catatonia I Disease
in I None
the I None
intact I None
, I None
pinealectomized I None
or I None
hypophysectomized I None
chick I None
and I None
rat I None
. I None
<eof> I None

<s> O None
In I None
the I None
pinealectomized I None
chick I None
, I None
pretreatment I None
with I None
dopamine I Chemical
increased I None
the I None
duration I None
of I None
catatonia I Disease
<eof> I None

<s> O None
( I None
DOC I None
) I None
after I None
ketamine I Chemical
, I None
but I None
pretreatment I None
with I None
norepinephrine I Chemical
did I None
not I None
. I None
<eof> I None

<s> O None
The I None
pineal I None
indolamines I None
exhibited I None
mixed I None
actions I None
. I None
<eof> I None

<s> O None
Serotonin I Chemical
and I None
N I Chemical
- O Chemical
acetyl O Chemical
serotonin O Chemical
which I None
augmented I None
ketamine I Chemical
DOC I None
, I None
did I None
not I None
do I None
so I None
in I None
the I None
absence I None
of I None
the I None
pineal I None
gland I None
, I None
whereas I None
melatonin I Chemical
potentiated I None
the I None
ketamine I Chemical
DOC I None
in I None
both I None
the I None
intact I None
and I None
pinealectomized I None
chick I None
. I None
<eof> I None

<s> O None
Ketamine I Chemical
was I None
more I None
potent I None
in I None
the I None
hypophysectomized I None
chick I None
and I None
the I None
circadian I None
rhythm I None
noted I None
in I None
the I None
intact I None
chick I None
was I None
absent I None
; I None
furthermore I None
, I None
melatonin I Chemical
did I None
not I None
augment I None
the I None
ketamine I Chemical
DOC I None
whereas I None
dopamine I Chemical
continued I None
to I None
do I None
so I None
. I None
<eof> I None

<s> O None
This I None
study I None
did I None
not I None
demonstrate I None
a I None
species I None
difference I None
regarding I None
the I None
role I None
of I None
the I None
amines I Chemical
on I None
the I None
pineal I None
in I None
spite I None
of I None
the I None
immature I None
blood I None
- I None
brain I None
barrier I None
in I None
the I None
young I None
chick I None
and I None
the I None
intact I None
barrier I None
in I None
the I None
rat I None
. I None
<eof> I None

<s> O None
In I None
addition I None
, I None
these I None
data I None
indicate I None
a I None
direct I None
role I None
of I None
the I None
pituitary I None
in I None
the I None
augmentation I None
of I None
ketamine I Chemical
DOC I None
induced I None
by I None
melatonin I Chemical
. I None
<eof> I None

<s> O None
Furthermore I None
, I None
dopamine I Chemical
appeared I None
to I None
act I None
on I None
systems I None
more I None
closely I None
involved I None
with I None
the I None
induction I None
of I None
ketamine I Chemical
catatonia I Disease
rather I None
than I None
directly I None
on I None
the I None
pituitary I None
. I None
<eof> I None

<s> O None
Multicenter I None
, I None
double I None
- I None
blind I None
, I None
multiple I None
- I None
dose I None
, I None
parallel I None
- I None
groups I None
efficacy I None
and I None
safety I None
trial I None
of I None
azelastine I Chemical
, I None
chlorpheniramine I Chemical
, I None
and I None
placebo I None
in I None
the I None
treatment I None
of I None
spring I Disease
allergic O Disease
rhinitis O Disease
. I None
<eof> I None

<s> O None
Azelastine I Chemical
, I None
a I None
novel I None
antiallergic I None
medication I None
, I None
was I None
compared I None
with I None
chlorpheniramine I Chemical
maleate O Chemical
and I None
placebo I None
for I None
efficacy I None
and I None
safety I None
in I None
the I None
treatment I None
of I None
spring I Disease
allergic O Disease
rhinitis O Disease
in I None
a I None
multicenter I None
, I None
double I None
- I None
blind I None
, I None
multiple I None
- I None
dose I None
, I None
parallel I None
- I None
groups I None
study I None
. I None
<eof> I None

<s> O None
One I None
hundred I None
fifty I None
- I None
five I None
subjects I None
participated I None
. I None
<eof> I None

<s> O None
Subjects I None
ranged I None
in I None
age I None
from I None
18 I None
to I None
60 I None
years I None
of I None
age I None
and I None
had I None
at I None
least I None
a I None
2-year I None
history I None
of I None
spring I Disease
allergic O Disease
rhinitis O Disease
, I None
confirmed I None
by I None
positive I None
skin I None
test I None
to I None
spring I None
aeroallergens I None
. I None
<eof> I None

<s> O None
Medications I None
were I None
given I None
four I None
times I None
daily I None
; I None
the I None
azelastine I Chemical
groups I None
received I None
0.5 I None
, I None
1.0 I None
, I None
or I None
2.0 I None
mg I None
in I None
the I None
morning I None
and I None
evening I None
with I None
placebo I None
in I None
the I None
early I None
and I None
late I None
afternoon I None
; I None
the I None
chlorpheniramine I Chemical
group I None
received I None
4.0 I None
mg I None
four I None
times I None
daily I None
. I None
<eof> I None

<s> O None
Daily I None
subject I None
symptom I None
cards I None
were I None
completed I None
during I None
a I None
screening I None
period I None
to I None
assess I None
pretreatment I None
symptoms I None
and I None
during I None
a I None
4-week I None
treatment I None
period I None
while I None
subjects I None
received I None
study I None
medications I None
. I None
<eof> I None

<s> O None
Individual I None
symptoms I None
, I None
total I None
symptoms I None
, I None
and I None
major I None
symptoms I None
were I None
compared I None
to I None
determine I None
efficacy I None
of I None
medication I None
. I None
<eof> I None

<s> O None
Elicited I None
, I None
volunteered I None
, I None
and I None
observed I None
adverse I None
experiences I None
were I None
recorded I None
for I None
each I None
subject I None
and I None
compared I None
among I None
groups I None
. I None
<eof> I None

<s> O None
Vital I None
signs I None
, I None
body I None
weights I None
, I None
serum I None
chemistry I None
values I None
, I None
complete I None
blood I None
cell I None
counts I None
, I None
urine I None
studies I None
, I None
and I None
electrocardiograms I None
were I None
obtained I None
for I None
each I None
subject I None
and I None
compared I None
among I None
groups I None
. I None
<eof> I None

<s> O None
Symptoms I None
relief I None
in I None
the I None
group I None
receiving I None
the I None
highest I None
concentration I None
of I None
azelastine I Chemical
<eof> I None

<s> O None
( I None
2.0 I None
mg I None
twice I None
daily I None
) I None
was I None
statistically I None
greater I None
than I None
in I None
the I None
placebo I None
group I None
during I None
all I None
weeks I None
of I None
the I None
study I None
. I None
<eof> I None

<s> O None
Lower I None
doses I None
of I None
azelastine I Chemical
were I None
statistically I None
more I None
effective I None
than I None
placebo I None
only I None
during I None
portions I None
of I None
the I None
first I None
3 I None
weeks I None
of I None
the I None
study I None
. I None
<eof> I None

<s> O None
In I None
contrast I None
, I None
although I None
the I None
chlorpheniramine I Chemical
group I None
did I None
have I None
fewer I None
symptoms I None
than I None
the I None
placebo I None
group I None
during I None
the I None
study I None
, I None
the I None
difference I None
never I None
reached I None
statistical I None
significance I None
during I None
any I None
week I None
of I None
the I None
study I None
. I None
<eof> I None

<s> O None
There I None
were I None
no I None
serious I None
side I None
effects I None
in I None
any I None
of I None
the I None
treatment I None
groups I None
. I None
<eof> I None

<s> O None
Drowsiness I Disease
and I None
altered I Disease
taste O Disease
perception O Disease
were I None
increased I None
significantly I None
over I None
placebo I None
only I None
in I None
the I None
high I None
- I None
dose I None
azelastine I Chemical
group I None
. I None
<eof> I None

<s> O None
Azelastine I Chemical
appears I None
to I None
be I None
a I None
safe I None
, I None
efficacious I None
medication I None
for I None
seasonal I Disease
allergic O Disease
rhinitis O Disease
. I None
<eof> I None

<s> O None
Obsolete I None
but I None
dangerous I None
antacid I None
preparations I None
. I None
<eof> I None

<s> O None
One I None
case I None
of I None
acute I None
hypercalcaemia I Disease
and I None
two I None
of I None
recurrent I None
nephrolithiasis I Disease
are I None
reported I None
in I None
patients I None
who I None
had I None
regularly I None
consumed I None
large I None
amounts I None
of I None
calcium I Chemical
carbon O Chemical
- O Chemical
ate O Chemical
- I None
sodium I Chemical
bicarbonate O Chemical
powders I None
for I None
more I None
than I None
20 I None
years I None
. I None
<eof> I None

<s> O None
The I None
powders I None
had I None
been I None
obtained I None
from I None
pharmacists I None
unknown I None
to I None
the I None
patients I None
' I None
medical I None
practitioners I None
. I None
<eof> I None

<s> O None
It I None
is I None
suggested I None
that I None
these I None
preparations I None
were I None
responsible I None
for I None
the I None
patient I None
's I None
problems I None
, I None
and I None
that I None
such I None
powders I None
should I None
no I None
longer I None
be I None
freely I None
obtainable I None
. I None
<eof> I None

<s> O None
Prolonged I None
paralysis I Disease
due I None
to I None
nondepolarizing I Chemical
neuromuscular O Chemical
blocking O Chemical
agents O Chemical
and I None
corticosteroids I Chemical
. I None
<eof> I None

<s> O None
The I None
long I None
- I None
term I None
use I None
of I None
nondepolarizing I Chemical
neuromuscular O Chemical
blocking O Chemical
agents O Chemical
<eof> I None

<s> O None
( I None
ND I Chemical
- O Chemical
NMBA O Chemical
) I None
has I None
recently I None
been I None
implicated I None
as I None
a I None
cause I None
of I None
prolonged I None
muscle I Disease
weakness O Disease
, I None
although I None
the I None
site I None
of I None
the I None
lesion I None
and I None
the I None
predisposing I None
factors I None
have I None
been I None
unclear I None
. I None
<eof> I None

<s> O None
We I None
report I None
3 I None
patients I None
( I None
age I None
37 I None
- I None
52 I None
years I None
) I None
with I None
acute I None
respiratory I Disease
insufficiency O Disease
who I None
developed I None
prolonged I None
weakness I Disease
following I None
the I None
discontinuation I None
of I None
ND I Chemical
- O Chemical
NMBAs O Chemical
. I None
<eof> I None

<s> O None
Two I None
patients I None
also I None
received I None
intravenous I None
corticosteroids I Chemical
. I None
<eof> I None

<s> O None
Renal I None
function I None
was I None
normal I None
but I None
hepatic I None
function I None
was I None
impaired I None
in I None
all I None
patients I None
, I None
and I None
all I None
had I None
acidosis I Disease
. I None
<eof> I None

<s> O None
Electrophysiologic I None
studies I None
revealed I None
low I None
amplitude I None
compound I None
motor I None
action I None
potentials I None
, I None
normal I None
sensory I None
studies I None
, I None
and I None
fibrillations I None
. I None
<eof> I None

<s> O None
Repetitive I None
stimulation I None
at I None
2 I None
Hz I None
showed I None
a I None
decremental I None
response I None
in I None
2 I None
patients I None
. I None
<eof> I None

<s> O None
The I None
serum I None
vecuronium I Chemical
level I None
measured I None
in I None
1 I None
patient I None
14 I None
days I None
after I None
the I None
drug I None
had I None
been I None
discontinued I None
was I None
172 I None
ng I None
/ I None
mL. I None
A I None
muscle I None
biopsy I None
in I None
this I None
patient I None
showed I None
loss I Disease
of O Disease
thick O Disease
, O Disease
myosin O Disease
filaments O Disease
. I None
<eof> I None

<s> O None
The I None
weakness I Disease
in I None
these I None
patients I None
is I None
due I None
to I None
pathology I Disease
at O Disease
both O Disease
the O Disease
neuromuscular O Disease
junction O Disease
<eof> I None

<s> O None
( I None
most I None
likely I None
due I None
to I None
ND I Chemical
- O Chemical
NMBA O Chemical
) I None
and I None
muscle I None
( I None
most I None
likely I None
due I None
to I None
corticosteroids I Chemical
) I None
. I None
<eof> I None

<s> O None
Hepatic I Disease
dysfunction O Disease
and I None
acidosis I Disease
are I None
contributing I None
risk I None
factors I None
. I None
<eof> I None

<s> O None
Prostaglandin I Chemical
E2 O Chemical
-induced I None
bladder I Disease
hyperactivity O Disease
in I None
normal I None
, I None
conscious I None
rats I None
: I None
involvement I None
of I None
tachykinins I Chemical
? I None
<eof> I None

<s> O None
In I None
normal I None
conscious I None
rats I None
investigated I None
by I None
continuous I None
cystometry I None
, I None
intravesically I None
instilled I None
prostaglandin I Chemical
( O Chemical
PG O Chemical
) O Chemical
E2 O Chemical
<eof> I None

<s> O None
facilitated I None
micturition I None
and I None
increased I None
basal I None
intravesical I None
pressure I None
. I None
<eof> I None

<s> O None
The I None
effect I None
was I None
attenuated I None
by I None
both I None
the I None
NK1 I None
receptor I None
selective I None
antagonist I None
RP I Chemical
67,580 O Chemical
and I None
the I None
NK2 I None
receptor I None
selective I None
antagonist I None
SR I Chemical
48,968 O Chemical
, I None
given I None
intra I None
- I None
arterially I None
, I None
suggesting I None
that I None
it I None
was I None
mediated I None
by I None
stimulation I None
of I None
both I None
NK1 I None
and I None
NK2 I None
receptors I None
. I None
<eof> I None

<s> O None
Intra I None
- I None
<eof> I None

<s> O None
arterially I None
given I None
PGE2 I Chemical
produced I None
a I None
distinct I None
increase I None
in I None
bladder I None
pressure I None
before I None
initiating I None
a I None
micturition I None
reflex I None
, I None
indicating I None
that I None
the I None
PG I Chemical
had I None
a I None
direct I None
contractant I None
effect I None
on I None
the I None
detrusor I None
smooth I None
muscle I None
. I None
<eof> I None

<s> O None
The I None
effect I None
of I None
intra I None
- I None
arterial I None
PGE2 I Chemical
could I None
not I None
be I None
blocked I None
by I None
intra I None
- I None
arterial I None
RP I Chemical
67,580 O Chemical
or I None
SR I Chemical
48,968 O Chemical
, I None
which I None
opens I None
the I None
possibility I None
that I None
the I None
micturition I None
reflex I None
elicited I None
by I None
intra I None
- I None
arterial I None
PGE2 I Chemical
was I None
mediated I None
by I None
pathways I None
other I None
than I None
the I None
reflex I None
initiated I None
when I None
the I None
PG I Chemical
was I None
given I None
intravesically I None
. I None
<eof> I None

<s> O None
The I None
present I None
results I None
thus I None
suggest I None
that I None
intra I None
- I None
arterial I None
PGE2 I Chemical
, I None
given I None
near I None
the I None
bladder I None
, I None
may I None
initiate I None
micturition I None
in I None
the I None
normal I None
rat I None
chiefly I None
by I None
directly I None
contracting I None
the I None
smooth I None
muscle I None
of I None
the I None
detrusor I None
. I None
<eof> I None

<s> O None
However I None
, I None
when I None
given I None
intravesically I None
, I None
PGE2 I Chemical
may I None
stimulate I None
micturition I None
by I None
releasing I None
tachykinins I Chemical
from I None
nerves I None
in I None
and/or I None
immediately I None
below I None
the I None
urothelium I None
. I None
<eof> I None

<s> O None
These I None
tachykinins I Chemical
, I None
in I None
turn I None
, I None
initiate I None
a I None
micturition I None
reflex I None
by I None
stimulating I None
NK1 I None
and I None
NK2 I None
receptors I None
. I None
<eof> I None

<s> O None
Prostanoids I Chemical
may I None
, I None
via I None
release I None
of I None
tachykinins I Chemical
, I None
contribute I None
to I None
both I None
urge I None
and I None
bladder I Disease
hyperactivity O Disease
seen I None
in I None
inflammatory I None
conditions I None
of I None
the I None
lower I None
urinary I None
tract I None
. I None
<eof> I None

<s> O None
Thiazide I Chemical
diuretics I None
, I None
hypokalemia I Disease
and I None
cardiac I Disease
arrhythmias O Disease
. I None
<eof> I None

<s> O None
Thiazide I Chemical
diuretics I None
are I None
widely I None
accepted I None
as I None
the I None
cornerstone I None
of I None
antihypertensive I None
treatment I None
programs I None
. I None
<eof> I None

<s> O None
Hypokalemia I Disease
is I None
a I None
commonly I None
encountered I None
metabolic I None
consequence I None
of I None
chronic I None
thiazide I Chemical
therapy I None
. I None
<eof> I None

<s> O None
We I None
treated I None
38 I None
patients I None
( I None
22 I None
low I None
renin I None
, I None
16 I None
normal I None
renin I None
) I None
with I None
moderate I None
diastolic I Disease
hypertension O Disease
with I None
hydrochlorothiazide I Chemical
<eof> I None

<s> O None
( I None
HCTC I Chemical
) I None
administered I None
on I None
a I None
twice I None
daily I None
schedule I None
. I None
<eof> I None

<s> O None
Initial I None
dose I None
was I None
50 I None
mg I None
and I None
the I None
dose I None
was I None
increased I None
at I None
monthly I None
intervals I None
to I None
100 I None
mg I None
, I None
150 I None
mg I None
and I None
200 I None
mg I None
daily I None
until I None
blood I None
pressure I None
normalized I None
. I None
<eof> I None

<s> O None
The I None
serum I None
K I Chemical
during I None
the I None
control I None
period I None
was I None
4.5 I None
+ I None
/- I None
<eof> I None

<s> O None
0.2 I None
mEq I None
/ I None
l I None
an I None
on I None
50 I None
, I None
100 I None
, I None
150 I None
and I None
200 I None
mg I None
HCTZ I Chemical
daily I None
3.9 I None
+ I None
/- I None
0.3 I None
, I None
3.4 I None
+ I None
/- I None
0.2 I None
, I None
2.9 I None
+ I None
/- I None
0.2 I None
, I None
and I None
2.4 I None
+ I None
/- I None
<eof> I None

<s> O None
0.3 I None
mEq I None
/ I None
l I None
, I None
respectively I None
. I None
<eof> I None

<s> O None
Corresponding I None
figures I None
for I None
whole I None
body I None
K I Chemical
were I None
4107 I None
+ I None
/- I None
<eof> I None

<s> O None
208 I None
, I None
3722 I None
+ I None
/- I None
319 I None
, I None
3628 I None
+ I None
/- I None
<eof> I None

<s> O None
257 I None
, I None
3551 I None
+ I None
/- I None
336 I None
, I None
and I None
3269 I None
+ I None
<eof> I None

<s> O None
/- I None
380 I None
mEq I None
, I None
respectively I None
. I None
<eof> I None

<s> O None
In I None
13 I None
patients I None
we I None
observed I None
the I None
effects I None
of I None
HCTZ I Chemical
therapy I None
( I None
100 I None
mg I None
daily I None
) I None
on I None
the I None
occurrence I None
of I None
PVC I None
's I None
during I None
rest I None
as I None
well I None
as I None
during I None
static I None
and I None
dynamic I None
exercise I None
. I None
<eof> I None

<s> O None
During I None
rest I None
we I None
observed I None
0.6 I None
+ I None
/- I None
<eof> I None

<s> O None
0.08 I None
PVC I None
beats I None
/ I None
min I None
+ I None
/- I None
SEM I None
and I None
during I None
static I None
and I None
dynamic I None
exercise I None
0.6 I None
+ I None
/- I None
0.06 I None
and I None
0.8 I None
+ I None
/- I None
0.15 I None
, I None
respectively I None
. I None
<eof> I None

<s> O None
Corresponding I None
figures I None
during I None
HCTZ I Chemical
therapy I None
100 I None
mg I None
daily I None
were I None
1.4 I None
+ I None
/- I None
<eof> I None

<s> O None
0.1 I None
, I None
3.6 I None
+ I None
/- I None
0.7 I None
and I None
5.7 I None
<eof> I None

<s> O None
4/- I None
0.8 I None
, I None
respectively I None
. I None
<eof> I None

<s> O None
The I None
occurrence I None
of I None
PVC I None
's I None
correlated I None
significantly I None
with I None
the I None
fall I None
in I None
serum I None
<eof> I None

<s> O None
K I Chemical
+ I None
observed I None
r I None
= I None
0.72 I None
, I None
p I None
less I None
than I None
0.001 I None
. I None
<eof> I None

<s> O None
In I None
conclusion I None
we I None
found I None
that I None
thiazide I Chemical
<eof> I None

<s> O None
diuretics I None
cause I None
<eof> I None

<s> O None
hypokalemia I Disease
and I None
depletion I None
of I None
body I None
potassium I Chemical
. I None
<eof> I None

<s> O None
The I None
more I None
profound I None
hypokalemia I Disease
, I None
the I None
greater I None
the I None
propensity I None
for I None
the I None
occurrence I None
of I None
PVC I None
's I None
. I None
<eof> I None

<s> O None
Diuretics I None
, I None
potassium I Chemical
and I None
arrhythmias I Disease
in I None
hypertensive I Disease
<eof> I None

<s> O None
coronary I Disease
disease O Disease
. I None
<eof> I None

<s> O None
It I None
has I None
been I None
proposed I None
that I None
modest I None
changes I None
in I None
plasma I None
potassium I Chemical
can I None
alter I None
the I None
tendency I None
towards I None
cardiac I Disease
arrhythmias O Disease
. I None
<eof> I None

<s> O None
If I None
this I None
were I None
so I None
, I None
patients I None
with I None
coronary I Disease
artery O Disease
disease O Disease
might I None
be I None
especially I None
susceptible I None
. I None
<eof> I None

<s> O None
Thus I None
, I None
myocardial I None
electrical I None
excitability I None
was I None
measured I None
in I None
patients I None
with I None
mild I None
essential I None
hypertension I Disease
and I None
known I None
coronary I Disease
artery O Disease
disease O Disease
after I None
8 I None
weeks I None
of I None
treatment I None
with I None
a I None
potassium I Chemical
-conserving I None
diuretic I None
( I None
amiloride I Chemical
) I None
and I None
a I None
similar I None
period I None
on I None
a I None
potassium I Chemical
-losing I None
diuretic I None
( I None
chlorthalidone I Chemical
) I None
in I None
a I None
randomised I None
study I None
. I None
<eof> I None

<s> O None
Plasma I None
potassium I Chemical
concentrations I None
were I None
on I None
average I None
1 I None
mmol I None
/ I None
L I None
lower I None
during I None
the I None
chlorthalidone I Chemical
phase I None
compared I None
to I None
amiloride I Chemical
therapy I None
. I None
<eof> I None

<s> O None
Blood I None
pressure I None
and I None
volume I None
states I None
as I None
assessed I None
by I None
bodyweight I None
, I None
plasma I None
renin I None
and I None
noradrenaline I Chemical
( I None
norepinephrine I Chemical
) I None
concentrations I None
were I None
similar I None
on I None
the I None
2 I None
regimens I None
. I None
<eof> I None

<s> O None
Compared I None
to I None
amiloride I Chemical
treatment I None
, I None
the I None
chlorthalidone I Chemical
phase I None
was I None
associated I None
with I None
an I None
increased I None
frequency I None
of I None
ventricular I Disease
ectopic O Disease
beats O Disease
<eof> I None

<s> O None
( I None
24-hour I None
Holter I None
monitoring I None
) I None
and I None
a I None
higher I None
Lown I None
grading I None
, I None
increased I None
upslope I None
and I None
duration I None
of I None
the I None
monophasic I None
action I None
potential I None
, I None
prolonged I None
ventricular I None
effective I None
refractory I None
period I None
, I None
and I None
increased I None
electrical I None
instability I None
during I None
programmed I None
ventricular I None
stimulation I None
. I None
<eof> I None

<s> O None
The I None
above I None
results I None
indicate I None
that I None
because I None
potassium I Chemical
-losing I None
diuretic I None
therapy I None
can I None
increase I None
myocardial I None
electrical I None
excitability I None
in I None
patients I None
with I None
ischaemic I Disease
heart O Disease
disease O Disease
, I None
even I None
minor I None
falls I None
in I None
plasma I None
potassium I Chemical
<eof> I None

<s> O None
concentrations I None
are I None
probably I None
best I None
avoided I None
in I None
such I None
patients I None
. I None
<eof> I None

<s> O None
GABA I Chemical
involvement I None
in I None
naloxone I Chemical
induced I None
reversal I None
of I None
respiratory I Disease
paralysis O Disease
produced I None
by I None
thiopental I Chemical
. I None
<eof> I None

<s> O None
No I None
agent I None
is I None
yet I None
available I None
to I None
reverse I None
respiratory I Disease
paralysis O Disease
produced I None
by I None
CNS I None
depressants I None
, I None
such I None
as I None
general I None
anesthetics I None
. I None
<eof> I None

<s> O None
In I None
this I None
study I None
naloxone I Chemical
reversed I None
<eof> I None

<s> O None
respiratory I Disease
paralysis O Disease
induced I None
by I None
thiopental I Chemical
in I None
rats I None
. I None
<eof> I None

<s> O None
25 I None
mg I None
/ I None
kg I None
, I None
i.v I None
. I None
<eof> I None

<s> O None
thiopental I Chemical
produced I None
anesthesia I None
without I None
altering I None
respiratory I None
rate I None
, I None
increased I None
<eof> I None

<s> O None
GABA I Chemical
, I None
decreased I None
<eof> I None

<s> O None
glutamate I Chemical
, I None
and I None
had I None
no I None
effect I None
on I None
aspartate I Chemical
or I None
glycine I Chemical
levels I None
compared I None
to I None
controls I None
in I None
rat I None
cortex I None
and I None
brain I None
stem I None
. I None
<eof> I None

<s> O None
Pretreatment I None
of I None
rats I None
with I None
thiosemicarbazide I Chemical
for I None
30 I None
minutes I None
abolished I None
the I None
anesthetic I None
action I None
as I None
well I None
as I None
the I None
respiratory I None
depressant I None
action I None
of I None
thiopental I Chemical
. I None
<eof> I None

<s> O None
50 I None
mg I None
/ I None
kg I None
, I None
i.v I None
. I None
<eof> I None

<s> O None
thiopental I Chemical
produced I None
<eof> I None

<s> O None
respiratory I Disease
arrest O Disease
with I None
further I None
increase I None
in I None
GABA I Chemical
and I None
decrease I None
in I None
glutamate I Chemical
again I None
in I None
cortex I None
and I None
brain I None
stem I None
without I None
affecting I None
any I None
of I None
the I None
amino I Chemical
acids O Chemical
studied I None
in I None
four I None
regions I None
of I None
rat I None
brain I None
. I None
<eof> I None

<s> O None
Naloxone I Chemical
( I None
2.5 I None
mg I None
/ I None
kg I None
, I None
i.v I None
. I None
) I None
reversed I None
respiratory I Disease
paralysis O Disease
, I None
glutamate I Chemical
and I None
GABA I Chemical
levels I None
to I None
control I None
values I None
in I None
brain I None
stem I None
and I None
cortex I None
with I None
no I None
changes I None
in I None
caudate I None
or I None
cerebellum I None
. I None
<eof> I None

<s> O None
These I None
data I None
suggest I None
naloxone I Chemical
reverses I None
<eof> I None

<s> O None
respiratory I Disease
paralysis O Disease
produced I None
by I None
thiopental I Chemical
and I None
involves I None
<eof> I None

<s> O None
GABA I Chemical
in I None
its I None
action I None
. I None
<eof> I None

<s> O None
National I None
project I None
on I None
the I None
prevention I None
of I None
mother I None
- I None
to I None
- I None
infant I None
infection I Disease
by O Disease
hepatitis O Disease
B O Disease
virus O Disease
in I None
Japan I None
. I None
<eof> I None

<s> O None
In I None
Japan I None
, I None
a I None
nationwide I None
prevention I None
program I None
against I None
mother I None
- I None
to I None
- I None
infant I None
infection I Disease
by O Disease
hepatitis O Disease
B O Disease
virus O Disease
( I None
HBV I None
) I None
started I None
in I None
1985 I None
. I None
<eof> I None

<s> O None
This I None
program I None
consists I None
of I None
double I None
screenings I None
of I None
pregnant I None
women I None
and I None
prophylactic I None
treatment I None
to I None
the I None
infants I None
born I None
to I None
both I None
hepatitis I Chemical
B O Chemical
surface O Chemical
antigen O Chemical
<eof> I None

<s> O None
( I None
HBsAg I Chemical
) I None
and I None
hepatitis I Chemical
B O Chemical
e O Chemical
antigen O Chemical
<eof> I None

<s> O None
( I None
HBeAg I Chemical
) I None
positive I None
mothers I None
. I None
<eof> I None

<s> O None
These I None
infants I None
are I None
treated I None
with I None
two I None
injections I None
of I None
hepatitis I Disease
B O Disease
immune I None
globulin I None
( I None
HBIG I None
) I None
and I None
at I None
least I None
three I None
injections I None
of I None
plasma I None
derived I None
hepatitis I Chemical
B O Chemical
vaccine O Chemical
. I None
<eof> I None

<s> O None
We I None
sent I None
questionnaires I None
about I None
the I None
numbers I None
of I None
each I None
procedure I None
or I None
examination I None
during I None
nine I None
months I None
of I None
investigation I None
period I None
to I None
each I None
local I None
government I None
in I None
1986 I None
and I None
1987 I None
. I None
<eof> I None

<s> O None
93.4 I None
% I None
pregnant I None
women I None
had I None
the I None
chance I None
to I None
be I None
examined I None
for I None
HBsAg I Chemical
, I None
and I None
the I None
positive I None
rate I None
was I None
1.4 I None
to I None
1.5 I None
% I None
. I None
<eof> I None

<s> O None
The I None
HBeAg I Chemical
positive I None
rate I None
in I None
HBsAg I Chemical
positive I None
was I None
23 I None
to I None
26 I None
% I None
. I None
<eof> I None

<s> O None
The I None
HBsAg I Chemical
positive I None
rate I None
in I None
neonates I None
and I None
in I None
infants I None
before I None
two I None
months I None
were I None
3 I None
% I None
and I None
2 I None
% I None
respectively I None
. I None
<eof> I None

<s> O None
Some I None
problems I None
may I None
arise I None
, I None
because I None
27 I None
to I None
30 I None
% I None
of I None
infants I None
need I None
the I None
fourth I None
vaccination I None
in I None
some I None
restricted I None
areas I None
. I None
<eof> I None

<s> O None
Nociceptive I None
effects I None
induced I None
by I None
intrathecal I None
administration I None
of I None
prostaglandin I None
D2 I None
, I None
E2 I None
, I None
or I None
F2 I None
alpha I None
to I None
conscious I None
mice I None
. I None
<eof> I None

<s> O None
The I None
effects I None
of I None
intrathecal I None
administration I None
of I None
prostaglandins I Chemical
on I None
pain I Disease
responses I None
in I None
conscious I None
mice I None
were I None
evaluated I None
by I None
using I None
hot I None
plate I None
and I None
acetic I Chemical
acid O Chemical
writhing I None
tests I None
. I None
<eof> I None

<s> O None
Prostaglandin I Chemical
D2 O Chemical
( I None
0.5 I None
- I None
3 I None
ng I None
/ I None
mouse I None
) I None
had I None
a I None
hyperalgesic I Disease
action I None
on I None
the I None
response I None
to I None
a I None
hot I None
plate I None
during I None
a I None
3 I None
- I None
60 I None
min I None
period I None
after I None
injection I None
. I None
<eof> I None

<s> O None
Prostaglandin I Chemical
E2 O Chemical
showed I None
a I None
hyperalgesic I Disease
effect I None
at I None
doses I None
of I None
1 I None
pg I Chemical
to I None
10 I None
ng I None
/ I None
mouse I None
, I None
but I None
the I None
effect I None
lasted I None
shorter I None
( I None
3 I None
- I None
30 I None
min I None
) I None
than I None
that I None
of I None
prostaglandin I Chemical
D2 O Chemical
. I None
<eof> I None

<s> O None
Similar I None
results I None
were I None
obtained I None
by I None
acetic I Chemical
acid O Chemical
<eof> I None

<s> O None
writhing I None
tests I None
. I None
<eof> I None

<s> O None
The I None
hyperalgesic I Disease
effect I None
of I None
prostaglandin I Chemical
D2 O Chemical
was I None
blocked I None
by I None
simultaneous I None
injection I None
of I None
a I None
substance I None
P I None
antagonist I None
( I None
greater I None
than I None
or I None
equal I None
to I None
100 I None
ng I None
) I None
but I None
not I None
by I None
AH6809 I Chemical
, I None
a I None
prostanoid I None
EP1-receptor I None
antagonist I None
. I None
<eof> I None

<s> O None
Conversely I None
, I None
prostaglandin I Chemical
E2 O Chemical
-induced I None
<eof> I None

<s> O None
hyperalgesia I Disease
was I None
blocked I None
by I None
AH6809 I Chemical
( I None
greater I None
than I None
or I None
equal I None
to I None
500 I None
ng I None
) I None
but I None
not I None
by I None
the I None
substance I None
P I None
antagonist I None
. I None
<eof> I None

<s> O None
Prostaglandin I Chemical
F2 O Chemical
alpha O Chemical
had I None
little I None
effect I None
on I None
pain I Disease
responses I None
. I None
<eof> I None

<s> O None
These I None
results I None
demonstrate I None
that I None
both I None
prostaglandin I Chemical
D2 O Chemical
and I None
prostaglandin I Chemical
E2 O Chemical
exert I None
hyperalgesia I Disease
in I None
the I None
spinal I None
cord I None
, I None
but I None
in I None
different I None
ways I None
. I None
<eof> I None

<s> O None
Swallowing I None
- I None
induced I None
atrial I Disease
tachyarrhythmia O Disease
triggered I None
by I None
salbutamol I Chemical
: I None
case I None
report I None
and I None
review I None
of I None
the I None
literature I None
. I None
<eof> I None

<s> O None
CASE I None
: I None
<eof> I None

<s> O None
A I None
49-year I None
- I None
old I None
patient I None
experienced I None
chest I None
discomfort I None
while I None
swallowing I None
. I None
<eof> I None

<s> O None
On I None
electrocardiogram I None
, I None
episodes I None
of I None
atrial I Disease
tachyarrhythmia O Disease
were I None
recorded I None
immediately I None
after I None
swallowing I None
; I None
24-hour I None
Holter I None
monitoring I None
recorded I None
several I None
events I None
. I None
<eof> I None

<s> O None
The I None
arrhythmia I Disease
resolved I None
after I None
therapy I None
with I None
atenolol I Chemical
, I None
but I None
recurred I None
a I None
year I None
later I None
. I None
<eof> I None

<s> O None
The I None
patient I None
noticed I None
that I None
before I None
these I None
episodes I None
he I None
had I None
been I None
using I None
an I None
inhalator I None
of I None
salbutamol I Chemical
. I None
<eof> I None

<s> O None
After I None
stopping I None
the I None
beta I None
- I None
agonist I None
, I None
and I None
after I None
a I None
week I None
with I None
the I None
atenolol I Chemical
, I None
the I None
arrhythmia I Disease
disappeared I None
. I None
<eof> I None

<s> O None
DISCUSSION I None
: I None
<eof> I None

<s> O None
Swallowing I None
- I None
induced I None
atrial I Disease
tachyarrhythmia O Disease
<eof> I None

<s> O None
( I None
SIAT I Disease
) I None
is I None
a I None
rare I None
phenomenon I None
. I None
<eof> I None

<s> O None
Fewer I None
than I None
50 I None
cases I None
of I None
SIAT I Disease
have I None
been I None
described I None
in I None
the I None
literature I None
. I None
<eof> I None

<s> O None
This I None
article I None
summarizes I None
all I None
the I None
cases I None
published I None
, I None
creating I None
a I None
comprehensive I None
review I None
of I None
the I None
current I None
knowledge I None
and I None
approach I None
to I None
SIAT I Disease
. I None
<eof> I None

<s> O None
It I None
discusses I None
demographics I None
, I None
clinical I None
characteristics I None
and I None
types I None
of I None
arrhythmia I Disease
, I None
postulated I None
mechanisms I None
of I None
SIAT I Disease
, I None
and I None
different I None
treatment I None
possibilities I None
such I None
as I None
medications I None
, I None
surgery I None
, I None
and I None
radiofrequency I None
catheter I None
ablation I None
( I None
RFCA I None
) I None
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
<eof> I None

<s> O None
Salbutamol I Chemical
is I None
presented I None
here I None
as I None
a I None
possible I None
trigger I None
for I None
SIAT I Disease
. I None
<eof> I None

<s> O None
Although I None
it I None
is I None
difficult I None
to I None
define I None
causality I None
in I None
a I None
case I None
report I None
, I None
it I None
is I None
logical I None
to I None
think I None
that I None
a I None
beta I None
- I None
agonist I None
like I None
salbutamol I Chemical
( I None
known I None
to I None
induce I None
tachycardia I Disease
) I None
may I None
be I None
the I None
trigger I None
of I None
adrenergic I None
reflexes I None
originating I None
in I None
the I None
esophagus I None
while I None
swallowing I None
and I None
that I None
a I None
beta I None
- I None
blocker I None
such I None
as I None
atenolol I Chemical
<eof> I None

<s> O None
( I None
that I None
blocks I None
the I None
adrenergic I None
activity I None
) I None
may I None
relieve I None
it I None
. I None
<eof> I None

<s> O None
Coenzyme I Chemical
Q10 O Chemical
treatment I None
ameliorates I None
acute I None
cisplatin I Chemical
nephrotoxicity I Disease
in I None
mice I None
. I None
<eof> I None

<s> O None
The I None
nephroprotective I None
effect I None
of I None
coenzyme I Chemical
Q10 O Chemical
was I None
investigated I None
in I None
mice I None
with I None
acute I Disease
renal O Disease
injury O Disease
induced I None
by I None
a I None
single I None
i.p I None
. I None
<eof> I None

<s> O None
injection I None
of I None
cisplatin I Chemical
<eof> I None

<s> O None
( I None
5 I None
mg I None
/ I None
kg I None
) I None
. I None
<eof> I None

<s> O None
Coenzyme I Chemical
Q10 O Chemical
treatment I None
( I None
10 I None
mg I None
/ I None
kg I None
/ I None
day I None
, I None
i.p I None
. I None
) I None
was I None
applied I None
for I None
6 I None
consecutive I None
days I None
, I None
starting I None
1 I None
day I None
before I None
cisplatin I Chemical
administration I None
. I None
<eof> I None

<s> O None
Coenzyme I Chemical
Q10 O Chemical
significantly I None
reduced I None
<eof> I None

<s> O None
blood I Chemical
urea O Chemical
nitrogen O Chemical
and I None
serum I None
creatinine I Chemical
levels I None
which I None
were I None
increased I None
by I None
cisplatin I Chemical
. I None
<eof> I None

<s> O None
Coenzyme I Chemical
Q10 O Chemical
significantly I None
compensated I None
deficits I None
in I None
the I None
antioxidant I None
defense I None
mechanisms I None
( I None
reduced I Chemical
glutathione O Chemical
level I None
and I None
superoxide I Chemical
dismutase I None
activity I None
) I None
, I None
suppressed I None
lipid I None
peroxidation I None
, I None
decreased I None
the I None
elevations I None
of I None
tumor I Disease
necrosis I Disease
factor I None
- I None
alpha I None
, I None
nitric I Chemical
oxide O Chemical
and I None
platinum I Chemical
ion I None
concentration I None
, I None
and I None
attenuated I None
the I None
reductions I None
of I None
selenium I Chemical
and I None
zinc I Chemical
ions I None
in I None
renal I None
tissue I None
resulted I None
from I None
cisplatin I Chemical
administration I None
. I None
<eof> I None

<s> O None
Also I None
, I None
histopathological I None
renal I Disease
tissue O Disease
damage O Disease
mediated I None
by I None
cisplatin I Chemical
was I None
ameliorated I None
by I None
coenzyme I Chemical
Q10 O Chemical
treatment I None
. I None
<eof> I None

<s> O None
Immunohistochemical I None
analysis I None
revealed I None
that I None
coenzyme I Chemical
Q10 O Chemical
significantly I None
decreased I None
the I None
cisplatin I Chemical
-induced I None
overexpression I None
of I None
inducible I None
nitric I Chemical
oxide O Chemical
synthase I None
, I None
nuclear I None
factor I None
- I None
kappaB I None
, I None
caspase-3 I None
and I None
p53 I None
in I None
renal I None
tissue I None
. I None
<eof> I None

<s> O None
It I None
was I None
concluded I None
that I None
coenzyme I Chemical
Q10 O Chemical
represents I None
a I None
potential I None
therapeutic I None
option I None
to I None
protect I None
against I None
acute I None
cisplatin I Chemical
nephrotoxicity I Disease
commonly I None
encountered I None
in I None
clinical I None
practice I None
. I None
<eof> I None

<s> O None
Metformin I Chemical
prevents I None
<eof> I None

<s> O None
experimental I None
gentamicin I Chemical
-induced I None
<eof> I None

<s> O None
nephropathy I Disease
by I None
a I None
mitochondria I None
- I None
dependent I None
pathway I None
. I None
<eof> I None

<s> O None
The I None
antidiabetic I None
drug I None
metformin I Chemical
can I None
diminish I None
apoptosis I None
induced I None
by I None
oxidative I None
stress I None
in I None
endothelial I None
cells I None
and I None
prevent I None
vascular I Disease
dysfunction O Disease
even I None
in I None
nondiabetic I None
patients I None
. I None
<eof> I None

<s> O None
Here I None
we I None
tested I None
whether I None
it I None
has I None
a I None
beneficial I None
effect I None
in I None
a I None
rat I None
model I None
of I None
gentamicin I Chemical
toxicity I Disease
. I None
<eof> I None

<s> O None
Mitochondrial I None
analysis I None
, I None
respiration I None
intensity I None
, I None
levels I None
of I None
reactive I None
oxygen I Chemical
species I None
, I None
permeability I None
transition I None
, I None
and I None
cytochrome I None
c I None
release I None
were I None
assessed I None
3 I None
and I None
6 I None
days I None
after I None
gentamicin I Chemical
administration I None
. I None
<eof> I None

<s> O None
Metformin I Chemical
treatment I None
fully I None
blocked I None
<eof> I None

<s> O None
gentamicin I Chemical
-mediated I None
acute I Disease
renal O Disease
failure O Disease
. I None
<eof> I None

<s> O None
This I None
was I None
accompanied I None
by I None
a I None
lower I None
activity I None
of I None
N I None
- I None
acetyl I None
- I None
beta I None
- I None
D I None
- I None
glucosaminidase I None
, I None
together I None
with I None
a I None
decrease I None
of I None
lipid I None
peroxidation I None
and I None
increase I None
of I None
antioxidant I None
systems I None
. I None
<eof> I None

<s> O None
Metformin I Chemical
also I None
protected I None
the I None
kidney I None
from I None
histological I None
damage I None
6 I None
days I None
after I None
gentamicin I Chemical
administration I None
. I None
<eof> I None

<s> O None
These I None
in I None
vivo I None
markers I None
of I None
kidney I Disease
dysfunction O Disease
and I None
their I None
correction I None
by I None
metformin I Chemical
were I None
complemented I None
by I None
in I None
vitro I None
studies I None
of I None
mitochondrial I None
function I None
. I None
<eof> I None

<s> O None
We I None
found I None
that I None
gentamicin I Chemical
treatment I None
depleted I None
respiratory I None
components I None
( I None
cytochrome I None
c I None
, I None
NADH I None
) I None
, I None
probably I None
due I None
to I None
the I None
opening I None
of I None
mitochondrial I None
transition I None
pores I None
. I None
<eof> I None

<s> O None
These I None
injuries I None
, I None
partly I None
mediated I None
by I None
a I None
rise I None
in I None
reactive I None
oxygen I Chemical
species I None
from I None
the I None
electron I None
transfer I None
chain I None
, I None
were I None
significantly I None
decreased I None
by I None
metformin I Chemical
. I None
<eof> I None

<s> O None
Thus I None
, I None
our I None
study I None
suggests I None
that I None
pleiotropic I None
effects I None
of I None
metformin I Chemical
can I None
lessen I None
gentamicin I Chemical
nephrotoxicity I Disease
and I None
improve I None
mitochondrial I None
homeostasis I None
. I None
<eof> I None

<s> O None
Sedation I None
depth I None
during I None
spinal I None
anesthesia I None
and I None
the I None
development I None
of I None
postoperative I None
delirium I None
in I None
elderly I None
patients I None
undergoing I None
hip I Disease
fracture O Disease
repair I None
. I None
<eof> I None

<s> O None
OBJECTIVE I None
: I None
<eof> I None

<s> O None
To I None
determine I None
whether I None
limiting I None
intraoperative I None
sedation I None
depth I None
during I None
spinal I None
anesthesia I None
for I None
hip I Disease
fracture O Disease
repair I None
in I None
elderly I None
patients I None
can I None
decrease I None
the I None
prevalence I None
of I None
postoperative I None
delirium I None
. I None
<eof> I None

<s> O None
PATIENTS I None
AND I None
METHODS I None
: I None
<eof> I None

<s> O None
We I None
performed I None
a I None
double I None
- I None
blind I None
, I None
randomized I None
controlled I None
trial I None
at I None
an I None
academic I None
medical I None
center I None
of I None
elderly I None
patients I None
( I None
> I None
or=65 I None
years I None
) I None
without I None
preoperative I None
delirium I Disease
or I None
severe I None
dementia I Disease
who I None
underwent I None
hip I Disease
fracture O Disease
repair I None
under I None
spinal I None
anesthesia I None
with I None
propofol I Chemical
sedation I None
. I None
<eof> I None

<s> O None
Sedation I None
depth I None
was I None
titrated I None
using I None
processed I None
electroencephalography I None
with I None
the I None
bispectral I None
index I None
( I None
BIS I None
) I None
, I None
and I None
patients I None
were I None
randomized I None
to I None
receive I None
either I None
deep I None
( I None
BIS I None
, I None
approximately I None
50 I None
) I None
or I None
light I None
( I None
BIS I None
, I None
> I None
or=80 I None
) I None
sedation I None
. I None
<eof> I None

<s> O None
Postoperative I None
delirium I None
was I None
assessed I None
as I None
defined I None
by I None
Diagnostic I None
and I None
Statistical I None
Manual I None
of I None
Mental I Disease
Disorders O Disease
<eof> I None

<s> O None
( I None
Third I None
Edition I None
Revised I None
) I None
criteria I None
using I None
the I None
Confusion I None
Assessment I None
Method I None
beginning I None
at I None
any I None
time I None
from I None
the I None
second I None
day I None
after I None
surgery I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
From I None
April I None
2 I None
, I None
2005 I None
, I None
through I None
October I None
30 I None
, I None
2008 I None
, I None
a I None
total I None
of I None
114 I None
patients I None
were I None
randomized I None
. I None
<eof> I None

<s> O None
The I None
prevalence I None
of I None
postoperative I None
delirium I None
was I None
significantly I None
lower I None
in I None
the I None
light I None
sedation I None
group I None
( I None
11/57 I None
[ I None
19 I None
% I None
] I None
vs I None
23/57 I None
[ I None
40 I None
% I None
] I None
in I None
the I None
deep I None
sedation I None
group I None
; I None
P=.02 I None
) I None
, I None
indicating I None
that I None
1 I None
incident I None
of I None
delirium I Disease
will I None
be I None
prevented I None
for I None
every I None
4.7 I None
patients I None
treated I None
with I None
light I None
sedation I None
. I None
<eof> I None

<s> O None
The I None
mean I None
+ I None
/- I None
SD I None
number I None
of I None
days I None
of I None
delirium I Disease
during I None
hospitalization I None
was I None
lower I None
in I None
the I None
light I None
sedation I None
group I None
than I None
in I None
the I None
deep I None
sedation I None
group I None
( I None
0.5+/-1.5 I None
days I None
vs I None
1.4+/-4.0 I None
days I None
; I None
P=.01 I None
) I None
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
<eof> I None

<s> O None
The I None
use I None
of I None
light I None
propofol I Chemical
sedation I None
decreased I None
the I None
prevalence I None
of I None
postoperative I None
delirium I None
by I None
50 I None
% I None
compared I None
with I None
deep I None
sedation I None
. I None
<eof> I None

<s> O None
Limiting I None
depth I None
of I None
sedation I None
during I None
spinal I None
anesthesia I None
is I None
a I None
simple I None
, I None
safe I None
, I None
and I None
cost I None
- I None
effective I None
intervention I None
for I None
preventing I None
postoperative I None
delirium I None
in I None
elderly I None
patients I None
that I None
could I None
be I None
widely I None
and I None
readily I None
adopted I None
. I None
<eof> I None

<s> O None
Sorafenib I Chemical
-induced I None
acute I None
myocardial I Disease
infarction O Disease
due I None
to I None
coronary I Disease
artery O Disease
spasm O Disease
. I None
<eof> I None

<s> O None
A I None
65-year I None
- I None
old I None
man I None
with I None
advanced I None
renal I Disease
cell O Disease
carcinoma O Disease
was I None
admitted I None
due I None
to I None
continuing I None
chest I Disease
pain O Disease
at I None
rest I None
. I None
<eof> I None

<s> O None
Two I None
weeks I None
before I None
his I None
admission I None
, I None
sorafenib I Chemical
had I None
been I None
started I None
. I None
<eof> I None

<s> O None
He I None
was I None
diagnosed I None
with I None
non I None
- I None
ST I None
- I None
elevation I None
myocardial I Disease
infarction O Disease
by I None
laboratory I None
data I None
and I None
electrocardiogram I None
. I None
<eof> I None

<s> O None
Enhanced I None
heart I None
magnetic I None
resonance I None
imaging I None
also I None
showed I None
subendocardial I Disease
infarction O Disease
. I None
<eof> I None

<s> O None
However I None
, I None
there I None
was I None
no I None
stenosis I None
in I None
coronary I None
arteries I None
on I None
angiography I None
. I None
<eof> I None

<s> O None
Coronary I Disease
artery O Disease
spasm O Disease
was I None
induced I None
by I None
a I None
provocative I None
test I None
. I None
<eof> I None

<s> O None
Cessation I None
of I None
sorafenib I Chemical
and I None
administration I None
of I None
Ca I Chemical
-channel I None
blocker I None
and I None
nitrates I Chemical
ameliorated I None
his I None
symptoms I None
, I None
but I None
relapse I None
occurred I None
after I None
resumption I None
of I None
sorafenib I Chemical
. I None
<eof> I None

<s> O None
Addition I None
of I None
oral I None
nicorandil I Chemical
reduced I None
his I None
symptoms I None
and I None
maintained I None
stable I Disease
angina O Disease
status I None
. I None
<eof> I None

<s> O None
We I None
report I None
the I None
first I None
case I None
of I None
sorafenib I Chemical
-induced I None
coronary I Disease
artery O Disease
spasm O Disease
. I None
<eof> I None

<s> O None
Sorafenib I Chemical
is I None
a I None
multikinase I None
inhibitor I None
that I None
targets I None
signaling I None
pathways I None
necessary I None
for I None
cellular I None
proliferation I None
and I None
survival I None
. I None
<eof> I None

<s> O None
On I None
the I None
other I None
hand I None
, I None
the I None
Rho I None
/ I None
ROCK I None
pathway I None
has I None
an I None
important I None
role I None
in I None
the I None
pathogenesis I None
of I None
coronary I Disease
artery O Disease
spasm O Disease
. I None
<eof> I None

<s> O None
Our I None
report I None
may I None
show I None
an I None
adverse I None
effect I None
on I None
the I None
Rho I None
/ I None
ROCK I None
pathway I None
by I None
sorafenib I Chemical
use I None
. I None
<eof> I None

<s> O None
Anxiogenic I None
potential I None
of I None
ciprofloxacin I Chemical
and I None
norfloxacin I Chemical
in I None
rats I None
. I None
<eof> I None

<s> O None
INTRODUCTION I None
: I None
<eof> I None

<s> O None
The I None
possible I None
anxiogenic I None
effects I None
of I None
fluoroquinolones I Chemical
, I None
namely I None
ciprofloxacin I Chemical
and I None
norfloxacin I Chemical
, I None
were I None
investigated I None
in I None
adult I None
Charles I None
Foster I None
albino I None
rats I None
of I None
either I None
sex I None
, I None
weighing I None
150 I None
- I None
200 I None
g. I None
METHODS I None
: I None
<eof> I None

<s> O None
The I None
drugs I None
were I None
given I None
orally I None
, I None
in I None
doses I None
of I None
50 I None
mg I None
/ I None
kg I None
for I None
five I None
consecutive I None
days I None
and I None
the I None
experiments I None
were I None
performed I None
on I None
the I None
fifth I None
day I None
. I None
<eof> I None

<s> O None
The I None
tests I None
included I None
open I None
- I None
field I None
exploratory I None
behaviour I None
, I None
elevated I None
plus I None
maze I None
and I None
elevated I None
zero I None
maze I None
, I None
social I None
interaction I None
and I None
novelty I None
- I None
suppressed I None
feeding I None
latency I None
behaviour I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
The I None
results I None
indicate I None
that I None
ciprofloxacin I Chemical
- I None
and I None
<eof> I None

<s> O None
norfloxacin I Chemical
-treated I None
rats I None
showed I None
<eof> I None

<s> O None
anxious I Disease
behaviour O Disease
in I None
comparison I None
to I None
control I None
rats I None
in I None
all I None
the I None
parameters I None
studied I None
. I None
<eof> I None

<s> O None
However I None
, I None
ciprofloxacin I Chemical
- I None
and I None
norfloxacin I Chemical
-treated I None
rats I None
did I None
not I None
differ I None
significantly I None
from I None
each I None
other I None
in I None
various I None
behavioural I None
parameters I None
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
<eof> I None

<s> O None
The I None
present I None
experimental I None
findings I None
substantiate I None
the I None
clinically I None
observed I None
anxiogenic I None
potential I None
of I None
ciprofloxacin I Chemical
and I None
norfloxacin I Chemical
. I None
<eof> I None

<s> O None
Myocardial I None
Fas I None
ligand I None
expression I None
increases I None
susceptibility I None
to I None
AZT I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
cardiomyopathy I Disease
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
<eof> I None

<s> O None
Dilated I Disease
cardiomyopathy O Disease
<eof> I None

<s> O None
( I None
DCM I Disease
) I None
and I None
myocarditis I Disease
occur I None
in I None
many I None
HIV I Disease
- O Disease
infected O Disease
individuals I None
, I None
resulting I None
in I None
symptomatic I None
heart I Disease
failure O Disease
in I None
up I None
to I None
5 I None
% I None
of I None
patients I None
. I None
<eof> I None

<s> O None
Highly I None
active I None
antiretroviral I None
therapy I None
( I None
HAART I None
) I None
has I None
significantly I None
reduced I None
morbidity I None
and I None
mortality I None
of I None
acquired I Disease
immunodeficiency O Disease
syndrome O Disease
<eof> I None

<s> O None
( I None
AIDS I Disease
) I None
, I None
but I None
has I None
resulted I None
in I None
an I None
increase I None
in I None
cardiac I Disease
and O Disease
skeletal O Disease
myopathies O Disease
. I None
<eof> I None

<s> O None
METHODS I None
AND I None
RESULTS I None
: I None
<eof> I None

<s> O None
In I None
order I None
to I None
investigate I None
whether I None
the I None
HAART I None
component I None
zidovudine I Chemical
<eof> I None

<s> O None
( I None
3'-azido-2',3'-deoxythymidine I Chemical
; I None
AZT I Chemical
) I None
triggers I None
the I None
Fas I None
- I None
dependent I None
cell I None
- I None
death I None
pathway I None
and I None
cause I None
cytoskeletal I None
disruption I None
in I None
a I None
murine I None
model I None
of I None
DCM I Disease
, I None
8-week I None
- I None
old I None
transgenic I None
( I None
expressing I None
Fas I None
ligand I None
in I None
the I None
myocardium I None
: I None
<eof> I None

<s> O None
FasL I None
Tg I None
) I None
and I None
non I None
- I None
transgenic I None
( I None
NTg I None
) I None
mice I None
received I None
water I None
ad I None
libitum I None
containing I None
different I None
concentrations I None
of I None
AZT I Chemical
<eof> I None

<s> O None
( I None
0 I None
, I None
0.07 I None
, I None
0.2 I None
, I None
and I None
0.7 I None
mg I None
/ I None
ml I None
) I None
. I None
<eof> I None

<s> O None
After I None
6 I None
weeks I None
, I None
cardiac I None
function I None
was I None
assessed I None
by I None
echocardiography I None
and I None
morphology I None
was I None
assessed I None
by I None
histopathologic I None
and I None
immunohistochemical I None
methods I None
. I None
<eof> I None

<s> O None
NTg I None
and I None
untreated I None
FasL I None
Tg I None
mice I None
showed I None
little I None
or I None
no I None
change I None
in I None
cardiac I None
structure I None
or I None
function I None
. I None
<eof> I None

<s> O None
In I None
contrast I None
, I None
AZT I Chemical
-treated I None
FasL I None
Tg I None
mice I None
developed I None
cardiac I Disease
dilation O Disease
and I None
depressed I None
cardiac I None
function I None
in I None
a I None
dose I None
- I None
dependent I None
manner I None
, I None
with I None
concomitant I None
inflammatory I None
infiltration I None
of I None
both I None
ventricles I None
. I None
<eof> I None

<s> O None
These I None
changes I None
were I None
associated I None
with I None
an I None
increased I None
sarcolemmal I None
expression I None
of I None
Fas I None
and I None
FasL I None
, I None
as I None
well I None
as I None
increased I None
activation I None
of I None
caspase I None
3 I None
, I None
translocation I None
of I None
calpain I None
1 I None
to I None
the I None
sarcolemma I None
and I None
sarcomere I None
, I None
and I None
increased I None
numbers I None
of I None
cells I None
undergoing I None
apoptosis I None
. I None
<eof> I None

<s> O None
These I None
were I None
associated I None
with I None
changes I None
in I None
dystrophin I None
and I None
cardiac I None
troponin I None
I I None
localization I None
, I None
as I None
well I None
as I None
loss I None
of I None
sarcolemmal I None
integrity I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
The I None
expression I None
of I None
Fas I None
ligand I None
in I None
the I None
myocardium I None
, I None
as I None
identified I None
in I None
HIV I None
- I None
positive I None
patients I None
, I None
might I None
increase I None
the I None
susceptibility I None
to I None
HAART I None
- I None
induced I None
cardiomyopathy I Disease
due I None
to I None
activation I None
of I None
apoptotic I None
pathways I None
, I None
resulting I None
in I None
cardiac I None
dilation I None
and I None
dysfunction I None
. I None
<eof> I None

<s> O None
Valproate I Chemical
-induced I None
chorea I Disease
and I None
encephalopathy I Disease
in I None
atypical I None
nonketotic I Disease
hyperglycinemia O Disease
. I None
<eof> I None

<s> O None
Nonketotic I Disease
hyperglycinemia O Disease
is I None
a I None
disorder I Disease
of O Disease
amino O Disease
acid O Disease
metabolism O Disease
in I None
which I None
a I None
defect I None
in I None
the I None
glycine I Chemical
cleavage I None
system I None
leads I None
to I None
an I None
accumulation I None
of I None
glycine I Chemical
in I None
the I None
brain I None
and I None
other I None
body I None
compartments I None
. I None
<eof> I None

<s> O None
In I None
the I None
classical I None
form I None
it I None
presents I None
as I None
neonatal I None
apnea I Disease
, I None
intractable I None
seizures I Disease
, I None
and I None
hypotonia I Disease
, I None
followed I None
by I None
significant I None
psychomotor I Disease
retardation O Disease
. I None
<eof> I None

<s> O None
An I None
important I None
subset I None
of I None
children I None
with I None
nonketotic I Disease
hyperglycinemia O Disease
are I None
atypical I None
variants I None
who I None
present I None
in I None
a I None
heterogeneous I None
manner I None
. I None
<eof> I None

<s> O None
This I None
report I None
describes I None
a I None
patient I None
with I None
mild I None
language I Disease
delay O Disease
and I None
mental I Disease
retardation O Disease
, I None
who I None
was I None
found I None
to I None
have I None
nonketotic I Disease
hyperglycinemia O Disease
following I None
her I None
presentation I None
with I None
acute I None
encephalopathy I Disease
and I None
chorea I Disease
shortly I None
after I None
initiation I None
of I None
valproate I Chemical
therapy I None
. I None
<eof> I None

<s> O None
Microinjection I None
of I None
ritanserin I Chemical
into I None
the I None
CA1 I None
region I None
of I None
hippocampus I None
improves I None
scopolamine I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
amnesia I Disease
in I None
adult I None
male I None
rats I None
. I None
<eof> I None

<s> O None
The I None
effect I None
of I None
ritanserin I Chemical
<eof> I None

<s> O None
( I None
5-HT2 I None
antagonist I None
) I None
on I None
scopolamine I Chemical
<eof> I None

<s> O None
( I None
muscarinic I None
cholinergic I None
<eof> I None

<s> O None
antagonist)-induced I None
amnesia I Disease
in I None
Morris I None
water I None
maze I None
( I None
MWM I None
) I None
was I None
investigated I None
. I None
<eof> I None

<s> O None
Rats I None
were I None
divided I None
into I None
eight I None
groups I None
and I None
bilaterally I None
cannulated I None
into I None
CA1 I None
region I None
of I None
the I None
hippocampus I None
. I None
<eof> I None

<s> O None
One I None
week I None
later I None
, I None
they I None
received I None
repeatedly I None
vehicles I None
( I None
saline I None
, I None
DMSO I Chemical
, I None
saline+ I None
DMSO I Chemical
) I None
, I None
scopolamine I Chemical
<eof> I None

<s> O None
( I None
2 I None
microg/0.5 I None
microl I None
saline I None
/ I None
side I None
; I None
30 I None
min I None
before I None
training I None
) I None
, I None
ritanserin I Chemical
( I None
2 I None
, I None
4 I None
and I None
8 I None
microg/0.5 I None
microl I None
<eof> I None

<s> O None
DMSO I Chemical
/side I None
; I None
20 I None
min I None
before I None
training I None
) I None
and I None
scopolamine I Chemical
<eof> I None

<s> O None
( I None
2 I None
microg/0.5 I None
microl I None
; I None
30 I None
min I None
before I None
ritanserin I Chemical
<eof> I None

<s> O None
injection)+ I None
ritanserin I Chemical
<eof> I None

<s> O None
( I None
4 I None
microg/0.5 I None
microl I None
DMSO I Chemical
) I None
through I None
cannulae I None
each I None
day I None
. I None
<eof> I None

<s> O None
Animals I None
were I None
tested I None
for I None
four I None
consecutive I None
days I None
( I None
4 I None
trial I None
/ I None
day I None
) I None
in I None
MWM I None
during I None
which I None
the I None
position I None
of I None
hidden I None
platform I None
was I None
unchanged I None
. I None
<eof> I None

<s> O None
In I None
the I None
fifth I None
day I None
, I None
the I None
platform I None
was I None
elevated I None
above I None
the I None
water I None
surface I None
in I None
another I None
position I None
to I None
evaluate I None
the I None
function I None
of I None
motor I None
, I None
motivational I None
and I None
visual I None
systems I None
. I None
<eof> I None

<s> O None
The I None
results I None
showed I None
a I None
significant I None
increase I None
in I None
escape I None
latencies I None
and I None
traveled I None
distances I None
to I None
find I None
platform I None
in I None
scopolamine I Chemical
-treated I None
group I None
as I None
compared I None
to I None
saline I None
group I None
. I None
<eof> I None

<s> O None
Ritanserin I Chemical
-treated I None
rats I None
( I None
4 I None
microg/0.5 I None
microl I None
/ I None
side I None
) I None
showed I None
a I None
significant I None
decrease I None
in I None
the I None
mentioned I None
parameters I None
as I None
compared I None
to I None
DMSO I Chemical
-treated I None
group I None
. I None
<eof> I None

<s> O None
However I None
, I None
scopolamine I Chemical
and I None
ritanserin I Chemical
co I None
- I None
administration I None
resulted I None
in I None
a I None
significant I None
decrease I None
in I None
escape I None
latencies I None
and I None
traveled I None
distances I None
as I None
compared I None
to I None
the I None
scopolamine I Chemical
-treated I None
rats I None
. I None
<eof> I None

<s> O None
Our I None
findings I None
show I None
that I None
microinjection I None
of I None
ritanserin I Chemical
into I None
the I None
CA1 I None
region I None
of I None
the I None
hippocampus I None
improves I None
the I None
scopolamine I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
amnesia I Disease
. I None
<eof> I None

<s> O None
Hypoxia I Disease
in I None
renal I Disease
disease O Disease
with I None
proteinuria I Disease
and/or I None
glomerular I None
hypertension I Disease
. I None
<eof> I None

<s> O None
Despite I None
the I None
increasing I None
need I None
to I None
identify I None
and I None
quantify I None
tissue I None
oxygenation I None
at I None
the I None
cellular I None
level I None
, I None
relatively I None
few I None
methods I None
have I None
been I None
available I None
. I None
<eof> I None

<s> O None
In I None
this I None
study I None
, I None
we I None
developed I None
a I None
new I None
hypoxia I Disease
-responsive I None
reporter I None
vector I None
using I None
a I None
hypoxia I Disease
-responsive I None
element I None
of I None
the I None
5 I None
' I None
vascular I None
endothelial I None
growth I None
factor I None
untranslated I None
region I None
and I None
generated I None
a I None
novel I None
hypoxia I Disease
-sensing I None
transgenic I None
rat I None
. I None
<eof> I None

<s> O None
We I None
then I None
applied I None
this I None
animal I None
model I None
to I None
the I None
detection I None
of I None
tubulointerstitial I None
hypoxia I Disease
in I None
the I None
diseased I Disease
kidney O Disease
. I None
<eof> I None

<s> O None
With I None
this I None
model I None
, I None
we I None
were I None
able I None
to I None
identify I None
diffuse I None
cortical I None
hypoxia I Disease
in I None
the I None
puromycin I Chemical
aminonucleoside O Chemical
-induced I None
<eof> I None

<s> O None
nephrotic I Disease
syndrome O Disease
and I None
focal I None
and I None
segmental I None
hypoxia I Disease
in I None
the I None
remnant I None
kidney I None
model I None
. I None
<eof> I None

<s> O None
Expression I None
of I None
the I None
hypoxia I Disease
-responsive I None
transgene I None
increased I None
throughout I None
the I None
observation I None
period I None
, I None
reaching I None
2.2-fold I None
at I None
2 I None
weeks I None
in I None
the I None
puromycin I Chemical
aminonucleoside O Chemical
model I None
and I None
2.6-fold I None
at I None
4 I None
weeks I None
in I None
the I None
remnant I None
kidney I None
model I None
, I None
whereas I None
that I None
of I None
vascular I None
endothelial I None
growth I None
factor I None
showed I None
a I None
mild I None
decrease I None
, I None
reflecting I None
distinct I None
behaviors I None
of I None
the I None
two I None
genes I None
. I None
<eof> I None

<s> O None
The I None
degree I None
of I None
hypoxia I Disease
showed I None
a I None
positive I None
correlation I None
with I None
microscopic I None
tubulointerstitial I Disease
injury O Disease
in I None
both I None
models I None
. I None
<eof> I None

<s> O None
Finally I None
, I None
we I None
identified I None
the I None
localization I None
of I None
proliferating I None
cell I None
nuclear I None
antigen I None
- I None
positive I None
, I None
ED-1-positive I None
, I None
and I None
terminal I None
dUTP I None
nick I None
- I None
end I None
labeled I None
- I None
positive I None
cells I None
in I None
the I None
hypoxic I Disease
cortical I None
area I None
in I None
the I None
remnant I None
kidney I None
model I None
. I None
<eof> I None

<s> O None
We I None
propose I None
here I None
a I None
possible I None
pathological I None
tie I None
between I None
chronic I None
tubulointerstitial I None
<eof> I None

<s> O None
hypoxia I Disease
and I None
progressive I None
glomerular I Disease
diseases O Disease
. I None
<eof> I None

<s> O None
Consensus I None
statement I None
concerning I None
cardiotoxicity I Disease
<eof> I None

<s> O None
occurring I None
during I None
haematopoietic I None
stem I None
cell I None
transplantation I None
in I None
the I None
treatment I None
of I None
autoimmune I Disease
diseases O Disease
, I None
with I None
special I None
reference I None
to I None
systemic I Disease
sclerosis O Disease
and I None
multiple I Disease
sclerosis O Disease
. I None
<eof> I None

<s> O None
Autologous I None
haematopoietic I None
stem I None
cell I None
transplantation I None
is I None
now I None
a I None
feasible I None
and I None
effective I None
treatment I None
for I None
selected I None
patients I None
with I None
severe I None
autoimmune I Disease
diseases O Disease
. I None
<eof> I None

<s> O None
Worldwide I None
, I None
over I None
650 I None
patients I None
have I None
been I None
transplanted I None
in I None
the I None
context I None
of I None
phase I None
I I None
and I None
II I None
clinical I None
trials I None
. I None
<eof> I None

<s> O None
The I None
results I None
are I None
encouraging I None
enough I None
to I None
begin I None
randomised I None
phase I None
III I None
trials I None
. I None
<eof> I None

<s> O None
However I None
, I None
as I None
predicted I None
, I None
significant I None
transplant I None
- I None
related I None
morbidity I None
and I None
mortality I None
have I None
been I None
observed I None
. I None
<eof> I None

<s> O None
This I None
is I None
primarily I None
due I None
to I None
complications I None
related I None
to I None
either I None
the I None
stage I None
of I None
the I None
disease I None
at I None
transplant I None
or I None
due I None
to I None
infections I Disease
. I None
<eof> I None

<s> O None
The I None
number I None
of I None
deaths I None
related I None
to I None
cardiac I Disease
toxicity O Disease
is I None
low I None
. I None
<eof> I None

<s> O None
However I None
, I None
caution I None
is I None
required I None
when I None
cyclophosphamide I Chemical
or I None
anthracyclines I Chemical
such I None
as I None
mitoxantrone I Chemical
are I None
used I None
in I None
patients I None
with I None
a I None
possible I None
underlying I None
heart I Disease
damage O Disease
, I None
for I None
example I None
, I None
systemic I Disease
sclerosis O Disease
patients I None
. I None
<eof> I None

<s> O None
In I None
November I None
2002 I None
, I None
a I None
meeting I None
was I None
held I None
in I None
Florence I None
, I None
bringing I None
together I None
a I None
number I None
of I None
experts I None
in I None
various I None
fields I None
, I None
including I None
rheumatology I None
, I None
cardiology I None
, I None
neurology I None
, I None
pharmacology I None
and I None
transplantation I None
medicine I None
. I None
<eof> I None

<s> O None
The I None
object I None
of I None
the I None
meeting I None
was I None
to I None
analyse I None
existing I None
data I None
, I None
both I None
published I None
or I None
available I None
, I None
in I None
the I None
European I None
Group I None
for I None
Blood I None
and I None
Marrow I None
Transplantation I None
<eof> I None

<s> O None
autoimmune I Disease
disease O Disease
database I None
, I None
and I None
to I None
propose I None
a I None
safe I None
approach I None
to I None
such I None
patients I None
. I None
<eof> I None

<s> O None
A I None
full I None
cardiological I None
assessment I None
before I None
and I None
during I None
the I None
transplant I None
emerged I None
as I None
the I None
major I None
recommendation I None
. I None
<eof> I None

<s> O None
Immunohistochemical I None
study I None
on I None
inducible I None
type I None
of I None
nitric I Chemical
oxide O Chemical
( I None
iNOS I None
) I None
, I None
basic I None
fibroblast I None
growth I None
factor I None
( I None
bFGF I None
) I None
and I None
tumor I Disease
growth I None
factor I None
- I None
beta1 I None
( I None
TGF I None
- I None
beta1 I None
) I None
in I None
arteritis I Disease
induced I None
in I None
rats I None
by I None
fenoldopam I Chemical
and I None
theophylline I Chemical
, I None
vasodilators I None
. I None
<eof> I None

<s> O None
Arteritis I Disease
induced I None
in I None
rats I None
by I None
vasodilators I None
, I None
fenoldopam I Chemical
and I None
theophylline I Chemical
, I None
was I None
examined I None
immunohistochemically I None
for I None
expressions I None
of I None
inducible I None
type I None
of I None
nitric I Chemical
oxide O Chemical
synthase I None
( I None
iNOS I None
) I None
, I None
basic I None
fibroblast I None
growth I None
factor I None
( I None
bFGF I None
) I None
and I None
tumor I Disease
growth I None
factor I None
- I None
beta1 I None
( I None
TGF I None
- I None
beta1 I None
) I None
. I None
<eof> I None

<s> O None
Rats I None
were I None
administered I None
<eof> I None

<s> O None
fenoldopam I Chemical
for I None
24 I None
hours I None
by I None
intravenous I None
infusion I None
with I None
or I None
without I None
following I None
repeated I None
daily I None
oral I None
administrations I None
of I None
theophylline I Chemical
. I None
<eof> I None

<s> O None
Irrespective I None
of I None
theophylline I Chemical
administration I None
, I None
iNOS I None
antigens I None
were I None
remarkably I None
abundant I None
in I None
ED-1-positive I None
cells I None
on I None
day I None
5 I None
and I None
<eof> I None

<s> O None
8 I None
post- I None
fenoldopam I Chemical
-infusion I None
( I None
DPI I None
) I None
; I None
bFGF I None
antigens I None
were I None
remarkably I None
abundant I None
in I None
ED-1-positive I None
cells I None
on I None
1 I None
and I None
3 I None
DPI I None
; I None
TGF I None
- I None
beta1 I None
antigens I None
were I None
observed I None
in I None
ED-1-positive I None
cells I None
on I None
and I None
after I None
5 I None
DPI I None
. I None
<eof> I None

<s> O None
These I None
results I None
suggest I None
that I None
the I None
peak I None
expression I None
of I None
iNOS I None
antigen I None
was I None
followed I None
by I None
that I None
of I None
bFGF I None
antigen I None
, I None
and I None
bFGF I None
may I None
have I None
a I None
suppressive I None
effect I None
on I None
iNOS I None
expression I None
in I None
these I None
rat I None
arteritis I Disease
models I None
. I None
<eof> I None

<s> O None
On I None
the I None
other I None
hand I None
, I None
TGF I None
- I None
beta1 I None
was I None
not I None
considered I None
to I None
have I None
a I None
suppressive I None
effect I None
on I None
iNOS I None
expression I None
in I None
these I None
models I None
. I None
<eof> I None

<s> O None
Low I Chemical
- O Chemical
molecular O Chemical
- O Chemical
weight O Chemical
heparin O Chemical
for I None
the I None
treatment I None
of I None
patients I None
with I None
mechanical I None
heart I None
valves I None
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
<eof> I None

<s> O None
The I None
interruption I None
of I None
oral I None
anticoagulant I None
( I None
OAC I None
) I None
administration I None
is I None
sometimes I None
indicated I None
in I None
patients I None
with I None
mechanical I None
heart I None
valves I None
, I None
mainly I None
before I None
noncardiac I None
surgery I None
, I None
non I None
- I None
surgical I None
interventions I None
, I None
and I None
pregnancy I None
. I None
<eof> I None

<s> O None
Unfractionated I Chemical
heparin O Chemical
<eof> I None

<s> O None
( I None
UH I Chemical
) I None
is I None
currently I None
the I None
substitute I None
for I None
selected I None
patients I None
. I None
<eof> I None

<s> O None
Low I Chemical
- O Chemical
molecular O Chemical
- O Chemical
weight O Chemical
heparin O Chemical
<eof> I None

<s> O None
( I None
LMWH I Chemical
) I None
offers I None
theoretical I None
advantages I None
over I None
UH I Chemical
, I None
but I None
is I None
not I None
currently I None
considered I None
in I None
clinical I None
guidelines I None
as I None
an I None
alternative I None
to I None
UH I Chemical
in I None
patients I None
with I None
prosthetic I None
valves I None
. I None
<eof> I None

<s> O None
HYPOTHESIS I None
: I None
<eof> I None

<s> O None
The I None
aim I None
of I None
the I None
present I None
study I None
was I None
to I None
review I None
the I None
data I None
accumulated I None
so I None
far I None
on I None
the I None
use I None
of I None
LMWH I Chemical
in I None
this I None
patient I None
population I None
and I None
to I None
discuss I None
its I None
applicability I None
in I None
common I None
practice I None
. I None
<eof> I None

<s> O None
METHODS I None
: I None
<eof> I None

<s> O None
For I None
this I None
paper I None
, I None
the I None
current I None
medical I None
literature I None
on I None
LMWH I Chemical
in I None
patients I None
with I None
mechanical I None
heart I None
valves I None
was I None
extensively I None
reviewed I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
There I None
were I None
eight I None
series I None
and I None
six I None
case I None
reports I None
. I None
<eof> I None

<s> O None
None I None
of I None
the I None
studies I None
was I None
randomized I None
, I None
and I None
only I None
one I None
was I None
prospective I None
. I None
<eof> I None

<s> O None
Data I None
to I None
establish I None
the I None
thromboembolic I Disease
risk I None
were I None
incomplete I None
. I None
<eof> I None

<s> O None
After I None
excluding I None
case I None
reports I None
, I None
the I None
following I None
groups I None
were I None
constructed I None
: I None
( I None
a I None
) I None
short I None
- I None
term I None
administration I None
, I None
after I None
valve I None
insertion I None
( I None
n I None
= I None
212 I None
) I None
; I None
( I None
b I None
) I None
short I None
- I None
term I None
, I None
perioperative I None
( I None
noncardiac)/periprocedural I None
( I None
n I None
= I None
114 I None
) I None
; I None
( I None
c I None
) I None
long I None
- I None
term I None
, I None
due I None
to I None
intolerance I None
to I None
OAC I None
( I None
n I None
= I None
16 I None
) I None
; I None
( I None
d I None
) I None
long I None
- I None
term I None
, I None
in I None
pregnancy I None
( I None
n I None
= I None
10 I None
) I None
. I None
<eof> I None

<s> O None
The I None
incidence I None
rate I None
of I None
thromboembolism I Disease
was I None
0.9 I None
% I None
for I None
all I None
the I None
studies I None
and I None
0.5 I None
, I None
0 I None
, I None
20 I None
, I None
and I None
0 I None
% I None
in I None
groups I None
a I None
, I None
b I None
, I None
c I None
, I None
and I None
d I None
, I None
respectively I None
; I None
for I None
hemorrhage I Disease
, I None
the I None
overall I None
rate I None
was I None
3.4 I None
% I None
( I None
3.8 I None
, I None
2.6 I None
, I None
10 I None
, I None
and I None
0 I None
% I None
for I None
the I None
respective I None
groups I None
) I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
In I None
patients I None
with I None
mechanical I None
heart I None
valves I None
, I None
short I None
- I None
term I None
LMWH I Chemical
therapy I None
compares I None
favorably I None
with I None
UH I Chemical
. I None
<eof> I None

<s> O None
Data I None
on I None
mid- I None
and I None
long I None
- I None
term I None
LMWH I Chemical
administration I None
in I None
these I None
patients I None
are I None
sparse I None
. I None
<eof> I None

<s> O None
Further I None
randomized I None
studies I None
are I None
needed I None
to I None
confirm I None
the I None
safety I None
and I None
precise I None
indications I None
for I None
the I None
use I None
of I None
LMWH I Chemical
in I None
patients I None
with I None
mechanical I None
heart I None
valves I None
. I None
<eof> I None

<s> O None
Topiramate I Chemical
-induced I None
nephrolithiasis I Disease
. I None
<eof> I None

<s> O None
Topiramate I Chemical
is I None
a I None
recently I None
developed I None
antiepileptic I None
medication I None
that I None
is I None
becoming I None
more I None
widely I None
prescribed I None
because I None
of I None
its I None
efficacy I None
in I None
treating I None
refractory I Disease
seizures O Disease
. I None
<eof> I None

<s> O None
Urologists I None
should I None
be I None
aware I None
that I None
this I None
medication I None
can I None
cause I None
metabolic I Disease
acidosis O Disease
in I None
patients I None
secondary I None
to I None
inhibition I None
of I None
carbonic I None
anhydrase I None
. I None
<eof> I None

<s> O None
In I None
addition I None
, I None
a I None
distal I None
tubular I None
acidification I None
defect I None
may I None
result I None
, I None
thus I None
impairing I None
the I None
normal I None
compensatory I None
drop I None
in I None
urine I None
pH. I None
These I None
factors I None
can I None
lead I None
to I None
the I None
development I None
of I None
calcium I Chemical
phosphate O Chemical
nephrolithiasis I Disease
. I None
<eof> I None

<s> O None
We I None
report I None
the I None
first I None
two I None
cases I None
of I None
topiramate I Chemical
-induced I None
nephrolithiasis I Disease
in I None
the I None
urologic I None
literature I None
. I None
<eof> I None

<s> O None
Spironolactone I Chemical
: I None
is I None
it I None
a I None
novel I None
drug I None
for I None
the I None
prevention I None
of I None
amphotericin I Chemical
B O Chemical
-related I None
hypokalemia I Disease
in I None
cancer I Disease
patients I None
? I None
<eof> I None

<s> O None
OBJECTIVE I None
: I None
<eof> I None

<s> O None
Nephrotoxicity I Disease
is I None
the I None
major I None
adverse I None
effect I None
of I None
amphotericin I Chemical
B O Chemical
<eof> I None

<s> O None
( I None
AmB I Chemical
) I None
, I None
often I None
limiting I None
administration I None
of I None
full I None
dosage I None
. I None
<eof> I None

<s> O None
Selective I None
distal I None
tubular I None
epithelial I None
<eof> I None

<s> O None
toxicity I Disease
seems I None
to I None
be I None
responsible I None
for I None
the I None
profound I None
potassium I Chemical
wasting I None
that I None
is I None
a I None
major I None
clinical I None
side I None
effect I None
of I None
treatment I None
with I None
AmB I Chemical
. I None
<eof> I None

<s> O None
Potassium I Chemical
depletion I None
also I None
potentiates I None
the I None
tubular I None
toxicity I Disease
of I None
AmB I Chemical
. I None
<eof> I None

<s> O None
This I None
study I None
was I None
designed I None
to I None
assess I None
the I None
ability I None
of I None
spironolactone I Chemical
to I None
reduce I None
potassium I Chemical
requirements I None
and I None
to I None
prevent I None
hypokalemia I Disease
in I None
neutropenic I Disease
patients I None
on I None
AmB I Chemical
treatment I None
. I None
<eof> I None

<s> O None
METHODS I None
: I None
<eof> I None

<s> O None
In I None
this I None
study I None
26 I None
patients I None
with I None
various I None
hematological I Disease
disorders O Disease
were I None
randomized I None
to I None
receive I None
either I None
intravenous I None
AmB I Chemical
alone I None
or I None
AmB I Chemical
and I None
oral I None
spironolactone I Chemical
100 I None
mg I None
twice I None
daily I None
when I None
developing I None
a I None
proven I None
or I None
suspected I None
fungal I Disease
infection O Disease
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
Patients I None
receiving I None
concomitant I None
AmB I Chemical
and I None
spironolactone I Chemical
had I None
significantly I None
higher I None
plasma I None
<eof> I None

<s> O None
potassium I Chemical
levels I None
than I None
those I None
receiving I None
AmB I Chemical
alone I None
( I None
P I None
= I None
0.0027 I None
) I None
. I None
<eof> I None

<s> O None
Those I None
patients I None
receiving I None
AmB I Chemical
and I None
spironolactone I Chemical
required I None
significantly I None
less I None
potassium I Chemical
supplementation I None
to I None
maintain I None
their I None
plasma I None
potassium I Chemical
within I None
the I None
normal I None
range I None
( I None
P I None
= I None
0.022 I None
) I None
. I None
<eof> I None

<s> O None
Moreover I None
, I None
urinary I None
potassium I Chemical
losses I None
were I None
significantly I None
less I None
in I None
patients I None
receiving I None
AmB I Chemical
and I None
spironolactone I Chemical
than I None
those I None
receiving I None
AmB I Chemical
alone I None
( I None
P I None
= I None
0.040 I None
) I None
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
<eof> I None

<s> O None
This I None
study I None
showed I None
that I None
spironolactone I Chemical
can I None
reduce I None
potassium I Chemical
requirements I None
and I None
prevent I None
hypokalemia I Disease
by I None
reducing I None
urinary I None
potassium I Chemical
loss I None
in I None
neutropenic I Disease
patients I None
on I None
AmB I Chemical
treatment I None
. I None
<eof> I None

<s> O None
Dopamine I Chemical
<eof> I None

<s> O None
D2 I None
receptor I None
signaling I None
controls I None
neuronal I None
cell I None
death I None
induced I None
by I None
muscarinic I None
and I None
glutamatergic I None
drugs I None
. I None
<eof> I None

<s> O None
Dopamine I Chemical
( I None
DA I Chemical
) I None
, I None
through I None
D1/D2 I None
receptor I None
- I None
mediated I None
signaling I None
, I None
plays I None
a I None
major I None
role I None
in I None
the I None
control I None
of I None
epileptic I Disease
seizures O Disease
arising I None
in I None
the I None
limbic I None
system I None
. I None
<eof> I None

<s> O None
Excitotoxicity I Disease
leading I None
to I None
neuronal I None
cell I None
death I None
in I None
the I None
affected I None
areas I None
is I None
a I None
major I None
consequence I None
of I None
seizures I Disease
at I None
the I None
cellular I None
level I None
. I None
<eof> I None

<s> O None
In I None
this I None
respect I None
, I None
little I None
is I None
known I None
about I None
the I None
role I None
of I None
DA I Chemical
receptors I None
in I None
the I None
occurrence I None
of I None
epilepsy I Disease
-induced I None
neuronal I None
cell I None
death I None
. I None
<eof> I None

<s> O None
Here I None
we I None
analyze I None
the I None
occurrence I None
of I None
seizures I Disease
and I None
neurotoxicity I Disease
in I None
D2R I None
<eof> I None

<s> O None
-/- I None
mice I None
treated I None
with I None
the I None
cholinergic I None
agonist I None
pilocarpine I Chemical
. I None
<eof> I None

<s> O None
We I None
compared I None
these I None
results I None
with I None
those I None
previously I None
obtained I None
with I None
kainic I Chemical
acid O Chemical
<eof> I None

<s> O None
( I None
KA I Chemical
) I None
, I None
a I None
potent I None
glutamate I Chemical
agonist I None
. I None
<eof> I None

<s> O None
Importantly I None
, I None
D2R I None
-/- I None
mice I None
develop I None
seizures I Disease
at I None
doses I None
of I None
both I None
drugs I None
that I None
are I None
not I None
epileptogenic I None
for I None
WT I None
littermates I None
and I None
show I None
greater I None
neurotoxicity I Disease
. I None
<eof> I None

<s> O None
However I None
, I None
pilocarpine I Chemical
-induced I None
<eof> I None

<s> O None
seizures I Disease
result I None
in I None
a I None
more I None
widespread I None
neuronal I None
death I None
in I None
both I None
WT I None
and I None
<eof> I None

<s> O None
D2R I None
<eof> I None

<s> O None
-/- I None
brains I None
in I None
comparison I None
to I None
KA I Chemical
. I None
<eof> I None

<s> O None
Thus I None
, I None
the I None
absence I None
of I None
D2R I None
lowers I None
the I None
threshold I None
for I None
seizures I Disease
induced I None
by I None
both I None
glutamate I Chemical
and I None
acetylcholine I Chemical
. I None
<eof> I None

<s> O None
Moreover I None
, I None
the I None
dopaminergic I None
control I None
of I None
epilepsy I Disease
-induced I None
neurodegeneration I Disease
seems I None
to I None
be I None
mediated I None
by I None
distinct I None
interactions I None
of I None
D2R I None
signaling I None
with I None
these I None
two I None
neurotransmitters I None
. I None
<eof> I None

<s> O None
Treatment I None
of I None
risperidone I Chemical
-induced I None
hyperprolactinemia I Disease
with I None
a I None
dopamine I Chemical
agonist I None
in I None
children I None
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
<eof> I None

<s> O None
Risperidone I Chemical
, I None
a I None
potent I None
antagonist I None
of I None
both I None
serotonergic I None
( I None
5HT2A I None
) I None
and I None
dopaminergic I None
D2 I None
receptors I None
is I None
associated I None
with I None
hyperprolactinemia I Disease
in I None
adults I None
and I None
children I None
. I None
<eof> I None

<s> O None
Chronically I None
elevated I None
prolactin I None
levels I None
in I None
children I None
with I None
prolactinomas I Disease
may I None
be I None
associated I None
with I None
arrested I None
growth I None
and I None
development I None
resulting I None
in I None
either I None
delayed I Disease
puberty O Disease
or I None
short I None
stature I None
. I None
<eof> I None

<s> O None
These I None
possibilities I None
stress I None
the I None
importance I None
of I None
developing I None
a I None
safe I None
and I None
effective I None
approach I None
to I None
drug I None
- I None
induced I None
hyperprolactinemia I Disease
in I None
youth I None
. I None
<eof> I None

<s> O None
We I None
report I None
the I None
successful I None
treatment I None
of I None
risperidone I Chemical
-induced I None
<eof> I None

<s> O None
hyperprolactinemia I Disease
with I None
cabergoline I Chemical
in I None
youth I None
. I None
<eof> I None

<s> O None
METHODS I None
<eof> I None

<s> O None
: I None
We I None
undertook I None
a I None
retrospective I None
case I None
review I None
of I None
four I None
children I None
with I None
risperidone I Chemical
-induced I None
<eof> I None

<s> O None
hyperprolactinemia I Disease
treated I None
with I None
cabergoline I Chemical
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
Four I None
males I None
( I None
age I None
6 I None
- I None
11 I None
years I None
) I None
with I None
Diagnostic I None
and I None
Statistical I None
Manual I None
of I None
Mental I Disease
Disorders O Disease
<eof> I None

<s> O None
( I None
fourth I None
edition I None
) I None
<eof> I None

<s> O None
bipolar I Disease
disorder O Disease
or I None
psychoses I Disease
, I None
with I None
<eof> I None

<s> O None
risperidone I Chemical
-induced I None
elevations I None
in I None
serum I None
prolactin I None
levels I None
( I None
57.5 I None
- I None
129 I None
ng I None
/ I None
mL I None
, I None
normal I None
5 I None
- I None
15 I None
ng I None
/ I None
mL I None
) I None
, I None
were I None
treated I None
with I None
cabergoline I Chemical
<eof> I None

<s> O None
( I None
mean I None
dose I None
2.13 I None
+ I None
/- I None
<eof> I None

<s> O None
0.09 I None
mg I None
/ I None
week I None
) I None
. I None
<eof> I None

<s> O None
When I None
serum I None
prolactin I None
levels I None
normalized I None
in I None
all I None
four I None
subjects I None
( I None
mean I None
11.2 I None
+ I None
/- I None
10.9 I None
ng I None
/ I None
mL I None
) I None
, I None
the I None
cabergoline I Chemical
dose I None
was I None
reduced I None
to I None
1 I None
mg I None
/ I None
week I None
in I None
three I None
of I None
four I None
subjects I None
. I None
<eof> I None

<s> O None
The I None
mean I None
duration I None
of I None
therapy I None
with I None
cabergoline I Chemical
was I None
523.5 I None
+ I None
/- I None
<eof> I None

<s> O None
129.7 I None
days I None
, I None
and I None
the I None
mean I None
duration I None
of I None
therapy I None
with I None
risperidone I Chemical
was I None
788.5 I None
+ I None
/- I None
<eof> I None

<s> O None
162.5 I None
days I None
. I None
<eof> I None

<s> O None
Cabergoline I Chemical
was I None
well I None
tolerated I None
without I None
adverse I None
effects I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
Cabergoline I Chemical
may I None
be I None
useful I None
for I None
the I None
treatment I None
of I None
<eof> I None

<s> O None
risperidone I Chemical
-induced I None
<eof> I None

<s> O None
hyperprolactinemia I Disease
in I None
youth I None
; I None
however I None
, I None
further I None
research I None
is I None
needed I None
. I None
<eof> I None

<s> O None
Cholestatic I Disease
jaundice O Disease
associated I None
with I None
the I None
use I None
of I None
metformin I Chemical
. I None
<eof> I None

<s> O None
We I None
report I None
a I None
patient I None
who I None
developed I None
cholestatic I Disease
jaundice O Disease
shortly I None
after I None
initiation I None
of I None
treatment I None
with I None
metformin I Chemical
hydrochloride O Chemical
. I None
<eof> I None

<s> O None
Ultrasound I None
of I None
the I None
liver I None
and I None
abdominal I None
CT I None
were I None
normal I None
. I None
<eof> I None

<s> O None
An I None
ERCP I None
showed I None
normal I None
biliary I None
anatomy I None
. I None
<eof> I None

<s> O None
A I None
percutaneous I None
liver I None
biopsy I None
was I None
obtained I None
showing I None
marked I None
cholestasis I Disease
, I None
with I None
portal I None
edema I Disease
, I None
ductular I None
proliferation I None
, I None
and I None
acute I None
inflammation I Disease
. I None
<eof> I None

<s> O None
Metformin I Chemical
hydrochloride O Chemical
was I None
discontinued I None
, I None
and I None
the I None
patient I None
's I None
jaundice I Disease
resolved I None
slowly I None
over I None
a I None
period I None
of I None
several I None
months I None
. I None
<eof> I None

<s> O None
Given I None
the I None
onset I None
of I None
his I None
jaundice I Disease
2 I None
wk I None
after I None
the I None
initiation I None
of I None
metformin I Chemical
, I None
we I None
believe I None
that I None
this I None
case I None
represents I None
an I None
example I None
of I None
metformin I Chemical
<eof> I None

<s> O None
-associated I None
<eof> I None

<s> O None
hepatotoxicity I Disease
, I None
the I None
first I None
such I None
case I None
reported I None
. I None
<eof> I None

<s> O None
Electro I None
- I None
oculography I None
, I None
electroretinography I None
, I None
visual I None
evoked I None
potentials I None
, I None
and I None
multifocal I None
electroretinography I None
in I None
patients I None
with I None
vigabatrin I Chemical
-attributed I None
visual I Disease
field O Disease
constriction O Disease
. I None
<eof> I None

<s> O None
PURPOSE I None
: I None
<eof> I None

<s> O None
Symptomatic I None
<eof> I None

<s> O None
visual I Disease
field O Disease
constriction O Disease
thought I None
to I None
be I None
associated I None
with I None
vigabatrin I Chemical
has I None
been I None
reported I None
. I None
<eof> I None

<s> O None
The I None
current I None
study I None
investigated I None
the I None
visual I None
fields I None
and I None
visual I None
electrophysiology I None
of I None
eight I None
patients I None
with I None
known I None
<eof> I None

<s> O None
vigabatrin I Chemical
-attributed I None
<eof> I None

<s> O None
visual I Disease
field O Disease
loss O Disease
, I None
three I None
of I None
whom I None
were I None
reported I None
previously I None
. I None
<eof> I None

<s> O None
Six I None
of I None
the I None
patients I None
were I None
no I None
longer I None
receiving I None
vigabatrin I Chemical
. I None
<eof> I None

<s> O None
METHODS I None
: I None
<eof> I None

<s> O None
The I None
central I None
and I None
peripheral I None
fields I None
were I None
examined I None
with I None
the I None
Humphrey I None
Visual I None
Field I None
Analyzer I None
. I None
<eof> I None

<s> O None
Full I None
visual I None
electrophysiology I None
, I None
including I None
flash I None
electroretinography I None
( I None
ERG I None
) I None
, I None
pattern I None
electroretinography I None
, I None
multifocal I None
ERG I None
using I None
the I None
VERIS I None
system I None
, I None
electro I None
- I None
oculography I None
, I None
and I None
flash I None
and I None
pattern I None
visual I None
evoked I None
potentials I None
, I None
was I None
undertaken I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
Seven I None
patients I None
showed I None
marked I None
visual I Disease
field O Disease
constriction O Disease
with I None
some I None
sparing I None
of I None
the I None
temporal I None
visual I None
field I None
. I None
<eof> I None

<s> O None
The I None
eighth I None
exhibited I None
concentric I None
constriction I None
. I None
<eof> I None

<s> O None
Most I None
electrophysiological I None
responses I None
were I None
usually I None
just I None
within I None
normal I None
limits I None
; I None
two I None
patients I None
had I None
subnormal I None
Arden I None
electro I None
- I None
oculography I None
indices I None
; I None
and I None
one I None
patient I None
showed I None
an I None
abnormally I None
delayed I None
photopic I None
b I None
wave I None
. I None
<eof> I None

<s> O None
However I None
, I None
five I None
patients I None
showed I None
delayed I None
30-Hz I None
flicker I None
b I None
waves I None
, I None
and I None
seven I None
patients I None
showed I None
delayed I None
oscillatory I None
potentials I None
. I None
<eof> I None

<s> O None
Multifocal I None
ERG I None
showed I None
abnormalities I None
that I None
sometimes I None
correlated I None
with I None
the I None
visual I None
field I None
appearance I None
and I None
confirmed I None
that I None
the I None
deficit I None
occurs I None
at I None
the I None
retinal I None
level I None
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
<eof> I None

<s> O None
Marked I None
visual I Disease
field O Disease
constriction O Disease
appears I None
to I None
be I None
associated I None
with I None
vigabatrin I Chemical
therapy I None
. I None
<eof> I None

<s> O None
The I None
field I None
defects I None
and I None
some I None
electrophysiological I None
abnormalities I None
persist I None
when I None
vigabatrin I Chemical
therapy I None
is I None
withdrawn I None
. I None
<eof> I None

<s> O None
Conversion I None
to I None
rapamycin I Chemical
immunosuppression I None
in I None
renal I None
transplant I None
recipients I None
: I None
report I None
of I None
an I None
initial I None
experience I None
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
<eof> I None

<s> O None
The I None
aim I None
of I None
this I None
study I None
is I None
to I None
evaluate I None
the I None
effects I None
of I None
RAPA I Chemical
conversion I None
in I None
patients I None
undergoing I None
cyclosporine I Chemical
<eof> I None

<s> O None
( I None
CsA I Chemical
) I None
or I None
tacrolimus I Chemical
<eof> I None

<s> O None
( I None
Tac I Chemical
) I None
toxicity I Disease
. I None
<eof> I None

<s> O None
METHODS I None
: I None
<eof> I None

<s> O None
Twenty I None
renal I None
transplant I None
recipients I None
were I None
switched I None
to I None
fixed I None
dose I None
rapamycin I Chemical
<eof> I None

<s> O None
( I None
RAPA I Chemical
) I None
( I None
5 I None
mg I None
/ I None
day I None
) I None
0 I None
<eof> I None

<s> O None
to I None
204 I None
months I None
posttransplant I None
. I None
<eof> I None

<s> O None
Drug I None
monitoring I None
was I None
not I None
initially I None
used I None
to I None
adjust I None
doses I None
. I None
<eof> I None

<s> O None
The I None
indications I None
for I None
switch I None
were I None
chronic I None
CsA I Chemical
or I None
Tac I Chemical
nephrotoxicity I Disease
<eof> I None

<s> O None
( I None
12 I None
) I None
, I None
acute I None
CsA I Chemical
or I None
Tac I Chemical
toxicity I Disease
<eof> I None

<s> O None
( I None
3 I None
) I None
, I None
severe I None
facial I Disease
dysmorphism O Disease
( I None
2 I None
) I None
, I None
posttransplant I Disease
lymphoproliferative O Disease
disorder O Disease
<eof> I None

<s> O None
( I None
PTLD I Disease
) I None
in I None
remission I None
( I None
2 I None
) I None
, I None
and I None
hepatotoxicity I Disease
in I None
1 I None
. I None
<eof> I None

<s> O None
Follow I None
- I None
up I None
is I None
7 I None
to I None
24 I None
months I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
In I None
the I None
12 I None
patients I None
switched I None
because I None
of I None
chronic I None
nephrotoxicity I Disease
<eof> I None

<s> O None
there I None
was I None
a I None
significant I None
decrease I None
in I None
serum I None
creatinine I Chemical
<eof> I None

<s> O None
[ I None
233+/-34 I None
to I None
210+/-56 I None
micromol I None
/ I None
liter I None
( I None
P<0.05 I None
) I None
at I None
6 I None
months I None
] I None
. I None
<eof> I None

<s> O None
Facial I Disease
dysmorphism O Disease
improved I None
in I None
two I None
patients I None
. I None
<eof> I None

<s> O None
No I None
relapse I None
of I None
PTLD I Disease
was I None
observed I None
. I None
<eof> I None

<s> O None
Five I None
patients I None
developed I None
pneumonia I Disease
<eof> I None

<s> O None
( I None
two I None
Pneumocystis I Disease
carinii O Disease
pneumonia O Disease
, I None
one I None
infectious I Disease
mononucleosis O Disease
with I None
polyclonal I None
PTLD I Disease
lung I None
infiltrate I None
) I None
and I None
two I None
had I None
bronchiolitis I Disease
obliterans O Disease
. I None
<eof> I None

<s> O None
There I None
were I None
no I None
deaths I None
. I None
<eof> I None

<s> O None
RAPA I Chemical
was I None
discontinued I None
in I None
four I None
patients I None
, I None
because I None
of I None
pneumonia I Disease
in I None
two I None
, I None
PTLD I Disease
in I None
one I None
, I None
and I None
oral I None
aphtous I Disease
ulcers O Disease
in I None
one I None
. I None
<eof> I None

<s> O None
RAPA I Chemical
levels I None
were I None
high I None
( I None
> I None
15 I None
ng I None
/ I None
ml I None
) I None
in I None
7 I None
of I None
13 I None
( I None
54 I None
% I None
) I None
patients I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
RAPA I Chemical
conversion I None
provides I None
adequate I None
immunosuppression I None
to I None
enable I None
CsA I Chemical
withdrawal I None
. I None
<eof> I None

<s> O None
However I None
, I None
when I None
converting I None
patients I None
to I None
RAPA I Chemical
drug I None
levels I None
should I None
be I None
monitored I None
to I None
avoid I None
over I None
- I None
immunosuppression I None
and I None
adequate I None
antiviral I None
and I None
Pneumocystis I Disease
carinii O Disease
pneumonia O Disease
prophylaxis I None
should I None
be I None
given I None
. I None
<eof> I None

<s> O None
Worsening I None
of I None
levodopa I Chemical
-induced I None
dyskinesias I Disease
by I None
motor I None
and I None
mental I None
tasks I None
. I None
<eof> I None

<s> O None
Ten I None
patients I None
who I None
had I None
Parkinson I Disease
's O Disease
disease O Disease
with I None
disabling I None
dyskinesia I Disease
were I None
included I None
in I None
this I None
study I None
to I None
evaluate I None
the I None
role I None
of I None
mental I None
( I None
mental I None
calculation I None
) I None
and I None
motor I None
( I None
flexion I None
/ I None
extension I None
of I None
right I None
fingers I None
, I None
flexion I None
/ I None
extension I None
of I None
left I None
fingers I None
, I None
flexion I None
/ I None
extension I None
of I None
the I None
neck I None
, I None
speaking I None
aloud I None
) I None
tasks I None
on I None
the I None
worsening I None
of I None
peak I None
- I None
dose I None
dyskinesia I Disease
following I None
administration I None
of I None
an I None
effective I None
single I None
dose I None
of I None
apomorphine I Chemical
. I None
<eof> I None

<s> O None
Compared I None
with I None
the I None
score I None
at I None
rest I None
( I None
1.3+/-0.3 I None
) I None
, I None
a I None
significant I None
aggravation I None
of I None
the I None
dyskinesia I Disease
score I None
was I None
observed I None
during I None
speaking I None
aloud I None
( I None
5.2+/-1.1 I None
, I None
p<0.05 I None
) I None
, I None
movements I None
of I None
right I None
<eof> I None

<s> O None
( I None
4.5+/-1.0 I None
, I None
p<0.05 I None
) I None
and I None
left I None
( I None
3.7+/-0.8 I None
, I None
p<0.05 I None
) I None
fingers I None
, I None
movements I None
of I None
the I None
neck I None
( I None
5.1+/-1.0 I None
, I None
p<0.05 I None
) I None
, I None
and I None
mental I None
calculation I None
( I None
3.1+/-1.0 I None
, I None
p<0.05 I None
) I None
. I None
<eof> I None

<s> O None
These I None
results I None
suggest I None
that I None
activation I None
tasks I None
such I None
as I None
" I None
speaking I None
aloud I None
" I None
could I None
be I None
used I None
for I None
objective I None
assessment I None
of I None
dyskinesia I Disease
severity I None
. I None
<eof> I None

<s> O None
Structural I Disease
and O Disease
functional O Disease
impairment O Disease
of O Disease
mitochondria O Disease
in I None
adriamycin I Chemical
-induced I None
<eof> I None

<s> O None
cardiomyopathy I Disease
in I None
mice I None
: I None
suppression I None
of I None
cytochrome I None
c I None
oxidase I None
II I None
gene I None
expression I None
. I None
<eof> I None

<s> O None
The I None
use I None
of I None
adriamycin I Chemical
<eof> I None

<s> O None
( I None
ADR I Chemical
) I None
in I None
cancer I Disease
chemotherapy I None
has I None
been I None
limited I None
due I None
to I None
its I None
cumulative I None
cardiovascular I Disease
toxicity O Disease
. I None
<eof> I None

<s> O None
Earlier I None
observations I None
that I None
ADR I Chemical
interacts I None
with I None
mitochondrial I None
cytochrome I None
c I None
oxidase I None
( I None
COX I None
) I None
and I None
suppresses I None
its I None
enzyme I None
activity I None
led I None
us I None
to I None
investigate I None
ADR I Chemical
's I None
action I None
on I None
the I None
cardiovascular I None
functions I None
and I None
heart I None
mitochondrial I None
morphology I None
in I None
Balb I None
- I None
c I None
mice I None
i.p I None
. I None
treated I None
with I None
ADR I Chemical
for I None
several I None
weeks I None
. I None
<eof> I None

<s> O None
At I None
various I None
times I None
during I None
treatment I None
, I None
the I None
animals I None
were I None
assessed I None
for I None
cardiovascular I None
functions I None
by I None
electrocardiography I None
and I None
for I None
heart I None
tissue I None
damage I None
by I None
electron I None
microscopy I None
. I None
<eof> I None

<s> O None
In I None
parallel I None
, I None
total I None
RNA I None
was I None
extracted I None
from I None
samples I None
of I None
dissected I None
heart I None
and I None
analyzed I None
by I None
Northern I None
blot I None
hybridization I None
to I None
determine I None
the I None
steady I None
- I None
state I None
level I None
of I None
three I None
RNA I None
transcripts I None
encoded I None
by I None
the I None
COXII I None
, I None
COXIII I None
, I None
and I None
COXIV I None
genes I None
. I None
<eof> I None

<s> O None
Similarly I None
, I None
samples I None
obtained I None
from I None
the I None
liver I None
of I None
the I None
same I None
animals I None
were I None
analyzed I None
for I None
comparative I None
studies I None
. I None
<eof> I None

<s> O None
Our I None
results I None
indicated I None
that I None
1 I None
) I None
treatment I None
of I None
mice I None
with I None
ADR I Chemical
caused I None
cardiovascular I Disease
arrhythmias O Disease
characterized I None
by I None
bradycardia I Disease
, I None
extension I None
of I None
ventricular I None
depolarization I None
time I None
( I None
tQRS I None
) I None
, I None
and I None
failure I None
of I None
QRS I None
at I None
high I None
concentrations I None
( I None
10 I None
- I None
14 I None
mg I None
/ I None
kg I None
body I None
weight I None
cumulative I None
dose I None
) I None
; I None
2 I None
) I None
the I None
heart I None
mitochondria I None
underwent I None
swelling I Disease
, I None
fusion I None
, I None
dissolution I None
, I None
and/or I None
disruption I None
of I None
mitochondrial I None
cristae I None
after I None
several I None
weeks I None
of I None
treatment I None
. I None
<eof> I None

<s> O None
Such I None
abnormalities I None
were I None
not I None
observed I None
in I None
the I None
mitochondria I None
of I None
liver I None
tissue I None
; I None
and I None
3 I None
) I None
among I None
the I None
three I None
genes I None
of I None
COX I None
enzyme I None
examined I None
, I None
only I None
COXII I None
gene I None
expression I None
was I None
suppressed I None
by I None
ADR I Chemical
treatment I None
, I None
mainly I None
after I None
8 I None
weeks I None
in I None
both I None
heart I None
and I None
liver I None
. I None
<eof> I None

<s> O None
Knowing I None
that I None
heart I None
mitochondria I None
represent I None
almost I None
40 I None
% I None
of I None
heart I None
muscle I None
by I None
weight I None
, I None
we I None
conclude I None
that I None
the I None
deteriorating I None
effects I None
of I None
ADR I Chemical
on I None
cardiovascular I None
function I None
involve I None
mitochondrial I Disease
structural O Disease
and O Disease
functional O Disease
impairment O Disease
. I None
<eof> I None

<s> O None
Enhanced I None
bradycardia I Disease
induced I None
by I None
beta I None
- I None
adrenoceptor I None
antagonists I None
in I None
rats I None
pretreated I None
with I None
isoniazid I Chemical
. I None
<eof> I None

<s> O None
High I None
doses I None
of I None
isoniazid I Chemical
increase I None
hypotension I Disease
<eof> I None

<s> O None
induced I None
by I None
vasodilators I None
and I None
change I None
the I None
accompanying I None
reflex I None
tachycardia I Disease
to I None
bradycardia I Disease
, I None
an I None
interaction I None
attributed I None
to I None
decreased I None
synthesis I None
of I None
brain I None
gamma I Chemical
- O Chemical
aminobutyric O Chemical
acid O Chemical
<eof> I None

<s> O None
( I None
GABA I Chemical
) I None
. I None
<eof> I None

<s> O None
In I None
the I None
present I None
study I None
, I None
the I None
possible I None
enhancement I None
by I None
isoniazid I Chemical
of I None
bradycardia I Disease
induced I None
by I None
beta I None
- I None
adrenoceptor I None
antagonists I None
was I None
determined I None
in I None
rats I None
anaesthetised I None
with I None
chloralose I Chemical
- I None
urethane I Chemical
. I None
<eof> I None

<s> O None
Isoniazid I Chemical
significantly I None
increased I None
<eof> I None

<s> O None
bradycardia I Disease
after I None
propranolol I Chemical
, I None
pindolol I Chemical
, I None
labetalol I Chemical
and I None
atenolol I Chemical
, I None
as I None
well I None
as I None
after I None
clonidine I Chemical
, I None
but I None
not I None
after I None
hexamethonium I Chemical
or I None
carbachol I Chemical
. I None
<eof> I None

<s> O None
Enhancement I None
was I None
not I None
observed I None
in I None
rats I None
pretreated I None
with I None
methylatropine I Chemical
or I None
previously I None
vagotomised I None
. I None
<eof> I None

<s> O None
These I None
results I None
are I None
compatible I None
with I None
interference I None
by I None
isoniazid I Chemical
with I None
GABAergic I None
inhibition I None
of I None
cardiac I None
parasympathetic I None
tone I None
. I None
<eof> I None

<s> O None
Such I None
interference I None
could I None
be I None
exerted I None
centrally I None
, I None
possibly I None
at I None
the I None
nucleus I None
ambiguus I None
, I None
or I None
peripherally I None
at I None
the I None
sinus I None
node I None
. I None
<eof> I None

<s> O None
Epileptogenic I None
activity I None
of I None
folic I Chemical
acid O Chemical
after I None
drug I None
induces I None
SLE I Disease
<eof> I None

<s> O None
( I None
folic I Chemical
acid O Chemical
and I None
epilepsy I Disease
) I None
OBJECTIVE I None
: I None
<eof> I None

<s> O None
To I None
study I None
the I None
effect I None
of I None
folic I Chemical
acid O Chemical
<eof> I None

<s> O None
-containing I None
multivitamin I None
supplementation I None
in I None
epileptic I Disease
women I None
before I None
and I None
during I None
pregnancy I None
in I None
order I None
to I None
determine I None
the I None
rate I None
of I None
structural I None
birth I Disease
defects O Disease
and I None
epilepsy I Disease
-related I None
side I None
effects I None
. I None
<eof> I None

<s> O None
STUDY I None
DESIGN I None
: I None
<eof> I None

<s> O None
First I None
a I None
randomised I None
trial I None
, I None
later I None
periconception I None
care I None
including I None
in I None
total I None
12225 I None
females I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
Of I None
60 I None
epileptic I Disease
<eof> I None

<s> O None
women I None
with I None
periconceptional I None
folic I Chemical
acid O Chemical
( I None
0.8 I None
mg)-containing I None
multivitamin I None
supplementation I None
, I None
no I None
one I None
developed I None
epilepsy I Disease
-related I None
side I None
effects I None
during I None
the I None
periconception I None
period I None
. I None
<eof> I None

<s> O None
One I None
epileptic I Disease
<eof> I None

<s> O None
woman I None
delivered I None
a I None
newborn I None
with I None
cleft I None
lip I None
and I None
palate I None
. I None
<eof> I None

<s> O None
Another I None
patient I None
exhibited I None
with I None
a I None
cluster I None
of I None
seizures I Disease
after I None
the I None
periconception I None
period I None
using I None
another I None
multivitamin I None
. I None
<eof> I None

<s> O None
This I None
22-year I None
- I None
old I None
epileptic I Disease
woman I None
was I None
treated I None
continuously I None
by I None
carbamazepine I Chemical
and I None
a I None
folic I Chemical
acid O Chemical
<eof> I None

<s> O None
( I None
1 I None
mg)-containing I None
multivitamin I None
from I None
the I None
20th I None
week I None
of I None
gestation I None
. I None
<eof> I None

<s> O None
She I None
developed I None
status I Disease
epilepticus O Disease
and I None
later I None
symptoms I None
of I None
systemic I Disease
lupus O Disease
erythematodes O Disease
. I None
<eof> I None

<s> O None
Her I None
pregnancy I None
ended I None
with I None
stillbirth I Disease
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
The I None
epileptic I Disease
pregnant I None
patient I None
's I None
autoimmune I Disease
disease O Disease
( I None
<eof> I None

<s> O None
probably I None
drug I None
- I None
induced I None
lupus I Disease
) I None
could I None
damage I None
the I None
blood I None
- I None
brain I None
barrier I None
, I None
therefore I None
the I None
therapeutic I None
dose I None
( I None
> I None
or I None
= I None
1 I None
mg I None
) I None
of I None
folic I Chemical
acid O Chemical
triggered I None
a I None
cluster I None
of I None
seizures I Disease
. I None
<eof> I None

<s> O None
Physiological I None
dose I None
( I None
< I None
1 I None
mg I None
) I None
of I None
<eof> I None

<s> O None
folic I Chemical
acid O Chemical
both I None
in I None
healthy I None
and I None
60 I None
epileptic I Disease
women I None
, I None
all I None
without I None
any I None
autoimmune I Disease
disease O Disease
, I None
did I None
not I None
increase I None
the I None
risk I None
for I None
epileptic I Disease
seizures O Disease
. I None
<eof> I None

<s> O None
Effects I None
of I None
cisapride I Chemical
on I None
symptoms I None
and I None
postcibal I None
small I None
- I None
bowel I None
motor I None
function I None
in I None
patients I None
with I None
irritable I Disease
bowel O Disease
syndrome O Disease
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
<eof> I None

<s> O None
Irritable I Disease
bowel O Disease
syndrome O Disease
is I None
a I None
common I None
cause I None
of I None
abdominal I Disease
pain O Disease
and I None
discomfort I None
and I None
may I None
be I None
related I None
to I None
disordered I Disease
gastrointestinal O Disease
motility O Disease
. I None
<eof> I None

<s> O None
Our I None
aim I None
was I None
to I None
assess I None
the I None
effects I None
of I None
long I None
- I None
term I None
treatment I None
with I None
a I None
prokinetic I None
agent I None
, I None
cisapride I Chemical
, I None
on I None
postprandial I None
jejunal I None
motility I None
and I None
symptoms I None
in I None
the I None
irritable I Disease
bowel O Disease
syndrome O Disease
<eof> I None

<s> O None
( I None
IBS I Disease
) I None
. I None
<eof> I None

<s> O None
METHODS I None
: I None
<eof> I None

<s> O None
Thirty I None
- I None
eight I None
patients I None
with I None
IBS I Disease
<eof> I None

<s> O None
( I None
constipation I Disease
-predominant I None
, I None
n I None
= I None
17 I None
; I None
diarrhoea I Disease
-predominant I None
, I None
n I None
= I None
21 I None
) I None
underwent I None
24-h I None
ambulatory I None
jejunal I None
manometry I None
before I None
and I None
after I None
12 I None
week I None
's I None
treatment I None
[ I None
cisapride I Chemical
, I None
5 I None
mg I None
three I None
times I None
daily I None
( I None
n I None
= I None
19 I None
) I None
or I None
placebo I None
( I None
n I None
= I None
19 I None
) I None
] I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
In I None
diarrhoea I Disease
<eof> I None

<s> O None
-predominant I None
<eof> I None

<s> O None
patients I None
significant I None
differences I None
in I None
contraction I None
characteristics I None
were I None
observed I None
between I None
the I None
cisapride I Chemical
and I None
placebo I None
groups I None
. I None
<eof> I None

<s> O None
In I None
cisapride I Chemical
-treated I None
<eof> I None

<s> O None
diarrhoea I Disease
<eof> I None

<s> O None
-predominant I None
patients I None
<eof> I None

<s> O None
the I None
mean I None
contraction I None
amplitude I None
was I None
higher I None
( I None
29.3 I None
+ I None
/- I None
<eof> I None

<s> O None
3.2 I None
versus I None
24.9 I None
+ I None
/- I None
<eof> I None

<s> O None
2.6 I None
mm I None
Hg I None
, I None
<eof> I None

<s> O None
cisapride I Chemical
versus I None
placebo I None
( I None
P I None
< I None
0.001 I None
) I None
; I None
pretreatment I None
, I None
25.7 I None
+ I None
/- I None
<eof> I None

<s> O None
6.0 I None
mm I None
Hg I None
) I None
, I None
the I None
mean I None
contraction I None
duration I None
longer I None
( I None
3.4 I None
+ I None
/- I None
0.2 I None
versus I None
3.0 I None
+ I None
/- I None
<eof> I None

<s> O None
0.2 I None
sec I None
, I None
<eof> I None

<s> O None
cisapride I Chemical
versus I None
placebo I None
( I None
P I None
< I None
0.001 I None
) I None
; I None
pretreatment I None
, I None
3.1 I None
+ I None
/- I None
<eof> I None

<s> O None
0.5 I None
sec I None
) I None
, I None
and I None
the I None
mean I None
contraction I None
frequency I None
lower I None
( I None
2.0 I None
+ I None
/- I None
0.2 I None
versus I None
2.5 I None
+ I None
/- I None
0.4 I None
cont./min I None
, I None
cisapride I Chemical
versus I None
placebo I None
( I None
P I None
< I None
0.001 I None
) I None
; I None
pretreatment I None
, I None
2.5 I None
+ I None
/- I None
<eof> I None

<s> O None
1.1 I None
cont./min I None
] I None
than I None
patients I None
treated I None
with I None
placebo I None
. I None
<eof> I None

<s> O None
No I None
significant I None
differences I None
in I None
jejunal I None
motility I None
were I None
found I None
in I None
the I None
constipation I Disease
-predominant I None
<eof> I None

<s> O None
IBS I Disease
group I None
. I None
<eof> I None

<s> O None
Symptoms I None
were I None
assessed I None
by I None
using I None
a I None
visual I None
analogue I None
scale I None
before I None
and I None
after I None
treatment I None
. I None
<eof> I None

<s> O None
Symptom I None
scores I None
relating I None
to I None
the I None
severity I None
of I None
constipation I Disease
were I None
lower I None
in I None
cisapride I Chemical
<eof> I None

<s> O None
-treated I None
<eof> I None

<s> O None
constipation I Disease
-predominant I None
<eof> I None

<s> O None
IBS I Disease
patients I None
[ I None
score I None
, I None
54 I None
+ I None
/- I None
5 I None
versus I None
67 I None
+ I None
/- I None
<eof> I None

<s> O None
14 I None
mm I None
, I None
cisapride I Chemical
versus I None
placebo I None
( I None
P I None
< I None
0.05 I None
) I None
; I None
pretreatment I None
, I None
62 I None
+ I None
/- I None
<eof> I None

<s> O None
19 I None
mm I None
] I None
. I None
<eof> I None

<s> O None
Diarrhoea I Disease
-predominant I None
<eof> I None

<s> O None
IBS I Disease
patients I None
had I None
a I None
higher I None
pain I Disease
score I None
after I None
cisapride I Chemical
therapy I None
[ I None
score I None
, I None
55 I None
+ I None
/- I None
15 I None
versus I None
34 I None
+ I None
/- I None
<eof> I None

<s> O None
12 I None
mm I None
, I None
cisapride I Chemical
versus I None
placebo I None
( I None
P I None
< I None
0.05 I None
) I None
; I None
pretreatment I None
, I None
67 I None
+ I None
/- I None
<eof> I None

<s> O None
19 I None
mm I None
] I None
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
<eof> I None

<s> O None
Cisapride I Chemical
affects I None
jejunal I None
contraction I None
characteristics I None
and I None
some I None
symptoms I None
in I None
IBS I Disease
. I None
<eof> I None

<s> O None
Clarithromycin I Chemical
-induced I None
ventricular I Disease
tachycardia O Disease
. I None
<eof> I None

<s> O None
Clarithromycin I Chemical
is I None
a I None
relatively I None
new I None
macrolide I Chemical
antibiotic I None
that I None
offers I None
twice I None
- I None
daily I None
dosing I None
. I None
<eof> I None

<s> O None
It I None
differs I None
from I None
erythromycin I Chemical
only I None
in I None
the I None
methylation I None
of I None
the I None
hydroxyl I None
group I None
at I None
position I None
6 I None
. I None
<eof> I None

<s> O None
Although I None
the I None
side I None
- I None
effect I None
profile I None
of I None
erythromycin I Chemical
is I None
established I None
, I None
including I None
gastroenteritis I Disease
and I None
interactions I None
with I None
other I None
drugs I None
subject I None
to I None
hepatic I None
mixed I None
- I None
function I None
oxidase I None
metabolism I None
, I None
experience I None
with I None
the I None
newer I None
macrolides I Chemical
is I None
still I None
being I None
recorded I None
. I None
<eof> I None

<s> O None
Cardiotoxicity I Disease
has I None
been I None
demonstrated I None
after I None
both I None
intravenous I None
and I None
oral I None
administration I None
of I None
erythromycin I Chemical
but I None
has I None
never I None
been I None
reported I None
with I None
the I None
newer I None
macrolides I Chemical
. I None
<eof> I None

<s> O None
We I None
report I None
a I None
case I None
of I None
ventricular I Disease
dysrhythmias O Disease
that I None
occurred I None
after I None
six I None
therapeutic I None
doses I None
of I None
clarithromycin I Chemical
. I None
<eof> I None

<s> O None
The I None
dysrhythmias I Disease
resolved I None
after I None
discontinuation I None
of I None
the I None
drug I None
. I None
<eof> I None

<s> O None
Persistent I None
nephrogenic I Disease
diabetes O Disease
insipidus O Disease
following I None
lithium I Chemical
therapy I None
. I None
<eof> I None

<s> O None
We I None
report I None
the I None
case I None
of I None
a I None
patient I None
who I None
developed I None
severe I None
hypernatraemic I None
dehydration I Disease
following I None
a I None
head I Disease
injury O Disease
. I None
<eof> I None

<s> O None
Ten I None
years I None
previously I None
he I None
had I None
been I None
diagnosed I None
to I None
have I None
lithium I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
nephrogenic I Disease
diabetes O Disease
insipidus O Disease
, I None
and I None
lithium I Chemical
therapy I None
had I None
been I None
discontinued I None
. I None
<eof> I None

<s> O None
He I None
remained I None
thirsty I None
and I None
polyuric I Disease
despite I None
cessation I None
of I None
lithium I Chemical
and I None
investigations I None
on I None
admission I None
showed I None
him I None
to I None
have I None
normal I None
osmoregulated I None
thirst I None
and I None
vasopressin I Chemical
secretion I None
, I None
with I None
clear I None
evidence I None
of I None
nephrogenic I Disease
diabetes O Disease
insipidus O Disease
. I None
<eof> I None

<s> O None
Lithium I Chemical
induced I None
nephrogenic I Disease
diabetes O Disease
insipidus O Disease
is I None
considered I None
to I None
be I None
reversible I None
on I None
cessation I None
of I None
therapy I None
but I None
polyuria I Disease
persisted I None
in I None
this I None
patient I None
for I None
ten I None
years I None
after I None
lithium I Chemical
was I None
stopped I None
. I None
<eof> I None

<s> O None
We I None
discuss I None
the I None
possible I None
renal I None
mechanisms I None
and I None
the I None
implications I None
for I None
management I None
of I None
patients I None
with I None
lithium I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
nephrogenic I Disease
diabetes O Disease
insipidus O Disease
. I None
<eof> I None

<s> O None
Late I None
cardiotoxicity I Disease
after I None
treatment I None
for I None
a I None
malignant I None
bone I Disease
tumor O Disease
. I None
<eof> I None

<s> O None
Cardiac I None
function I None
was I None
assessed I None
in I None
long I None
- I None
term I None
survivors I None
of I None
malignant I None
bone I Disease
tumors O Disease
who I None
were I None
treated I None
according I None
to I None
Rosen I Chemical
's O Chemical
T5 O Chemical
or O Chemical
T10 O Chemical
protocol O Chemical
, I None
both I None
including I None
doxorubicin I Chemical
. I None
<eof> I None

<s> O None
Thirty I None
- I None
one I None
patients I None
, I None
age I None
10 I None
- I None
45 I None
years I None
( I None
median I None
age I None
17.8 I None
years I None
) I None
were I None
evaluated I None
2.3 I None
- I None
14.1 I None
years I None
( I None
median I None
8.9 I None
years I None
) I None
following I None
completion I None
of I None
treatment I None
. I None
<eof> I None

<s> O None
Cumulative I None
doses I None
of I None
doxorubicin I Chemical
were I None
225 I None
- I None
550 I None
mg I None
/ I None
m2 I None
( I None
median I None
dose I None
360 I None
) I None
. I None
<eof> I None

<s> O None
The I None
evaluation I None
consisted I None
of I None
a I None
history I None
, I None
physical I None
examination I None
, I None
electrocardiogram I None
( I None
ECG I None
) I None
, I None
signal I None
averaged I None
ECG I None
, I None
24-hour I None
ambulatory I None
ECG I None
, I None
echocardiography I None
and I None
radionuclide I None
angiography I None
. I None
<eof> I None

<s> O None
Eighteen I None
of I None
31 I None
( I None
58 I None
% I None
) I None
<eof> I None

<s> O None
patients I None
showed I None
cardiac I Disease
toxicity O Disease
, I None
defined I None
as I None
having I None
one I None
or I None
more I None
of I None
the I None
following I None
abnormalities I None
: I None
late I None
potentials I None
, I None
complex I None
ventricular I Disease
arrhythmias O Disease
, I None
left I None
ventricular I Disease
dilation O Disease
, I None
decreased I None
shortening I None
fraction I None
, I None
or I None
decreased I None
ejection I None
fraction I None
. I None
<eof> I None

<s> O None
The I None
incidence I None
of I None
cardiac I Disease
abnormalities O Disease
increased I None
with I None
length I None
of I None
follow I None
- I None
up I None
( I None
P I None
< I None
or I None
= I None
.05 I None
) I None
. I None
<eof> I None

<s> O None
No I None
correlation I None
could I None
be I None
demonstrated I None
between I None
cumulative I None
dose I None
of I None
doxorubicin I Chemical
and I None
cardiac I None
status I None
, I None
except I None
for I None
heart I None
rate I None
variability I None
. I None
<eof> I None

<s> O None
When I None
adjusted I None
to I None
body I None
surface I None
area I None
, I None
the I None
left I None
ventricular I None
posterior I None
wall I None
thickness I None
( I None
LVPW I None
index I None
) I None
was I None
decreased I None
in I None
all I None
patients I None
. I None
<eof> I None

<s> O None
The I None
incidence I None
of I None
doxorubicin I Chemical
-induced I None
cardiotoxicity I Disease
is I None
high I None
and I None
increases I None
with I None
follow I None
- I None
up I None
, I None
irrespective I None
of I None
cumulative I None
dose I None
. I None
<eof> I None

<s> O None
Life I None
- I None
long I None
cardiac I None
follow I None
- I None
up I None
in I None
these I None
patients I None
is I None
warranted I None
. I None
<eof> I None

<s> O None
The I None
results I None
of I None
our I None
study I None
suggest I None
that I None
heart I None
rate I None
variability I None
and I None
LVPW I None
index I None
could I None
be I None
sensitive I None
indicators I None
for I None
cardiotoxicity I Disease
. I None
<eof> I None

<s> O None
Venous I Disease
complications O Disease
of I None
midazolam I Chemical
versus I None
diazepam I Chemical
. I None
<eof> I None

<s> O None
Although I None
some I None
studies I None
have I None
suggested I None
fewer I None
venous I Disease
complications O Disease
are I None
associated I None
with I None
midazolam I Chemical
than I None
with I None
diazepam I Chemical
for I None
endoscopic I None
procedures I None
, I None
this I None
variable I None
has I None
not I None
been I None
well I None
documented I None
. I None
<eof> I None

<s> O None
We I None
prospectively I None
evaluated I None
the I None
incidence I None
of I None
venous I Disease
complications O Disease
after I None
intravenous I None
injection I None
of I None
diazepam I Chemical
or I None
midazolam I Chemical
in I None
122 I None
consecutive I None
patients I None
undergoing I None
colonoscopy I None
and I None
esophagogastroduodenoscopy I None
. I None
<eof> I None

<s> O None
Overall I None
, I None
venous I Disease
complications O Disease
were I None
more I None
frequent I None
with I None
diazepam I Chemical
<eof> I None

<s> O None
( I None
22 I None
of I None
62 I None
patients I None
) I None
than I None
with I None
midazolam I Chemical
<eof> I None

<s> O None
( I None
4 I None
of I None
60 I None
patients I None
) I None
( I None
p I None
< I None
0.001 I None
) I None
. I None
<eof> I None

<s> O None
A I None
palpable I None
venous I None
cord I None
was I None
present I None
in I None
23 I None
% I None
( I None
14 I None
of I None
62 I None
) I None
of I None
patients I None
in I None
the I None
diazepam I Chemical
group I None
, I None
compared I None
with I None
2 I None
% I None
( I None
1 I None
of I None
60 I None
patients I None
) I None
in I None
the I None
midazolam I Chemical
group I None
( I None
p I None
< I None
0.002 I None
) I None
. I None
<eof> I None

<s> O None
Pain I Disease
at I None
the I None
injection I None
site I None
occurred I None
in I None
35 I None
% I None
( I None
22 I None
of I None
62 I None
) I None
of I None
patients I None
in I None
the I None
diazepam I Chemical
group I None
compared I None
with I None
7 I None
% I None
( I None
4 I None
of I None
60 I None
patients I None
) I None
in I None
the I None
midazolam I Chemical
group I None
( I None
p I None
< I None
0.001 I None
) I None
. I None
<eof> I None

<s> O None
Swelling I Disease
and I None
warmth I None
at I None
the I None
injection I None
site I None
were I None
not I None
significantly I None
different I None
between I None
the I None
two I None
groups I None
. I None
<eof> I None

<s> O None
Smoking I None
, I None
nonsteroidal I None
anti I None
- I None
inflammatory I None
drug I None
use I None
, I None
intravenous I None
catheter I None
site I None
, I None
dwell I None
time I None
of I None
the I None
needle I None
, I None
alcohol I Chemical
use I None
, I None
and I None
pain I Disease
during I None
the I None
injection I None
had I None
no I None
effect I None
on I None
the I None
incidence I None
of I None
venous I Disease
complications O Disease
. I None
<eof> I None

<s> O None
Tetany I Disease
and I None
rhabdomyolysis I Disease
due I None
to I None
surreptitious I None
furosemide I Chemical
--importance I None
of I None
magnesium I Chemical
supplementation I None
. I None
<eof> I None

<s> O None
Diuretics I None
may I None
induce I None
hypokalemia I Disease
, I None
hypocalcemia I Disease
and I None
hypomagnesemia I Disease
. I None
<eof> I None

<s> O None
While I None
severe I None
hypokalemia I Disease
may I None
cause I None
muscle I Disease
weakness O Disease
, I None
severe I None
hypomagnesemia I Disease
is I None
associated I None
with I None
muscle I Disease
spasms O Disease
and I None
tetany I Disease
which I None
can I None
not I None
be I None
corrected I None
by I None
potassium I Chemical
and I None
calcium I Chemical
supplementation I None
alone I None
( I None
1,2 I None
) I None
. I None
<eof> I None

<s> O None
Surreptitious I None
diuretic I None
ingestion I None
has I None
been I None
described I None
, I None
mainly I None
in I None
women I None
who I None
are I None
concerned I None
that I None
they I None
are I None
obese I Disease
or I None
edematous I Disease
. I None
<eof> I None

<s> O None
Symptomatic I None
<eof> I None

<s> O None
hypokalemia I Disease
has I None
been I None
reported I None
in I None
such I None
patients I None
( I None
3 I None
- I None
7 I None
) I None
and I None
in I None
one I None
case I None
hypocalcemia I Disease
was I None
observed I None
( I None
8) I None
, I None
but I None
the I None
effects I None
of I None
magnesium I Chemical
depletion I None
were I None
not I None
noted I None
in I None
these I None
patients I None
. I None
<eof> I None

<s> O None
Loss I None
of I None
glutamate I Chemical
decarboxylase I None
mRNA I None
- I None
containing I None
neurons I None
in I None
the I None
rat I None
dentate I None
gyrus I None
following I None
pilocarpine I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
seizures I Disease
. I None
<eof> I None

<s> O None
In I None
situ I None
hybridization I None
methods I None
were I None
used I None
to I None
determine I None
if I None
glutamic I Chemical
acid O Chemical
decarboxylase I None
( I None
GAD I None
) I None
<eof> I None

<s> O None
mRNA I None
- I None
containing I None
neurons I None
within I None
the I None
hilus I None
of I None
the I None
dentate I None
gyrus I None
are I None
vulnerable I None
to I None
seizure I Disease
-induced I None
damage I None
in I None
a I None
model I None
of I None
chronic I None
seizures I Disease
. I None
<eof> I None

<s> O None
Sprague I None
- I None
Dawley I None
rats I None
were I None
injected I None
intraperitoneally I None
with I None
pilocarpine I Chemical
, I None
and I None
the I None
hippocampal I None
formation I None
was I None
studied I None
histologically I None
at I None
1 I None
, I None
2 I None
, I None
4 I None
, I None
and I None
8 I None
week I None
intervals I None
after I None
pilocarpine I Chemical
<eof> I None

<s> O None
-induced I None
seizures I Disease
. I None
<eof> I None

<s> O None
In I None
situ I None
hybridization I None
histochemistry I None
, I None
using I None
a I None
digoxigenin I Chemical
-labeled I None
GAD I None
cRNA I None
probe I None
, I None
demonstrated I None
a I None
substantial I None
decrease I None
in I None
the I None
number I None
of I None
GAD I None
mRNA I None
- I None
containing I None
neurons I None
in I None
the I None
hilus I None
of I None
the I None
dentate I None
gyrus I None
in I None
the I None
pilocarpine I Chemical
-treated I None
rats I None
as I None
compared I None
to I None
controls I None
at I None
all I None
time I None
intervals I None
. I None
<eof> I None

<s> O None
Additional I None
neuronanatomical I None
studies I None
, I None
including I None
cresyl I Chemical
violet O Chemical
staining I None
, I None
neuronal I Disease
degeneration O Disease
methods I None
, I None
and I None
histochemical I None
localization I None
of I None
glial I None
fibrillary I None
acidic I None
protein I None
, I None
suggested I None
that I None
the I None
decrease I None
in I None
the I None
number I None
of I None
GAD I None
mRNA I None
- I None
containing I None
neurons I None
was I None
related I None
to I None
neuronal I Disease
loss O Disease
rather I None
than I None
to I None
a I None
decrease I None
in I None
GAD I None
mRNA I None
levels I None
. I None
<eof> I None

<s> O None
The I None
loss I None
of I None
GAD I None
mRNA I None
- I None
containing I None
neurons I None
in I None
the I None
hilus I None
contrasted I None
with I None
the I None
relative I None
preservation I None
of I None
labeled I None
putative I None
basket I None
cells I None
along I None
the I None
inner I None
margin I None
of I None
the I None
granule I None
cell I None
layer I None
. I None
<eof> I None

<s> O None
Quantitative I None
analyses I None
of I None
labeled I None
neurons I None
in I None
three I None
regions I None
of I None
the I None
dentate I None
gyrus I None
in I None
the I None
1 I None
and I None
2 I None
week I None
groups I None
showed I None
statistically I None
significant I None
decreases I None
in I None
the I None
mean I None
number I None
of I None
GAD I None
mRNA I None
- I None
containing I None
neurons I None
in I None
the I None
hilus I None
of I None
both I None
groups I None
of I None
experimental I None
animals I None
. I None
<eof> I None

<s> O None
No I None
significant I None
differences I None
were I None
found I None
in I None
the I None
molecular I None
layer I None
or I None
the I None
granule I None
cell I None
layer I None
, I None
which I None
included I None
labeled I None
neurons I None
along I None
the I None
lower I None
margin I None
of I None
the I None
granule I None
cell I None
layer I None
. I None
<eof> I None

<s> O None
The I None
results I None
indicate I None
that I None
, I None
in I None
this I None
model I None
, I None
a I None
subpopulation I None
of I None
GAD I None
mRNA I None
- I None
containing I None
neurons I None
within I None
the I None
dentate I None
gyrus I None
is I None
selectively I None
vulnerable I None
to I None
seizure I Disease
-induced I None
damage I None
. I None
<eof> I None

<s> O None
Such I None
differential I None
vulnerability I None
appears I None
to I None
be I None
another I None
indication I None
of I None
the I None
heterogeneity I None
of I None
GABA I Chemical
neurons I None
. I None
<eof> I None

<s> O None
Protective I None
effect I None
of I None
misoprostol I Chemical
on I None
indomethacin I Chemical
induced I None
<eof> I None

<s> O None
renal I Disease
dysfunction O Disease
in I None
elderly I None
patients I None
. I None
<eof> I None

<s> O None
OBJECTIVE I None
: I None
<eof> I None

<s> O None
To I None
evaluate I None
the I None
possible I None
protective I None
effects I None
of I None
misoprostol I Chemical
on I None
renal I None
function I None
in I None
hospitalized I None
elderly I None
patients I None
treated I None
with I None
indomethacin I Chemical
. I None
<eof> I None

<s> O None
METHODS I None
: I None
Forty I None
- I None
five I None
hospitalized I None
elderly I None
patients I None
( I None
> I None
65 I None
years I None
old I None
) I None
who I None
required I None
therapy I None
with I None
nonsteroidal I None
antiinflammatory I None
drugs I None
( I None
NSAID I None
) I None
were I None
randomly I None
assigned I None
to I None
receive I None
either I None
indomethacin I Chemical
, I None
150 I None
mg I None
/ I None
day I None
( I None
Group I None
A I None
) I None
, I None
or I None
indomethacin I Chemical
150 I None
mg I None
/ I None
day I None
plus I None
misoprostol I Chemical
at I None
0.6 I None
mg I None
/ I None
day I None
( I None
Group I None
B I None
) I None
. I None
<eof> I None

<s> O None
Laboratory I None
variables I None
of I None
renal I None
function I None
[ I None
serum I None
<eof> I None

<s> O None
creatinine I Chemical
, I None
blood I Chemical
urea O Chemical
nitrogen O Chemical
<eof> I None

<s> O None
( I None
BUN I Chemical
) I None
and I None
electrolytes I None
] I None
were I None
evaluated I None
before I None
initiation I None
of I None
therapy I None
and I None
every I None
2 I None
days I None
, I None
until I None
termination I None
of I None
the I None
study I None
( I None
a I None
period I None
of I None
at I None
least I None
6 I None
days I None
) I None
. I None
<eof> I None

<s> O None
Response I None
to I None
treatment I None
was I None
estimated I None
by I None
the I None
visual I None
analog I None
scale I None
for I None
severity I None
of I None
pain I Disease
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
Forty I None
- I None
two I None
patients I None
completed I None
the I None
study I None
, I None
22 I None
in I None
Group I None
A I None
and I None
20 I None
in I None
Group I None
B. I None
BUN I Chemical
and I None
creatinine I Chemical
increased I None
by I None
> I None
50 I None
% I None
of I None
baseline I None
levels I None
in I None
54 I None
and I None
45 I None
% I None
of I None
Group I None
A I None
patients I None
, I None
respectively I None
, I None
compared I None
to I None
only I None
20 I None
and I None
10 I None
% I None
of I None
Group I None
B I None
patients I None
( I None
p I None
< I None
0.05 I None
) I None
. I None
<eof> I None

<s> O None
Potassium I Chemical
<eof> I None

<s> O None
( I None
K I Chemical
) I None
increment I None
of I None
0.6 I None
mEq I None
/ I None
l I None
or I None
more I None
was I None
observed I None
in I None
50 I None
% I None
of I None
Group I None
A I None
, I None
but I None
in I None
only I None
15 I None
% I None
of I None
Group I None
B I None
patients I None
( I None
p I None
< I None
0.05 I None
) I None
. I None
<eof> I None

<s> O None
The I None
mean I None
increments I None
in I None
BUN I Chemical
, I None
creatinine I Chemical
, I None
and I None
K I Chemical
were I None
reduced I None
by I None
63 I None
, I None
80 I None
, I None
and I None
42 I None
% I None
, I None
respectively I None
, I None
in I None
Group I None
B I None
patients I None
compared I None
to I None
Group I None
A. I None
Response I None
to I None
treatment I None
did I None
not I None
differ I None
significantly I None
between I None
the I None
2 I None
groups I None
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
Hospitalized I None
elderly I None
patients I None
are I None
at I None
risk I None
for I None
developing I None
indomethacin I Chemical
related I None
renal I Disease
dysfunction O Disease
. I None
<eof> I None

<s> O None
Addition I None
of I None
misoprostol I Chemical
can I None
minimize I None
this I None
renal I Disease
impairment O Disease
without I None
affecting I None
pain I Disease
control I None
. I None
<eof> I None

<s> O None
Nephrotoxic I Disease
effects I None
of I None
aminoglycoside I Chemical
treatment I None
on I None
renal I None
protein I None
reabsorption I None
and I None
accumulation I None
. I None
<eof> I None

<s> O None
To I None
quantify I None
the I None
effects I None
of I None
gentamicin I Chemical
, I None
kanamycin I Chemical
and I None
netilmicin I Chemical
on I None
renal I None
protein I None
reabsorption I None
and I None
accumulation I None
, I None
these I None
drugs I None
were I None
administered I None
to I None
rats I None
intraperitoneally I None
( I None
30 I None
mg I None
/ I None
kg I None
/ I None
day I None
) I None
for I None
7 I None
, I None
14 I None
or I None
21 I None
days I None
. I None
<eof> I None

<s> O None
Scanning I None
electron I None
microscopy I None
of I None
the I None
glomerular I None
endothelia I None
, I None
urinary I None
measurements I None
of I None
sodium I Chemical
, I None
potassium I Chemical
, I None
endogenous I None
lysozyme I None
, I None
N I None
- I None
acetyl I None
- I None
beta I None
- I None
D I None
- I None
glucosaminidase I None
( I None
NAG I None
) I None
as I None
well I None
as I None
clearance I None
and I None
accumulation I None
experiments I None
after I None
i.v I None
. I None
<eof> I None

<s> O None
administration I None
of I None
egg I None
- I None
white I None
lysozyme I None
and I None
measurements I None
of I None
inulin I None
clearance I None
( I None
GFR I None
) I None
were I None
done I None
in I None
each I None
treatment I None
group I None
. I None
<eof> I None

<s> O None
Gentamicin I Chemical
administration I None
decreased I None
diameter I None
, I None
density I None
and I None
shape I None
of I None
endothelial I None
fenestrae I None
. I None
<eof> I None

<s> O None
Kanamycin I Chemical
and I None
netilmicin I Chemical
appeared I None
to I None
have I None
no I None
effect I None
at I None
the I None
dose I None
used I None
. I None
<eof> I None

<s> O None
All I None
three I None
aminoglycosides I Chemical
decreased I None
GFR I None
and I None
increased I None
urinary I None
excretion I None
of I None
sodium I Chemical
and I None
potassium I Chemical
. I None
<eof> I None

<s> O None
While I None
gentamicin I Chemical
and I None
kanamycin I Chemical
decreased I None
the I None
percentage I None
reabsorption I None
and I None
accumulation I None
of I None
lysozyme I None
after I None
i.v I None
. I None
<eof> I None

<s> O None
administration I None
of I None
egg I None
- I None
white I None
lysozyme I None
netilmicin I Chemical
had I None
no I None
effect I None
. I None
<eof> I None

<s> O None
Daily I None
excretion I None
of I None
total I None
protein I None
, I None
endogenous I None
lysozyme I None
and I None
NAG I None
increased I None
only I None
after I None
treatment I None
with I None
kanamycin I Chemical
and I None
gentamicin I Chemical
. I None
<eof> I None

<s> O None
Thus I None
, I None
aminoglycosides I Chemical
may I None
act I None
as I None
nephrotoxicants I None
at I None
glomerular I None
and/or I None
tubular I None
level I None
inducing I None
impairment I Disease
of O Disease
renal O Disease
reabsorption O Disease
and I None
accumulation I None
of I None
proteins I None
. I None
<eof> I None

<s> O None
Pharmacology I None
of I None
GYKI-41 I Chemical
099 O Chemical
<eof> I None

<s> O None
( I None
chlorpropanol I Chemical
, I None
Tobanum I Chemical
) I None
a I None
new I None
potent I None
beta I None
- I None
adrenergic I None
antagonist I None
. I None
<eof> I None

<s> O None
The I None
compound I None
GYKI-41 I Chemical
099 O Chemical
, I None
as I None
a I None
beta I None
- I None
adrenergic I None
antagonist I None
, I None
is I None
3 I None
- I None
8 I None
times I None
more I None
potent I None
than I None
propranolol I Chemical
in I None
vitro I None
and I None
in I None
vivo I None
. I None
<eof> I None

<s> O None
Its I None
antiarrhythmic I None
effectiveness I None
surpasses I None
that I None
of I None
propranolol I Chemical
and I None
pindolol I Chemical
inhibiting I None
the I None
ouabain I Chemical
arrhythmia I Disease
in I None
dogs I None
and I None
cats I None
. I None
<eof> I None

<s> O None
GYKI-41 I Chemical
900 O Chemical
has I None
a I None
negligible I None
cardiodepressant I None
activity I None
; I None
it I None
is I None
not I None
cardioselective I None
. I None
<eof> I None

<s> O None
The I None
compound I None
shows I None
a I None
rapid I None
and I None
long I None
lasting I None
effect I None
. I None
<eof> I None

<s> O None
There I None
was I None
a I None
prolonged I None
elimination I None
of I None
the I None
radioactivity I None
after I None
the I None
injection I None
of I None
14C-41 I Chemical
099 O Chemical
to I None
rats I None
and I None
dogs I None
. I None
<eof> I None

<s> O None
The I None
half I None
life I None
of I None
the I None
unlabeled I None
substance I None
in I None
humans I None
was I None
more I None
than I None
10 I None
hours I None
. I None
<eof> I None

<s> O None
Chorea I Disease
associated I None
with I None
oral I Chemical
contraception O Chemical
. I None
<eof> I None

<s> O None
Three I None
patients I None
developed I None
chorea I Disease
while I None
receiving I None
oral I Chemical
contraceptives O Chemical
. I None
<eof> I None

<s> O None
Two I None
were I None
young I None
patients I None
whose I None
chorea I Disease
developed I None
long I None
after I None
treatment I None
had I None
been I None
started I None
and I None
disappeared I None
soon I None
after I None
it I None
had I None
been I None
discontinued I None
. I None
<eof> I None

<s> O None
The I None
third I None
patient I None
had I None
acute I None
<eof> I None

<s> O None
amphetamine I Chemical
-induced I None
<eof> I None

<s> O None
chorea I Disease
after I None
prolonged I None
oral I Chemical
contraception O Chemical
. I None
<eof> I None

<s> O None
Prolonged I None
administration I None
of I None
female I None
sex I None
hormones I None
is I None
a I None
possible I None
cause I None
of I None
chorea I Disease
in I None
women I None
who I None
have I None
not I None
previously I None
had I None
chorea I Disease
or I None
rheumatic I Disease
fever O Disease
. I None
<eof> I None

<s> O None
Reversal I None
of I None
ammonia I Chemical
coma I Disease
in I None
rats I None
by I None
L I Chemical
- O Chemical
dopa O Chemical
: I None
a I None
peripheral I None
effect I None
. I None
<eof> I None

<s> O None
Ammonia I Chemical
coma I Disease
was I None
produced I None
in I None
rats I None
within I None
10 I None
to I None
15 I None
minutes I None
of I None
an I None
intraperitonealinjection I None
of I None
1.7 I None
mmol I None
NH4CL I Chemical
. I None
<eof> I None

<s> O None
This I None
coma I Disease
was I None
prevented I None
with I None
1.68 I None
mmol I None
L I Chemical
- O Chemical
dopa O Chemical
<eof> I None

<s> O None
given I None
by I None
gastric I None
intubation I None
15 I None
minutes I None
before I None
the I None
ammonium I Chemical
salt O Chemical
injection I None
. I None
<eof> I None

<s> O None
The I None
effect I None
of I None
L I Chemical
- O Chemical
dopa O Chemical
was I None
correlated I None
with I None
a I None
decrease I None
in I None
blood I None
and I None
brain I None
ammonia I Chemical
, I None
an I None
increase I None
in I None
brain I None
dopamine I Chemical
, I None
and I None
an I None
increase I None
in I None
renal I None
excretion I None
of I None
ammonia I Chemical
and I None
urea I Chemical
. I None
<eof> I None

<s> O None
Intraventricular I None
infusion I None
of I None
dopamine I Chemical
sufficient I None
to I None
raise I None
the I None
brain I None
dopamine I Chemical
to I None
the I None
same I None
extent I None
did I None
not I None
prevent I None
the I None
ammonia I Chemical
coma I Disease
nor I None
affect I None
the I None
blood I None
and I None
brain I None
ammonia I Chemical
concentrations I None
. I None
<eof> I None

<s> O None
Bilateral I None
nephrectomy I None
eliminated I None
the I None
beneficial I None
effect I None
of I None
L I Chemical
- O Chemical
dopa O Chemical
on I None
blood I None
and I None
brain I None
ammonia I Chemical
and I None
the I None
ammonia I Chemical
<eof> I None

<s> O None
coma I Disease
was I None
not I None
prevented I None
. I None
<eof> I None

<s> O None
Thus I None
, I None
the I None
reduction I None
in I None
blood I None
and I None
brain I None
ammonia I Chemical
and I None
the I None
prevention I None
of I None
ammonia I Chemical
coma I Disease
after I None
L I Chemical
- O Chemical
dopa O Chemical
, I None
can I None
be I None
accounted I None
for I None
by I None
the I None
peripheral I None
effect I None
of I None
dopamine I Chemical
on I None
renal I None
function I None
rather I None
than I None
its I None
central I None
action I None
. I None
<eof> I None

<s> O None
These I None
results I None
provide I None
a I None
reasonable I None
explanation I None
for I None
the I None
beneficial I None
effects I None
observed I None
in I None
some I None
encephalopathic I Disease
patients I None
receiving I None
L I Chemical
- O Chemical
dopa O Chemical
. I None
<eof> I None

<s> O None
Heparin I Chemical
-induced I None
thrombocytopenia I Disease
after I None
liver I None
transplantation I None
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
<eof> I None

<s> O None
Unfractionated I Chemical
heparin O Chemical
sodium O Chemical
<eof> I None

<s> O None
( I None
UFH I Chemical
) I None
or I None
low I Chemical
- O Chemical
molecular O Chemical
weight O Chemical
heparin O Chemical
( I None
LMWH I None
) I None
is I None
used I None
in I None
anticoagulant I None
protocols I None
at I None
several I None
institutions I None
to I None
prevent I None
thrombosis I Disease
after I None
liver I None
transplantation I None
. I None
<eof> I None

<s> O None
Heparin I Chemical
-induced I None
<eof> I None

<s> O None
thrombocytopenia I Disease
<eof> I None

<s> O None
( I None
HIT I Disease
) I None
is I None
an I None
adverse I None
immune I None
- I None
mediated I None
reaction I None
to I None
heparin I Chemical
, I None
resulting I None
in I None
platelet I None
count I None
decreases I None
of I None
more I None
than I None
50 I None
% I None
. I None
<eof> I None

<s> O None
The I None
frequencies I None
of I None
HIT I Disease
after I None
liver I None
transplantation I None
and I None
platelet I None
factor I None
<eof> I None

<s> O None
4/ I None
<eof> I None

<s> O None
heparin I Chemical
-reactive I None
antibody I None
( I None
HIT I Disease
antibody I None
) I None
<eof> I None

<s> O None
positivity I None
in I None
liver I None
transplantation I None
patients I None
, I None
however I None
, I None
are I None
unknown I None
. I None
<eof> I None

<s> O None
PATIENTS I None
AND I None
METHODS I None
: I None
<eof> I None

<s> O None
The I None
32 I None
men I None
and I None
20 I None
women I None
underwent I None
living I None
donor I None
liver I None
transplantation I None
. I None
<eof> I None

<s> O None
We I None
started I None
LMWH I None
( I None
25 I None
IU I None
/ I None
kg I None
/ I None
h I None
) I None
on I None
postoperative I None
day I None
( I None
POD I None
) I None
1 I None
, I None
switching I None
to I None
UFH I Chemical
<eof> I None

<s> O None
( I None
5000 I None
U I None
/ I None
d I None
) I None
on I None
POD I None
2 I None
or I None
3 I None
. I None
<eof> I None

<s> O None
The I None
dose I None
of I None
UFH I Chemical
was I None
changed I None
according I None
to I None
the I None
activated I None
clotting I None
time I None
level I None
. I None
<eof> I None

<s> O None
HIT I Disease
antibody I None
levels I None
were I None
measured I None
the I None
day I None
before I None
surgery I None
and I None
on I None
POD I None
7 I None
and I None
14 I None
. I None
<eof> I None

<s> O None
Platelet I None
count I None
was I None
measured I None
daily I None
for I None
3 I None
weeks I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
The I None
average I None
platelet I None
counts I None
preoperatively I None
, I None
and I None
on I None
POD I None
7 I None
, I None
14 I None
, I None
and I None
21 I None
were I None
65 I None
, I None
88 I None
, I None
149 I None
, I None
and I None
169 I None
x I None
10(9)/L I None
, I None
respectively I None
. I None
<eof> I None

<s> O None
Two I None
patients I None
developed I None
hepatic I None
artery I None
thrombosis I Disease
on I None
POD I None
11 I None
and I None
19 I None
, I None
respectively I None
, I None
although I None
they I None
were I None
HIT I Disease
<eof> I None

<s> O None
antibody I None
- I None
negative I None
and I None
their I None
platelet I None
counts I None
were I None
stable I None
. I None
<eof> I None

<s> O None
In I None
2 I None
other I None
patients I None
, I None
the I None
platelet I None
count I None
decreased I None
suddenly I None
from I None
107 I None
x I None
10(9)/L I None
on I None
POD I None
4 I None
to I None
65 I None
x I None
10(9)/L I None
on I None
POD I None
6 I None
and I None
from I None
76 I None
x I None
10(9)/L I None
on I None
POD I None
7 I None
to I None
33 I None
x I None
10(9)/L I None
on I None
POD I None
9 I None
, I None
respectively I None
. I None
<eof> I None

<s> O None
The I None
heparin I Chemical
-induced I None
platelet I Disease
aggregation O Disease
test I None
was I None
negative I None
in I None
these I None
patients I None
. I None
<eof> I None

<s> O None
The I None
percentage I None
of I None
HIT I Disease
<eof> I None

<s> O None
antibody I None
- I None
positive I None
patients I None
was I None
0.5 I None
% I None
preoperatively I None
, I None
5.6 I None
% I None
on I None
POD I None
7 I None
, I None
and I None
5.6 I None
% I None
on I None
POD I None
14 I None
. I None
<eof> I None

<s> O None
None I None
of I None
the I None
subjects I None
/ I None
patients I None
developed I None
UFH I Chemical
<eof> I None

<s> O None
-related I None
<eof> I None

<s> O None
HIT I Disease
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
In I None
our I None
series I None
, I None
the I None
occurrence I None
of I None
HIT I Disease
<eof> I None

<s> O None
after I None
liver I None
transplantation I None
was I None
uncommon I None
. I None
<eof> I None

<s> O None
PTU I Chemical
-associated I None
vasculitis I Disease
in I None
a I None
girl I None
with I None
Turner I Disease
Syndrome O Disease
and I None
Graves I Disease
' O Disease
disease O Disease
. I None
<eof> I None

<s> O None
Palpable I None
<eof> I None

<s> O None
purpura I Disease
is I None
a I None
concerning I None
clinical I None
finding I None
in I None
pediatric I None
patients I None
and I None
can I None
have I None
many I None
causes I None
, I None
including I None
infectious I None
and I None
autoimmune I None
processes I None
. I None
<eof> I None

<s> O None
A I None
rare I None
cause I None
, I None
drug I None
- I None
induced I None
vasculitis I Disease
, I None
may I None
result I None
from I None
the I None
production I None
of I None
antineutrophil I None
cytoplasmic I None
antibodies I None
( I None
ANCAs I None
) I None
in I None
response I None
to I None
a I None
medication I None
. I None
<eof> I None

<s> O None
We I None
report I None
a I None
girl I None
with I None
Turner I Disease
syndrome O Disease
and I None
Graves I Disease
' O Disease
disease O Disease
who I None
presented I None
with I None
palpable I None
purpuric I Disease
lesions O Disease
. I None
<eof> I None

<s> O None
The I None
diagnosis I None
of I None
propylthiouracil I Chemical
<eof> I None

<s> O None
( I None
PTU I Chemical
) I None
-associated I None
<eof> I None

<s> O None
vasculitis I Disease
was I None
made I None
by I None
observation I None
of I None
consistent I None
clinical I None
features I None
, I None
the I None
detection I None
of I None
elevated I None
ANA I None
and I None
ANCA I None
in I None
the I None
blood I None
, I None
and I None
the I None
observed I None
clinical I None
resolution I None
of I None
symptoms I None
following I None
withdrawal I None
of I None
PTU I Chemical
. I None
<eof> I None

<s> O None
Subsequent I None
treatment I None
of I None
persistent I None
hyperthyroidism I Disease
with I None
radioablation I None
did I None
not I None
result I None
in I None
an I None
exacerbation I None
of I None
the I None
vasculitis I Disease
, I None
a I None
complication I None
described I None
in I None
prior I None
case I None
reports I None
. I None
<eof> I None

<s> O None
Succinylcholine I Chemical
-induced I None
masseter I Disease
muscle O Disease
rigidity O Disease
during I None
bronchoscopic I None
removal I None
of I None
a I None
tracheal I None
foreign I None
body I None
. I None
<eof> I None

<s> O None
Masseter I Disease
muscle O Disease
rigidity O Disease
during I None
general I None
anesthesia I None
is I None
considered I None
an I None
early I None
warning I None
sign I None
of I None
a I None
possible I None
episode I None
of I None
malignant I Disease
hyperthermia O Disease
. I None
<eof> I None

<s> O None
The I None
decision I None
whether I None
to I None
continue I None
or I None
discontinue I None
the I None
procedure I None
depends I None
on I None
the I None
urgency I None
of I None
the I None
surgery I None
and I None
severity I None
of I None
masseter I Disease
muscle O Disease
rigidity O Disease
. I None
<eof> I None

<s> O None
Here I None
, I None
we I None
describe I None
a I None
case I None
of I None
severe I None
masseter I Disease
muscle O Disease
rigidity O Disease
<eof> I None

<s> O None
( I None
jaw I Disease
of O Disease
steel O Disease
) I None
after I None
succinylcholine I Chemical
<eof> I None

<s> O None
( I None
Sch I Chemical
) I None
administration I None
during I None
general I None
anesthetic I None
management I None
for I None
rigid I None
bronchoscopic I None
removal I None
of I None
a I None
tracheal I None
foreign I None
body I None
. I None
<eof> I None

<s> O None
Anesthesia I None
was I None
continued I None
uneventfully I None
with I None
propofol I Chemical
infusion I None
while I None
all I None
facilities I None
were I None
available I None
to I None
detect I None
and I None
treat I None
malignant I Disease
hyperthermia O Disease
. I None
<eof> I None

<s> O None
Minor I None
neurological I Disease
dysfunction O Disease
, I None
cognitive I None
development I None
, I None
and I None
somatic I None
development I None
at I None
the I None
age I None
of I None
3 I None
to I None
7 I None
years I None
after I None
dexamethasone I Chemical
treatment I None
in I None
very I None
- I None
low I None
birth I None
- I None
weight I None
infants I None
. I None
<eof> I None

<s> O None
The I None
objective I None
of I None
this I None
study I None
was I None
to I None
assess I None
minor I None
neurological I Disease
dysfunction O Disease
, I None
cognitive I None
development I None
, I None
and I None
somatic I None
development I None
after I None
dexamethasone I Chemical
therapy I None
in I None
very I None
- I None
low I None
- I None
birthweight I None
infants I None
. I None
<eof> I None

<s> O None
Thirty I None
- I None
three I None
children I None
after I None
dexamethasone I Chemical
treatment I None
were I None
matched I None
to I None
33 I None
children I None
without I None
dexamethasone I Chemical
treatment I None
. I None
<eof> I None

<s> O None
Data I None
were I None
assessed I None
at I None
the I None
age I None
of I None
3 I None
- I None
7 I None
years I None
. I None
<eof> I None

<s> O None
Dexamethasone I Chemical
was I None
started I None
between I None
the I None
7th I None
and I None
the I None
28th I None
day I None
of I None
life I None
over I None
7 I None
days I None
with I None
a I None
total I None
dose I None
of I None
2.35 I None
mg I None
/ I None
kg I None
/ I None
day I None
. I None
<eof> I None

<s> O None
Exclusion I None
criteria I None
were I None
asphyxia I Disease
, I None
malformations I Disease
, I None
major I None
surgical I None
interventions I None
, I None
small I None
for I None
gestational I None
age I None
, I None
intraventricular I None
haemorrhage I Disease
grades I None
III I None
and I None
IV I None
, I None
periventricular I Disease
leukomalacia O Disease
, I None
and I None
severe I None
psychomotor I Disease
retardation O Disease
. I None
<eof> I None

<s> O None
Each I None
child I None
was I None
examined I None
by I None
a I None
neuropediatrician I None
for I None
minor I None
neurological I Disease
dysfunctions O Disease
and I None
tested I None
by I None
a I None
psychologist I None
for I None
cognitive I None
development I None
with I None
a I None
Kaufman I None
Assessment I None
Battery I None
for I None
Children I None
and I None
a I None
Draw I None
- I None
a I None
- I None
Man I None
Test I None
. I None
<eof> I None

<s> O None
There I None
were I None
no I None
differences I None
in I None
demographic I None
data I None
, I None
growth I None
, I None
and I None
socio I None
- I None
economic I None
status I None
between I None
the I None
two I None
groups I None
. I None
<eof> I None

<s> O None
Fine I None
motor I None
skills I None
and I None
gross I None
motor I None
function I None
were I None
significantly I None
better I None
in I None
the I None
control I None
group I None
( I None
p<0.01 I None
) I None
. I None
<eof> I None

<s> O None
In I None
the I None
Draw I None
- I None
a I None
- I None
Man I None
Test I None
, I None
the I None
control I None
group I None
showed I None
better I None
results I None
( I None
p<0.001 I None
) I None
. I None
<eof> I None

<s> O None
There I None
were I None
no I None
differences I None
in I None
development I None
of I None
speech I None
, I None
social I None
development I None
, I None
and I None
the I None
Kaufman I None
Assessment I None
Battery I None
for I None
Children I None
. I None
<eof> I None

<s> O None
After I None
dexamethasone I Chemical
treatment I None
, I None
children I None
showed I None
a I None
higher I None
rate I None
of I None
minor I None
neurological I Disease
dysfunctions O Disease
. I None
<eof> I None

<s> O None
Neurological I None
development I None
was I None
affected I None
even I None
without I None
neurological I None
diagnosis I None
. I None
<eof> I None

<s> O None
Further I None
long I None
- I None
term I None
follow I None
- I None
up I None
studies I None
will I None
be I None
necessary I None
to I None
fully I None
evaluate I None
the I None
impact I None
of I None
dexamethasone I Chemical
on I None
neurological I None
and I None
cognitive I None
development I None
. I None
<eof> I None

<s> O None
Force I None
overflow I None
and I None
levodopa I Chemical
-induced I None
<eof> I None

<s> O None
dyskinesias I Disease
in I None
Parkinson I Disease
's O Disease
disease O Disease
. I None
<eof> I None

<s> O None
We I None
assessed I None
force I None
coordination I None
of I None
the I None
hand I None
in I None
<eof> I None

<s> O None
Parkinson I Disease
's O Disease
disease O Disease
and I None
its I None
relationship I None
to I None
motor I None
complications I None
of I None
levodopa I Chemical
therapy I None
, I None
particularly I None
to I None
levodopa I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
dyskinesias I Disease
<eof> I None

<s> O None
( I None
LID I Disease
) I None
. I None
<eof> I None

<s> O None
We I None
studied I None
two I None
groups I None
of I None
Parkinson I Disease
's O Disease
disease O Disease
patients I None
with I None
( I None
Parkinson I Disease
's O Disease
disease O Disease
+ I None
LID I Disease
, I None
n I None
= I None
23 I None
) I None
and I None
without I None
<eof> I None

<s> O None
levodopa I Chemical
-induced I None
<eof> I None

<s> O None
dyskinesias I Disease
<eof> I None

<s> O None
( I None
Parkinson I Disease
's O Disease
disease O Disease
- I None
LID I Disease
, I None
n I None
= I None
10 I None
) I None
, I None
and I None
age I None
- I None
matched I None
healthy I None
controls I None
. I None
<eof> I None

<s> O None
The I None
motor I None
score I None
of I None
the I None
Unified I None
Parkinson I Disease
's O Disease
Disease O Disease
<eof> I None

<s> O None
Rating I None
Scale I None
, I None
a I None
dyskinesia I Disease
score I None
and I None
force I None
in I None
a I None
grip I None
- I None
lift I None
paradigm I None
were I None
assessed I None
ON I None
and I None
OFF I None
levodopa I Chemical
. I None
<eof> I None

<s> O None
A I None
pathological I None
increase I None
of I None
forces I None
was I None
seen I None
in I None
ON I None
- I None
state I None
in I None
Parkinson I Disease
's O Disease
disease O Disease
+ I None
<eof> I None

<s> O None
LID I Disease
only I None
. I None
<eof> I None

<s> O None
In I None
Parkinson I Disease
's O Disease
disease O Disease
+ I None
LID I Disease
, I None
the I None
force I None
involved I None
in I None
pressing I None
down I None
the I None
object I None
before I None
lifting I None
was I None
significantly I None
increased I None
by I None
levodopa I Chemical
<eof> I None

<s> O None
( I None
by I None
61 I None
% I None
, I None
P I None
< I None
0.05 I None
) I None
. I None
<eof> I None

<s> O None
An I None
overshooting I None
of I None
peak I None
grip I None
force I None
by I None
51 I None
% I None
( I None
P I None
< I None
0.05 I None
) I None
and I None
of I None
static I None
grip I None
force I None
by I None
45 I None
% I None
( I None
P I None
< I None
0.01 I None
) I None
was I None
observed I None
in I None
the I None
ON- I None
compared I None
with I None
the I None
OFF I None
- I None
drug I None
condition I None
. I None
<eof> I None

<s> O None
In I None
contrast I None
, I None
no I None
excessive I None
force I None
was I None
found I None
in I None
Parkinson I Disease
's O Disease
disease O Disease
- I None
LID I Disease
. I None
<eof> I None

<s> O None
Peak I None
grip I None
force I None
in I None
ON I None
- I None
state I None
was I None
140 I None
% I None
( I None
P I None
< I None
0.05 I None
) I None
higher I None
in I None
Parkinson I Disease
's O Disease
disease O Disease
+ I None
LID I Disease
than I None
in I None
Parkinson I Disease
's O Disease
disease O Disease
- I None
LID I Disease
, I None
while I None
static I None
grip I None
force I None
was I None
increased I None
by I None
138 I None
% I None
( I None
P I None
< I None
0.01 I None
) I None
between I None
groups I None
. I None
<eof> I None

<s> O None
Severity I None
of I None
peak I None
- I None
dose I None
dyskinesias I Disease
was I None
strongly I None
correlated I None
with I None
grip I None
force I None
in I None
ON I None
- I None
state I None
( I None
r I None
= I None
0.79 I None
with I None
peak I None
force I None
, I None
P I None
< I None
0.01 I None
) I None
. I None
<eof> I None

<s> O None
No I None
correlation I None
was I None
observed I None
between I None
forces I None
and I None
the I None
motor I None
score I None
as I None
well I None
as I None
with I None
the I None
daily I None
dose I None
of I None
dopaminergic I None
medication I None
. I None
<eof> I None

<s> O None
Force I None
excess I None
was I None
only I None
observed I None
in I None
patients I None
with I None
LID I Disease
and I None
motor I None
fluctuations I None
. I None
<eof> I None

<s> O None
A I None
close I None
relationship I None
was I None
seen I None
between I None
the I None
overshooting I None
of I None
forces I None
and I None
dyskinesias I Disease
in I None
the I None
ON I None
- I None
drug I None
condition I None
. I None
<eof> I None

<s> O None
We I None
postulate I None
that I None
both I None
LID I Disease
and I None
grip I None
force I None
excess I None
share I None
common I None
pathophysiological I None
mechanisms I None
related I None
to I None
motor I None
fluctuations I None
. I None
<eof> I None

<s> O None
Postinfarction I None
ventricular I Disease
septal O Disease
defect O Disease
associated I None
with I None
long I None
- I None
term I None
steroid I Chemical
therapy I None
. I None
<eof> I None

<s> O None
Two I None
cases I None
of I None
postinfarction I None
ventricular I Disease
septal O Disease
rupture O Disease
in I None
patients I None
on I None
long I None
- I None
term I None
steroid I Chemical
therapy I None
are I None
presented I None
and I None
the I None
favourable I None
outcome I None
in I None
both I None
cases I None
described I None
. I None
<eof> I None

<s> O None
A I None
possible I None
association I None
between I None
steroid I Chemical
therapy I None
and I None
subsequent I None
postinfarction I None
septal I Disease
rupture O Disease
is I None
discussed I None
. I None
<eof> I None

<s> O None
Angioedema I Disease
associated I None
with I None
droperidol I Chemical
administration I None
. I None
<eof> I None

<s> O None
Angioedema I Disease
, I None
also I None
known I None
as I None
angioneurotic I Disease
edema O Disease
or I None
Quincke I Disease
's O Disease
disease O Disease
, I None
is I None
a I None
well I None
- I None
demarcated I None
, I None
localized I None
edema I Disease
involving I None
the I None
subcutaneous I None
tissues I None
that I None
may I None
cause I None
upper I Disease
- O Disease
airway O Disease
obstruction O Disease
. I None
<eof> I None

<s> O None
We I None
report I None
the I None
case I None
of I None
a I None
previously I None
healthy I None
19-year I None
- I None
old I None
man I None
with I None
no I None
known I None
drug I Disease
allergies O Disease
in I None
whom I None
angioedema I Disease
with I None
significant I None
tongue I None
swelling I None
and I None
protrusion I None
developed I None
within I None
10 I None
minutes I None
of I None
the I None
administration I None
of I None
a I None
single I None
IV I None
dose I None
of I None
droperidol I Chemical
. I None
<eof> I None

<s> O None
Clarithromycin I Chemical
-associated I None
visual I Disease
hallucinations O Disease
in I None
a I None
patient I None
with I None
chronic I Disease
renal O Disease
failure O Disease
on I None
continuous I None
ambulatory I None
peritoneal I None
dialysis I None
. I None
<eof> I None

<s> O None
Visual I Disease
hallucinations O Disease
are I None
a I None
rare I None
event I None
in I None
chronic I Disease
renal O Disease
failure O Disease
and I None
not I None
related I None
to I None
uremia I Disease
per I None
se I None
. I None
<eof> I None

<s> O None
Unreported I None
in I None
the I None
literature I None
is I None
visual I Disease
hallucinations O Disease
<eof> I None

<s> O None
occurring I None
in I None
association I None
with I None
the I None
new I None
macrolide I Chemical
antibiotic I None
, I None
clarithromycin I Chemical
. I None
<eof> I None

<s> O None
We I None
describe I None
such I None
a I None
case I None
in I None
a I None
patient I None
with I None
end I Disease
- O Disease
stage O Disease
renal O Disease
disease O Disease
<eof> I None

<s> O None
( I None
ESRD I Disease
) I None
maintained I None
on I None
continuous I None
ambulatory I None
peritoneal I None
dialysis I None
( I None
CAPD I None
) I None
. I None
<eof> I None

<s> O None
The I None
combination I None
of I None
a I None
relatively I None
high I None
dose I None
of I None
clarithromycin I Chemical
in I None
face I None
of I None
chronic I Disease
renal O Disease
failure O Disease
in I None
a I None
functionally I None
anephric I None
patient I None
, I None
with I None
underlying I None
aluminum I Chemical
intoxication I None
, I None
may I None
have I None
facilitated I None
the I None
appearance I None
of I None
this I None
neurotoxic I Disease
side I None
effect I None
. I None
<eof> I None

<s> O None
It I None
is I None
important I None
to I None
understand I None
the I None
pharmacokinetics I None
of I None
medications I None
in I None
face I None
of I None
chronic I Disease
renal O Disease
failure O Disease
, I None
the I None
possibility I None
of I None
drug I None
interactions I None
, I None
and I None
how I None
these I None
factors I None
should I None
help I None
guide I None
medication I None
therapy I None
in I None
the I None
ESRD I Disease
patient I None
. I None
<eof> I None

<s> O None
Acute I None
renal I Disease
toxicity O Disease
of I None
<eof> I None

<s> O None
doxorubicin I Chemical
<eof> I None

<s> O None
( I None
adriamycin I Chemical
) I None
-loaded I None
<eof> I None

<s> O None
cyanoacrylate I Chemical
nanoparticles I None
. I None
<eof> I None

<s> O None
Acute I None
doxorubicin I Chemical
-loaded I None
nanoparticle I None
( I None
DXNP I None
) I None
<eof> I None

<s> O None
renal I Disease
toxicity O Disease
was I None
explored I None
in I None
both I None
normal I None
rats I None
and I None
rats I None
with I None
experimental I None
glomerulonephritis I Disease
. I None
<eof> I None

<s> O None
In I None
normal I None
rats I None
, I None
2/6 I None
rats I None
given I None
free I None
doxorubicin I Chemical
<eof> I None

<s> O None
( I None
DX I Chemical
) I None
( I None
5 I None
mg I None
/ I None
kg I None
) I None
died I None
within I None
one I None
week I None
, I None
whereas I None
all I None
control I None
animals I None
and I None
all I None
rats I None
having I None
received I None
free I None
NP I None
or I None
DXNP I None
survived I None
. I None
<eof> I None

<s> O None
A I None
3 I None
times I None
higher I None
proteinuria I Disease
appeared I None
in I None
animals I None
treated I None
with I None
DXNP I None
than I None
in I None
those I None
treated I None
with I None
DX I Chemical
. I None
<eof> I None

<s> O None
Free I None
NP I None
did I None
not I None
provoke I None
any I None
proteinuria I Disease
. I None
<eof> I None

<s> O None
Two I None
hr I None
post I None
- I None
injection I None
, I None
DXNP I None
was I None
2.7 I None
times I None
more I None
concentrated I None
in I None
kidneys I None
than I None
free I None
DX I Chemical
<eof> I None

<s> O None
( I None
p I None
< I None
0.025 I None
) I None
. I None
<eof> I None

<s> O None
In I None
rats I None
with I None
immune I None
experimental I None
glomerulonephritis I Disease
, I None
5/6 I None
rats I None
given I None
DX I Chemical
died I None
within I None
7 I None
days I None
, I None
in I None
contrast I None
to I None
animals I None
treated I None
by I None
DXNP I None
, I None
NP I None
, I None
or I None
untreated I None
, I None
which I None
all I None
survived I None
. I None
<eof> I None

<s> O None
Proteinuria I Disease
appeared I None
in I None
all I None
series I None
, I None
but I None
was I None
2 I None
- I None
5 I None
times I None
more I None
intense I None
( I None
p I None
> I None
0.001 I None
) I None
and I None
prolonged I None
after I None
doxorubicin I Chemical
treatment I None
( I None
400 I None
- I None
700 I None
mg I None
/ I None
day I None
) I None
, I None
without I None
significant I None
difference I None
between I None
DXNP I None
and I None
DX I Chemical
. I None
<eof> I None

<s> O None
Rats I None
treated I None
by I None
unloaded I None
NP I None
behaved I None
as I None
controls I None
. I None
<eof> I None

<s> O None
These I None
results I None
demonstrate I None
that I None
, I None
in I None
these I None
experimental I None
conditions I None
, I None
DXNP I None
killed I None
less I None
animals I None
than I None
free I None
DX I Chemical
, I None
despite I None
of I None
an I None
enhanced I None
renal I Disease
toxicity O Disease
of I None
the I None
former I None
. I None
<eof> I None

<s> O None
Both I None
effects I None
( I None
better I None
survival I None
and I None
nephrosis I Disease
) I None
are I None
most I None
probably I None
related I None
to I None
an I None
enhanced I None
capture I None
of I None
DXNP I None
by I None
cells I None
of I None
the I None
mononuclear I None
phagocyte I None
system I None
, I None
including I None
mesangial I None
cells I None
. I None
<eof> I None

<s> O None
Etoposide I Chemical
-related I None
myocardial I Disease
infarction O Disease
. I None
<eof> I None

<s> O None
The I None
occurrence I None
of I None
a I None
myocardial I Disease
infarction O Disease
is I None
reported I None
after I None
chemotherapy I None
containing I None
etoposide I Chemical
, I None
in I None
a I None
man I None
with I None
no I None
risk I None
factors I None
for I None
coronary I Disease
heart O Disease
disease O Disease
. I None
<eof> I None

<s> O None
Possible I None
causal I None
mechanisms I None
are I None
discussed I None
. I None
<eof> I None

<s> O None
Subjective I None
assessment I None
of I None
sexual I Disease
dysfunction O Disease
of I None
patients I None
on I None
long I None
- I None
term I None
administration I None
of I None
digoxin I Chemical
. I None
<eof> I None

<s> O None
Various I None
data I None
suggest I None
that I None
male I None
patients I None
who I None
have I None
received I None
digoxin I Chemical
on I None
a I None
longterm I None
basis I None
have I None
increased I None
levels I None
of I None
serum I None
estrogen I Chemical
and I None
decreased I None
levels I None
of I None
plasma I None
testosterone I Chemical
and I None
luteinizing I None
hormone I None
( I None
LH I None
) I None
. I None
<eof> I None

<s> O None
This I None
study I None
was I None
undertaken I None
to I None
investigate I None
the I None
links I None
between I None
the I None
long I None
- I None
term I None
administration I None
of I None
digoxin I Chemical
therapy I None
and I None
sexual I None
behavior I None
, I None
and I None
the I None
effect I None
of I None
digoxin I Chemical
on I None
plasma I None
levels I None
of I None
estradiol I Chemical
, I None
testosterone I Chemical
, I None
and I None
LH I None
. I None
<eof> I None

<s> O None
The I None
patients I None
of I None
the I None
study I None
and I None
control I None
group I None
( I None
without I None
digoxin I Chemical
) I None
were I None
of I None
similar I None
cardiac I None
functional I None
capacity I None
and I None
age I None
( I None
25 I None
- I None
40 I None
years I None
) I None
and I None
were I None
randomly I None
selected I None
from I None
the I None
rheumatic I Disease
heart O Disease
disease O Disease
patients I None
. I None
<eof> I None

<s> O None
A I None
subjective I None
assessment I None
of I None
sexual I None
behavior I None
in I None
the I None
study I None
and I None
control I None
groups I None
was I None
carried I None
out I None
, I None
using I None
parameters I None
such I None
as I None
sexual I None
desire I None
, I None
sexual I None
excitement I None
, I None
and I None
frequency I None
of I None
sexual I None
relations I None
. I None
<eof> I None

<s> O None
Personal I None
interviews I None
and I None
a I None
questionnaire I None
were I None
also I None
used I None
for I None
the I None
evaluation I None
of I None
sexual I None
behavior I None
. I None
<eof> I None

<s> O None
The I None
findings I None
support I None
the I None
reports I None
concerning I None
digoxin I Chemical
effect I None
on I None
plasma I None
estradiol I Chemical
, I None
testosterone I Chemical
, I None
and I None
LH I None
. I None
<eof> I None

<s> O None
The I None
differences I None
in I None
the I None
means I None
were I None
significant I None
. I None
<eof> I None

<s> O None
Tests I None
used I None
to I None
evaluate I None
the I None
changes I None
in I None
sexual I None
behavior I None
showed I None
a I None
significant I None
decrease I Disease
in O Disease
sexual O Disease
desire O Disease
, I None
sexual I None
excitement I None
phase I None
( I None
erection I None
) I None
, I None
and I None
frequency I None
of I None
sexual I None
relations I None
in I None
the I None
study I None
group I None
. I None
<eof> I None

<s> O None
Fatal I None
aplastic I Disease
anemia O Disease
due I None
to I None
indomethacin I Chemical
--lymphocyte I None
transformation I None
tests I None
in I None
vitro I None
. I None
<eof> I None

<s> O None
Although I None
indomethacin I Chemical
has I None
been I None
implicated I None
as I None
a I None
possible I None
cause I None
of I None
aplastic I Disease
anemia O Disease
on I None
the I None
basis I None
of I None
a I None
few I None
clinical I None
observations I None
, I None
its I None
role I None
has I None
not I None
been I None
definitely I None
established I None
. I None
<eof> I None

<s> O None
A I None
case I None
of I None
fatal I None
aplastic I Disease
anemia O Disease
is I None
described I None
in I None
which I None
no I None
drugs I None
other I None
than I None
allopurinol I Chemical
and I None
indomethacin I Chemical
were I None
given I None
. I None
<eof> I None

<s> O None
Indomethacin I Chemical
was I None
first I None
given I None
four I None
weeks I None
prior I None
to I None
the I None
onset I None
of I None
symptoms I None
. I None
<eof> I None

<s> O None
A I None
positive I None
lymphocyte I None
transformation I None
test I None
with I None
indomethacin I Chemical
<eof> I None

<s> O None
in I None
vitro I None
further I None
substantiates I None
the I None
potential I None
role I None
of I None
this I None
drug I None
in I None
causing I None
aplastic I Disease
anemia O Disease
in I None
a I None
susceptible I None
patient I None
. I None
<eof> I None

<s> O None
Fortunately I None
, I None
this I None
seems I None
to I None
be I None
a I None
very I None
rare I None
complication I None
. I None
<eof> I None

<s> O None
Plasma I None
and I None
urinary I None
lipids I None
and I None
lipoproteins I None
during I None
the I None
development I None
of I None
nephrotic I Disease
syndrome O Disease
induced I None
in I None
the I None
rat I None
by I None
puromycin I Chemical
aminonucleoside O Chemical
. I None
<eof> I None

<s> O None
This I None
study I None
was I None
undertaken I None
to I None
ascertain I None
whether I None
the I None
alterations I None
of I None
plasma I None
lipoproteins I None
found I None
in I None
nephrotic I Disease
syndrome O Disease
induced I None
by I None
puromycin I Chemical
aminonucleoside O Chemical
were I None
due I None
to I None
nephrotic I Disease
syndrome O Disease
per I None
se I None
, I None
or I None
, I None
at I None
least I None
in I None
part I None
, I None
to I None
the I None
aminonucleoside I Chemical
. I None
<eof> I None

<s> O None
The I None
purpose I None
of I None
the I None
present I None
study I None
was I None
to I None
investigate I None
the I None
changes I None
in I None
plasma I None
and I None
urinary I None
lipoproteins I None
during I None
the I None
administration I None
of I None
puromycin I Chemical
aminonucleoside O Chemical
<eof> I None

<s> O None
( I None
20 I None
mg I None
/ I None
kg I None
for I None
7 I None
days I None
) I None
and I None
the I None
subsequent I None
development I None
of I None
nephrotic I Disease
syndrome O Disease
. I None
<eof> I None

<s> O None
Since I None
massive I None
albuminuria I Disease
occurred I None
after I None
6 I None
days I None
of I None
treatment I None
, I None
the I None
time I None
- I None
course I None
study I None
was I None
divided I None
into I None
two I None
stages I None
: I None
pre- I None
nephrotic I Disease
stage I None
( I None
day I None
1 I None
- I None
5 I None
) I None
and I None
nephrotic I Disease
stage I None
( I None
day I None
6 I None
- I None
11 I None
) I None
. I None
<eof> I None

<s> O None
In I None
pre- I None
<eof> I None

<s> O None
nephrotic I Disease
stage I None
the I None
plasma I None
level I None
of I None
fatty I Chemical
acids O Chemical
, I None
triacylglycerol I Chemical
and I None
VLDL I None
decreased I None
while I None
that I None
of I None
phospholipid I None
, I None
cholesteryl I Chemical
esters O Chemical
and I None
HDL I None
remained I None
constant I None
. I None
<eof> I None

<s> O None
Plasma I None
apolipoprotein I None
<eof> I None

<s> O None
A I None
- I None
I I None
tended I None
to I None
increase I None
( I None
40 I None
% I None
increase I None
at I None
day I None
5 I None
) I None
. I None
<eof> I None

<s> O None
At I None
the I None
beginning I None
of I None
nephrotic I Disease
stage I None
( I None
day I None
6 I None
) I None
the I None
concentration I None
of I None
plasma I None
albumin I None
dropped I None
to I None
a I None
very I None
low I None
level I None
, I None
while I None
that I None
of I None
<eof> I None

<s> O None
apolipoprotein I None
A I None
- I None
I I None
increased I None
abruptly I None
( I None
4-fold I None
increase I None
) I None
and I None
continued I None
to I None
rise I None
, I None
although I None
less I None
steeply I None
, I None
in I None
the I None
following I None
days I None
. I None
<eof> I None

<s> O None
The I None
plasma I None
concentration I None
of I None
HDL I None
followed I None
the I None
same I None
pattern I None
. I None
<eof> I None

<s> O None
Plasma I None
VLDL I None
and I None
LDL I None
increased I None
at I None
a I None
later I None
stage I None
( I None
day I None
9 I None
) I None
. I None
<eof> I None

<s> O None
Plasma I None
apolipoprotein I None
<eof> I None

<s> O None
A I None
- I None
I I None
was I None
found I None
not I None
only I None
in I None
HDL I None
( I None
1.063 I None
- I None
1.210 I None
g I None
/ I None
ml I None
) I None
but I None
also I None
in I None
the I None
LDL I None
density I None
class I None
( I None
1.025 I None
- I None
1.050 I None
g I None
/ I None
ml I None
) I None
. I None
<eof> I None

<s> O None
In I None
the I None
pre- I None
<eof> I None

<s> O None
nephrotic I Disease
stage I None
lipoproteinuria I None
was I None
negligible I None
, I None
while I None
in I None
the I None
early I None
nephrotic I Disease
stage I None
the I None
urinary I None
loss I None
of I None
plasma I None
lipoproteins I None
consisted I None
mainly I None
of I None
HDL I None
. I None
<eof> I None

<s> O None
These I None
observations I None
indicate I None
that I None
puromycin I Chemical
aminonucleoside O Chemical
alters I None
plasma I None
lipoproteins I None
by I None
lowering I None
VLDL I None
and I None
increasing I None
HDL I None
. I None
<eof> I None

<s> O None
It I None
is I None
likely I None
that I None
the I None
early I None
and I None
striking I None
increase I None
of I None
plasma I None
HDL I None
found I None
in I None
nephrotic I Disease
rats I None
is I None
related I None
to I None
a I None
direct I None
effect I None
of I None
the I None
drug I None
on I None
HDL I None
metabolism I None
. I None
<eof> I None

<s> O None
Circulating I None
lysosomal I None
enzymes I None
and I None
acute I Disease
hepatic O Disease
necrosis O Disease
. I None
<eof> I None

<s> O None
The I None
activities I None
of I None
the I None
lysosomal I None
enzymes I None
acid I None
and I None
neutral I None
protease I None
, I None
N I None
- I None
acetylglucosaminidase I None
, I None
and I None
acid I None
phosphatase I None
were I None
measured I None
in I None
the I None
serum I None
of I None
patients I None
with I None
fulminant I Disease
hepatic O Disease
failure O Disease
. I None
<eof> I None

<s> O None
Acid I None
protease I None
( I None
cathepsin I None
D I None
) I None
activity I None
was I None
increased I None
about I None
tenfold I None
in I None
patients I None
who I None
died I None
and I None
nearly I None
fourfold I None
in I None
those I None
who I None
survived I None
fulminant I Disease
hepatic O Disease
failure O Disease
after I None
paracetamol I Chemical
overdose I Disease
, I None
whereas I None
activities I None
were I None
increased I None
equally I None
in I None
patients I None
with I None
fulminant I Disease
hepatic O Disease
failure O Disease
due I None
to I None
viral I Disease
hepatitis O Disease
whether I None
or I None
not I None
they I None
survived I None
. I None
<eof> I None

<s> O None
A I None
correlation I None
was I None
found I None
between I None
serum I None
acid I None
protease I None
activity I None
and I None
prothrombin I None
time I None
, I None
and I None
the I None
increase I None
in I None
cathepsin I None
D I None
activity I None
was I None
sustained I None
over I None
several I None
days I None
compared I None
with I None
aspartate I Chemical
aminotransferase I None
, I None
which I None
showed I None
a I None
sharp I None
early I None
peak I None
and I None
then I None
a I None
fall I None
. I None
<eof> I None

<s> O None
Circulating I None
lysosomal I None
proteases I None
can I None
damage I None
other I None
organs I None
, I None
and I None
measurement I None
of I None
their I None
activity I None
may I None
therefore I None
be I None
of I None
added I None
value I None
in I None
assessing I None
prognosis I None
in I None
this I None
condition I None
. I None
<eof> I None

<s> O None
Transketolase I None
abnormality I None
in I None
tolazamide I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
Wernicke I Disease
's O Disease
encephalopathy O Disease
. I None
<eof> I None

<s> O None
We I None
studied I None
a I None
thiamine I Chemical
-dependent I None
enzyme I None
, I None
transketolase I None
, I None
from I None
fibroblasts I None
of I None
a I None
diabetic I Disease
patient I None
who I None
developed I None
Wernicke I Disease
's O Disease
encephalopathy O Disease
when I None
treated I None
with I None
tolazamide I Chemical
, I None
in I None
order I None
to I None
delineate I None
if I None
this I None
patient I None
also I None
had I None
transketolase I None
abnormality I None
[ I None
high I None
Km I None
for I None
thiamine I Chemical
pyrophosphate O Chemical
<eof> I None

<s> O None
( I None
TPP I Chemical
) I None
] I None
, I None
as I None
previously I None
reported I None
in I None
postalcoholic I None
Wernicke I Disease
- O Disease
Korsakoff O Disease
syndrome O Disease
. I None
<eof> I None

<s> O None
In I None
addition I None
to I None
this I None
patient I None
, I None
we I None
also I None
studied I None
this I None
enzyme I None
from I None
three I None
diabetic I Disease
kindreds I None
without I None
any I None
history I None
of I None
Wernicke I Disease
's O Disease
encephalopathy O Disease
and I None
from I None
four I None
normal I None
controls I None
. I None
<eof> I None

<s> O None
We I None
found I None
that I None
the I None
above I None
- I None
mentioned I None
patient I None
and I None
one I None
of I None
the I None
diabetic I Disease
kindreds I None
with I None
no I None
history I None
of I None
Wernicke I Disease
's O Disease
encephalopathy O Disease
<eof> I None

<s> O None
had I None
abnormal I None
transketolase I None
as I None
determined I None
by I None
its I None
Km I None
for I None
TPP I Chemical
. I None
<eof> I None

<s> O None
These I None
data I None
suggest I None
a I None
similarity I None
between I None
postalcoholic I None
Wernicke I Disease
- O Disease
Korsakoff O Disease
syndrome O Disease
and I None
the I None
patient I None
with I None
tolazamide I Chemical
-induced I None
<eof> I None

<s> O None
Wernicke I Disease
's O Disease
encephalopathy O Disease
from I None
the I None
standpoint I None
of I None
transketolase I None
abnormality I None
. I None
<eof> I None

<s> O None
Mechanisms I None
of I None
myocardial I Disease
ischemia O Disease
induced I None
by I None
epinephrine I Chemical
: I None
comparison I None
with I None
exercise I None
- I None
induced I None
ischemia I Disease
. I None
<eof> I None

<s> O None
The I None
role I None
of I None
epinephrine I Chemical
in I None
eliciting I None
myocardial I Disease
ischemia O Disease
was I None
examined I None
in I None
patients I None
with I None
coronary I Disease
artery O Disease
disease O Disease
. I None
<eof> I None

<s> O None
Objective I None
signs I None
of I None
ischemia I Disease
and I None
factors I None
increasing I None
myocardial I None
oxygen I Chemical
consumption I None
were I None
compared I None
during I None
epinephrine I Chemical
infusion I None
and I None
supine I None
bicycle I None
exercise I None
. I None
<eof> I None

<s> O None
Both I None
epinephrine I Chemical
and I None
exercise I None
produced I None
<eof> I None

<s> O None
myocardial I Disease
ischemia O Disease
as I None
evidenced I None
by I None
ST I None
segment I None
depression I Disease
and I None
angina I Disease
. I None
<eof> I None

<s> O None
However I None
, I None
the I None
mechanisms I None
of I None
myocardial I Disease
ischemia O Disease
induced I None
by I None
epinephrine I Chemical
were I None
significantly I None
different I None
from I None
those I None
of I None
exercise I None
. I None
<eof> I None

<s> O None
Exercise I None
- I None
induced I None
<eof> I None

<s> O None
myocardial I Disease
ischemia O Disease
was I None
marked I None
predominantly I None
by I None
increased I None
heart I None
rate I None
and I None
rate I None
- I None
pressure I None
product I None
with I None
a I None
minor I None
contribution I None
of I None
end I None
- I None
diastolic I None
volume I None
, I None
while I None
<eof> I None

<s> O None
epinephrine I Chemical
-induced I None
ischemia I Disease
was I None
characterized I None
by I None
a I None
marked I None
increase I None
in I None
contractility I None
and I None
a I None
less I None
pronounced I None
increase I None
in I None
heart I None
rate I None
and I None
rate I None
- I None
pressure I None
product I None
. I None
<eof> I None

<s> O None
These I None
findings I None
indicate I None
that I None
ischemia I Disease
produced I None
by I None
epinephrine I Chemical
, I None
as I None
may I None
occur I None
during I None
states I None
of I None
emotional I None
distress I None
, I None
has I None
a I None
mechanism I None
distinct I None
from I None
that I None
due I None
to I None
physical I None
exertion I None
. I None
<eof> I None

<s> O None
Transient I None
contralateral I Disease
rotation O Disease
following I None
unilateral I None
substantia I Disease
nigra O Disease
lesion O Disease
reflects I None
susceptibility I None
of I None
the I None
nigrostriatal I None
system I None
to I None
exhaustion I None
by I None
amphetamine I Chemical
. I None
<eof> I None

<s> O None
Following I None
unilateral I None
6-OHDA I Chemical
induced I None
SN I Disease
lesion O Disease
, I None
a I None
transient I None
period I None
of I None
contralateral I Disease
rotation O Disease
has I None
been I None
reported I None
to I None
precede I None
the I None
predominant I None
ipsilateral I Disease
circling O Disease
. I None
<eof> I None

<s> O None
In I None
order I None
to I None
clarify I None
the I None
nature I None
of I None
this I None
initial I None
contralateral I Disease
rotation O Disease
<eof> I None

<s> O None
we I None
examined I None
the I None
effect I None
of I None
the I None
duration I None
of I None
recovery I None
period I None
after I None
the I None
lesion I None
, I None
on I None
amphetamine I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
rotational I Disease
behavior O Disease
. I None
<eof> I None

<s> O None
Three I None
days I None
post I None
lesion I None
, I None
most I None
rats I None
circled I None
predominantly I None
contralaterally I None
to I None
the I None
lesion I None
. I None
<eof> I None

<s> O None
Such I None
contralateral I Disease
rotation O Disease
may I None
result I None
from I None
either I None
degeneration I None
- I None
induced I None
breakdown I None
of I None
the I None
DA I None
pool I None
, I None
or I None
lesion I None
- I None
induced I None
increase I None
of I None
DA I None
turnover I None
in I None
the I None
spared I None
neurons I None
. I None
<eof> I None

<s> O None
A I None
substantial I None
degree I None
of I None
contralateral I None
preference I None
was I None
still I None
evident I None
when I None
amphetamine I Chemical
was I None
administered I None
for I None
the I None
first I None
time I None
24 I None
days I None
after I None
lesioning I None
, I None
indicating I None
involvement I None
of I None
spared I None
cells I None
in I None
the I None
contralateral I Disease
rotation O Disease
. I None
<eof> I None

<s> O None
However I None
, I None
regardless I None
of I None
the I None
duration I None
of I None
recovery I None
( I None
and I None
irrespective I None
of I None
either I None
lesion I None
volume I None
, I None
amphetamine I Chemical
dose I None
, I None
or I None
post I None
- I None
lesion I None
motor I None
exercise I None
) I None
, I None
amphetamine I Chemical
-induced I None
<eof> I None

<s> O None
rotation I Disease
tended I None
to I None
become I None
gradually I None
more I None
ipsilateral I None
as I None
the I None
observation I None
session I None
progressed I None
, I None
and I None
all I None
rats I None
circled I None
ipsilaterally I None
to I None
the I None
lesion I None
in I None
response I None
to I None
further I None
amphetamine I Chemical
injections I None
. I None
<eof> I None

<s> O None
These I None
findings I None
suggest I None
that I None
amphetamine I Chemical
has I None
an I None
irreversible I None
effect I None
on I None
the I None
post I None
- I None
lesion I None
DA I None
pool I None
contributing I None
to I None
contralateral I Disease
rotation O Disease
. I None
<eof> I None

<s> O None
Thyroid I None
function I None
and I None
urine I None
- I None
concentrating I None
ability I None
during I None
lithium I Chemical
treatment I None
. I None
<eof> I None

<s> O None
It I None
has I None
been I None
suggested I None
that I None
adenylate I None
cyclase I None
inhibition I None
may I None
be I None
important I None
in I None
the I None
development I None
of I None
both I None
nephrogenic I Disease
diabetes O Disease
insipidus O Disease
and I None
hypothyroidism I Disease
during I None
lithium I Chemical
treatment I None
. I None
<eof> I None

<s> O None
We I None
measured I None
serum I None
thyroxine I Chemical
and I None
urine I None
- I None
concentrating I None
ability I None
<eof> I None

<s> O None
( I None
Umax I None
) I None
in I None
response I None
to I None
desmopressin I None
( I None
DDAVP I None
) I None
in I None
85 I None
patients I None
receiving I None
lithium I Chemical
. I None
<eof> I None

<s> O None
Hypothyroidism I Disease
developed I None
in I None
eight I None
patients I None
while I None
they I None
were I None
taking I None
lithium I Chemical
. I None
<eof> I None

<s> O None
Impaired I None
Umax I None
was I None
found I None
in I None
both I None
euthyroid I None
and I None
hypothyroid I Disease
patients I None
while I None
some I None
hypothyroid I Disease
patients I None
concentrated I None
their I None
urine I None
well I None
. I None
<eof> I None

<s> O None
It I None
is I None
concluded I None
that I None
the I None
dominant I None
mechanisms I None
by I None
which I None
lithium I Chemical
exerts I None
these I None
two I None
effects I None
are I None
different I None
. I None
<eof> I None

<s> O None
Sensitivity I None
of I None
erythroid I None
progenitor I None
colonies I None
to I None
erythropoietin I None
in I None
azidothymidine I Chemical
treated I None
immunodeficient I Disease
mice I None
. I None
<eof> I None

<s> O None
The I None
anaemia I Disease
induced I None
by I None
3'-azido-3'dideoxythymidine I Chemical
<eof> I None

<s> O None
( I None
AZT I Chemical
) I None
is I None
poorly I None
understood I None
. I None
<eof> I None

<s> O None
We I None
have I None
used I None
a I None
murine I None
model I None
of I None
AIDS I Disease
, I None
infection I Disease
of I None
female I None
C57BL/6 I None
mice I None
with I None
LP I None
- I None
BM5 I None
murine I None
leukaemia I Disease
<eof> I None

<s> O None
( I None
MuLV I None
) I None
virus I None
, I None
to I None
determine I None
if I None
AZT I Chemical
-induced I None
anaemia I Disease
is I None
due I None
, I None
in I None
part I None
, I None
to I None
decreased I None
responsiveness I None
of I None
erythropoietic I None
precursors I None
( I None
BFU I None
- I None
e I None
) I None
to I None
erythropoietin I None
( I None
EPO I None
) I None
. I None
<eof> I None

<s> O None
Mice I None
in I None
the I None
early I None
stage I None
of I None
LP I None
- I None
BM5 I None
MuLV I None
disease I None
were I None
given I None
AZT I Chemical
in I None
their I None
drinking I None
water I None
at I None
1.0 I None
and I None
2.5 I None
mg I None
/ I None
ml I None
. I None
<eof> I None

<s> O None
AZT I Chemical
produced I None
<eof> I None

<s> O None
anaemia I Disease
in I None
both I None
groups I None
, I None
in I None
a I None
dose I None
- I None
dependent I None
fashion I None
. I None
<eof> I None

<s> O None
Despite I None
the I None
anaemia I Disease
, I None
the I None
number I None
of I None
splenic I None
and I None
bone I None
marrow I None
BFU I None
- I None
e I None
in I None
AZT I Chemical
treated I None
mice I None
increased I None
up I None
to I None
five I None
- I None
fold I None
over I None
levels I None
observed I None
in I None
infected I None
untreated I None
animals I None
after I None
15 I None
d I None
of I None
treatment I None
. I None
<eof> I None

<s> O None
Colony I None
formation I None
by I None
splenic I None
and I None
bone I None
marrow I None
BFUe I None
was I None
stimulated I None
at I None
lower I None
concentrations I None
of I None
EPO I None
in I None
mice I None
receiving I None
AZT I Chemical
for I None
15 I None
d I None
than I None
for I None
infected I None
, I None
untreated I None
mice I None
. I None
<eof> I None

<s> O None
By I None
day I None
30 I None
, I None
sensitivity I None
of I None
both I None
splenic I None
and I None
bone I None
marrow I None
BFU I None
- I None
e I None
of I None
treated I None
animals I None
returned I None
to I None
that I None
observed I None
from I None
cells I None
of I None
infected I None
untreated I None
animals I None
. I None
<eof> I None

<s> O None
The I None
mean I None
plasma I None
levels I None
of I None
EPO I None
observed I None
in I None
AZT I Chemical
<eof> I None

<s> O None
treated I None
mice I None
were I None
appropriate I None
for I None
the I None
degree I None
of I None
anaemia I Disease
observed I None
when I None
compared I None
with I None
phenylhydrazine I Chemical
<eof> I None

<s> O None
( I None
PHZ I Chemical
) I None
treated I None
mice I None
. I None
<eof> I None

<s> O None
The I None
numbers I None
of I None
BFU I None
- I None
e I None
and I None
the I None
percentage I None
of I None
bone I None
marrow I None
erythroblasts I None
observed I None
were I None
comparable I None
in I None
AZT I Chemical
and I None
PHZ I Chemical
treated I None
mice I None
with I None
similar I None
degrees I None
of I None
anaemia I Disease
. I None
<eof> I None

<s> O None
However I None
, I None
reticulocytosis I Disease
was I None
inappropriate I None
for I None
the I None
degree I None
of I None
anaemia I Disease
observed I None
in I None
AZT I Chemical
treated I None
infected I None
mice I None
. I None
<eof> I None

<s> O None
AZT I Chemical
-induced I None
peripheral I None
anaemia I Disease
in I None
the I None
face I None
of I None
increased I None
numbers I None
of I None
BFU I None
- I None
e I None
and I None
increased I None
levels I None
of I None
plasma I None
EPO I None
suggest I None
a I None
lesion I None
in I None
terminal I None
differentiation I None
. I None
<eof> I None

<s> O None
Detection I None
of I None
abnormal I None
cardiac I None
adrenergic I None
neuron I None
activity I None
in I None
adriamycin I Chemical
-induced I None
cardiomyopathy I Disease
with I None
iodine-125-metaiodobenzylguanidine I Chemical
. I None
<eof> I None

<s> O None
Radiolabeled I Chemical
metaiodobenzylguanidine O Chemical
( I None
MIBG I Chemical
) I None
, I None
an I None
analog I None
of I None
norepinephrine I Chemical
<eof> I None

<s> O None
( I None
NE I Chemical
) I None
, I None
serves I None
as I None
an I None
index I None
of I None
adrenergic I None
neuron I None
integrity I None
and I None
function I None
. I None
<eof> I None

<s> O None
Using I None
a I None
rat I None
model I None
of I None
adriamycin I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
cardiomyopathy I Disease
, I None
we I None
tested I None
the I None
hypothesis I None
that I None
abnormal I None
cardiac I None
adrenergic I None
neuron I None
activity I None
may I None
appear I None
and I None
be I None
exacerbated I None
<eof> I None

<s> O None
dose I None
- I None
dependently I None
in I None
adriamycin I Chemical
cardiomyopathy I Disease
. I None
<eof> I None

<s> O None
The I None
degree I None
of I None
vacuolar I Disease
degeneration O Disease
of O Disease
myocardial O Disease
cells O Disease
was I None
analyzed I None
in I None
relation I None
to I None
the I None
duration I None
of I None
adriamycin I Chemical
treatment I None
( I None
2 I None
mg I None
/ I None
kg I None
, I None
once I None
a I None
week I None
) I None
. I None
<eof> I None

<s> O None
There I None
were I None
no I None
abnormalities I None
or I None
only I None
isolated I None
degeneration I None
in I None
the I None
1- I None
or I None
2-wk I None
treatment I None
groups I None
, I None
isolated I None
or I None
scattered I None
degeneration I None
in I None
half I None
of I None
the I None
3-wk I None
group I None
, I None
frequent I None
scattered I None
degeneration I None
in I None
the I None
4-wk I None
group I None
, I None
scattered I None
or I None
focal I None
degeneration I None
in I None
the I None
5-wk I None
group I None
, I None
and I None
extensive I None
degeneration I None
in I None
the I None
8-wk I None
group I None
. I None
<eof> I None

<s> O None
Myocardial I None
accumulation I None
of I None
[ I None
125I I None
] I None
MIBG I Chemical
4 I None
hr I None
after I None
intravenous I None
injection I None
did I None
not I None
differ I None
between I None
the I None
controls I None
and I None
the I None
groups I None
treated I None
3 I None
wk I None
or I None
less I None
. I None
<eof> I None

<s> O None
However I None
, I None
the I None
4-wk I None
group I None
had I None
a I None
slightly I None
lower I None
accumulation I None
in I None
the I None
right I None
ventricular I None
wall I None
( I None
82 I None
% I None
of I None
the I None
control I None
) I None
and I None
significantly I None
lower I None
accumulation I None
in I None
the I None
left I None
ventricular I None
wall I None
( I None
about I None
66 I None
% I None
of I None
the I None
control I None
: I None
p I None
less I None
than I None
0.05 I None
) I None
. I None
<eof> I None

<s> O None
In I None
the I None
5-wk I None
group I None
, I None
MIBG I Chemical
accumulation I None
in I None
the I None
right I None
and I None
left I None
ventricular I None
wall I None
was I None
35 I None
% I None
and I None
27 I None
% I None
of I None
that I None
in I None
controls I None
, I None
respectively I None
( I None
p I None
less I None
than I None
0.001 I None
) I None
. I None
<eof> I None

<s> O None
In I None
the I None
8-wk I None
group I None
, I None
MIBG I Chemical
accumulation I None
in I None
the I None
right I None
and I None
left I None
ventricular I None
wall I None
was I None
18 I None
% I None
and I None
14 I None
% I None
of I None
that I None
in I None
controls I None
, I None
respectively I None
( I None
p I None
less I None
than I None
0.001 I None
) I None
. I None
<eof> I None

<s> O None
Thus I None
, I None
MIBG I Chemical
accumulation I None
in I None
the I None
myocardium I None
decreased I None
in I None
an I None
adriamycin I Chemical
dose I None
- I None
dependent I None
manner I None
. I None
<eof> I None

<s> O None
The I None
appearance I None
of I None
impaired I None
cardiac I None
adrenergic I None
neuron I None
activity I None
in I None
the I None
presence I None
of I None
slight I None
myocardial I Disease
impairment O Disease
( I None
scattered I None
or I None
focal I None
vacuolar I Disease
degeneration O Disease
) I None
indicates I None
that I None
MIBG I Chemical
scintigraphy I None
may I None
be I None
a I None
useful I None
method I None
for I None
detection I None
of I None
adriamycin I Chemical
-induced I None
cardiomyopathy I Disease
. I None
<eof> I None

<s> O None
Amnestic I Disease
syndrome O Disease
associated I None
with I None
propranolol I Chemical
<eof> I None

<s> O None
toxicity I Disease
: I None
a I None
case I None
report I None
. I None
<eof> I None

<s> O None
An I None
elderly I None
woman I None
developed I None
an I None
Alzheimer I Disease
-like I None
subacute I None
<eof> I None

<s> O None
dementia I Disease
as I None
a I None
result I None
of I None
propranolol I Chemical
toxicity I Disease
. I None
<eof> I None

<s> O None
Analysis I None
of I None
the I None
manifestations I None
showed I None
that I None
severe I None
impairment I None
of I None
memory I None
accounted I None
for I None
virtually I None
all I None
of I None
the I None
abnormalities I None
. I None
<eof> I None

<s> O None
There I None
is I None
evidence I None
that I None
cerebral I None
reactions I None
to I None
drug I None
toxicity I Disease
can I None
exhibit I None
patterns I None
that I None
suggest I None
highly I None
selective I None
involvement I None
of I None
functional I None
subdivisions I None
of I None
the I None
brain I None
. I None
<eof> I None

<s> O None
Biphasic I None
response I None
of I None
the I None
SA I None
node I None
of I None
the I None
dog I None
heart I None
in I None
vivo I None
to I None
selective I None
administration I None
of I None
ketamine I Chemical
. I None
<eof> I None

<s> O None
Effect I None
of I None
<eof> I None

<s> O None
ketamine I Chemical
on I None
the I None
SA I None
node I None
of I None
the I None
dog I None
heart I None
was I None
studied I None
in I None
vivo I None
using I None
a I None
selective I None
perfusion I None
technique I None
of I None
the I None
SA I None
node I None
artery I None
. I None
<eof> I None

<s> O None
Injections I None
of I None
ketamine I Chemical
in I None
doses I None
from I None
100 I None
microgram I None
to I None
3 I None
mg I None
into I None
the I None
artery I None
produced I None
a I None
depression I Disease
of I None
the I None
SA I None
nodal I None
activity I None
by I None
a I None
direct I None
action I None
. I None
<eof> I None

<s> O None
This I None
<eof> I None

<s> O None
depression I Disease
was I None
followed I None
by I None
the I None
sudden I None
appearance I None
of I None
a I None
stimulatory I None
phase I None
. I None
<eof> I None

<s> O None
Bilateral I None
vagotomy I None
and I None
sympathectomy I None
or I None
prior I None
administration I None
of I None
a I None
ganglion I None
blocker I None
failed I None
to I None
inhibit I None
the I None
occurrence I None
of I None
the I None
ketamine I Chemical
-induced I None
tachycardia I Disease
, I None
while I None
it I None
was I None
completely I None
abolished I None
in I None
the I None
reserpinized I None
dogs I None
or I None
by I None
a I None
prior I None
injection I None
of I None
a I None
beta I None
- I None
blocking I None
agent I None
into I None
the I None
SA I None
node I None
artery I None
. I None
<eof> I None

<s> O None
This I None
may I None
indicate I None
that I None
an I None
activation I None
of I None
the I None
peripheral I None
adrenergic I None
mechanism I None
plays I None
an I None
important I None
role I None
in I None
the I None
induction I None
of I None
the I None
excitatory I None
effect I None
of I None
ketamine I Chemical
injected I None
in I None
the I None
SA I None
node I None
artery I None
. I None
<eof> I None

<s> O None
The I None
use I None
of I None
serum I None
cholinesterase I None
in I None
succinylcholine I Chemical
<eof> I None

<s> O None
apnoea I Disease
. I None
<eof> I None

<s> O None
Fifteen I None
patients I None
demonstrating I None
unexpected I None
prolonged I None
apnoea I Disease
lasting I None
several I None
hours I None
after I None
succinylcholine I Chemical
have I None
been I None
treated I None
by I None
a I None
new I None
preparation I None
of I None
human I None
serum I None
cholinesterase I None
. I None
<eof> I None

<s> O None
Adequate I None
spontaneous I None
respiration I None
was I None
re I None
- I None
established I None
in I None
an I None
average I None
period I None
of I None
ten I None
minutes I None
after I None
the I None
injection I None
. I None
<eof> I None

<s> O None
In I None
12 I None
patients I None
biochemical I None
genetic I None
examinations I None
confirmed I None
the I None
presence I None
of I None
an I None
atypical I None
serum I None
cholinesterase I None
. I None
<eof> I None

<s> O None
In I None
three I None
patients I None
none I None
of I None
the I None
usual I None
variants I None
were I None
found I None
. I None
<eof> I None

<s> O None
It I None
is I None
therefore I None
supposed I None
that I None
other I None
unknown I None
variants I None
of I None
serum I None
cholinesterase I None
exist I None
which I None
can I None
not I None
hydrolyze I None
succinylcholine I Chemical
. I None
<eof> I None

<s> O None
The I None
use I None
of I None
serum I None
cholinesterase I None
in I None
succinylcholine I Chemical
<eof> I None

<s> O None
apnoea I Disease
provided I None
considerable I None
relief I None
to I None
both I None
patient I None
and I None
anaesthetist I None
. I None
<eof> I None

<s> O None
Orthostatic I Disease
hypotension O Disease
occurs I None
following I None
alpha I None
2-adrenoceptor I None
blockade I None
in I None
chronic I None
<eof> I None

<s> O None
prazosin I Chemical
-pretreated I None
conscious I None
spontaneously I None
hypertensive I Disease
rats I None
. I None
<eof> I None

<s> O None
1 I None
. I None
<eof> I None

<s> O None
Studies I None
were I None
performed I None
to I None
evaluate I None
whether I None
chronic I None
prazosin I Chemical
treatment I None
alters I None
the I None
alpha I None
2-adrenoceptor I None
function I None
for I None
orthostatic I None
control I None
of I None
arterial I None
blood I None
pressure I None
in I None
conscious I None
spontaneously I None
hypertensive I Disease
rats I None
( I None
SHR I None
) I None
. I None
<eof> I None

<s> O None
2 I None
. I None
<eof> I None

<s> O None
Conscious I None
SHR I None
( I None
male I None
300 I None
- I None
350 I None
g I None
) I None
were I None
subjected I None
to I None
90 I None
degrees I None
head I None
- I None
up I None
tilts I None
for I None
60 I None
s I None
following I None
acute I None
administration I None
of I None
prazosin I Chemical
<eof> I None

<s> O None
( I None
0.1 I None
mg I None
kg-1 I None
i.p I None
. I None
) I None
or I None
rauwolscine I Chemical
( I None
3 I None
mg I None
kg-1 I None
i.v I None
. I None
) I None
. I None
<eof> I None

<s> O None
Orthostatic I Disease
hypotension O Disease
was I None
determined I None
by I None
the I None
average I None
decrease I None
( I None
% I None
) I None
in I None
mean I None
arterial I None
pressure I None
( I None
MAP I None
femoral I None
) I None
over I None
the I None
60-s I None
tilt I None
period I None
. I None
<eof> I None

<s> O None
The I None
basal I None
MAP I None
of I None
conscious I None
SHR I None
was I None
reduced I None
to I None
a I None
similar I None
extent I None
by I None
prazosin I Chemical
<eof> I None

<s> O None
( I None
-23%(-)-26 I None
% I None
MAP I None
) I None
and I None
rauwolscine I Chemical
<eof> I None

<s> O None
( I None
-16%(-)-33 I None
% I None
MAP I None
) I None
. I None
<eof> I None

<s> O None
However I None
, I None
the I None
head I None
- I None
up I None
tilt I None
induced I None
orthostatic I Disease
hypotension O Disease
in I None
the I None
SHR I None
treated I None
with I None
prazosin I Chemical
<eof> I None

<s> O None
( I None
-16 I None
% I None
MAP I None
, I None
n I None
= I None
6 I None
) I None
, I None
but I None
not I None
in I None
the I None
SHR I None
treated I None
with I None
rauwolscine I Chemical
<eof> I None

<s> O None
( I None
less I None
than I None
+ I None
2 I None
% I None
MAP I None
, I None
n I None
= I None
6 I None
) I None
. I None
<eof> I None

<s> O None
3 I None
. I None
<eof> I None

<s> O None
Conscious I None
SHR I None
were I None
treated I None
for I None
4 I None
days I None
with I None
prazosin I Chemical
at I None
2 I None
mg I None
kg-1 I None
day-1 I None
i.p I None
. I None
for I None
chronic I None
alpha I None
1-adrenoceptor I None
blockade I None
. I None
<eof> I None

<s> O None
MAP I None
in I None
conscious I None
SHR I None
after I None
chronic I None
prazosin I Chemical
treatment I None
was I None
14 I None
% I None
lower I None
than I None
in I None
the I None
untreated I None
SHR I None
( I None
n I None
= I None
8) I None
. I None
<eof> I None

<s> O None
Head I None
- I None
up I None
tilts I None
in I None
these I None
rats I None
did I None
not I None
produce I None
orthostatic I Disease
hypotension O Disease
when I None
performed I None
either I None
prior I None
to I None
or I None
after I None
acute I None
dosing I None
of I None
prazosin I Chemical
<eof> I None

<s> O None
( I None
0.1 I None
mg I None
kg-1 I None
i.p I None
. I None
) I None
. I None
<eof> I None

<s> O None
Conversely I None
, I None
administration I None
of I None
rauwolscine I Chemical
<eof> I None

<s> O None
( I None
3 I None
mg I None
kg-1 I None
i.v I None
. I None
) I None
in I None
chronic I None
prazosin I Chemical
treated I None
SHR I None
decreased I None
the I None
basal I None
MAP I None
by I None
12 I None
- I None
31 I None
% I None
( I None
n I None
= I None
4 I None
) I None
, I None
and I None
subsequent I None
tilts I None
induced I None
further I None
drops I None
of I None
MAP I None
by I None
19 I None
- I None
23 I None
% I None
in I None
these I None
rats I None
. I None
<eof> I None

<s> O None
4 I None
. I None
<eof> I None

<s> O None
The I None
pressor I None
responses I None
and I None
bradycardia I Disease
to I None
the I None
alpha I None
1-agonist I None
cirazoline I Chemical
( I None
0.6 I None
and I None
2 I None
micrograms I None
kg-1 I None
i.v I None
. I None
) I None
, I None
the I None
alpha I None
2-agonist I None
Abbott-53693 I Chemical
( I None
1 I None
and I None
3 I None
micrograms I None
kg-1 I None
i.v I None
. I None
) I None
, I None
and I None
noradrenaline I Chemical
( I None
0.1 I None
and I None
1.0 I None
micrograms I None
kg-1 I None
i.v I None
. I None
) I None
were I None
determined I None
in I None
conscious I None
SHR I None
with I None
and I None
without I None
chronic I None
prazosin I Chemical
pretreatment I None
. I None
<eof> I None

<s> O None
Both I None
the I None
pressor I None
and I None
bradycardia I Disease
effects I None
of I None
cirazoline I Chemical
were I None
abolished I None
in I None
chronic I None
prazosin I Chemical
treated I None
SHR I None
( I None
n I None
= I None
4 I None
) I None
as I None
compared I None
to I None
the I None
untreated I None
SHR I None
( I None
n I None
= I None
4 I None
) I None
. I None
<eof> I None

<s> O None
On I None
the I None
other I None
hand I None
, I None
the I None
pressor I None
effects I None
of I None
Abbott-53693 I Chemical
were I None
similar I None
in I None
both I None
groups I None
of I None
SHR I None
, I None
but I None
the I None
accompanying I None
bradycardia I Disease
was I None
greater I None
in I None
SHR I None
with I None
chronic I None
prazosin I Chemical
treatment I None
than I None
without I None
such I None
treatment I None
. I None
<eof> I None

<s> O None
Furthermore I None
, I None
the I None
bradycardia I Disease
that I None
accompanied I None
the I None
noradrenaline I Chemical
-induced I None
pressor I None
effect I None
in I None
SHR I None
was I None
similar I None
with I None
and I None
without I None
chronic I None
prazosin I Chemical
treatment I None
despite I None
a I None
47 I None
- I None
71 I None
% I None
reduction I None
of I None
the I None
pressor I None
effect I None
in I None
chronic I None
alpha I None
1-receptor I None
blocked I None
SHR.(ABSTRACT I None
TRUNCATED I None
AT I None
400 I None
WORDS I None
) I None
<eof> I None

<s> O None
Coexistence I None
of I None
cerebral I None
venous I None
sinus I None
and I None
internal I None
carotid I None
artery I None
thrombosis I None
associated I None
with I None
exogenous I None
sex I None
hormones I None
. I None
<eof> I None

<s> O None
A I None
case I None
report I None
. I None
<eof> I None

<s> O None
A I None
forty I None
- I None
six I None
year I None
- I None
old I None
premenopausal I None
woman I None
developed I None
<eof> I None

<s> O None
headache I Disease
, I None
nausea I Disease
and I None
vomiting I Disease
, I None
left I None
<eof> I None

<s> O None
hemiparesis I Disease
and I None
seizure I Disease
two I None
days I None
after I None
parenteral I None
use I None
of I None
progesterone I Chemical
and I None
estradiol I Chemical
. I None
<eof> I None

<s> O None
Diabetes I Disease
mellitus O Disease
<eof> I None

<s> O None
( I None
DM I Disease
) I None
was I None
found I None
during I None
admission I None
. I None
<eof> I None

<s> O None
Computed I None
tomography I None
showed I None
a I None
hemorrhagic I None
infarct I None
in I None
the I None
right I None
frontal I None
lobe I None
and I None
increased I None
density I None
in I None
the I None
superior I None
sagittal I None
sinus I None
( I None
SSS I None
) I None
. I None
<eof> I None

<s> O None
Left I None
carotid I None
angiography I None
found I None
occlusion I Disease
of O Disease
the O Disease
left O Disease
internal O Disease
carotid O Disease
artery O Disease
( I None
ICA I None
) I None
. I None
<eof> I None

<s> O None
Right I None
carotid I None
angiograms I None
failed I None
to I None
show I None
the I None
SSS I None
and I None
inferior I None
sagittal I None
sinus I None
, I None
suggestive I None
of I None
venous I Disease
sinus O Disease
thrombosis O Disease
. I None
<eof> I None

<s> O None
Coexistence I None
of I None
the I None
cerebral I None
artery I None
and I None
the I None
venous I None
sinus I None
occlusion I None
has I None
been I None
described I None
infrequently I None
. I None
<eof> I None

<s> O None
In I None
this I None
case I None
, I None
the I None
authors I None
postulate I None
that I None
the I None
use I None
of I None
estradiol I Chemical
and I None
progesterone I Chemical
and I None
the I None
underlying I None
DM I Disease
increased I None
vascular I None
thrombogenicity I None
, I None
which I None
provided I None
a I None
common I None
denominator I None
for I None
thrombosis I None
of I None
both I None
the I None
ICA I None
and I None
the I None
venous I None
sinus I None
. I None
<eof> I None

<s> O None
Chloroquine I Chemical
related I None
complete I None
heart I Disease
block O Disease
with I None
blindness I Disease
: I None
case I None
report I None
. I None
<eof> I None

<s> O None
A I None
27-year I None
old I None
African I None
woman I None
with I None
history I None
of I None
regular I None
chloroquine I Chemical
ingestion I None
presented I None
with I None
progressive I None
deterioration I Disease
of O Disease
vision O Disease
, I None
easy I None
fatiguability I Disease
, I None
dyspnoea I Disease
, I None
dizziness I Disease
progressing I None
to I None
syncopal I Disease
attacks O Disease
. I None
<eof> I None

<s> O None
Ophthalmological I None
assessment I None
revealed I None
features I None
of I None
chloroquine I Chemical
retinopathy I Disease
, I None
cardiac I None
assessment I None
revealed I None
features I None
of I None
heart I Disease
failure O Disease
and I None
a I None
complete I None
heart I Disease
block O Disease
with I None
right I Disease
bundle O Disease
branch O Disease
block O Disease
pattern I None
. I None
<eof> I None

<s> O None
The I None
heart I Disease
block O Disease
was I None
treated I None
by I None
pacemaker I None
insertion I None
and I None
the I None
heart I Disease
failure O Disease
resolved I None
spontaneously I None
following I None
chloroquine I Chemical
discontinuation I None
. I None
<eof> I None

<s> O None
She I None
however I None
remains I None
blind I Disease
. I None
<eof> I None

<s> O None
Systemic I None
toxicity I Disease
and I None
resuscitation I None
in I None
bupivacaine I Chemical
- I None
, I None
levobupivacaine I Chemical
- I None
, I None
or I None
ropivacaine I Chemical
-infused I None
rats I None
. I None
<eof> I None

<s> O None
We I None
compared I None
the I None
systemic I None
toxicity I Disease
of I None
bupivacaine I Chemical
, I None
levobupivacaine I Chemical
, I None
and I None
ropivacaine I Chemical
in I None
anesthetized I None
rats I None
. I None
<eof> I None

<s> O None
We I None
also I None
compared I None
the I None
ability I None
to I None
resuscitate I None
rats I None
after I None
lethal I None
doses I None
of I None
these I None
local I None
anesthetics I None
. I None
<eof> I None

<s> O None
Bupivacaine I Chemical
, I None
levobupivacaine I Chemical
, I None
or I None
ropivacaine I Chemical
was I None
infused I None
at I None
a I None
rate I None
of I None
2 I None
mg I None
. I None
<eof> I None

<s> O None
kg(-1 I None
) I None
. I None
<eof> I None

<s> O None
min(-1 I None
) I None
<eof> I None

<s> O None
while I None
electrocardiogram I None
, I None
electroencephalogram I None
, I None
and I None
arterial I None
pressure I None
were I None
continuously I None
monitored I None
. I None
<eof> I None

<s> O None
When I None
asystole I Disease
was I None
recorded I None
, I None
drug I None
infusion I None
was I None
stopped I None
and I None
a I None
resuscitation I None
sequence I None
was I None
begun I None
. I None
<eof> I None

<s> O None
Epinephrine I Chemical
0.01 I None
mg I None
/ I None
kg I None
was I None
administered I None
at I None
1-min I None
intervals I None
while I None
external I None
cardiac I None
compressions I None
were I None
applied I None
. I None
<eof> I None

<s> O None
Resuscitation I None
was I None
considered I None
successful I None
when I None
a I None
systolic I None
arterial I None
pressure I None
> I None
or I None
= I None
100 I None
mm I None
Hg I None
was I None
achieved I None
within I None
5 I None
min I None
. I None
<eof> I None

<s> O None
The I None
cumulative I None
doses I None
of I None
levobupivacaine I Chemical
and I None
ropivacaine I Chemical
that I None
produced I None
seizures I Disease
were I None
similar I None
and I None
were I None
larger I None
than I None
those I None
of I None
bupivacaine I Chemical
. I None
<eof> I None

<s> O None
The I None
cumulative I None
doses I None
of I None
levobupivacaine I Chemical
that I None
produced I None
dysrhythmias I Disease
and I None
asystole I Disease
were I None
smaller I None
than I None
the I None
corresponding I None
doses I None
of I None
ropivacaine I Chemical
, I None
but I None
they I None
were I None
larger I None
than I None
those I None
of I None
bupivacaine I Chemical
. I None
<eof> I None

<s> O None
The I None
number I None
of I None
successful I None
resuscitations I None
did I None
not I None
differ I None
among I None
groups I None
. I None
<eof> I None

<s> O None
However I None
, I None
a I None
smaller I None
dose I None
of I None
epinephrine I Chemical
was I None
required I None
in I None
the I None
Ropivacaine I Chemical
group I None
than I None
in I None
the I None
other I None
groups I None
. I None
<eof> I None

<s> O None
We I None
conclude I None
that I None
the I None
systemic I None
toxicity I Disease
of I None
levobupivacaine I Chemical
is I None
intermediate I None
between I None
that I None
of I None
ropivacaine I Chemical
and I None
bupivacaine I Chemical
when I None
administered I None
at I None
the I None
same I None
rate I None
and I None
that I None
<eof> I None

<s> O None
ropivacaine I Chemical
-induced I None
<eof> I None

<s> O None
cardiac I Disease
arrest O Disease
appears I None
to I None
be I None
more I None
susceptible I None
to I None
treatment I None
than I None
that I None
induced I None
by I None
bupivacaine I Chemical
or I None
levobupivacaine I Chemical
. I None
<eof> I None

<s> O None
22-oxacalcitriol I Chemical
suppresses I None
<eof> I None

<s> O None
secondary I Disease
hyperparathyroidism O Disease
without I None
inducing I None
low I Disease
bone O Disease
turnover O Disease
in I None
dogs I None
with I None
renal I Disease
failure O Disease
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
<eof> I None

<s> O None
Calcitriol I Chemical
therapy I None
suppresses I None
serum I None
levels I None
of I None
parathyroid I None
hormone I None
( I None
PTH I None
) I None
in I None
patients I None
with I None
renal I Disease
failure O Disease
but I None
has I None
several I None
drawbacks I None
, I None
including I None
hypercalcemia I Disease
and/or I None
marked I None
suppression I Disease
of O Disease
bone O Disease
turnover O Disease
, I None
which I None
may I None
lead I None
to I None
adynamic I Disease
bone O Disease
disease O Disease
. I None
<eof> I None

<s> O None
A I None
new I None
vitamin I Chemical
D O Chemical
analogue I None
, I None
22-oxacalcitriol I Chemical
<eof> I None

<s> O None
( I None
OCT I Chemical
) I None
, I None
has I None
been I None
shown I None
to I None
have I None
promising I None
characteristics I None
. I None
<eof> I None

<s> O None
This I None
study I None
was I None
undertaken I None
to I None
determine I None
the I None
effects I None
of I None
OCT I Chemical
on I None
serum I None
PTH I None
levels I None
and I None
bone I None
turnover I None
in I None
states I None
of I None
normal I None
or I None
impaired I Disease
renal O Disease
function O Disease
. I None
<eof> I None

<s> O None
METHODS I None
: I None
<eof> I None

<s> O None
Sixty I None
dogs I None
were I None
either I None
nephrectomized I None
( I None
Nx I None
, I None
N I None
= I None
38 I None
) I None
or I None
sham I None
- I None
operated I None
( I None
Sham I None
, I None
N I None
= I None
22 I None
) I None
. I None
<eof> I None

<s> O None
The I None
animals I None
received I None
supplemental I None
<eof> I None

<s> O None
phosphate I Chemical
to I None
enhance I None
PTH I None
secretion I None
. I None
<eof> I None

<s> O None
Fourteen I None
weeks I None
after I None
the I None
start I None
of I None
phosphate I Chemical
supplementation I None
, I None
half I None
of I None
the I None
Nx I None
and I None
Sham I None
dogs I None
received I None
doses I None
of I None
OCT I Chemical
<eof> I None

<s> O None
( I None
three I None
times I None
per I None
week I None
) I None
; I None
the I None
other I None
half I None
were I None
given I None
vehicle I None
for I None
60 I None
weeks I None
. I None
<eof> I None

<s> O None
Thereafter I None
, I None
the I None
treatment I None
modalities I None
for I None
a I None
subset I None
of I None
animals I None
were I None
crossed I None
over I None
for I None
an I None
additional I None
eight I None
months I None
. I None
<eof> I None

<s> O None
Biochemical I None
and I None
hormonal I None
indices I None
of I None
calcium I Chemical
and I None
bone I None
metabolism I None
were I None
measured I None
throughout I None
the I None
study I None
, I None
and I None
bone I None
biopsies I None
were I None
done I None
at I None
baseline I None
, I None
60 I None
weeks I None
after I None
OCT I Chemical
or I None
vehicle I None
treatment I None
, I None
and I None
at I None
the I None
end I None
of I None
the I None
crossover I None
period I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
In I None
Nx I None
dogs I None
, I None
OCT I Chemical
significantly I None
decreased I None
serum I None
PTH I None
levels I None
soon I None
after I None
the I None
induction I None
of I None
renal I Disease
insufficiency O Disease
. I None
<eof> I None

<s> O None
In I None
long I None
- I None
standing I None
secondary I Disease
hyperparathyroidism O Disease
, I None
OCT I Chemical
( I None
0.03 I None
microg I None
/ I None
kg I None
) I None
stabilized I None
serum I None
PTH I None
levels I None
during I None
the I None
first I None
months I None
. I None
<eof> I None

<s> O None
Serum I None
PTH I None
levels I None
rose I None
thereafter I None
, I None
but I None
the I None
rise I None
was I None
less I None
pronounced I None
compared I None
with I None
baseline I None
than I None
the I None
rise I None
seen I None
in I None
Nx I None
control I None
. I None
<eof> I None

<s> O None
These I None
effects I None
were I None
accompanied I None
by I None
episodes I None
of I None
hypercalcemia I Disease
and I None
hyperphosphatemia I Disease
. I None
<eof> I None

<s> O None
In I None
animals I None
with I None
normal I None
renal I None
function I None
, I None
OCT I Chemical
induced I None
a I None
transient I None
decrease I None
in I None
serum I None
PTH I None
levels I None
at I None
a I None
dose I None
of I None
0.1 I None
microg I None
/ I None
kg I None
, I None
which I None
was I None
not I None
sustained I None
with I None
lowering I None
of I None
the I None
doses I None
. I None
<eof> I None

<s> O None
In I None
Nx I None
dogs I None
, I None
OCT I Chemical
reversed I None
abnormal I None
bone I None
formation I None
, I None
such I None
as I None
woven I Disease
osteoid O Disease
and I None
fibrosis I Disease
, I None
but I None
did I None
not I None
significantly I None
alter I None
the I None
level I None
of I None
bone I None
turnover I None
. I None
<eof> I None

<s> O None
In I None
addition I None
, I None
OCT I Chemical
<eof> I None

<s> O None
improved I None
mineralization I None
lag I None
time I None
, I None
( I None
that I None
is I None
, I None
the I None
rate I None
at I None
which I None
osteoid I None
mineralizes I None
) I None
in I None
both I None
Nx I None
and I None
Sham I None
dogs I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
These I None
results I None
indicate I None
that I None
even I None
though I None
OCT I Chemical
does I None
not I None
completely I None
prevent I None
the I None
occurrence I None
of I None
hypercalcemia I Disease
in I None
experimental I None
dogs I None
with I None
renal I Disease
insufficiency O Disease
, I None
it I None
may I None
be I None
of I None
use I None
in I None
the I None
management I None
of I None
secondary I Disease
hyperparathyroidism O Disease
because I None
it I None
does I None
not I None
induce I None
low I Disease
bone O Disease
turnover O Disease
and I None
, I None
therefore I None
, I None
does I None
not I None
increase I None
the I None
risk I None
of I None
adynamic I Disease
bone O Disease
disease O Disease
. I None
<eof> I None

<s> O None
Chemotherapy I None
of I None
advanced I None
inoperable I None
non I Disease
- O Disease
small O Disease
cell O Disease
lung O Disease
cancer O Disease
with I None
paclitaxel I Chemical
: I None
a I None
phase I None
II I None
trial I None
. I None
<eof> I None

<s> O None
Paclitaxel I Chemical
<eof> I None

<s> O None
( I None
Taxol I Chemical
; I None
Bristol I None
- I None
Myers I None
Squibb I None
Company I None
, I None
Princeton I None
, I None
NJ I None
) I None
has I None
demonstrated I None
significant I None
antineoplastic I None
activity I None
against I None
different I None
tumor I Disease
types I None
, I None
notably I None
ovarian I None
and I None
breast I None
carcinoma I None
. I None
<eof> I None

<s> O None
Two I None
phase I None
II I None
trials I None
of I None
24-hour I None
paclitaxel I Chemical
infusions I None
in I None
chemotherapy I None
- I None
naive I None
patients I None
with I None
stage I None
IIIB I None
or I None
IV I None
non I Disease
- O Disease
small O Disease
cell O Disease
lung O Disease
cancer O Disease
<eof> I None

<s> O None
( I None
NSCLC I Disease
) I None
reported I None
response I None
rates I None
of I None
21 I None
% I None
and I None
24 I None
% I None
. I None
<eof> I None

<s> O None
Leukopenia I Disease
was I None
dose I None
limiting I None
: I None
<eof> I None

<s> O None
as I None
many I None
as I None
62.5 I None
% I None
of I None
patients I None
experienced I None
grade I None
4 I None
leukopenia I Disease
. I None
<eof> I None

<s> O None
We I None
investigated I None
the I None
efficacy I None
and I None
toxicity I Disease
of I None
a I None
3-hour I None
paclitaxel I Chemical
infusion I None
in I None
a I None
phase I None
II I None
trial I None
in I None
patients I None
with I None
inoperable I None
stage I None
IIIB I None
or I None
IV I None
NSCLC I Disease
. I None
<eof> I None

<s> O None
The I None
58 I None
patients I None
treated I None
( I None
41 I None
men I None
and I None
17 I None
women I None
) I None
had I None
a I None
median I None
age I None
of I None
59 I None
years I None
( I None
age I None
range I None
, I None
25 I None
to I None
75 I None
) I None
and I None
a I None
performance I None
status I None
of I None
0 I None
through I None
2 I None
. I None
<eof> I None

<s> O None
Most I None
patients I None
( I None
72.4 I None
% I None
) I None
had I None
stage I None
IV I None
NSCLC I Disease
. I None
<eof> I None

<s> O None
Paclitaxel I Chemical
225 I None
mg I None
/ I None
m2 I None
was I None
infused I None
over I None
3 I None
hours I None
every I None
3 I None
weeks I None
with I None
standard I None
prophylactic I None
premedication I None
. I None
<eof> I None

<s> O None
Of I None
50 I None
patients I None
evaluable I None
for I None
response I None
, I None
12 I None
( I None
24 I None
% I None
) I None
had I None
partial I None
remission I None
, I None
26 I None
( I None
52 I None
% I None
) I None
had I None
no I None
change I None
, I None
and I None
12 I None
had I None
disease I None
progression I None
( I None
24 I None
% I None
) I None
. I None
<eof> I None

<s> O None
Hematologic I None
toxicities I Disease
were I None
mild I None
: I None
<eof> I None

<s> O None
only I None
one I None
patient I None
( I None
2 I None
% I None
) I None
developed I None
grade I None
3 I None
or I None
4 I None
neutropenia I Disease
, I None
while I None
29 I None
% I None
had I None
grade I None
1 I None
or I None
2 I None
. I None
<eof> I None

<s> O None
Grade I None
1 I None
or I None
2 I None
polyneuropathy I Disease
affected I None
56 I None
% I None
of I None
patients I None
while I None
only I None
one I None
( I None
2 I None
% I None
) I None
experienced I None
severe I None
polyneuropathy I Disease
. I None
<eof> I None

<s> O None
Similarly I None
, I None
grade I None
1 I None
or I None
2 I None
myalgia I Disease
/ I None
arthralgia I Disease
was I None
observed I None
in I None
63.2 I None
% I None
of I None
patients I None
, I None
but I None
only I None
14.3 I None
% I None
experienced I None
grade I None
3 I None
or I None
4 I None
. I None
<eof> I None

<s> O None
Nausea I Disease
and I None
vomiting I Disease
were I None
infrequent I None
, I None
with I None
14 I None
% I None
of I None
patients I None
experiencing I None
grade I None
1 I None
or I None
2 I None
and I None
only I None
2 I None
% I None
experiencing I None
grade I None
3 I None
or I None
4 I None
. I None
<eof> I None

<s> O None
Paclitaxel I Chemical
is I None
thus I None
an I None
active I None
single I None
agent I None
in I None
this I None
patient I None
population I None
, I None
with I None
a I None
3-hour I None
infusion I None
proving I None
comparably I None
effective I None
to I None
a I None
24-hour I None
infusion I None
and I None
superior I None
in I None
terms I None
of I None
the I None
incidence I None
of I None
hematologic I None
and I None
nonhematologic I None
toxicity I Disease
. I None
<eof> I None

<s> O None
Further I None
phase I None
II I None
studies I None
with I None
paclitaxel I Chemical
combined I None
with I None
other I None
drugs I None
active I None
against I None
NSCLC I Disease
are I None
indicated I None
, I None
and I None
<eof> I None

<s> O None
phase I None
III I None
studies I None
comparing I None
paclitaxel I Chemical
with I None
standard I None
chemotherapy I None
remain I None
to I None
be I None
completed I None
. I None
<eof> I None

<s> O None
Cerebral I Disease
hemorrhage O Disease
associated I None
with I None
phenylpropanolamine I Chemical
in I None
combination I None
with I None
caffeine I Chemical
. I None
<eof> I None

<s> O None
Phenylpropanolamine I Chemical
<eof> I None

<s> O None
( I None
PPA I Chemical
) I None
is I None
a I None
drug I None
that I None
has I None
been I None
associated I None
with I None
serious I None
side I None
effects I None
including I None
stroke I Disease
. I None
<eof> I None

<s> O None
It I None
is I None
often I None
combined I None
with I None
caffeine I Chemical
in I None
diet I None
preparations I None
and I None
" I None
look I None
- I None
alike I None
" I None
pills I None
. I None
<eof> I None

<s> O None
In I None
order I None
to I None
determine I None
if I None
PPA I Chemical
/ I None
caffeine I Chemical
can I None
lead I None
to I None
stroke I Disease
in I None
normotensive I None
and/or I None
hypertensive I Disease
rats I None
, I None
we I None
administered I None
the I None
combination I None
in I None
six I None
times I None
the I None
allowed I None
human I None
dose I None
calculated I None
on I None
a I None
per I None
weight I None
basis I None
for I None
the I None
rats I None
two I None
times I None
per I None
day I None
for I None
five I None
days I None
. I None
<eof> I None

<s> O None
Subarachnoid I None
and I None
cerebral I None
hemorrhage I None
was I None
noted I None
in I None
18 I None
% I None
of I None
the I None
hypertensive I Disease
rats I None
. I None
<eof> I None

<s> O None
A I None
single I None
PPA I Chemical
/ I None
caffeine I Chemical
administration I None
( I None
same I None
dose I None
) I None
lead I None
to I None
acute I None
hypertension I Disease
in I None
both I None
the I None
normotensive I None
and I None
hypertensive I Disease
animals I None
. I None
<eof> I None

<s> O None
These I None
results I None
suggest I None
that I None
PPA I Chemical
/ I None
caffeine I Chemical
can I None
lead I None
to I None
cerebral I Disease
hemorrhage O Disease
in I None
previously I None
hypertensive I Disease
animals I None
when I None
administered I None
in I None
greater I None
than I None
the I None
allowed I None
dosage I None
. I None
<eof> I None

<s> O None
An I None
acute I None
elevation I None
in I None
blood I None
pressure I None
may I None
be I None
a I None
contributing I None
factor I None
. I None
<eof> I None

<s> O None
Long I None
- I None
term I None
efficacy I None
and I None
toxicity I Disease
of I None
high I None
- I None
dose I None
amiodarone I Chemical
therapy I None
for I None
ventricular I Disease
tachycardia O Disease
or I None
ventricular I Disease
fibrillation O Disease
. I None
<eof> I None

<s> O None
Amiodarone I Chemical
was I None
administered I None
to I None
154 I None
patients I None
who I None
had I None
sustained I None
, I None
symptomatic I None
ventricular I Disease
tachycardia O Disease
( I None
VT I Disease
) I None
( I None
n I None
= I None
118 I None
) I None
or I None
a I None
cardiac I Disease
arrest O Disease
<eof> I None

<s> O None
( I None
n I None
= I None
36 I None
) I None
and I None
who I None
were I None
refractory I None
to I None
conventional I None
antiarrhythmic I None
drugs I None
. I None
<eof> I None

<s> O None
The I None
loading I None
dose I None
was I None
800 I None
mg I None
/ I None
day I None
for I None
6 I None
weeks I None
and I None
the I None
maintenance I None
dose I None
was I None
600 I None
mg I None
/ I None
day I None
. I None
<eof> I None

<s> O None
Sixty I None
- I None
nine I None
percent I None
of I None
patients I None
continued I None
treatment I None
with I None
amiodarone I Chemical
and I None
had I None
no I None
recurrence I None
of I None
symptomatic I None
VT I Disease
or I None
ventricular I Disease
fibrillation O Disease
<eof> I None

<s> O None
( I None
VF I Disease
) I None
over I None
a I None
follow I None
- I None
up I None
of I None
6 I None
to I None
52 I None
months I None
( I None
mean I None
+ I None
/- I None
<eof> I None

<s> O None
standard I None
deviation I None
14.2 I None
+ I None
/- I None
8.2 I None
) I None
. I None
<eof> I None

<s> O None
Six I None
percent I None
of I None
the I None
patients I None
had I None
a I None
nonfatal I None
recurrence I None
of I None
VT I Disease
and I None
were I None
successfully I None
managed I None
by I None
continuing I None
amiodarone I Chemical
at I None
a I None
higher I None
dose I None
or I None
by I None
the I None
addition I None
of I None
a I None
conventional I None
antiarrhythmic I None
drug I None
. I None
<eof> I None

<s> O None
One I None
or I None
more I None
adverse I None
drug I None
reactions I None
occurred I None
in I None
51 I None
% I None
of I None
patients I None
. I None
<eof> I None

<s> O None
Adverse I None
effects I None
forced I None
a I None
reduction I None
in I None
the I None
dose I None
of I None
amiodarone I Chemical
in I None
41 I None
% I None
and I None
discontinuation I None
of I None
amiodarone I Chemical
in I None
10 I None
% I None
of I None
patients I None
. I None
<eof> I None

<s> O None
The I None
most I None
common I None
symptomatic I None
adverse I None
reactions I None
were I None
tremor I Disease
or I None
ataxia I Disease
( I None
35 I None
% I None
) I None
, I None
<eof> I None

<s> O None
nausea I Disease
and I None
anorexia I Disease
( I None
8 I None
% I None
) I None
, I None
visual I Disease
halos O Disease
or O Disease
blurring O Disease
<eof> I None

<s> O None
( I None
6 I None
% I None
) I None
, I None
<eof> I None

<s> O None
thyroid I Disease
function O Disease
abnormalities O Disease
( I None
6 I None
% I None
) I None
and I None
pulmonary I Disease
interstitial O Disease
infiltrates O Disease
( I None
5 I None
% I None
) I None
. I None
<eof> I None

<s> O None
Although I None
large I None
- I None
dose I None
amiodarone I Chemical
is I None
highly I None
effective I None
in I None
the I None
long I None
- I None
term I None
treatment I None
of I None
VT I Disease
or I None
VF I Disease
refractory I None
to I None
conventional I None
antiarrhythmic I None
drugs I None
, I None
it I None
causes I None
significant I None
toxicity I Disease
in I None
approximately I None
50 I None
% I None
of I None
patients I None
. I None
<eof> I None

<s> O None
However I None
, I None
when I None
the I None
dose I None
is I None
adjusted I None
based I None
on I None
clinical I None
response I None
or I None
the I None
development I None
of I None
adverse I None
effects I None
, I None
75 I None
% I None
of I None
patients I None
with I None
VT I Disease
or I None
VF I Disease
can I None
be I None
successfully I None
managed I None
with I None
amiodarone I Chemical
. I None
<eof> I None

<s> O None
Effect I None
of I None
calcium I Chemical
chloride O Chemical
and I None
4-aminopyridine I Chemical
therapy I None
on I None
desipramine I Chemical
toxicity I Disease
in I None
rats I None
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
<eof> I None

<s> O None
Hypotension I Disease
is I None
a I None
major I None
contributor I None
to I None
mortality I None
in I None
tricyclic I None
antidepressant I None
overdose I Disease
. I None
<eof> I None

<s> O None
Recent I None
data I None
suggest I None
that I None
tricyclic I None
antidepressants I None
inhibit I None
calcium I Chemical
influx I None
in I None
some I None
tissues I None
. I None
<eof> I None

<s> O None
This I None
study I None
addressed I None
the I None
potential I None
role I None
of I None
calcium I Chemical
channel I None
blockade I None
in I None
tricyclic I None
antidepressant I None
- I None
induced I None
hypotension I Disease
. I None
<eof> I None

<s> O None
METHODS I None
: I None
<eof> I None

<s> O None
Two I None
interventions I None
were I None
studied I None
that I None
have I None
been I None
shown I None
previously I None
to I None
improve I None
blood I None
pressure I None
with I None
calcium I Chemical
channel I None
blocker I None
overdose I Disease
. I None
<eof> I None

<s> O None
CaCl2 I Chemical
and I None
4-aminopyridine I Chemical
. I None
<eof> I None

<s> O None
Anesthetized I None
rats I None
received I None
the I None
tricyclic I None
antidepressant I None
desipramine I Chemical
IP I None
to I None
produce I None
hypotension I Disease
, I None
QRS I None
prolongation I None
, I None
and I None
bradycardia I Disease
. I None
<eof> I None

<s> O None
Fifteen I None
min I None
later I None
, I None
animals I None
received I None
CaCl2 I Chemical
, I None
NaHCO3 I Chemical
, I None
or I None
saline I None
. I None
<eof> I None

<s> O None
In I None
a I None
second I None
experiment I None
, I None
rats I None
received I None
tricyclic I None
antidepressant I None
desipramine I Chemical
<eof> I None

<s> O None
IP I None
followed I None
in I None
15 I None
min I None
by I None
4-aminopyridine I Chemical
or I None
saline I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
NaHCO3 I Chemical
briefly I None
( I None
5 I None
min I None
) I None
reversed I None
hypotension I Disease
and I None
QRS I None
prolongation I None
. I None
<eof> I None

<s> O None
CaCl2 I Chemical
and I None
4-aminopyridine I Chemical
failed I None
to I None
improve I None
blood I None
pressure I None
. I None
<eof> I None

<s> O None
The I None
incidence I None
of I None
ventricular I Disease
arrhythmias O Disease
<eof> I None

<s> O None
( I None
p I None
= I None
0.004 I None
) I None
and I None
seizures I Disease
<eof> I None

<s> O None
( I None
p I None
= I None
0.03 I None
) I None
in I None
the I None
CaCl2 I Chemical
group I None
was I None
higher I None
than I None
the I None
other I None
groups I None
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
<eof> I None

<s> O None
The I None
administration I None
of I None
CaCl2 I Chemical
or I None
4-aminopyridine I Chemical
did I None
not I None
reverse I None
tricyclic I None
antidepressant I None
- I None
induced I None
hypotension I Disease
in I None
rats I None
. I None
<eof> I None

<s> O None
CaCl2 I Chemical
therapy I None
may I None
possibly I None
worsen I None
both I None
cardiovascular I None
and I None
central I None
nervous I None
system I None
toxicity I None
. I None
<eof> I None

<s> O None
These I None
findings I None
do I None
not I None
support I None
a I None
role I None
for I None
calcium I Chemical
channel I None
inhibition I None
in I None
the I None
pathogenesis I None
of I None
tricyclic I None
antidepressant I None
- I None
induced I None
hypotension I Disease
. I None
<eof> I None

<s> O None
Phase I None
I I None
trial I None
of I None
13-cis I Chemical
- O Chemical
retinoic O Chemical
acid O Chemical
in I None
children I None
with I None
neuroblastoma I Disease
<eof> I None

<s> O None
following I None
bone I None
marrow I None
transplantation I None
. I None
<eof> I None

<s> O None
PURPOSE I None
: I None
Treatment I None
of I None
neuroblastoma I Disease
cell I None
lines I None
with I None
13-cis I Chemical
- O Chemical
retinoic O Chemical
acid O Chemical
<eof> I None

<s> O None
( I None
cis I Chemical
- O Chemical
RA O Chemical
) I None
can I None
cause I None
sustained I None
inhibition I None
of I None
proliferation I None
. I None
<eof> I None

<s> O None
Since I None
cis I Chemical
- O Chemical
RA O Chemical
has I None
demonstrated I None
clinical I None
responses I None
in I None
neuroblastoma I Disease
patients I None
, I None
it I None
may I None
be I None
effective I None
in I None
preventing I None
relapse I None
after I None
cytotoxic I None
therapy I None
. I None
<eof> I None

<s> O None
This I None
phase I None
I I None
trial I None
was I None
designed I None
to I None
determine I None
the I None
maximal I None
- I None
tolerated I None
dosage I None
( I None
MTD I None
) I None
, I None
toxicities I Disease
, I None
and I None
pharmacokinetics I None
of I None
cis I Chemical
- O Chemical
RA O Chemical
administered I None
on I None
an I None
intermittent I None
schedule I None
in I None
children I None
with I None
neuroblastoma I Disease
<eof> I None

<s> O None
following I None
bone I None
marrow I None
transplantation I None
( I None
BMT I None
) I None
. I None
<eof> I None

<s> O None
PATIENTS I None
AND I None
METHODS I None
: I None
<eof> I None

<s> O None
Fifty I None
- I None
one I None
assessable I None
patients I None
, I None
2 I None
to I None
12 I None
years I None
of I None
age I None
, I None
were I None
treated I None
with I None
oral I None
cis I Chemical
- O Chemical
RA O Chemical
administered I None
in I None
two I None
equally I None
divided I None
doses I None
daily I None
for I None
2 I None
weeks I None
, I None
followed I None
by I None
a I None
2-week I None
rest I None
period I None
, I None
for I None
up I None
to I None
12 I None
courses I None
. I None
<eof> I None

<s> O None
The I None
dose I None
was I None
escalated I None
from I None
100 I None
to I None
200 I None
mg I None
/ I None
m2/d I None
until I None
dose I None
- I None
limiting I None
toxicity I Disease
<eof> I None

<s> O None
( I None
DLT I None
) I None
was I None
observed I None
. I None
<eof> I None

<s> O None
A I None
single I None
intrapatient I None
dose I None
escalation I None
was I None
permitted I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
The I None
MTD I None
of I None
cis I Chemical
- O Chemical
RA O Chemical
was I None
160 I None
mg I None
/ I None
m2/d I None
. I None
<eof> I None

<s> O None
Dose I None
- I None
limiting I None
<eof> I None

<s> O None
toxicities I Disease
in I None
six I None
of I None
nine I None
patients I None
at I None
200 I None
mg I None
/ I None
m2/d I None
included I None
hypercalcemia I Disease
<eof> I None

<s> O None
( I None
n I None
= I None
3 I None
) I None
, I None
<eof> I None

<s> O None
rash I Disease
( I None
n I None
= I None
2 I None
) I None
, I None
and I None
anemia I Disease
/ I None
thrombocytopenia I Disease
/ I None
emesis I Disease
/ I None
rash I Disease
( I None
n I None
= I None
1 I None
) I None
. I None
<eof> I None

<s> O None
All I None
toxicities I Disease
resolved I None
after I None
cis I Chemical
- O Chemical
RA O Chemical
was I None
discontinued I None
. I None
<eof> I None

<s> O None
Three I None
complete I None
responses I None
were I None
observed I None
in I None
marrow I None
metastases I Disease
. I None
<eof> I None

<s> O None
Serum I None
levels I None
of I None
7.4 I None
+ I None
/- I None
<eof> I None

<s> O None
3.0 I None
mumol I None
/ I None
L I None
( I None
peak I None
) I None
and I None
4.0 I None
+ I None
/- I None
<eof> I None

<s> O None
2.8 I None
mumol I None
/ I None
L I None
( I None
trough I None
) I None
at I None
the I None
MTD I None
were I None
maintained I None
during I None
14 I None
days I None
of I None
therapy I None
. I None
<eof> I None

<s> O None
The I None
DLT I None
correlated I None
with I None
serum I None
levels I None
> I None
or I None
= I None
10 I None
mumol I None
/ I None
L. I None
CONCLUSION I None
: I None
The I None
MTD I None
of I None
cis I Chemical
- O Chemical
RA O Chemical
given I None
on I None
this I None
intermittent I None
schedule I None
<eof> I None

<s> O None
was I None
160 I None
mg I None
/ I None
m2/d I None
. I None
<eof> I None

<s> O None
Serum I None
levels I None
known I None
to I None
be I None
effective I None
against I None
neuroblastoma I Disease
in I None
vitro I None
were I None
achieved I None
at I None
this I None
dose I None
. I None
<eof> I None

<s> O None
The I None
DLT I None
included I None
hypercalcemia I Disease
, I None
and I None
may I None
be I None
predicted I None
by I None
serum I None
cis I Chemical
- O Chemical
RA O Chemical
levels I None
. I None
<eof> I None

<s> O None
Monitoring I None
of I None
serum I None
calcium I Chemical
and I None
cis I Chemical
- O Chemical
RA O Chemical
levels I None
is I None
indicated I None
in I None
future I None
trials I None
. I None
<eof> I None

<s> O None
Effect I None
of I None
calcium I Chemical
chloride O Chemical
on I None
gross I None
behavioural I None
changes I None
produced I None
by I None
carbachol I Chemical
and I None
eserine I Chemical
in I None
cats I None
. I None
<eof> I None

<s> O None
The I None
effect I None
of I None
calcium I Chemical
chloride O Chemical
injected I None
into I None
the I None
cerebral I None
ventricles I None
of I None
group I None
- I None
housed I None
unanaesthetized I None
cats I None
upon I None
vocalization I None
( I None
rage I None
, I None
hissing I None
and I None
snarling I None
) I None
, I None
fighting I None
( I None
attack I None
with I None
paws I None
and I None
claws I None
, I None
defense I None
with I None
paws I None
and I None
claws I None
and I None
biting I None
) I None
, I None
mydriasis I Disease
, I None
tremor I Disease
and I None
clonic I Disease
- O Disease
tonic O Disease
convulsions O Disease
produced I None
by I None
carbachol I Chemical
and I None
eserine I Chemical
injected I None
similarly I None
was I None
investigated I None
. I None
<eof> I None

<s> O None
Calcium I Chemical
chloride O Chemical
depressed I None
or I None
almost I None
completely I None
abolished I None
the I None
vocalization I None
and I None
fighting I None
due I None
to I None
carbachol I Chemical
and I None
eserine I Chemical
. I None
<eof> I None

<s> O None
On I None
the I None
other I None
hand I None
, I None
mydriasis I Disease
, I None
<eof> I None

<s> O None
tremor I Disease
and I None
clonic I Disease
- O Disease
tonic O Disease
convulsions O Disease
evoked I None
by I None
carbachol I Chemical
and I None
eserine I Chemical
were I None
not I None
significantly I None
changed I None
by I None
calcium I Chemical
chloride O Chemical
. I None
<eof> I None

<s> O None
It I None
is I None
apparent I None
that I None
calcium I Chemical
chloride O Chemical
can I None
" I None
dissociate I None
" I None
vocalization I None
and I None
fighting I None
from I None
autonomic I None
and I None
motor I None
phenomena I None
such I None
as I None
mydriasis I Disease
, I None
tremor I Disease
and I None
clonic I Disease
- O Disease
tonic O Disease
convulsions O Disease
caused I None
by I None
carbachol I Chemical
and I None
eserine I Chemical
. I None
<eof> I None

<s> O None
Calcium I Chemical
chloride O Chemical
inhibited I None
the I None
vocalization I None
and I None
fighting I None
produced I None
by I None
carbachol I Chemical
and I None
eserine I Chemical
most I None
probably I None
by I None
a I None
nonspecific I None
stabilizing I None
action I None
on I None
central I None
muscarinic I None
cholinoceptive I None
sites I None
. I None
<eof> I None

<s> O None
These I None
results I None
further I None
support I None
the I None
view I None
that I None
calcium I Chemical
ions I None
in I None
excess I None
have I None
an I None
atropine I Chemical
-like I None
action I None
also I None
in I None
the I None
central I None
nervous I None
system I None
. I None
<eof> I None

<s> O None
Multiple I None
side I None
effects I None
of I None
penicillamine I Chemical
therapy I None
in I None
one I None
patient I None
with I None
rheumatoid I Disease
arthritis O Disease
. I None
<eof> I None

<s> O None
Skin I Disease
rashes O Disease
, I None
proteinuria I Disease
, I None
systemic I Disease
lupus O Disease
erythematosus O Disease
, I None
polymyositis I Disease
and I None
myasthenia I Disease
gravis O Disease
have I None
all I None
been I None
recorded I None
as I None
complications I None
of I None
penicillamine I Chemical
therapy I None
in I None
patients I None
with I None
rheumatoid I Disease
arthritis O Disease
. I None
<eof> I None

<s> O None
A I None
patient I None
who I None
had I None
developed I None
all I None
5 I None
is I None
now I None
described I None
. I None
<eof> I None

<s> O None
The I None
skin I Disease
lesion O Disease
resembled I None
elastosis I Disease
perforans O Disease
serpiginosa O Disease
, I None
which I None
has I None
been I None
reported I None
as I None
a I None
rare I None
side I None
effect I None
in I None
patients I None
with I None
Wilson I Disease
's O Disease
disease O Disease
but I None
not I None
in I None
patients I None
with I None
rheumatoid I Disease
arthritis O Disease
treated I None
with I None
penicillamine I Chemical
. I None
<eof> I None

<s> O None
Electrocardiographic I None
changes I None
and I None
cardiac I Disease
arrhythmias O Disease
in I None
patients I None
receiving I None
psychotropic I None
drugs I None
. I None
<eof> I None

<s> O None
Eight I None
patients I None
had I None
cardiac I None
manifestations I None
that I None
were I None
life I None
- I None
threatening I None
in I None
five I None
while I None
taking I None
psychotropic I None
drugs I None
, I None
either I None
phenothiazines I Chemical
or I None
tricyclic I None
antidepressants I None
. I None
<eof> I None

<s> O None
Although I None
most I None
patients I None
were I None
receiving I None
several I None
drugs I None
, I None
Mellaril I Chemical
<eof> I None

<s> O None
( I None
thioridazine I Chemical
) I None
appeared I None
to I None
be I None
responsible I None
for I None
five I None
cases I None
of I None
ventricular I Disease
tachycardia O Disease
, I None
one I None
of I None
which I None
was I None
fatal I None
in I None
a I None
35 I None
year I None
old I None
woman I None
. I None
<eof> I None

<s> O None
Supraventricular I Disease
tachycardia O Disease
developed I None
in I None
one I None
patient I None
receiving I None
Thorazine I Chemical
<eof> I None

<s> O None
( I None
chlorpromazine I Chemical
) I None
. I None
<eof> I None

<s> O None
Aventyl I Chemical
<eof> I None

<s> O None
( I None
nortriptyline I Chemical
) I None
and I None
Elavil I Chemical
<eof> I None

<s> O None
( I None
amitriptyline I Chemical
) I None
<eof> I None

<s> O None
each I None
produced I None
left I Disease
bundle O Disease
branch O Disease
block O Disease
in I None
a I None
73 I None
year I None
old I None
woman I None
. I None
<eof> I None

<s> O None
Electrocardiographic I None
T I None
and I None
U I None
wave I None
abnormalities I None
were I None
present I None
in I None
most I None
patients I None
. I None
<eof> I None

<s> O None
The I None
ventricular I Disease
arrhythmias O Disease
responded I None
to I None
intravenous I None
administration I None
of I None
lidocaine I Chemical
and I None
to I None
direct I None
current I None
electric I None
shock I None
; I None
ventricular I None
pacing I None
was I None
required I None
in I None
some I None
instances I None
and I None
intravenous I None
administration I None
of I None
propranolol I Chemical
combined I None
with I None
ventricular I None
pacing I None
in I None
one I None
. I None
<eof> I None

<s> O None
The I None
tachyarrhythmias I Disease
generally I None
subsided I None
within I None
48 I None
hours I None
after I None
administration I None
of I None
the I None
drugs I None
was I None
stopped I None
. I None
<eof> I None

<s> O None
Five I None
of I None
the I None
eight I None
patients I None
were I None
50 I None
years I None
of I None
age I None
or I None
younger I None
; I None
only I None
one I None
clearly I None
had I None
antecedent I None
heart I Disease
disease O Disease
. I None
<eof> I None

<s> O None
Major I None
cardiac I Disease
arrhythmias O Disease
are I None
a I None
potential I None
hazard I None
in I None
patients I None
without I None
heart I Disease
disease O Disease
who I None
are I None
receiving I None
customary I None
therapeutic I None
doses I None
of I None
psychotropic I None
drugs I None
. I None
<eof> I None

<s> O None
A I None
prospective I None
clinical I None
trial I None
is I None
suggested I None
to I None
quantify I None
the I None
risk I None
of I None
cardiac I Disease
complications O Disease
to I None
patients I None
receiving I None
phenothiazines I Chemical
or I None
tricyclic I None
antidepressant I None
drugs I None
. I None
<eof> I None

<s> O None
Serotonergic I None
drugs I None
, I None
benzodiazepines I Chemical
and I None
baclofen I Chemical
block I None
muscimol I Chemical
-induced I None
myoclonic I Disease
jerks O Disease
in I None
a I None
strain I None
of I None
mice I None
. I None
<eof> I None

<s> O None
In I None
male I None
Swiss I None
mice I None
, I None
muscimol I Chemical
produced I None
myoclonic I Disease
jerks O Disease
. I None
<eof> I None

<s> O None
A I None
3 I None
mg I None
/ I None
kg I None
( I None
i.p I None
. I None
) I None
<eof> I None

<s> O None
dose I None
induced I None
this I None
response I None
in I None
all I None
of I None
the I None
mice I None
tested I None
and I None
the I None
peak I None
response I None
of I None
73 I None
jerks I None
per I None
min I None
was I None
observed I None
between I None
27 I None
and I None
45 I None
min I None
. I None
<eof> I None

<s> O None
Increasing I None
the I None
brain I None
<eof> I None

<s> O None
serotonin I Chemical
levels I None
by I None
the I None
administration I None
of I None
5-hydroxytryptophan I Chemical
<eof> I None

<s> O None
( I None
80 I None
- I None
160 I None
mg I None
/ I None
kg I None
) I None
in I None
combination I None
with I None
a I None
peripheral I None
decarboxylase I None
inhibitor I None
resulted I None
in I None
an I None
inhibition I None
of I None
the I None
muscimol I Chemical
effect I None
. I None
<eof> I None

<s> O None
However I None
, I None
in I None
a I None
similar I None
experiment I None
l I Chemical
- O Chemical
dopa O Chemical
<eof> I None

<s> O None
( I None
80 I None
- I None
160 I None
mg I None
/ I None
kg I None
) I None
was I None
without I None
effect I None
. I None
<eof> I None

<s> O None
In I None
doses I None
of I None
3 I None
- I None
10 I None
mg I None
/ I None
kg I None
, I None
the I None
serotonin I Chemical
receptor I None
agonist I None
MK-212 I Chemical
caused I None
a I None
dose I None
- I None
dependent I None
blockade I None
of I None
the I None
response I None
of I None
muscimol I Chemical
. I None
<eof> I None

<s> O None
Of I None
the I None
benzodiazepines I Chemical
, I None
clonazepam I Chemical
( I None
0.1 I None
- I None
0.3 I None
mg I None
/ I None
kg I None
) I None
was I None
found I None
to I None
be I None
several I None
fold I None
more I None
potent I None
than I None
diazepam I Chemical
( I None
0.3 I None
- I None
3 I None
mg I None
/ I None
kg I None
) I None
in I None
blocking I None
the I None
myoclonic I Disease
jerks O Disease
. I None
<eof> I None

<s> O None
While I None
( I None
-)- I None
baclofen I Chemical
( I None
1 I None
- I None
3 I None
mg I None
/ I None
kg I None
) I None
proved I None
to I None
be I None
an I None
effective I None
antagonist I None
of I None
muscimol I Chemical
, I None
its I None
( I None
+ I None
) I None
-isomer I None
( I None
5 I None
- I None
20 I None
mg I None
/ I None
kg I None
) I None
lacked I None
this I None
property I None
. I None
<eof> I None

<s> O None
Considering I None
the I None
fact I None
that I None
5-HTP I Chemical
and I None
the I None
benzodiazepines I Chemical
have I None
been I None
found I None
to I None
be I None
beneficial I None
in I None
the I None
management I None
of I None
clinical I None
myoclonus I Disease
, I None
the I None
muscimol I Chemical
-induced I None
myoclonus I Disease
seems I None
to I None
be I None
a I None
satisfactory I None
animal I None
model I None
that I None
may I None
prove I None
useful I None
for I None
the I None
development I None
of I None
new I None
drug I None
treatments I None
for I None
this I None
condition I None
. I None
<eof> I None

<s> O None
Our I None
present I None
study I None
indicated I None
the I None
possible I None
value I None
of I None
MK-212 I Chemical
and I None
<eof> I None

<s> O None
( I None
-)- I None
<eof> I None

<s> O None
baclofen I Chemical
in I None
the I None
management I None
of I None
clinical I None
myoclonus I Disease
. I None
<eof> I None

<s> O None
Hyperglycemic I None
acidotic I None
coma I None
and I None
death I None
in I None
Kearns I Disease
- O Disease
Sayre O Disease
syndrome O Disease
. I None
<eof> I None

<s> O None
This I None
paper I None
presents I None
the I None
clinical I None
and I None
metabolic I None
findings I None
in I None
two I None
young I None
boys I None
with I None
long I None
- I None
standing I None
Kearns I Disease
- O Disease
Sayre O Disease
syndrome O Disease
. I None
<eof> I None

<s> O None
Following I None
short I None
exposure I None
to I None
oral I None
prednisone I Chemical
, I None
both I None
boys I None
developed I None
lethargy I Disease
, I None
increasing I None
somnolence I Disease
, I None
polydipsia I Disease
, I None
polyphagia I Disease
, I None
and I None
polyuria I Disease
. I None
<eof> I None

<s> O None
Both I None
presented I None
in I None
the I None
emergency I None
room I None
with I None
profound I None
coma I Disease
, I None
hypotension I Disease
, I None
severe I None
hyperglycemia I Disease
, I None
and I None
acidosis I Disease
. I None
<eof> I None

<s> O None
Nonketotic I None
lactic I Disease
acidosis O Disease
was I None
present I None
in I None
one I None
and I None
ketosis I Disease
without I None
a I None
known I None
serum I None
<eof> I None

<s> O None
lactate I Chemical
level I None
was I None
present I None
in I None
the I None
other I None
. I None
<eof> I None

<s> O None
Respiratory I Disease
failure O Disease
rapidly I None
ensued I None
and I None
both I None
patients I None
expired I None
in I None
spite I None
of I None
efforts I None
at I None
resuscitation I None
. I None
<eof> I None

<s> O None
We I None
believe I None
these I None
two I None
cases I None
represent I None
a I None
newly I None
described I None
and I None
catastrophic I None
metabolic I Disease
- O Disease
endocrine O Disease
failure O Disease
in I None
the I None
Kearns I Disease
- O Disease
Sayre O Disease
syndrome O Disease
. I None
<eof> I None

<s> O None
Effects I None
of I None
active I None
constituents I None
of I None
Crocus I None
sativus I None
L. I None
, I None
crocin I Chemical
on I None
streptozocin I Chemical
-induced I None
model I None
of I None
sporadic I None
Alzheimer I Disease
's O Disease
disease O Disease
in I None
male I None
rats I None
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
<eof> I None

<s> O None
The I None
involvement I None
of I None
water I None
- I None
soluble I None
carotenoids I Chemical
, I None
crocins I Chemical
, I None
as I None
the I None
main I None
and I None
active I None
components I None
of I None
Crocus I None
sativus I None
L. I None
extract I None
in I None
learning I None
and I None
memory I None
processes I None
has I None
been I None
proposed I None
. I None
<eof> I None

<s> O None
In I None
the I None
present I None
study I None
, I None
the I None
effect I None
of I None
crocins I Chemical
on I None
sporadic I None
Alzheimer I Disease
's O Disease
disease O Disease
induced I None
by I None
intracerebroventricular I None
( I None
icv I None
) I None
streptozocin I Chemical
<eof> I None

<s> O None
( I None
STZ I Chemical
) I None
in I None
male I None
rats I None
was I None
investigated I None
. I None
<eof> I None

<s> O None
METHODS I None
: I None
<eof> I None

<s> O None
Male I None
adult I None
Wistar I None
rats I None
( I None
n I None
= I None
90 I None
and I None
260 I None
- I None
290 I None
g I None
) I None
were I None
divided I None
into I None
1 I None
, I None
control I None
; I None
2 I None
and I None
3 I None
, I None
crocins I Chemical
( I None
15 I None
and I None
30 I None
mg I None
/ I None
kg I None
) I None
; I None
4 I None
, I None
STZ I Chemical
; I None
5 I None
and I None
6 I None
, I None
STZ I Chemical
+ I None
crocins I Chemical
( I None
15 I None
and I None
30 I None
mg I None
/ I None
kg I None
) I None
groups I None
. I None
<eof> I None

<s> O None
In I None
Alzheimer I Disease
's O Disease
disease O Disease
groups I None
, I None
rats I None
were I None
injected I None
with I None
STZ I Chemical
-icv I None
bilaterally I None
( I None
3 I None
mg I None
/ I None
kg I None
) I None
in I None
first I None
day I None
and I None
3 I None
days I None
later I None
, I None
a I None
similar I None
STZ I Chemical
-icv I None
application I None
was I None
repeated I None
. I None
<eof> I None

<s> O None
In I None
STZ I Chemical
+ I None
crocin I Chemical
animal I None
groups I None
, I None
crocin I Chemical
was I None
applied I None
in I None
doses I None
of I None
15 I None
and I None
30 I None
mg I None
/ I None
kg I None
, I None
i.p I None
. I None
<eof> I None

<s> O None
, I None
one I None
day I None
<eof> I None

<s> O None
pre I None
- I None
surgery I None
and I None
continued I None
for I None
three I None
weeks I None
. I None
<eof> I None

<s> O None
Prescription I None
of I None
crocin I Chemical
in I None
each I None
dose I None
was I None
repeated I None
once I None
for I None
two I None
days I None
. I None
<eof> I None

<s> O None
However I None
, I None
the I None
learning I None
and I None
memory I None
performance I None
was I None
assessed I None
using I None
passive I None
avoidance I None
paradigm I None
, I None
and I None
for I None
spatial I None
cognition I None
evaluation I None
, I None
Y I None
- I None
maze I None
task I None
was I None
used I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
It I None
was I None
found I None
out I None
that I None
crocin I Chemical
<eof> I None

<s> O None
( I None
30 I None
mg I None
/ I None
kg)-treated I None
<eof> I None

<s> O None
STZ I Chemical
-injected I None
rats I None
show I None
higher I None
correct I None
choices I None
and I None
lower I None
errors I None
in I None
Y I None
- I None
maze I None
than I None
vehicle I None
- I None
treated I None
STZ I Chemical
-injected I None
rats I None
. I None
<eof> I None

<s> O None
In I None
addition I None
, I None
crocin I Chemical
in I None
the I None
mentioned I None
dose I None
could I None
significantly I None
attenuated I None
learning I None
and I None
memory I None
impairment I None
in I None
treated I None
STZ I Chemical
-injected I None
group I None
in I None
passive I None
avoidance I None
test I None
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
<eof> I None

<s> O None
Therefore I None
, I None
these I None
results I None
demonstrate I None
the I None
effectiveness I None
of I None
crocin I Chemical
<eof> I None

<s> O None
( I None
30 I None
mg I None
/ I None
kg I None
) I None
in I None
antagonizing I None
the I None
cognitive I Disease
deficits O Disease
<eof> I None

<s> O None
caused I None
by I None
<eof> I None

<s> O None
STZ I Chemical
-icv I None
in I None
rats I None
and I None
its I None
potential I None
in I None
the I None
treatment I None
of I None
neurodegenerative I Disease
diseases O Disease
such I None
as I None
Alzheimer I Disease
's O Disease
disease O Disease
. I None
<eof> I None

<s> O None
Rosaceiform I None
dermatitis I Disease
associated I None
with I None
topical I None
tacrolimus I Chemical
treatment I None
. I None
<eof> I None

<s> O None
We I None
describe I None
herein I None
3 I None
patients I None
who I None
developed I None
rosacea I Disease
-like I None
<eof> I None

<s> O None
dermatitis I Disease
<eof> I None

<s> O None
eruptions I Disease
while I None
using I None
0.03 I None
% I None
or I None
0.1 I None
% I None
tacrolimus I Chemical
ointment I None
for I None
facial I Disease
dermatitis O Disease
. I None
<eof> I None

<s> O None
Skin I None
biopsy I None
specimens I None
showed I None
<eof> I None

<s> O None
telangiectasia I Disease
and I None
noncaseating I None
epithelioid I None
granulomatous I None
tissue I None
formation I None
in I None
the I None
papillary I None
to I None
mid I None
dermis I None
. I None
<eof> I None

<s> O None
Continuous I None
topical I None
use I None
of I None
immunomodulators I None
such I None
as I None
tacrolimus I Chemical
or I None
pimecrolimus I Chemical
should I None
be I None
regarded I None
as I None
a I None
potential I None
cause I None
of I None
rosaceiform I None
dermatitis I Disease
, I None
although I None
many I None
cases I None
have I None
not I None
been I None
reported I None
. I None
<eof> I None

<s> O None
A I None
novel I None
animal I None
model I None
to I None
evaluate I None
the I None
ability I None
of I None
a I None
drug I None
delivery I None
system I None
to I None
promote I None
the I None
passage I None
through I None
the I None
BBB I None
. I None
<eof> I None

<s> O None
The I None
purpose I None
of I None
this I None
investigation I None
was I None
to I None
explore I None
the I None
potentiality I None
of I None
a I None
novel I None
animal I None
model I None
to I None
be I None
used I None
for I None
the I None
in I None
vivo I None
evaluation I None
of I None
the I None
ability I None
of I None
a I None
drug I None
delivery I None
system I None
to I None
promote I None
the I None
passage I None
through I None
the I None
blood I None
- I None
brain I None
barrier I None
( I None
BBB I None
) I None
and/or I None
to I None
improve I None
the I None
brain I None
localization I None
of I None
a I None
bioactive I None
compound I None
. I None
<eof> I None

<s> O None
A I None
Tween I None
80-coated I None
poly I Chemical
- O Chemical
L O Chemical
- O Chemical
lactid O Chemical
acid O Chemical
nanoparticles I None
was I None
used I None
as I None
a I None
model I None
of I None
colloidal I None
drug I None
delivery I None
system I None
, I None
able I None
to I None
trespass I None
the I None
BBB I None
. I None
<eof> I None

<s> O None
Tacrine I Chemical
, I None
administered I None
in I None
LiCl I Chemical
pre I None
- I None
treated I None
rats I None
, I None
induces I None
electrocorticographic I None
seizures I Disease
and I None
delayed I None
hippocampal I Disease
damage O Disease
. I None
<eof> I None

<s> O None
The I None
toxic I None
effects I None
of I None
tacrine I Chemical
-loaded I None
poly I Chemical
- O Chemical
L O Chemical
- O Chemical
lactid O Chemical
acid O Chemical
nanoparticles I None
( I None
5mg I None
/ I None
kg I None
) I None
, I None
a I None
saline I None
solution I None
of I None
tacrine I Chemical
<eof> I None

<s> O None
( I None
5mg I None
/ I None
kg I None
) I None
and I None
an I None
empty I None
colloidal I None
nanoparticle I None
suspension I None
were I None
compared I None
following I None
i.p I None
. I None
<eof> I None

<s> O None
administration I None
in I None
LiCl I Chemical
<eof> I None

<s> O None
-pre I None
- I None
treated I None
Wistar I None
rats I None
. I None
<eof> I None

<s> O None
All I None
the I None
animals I None
treated I None
with I None
tacrine I Chemical
<eof> I None

<s> O None
-loaded I None
nanoparticles I None
showed I None
an I None
earlier I None
outcome I None
of I None
CNS I None
adverse I None
symptoms I None
, I None
i.e. I None
epileptic I Disease
onset I None
, I None
with I None
respect I None
to I None
those I None
animals I None
treated I None
with I None
the I None
free I None
compound I None
( I None
10 I None
min I None
vs. I None
22 I None
min I None
respectively I None
) I None
. I None
<eof> I None

<s> O None
In I None
addition I None
, I None
tacrine I Chemical
-loaded I None
nanoparticles I None
administration I None
induced I None
damage I Disease
of O Disease
neuronal O Disease
cells O Disease
in I None
CA1 I None
field I None
of I None
the I None
hippocampus I None
in I None
all I None
treated I None
animals I None
, I None
while I None
the I None
saline I None
solution I None
of I None
tacrine I Chemical
only I None
in I None
60 I None
% I None
of I None
animals I None
. I None
<eof> I None

<s> O None
Empty I None
nanoparticles I None
provided I None
similar I None
results I None
to I None
control I None
( I None
saline I None
- I None
treated I None
) I None
group I None
of I None
animals I None
. I None
<eof> I None

<s> O None
In I None
conclusion I None
, I None
the I None
evaluation I None
of I None
time I None
- I None
to I None
- I None
onset I None
of I None
symptoms I None
and I None
the I None
severity I None
of I None
neurodegenerative I None
processes I None
induced I None
by I None
the I None
tacrine I Chemical
- I None
lithium I Chemical
model I None
of I None
epilepsy I Disease
in I None
the I None
rat I None
, I None
could I None
be I None
used I None
to I None
evaluate I None
preliminarily I None
the I None
capability I None
of I None
a I None
drug I None
delivery I None
system I None
to I None
trespass I None
( I None
or I None
not I None
) I None
the I None
BBB I None
in I None
vivo I None
. I None
<eof> I None

<s> O None
The I None
antiarrhythmic I None
effect I None
and I None
possible I None
ionic I None
mechanisms I None
of I None
pilocarpine I Chemical
on I None
animal I None
models I None
. I None
<eof> I None

<s> O None
This I None
study I None
was I None
designed I None
to I None
evaluate I None
the I None
effects I None
of I None
pilocarpine I Chemical
and I None
explore I None
the I None
underlying I None
ionic I None
mechanism I None
, I None
using I None
both I None
aconitine I Chemical
-induced I None
rat I None
and I None
ouabain I Chemical
-induced I None
guinea I None
pig I None
arrhythmia I Disease
models I None
. I None
<eof> I None

<s> O None
Confocal I None
microscopy I None
was I None
used I None
to I None
measure I None
intracellular I None
free- I None
calcium I Chemical
concentrations I None
( I None
[ I None
Ca I Chemical
( I None
2+)](i I None
) I None
) I None
in I None
isolated I None
myocytes I None
. I None
<eof> I None

<s> O None
The I None
current I None
data I None
showed I None
that I None
pilocarpine I Chemical
significantly I None
delayed I None
onset I None
of I None
arrhythmias I Disease
, I None
decreased I None
the I None
time I None
course I None
of I None
ventricular I None
tachycardia I None
and I None
fibrillation I None
, I None
reduced I None
arrhythmia I Disease
score I None
, I None
and I None
increased I None
the I None
survival I None
time I None
of I None
arrhythmic I Disease
rats I None
and I None
guinea I None
pigs I None
. I None
<eof> I None

<s> O None
[ I None
Ca I Chemical
( I None
2+)](i I None
) I None
overload I None
induced I None
by I None
aconitine I Chemical
or I None
ouabain I Chemical
was I None
reduced I None
in I None
isolated I None
myocytes I None
pretreated I None
with I None
pilocarpine I Chemical
. I None
<eof> I None

<s> O None
Moreover I None
, I None
M(3)-muscarinic I None
acetylcholine I Chemical
receptor I None
( I None
mAChR I None
) I None
antagonist I None
4-DAMP I Chemical
<eof> I None

<s> O None
( I None
4-diphenylacetoxy I Chemical
- O Chemical
N O Chemical
- O Chemical
methylpiperidine O Chemical
- O Chemical
methiodide O Chemical
) I None
partially I None
abolished I None
the I None
beneficial I None
effects I None
of I None
pilocarpine I Chemical
. I None
<eof> I None

<s> O None
These I None
data I None
suggest I None
that I None
pilocarpine I Chemical
produced I None
antiarrhythmic I None
actions I None
on I None
arrhythmic I Disease
rat I None
and I None
guinea I None
pig I None
models I None
induced I None
by I None
aconitine I Chemical
or I None
ouabain I Chemical
via I None
stimulating I None
the I None
cardiac I None
<eof> I None

<s> O None
M(3)-mAChR. I None
<eof> I None

<s> O None
The I None
mechanism I None
may I None
be I None
related I None
to I None
the I None
improvement I None
of I None
Ca I Chemical
<eof> I None

<s> O None
( I None
2 I None
+ I None
) I None
handling I None
. I None
<eof> I None

<s> O None
Disulfiram I Chemical
-induced I None
transient I None
optic I None
and I None
peripheral I None
neuropathy I None
: I None
a I None
case I None
report I None
. I None
<eof> I None

<s> O None
AIM I None
: I None
To I None
report I None
a I None
case I None
of I None
optic I None
and I None
peripheral I None
neuropathy I None
after I None
chronic I None
use I None
of I None
disulfiram I Chemical
for I None
alcohol I Disease
dependence O Disease
management I None
. I None
<eof> I None

<s> O None
MATERIALS I None
AND I None
METHODS I None
: I None
<eof> I None

<s> O None
A I None
case I None
report I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
A I None
57-year I None
- I None
old I None
male I None
presented I None
with I None
gradual I None
loss I Disease
of O Disease
vision O Disease
in I None
both I None
eyes I None
with I None
intermittent I None
headaches I Disease
for I None
2 I None
months I None
. I None
<eof> I None

<s> O None
He I None
also I None
complained I None
of I None
paraesthesia I Disease
with I None
numbness I Disease
in I None
both I None
feet I None
. I None
<eof> I None

<s> O None
His I None
vision I None
was I None
6/15 I None
and I None
2/60 I None
in I None
the I None
right I None
and I None
left I None
eyes I None
, I None
respectively I None
. I None
<eof> I None

<s> O None
Fundoscopy I None
revealed I None
bilaterally I None
swollen I None
optic I None
nerve I None
heads I None
. I None
<eof> I None

<s> O None
Visual I None
field I None
testing I None
confirmed I None
bilateral I None
central I None
- I None
caecal I None
scotomata I Disease
. I None
<eof> I None

<s> O None
He I None
had I None
been I None
taking I None
disulfiram I Chemical
for I None
alcohol I Disease
dependence O Disease
for I None
the I None
preceding I None
3 I None
years I None
. I None
<eof> I None

<s> O None
Disulfiram I Chemical
discontinuation I None
lead I None
to I None
an I None
immediate I None
symptomatic I None
improvement I None
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
<eof> I None

<s> O None
Physicians I None
initiating I None
long I None
- I None
term I None
disulfiram I Chemical
therapy I None
should I None
be I None
aware I None
of I None
these I None
adverse I None
effects I None
. I None
<eof> I None

<s> O None
They I None
should I None
recommend I None
annual I None
ophthalmic I None
reviews I None
with I None
visual I None
field I None
testing I None
. I None
<eof> I None

<s> O None
Patients I None
should I None
be I None
reassured I None
with I None
respect I None
to I None
the I None
reversibility I None
of I None
these I None
adverse I None
effects I None
. I None
<eof> I None

<s> O None
Sustained I None
clinical I None
improvement I None
of I None
a I None
patient I None
with I None
decompensated I None
hepatitis I Disease
B O Disease
virus I None
- I None
related I None
cirrhosis I Disease
after I None
treatment I None
with I None
lamivudine I Chemical
monotherapy I None
. I None
<eof> I None

<s> O None
Hepatitis I Disease
B O Disease
virus O Disease
( O Disease
HBV O Disease
) O Disease
infection O Disease
, I None
which I None
causes I None
liver I Disease
cirrhosis O Disease
and I None
hepatocellular I Disease
carcinoma O Disease
, I None
remains I None
a I None
major I None
health I None
problem I None
in I None
Asian I None
countries I None
. I None
<eof> I None

<s> O None
Recent I None
development I None
of I None
vaccine I None
for I None
prevention I None
is I None
reported I None
to I None
be I None
successful I None
in I None
reducing I None
the I None
size I None
of I None
chronically I None
infected I None
carriers I None
, I None
although I None
the I None
standard I None
medical I None
therapies I None
have I None
not I None
been I None
established I None
up I None
to I None
now I None
. I None
<eof> I None

<s> O None
In I None
this I None
report I None
, I None
we I None
encountered I None
a I None
patient I None
with I None
decompensated I None
HBV I None
- I None
related I None
cirrhosis I Disease
who I None
exhibited I None
the I None
dramatic I None
improvements I None
after I None
antiviral I None
therapy I None
. I None
<eof> I None

<s> O None
The I None
patient I None
was I None
a I None
50-year I None
- I None
old I None
woman I None
. I None
<eof> I None

<s> O None
Previous I None
conventional I None
medical I None
treatments I None
were I None
not I None
effective I None
for I None
this I None
patient I None
, I None
thus I None
this I None
patient I None
had I None
been I None
referred I None
to I None
our I None
hospital I None
. I None
<eof> I None

<s> O None
However I None
, I None
the I None
administration I None
of I None
lamivudine I Chemical
, I None
a I None
reverse I None
transcriptase I None
inhibitor I None
, I None
for I None
23 I None
months I None
dramatically I None
improved I None
her I None
liver I None
severity I None
. I None
<eof> I None

<s> O None
During I None
this I None
period I None
, I None
no I None
drug I None
resistant I None
mutant I None
HBV I None
emerged I None
, I None
and I None
the I None
serum I None
HBV I None
- I None
DNA I None
level I None
was I None
continuously I None
suppressed I None
. I None
<eof> I None

<s> O None
These I None
virological I None
responses I None
were I None
also I None
maintained I None
even I None
after I None
the I None
antiviral I None
therapy I None
was I None
discontinued I None
. I None
<eof> I None

<s> O None
Moreover I None
, I None
both I None
hepatitis I None
B I None
surface I None
antigen I None
and I None
e I None
antigen I None
were I None
observed I None
to I None
have I None
disappeared I None
in I None
this I None
patient I None
. I None
<eof> I None

<s> O None
The I None
administration I None
of I None
lamivudine I Chemical
to I None
patients I None
with I None
HBV I None
- I None
related I None
cirrhosis I Disease
, I None
like I None
our I None
present I None
case I None
, I None
should I None
be I None
considered I None
as I None
an I None
initial I None
medical I None
therapeutic I None
option I None
, I None
especially I None
in I None
countries I None
where I None
liver I None
transplantation I None
is I None
not I None
reliably I None
available I None
. I None
<eof> I None

<s> O None
Dual I None
effects I None
of I None
melatonin I Chemical
on I None
barbiturate I Chemical
-induced I None
narcosis I Disease
in I None
rats I None
. I None
<eof> I None

<s> O None
Melatonin I Chemical
affects I None
the I None
circadian I None
sleep I None
<eof> I None

<s> O None
/ I None
wake I None
cycle I None
, I None
but I None
it I None
is I None
not I None
clear I None
whether I None
it I None
may I None
influence I None
drug I None
- I None
induced I None
narcosis I Disease
. I None
<eof> I None

<s> O None
Sodium I Chemical
thiopenthal O Chemical
was I None
administered I None
intraperitoneally I None
into I None
male I None
rats I None
pre I None
- I None
treated I None
with I None
melatonin I Chemical
( I None
0.05 I None
, I None
0.5 I None
, I None
5 I None
and I None
50 I None
mg I None
/ I None
kg I None
) I None
. I None
<eof> I None

<s> O None
Melatonin I Chemical
<eof> I None

<s> O None
pre I None
- I None
treatment I None
affected I None
in I None
a I None
dual I None
manner I None
barbiturate I Chemical
narcosis I Disease
, I None
however I None
, I None
no I None
dose I None
- I None
effect I None
correlation I None
was I None
found I None
. I None
<eof> I None

<s> O None
In I None
particular I None
, I None
low I None
doses I None
reduced I None
the I None
latency I None
to I None
and I None
prolonged I None
the I None
duration I None
of I None
barbiturate I Chemical
narcosis I Disease
. I None
<eof> I None

<s> O None
In I None
contrast I None
, I None
the I None
highest I None
dose I None
of I None
melatonin I Chemical
<eof> I None

<s> O None
( I None
50 I None
mg I None
/ I None
kg I None
) I None
caused I None
a I None
paradoxical I None
increase I None
in I None
the I None
latency I None
and I None
produced I None
a I None
sustained I None
reduction I None
of I None
the I None
duration I None
of I None
narcosis I Disease
, I None
and I None
a I None
reduction I None
in I None
mortality I None
rate I None
. I None
<eof> I None

<s> O None
Melatonin I Chemical
0.5 I None
and I None
5 I None
mg I None
/ I None
kg I None
influenced I None
the I None
duration I None
but I None
not I None
the I None
latency I None
of I None
ketamine I Chemical
- I None
or I None
diazepam I Chemical
-induced I None
<eof> I None

<s> O None
narcosis I Disease
. I None
<eof> I None

<s> O None
Thus I None
, I None
the I None
dual I None
action I None
of I None
melatonin I Chemical
on I None
pharmacological I None
narcosis I Disease
seems I None
to I None
be I None
specific I None
for I None
the I None
barbiturate I Chemical
mechanism I None
of I None
action I None
. I None
<eof> I None

<s> O None
Effects I None
of I None
NIK-247 I Chemical
on I None
cholinesterase I None
and I None
scopolamine I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
amnesia I Disease
. I None
<eof> I None

<s> O None
The I None
effects I None
of I None
NIK-247 I Chemical
on I None
cholinesterase I None
, I None
scopolamine I Chemical
-induced I None
amnesia I Disease
and I None
spontaneous I None
movement I None
were I None
examined I None
and I None
compared I None
with I None
those I None
of I None
the I None
well I None
- I None
known I None
cholinesterase I None
inhibitors I None
tacrine I Chemical
and I None
E-2020 I Chemical
. I None
<eof> I None

<s> O None
NIK-247 I Chemical
, I None
<eof> I None

<s> O None
tacrine I Chemical
and I None
E-2020 I Chemical
all I None
strongly I None
inhibited I None
acetylcholinesterase I None
( I None
AChE I None
) I None
in I None
human I None
red I None
blood I None
cells I None
( I None
IC50s I None
= I None
1.0 I None
x I None
10(-6 I None
) I None
, I None
2.9 I None
x I None
10(-7 I None
) I None
and I None
3.7 I None
x I None
10(-8 I None
<eof> I None

<s> O None
) I None
M I None
, I None
respectively I None
) I None
. I None
<eof> I None

<s> O None
In I None
addition I None
, I None
NIK-247 I Chemical
and I None
tacrine I Chemical
, I None
but I None
not I None
E-2020 I Chemical
, I None
strongly I None
inhibited I None
butyrylcholinestrase I None
( I None
BuChE I None
) I None
in I None
human I None
serum I None
. I None
<eof> I None

<s> O None
All I None
three I None
drugs I None
produced I None
mixed I None
inhibition I None
of I None
AChE I None
activity I None
. I None
<eof> I None

<s> O None
Moreover I None
, I None
the I None
inhibitory I None
effect I None
of I None
NIK-247 I Chemical
on I None
AChE I None
was I None
reversible I None
. I None
<eof> I None

<s> O None
All I None
compounds I None
at I None
0.1 I None
- I None
1 I None
mg I None
/ I None
kg I None
p.o I None
. I None
<eof> I None

<s> O None
significantly I None
improved I None
the I None
amnesia I Disease
induced I None
by I None
scopolamine I Chemical
<eof> I None

<s> O None
( I None
0.5 I None
mg I None
/ I None
kg I None
s.c I None
. I None
) I None
<eof> I None

<s> O None
in I None
rats I None
performing I None
a I None
passive I None
avoidance I None
task I None
. I None
<eof> I None

<s> O None
The I None
three I None
compounds I None
at I None
1 I None
and I None
3 I None
mg I None
/ I None
kg I None
p.o I None
. I None
<eof> I None

<s> O None
did I None
not I None
significantly I None
decrease I None
spontaneous I None
movement I None
by I None
rats I None
. I None
<eof> I None

<s> O None
These I None
findings I None
suggest I None
that I None
NIK-247 I Chemical
at I None
a I None
low I None
dose I None
( I None
0.1 I None
- I None
1 I None
mg I None
/ I None
kg I None
p.o I None
. I None
) I None
improves I None
<eof> I None

<s> O None
scopolamine I Chemical
-induced I None
<eof> I None

<s> O None
amnesia I Disease
but I None
does I None
not I None
affect I None
spontaneous I None
movement I None
. I None
<eof> I None

<s> O None
The I None
findings I None
suggest I None
that I None
NIK-247 I Chemical
may I None
be I None
a I None
useful I None
drug I None
for I None
the I None
treatment I None
of I None
Alzheimer I Disease
's O Disease
disease O Disease
. I None
<eof> I None

<s> O None
Nightmares I None
and I None
hallucinations I Disease
after I None
long I None
- I None
term I None
intake I None
of I None
tramadol I Chemical
combined I None
with I None
antidepressants I None
. I None
<eof> I None

<s> O None
Tramadol I Chemical
is I None
a I None
weak I None
opioid I None
with I None
effects I None
on I None
adrenergic I None
and I None
serotonergic I None
neurotransmission I None
that I None
is I None
used I None
to I None
treat I None
cancer I Disease
pain I Disease
and I None
chronic I None
non I None
malignant I None
pain I Disease
. I None
<eof> I None

<s> O None
This I None
drug I None
was I None
initiated I None
in I None
association I None
with I None
paroxetine I Chemical
and I None
dosulepine I Chemical
hydrochloride O Chemical
in I None
a I None
tetraparetic I Disease
patient I None
with I None
chronic I Disease
pain O Disease
. I None
<eof> I None

<s> O None
Fifty I None
- I None
six I None
days I None
after I None
initiation I None
of I None
the I None
treatment I None
the I None
patient I None
presented I None
hallucinations I Disease
that I None
only I None
stopped I None
after I None
the I None
withdrawal I None
of I None
psycho I None
- I None
active I None
drugs I None
and I None
tramadol I Chemical
. I None
<eof> I None

<s> O None
The I None
case I None
report I None
questions I None
the I None
long I None
term I None
use I None
of I None
pain I Disease
killers I None
combined I None
with I None
psycho I None
- I None
active I None
drugs I None
in I None
chronic I None
non I None
malignant I None
pain I Disease
, I None
especially I None
if I None
pain I Disease
is I None
under I None
control I None
. I None
<eof> I None

<s> O None
Apparent I None
cure I None
of I None
rheumatoid I Disease
arthritis O Disease
by I None
bone I None
marrow I None
transplantation I None
. I None
<eof> I None

<s> O None
We I None
describe I None
the I None
induction I None
of I None
sustained I None
remissions I None
and I None
possible I None
cure I None
of I None
severe I None
erosive I None
rheumatoid I Disease
arthritis O Disease
<eof> I None

<s> O None
( I None
RA I Disease
) I None
by I None
bone I None
marrow I None
transplantation I None
( I None
BMT I None
) I None
in I None
2 I None
patients I None
. I None
<eof> I None

<s> O None
BMT I None
was I None
used I None
to I None
treat I None
severe I None
aplastic I Disease
anemia O Disease
which I None
was I None
caused I None
by I None
gold I Chemical
in I None
one I None
case I None
and I None
D I Chemical
- O Chemical
penicillamine O Chemical
in I None
the I None
other I None
. I None
<eof> I None

<s> O None
In I None
the I None
8 I None
and I None
6 I None
years I None
since I None
the I None
transplants I None
( I None
representing I None
8 I None
and I None
4 I None
years I None
since I None
cessation I None
of I None
all I None
immunosuppressive I None
therapy I None
, I None
respectively I None
) I None
, I None
the I None
RA I Disease
in I None
each I None
case I None
has I None
been I None
completely I None
quiescent I None
. I None
<eof> I None

<s> O None
Although I None
short I None
term I None
remission I None
of I None
severe I None
RA I Disease
following I None
BMT I None
has I None
been I None
reported I None
, I None
these I None
are I None
the I None
first I None
cases I None
for I None
which I None
prolonged I None
followup I None
has I None
been I None
available I None
. I None
<eof> I None

<s> O None
This I None
experience I None
raises I None
the I None
question I None
of I None
the I None
role I None
of I None
BMT I None
itself I None
as I None
a I None
therapeutic I None
option I None
for I None
patients I None
with I None
uncontrolled I None
destructive I None
synovitis I Disease
. I None
<eof> I None

<s> O None
Urinary I None
enzymes I None
and I None
protein I None
patterns I None
as I None
indicators I None
of I None
injury I Disease
to O Disease
different O Disease
regions O Disease
of O Disease
the O Disease
kidney O Disease
. I None
<eof> I None

<s> O None
Acute I Disease
experimental O Disease
models O Disease
of O Disease
renal O Disease
damage O Disease
to I None
the I None
proximal I None
tubular I None
, I None
glomerular I None
, I None
and I None
papillary I None
regions I None
of I None
the I None
rat I None
were I None
produced I None
by I None
administration I None
of I None
hexachloro-1:3-butadiene I Chemical
<eof> I None

<s> O None
( I None
HCBD I Chemical
) I None
, I None
puromycin I Chemical
aminonucleoside O Chemical
<eof> I None

<s> O None
( I None
PAN I Chemical
) I None
, I None
and I None
2-bromoethylamine I Chemical
( I None
BEA I Chemical
) I None
, I None
respectively I None
. I None
<eof> I None

<s> O None
Several I None
routine I None
indicators I None
of I None
nephrotoxicity I Disease
, I None
the I None
enzymes I None
alkaline I None
phosphatase I None
and I None
N I None
- I None
acetyl I None
- I None
beta I None
- I None
glucosaminidase I None
, I None
and I None
the I None
molecular I None
weight I None
of I None
protein I Disease
excretion O Disease
were I None
determined I None
on I None
urine I None
samples I None
. I None
<eof> I None

<s> O None
Tubular I None
damage I None
produced I None
by I None
HCBD I Chemical
or I None
BEA I Chemical
was I None
discriminated I None
both I None
quantitatively I None
and I None
qualitatively I None
from I None
glomerular I Disease
damage O Disease
produced I None
by I None
PAN I Chemical
. I None
<eof> I None

<s> O None
The I None
latter I None
was I None
characterized I None
by I None
a I None
pronounced I None
increase I None
in I None
protein I Disease
excretion O Disease
, I None
especially I None
proteins I None
with I None
molecular I None
weight I None
greater I None
than I None
40,000 I None
Da I None
. I None
<eof> I None

<s> O None
In I None
contrast I None
, I None
protein I Disease
excretion O Disease
in I None
tubular I None
damage I None
was I None
raised I None
only I None
slightly I None
and I None
characterized I None
by I None
excretion I Disease
of O Disease
proteins O Disease
of I None
a I None
wide I None
range I None
of I None
molecular I None
weights I None
. I None
<eof> I None

<s> O None
Proximal I None
tubular I None
damage I None
caused I None
by I None
HCBD I Chemical
and I None
papillary I None
damage I None
caused I None
by I None
BEA I Chemical
were I None
distinguished I None
both I None
by I None
conventional I None
urinalysis I None
( I None
volume I None
and I None
specific I None
gravity I None
) I None
and I None
by I None
measurement I None
of I None
the I None
two I None
urinary I None
enzymes I None
. I None
<eof> I None

<s> O None
Alkaline I None
phosphatase I None
and I None
glucose I Chemical
were I None
markedly I None
and I None
transiently I None
elevated I None
in I None
proximal I None
tubular I None
damage I None
and I None
N I None
- I None
acetyl I None
- I None
beta I None
- I None
glucosaminidase I None
showed I None
a I None
sustained I None
elevation I None
in I None
papillary I None
damage I None
. I None
<eof> I None

<s> O None
It I None
is I None
concluded I None
that I None
both I None
selective I None
urinary I None
enzymes I None
and I None
the I None
molecular I None
weight I None
pattern I None
of I None
urinary I None
proteins I None
can I None
be I None
used I None
to I None
provide I None
diagnostic I None
information I None
about I None
the I None
possible I None
site I None
of I None
renal I Disease
damage O Disease
. I None
<eof> I None

<s> O None
Neuromuscular I Disease
blockade O Disease
with I None
magnesium I Chemical
sulfate O Chemical
and I None
nifedipine I Chemical
. I None
<eof> I None

<s> O None
A I None
patient I None
who I None
received I None
tocolysis I None
with I None
nifedipine I Chemical
developed I None
<eof> I None

<s> O None
neuromuscular I Disease
blockade O Disease
after I None
500 I None
mg I None
of I None
<eof> I None

<s> O None
magnesium I Chemical
sulfate O Chemical
was I None
administered I None
. I None
<eof> I None

<s> O None
This I None
reaction I None
demonstrates I None
that I None
nifedipine I Chemical
can I None
seriously I None
potentiate I None
the I None
toxicity I Disease
of I None
magnesium I Chemical
. I None
<eof> I None

<s> O None
Caution I None
should I None
be I None
exercised I None
when I None
these I None
two I None
tocolytics I None
are I None
combined I None
. I None
<eof> I None

<s> O None
Ifosfamide I Chemical
continuous I None
infusion I None
without I None
mesna I Chemical
. I None
<eof> I None

<s> O None
A I None
phase I None
I I None
trial I None
of I None
a I None
14-day I None
cycle I None
. I None
<eof> I None

<s> O None
Twenty I None
patients I None
received I None
27 I None
courses I None
of I None
ifosfamide I Chemical
administered I None
as I None
a I None
24-hour I None
continuous I None
infusion I None
for I None
14 I None
days I None
without I None
Mesna I Chemical
. I None
<eof> I None

<s> O None
The I None
goal I None
of I None
the I None
study I None
was I None
to I None
deliver I None
a I None
dose I None
rate I None
and I None
total I None
cumulative I None
dose I None
of I None
ifosfamide I Chemical
that I None
would I None
be I None
comparable I None
to I None
standard I None
bolus I None
or I None
short I None
- I None
term I None
infusions I None
administered I None
with I None
Mesna I Chemical
. I None
<eof> I None

<s> O None
Dose I None
escalations I None
proceeded I None
from I None
200 I None
to I None
300 I None
, I None
400 I None
, I None
450 I None
, I None
500 I None
, I None
and I None
550 I None
mg I None
/ I None
m2/d I None
. I None
<eof> I None

<s> O None
Four I None
patients I None
developed I None
transient I None
microscopic I None
<eof> I None

<s> O None
hematuria I Disease
at I None
400 I None
, I None
450 I None
, I None
and I None
500 I None
mg I None
/ I None
m2/d I None
. I None
<eof> I None

<s> O None
There I None
were I None
no I None
instances I None
of I None
macroscopic I None
hematuria I Disease
. I None
<eof> I None

<s> O None
At I None
550 I None
mg I None
/ I None
m2/d I None
, I None
three I None
patients I None
experienced I None
nonurologic I None
toxicity I Disease
; I None
confusion I Disease
( I None
1 I None
) I None
, I None
nausea I Disease
<eof> I None

<s> O None
( I None
1 I None
) I None
, I None
and I None
Grade I None
2 I None
leukopenia I Disease
( I None
1 I None
) I None
. I None
<eof> I None

<s> O None
The I None
recommended I None
dose I None
of I None
500 I None
mg I None
/ I None
m2/d I None
delivers I None
a I None
total I None
dose I None
of I None
7 I None
g I None
/ I None
m2 I None
per I None
cycle I None
, I None
which I None
is I None
comparable I None
to I None
that I None
delivered I None
in I None
clinical I None
practice I None
for I None
bolus I None
or I None
short I None
- I None
term I None
infusion I None
. I None
<eof> I None

<s> O None
Because I None
few I None
patients I None
received I None
multiple I None
courses I None
over I None
time I None
, I None
the I None
cumulative I None
effects I None
are I None
indeterminate I None
in I None
the I None
present I None
trial I None
. I None
<eof> I None

<s> O None
The I None
frequency I None
and I None
predictability I None
of I None
hematuria I Disease
are I None
not I None
precise I None
, I None
and I None
at I None
least I None
daily I None
monitoring I None
by I None
urine I None
Hematest I None
is I None
essential I None
, I None
adding I None
Mesna I Chemical
to I None
the I None
infusate I None
in I None
patients I None
with I None
persistent I None
hematuria I Disease
. I None
<eof> I None

<s> O None
The I None
protracted I None
infusion I None
schedule I None
for I None
ifosfamide I Chemical
permits I None
convenient I None
outpatient I None
administration I None
without I None
Mesna I Chemical
and I None
reduces I None
the I None
drug I None
cost I None
of I None
clinical I None
usage I None
of I None
this I None
agent I None
by I None
up I None
to I None
890 I None
per I None
cycle I None
. I None
<eof> I None

<s> O None
Clinical I None
activity I None
was I None
demonstrated I None
in I None
a I None
single I None
patient I None
, I None
but I None
a I None
comparative I None
trial I None
of I None
standard I None
bolus I None
schedules I None
with I None
the I None
protracted I None
infusion I None
schedule I None
will I None
be I None
necessary I None
to I None
determine I None
if I None
the I None
clinical I None
effectiveness I None
of I None
the I None
drug I None
is I None
maintained I None
. I None
<eof> I None

<s> O None
Myocardial I Disease
infarction O Disease
in I None
pregnancy I None
associated I None
with I None
clomiphene I Chemical
citrate O Chemical
for I None
ovulation I None
induction I None
: I None
a I None
case I None
report I None
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
<eof> I None

<s> O None
Clomiphene I Chemical
citrate O Chemical
<eof> I None

<s> O None
( I None
CC I Chemical
) I None
is I None
commonly I None
prescribed I None
for I None
ovulation I None
induction I None
. I None
<eof> I None

<s> O None
It I None
is I None
considered I None
safe I None
, I None
with I None
minimal I None
side I None
effects I None
. I None
<eof> I None

<s> O None
Thromboembolism I Disease
is I None
a I None
rare I None
but I None
life I None
- I None
threatening I None
complication I None
that I None
has I None
been I None
reported I None
after I None
ovulation I None
induction I None
with I None
CC I Chemical
. I None
<eof> I None

<s> O None
Spontaneous I None
coronary I Disease
thrombosis O Disease
or I None
thromboembolism I Disease
with I None
subsequent I None
clot I None
lysis I None
has I None
been I None
suggested I None
as I None
one I None
of I None
the I None
most I None
common I None
causes I None
of I None
myocardial I Disease
infarction O Disease
<eof> I None

<s> O None
( I None
MI I Disease
) I None
during I None
pregnancy I None
, I None
with I None
a I None
subsequently I None
normal I None
coronary I None
angiogram I None
. I None
<eof> I None

<s> O None
CASE I None
: I None
<eof> I None

<s> O None
A I None
33-year I None
- I None
old I None
woman I None
with I None
a I None
5-week I None
gestation I None
had I None
recently I None
received I None
CC I Chemical
for I None
ovulation I None
induction I None
and I None
presented I None
with I None
chest I Disease
pain O Disease
. I None
<eof> I None

<s> O None
An I None
electrocardiogram I None
showed I None
a I None
lateral I None
and I None
anterior I None
wall I None
myocardial I Disease
infarction O Disease
. I None
<eof> I None

<s> O None
Cardiac I None
enzymes I None
showed I None
a I None
peak I None
rise I None
in I None
troponin I None
<eof> I None

<s> O None
I I None
to I None
9.10 I None
ng I None
/ I None
mL. I None
<eof> I None

<s> O None
An I None
initial I None
exercise I None
stress I None
test I None
was I None
normal I None
. I None
<eof> I None

<s> O None
At I None
the I None
time I None
of I None
admission I None
, I None
the I None
patient I None
was I None
at I None
high I None
risk I None
of I None
radiation I Disease
injury O Disease
to I None
the I None
fetus I None
, I None
so I None
a I None
coronary I None
angiogram I None
was I None
postponed I None
until I None
the I None
second I None
trimester I None
. I None
<eof> I None

<s> O None
It I None
showed I None
normal I None
coronary I None
vessels I None
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
<eof> I None

<s> O None
This I None
appears I None
to I None
be I None
the I None
first I None
reported I None
case I None
documenting I None
a I None
possible I None
association I None
between I None
CC I Chemical
and I None
myocardial I Disease
infarction O Disease
. I None
<eof> I None

<s> O None
Thrombosis I Disease
might I None
be I None
a I None
rare I None
but I None
hazardous I None
complication I None
of I None
CC I Chemical
. I None
<eof> I None

<s> O None
Given I None
this I None
life I None
- I None
threatening I None
complication I None
, I None
appropriate I None
prophylactic I None
measures I None
should I None
be I None
used I None
in I None
high I None
- I None
risk I None
woman I None
undergoing I None
ovarian I None
stimulation I None
. I None
<eof> I None

<s> O None
Hepatonecrosis I Disease
and I None
cholangitis I Disease
related I None
to I None
long I None
- I None
term I None
phenobarbital I Chemical
therapy I None
: I None
an I None
autopsy I None
report I None
of I None
two I None
patients I None
. I None
<eof> I None

<s> O None
Phenobarbital I Chemical
<eof> I None

<s> O None
( I None
PB I Chemical
) I None
has I None
a I None
reputation I None
for I None
safety I None
, I None
and I None
it I None
is I None
commonly I None
believed I None
that I None
PB I Chemical
<eof> I None

<s> O None
-related I None
increases I None
in I None
serum I None
aminotransferase I None
levels I None
do I None
not I None
indicate I None
or I None
predict I None
the I None
development I None
of I None
significant I None
chronic I None
liver I Disease
disease O Disease
. I None
<eof> I None

<s> O None
Here I None
we I None
report I None
of I None
two I None
adult I None
patients I None
with I None
a I None
long I None
history I None
of I None
<eof> I None

<s> O None
epilepsy I Disease
treated I None
with I None
PB I Chemical
who I None
died I None
suddenly I None
: I None
one I None
as I None
consequence I None
of I None
cardiac I Disease
arrest O Disease
, I None
the I None
other I None
of I None
acute I None
bronchopneumonia I Disease
. I None
<eof> I None

<s> O None
At I None
autopsy I None
, I None
analysis I None
of I None
liver I None
parenchyma I None
revealed I None
rich I None
portal I None
inflammatory I None
infiltrate I None
, I None
which I None
consisted I None
of I None
mixed I None
eosinophil I None
and I None
monocyte I None
cells I None
, I None
associated I None
with I None
several I None
foci I None
of I None
necrosis I Disease
surrounded I None
by I None
a I None
hard I None
ring I None
of I None
non I None
- I None
specific I None
granulomatous I None
tissue I None
. I None
<eof> I None

<s> O None
Inflammatory I None
reactions I None
of I None
internal I None
and I None
external I None
hepatic I None
biliary I None
ducts I None
were I None
also I None
seen I None
. I None
<eof> I None

<s> O None
Our I None
findings I None
illustrate I None
that I None
PB I Chemical
may I None
be I None
associated I None
with I None
chronic I None
liver I Disease
damage O Disease
, I None
which I None
may I None
lead I None
to I None
more I None
serious I None
and I None
deleterious I None
consequences I None
. I None
<eof> I None

<s> O None
For I None
this I None
reason I None
, I None
each I None
clinician I None
should I None
recognize I None
this I None
entity I None
in I None
the I None
differential I None
diagnosis I None
of I None
PB I Chemical
-related I None
asymptomatic I None
chronic I Disease
hepatic O Disease
enzyme O Disease
dysfunction O Disease
. I None
<eof> I None

<s> O None
Ethambutol I Chemical
-associated I None
optic I Disease
neuropathy O Disease
. I None
<eof> I None

<s> O None
INTRODUCTION I None
: I None
<eof> I None

<s> O None
Ethambutol I Chemical
is I None
used I None
in I None
the I None
treatment I None
of I None
tuberculosis I Disease
, I None
which I None
is I None
still I None
prevalent I None
in I None
Southeast I None
Asia I None
, I None
and I None
can I None
be I None
associated I None
with I None
permanent I None
visual I Disease
loss O Disease
. I None
<eof> I None

<s> O None
We I None
report I None
3 I None
cases I None
which I None
presented I None
with I None
bitemporal I Disease
hemianopia O Disease
. I None
<eof> I None

<s> O None
CLINICAL I None
PICTURE I None
: I None
<eof> I None

<s> O None
Three I None
patients I None
with I None
ethambutol I Chemical
<eof> I None

<s> O None
-associated I None
<eof> I None

<s> O None
toxic I None
optic I Disease
neuropathy O Disease
are I None
described I None
. I None
<eof> I None

<s> O None
All I None
3 I None
patients I None
had I None
loss I Disease
of O Disease
central O Disease
visual O Disease
acuity O Disease
, O Disease
colour O Disease
vision O Disease
( O Disease
Ishihara O Disease
) O Disease
and O Disease
visual O Disease
field O Disease
. I None
<eof> I None

<s> O None
The I None
visual I Disease
field O Disease
loss O Disease
had I None
a I None
bitemporal I None
flavour I None
, I None
suggesting I None
involvement I None
of I None
the I None
optic I None
chiasm I None
. I None
<eof> I None

<s> O None
TREATMENT I None
: I None
<eof> I None

<s> O None
Despite I None
stopping I None
ethambutol I Chemical
on I None
diagnosis I None
, I None
visual I None
function I None
continued I None
to I None
deteriorate I None
for I None
a I None
few I None
months I None
. I None
<eof> I None

<s> O None
Subsequent I None
improvement I None
was I None
mild I None
in I None
2 I None
cases I None
. I None
<eof> I None

<s> O None
In I None
the I None
third I None
case I None
, I None
visual I None
acuity I None
and I None
colour I None
vision I None
normalised I None
but I None
the I None
optic I None
discs I None
were I None
pale I None
. I None
<eof> I None

<s> O None
OUTCOME I None
: I None
<eof> I None

<s> O None
All I None
3 I None
patients I None
had I None
some I None
permanent I None
loss I Disease
of O Disease
visual O Disease
function O Disease
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
Ethambutol I Chemical
usage I None
is I None
associated I None
with I None
permanent I None
visual I Disease
loss O Disease
and I None
should I None
be I None
avoided I None
if I None
possible I None
or I None
used I None
with I None
caution I None
and I None
proper I None
ophthalmological I None
follow I None
- I None
up I None
. I None
<eof> I None

<s> O None
The I None
author I None
postulates I None
that I None
in I None
cases I None
of I None
ethambutol I Chemical
associated I None
chiasmopathy I None
, I None
ethambutol I Chemical
may I None
initially I None
affect I None
the I None
optic I None
nerves I None
and I None
subsequently I None
progress I None
to I None
involve I None
the I None
optic I None
chiasm I None
. I None
<eof> I None

<s> O None
Tolerability I None
of I None
nimesulide I Chemical
and I None
paracetamol I Chemical
in I None
patients I None
with I None
NSAID I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
urticaria I Disease
/ I None
angioedema I Disease
. I None
<eof> I None

<s> O None
Previous I None
studies I None
evaluated I None
the I None
tolerance I None
of I None
nimesulide I Chemical
and I None
paracetamol I Chemical
in I None
subjects I None
with I None
cutaneous I None
, I None
respiratory I None
and I None
anaphylactoid I None
reactions I None
induced I None
by I None
nonsteroidal I Chemical
anti O Chemical
- O Chemical
inflammatory O Chemical
drugs O Chemical
<eof> I None

<s> O None
( I None
NSAIDs I Chemical
) I None
. I None
<eof> I None

<s> O None
In I None
this I None
study I None
we I None
investigated I None
tolerability I None
and I None
reliability I None
of I None
nimesulide I Chemical
and I None
paracetamol I Chemical
in I None
a I None
very I None
large I None
number I None
of I None
patients I None
with I None
an I None
exclusive I None
well I None
- I None
documented I None
history I None
of I None
NSAID I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
urticaria I Disease
/ I None
angioedema I Disease
. I None
<eof> I None

<s> O None
Furthermore I None
, I None
we I None
evaluated I None
whether I None
some I None
factors I None
have I None
the I None
potential I None
to I None
increase I None
the I None
risk I None
of I None
reaction I None
to I None
paracetamol I Chemical
and I None
nimesulide I Chemical
. I None
<eof> I None

<s> O None
A I None
single I None
- I None
placebo I None
- I None
controlled I None
oral I None
challenge I None
procedure I None
with I None
nimesulide I Chemical
or I None
paracetamol I Chemical
was I None
applied I None
to I None
829 I None
patients I None
with I None
a I None
history I None
of I None
NSAID I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
urticaria I Disease
/ I None
angioedema I Disease
. I None
<eof> I None

<s> O None
A I None
total I None
of I None
75/829 I None
( I None
9.4 I None
% I None
) I None
<eof> I None

<s> O None
patients I None
experienced I None
reactions I None
to I None
nimesulide I Chemical
or I None
paracetamol I Chemical
. I None
<eof> I None

<s> O None
Of I None
the I None
715 I None
patients I None
tested I None
with I None
nimesulide I Chemical
62 I None
( I None
8.6 I None
% I None
) I None
showed I None
a I None
positive I None
test I None
, I None
while I None
of I None
114 I None
subjects I None
submitted I None
to I None
the I None
challenge I None
with I None
paracetamol I Chemical
, I None
13 I None
( I None
9.6 I None
% I None
) I None
did I None
not I None
tolerate I None
this I None
drug I None
. I None
<eof> I None

<s> O None
Furthermore I None
, I None
18.28 I None
% I None
of I None
patients I None
with I None
a I None
history I None
of I None
chronic I None
urticaria I Disease
and I None
11.8 I None
% I None
of I None
subjects I None
with I None
an I None
history I None
of I None
NSAID I Chemical
-induced I None
urticaria I Disease
/ I None
angioedema I Disease
or I None
angioedema I Disease
alone I None
( I None
with I None
or I None
without I None
chronic I None
urticaria I Disease
) I None
resulted I None
to I None
be I None
intolerant I None
to I None
alternative I None
drugs I None
. I None
<eof> I None

<s> O None
Taken I None
together I None
, I None
our I None
results I None
confirm I None
the I None
good I None
tolerability I None
of I None
nimesulide I Chemical
and I None
paracetamol I Chemical
in I None
patients I None
who I None
experienced I None
urticaria I Disease
/ I None
angioedema I Disease
caused I None
by I None
NSAIDs I Chemical
. I None
<eof> I None

<s> O None
However I None
, I None
the I None
risk I None
of I None
reaction I None
to I None
these I None
alternative I None
study I None
drugs I None
is I None
statistically I None
increased I None
by I None
a I None
history I None
of I None
chronic I None
urticaria I Disease
and I None
, I None
above I None
all I None
, I None
by I None
a I None
history I None
of I None
NSAID I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
angioedema I Disease
. I None
<eof> I None

<s> O None
Effects I None
of I None
verapamil I Chemical
on I None
atrial I Disease
fibrillation O Disease
and I None
its I None
electrophysiological I None
determinants I None
in I None
dogs I None
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
<eof> I None

<s> O None
Atrial I Disease
tachycardia O Disease
-induced I None
remodeling I None
promotes I None
the I None
occurrence I None
and I None
maintenance I None
of I None
atrial I Disease
fibrillation O Disease
<eof> I None

<s> O None
( I None
AF I Disease
) I None
and I None
decreases I None
L I None
- I None
type I None
Ca I Chemical
( I None
2 I None
+ I None
) I None
current I None
. I None
<eof> I None

<s> O None
There I None
is I None
also I None
a I None
clinical I None
suggestion I None
that I None
acute I None
L I None
- I None
type I None
Ca I Chemical
( I None
2 I None
) I None
channel I None
blockade I None
can I None
promote I None
AF I Disease
, I None
consistent I None
with I None
an I None
AF I Disease
promoting I None
effect I None
of I None
Ca I Chemical
<eof> I None

<s> O None
( I None
2 I None
+ I None
) I None
channel I None
inhibition I None
. I None
<eof> I None

<s> O None
METHODS I None
: I None
To I None
evaluate I None
the I None
potential I None
mechanisms I None
of I None
AF I Disease
promotion I None
by I None
Ca I Chemical
<eof> I None

<s> O None
( I None
2 I None
+ I None
) I None
channel I None
blockers I None
, I None
we I None
administered I None
verapamil I Chemical
to I None
morphine I Chemical
- I None
chloralose I Chemical
anesthetized I None
dogs I None
. I None
<eof> I None

<s> O None
Diltiazem I Chemical
was I None
used I None
as I None
a I None
comparison I None
drug I None
and I None
autonomic I None
blockade I None
with I None
atropine I Chemical
and I None
nadolol I Chemical
was I None
applied I None
in I None
some I None
experiments I None
. I None
<eof> I None

<s> O None
Epicardial I None
mapping I None
with I None
240 I None
epicardial I None
electrodes I None
was I None
used I None
to I None
evaluate I None
activation I None
during I None
AF I Disease
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
Verapamil I Chemical
caused I None
AF I Disease
promotion I None
in I None
six I None
dogs I None
, I None
increasing I None
mean I None
duration I None
of I None
AF I Disease
induced I None
by I None
burst I None
pacing I None
, I None
from I None
8+/-4 I None
s I None
( I None
mean+/-S.E. I None
) I None
to I None
95+/-39 I None
s I None
<eof> I None

<s> O None
( I None
P<0.01 I None
vs. I None
control I None
) I None
at I None
a I None
loading I None
dose I None
of I None
0.1 I None
mg I None
/ I None
kg I None
and I None
228+/-101 I None
<eof> I None

<s> O None
s I None
( I None
P<0.0005 I None
vs. I None
control I None
) I None
at I None
a I None
dose I None
of I None
0.2 I None
mg I None
/ I None
kg I None
. I None
<eof> I None

<s> O None
Underlying I None
electrophysiological I None
mechanisms I None
were I None
studied I None
in I None
detail I None
in I None
five I None
additional I None
dogs I None
under I None
control I None
conditions I None
and I None
in I None
the I None
presence I None
of I None
the I None
higher I None
dose I None
of I None
verapamil I Chemical
. I None
<eof> I None

<s> O None
In I None
these I None
experiments I None
, I None
verapamil I Chemical
shortened I None
mean I None
effective I None
refractory I None
period I None
( I None
ERP I None
) I None
from I None
122+/-5 I None
to I None
114+/-4 I None
ms I None
( I None
P<0.02 I None
) I None
at I None
a I None
cycle I None
length I None
of I None
300 I None
ms I None
, I None
decreased I None
ERP I None
heterogeneity I None
( I None
from I None
15+/-1 I None
to I None
10+/-1 I None
% I None
, I None
P<0.05 I None
) I None
, I None
heterogeneously I None
accelerated I None
atrial I None
conduction I None
and I None
decreased I None
the I None
cycle I None
length I None
of I None
AF I Disease
<eof> I None

<s> O None
( I None
94+/-4 I None
to I None
84+/-3 I None
ms I None
, I None
P<0.005 I None
) I None
. I None
<eof> I None

<s> O None
Diltiazem I Chemical
did I None
not I None
affect I None
ERP I None
, I None
AF I Disease
cycle I None
length I None
or I None
AF I Disease
duration I None
, I None
but I None
produced I None
conduction I None
acceleration I None
similar I None
to I None
that I None
caused I None
by I None
verapamil I Chemical
<eof> I None

<s> O None
( I None
n=5 I None
) I None
. I None
<eof> I None

<s> O None
In I None
the I None
presence I None
of I None
autonomic I None
blockade I None
, I None
verapamil I Chemical
failed I None
to I None
promote I None
AF I Disease
and I None
increased I None
, I None
rather I None
than I None
decreasing I None
, I None
refractoriness I None
. I None
<eof> I None

<s> O None
Neither I None
verapamil I Chemical
nor I None
diltiazem I Chemical
affected I None
atrial I None
conduction I None
in I None
the I None
presence I None
of I None
autonomic I None
blockade I None
. I None
<eof> I None

<s> O None
Epicardial I None
mapping I None
suggested I None
that I None
verapamil I Chemical
promoted I None
AF I Disease
by I None
increasing I None
the I None
number I None
of I None
simultaneous I None
wavefronts I None
reflected I None
by I None
separate I None
zones I None
of I None
reactivation I None
in I None
each I None
cycle I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
Verapamil I Chemical
promotes I None
<eof> I None

<s> O None
AF I Disease
in I None
normal I None
dogs I None
by I None
promoting I None
multiple I None
circuit I None
reentry I None
, I None
an I None
effect I None
dependent I None
on I None
intact I None
autonomic I None
tone I None
and I None
not I None
shared I None
by I None
diltiazem I Chemical
. I None
<eof> I None

<s> O None
Hypotension I Disease
, I None
bradycardia I Disease
, I None
and I None
asystole I Disease
after I None
high I None
- I None
dose I None
intravenous I None
methylprednisolone I Chemical
in I None
a I None
monitored I None
patient I None
. I None
<eof> I None

<s> O None
We I None
report I None
a I None
case I None
of I None
hypotension I Disease
, I None
bradycardia I Disease
, I None
and I None
asystole I Disease
after I None
intravenous I None
administration I None
of I None
high I None
- I None
dose I None
methylprednisolone I Chemical
in I None
a I None
73-year I None
- I None
old I None
patient I None
who I None
underwent I None
electrocardiographic I None
( I None
ECG I None
) I None
monitoring I None
throughout I None
the I None
episode I None
. I None
<eof> I None

<s> O None
There I None
was I None
a I None
history I None
of I None
ischemic I Disease
<eof> I None

<s> O None
cardiac I Disease
disease O Disease
9 I None
years I None
earlier I None
. I None
<eof> I None

<s> O None
The I None
patient I None
was I None
admitted I None
with I None
a I None
pulmonary I Disease
- O Disease
renal O Disease
syndrome O Disease
with I None
hemoptysis I Disease
, I None
rapidly I None
progressive I None
renal I Disease
failure O Disease
, I None
and I None
hypoxemia I Disease
that I None
required I None
mechanical I None
ventilation I None
in I None
the I None
intensive I None
care I None
unit I None
. I None
<eof> I None

<s> O None
After I None
receiving I None
advanced I None
cardiopulmonary I None
resuscitation I None
, I None
the I None
patient I None
recovered I None
cardiac I None
rhythm I None
. I None
<eof> I None

<s> O None
The I None
ECG I None
showed I None
a I None
junctional I None
rhythm I None
without I None
ventricular I Disease
arrhythmia O Disease
. I None
<eof> I None

<s> O None
This I None
study I None
reviews I None
the I None
current I None
proposed I None
mechanisms I None
of I None
sudden I Disease
death O Disease
after I None
a I None
high I None
dose I None
of I None
intravenous I None
methylprednisolone I Chemical
<eof> I None

<s> O None
( I None
IVMP I Chemical
) I None
. I None
<eof> I None

<s> O None
These I None
mechanisms I None
are I None
not I None
well I None
understood I None
because I None
, I None
in I None
most I None
cases I None
, I None
the I None
patients I None
were I None
not I None
monitored I None
at I None
the I None
moment I None
of I None
the I None
event I None
. I None
<eof> I None

<s> O None
Rapid I None
infusion I None
and I None
underlying I None
cardiac I Disease
disease O Disease
were I None
important I None
risk I None
factors I None
in I None
the I None
case I None
reported I None
here I None
, I None
and I None
the I None
authors I None
discount I None
ventricular I Disease
arrhythmia O Disease
as I None
the I None
main I None
mechanism I None
. I None
<eof> I None

<s> O None
Lifetime I None
treatment I None
of I None
mice I None
with I None
azidothymidine I Chemical
<eof> I None

<s> O None
( I None
AZT I Chemical
) I None
produces I None
myelodysplasia I Disease
. I None
<eof> I None

<s> O None
AZT I Chemical
has I None
induced I None
a I None
macrocytic I Disease
anemia O Disease
in I None
AIDS I Disease
patients I None
on I None
long I None
term I None
AZT I Chemical
therapy I None
. I None
<eof> I None

<s> O None
It I None
is I None
generally I None
assumed I None
that I None
DNA I None
elongation I None
is I None
stopped I None
by I None
the I None
insertion I None
of I None
AZT I Chemical
into I None
the I None
chain I None
in I None
place I None
of I None
thymidine I Chemical
thus I None
preventing I None
the I None
phosphate I Chemical
hydroxyl I None
linkages I None
and I None
therefore I None
suppresses I None
hemopoietic I None
progenitor I None
cell I None
proliferation I None
in I None
an I None
early I None
stage I None
of I None
differentiation I None
. I None
<eof> I None

<s> O None
CBA I None
/ I None
Ca I None
male I None
mice I None
started I None
on I None
AZT I Chemical
<eof> I None

<s> O None
0.75 I None
mg I None
/ I None
ml I None
H2O I None
at I None
84 I None
days I None
of I None
age I None
and I None
kept I None
on I None
it I None
for I None
687 I None
days I None
when I None
dosage I None
reduced I None
to I None
0.5 I None
mg I None
/ I None
ml I None
H2O I None
for I None
a I None
group I None
, I None
another I None
group I None
removed I None
from I None
AZT I Chemical
to I None
see I None
recovery I None
, I None
and I None
third I None
group I None
remained I None
on I None
0.75 I None
mg I None
. I None
<eof> I None

<s> O None
At I None
687 I None
days I None
mice I None
that I None
had I None
been I None
on I None
0.75 I None
mg I None
had I None
average I None
platelet I None
counts I None
of I None
2.5 I None
x I None
10(6 I None
) I None
. I None
<eof> I None

<s> O None
Histological I None
examination I None
on I None
9 I None
of I None
10 I None
mice I None
with I None
such I None
thrombocytopenia I Disease
showed I None
changes I None
compatible I None
with I None
myelodysplastic I Disease
syndrome O Disease
<eof> I None

<s> O None
( I None
MDS I Disease
) I None
. I None
<eof> I None

<s> O None
A I None
variety I None
of I None
histological I None
patterns I None
was I None
observed I None
. I None
<eof> I None

<s> O None
There I None
were I None
two I None
cases I None
of I None
hypocellular I None
myelodysplasia I Disease
, I None
two I None
cases I None
of I None
hypersegmented I None
myelodysplastic I Disease
granulocytosis I None
, I None
two I None
cases I None
of I None
hypercellular I None
marrow I None
with I None
abnormal I None
megakaryocytes I None
with I None
bizarre I None
nuclei I None
, I None
one I None
case I None
of I None
megakaryocytic I None
myelosis I None
associated I None
with I None
a I None
hyperplastic I Disease
marrow O Disease
, I None
dysmyelopoiesis I Disease
and I None
a I None
hypocellular I Disease
marrow O Disease
and I None
two I None
cases I None
of I None
myelodysplasia I Disease
with I None
dyserythropoiesis I Disease
, I None
hemosiderosis I Disease
and I None
a I None
hypocellular I Disease
marrow O Disease
. I None
<eof> I None

<s> O None
Above I None
mentioned I None
AZT I Chemical
<eof> I None

<s> O None
incorporation I None
may I None
have I None
induced I None
an I None
ineffective I None
hemopoiesis I None
in I None
the I None
primitive I None
hemopoietic I None
progenitor I None
cells I None
, I None
which I None
is I None
known I None
to I None
be I None
seen I None
commonly I None
in I None
the I None
myelodysplastic I Disease
syndrome O Disease
. I None
<eof> I None

<s> O None
Influence I None
of I None
diet I None
free I None
of I None
NAD I Chemical
-precursors I None
on I None
acetaminophen I Chemical
<eof> I None

<s> O None
hepatotoxicity I Disease
in I None
mice I None
. I None
<eof> I None

<s> O None
Recently I None
, I None
we I None
demonstrated I None
the I None
hepatoprotective I None
effects I None
of I None
nicotinic I Chemical
acid O Chemical
amide O Chemical
, I None
a I None
selective I None
inhibitor I None
of I None
poly(ADP I Chemical
- O Chemical
ribose O Chemical
) O Chemical
polymerase I None
( I None
PARP I None
; I None
EC I None
2.4.2.30 I None
) I None
on I None
mice I None
suffering I None
from I None
acetaminophen I Chemical
<eof> I None

<s> O None
( I None
AAP I Chemical
) I None
- I None
hepatitis I Disease
, I None
suggesting I None
that I None
the I None
AAP I Chemical
-induced I None
liver I Disease
injury O Disease
involves I None
a I None
step I None
which I None
depends I None
on I None
adenoribosylation I None
. I None
<eof> I None

<s> O None
The I None
present I None
study I None
investigates I None
the I None
effects I None
of I None
a I None
diet I None
free I None
of I None
precursors I None
of I None
NAD I Chemical
, I None
the I None
substrate I None
on I None
which I None
PARP I None
acts I None
, I None
in I None
female I None
NMRI I None
mice I None
with I None
AAP I Chemical
hepatitis I Disease
and I None
evaluates I None
the I None
influence I None
of I None
simultaneous I None
ethanol I Chemical
consumption I None
in I None
these I None
animals I None
. I None
<eof> I None

<s> O None
Liver I Disease
injuries O Disease
were I None
quantified I None
as I None
serum I None
activities I None
of I None
glutamate I Chemical
- I None
oxaloacetate I Chemical
transaminase I None
( I None
GOT I None
) I None
and I None
glutamate I Chemical
- I None
pyruvate I Chemical
transaminase I None
( I None
GPT I None
) I None
. I None
<eof> I None

<s> O None
While I None
AAP I Chemical
caused I None
a I None
117-fold I None
elevation I None
of I None
serum I None
transaminase I None
activities I None
in I None
mice I None
kept I None
on I None
a I None
standard I None
laboratory I None
diet I None
, I None
which I None
was I None
significantly I None
exacerbated I None
by I None
ethanol I Chemical
and I None
inhibited I None
by I None
nicotinic I Chemical
acid O Chemical
amide O Chemical
<eof> I None

<s> O None
( I None
NAA I Chemical
) I None
, I None
adverse I None
effects I None
were I None
noted I None
in I None
animals I None
fed I None
a I None
diet I None
free I None
of I None
precursors I None
of I None
NAD I Chemical
. I None
<eof> I None

<s> O None
In I None
these I None
animals I None
, I None
only I None
minor I None
increases I None
of I None
serum I None
transaminase I None
activities I None
were I None
measured I None
in I None
the I None
presence I None
of I None
AAP I Chemical
, I None
and I None
unlike I None
the I None
exacerbation I None
caused I None
by I None
ethanol I Chemical
in I None
mice I None
on I None
a I None
standard I None
diet I None
, I None
the I None
liver I Disease
damage O Disease
was I None
inhibited I None
by I None
50 I None
% I None
by I None
ethanol I Chemical
. I None
<eof> I None

<s> O None
A I None
further I None
64 I None
% I None
reduction I None
of I None
hepatitis I Disease
was I None
observed I None
, I None
when I None
NAA I Chemical
was I None
given I None
to I None
ethanol I Chemical
/ I None
AAP I Chemical
-mice I None
. I None
<eof> I None

<s> O None
Our I None
results I None
provide I None
evidence I None
that I None
the I None
AAP I Chemical
-induced I None
hepatitis I Disease
and I None
its I None
exacerbation I None
by I None
ethanol I Chemical
can I None
either I None
be I None
reduced I None
by I None
end I None
- I None
product I None
inhibition I None
of I None
PARP I None
by I None
NAA I Chemical
or I None
by I None
dietary I None
depletion I None
of I None
the I None
enzyme I None
's I None
substrate I None
NAD I Chemical
. I None
<eof> I None

<s> O None
We I None
see I None
the I None
main I None
application I None
of I None
NAA I Chemical
as I None
for I None
the I None
combinational I None
use I None
in I None
pharmaceutical I None
preparations I None
of I None
acetaminophen I Chemical
in I None
order I None
to I None
avoid I None
hepatic I Disease
damage O Disease
in I None
patients I None
treated I None
with I None
this I None
widely I None
used I None
analgesic I None
. I None
<eof> I None

<s> O None
Antiarrhythmic I None
plasma I None
concentrations I None
of I None
cibenzoline I Chemical
on I None
canine I None
ventricular I Disease
arrhythmias O Disease
. I None
<eof> I None

<s> O None
Using I None
two I None
- I None
stage I None
coronary I None
ligation- I None
, I None
digitalis I Chemical
- I None
, I None
and I None
adrenaline I Chemical
-induced I None
canine I None
ventricular I Disease
arrhythmias O Disease
, I None
antiarrhythmic I None
effects I None
of I None
cibenzoline I Chemical
were I None
examined I None
and I None
the I None
minimum I None
effective I None
plasma I None
concentration I None
for I None
each I None
arrhythmia I Disease
model I None
was I None
determined I None
. I None
<eof> I None

<s> O None
Cibenzoline I Chemical
suppressed I None
all I None
the I None
arrhythmias I Disease
, I None
and I None
the I None
minimum I None
effective I None
plasma I None
concentrations I None
for I None
arrhythmias I Disease
induced I None
by I None
24-h I None
coronary I None
ligation I None
, I None
48-h I None
coronary I None
ligation I None
, I None
digitalis I Chemical
, I None
and I None
adrenaline I Chemical
were I None
1.9 I None
+ I None
/- I None
0.9 I None
( I None
by I None
8 I None
mg I None
/ I None
kg I None
i.v I None
. I None
) I None
, I None
1.6 I None
+ I None
/- I None
0.5 I None
( I None
by I None
8 I None
mg I None
/ I None
kg I None
i.v I None
. I None
) I None
, I None
0.6 I None
+ I None
/- I None
0.2 I None
( I None
by I None
2 I None
mg I None
/ I None
kg I None
i.v I None
. I None
) I None
, I None
and I None
3.5 I None
+ I None
/- I None
1.3 I None
( I None
by I None
5 I None
mg I None
/ I None
kg I None
i.v I None
. I None
) I None
<eof> I None

<s> O None
micrograms I None
/ I None
ml I None
, I None
respectively I None
( I None
mean I None
+ I None
/- I None
SDM I None
, I None
n I None
= I None
6 I None
- I None
7 I None
) I None
. I None
<eof> I None

<s> O None
The I None
concentration I None
for I None
adrenaline I Chemical
-induced I None
<eof> I None

<s> O None
arrhythmia I Disease
was I None
significantly I None
higher I None
than I None
those I None
for I None
the I None
other I None
types I None
of I None
arrhythmias I Disease
. I None
<eof> I None

<s> O None
This I None
pharmacological I None
profile I None
is I None
similar I None
to I None
those I None
of I None
mexiletine I Chemical
and I None
tocainide I Chemical
, I None
and I None
all I None
three I None
drugs I None
have I None
central I None
nervous I None
system I None
( I None
CNS I None
) I None
stimulant I None
action I None
. I None
<eof> I None

<s> O None
Because I None
cibenzoline I Chemical
had I None
only I None
weak I None
hypotensive I Disease
and I None
sinus I None
node I None
<eof> I None

<s> O None
depressive I Disease
effects I None
and I None
was I None
found I None
to I None
be I None
orally I None
active I None
when I None
given I None
to I None
coronary I None
ligation I None
arrhythmia I Disease
dogs I None
, I None
its I None
clinical I None
usefulness I None
is I None
expected I None
. I None
<eof> I None

<s> O None
Immunopathology I None
of I None
penicillamine I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
glomerular I Disease
disease O Disease
. I None
<eof> I None

<s> O None
Four I None
patients I None
with I None
rheumatoid I Disease
arthritis O Disease
developed I None
heavy I None
proteinuria I Disease
after I None
five I None
to I None
12 I None
months I None
of I None
treatment I None
with I None
D I Chemical
- O Chemical
penicillamine O Chemical
. I None
<eof> I None

<s> O None
Light I None
microscopy I None
of I None
renal I None
biopsy I None
samples I None
showed I None
minimal I None
glomerular I None
capillary I None
wall I None
thickening I None
and I None
mesangial I None
matrix I None
increase I None
, I None
or I None
no I None
departure I None
from I None
normal I None
. I None
<eof> I None

<s> O None
Electron I None
microscopy I None
, I None
however I None
, I None
revealed I None
subepithelial I None
electron I None
- I None
dense I None
deposits I None
, I None
fusion I None
of I None
epithelial I None
cell I None
foot I None
processes I None
, I None
and I None
evidence I None
of I None
mesangial I None
cell I None
hyperactivity I None
. I None
<eof> I None

<s> O None
Immunofluorescence I None
microscopy I None
demonstrated I None
granular I None
capillary I None
wall I None
deposits I None
of I None
IgG I None
and I None
C3 I None
. I None
<eof> I None

<s> O None
The I None
findings I None
were I None
similar I None
to I None
those I None
in I None
early I None
membranous I Disease
glomerulonephritis O Disease
, I None
differences I None
being I None
observed I None
however I None
in I None
the I None
results I None
of I None
staining I None
for I None
the I None
early I None
- I None
acting I None
complement I None
components I None
C1q I None
and I None
C4 I None
. I None
<eof> I None

<s> O None
It I None
is I None
tentatively I None
concluded I None
that I None
complement I None
was I None
activated I None
by I None
the I None
classical I None
pathway I None
. I None
<eof> I None

<s> O None
Ventricular I Disease
fibrillation O Disease
from I None
diatrizoate I Chemical
with I None
and I None
without I None
chelating I None
agents I None
. I None
<eof> I None

<s> O None
The I None
toxicity I Disease
of I None
Renografin I Chemical
76 O Chemical
% O Chemical
was I None
compared I None
with I None
that I None
of I None
Hypaque I Chemical
76 O Chemical
% O Chemical
by I None
selective I None
injection I None
of I None
each I None
into I None
the I None
right I None
coronary I None
artery I None
of I None
dogs I None
. I None
<eof> I None

<s> O None
Renografin I Chemical
contains I None
the I None
chelating I None
agents I None
sodium I Chemical
citrate O Chemical
and I None
disodium I Chemical
edetate O Chemical
, I None
while I None
Hypaque I Chemical
contains I None
calcium I Chemical
disodium O Chemical
edetate O Chemical
and I None
no I None
sodium I Chemical
citrate O Chemical
. I None
<eof> I None

<s> O None
Ventricular I Disease
fibrillation O Disease
occurred I None
significantly I None
more I None
often I None
with I None
Renografin I Chemical
, I None
suggesting I None
that I None
chelating I None
agents I None
contribute I None
to I None
toxicity I Disease
in I None
coronary I None
angiography I None
. I None
<eof> I None

<s> O None
Rapid I None
reversal I None
of I None
anticoagulation I None
reduces I None
hemorrhage I Disease
volume I None
in I None
a I None
mouse I None
model I None
of I None
warfarin I Chemical
<eof> I None

<s> O None
-associated I None
<eof> I None

<s> O None
intracerebral I Disease
hemorrhage O Disease
. I None
<eof> I None

<s> O None
Warfarin I Chemical
<eof> I None

<s> O None
-associated I None
<eof> I None

<s> O None
intracerebral I Disease
hemorrhage O Disease
<eof> I None

<s> O None
( I None
W- I None
ICH I Disease
) I None
is I None
a I None
severe I None
type I None
of I None
stroke I Disease
. I None
<eof> I None

<s> O None
There I None
is I None
no I None
consensus I None
on I None
the I None
optimal I None
treatment I None
for I None
W- I None
ICH I Disease
. I None
<eof> I None

<s> O None
Using I None
a I None
mouse I None
model I None
, I None
we I None
tested I None
whether I None
the I None
rapid I None
reversal I None
of I None
anticoagulation I None
using I None
human I None
prothrombin I Chemical
complex O Chemical
concentrate O Chemical
<eof> I None

<s> O None
( I None
PCC I Chemical
) I None
can I None
reduce I None
hemorrhagic I None
blood I None
volume I None
. I None
<eof> I None

<s> O None
Male I None
CD-1 I None
mice I None
were I None
treated I None
with I None
warfarin I Chemical
<eof> I None

<s> O None
( I None
2 I None
mg I None
/ I None
kg I None
over I None
24 I None
h I None
) I None
, I None
resulting I None
in I None
a I None
mean I None
( I None
+ I None
/-s.d I None
. I None
) I None
<eof> I None

<s> O None
International I None
Normalized I None
Ratio I None
of I None
3.5+/-0.9 I None
. I None
<eof> I None

<s> O None
First I None
, I None
we I None
showed I None
that I None
an I None
intravenous I None
administration I None
of I None
human I None
PCC I Chemical
rapidly I None
reversed I None
anticoagulation I None
in I None
mice I None
. I None
<eof> I None

<s> O None
Second I None
, I None
a I None
stereotactic I None
injection I None
of I None
collagenase I None
was I None
administered I None
to I None
induce I None
hemorrhage I Disease
in I None
the I None
right I None
striatum I None
. I None
<eof> I None

<s> O None
Forty I None
- I None
five I None
minutes I None
later I None
, I None
the I None
animals I None
were I None
randomly I None
treated I None
with I None
PCC I Chemical
<eof> I None

<s> O None
( I None
100 I None
U I None
/ I None
kg I None
) I None
or I None
saline I None
i.v I None
. I None
<eof> I None

<s> O None
( I None
n=12 I None
per I None
group I None
) I None
. I None
<eof> I None

<s> O None
Twenty I None
- I None
four I None
hours I None
after I None
hemorrhage I Disease
induction I None
, I None
hemorrhagic I None
blood I None
volume I None
was I None
quantified I None
using I None
a I None
photometric I None
hemoglobin I None
assay I None
. I None
<eof> I None

<s> O None
The I None
mean I None
hemorrhagic I None
blood I None
volume I None
was I None
reduced I None
in I None
PCC I Chemical
<eof> I None

<s> O None
-treated I None
animals I None
( I None
6.5+/-3.1 I None
microL I None
) I None
compared I None
with I None
saline I None
controls I None
( I None
15.3+/-11.2 I None
microL I None
, I None
P=0.015 I None
) I None
. I None
<eof> I None

<s> O None
In I None
the I None
saline I None
group I None
, I None
45 I None
% I None
of I None
the I None
mice I None
developed I None
large I None
hematomas I Disease
<eof> I None

<s> O None
( I None
i.e. I None
, I None
> I None
15 I None
microL I None
) I None
. I None
<eof> I None

<s> O None
In I None
contrast I None
, I None
such I None
extensive I None
lesions I None
were I None
never I None
found I None
in I None
the I None
PCC I Chemical
group I None
. I None
<eof> I None

<s> O None
We I None
provide I None
experimental I None
data I None
suggesting I None
PCC I Chemical
to I None
be I None
an I None
effective I None
acute I None
treatment I None
for I None
W- I None
ICH I Disease
in I None
terms I None
of I None
reducing I None
hemorrhagic I None
blood I None
volume I None
. I None
<eof> I None

<s> O None
Future I None
studies I None
are I None
needed I None
to I None
assess I None
the I None
therapeutic I None
potential I None
emerging I None
from I None
our I None
finding I None
for I None
human I None
W- I None
ICH I Disease
. I None
<eof> I None

<s> O None
Impact I None
of I None
alcohol I Chemical
exposure I None
after I None
pregnancy I None
recognition I None
on I None
ultrasonographic I None
fetal I None
growth I None
measures I None
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
<eof> I None

<s> O None
More I None
than I None
3 I None
decades I None
after I None
Jones I None
and I None
Smith I None
( I None
1973 I None
) I None
reported I None
on I None
the I None
devastation I None
caused I None
by I None
alcohol I Chemical
exposure I None
on I None
fetal I None
development I None
, I None
the I None
rates I None
of I None
heavy I None
drinking I None
during I None
pregnancy I None
remain I None
relatively I None
unchanged I None
. I None
<eof> I None

<s> O None
Early I None
identification I None
of I None
fetal I None
alcohol I Chemical
exposure I None
and I None
maternal I None
abstinence I None
led I None
to I None
better I None
infant I None
outcomes I None
. I None
<eof> I None

<s> O None
This I None
study I None
examined I None
the I None
utility I None
of I None
biometry I None
for I None
detecting I None
alcohol I Chemical
-related I None
fetal I None
growth I Disease
impairment O Disease
. I None
<eof> I None

<s> O None
METHODS I None
: I None
<eof> I None

<s> O None
We I None
obtained I None
fetal I None
ultrasound I None
measures I None
from I None
routine I None
ultrasound I None
examinations I None
for I None
167 I None
pregnant I None
hazardous I None
drinkers I None
who I None
were I None
enrolled I None
in I None
a I None
brief I None
alcohol I Chemical
intervention I None
study I None
. I None
<eof> I None

<s> O None
The I None
fetal I None
measures I None
for I None
women I None
who I None
quit I None
after I None
learning I None
of I None
their I None
pregnancies I None
were I None
compared I None
with I None
measures I None
for I None
women I None
who I None
continued I None
some I None
drinking I None
throughout I None
the I None
course I None
of I None
their I None
pregnancies I None
. I None
<eof> I None

<s> O None
Because I None
intensity I None
of I None
alcohol I Chemical
consumption I None
is I None
associated I None
with I None
poorer I None
fetal I None
outcomes I None
, I None
separate I None
analyses I None
were I None
conducted I None
for I None
the I None
heavy I None
( I None
average I None
of I None
> I None
or=5 I None
drinks I None
per I None
drinking I None
day I None
) I None
<eof> I None

<s> O None
alcohol I Chemical
consumers I None
. I None
<eof> I None

<s> O None
Fetal I None
measures I None
from I None
the I None
heavy I None
- I None
exposed I None
fetuses I None
were I None
also I None
compared I None
with I None
measures I None
from I None
a I None
nondrinking I None
group I None
that I None
was I None
representative I None
of I None
normal I None
, I None
uncomplicated I None
pregnancies I None
from I None
our I None
clinics I None
. I None
<eof> I None

<s> O None
Analyses I None
of I None
covariance I None
were I None
used I None
to I None
determine I None
whether I None
there I None
were I None
differences I None
between I None
groups I None
after I None
controlling I None
for I None
influences I None
of I None
gestational I None
age I None
and I None
drug I Disease
abuse O Disease
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
Nearly I None
half I None
of I None
the I None
pregnant I None
drinkers I None
abstained I None
after I None
learning I None
of I None
their I None
pregnancies I None
. I None
<eof> I None

<s> O None
When I None
women I None
reportedly I None
quit I None
drinking I None
early I None
in I None
their I None
pregnancies I None
, I None
fetal I None
growth I None
measures I None
were I None
not I None
significantly I None
different I None
from I None
a I None
non- I None
alcohol I Chemical
-exposed I None
group I None
, I None
regardless I None
of I None
prior I None
drinking I None
patterns I None
. I None
<eof> I None

<s> O None
Any I None
alcohol I Chemical
consumption I None
postpregnancy I None
recognition I None
among I None
the I None
heavy I None
drinkers I None
resulted I None
in I None
reduced I Disease
cerebellar O Disease
growth O Disease
as I None
well I None
as I None
decreased I Disease
cranial O Disease
to O Disease
body O Disease
growth O Disease
in I None
comparison I None
with I None
women I None
who I None
either I None
quit I None
drinking I None
or I None
who I None
were I None
nondrinkers I None
. I None
<eof> I None

<s> O None
Amphetamine I Chemical
abuse I None
was I None
predictive I None
of I None
larger I None
cranial I None
to I None
body I None
growth I None
ratios I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
Alterations I None
in I None
fetal I None
biometric I None
measurements I None
were I None
observed I None
among I None
the I None
heavy I None
drinkers I None
only I None
when I None
they I None
continued I None
drinking I None
after I None
becoming I None
aware I None
of I None
their I None
pregnancies I None
. I None
<eof> I None

<s> O None
Although I None
the I None
reliance I None
on I None
self I None
- I None
reported I None
drinking I None
is I None
a I None
limitation I None
in I None
this I None
study I None
, I None
these I None
findings I None
support I None
the I None
benefits I None
of I None
early I None
abstinence I None
and I None
the I None
potential I None
for I None
ultrasound I None
examinations I None
in I None
the I None
detection I None
of I None
fetal I None
alcohol I Chemical
effects I None
. I None
<eof> I None

<s> O None
Urinary I None
symptoms I None
and I None
quality I None
of I None
life I None
changes I None
in I None
Thai I None
women I None
with I None
overactive I Disease
bladder O Disease
after I None
tolterodine I Chemical
treatment I None
. I None
<eof> I None

<s> O None
OBJECTIVES I None
: I None
<eof> I None

<s> O None
To I None
study I None
the I None
urinary I None
symptoms I None
and I None
quality I None
of I None
life I None
changes I None
in I None
Thai I None
women I None
with I None
overactive I Disease
bladder O Disease
<eof> I None

<s> O None
( I None
OAB I Disease
) I None
after I None
tolterodine I Chemical
treatment I None
. I None
<eof> I None

<s> O None
MATERIAL I None
AND I None
METHOD I None
: I None
Thirty I None
women I None
( I None
aged I None
30 I None
- I None
77 I None
years I None
) I None
diagnosed I None
as I None
having I None
OAB I Disease
at I None
the I None
Gynecology I None
Clinic I None
, I None
King I None
Chulalongkorn I None
Memorial I None
Hospital I None
from I None
January I None
to I None
April I None
2004 I None
were I None
included I None
in I None
the I None
present I None
study I None
. I None
<eof> I None

<s> O None
Tolterodine I Chemical
2 I None
mg I None
, I None
twice I None
daily I None
was I None
given I None
. I None
<eof> I None

<s> O None
After I None
8 I None
weeks I None
treatment I None
, I None
changes I None
in I None
micturition I None
diary I None
variables I None
and I None
tolerability I None
were I None
determined I None
. I None
<eof> I None

<s> O None
Short I None
form I None
36 I None
( I None
SF36 I None
) I None
questionaires I None
( I None
Thai I None
version I None
) I None
were I None
given I None
before I None
and I None
after I None
8 I None
weeks I None
of I None
treatment I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
At I None
8 I None
weeks I None
, I None
all I None
micturition I None
per I None
day I None
decreased I None
from I None
16 I None
. I None
<eof> I None

<s> O None
7 I None
+ I None
/- I None
5 I None
. I None
<eof> I None

<s> O None
3 I None
to I None
6 I None
. I None
7 I None
+ I None
/- I None
<eof> I None

<s> O None
2.4 I None
times I None
per I None
day I None
. I None
<eof> I None

<s> O None
The I None
number I None
of I None
nocturia I Disease
episodes I None
decreased I None
from I None
5.4 I None
+ I None
/- I None
<eof> I None

<s> O None
4.2 I None
to I None
1.1 I None
+ I None
/- I None
<eof> I None

<s> O None
1.0 I None
times I None
per I None
night I None
. I None
<eof> I None

<s> O None
The I None
most I None
common I None
side I None
effect I None
was I None
dry I Disease
month O Disease
in I None
5 I None
cases I None
( I None
16.7 I None
% I None
) I None
with I None
2 I None
cases I None
reporting I None
a I None
moderate I None
degree I None
and I None
1 I None
case I None
with I None
severe I None
degree I None
. I None
<eof> I None

<s> O None
Only I None
one I None
case I None
( I None
3.3 I None
% I None
) I None
withdrew I None
from I None
the I None
present I None
study I None
due I None
to I None
a I None
severe I None
dry I Disease
mouth O Disease
. I None
<eof> I None

<s> O None
The I None
SF-36 I None
scores I None
changed I None
significantly I None
in I None
the I None
domains I None
of I None
physical I None
functioning I None
, I None
role I None
function I None
emotional I None
, I None
social I None
function I None
and I None
mental I None
heath I None
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
<eof> I None

<s> O None
Tolterodine I Chemical
was I None
well I None
tolerated I None
and I None
its I None
effects I None
improved I None
the I None
quality I None
of I None
life I None
in I None
Thai I None
women I None
with I None
OAB I Disease
. I None
<eof> I None

<s> O None
Absence I None
of I None
acute I None
cerebral I None
vasoconstriction I None
after I None
cocaine I Chemical
-associated I None
subarachnoid I Disease
hemorrhage O Disease
. I None
<eof> I None

<s> O None
INTRODUCTION I None
: I None
<eof> I None

<s> O None
Cocaine I Chemical
use I None
has I None
been I None
associated I None
with I None
neurovascular I Disease
complications O Disease
, I None
including I None
arterial I None
vasoconstriction I None
and I None
vasculitis I Disease
. I None
<eof> I None

<s> O None
However I None
, I None
there I None
are I None
few I None
studies I None
of I None
angiographic I None
effects I None
of I None
cocaine I Chemical
on I None
human I None
cerebral I None
arteries I None
. I None
<eof> I None

<s> O None
Information I None
on I None
these I None
effects I None
could I None
be I None
obtained I None
from I None
angiograms I None
of I None
patients I None
with I None
cocaine I Chemical
<eof> I None

<s> O None
-associated I None
<eof> I None

<s> O None
subarachnoid I Disease
hemorrhage O Disease
<eof> I None

<s> O None
( I None
SAH I Disease
) I None
who I None
underwent I None
angiography I None
shortly I None
after I None
cocaine I Chemical
use I None
. I None
<eof> I None

<s> O None
METHODS I None
: I None
<eof> I None

<s> O None
We I None
screened I None
patients I None
with I None
SAH I Disease
retrospectively I None
and I None
identified I None
those I None
with I None
positive I None
urine I None
toxicology I None
for I None
cocaine I Chemical
or I None
its I None
metabolites I None
. I None
<eof> I None

<s> O None
Quantitative I None
arterial I None
diameter I None
measurements I None
from I None
angiograms I None
of I None
these I None
patients I None
were I None
compared I None
to I None
measurements I None
from I None
control I None
patients I None
with I None
SAH I Disease
who I None
were I None
matched I None
for I None
factors I None
known I None
to I None
influence I None
arterial I None
diameter I None
. I None
<eof> I None

<s> O None
Qualitative I None
comparisons I None
of I None
small I None
artery I None
changes I None
also I None
were I None
made I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
Thirteen I None
patients I None
with I None
positive I None
cocaine I Chemical
toxicology I None
were I None
compared I None
to I None
26 I None
controls I None
. I None
<eof> I None

<s> O None
There I None
were I None
no I None
significant I None
differences I None
between I None
groups I None
in I None
the I None
mean I None
diameters I None
of I None
the I None
intradural I None
internal I None
carotid I None
, I None
sphenoidal I None
segment I None
of I None
the I None
middle I None
cerebral I None
, I None
precommunicating I None
segment I None
of I None
the I None
anterior I None
cerebral I None
, I None
or I None
basilar I None
arteries I None
( I None
p I None
greater I None
than I None
0.05 I None
for I None
all I None
comparisons I None
, I None
unpaired I None
t I None
- I None
tests I None
) I None
. I None
<eof> I None

<s> O None
There I None
also I None
were I None
no I None
significant I None
differences I None
between I None
groups I None
when I None
expressing I None
diameters I None
as I None
the I None
sum I None
of I None
the I None
precommunicating I None
segment I None
of I None
the I None
anterior I None
cerebral I None
+ I None
sphenoidal I None
segment I None
of I None
the I None
middle I None
cerebral I None
+ I None
supraclinoid I None
internal I None
carotid I None
artery I None
+ I None
basilar I None
artery I None
divided I None
by I None
the I None
diameter I None
of I None
the I None
petrous I None
internal I None
carotid I None
artery I None
( I None
p I None
greater I None
than I None
0.05 I None
, I None
unpaired I None
t I None
- I None
tests I None
) I None
. I None
<eof> I None

<s> O None
Qualitative I None
assessments I None
showed I None
two I None
arterial I None
irregularities I None
in I None
the I None
distal I None
vasculature I None
in I None
each I None
group I None
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
<eof> I None

<s> O None
No I None
quantitative I None
evidence I None
for I None
narrowing I None
of I None
large I None
cerebral I None
arteries I None
or I None
qualitative I None
angiographic I None
evidence I None
for I None
distal I None
narrowing I None
or I None
vasculitis I Disease
could I None
be I None
found I None
in I None
patients I None
who I None
underwent I None
angiography I None
after I None
aneurysmal I Disease
SAH I Disease
associated I None
with I None
cocaine I Chemical
use I None
. I None
<eof> I None

<s> O None
Atrial I Disease
fibrillation O Disease
following I None
chemotherapy I None
for I None
stage I None
IIIE I None
diffuse I None
large I None
B I None
- I None
cell I None
gastric I Disease
lymphoma O Disease
in I None
a I None
patient I None
with I None
myotonic I Disease
dystrophy O Disease
<eof> I None

<s> O None
( I None
Steinert I Disease
's O Disease
disease O Disease
) I None
. I None
<eof> I None

<s> O None
The I None
authors I None
describe I None
the I None
unusual I None
association I None
between I None
diffuse I None
B I None
- I None
cell I None
gastric I Disease
lymphoma O Disease
and I None
myotonic I Disease
dystrophy O Disease
, I None
the I None
most I None
common I None
form I None
of I None
adult I None
muscular I Disease
dystrophy O Disease
, I None
and I None
sudden I None
atrial I Disease
fibrillation O Disease
following I None
one I None
cycle I None
of I None
doxorubicin I Chemical
-based I None
chemotherapy I None
in I None
the I None
same I None
patient I None
. I None
<eof> I None

<s> O None
Atrial I Disease
fibrillation O Disease
or I None
other I None
cardiac I Disease
arrhythmias O Disease
are I None
unusual I None
complications I None
in I None
patients I None
treated I None
with I None
chemotherapy I None
. I None
<eof> I None

<s> O None
The I None
cardiac I Disease
toxicity O Disease
intrinsically I None
associated I None
with I None
the I None
aggressive I None
chemotherapy I None
employed I None
could I None
function I None
as I None
a I None
triggering I None
factor I None
for I None
the I None
arrhythmia I Disease
in I None
the I None
predisposed I None
myocardium I None
of I None
this I None
patient I None
. I None
<eof> I None

<s> O None
A I None
phase I None
II I None
study I None
of I None
thalidomide I Chemical
in I None
advanced I None
metastatic I None
renal I Disease
cell O Disease
carcinoma O Disease
. I None
<eof> I None

<s> O None
OBJECTIVES I None
: I None
<eof> I None

<s> O None
To I None
evaluate I None
the I None
toxicity I Disease
and I None
activity I None
of I None
thalidomide I Chemical
in I None
patients I None
with I None
advanced I None
metastatic I None
renal I Disease
cell O Disease
cancer O Disease
and I None
to I None
measure I None
changes I None
of I None
one I None
angiogenic I None
factor I None
, I None
vascular I None
endothelial I None
growth I None
factor I None
( I None
VEGF)165 I None
, I None
with I None
therapy I None
. I None
<eof> I None

<s> O None
PATIENTS I None
AND I None
METHODS I None
: I None
29 I None
patients I None
were I None
enrolled I None
on I None
a I None
study I None
of I None
thalidomide I Chemical
using I None
an I None
intra I None
- I None
patient I None
dose I None
escalation I None
schedule I None
. I None
<eof> I None

<s> O None
Patients I None
began I None
<eof> I None

<s> O None
thalidomide I Chemical
at I None
400 I None
mg I None
/ I None
d I None
and I None
escalated I None
as I None
tolerated I None
to I None
1200 I None
mg I None
/ I None
d I None
by I None
day I None
54 I None
. I None
<eof> I None

<s> O None
Fifty I None
- I None
nine I None
per I None
cent I None
of I None
patients I None
had I None
had I None
previous I None
therapy I None
with I None
IL-2 I None
and I None
52 I None
% I None
were I None
performance I None
status I None
2 I None
or I None
3 I None
. I None
<eof> I None

<s> O None
Systemic I None
plasma I None
VEGF165 I None
levels I None
were I None
measured I None
by I None
dual I None
monoclonal I None
ELISA I None
in I None
8 I None
patients I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
24 I None
patients I None
were I None
evaluable I None
for I None
response I None
with I None
one I None
partial I None
response I None
of I None
11 I None
months I None
duration I None
of I None
a I None
patient I None
with I None
hepatic I None
and I None
pulmonary I None
metastases I Disease
( I None
4 I None
% I None
) I None
, I None
one I None
minor I None
response I None
, I None
and I None
2 I None
patients I None
stable I None
for I None
over I None
6 I None
months I None
. I None
<eof> I None

<s> O None
Somnolence I Disease
and I None
constipation I Disease
were I None
prominent I None
<eof> I None

<s> O None
toxicities I Disease
and I None
most I None
patients I None
could I None
not I None
tolerate I None
the I None
1200 I None
mg I None
/ I None
day I None
dose I None
level I None
. I None
<eof> I None

<s> O None
Systemic I None
plasma I None
VEGF165 I None
levels I None
did I None
not I None
change I None
with I None
therapy I None
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
<eof> I None

<s> O None
These I None
results I None
are I None
consistent I None
with I None
a I None
low I None
level I None
of I None
activity I None
of I None
thalidomide I Chemical
in I None
renal I Disease
cell O Disease
carcinoma O Disease
. I None
<eof> I None

<s> O None
Administration I None
of I None
doses I None
over I None
800 I None
mg I None
/ I None
day I None
was I None
difficult I None
to I None
achieve I None
in I None
this I None
patient I None
population I None
, I None
however I None
lower I None
doses I None
were I None
practical I None
. I None
<eof> I None

<s> O None
The I None
dose I None
- I None
response I None
relationship I None
, I None
if I None
any I None
, I None
of I None
thalidomide I Chemical
for I None
renal I Disease
cell O Disease
carcinoma O Disease
is I None
unclear I None
. I None
<eof> I None

<s> O None
The I None
striatum I None
as I None
a I None
target I None
for I None
anti I None
- I None
rigor I None
effects I None
of I None
an I None
antagonist I None
of I None
mGluR1 I None
, I None
but I None
not I None
an I None
agonist I None
of I None
group I None
II I None
metabotropic I None
glutamate I Chemical
receptors I None
. I None
<eof> I None

<s> O None
The I None
aim I None
of I None
the I None
present I None
study I None
was I None
to I None
find I None
out I None
whether I None
the I None
metabotropic I None
receptor I None
1 I None
( I None
mGluR1 I None
) I None
and I None
group I None
II I None
mGluRs I None
, I None
localized I None
in I None
the I None
striatum I None
, I None
are I None
involved I None
in I None
antiparkinsonian I None
- I None
like I None
effects I None
in I None
rats I None
. I None
<eof> I None

<s> O None
Haloperidol I Chemical
( I None
1 I None
mg I None
/ I None
kg I None
ip I None
) I None
induced I None
<eof> I None

<s> O None
parkinsonian I Disease
-like I None
<eof> I None

<s> O None
muscle I Disease
rigidity O Disease
, I None
measured I None
as I None
an I None
increased I None
resistance I None
of I None
a I None
rat I None
's I None
hind I None
foot I None
to I None
passive I None
flexion I None
and I None
extension I None
at I None
the I None
ankle I None
joint I None
. I None
<eof> I None

<s> O None
( I Chemical
RS)-1-aminoindan-1,5-dicarboxylic O Chemical
acid O Chemical
<eof> I None

<s> O None
( I None
AIDA I Chemical
; I None
0.5 I None
- I None
15 I None
microg/0.5 I None
microl I None
) I None
, I None
a I None
potent I None
and I None
selective I None
mGluR1 I None
antagonist I None
, I None
or I None
( I Chemical
2R,4R)-4-aminopyrrolidine-2,4-dicarboxylate O Chemical
<eof> I None

<s> O None
( I None
2R,4R I Chemical
- O Chemical
APDC O Chemical
; I None
7.5 I None
- I None
15 I None
microg/0.5 I None
microl I None
) I None
, I None
a I None
selective I None
group I None
II I None
agonist I None
, I None
was I None
injected I None
bilaterally I None
into I None
the I None
striatum I None
of I None
haloperidol I Chemical
<eof> I None

<s> O None
-treated I None
animals I None
. I None
<eof> I None

<s> O None
AIDA I Chemical
in I None
doses I None
of I None
7.5 I None
- I None
15 I None
microg/0.5 I None
microl I None
diminished I None
the I None
haloperidol I Chemical
-induced I None
muscle I Disease
rigidity O Disease
. I None
<eof> I None

<s> O None
In I None
contrast I None
, I None
2R,4R I Chemical
- O Chemical
APDC O Chemical
injections I None
were I None
ineffective I None
. I None
<eof> I None

<s> O None
The I None
present I None
results I None
may I None
suggest I None
that I None
the I None
blockade I None
of I None
striatal I None
mGluR1 I None
, I None
but I None
not I None
the I None
stimulation I None
of I None
group I None
II I None
mGluRs I None
, I None
may I None
ameliorate I None
parkinsonian I Disease
muscle I Disease
rigidity O Disease
. I None
<eof> I None

<s> O None
Acute I None
cholestatic I None
hepatitis I None
after I None
exposure I None
to I None
isoflurane I Chemical
. I None
<eof> I None

<s> O None
OBJECTIVE I None
: I None
<eof> I None

<s> O None
To I None
report I None
a I None
case I None
of I None
acute I None
cholestatic I None
hepatitis I None
following I None
exposure I None
to I None
the I None
inhalational I None
anesthetic I None
isoflurane I Chemical
. I None
<eof> I None

<s> O None
CASE I None
SUMMARY I None
: I None
<eof> I None

<s> O None
A I None
70-year I None
- I None
old I None
healthy I None
woman I None
from I None
Iraq I None
developed I None
acute I None
cholestatic I None
hepatitis I None
3 I None
weeks I None
following I None
repair I None
of I None
the I None
right I None
rotator I None
cuff I None
under I None
general I None
anesthesia I None
. I None
<eof> I None

<s> O None
There I None
was I None
no I None
evidence I None
for I None
viral I None
, I None
autoimmune I None
, I None
or I None
metabolic I None
causes I None
of I None
hepatitis I Disease
. I None
<eof> I None

<s> O None
No I None
other I None
medications I None
were I None
involved I None
except I None
for I None
dipyrone I Chemical
for I None
analgesia I Disease
. I None
<eof> I None

<s> O None
The I None
alanine I Chemical
aminotransferase I None
was I None
elevated I None
to I None
a I None
peak I None
concentration I None
of I None
1533 I None
U I None
/ I None
L I None
and I None
the I None
serum I None
bilirubin I Chemical
reached I None
a I None
peak I None
of I None
17.0 I None
mg I None
/ I None
dL. I None
<eof> I None

<s> O None
There I None
was I None
slow I None
improvement I None
over I None
4 I None
months I None
. I None
<eof> I None

<s> O None
Accidental I None
reexposure I None
by I None
the I None
patient I None
to I None
<eof> I None

<s> O None
dipyrone I Chemical
was I None
uneventful I None
. I None
<eof> I None

<s> O None
DISCUSSION I None
: I None
<eof> I None

<s> O None
The I None
clinical I None
and I None
histologic I None
picture I None
of I None
this I None
case I None
resembles I None
halothane I Disease
hepatitis O Disease
, I None
which I None
has I None
a I None
significant I None
mortality I None
rate I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
Isoflurane I Chemical
, I None
a I None
common I None
anesthetic I None
agent I None
, I None
can I None
cause I None
severe I None
cholestatic I None
hepatitis I None
. I None
<eof> I None

<s> O None
Calcitonin I None
gene I None
- I None
related I None
peptide I None
levels I None
during I None
<eof> I None

<s> O None
nitric I Chemical
oxide O Chemical
-induced I None
<eof> I None

<s> O None
headache I Disease
in I None
patients I None
with I None
chronic I None
tension I Disease
- O Disease
type O Disease
headache O Disease
. I None
<eof> I None

<s> O None
It I None
has I None
been I None
proposed I None
that I None
nitric I Chemical
oxide O Chemical
<eof> I None

<s> O None
( I None
NO I Chemical
) I None
induced I None
<eof> I None

<s> O None
headache I Disease
in I None
primary I Disease
headaches O Disease
may I None
be I None
associated I None
with I None
release I None
of I None
calcitonin I None
gene I None
- I None
related I None
peptide I None
( I None
CGRP I None
) I None
. I None
<eof> I None

<s> O None
In I None
the I None
present I None
study I None
we I None
aimed I None
to I None
investigate I None
plasma I None
levels I None
of I None
CGRP I None
during I None
headache I Disease
induced I None
by I None
the I None
NO I Chemical
donor I None
glyceryl I Chemical
trinitrate O Chemical
<eof> I None

<s> O None
( I None
GTN I Chemical
) I None
in I None
16 I None
patients I None
with I None
chronic I None
tension I Disease
- O Disease
type O Disease
headache O Disease
and I None
16 I None
healthy I None
controls I None
. I None
<eof> I None

<s> O None
The I None
subjects I None
were I None
randomly I None
allocated I None
to I None
receive I None
0.5 I None
microg I None
/ I None
kg I None
/ I None
min I None
<eof> I None

<s> O None
GTN I Chemical
or I None
placebo I None
over I None
20 I None
min I None
on I None
two I None
headache I Disease
-free I None
days I None
. I None
<eof> I None

<s> O None
Blood I None
samples I None
were I None
collected I None
at I None
baseline I None
, I None
10 I None
, I None
20 I None
and I None
60 I None
min I None
after I None
start I None
of I None
infusion I None
. I None
<eof> I None

<s> O None
Both I None
patients I None
and I None
controls I None
developed I None
significantly I None
stronger I None
immediate I None
headache I Disease
on I None
the I None
GTN I Chemical
day I None
than I None
on I None
the I None
placebo I None
day I None
and I None
the I None
headache I Disease
was I None
significantly I None
more I None
pronounced I None
in I None
patients I None
than I None
in I None
controls I None
. I None
<eof> I None

<s> O None
There I None
was I None
no I None
difference I None
between I None
the I None
area I None
under I None
the I None
CGRP I None
curve I None
( I None
AUCCGRP I None
) I None
on I None
<eof> I None

<s> O None
GTN I Chemical
vs. I None
<eof> I None

<s> O None
placebo I None
day I None
in I None
either I None
patients I None
( I None
P=0.65 I None
) I None
or I None
controls I None
( I None
P=0.48 I None
) I None
. I None
<eof> I None

<s> O None
The I None
AUCCGRP I None
recorded I None
on I None
the I None
GTN I Chemical
day I None
did I None
not I None
differ I None
between I None
patients I None
and I None
controls I None
( I None
P=0.36 I None
) I None
. I None
<eof> I None

<s> O None
Both I None
in I None
patients I None
and I None
controls I None
, I None
CGRP I None
levels I None
changed I None
significantly I None
over I None
time I None
, I None
on I None
both I None
the I None
GTN I Chemical
and I None
placebo I None
days I None
( I None
P I None
< I None
0.05 I None
) I None
. I None
<eof> I None

<s> O None
The I None
present I None
study I None
indicates I None
that I None
NO I Chemical
-induced I None
immediate I None
headache I Disease
is I None
not I None
associated I None
with I None
release I None
of I None
CGRP I None
. I None
<eof> I None

<s> O None
Myocardial I Disease
ischemia O Disease
due I None
to I None
coronary I Disease
artery O Disease
spasm O Disease
during I None
dobutamine I Chemical
stress I None
echocardiography I None
. I None
<eof> I None

<s> O None
Dobutamine I Chemical
stress I None
echocardiography I None
( I None
DSE I None
) I None
is I None
a I None
useful I None
and I None
safe I None
provocation I None
test I None
for I None
myocardial I Disease
ischemia O Disease
. I None
<eof> I None

<s> O None
Until I None
now I None
, I None
the I None
test I None
has I None
been I None
focused I None
only I None
on I None
the I None
organic I None
lesion I None
in I None
the I None
coronary I None
artery I None
, I None
and I None
positive I None
DSE I None
has I None
indicated I None
the I None
presence I None
of I None
significant I None
fixed I None
coronary I Disease
artery O Disease
stenosis O Disease
. I None
<eof> I None

<s> O None
The I None
aim I None
of I None
the I None
present I None
study I None
is I None
to I None
examine I None
whether I None
myocardial I Disease
ischemia O Disease
due I None
to I None
coronary I Disease
spasm O Disease
is I None
induced I None
by I None
dobutamine I Chemical
. I None
<eof> I None

<s> O None
We I None
performed I None
DSE I None
on I None
51 I None
patients I None
with I None
coronary I Disease
spastic O Disease
angina O Disease
but I None
without I None
significant I None
fixed I None
coronary I Disease
artery O Disease
stenosis O Disease
. I None
<eof> I None

<s> O None
All I None
patients I None
had I None
anginal I Disease
attacks I None
at I None
rest I None
with I None
ST I None
elevation I None
on I None
the I None
electrocardiogram I None
( I None
variant I Disease
angina O Disease
) I None
. I None
<eof> I None

<s> O None
Coronary I None
spasm I None
was I None
induced I None
by I None
intracoronary I None
injection I None
of I None
acetylcholine I Chemical
, I None
and I None
no I None
fixed I None
coronary I Disease
artery O Disease
stenosis O Disease
was I None
documented I None
on I None
angiograms I None
in I None
all I None
patients I None
. I None
<eof> I None

<s> O None
DSE I None
was I None
performed I None
with I None
intravenous I None
dobutamine I Chemical
infusion I None
with I None
an I None
incremental I None
doses I None
of I None
5 I None
, I None
10 I None
, I None
20 I None
, I None
30 I None
, I None
and I None
40 I None
microg I None
/ I None
kg I None
/ I None
<eof> I None

<s> O None
min I None
every I None
5 I None
minutes I None
. I None
<eof> I None

<s> O None
Of I None
the I None
51 I None
patients I None
, I None
7 I None
patients I None
showed I None
asynergy I None
with I None
ST I None
elevation I None
. I None
<eof> I None

<s> O None
All I None
7 I None
patients I None
( I None
13.7 I None
% I None
) I None
had I None
chest I Disease
pain O Disease
during I None
asynergy I None
, I None
and I None
both I None
chest I Disease
pain O Disease
and I None
electrocardiographic I None
changes I None
were I None
preceded I None
by I None
asynergy I None
. I None
<eof> I None

<s> O None
These I None
findings I None
indicate I None
that I None
dobutamine I Chemical
can I None
provoke I None
coronary I Disease
spasm O Disease
in I None
some I None
patients I None
with I None
coronary I Disease
spastic O Disease
angina O Disease
. I None
<eof> I None

<s> O None
When I None
DSE I None
is I None
performed I None
to I None
evaluate I None
coronary I Disease
artery O Disease
disease O Disease
, I None
not I None
only I None
fixed I None
coronary I Disease
stenosis O Disease
, I None
but I None
also I None
coronary I Disease
spasm O Disease
should I None
be I None
considered I None
as I None
a I None
genesis I None
of I None
asynergy I None
. I None
<eof> I None

<s> O None
Nitric I Chemical
oxide O Chemical
synthase I None
expression I None
in I None
the I None
course I None
of I None
lead I Chemical
-induced I None
hypertension I Disease
. I None
<eof> I None

<s> O None
We I None
recently I None
showed I None
elevated I None
reactive I None
oxygen I Chemical
species I None
( I None
ROS I None
) I None
, I None
reduced I None
urinary I None
excretion I None
of I None
NO I Chemical
metabolites I None
( I None
NOx I None
) I None
, I None
and I None
increased I None
NO I Chemical
sequestration I None
as I None
nitrotyrosine I Chemical
in I None
various I None
tissues I None
in I None
rats I None
with I None
lead I Chemical
-induced I None
hypertension I Disease
. I None
<eof> I None

<s> O None
This I None
study I None
was I None
designed I None
to I None
discern I None
whether I None
the I None
reduction I None
in I None
urinary I None
NOx I None
in I None
lead I Chemical
-induced I None
hypertension I Disease
is I None
, I None
in I None
part I None
, I None
due I None
to I None
depressed I None
NO I Chemical
synthase I None
( I None
NOS I None
) I None
expression I None
. I None
<eof> I None

<s> O None
Male I None
Sprague I None
- I None
Dawley I None
rats I None
were I None
randomly I None
assigned I None
to I None
a I None
lead I Chemical
-treated I None
group I None
( I None
given I None
lead I Chemical
acetate O Chemical
, I None
100 I None
ppm I None
, I None
in I None
drinking I None
water I None
and I None
regular I None
rat I None
chow I None
) I None
, I None
a I None
group I None
given I None
lead I Chemical
and I None
vitamin I Chemical
E O Chemical
<eof> I None

<s> O None
-fortified I None
chow I None
, I None
or I None
a I None
normal I None
control I None
group I None
given I None
either I None
regular I None
food I None
and I None
water I None
or I None
vitamin I Chemical
E O Chemical
<eof> I None

<s> O None
-fortified I None
food I None
for I None
12 I None
weeks I None
. I None
<eof> I None

<s> O None
Tail I None
blood I None
pressure I None
, I None
urinary I None
NOx I None
excretion I None
, I None
plasma I None
malondialdehyde I Chemical
<eof> I None

<s> O None
( I None
MDA I Chemical
) I None
, I None
and I None
endothelial I None
and I None
inducible I None
NOS I None
( I None
eNOS I None
and I None
iNOS I None
) I None
isotypes I None
in I None
the I None
aorta I None
and I None
kidney I None
were I None
measured I None
. I None
<eof> I None

<s> O None
The I None
lead I Chemical
-treated I None
group I None
exhibited I None
a I None
rise I None
in I None
blood I None
pressure I None
and I None
plasma I None
<eof> I None

<s> O None
MDA I Chemical
concentration I None
, I None
a I None
fall I None
in I None
urinary I None
NOx I None
excretion I None
, I None
and I None
a I None
paradoxical I None
rise I None
in I None
vascular I None
and I None
renal I None
tissue I None
eNOS I None
and I None
iNOS I None
expression I None
. I None
<eof> I None

<s> O None
Vitamin I Chemical
E O Chemical
supplementation I None
ameliorated I None
<eof> I None

<s> O None
hypertension I Disease
, I None
lowered I None
plasma I None
<eof> I None

<s> O None
MDA I Chemical
concentration I None
, I None
and I None
raised I None
urinary I None
NOx I None
excretion I None
while I None
significantly I None
lowering I None
vascular I None
, I None
but I None
not I None
renal I None
, I None
tissue I None
eNOS I None
and I None
iNOS I None
expression I None
. I None
<eof> I None

<s> O None
Vitamin I Chemical
E O Chemical
supplementation I None
had I None
no I None
effect I None
on I None
either I None
blood I None
pressure I None
, I None
plasma I None
MDA I Chemical
, I None
or I None
NOS I None
expression I None
in I None
the I None
control I None
group I None
. I None
<eof> I None

<s> O None
The I None
study I None
also I None
revealed I None
significant I None
inhibition I None
of I None
NOS I None
enzymatic I None
activity I None
by I None
lead I Chemical
in I None
cell I None
- I None
free I None
preparations I None
. I None
<eof> I None

<s> O None
In I None
conclusion I None
, I None
lead I Chemical
-induced I None
hypertension I Disease
in I None
this I None
model I None
was I None
associated I None
with I None
a I None
compensatory I None
upregulation I None
of I None
renal I None
and I None
vascular I None
eNOS I None
and I None
iNOS I None
expression I None
. I None
<eof> I None

<s> O None
This I None
is I None
, I None
in I None
part I None
, I None
due I None
to I None
ROS I None
- I None
mediated I None
NO I Chemical
inactivation I None
, I None
<eof> I None

<s> O None
lead I Chemical
-associated I None
inhibition I None
of I None
NOS I None
activity I None
, I None
and I None
perhaps I None
stimulatory I None
actions I None
of I None
increased I None
shear I None
stress I None
associated I None
with I None
hypertension I Disease
. I None
<eof> I None

<s> O None
Risk I None
for I None
valvular I Disease
heart O Disease
disease O Disease
among I None
users I None
of I None
fenfluramine I Chemical
and I None
dexfenfluramine I Chemical
who I None
underwent I None
echocardiography I None
before I None
use I None
of I None
medication I None
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
<eof> I None

<s> O None
Because I None
uncontrolled I None
echocardiographic I None
surveys I None
suggested I None
that I None
up I None
to I None
30 I None
% I None
to I None
38 I None
% I None
of I None
users I None
of I None
fenfluramine I Chemical
and I None
dexfenfluramine I Chemical
had I None
valvular I Disease
disease O Disease
, I None
these I None
drugs I None
were I None
withdrawn I None
from I None
the I None
market I None
. I None
<eof> I None

<s> O None
OBJECTIVE I None
: I None
<eof> I None

<s> O None
To I None
determine I None
the I None
risk I None
for I None
new I None
or I None
worsening I None
valvular I Disease
abnormalities O Disease
among I None
users I None
of I None
fenfluramine I Chemical
or I None
dexfenfluramine I Chemical
who I None
underwent I None
echocardiography I None
before I None
they I None
began I None
to I None
take I None
these I None
medications I None
. I None
<eof> I None

<s> O None
DESIGN I None
: I None
<eof> I None

<s> O None
Cohort I None
study I None
. I None
<eof> I None

<s> O None
SETTING I None
: I None
<eof> I None

<s> O None
Academic I None
primary I None
care I None
practices I None
. I None
<eof> I None

<s> O None
PATIENTS I None
: I None
46 I None
patients I None
who I None
used I None
fenfluramine I Chemical
or I None
dexfenfluramine I Chemical
for I None
14 I None
days I None
or I None
more I None
and I None
had I None
echocardiograms I None
obtained I None
before I None
therapy I None
. I None
<eof> I None

<s> O None
MEASUREMENTS I None
: I None
Follow I None
- I None
up I None
echocardiography I None
. I None
<eof> I None

<s> O None
The I None
primary I None
outcome I None
was I None
new I None
or I None
worsening I None
valvulopathy I Disease
, I None
defined I None
as I None
progression I None
of I None
either I None
aortic I None
or I None
mitral I None
regurgitation I None
by I None
at I None
least I None
one I None
degree I None
of I None
severity I None
and I None
disease I None
that I None
met I None
U.S. I None
Food I None
and I None
Drug I None
Administration I None
criteria I None
( I None
at I None
least I None
mild I None
aortic I Disease
regurgitation O Disease
or I None
moderate I None
mitral I Disease
regurgitation O Disease
) I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
Two I None
patients I None
( I None
4.3 I None
% I None
[ I None
95 I None
% I None
CI I None
, I None
0.6 I None
% I None
to I None
14.8 I None
% I None
] I None
) I None
receiving I None
fenfluramine I Chemical
- I None
phentermine I Chemical
developed I None
valvular I Disease
heart O Disease
disease O Disease
. I None
<eof> I None

<s> O None
One I None
had I None
baseline I None
bicuspid I Disease
aortic O Disease
valve O Disease
and I None
mild I None
aortic I Disease
regurgitation O Disease
that I None
progressed I None
to I None
moderate I None
regurgitation I None
. I None
<eof> I None

<s> O None
The I None
second I None
patient I None
developed I None
new I None
moderate I None
aortic I Disease
insufficiency O Disease
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
<eof> I None

<s> O None
Users I None
of I None
diet I None
medications I None
are I None
at I None
risk I None
for I None
valvular I Disease
heart O Disease
disease O Disease
. I None
<eof> I None

<s> O None
However I None
, I None
the I None
incidence I None
may I None
be I None
lower I None
than I None
that I None
reported I None
previously I None
. I None
<eof> I None

<s> O None
Carboplatin I Chemical
toxic I None
effects I None
on I None
the I None
peripheral I None
nervous I None
system I None
of I None
the I None
rat I None
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
<eof> I None

<s> O None
The I None
most I None
striking I None
of I None
carboplatin I Chemical
's I None
advantages I None
( I None
CBDCA I Chemical
) I None
over I None
cisplatin I Chemical
<eof> I None

<s> O None
( I None
CDDP I Chemical
) I None
is I None
its I None
markedly I None
reduced I None
rate I None
of I None
neurotoxic I Disease
effects I None
. I None
<eof> I None

<s> O None
However I None
, I None
the I None
use I None
of I None
CBDCA I Chemical
higher I None
- I None
intensity I None
schedules I None
and I None
the I None
association I None
with I None
other I None
neurotoxic I Disease
drugs I None
in I None
polychemotherapy I None
may I None
cause I None
some I None
concern I None
about I None
its I None
safety I None
with I None
respect I None
to I None
peripheral I Disease
nervous O Disease
system O Disease
damage O Disease
. I None
<eof> I None

<s> O None
MATERIALS I None
AND I None
METHODS I None
: I None
<eof> I None

<s> O None
Two I None
different I None
schedules I None
of I None
CBDCA I Chemical
administration I None
( I None
10 I None
mg I None
/ I None
kg I None
and I None
15 I None
mg I None
/ I None
kg I None
i.p I None
. I None
twice I None
a I None
week I None
for I None
nine I None
times I None
) I None
were I None
evaluated I None
in I None
Wistar I None
rats I None
. I None
<eof> I None

<s> O None
Neurotoxicity I Disease
was I None
assessed I None
for I None
behavioral I None
( I None
tail I None
- I None
flick I None
test I None
) I None
, I None
neurophysiological I None
( I None
nerve I None
conduction I None
velocity I None
in I None
the I None
tail I None
nerve I None
) I None
, I None
morphological I None
, I None
morphometrical I None
and I None
analytical I None
effects I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
CBDCA I Chemical
administration I None
induced I None
dose I None
- I None
dependent I None
peripheral I Disease
neurotoxicity O Disease
. I None
<eof> I None

<s> O None
Pain I Disease
perception I None
and I None
nerve I None
conduction I None
velocity I None
in I None
the I None
tail I None
were I None
significantly I None
impaired I None
, I None
particularly I None
after I None
the I None
high I None
- I None
dose I None
treatment I None
. I None
<eof> I None

<s> O None
The I None
dorsal I None
root I None
ganglia I None
sensory I None
neurons I None
and I None
, I None
to I None
a I None
lesser I None
extent I None
, I None
satellite I None
cells I None
showed I None
the I None
same I None
changes I None
as I None
those I None
induced I None
by I None
CDDP I Chemical
, I None
mainly I None
affecting I None
the I None
nucleus I None
and I None
nucleolus I None
of I None
ganglionic I None
sensory I None
neurons I None
. I None
<eof> I None

<s> O None
Moreover I None
, I None
significant I None
amounts I None
of I None
platinum I Chemical
were I None
detected I None
in I None
the I None
dorsal I None
root I None
ganglia I None
and I None
kidney I None
after I None
CBDCA I Chemical
treatment I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
CBDCA I Chemical
is I None
<eof> I None

<s> O None
neurotoxic I Disease
in I None
our I None
model I None
, I None
and I None
the I None
type I None
of I None
pathological I None
changes I None
it I None
induces I None
are I None
so I None
closely I None
similar I None
to I None
those I None
caused I None
by I None
CDDP I Chemical
that I None
it I None
is I None
probable I None
that I None
neurotoxicity I Disease
is I None
induced I None
in I None
the I None
two I None
drugs I None
by I None
the I None
same I None
mechanism I None
. I None
<eof> I None

<s> O None
This I None
model I None
can I None
be I None
used I None
alone I None
or I None
in I None
combination I None
with I None
other I None
drugs I None
to I None
explore I None
the I None
effect I None
of I None
CBDCA I Chemical
on I None
the I None
peripheral I None
nervous I None
system I None
. I None
<eof> I None

<s> O None
Iatrogenic I None
risks I None
of I None
endometrial I Disease
carcinoma O Disease
after I None
treatment I None
for I None
breast I Disease
cancer O Disease
in I None
a I None
large I None
French I None
case I None
- I None
control I None
study I None
. I None
<eof> I None

<s> O None
F I None
d I None
ration I None
Nationale I None
des I None
Centres I None
de I None
Lutte I None
Contre I None
le I None
Cancer I None
( I None
FNCLCC I None
) I None
. I None
<eof> I None

<s> O None
Since I None
<eof> I None

<s> O None
tamoxifen I Chemical
is I None
widely I None
used I None
in I None
breast I Disease
cancer O Disease
treatment I None
and I None
has I None
been I None
proposed I None
for I None
the I None
prevention I None
of I None
breast I Disease
cancer O Disease
, I None
its I None
endometrial I None
iatrogenic I None
effects I None
must I None
be I None
carefully I None
examined I None
. I None
<eof> I None

<s> O None
We I None
have I None
investigated I None
the I None
association I None
between I None
endometrial I Disease
cancer O Disease
and I None
tamoxifen I Chemical
use I None
or I None
other I None
treatments I None
in I None
women I None
treated I None
for I None
breast I Disease
cancer O Disease
in I None
a I None
case I None
- I None
control I None
study I None
. I None
<eof> I None

<s> O None
Cases I None
of I None
endometrial I Disease
cancer O Disease
diagnosed I None
after I None
breast I Disease
cancer O Disease
<eof> I None

<s> O None
( I None
n I None
= I None
135 I None
) I None
and I None
467 I None
controls I None
matched I None
for I None
age I None
, I None
year I None
of I None
diagnosis I None
of I None
breast I Disease
cancer O Disease
and I None
hospital I None
and I None
survival I None
time I None
with I None
an I None
intact I None
uterus I None
were I None
included I None
. I None
<eof> I None

<s> O None
Women I None
who I None
had I None
received I None
tamoxifen I Chemical
were I None
significantly I None
more I None
likely I None
to I None
have I None
endometrial I Disease
cancer O Disease
diagnosed I None
than I None
those I None
who I None
had I None
not I None
( I None
crude I None
relative I None
risk I None
= I None
4.9 I None
, I None
p I None
= I None
0.0001 I None
) I None
. I None
<eof> I None

<s> O None
Univariate I None
and I None
adjusted I None
analyses I None
showed I None
that I None
the I None
risk I None
increased I None
with I None
the I None
length I None
of I None
treatment I None
( I None
p I None
= I None
0.0001 I None
) I None
or I None
the I None
cumulative I None
dose I None
of I None
tamoxifen I Chemical
received I None
( I None
p I None
= I None
0.0001 I None
) I None
, I None
irrespective I None
of I None
the I None
daily I None
dose I None
. I None
<eof> I None

<s> O None
Women I None
who I None
had I None
undergone I None
pelvic I None
radiotherapy I None
also I None
had I None
a I None
higher I None
risk I None
( I None
crude I None
relative I None
risk I None
= I None
7.8 I None
, I None
p I None
= I None
0.0001 I None
) I None
. I None
<eof> I None

<s> O None
After I None
adjusting I None
for I None
confounding I None
factors I None
, I None
the I None
risk I None
was I None
higher I None
for I None
tamoxifen I Chemical
users I None
( I None
p I None
= I None
0.0012 I None
) I None
, I None
treatment I None
for I None
more I None
than I None
3 I None
years I None
( I None
all I None
p I None
< I None
0.03 I None
) I None
and I None
pelvic I None
radiotherapy I None
( I None
p I None
= I None
0.012 I None
) I None
. I None
<eof> I None

<s> O None
Women I None
who I None
had I None
endometrial I Disease
cancer O Disease
and I None
had I None
received I None
tamoxifen I Chemical
had I None
more I None
advanced I Disease
disease O Disease
and I None
poorer I None
prognosis I None
than I None
those I None
with I None
endometrial I Disease
cancer O Disease
who I None
had I None
not I None
received I None
this I None
treatment I None
. I None
<eof> I None

<s> O None
Our I None
results I None
suggest I None
a I None
causal I None
role I None
of I None
tamoxifen I Chemical
in I None
endometrial I Disease
cancer O Disease
, I None
particularly I None
when I None
used I None
as I None
currently I None
proposed I None
for I None
breast I Disease
cancer O Disease
prevention I None
. I None
<eof> I None

<s> O None
Pelvic I None
radiotherapy I None
may I None
be I None
an I None
additional I None
iatrogenic I None
factor I None
for I None
women I None
with I None
breast I Disease
cancer O Disease
. I None
<eof> I None

<s> O None
Endometrial I Disease
cancers O Disease
diagnosed I None
in I None
women I None
treated I None
with I None
tamoxifen I Chemical
have I None
poorer I None
prognosis I None
. I None
<eof> I None

<s> O None
Women I None
who I None
receive I None
tamoxifen I Chemical
for I None
breast I Disease
cancer O Disease
should I None
be I None
offered I None
gynaecological I None
surveillance I None
during I None
and I None
after I None
treatment I None
. I None
<eof> I None

<s> O None
A I None
long I None
- I None
term I None
evaluation I None
of I None
the I None
risk I None
- I None
benefit I None
ratio I None
of I None
tamoxifen I Chemical
as I None
a I None
preventive I None
treatment I None
for I None
breast I Disease
cancer O Disease
is I None
clearly I None
warranted I None
. I None
<eof> I None

<s> O None
Granulosa I Disease
cell O Disease
tumor O Disease
of O Disease
the O Disease
ovary O Disease
associated I None
with I None
antecedent I None
tamoxifen I Chemical
use I None
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
<eof> I None

<s> O None
Increased I None
attention I None
has I None
been I None
focused I None
recently I None
on I None
the I None
estrogenic I None
effects I None
of I None
tamoxifen I Chemical
. I None
<eof> I None

<s> O None
Review I None
of I None
the I None
literature I None
reveals I None
an I None
association I None
between I None
tamoxifen I Chemical
use I None
and I None
gynecologic I None
tumors I Disease
. I None
<eof> I None

<s> O None
CASE I None
: I None
<eof> I None

<s> O None
A I None
52-year I None
- I None
old I None
postmenopausal I None
woman I None
was I None
treated I None
with I None
tamoxifen I Chemical
for I None
stage I None
II I None
<eof> I None

<s> O None
estrogen I Chemical
receptor I None
- I None
positive I None
breast I Disease
carcinoma O Disease
. I None
<eof> I None

<s> O None
Her I None
aspartate I Chemical
transaminase I None
and I None
alanine I Chemical
transaminase I None
levels I None
increase I None
markedly I None
after I None
6 I None
months I None
of I None
tamoxifen I Chemical
use I None
. I None
<eof> I None

<s> O None
After I None
an I None
additional I None
17 I None
months I None
of I None
elevated I None
serum I None
transaminases I None
, I None
the I None
patient I None
was I None
found I None
to I None
have I None
a I None
stage I None
Ic I None
granulosa I Disease
cell O Disease
tumor O Disease
of O Disease
the O Disease
ovary O Disease
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
<eof> I None

<s> O None
Patients I None
with I None
tamoxifen I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
liver I Disease
dysfunction O Disease
may I None
be I None
at I None
increased I None
risk I None
for I None
granulosa I Disease
cell O Disease
tumors O Disease
because I None
of I None
alterations I None
in I None
tamoxifen I Chemical
metabolism I None
. I None
<eof> I None

<s> O None
A I None
murine I None
model I None
of I None
adenomyosis I Disease
: I None
the I None
effects I None
of I None
hyperprolactinemia I Disease
induced I None
by I None
fluoxetine I Chemical
hydrochloride O Chemical
, I None
a I None
selective I None
serotonin I Chemical
reuptake I None
inhibitor I None
, I None
on I None
adenomyosis I Disease
induction I None
in I None
Wistar I None
albino I None
rats I None
. I None
<eof> I None

<s> O None
OBJECTIVE I None
: I None
<eof> I None

<s> O None
The I None
aim I None
of I None
this I None
study I None
was I None
to I None
investigate I None
whether I None
fluoxetine I Chemical
given I None
to I None
castrated I None
and I None
noncastrated I None
rats I None
caused I None
hyperprolactinemia I Disease
and I None
its I None
effects I None
with I None
respect I None
to I None
adenomyosis I Disease
. I None
<eof> I None

<s> O None
DESIGN I None
: I None
<eof> I None

<s> O None
Fluoxetine I Chemical
, I None
a I None
serotonin I Chemical
reuptake I None
inhibitor I None
, I None
was I None
given I None
to I None
Wistar I None
Albino I None
rats I None
for I None
98 I None
days I None
to I None
produce I None
hyperprolactinemia I Disease
. I None
<eof> I None

<s> O None
The I None
drug I None
was I None
given I None
to I None
two I None
groups I None
consisting I None
of I None
castrated I None
and I None
noncastrated I None
rats I None
and I None
compared I None
to I None
two I None
groups I None
of I None
castrated I None
and I None
noncastrated I None
controls I None
. I None
<eof> I None

<s> O None
Prolactin I None
levels I None
were I None
measured I None
and I None
the I None
uteri I None
of I None
the I None
rats I None
were I None
removed I None
for I None
histopathological I None
analysis I None
at I None
the I None
end I None
of I None
98 I None
days I None
. I None
<eof> I None

<s> O None
SETTING I None
: I None
<eof> I None

<s> O None
Marmara I None
University I None
School I None
of I None
Medicine I None
, I None
Department I None
of I None
Histology I None
and I None
Embryology I None
, I None
Zeynep I None
Kamil I None
Women I None
and I None
Children I None
's I None
Hospital I None
. I None
<eof> I None

<s> O None
MAIN I None
OUTCOME I None
MEASURES I None
: I None
<eof> I None

<s> O None
Serum I None
prolactin I None
levels I None
, I None
uterine I None
histopathology I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
The I None
prolactin I None
levels I None
of I None
castrated I None
and I None
noncastrated I None
groups I None
treated I None
with I None
fluoxetine I Chemical
were I None
statistically I None
significantly I None
higher I None
when I None
compared I None
to I None
their I None
respective I None
control I None
groups I None
. I None
<eof> I None

<s> O None
Histological I None
studies I None
revealed I None
11 I None
cases I None
of I None
adenomyosis I Disease
, I None
all I None
within I None
the I None
noncastrated I None
group I None
receiving I None
fluoxetine I Chemical
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
<eof> I None

<s> O None
It I None
was I None
suggested I None
that I None
high I None
serum I None
prolactin I None
levels I None
cause I None
degeneration I None
of I None
myometrial I None
cells I None
in I None
the I None
presence I None
of I None
ovarian I None
steroids I Chemical
<eof> I None

<s> O None
that I None
results I None
in I None
a I None
myometrial I None
invasion I None
by I None
endometrial I None
stroma I None
. I None
<eof> I None

<s> O None
This I None
invasion I None
eventually I None
progresses I None
to I None
adenomyosis I Disease
. I None
<eof> I None

<s> O None
Effects I None
of I None
deliberate I None
hypotension I Disease
induced I None
by I None
labetalol I Chemical
with I None
isoflurane I Chemical
on I None
neuropsychological I None
function I None
. I None
<eof> I None

<s> O None
The I None
effect I None
of I None
deliberate I None
hypotension I Disease
on I None
brain I None
function I None
measured I None
by I None
neuropsychological I None
tests I None
was I None
studied I None
in I None
41 I None
adult I None
patients I None
. I None
<eof> I None

<s> O None
Twenty I None
- I None
four I None
patients I None
were I None
anaesthetized I None
for I None
middle I None
- I None
ear I None
surgery I None
with I None
deliberate I None
hypotension I Disease
induced I None
by I None
labetalol I Chemical
with I None
isoflurane I Chemical
<eof> I None

<s> O None
( I None
hypotensive I Disease
group I None
) I None
. I None
<eof> I None

<s> O None
Seventeen I None
patients I None
without I None
hypotension I Disease
served I None
as I None
a I None
control I None
group I None
. I None
<eof> I None

<s> O None
The I None
mean I None
arterial I None
pressure I None
was I None
77 I None
+ I None
/- I None
<eof> I None

<s> O None
2 I None
mmHg I None
( I None
10.3 I None
+ I None
/- I None
0.3 I None
kPa I None
) I None
before I None
<eof> I None

<s> O None
hypotension I Disease
and I None
50 I None
+ I None
/- I None
0 I None
<eof> I None

<s> O None
mmHg I None
( I None
6.7 I None
+ I None
/- I None
<eof> I None

<s> O None
0.0 I None
kPa I None
) I None
during I None
<eof> I None

<s> O None
hypotension I Disease
in I None
the I None
hypotensive I Disease
group I None
, I None
and I None
86 I None
+ I None
/- I None
<eof> I None

<s> O None
2 I None
mmHg I None
( I None
11.5 I None
+ I None
/- I None
0.3 I None
kPa I None
) I None
during I None
anaesthesia I None
in I None
the I None
control I None
group I None
. I None
<eof> I None

<s> O None
The I None
following I None
psychological I None
tests I None
were I None
performed I None
: I None
four I None
subtests I None
of I None
the I None
Wechsler I None
Adult I None
Intelligence I None
Scale I None
( I None
similarities I None
, I None
digit I None
span I None
, I None
vocabulary I None
and I None
digit I None
symbol I None
) I None
, I None
Trail I None
- I None
Making I None
tests I None
A I None
and I None
B I None
, I None
Zung I None
tests I None
( I None
self I None
- I None
rating I None
anxiety I Disease
scale I None
and I None
self I None
- I None
rating I None
depression I Disease
scale I None
) I None
and I None
two I None
- I None
part I None
memory I None
test I None
battery I None
with I None
immediate I None
and I None
delayed I None
recall I None
. I None
<eof> I None

<s> O None
The I None
tests I None
were I None
performed I None
preoperatively I None
and I None
2 I None
days I None
postoperatively I None
. I None
<eof> I None

<s> O None
There I None
were I None
no I None
statistically I None
significant I None
differences I None
between I None
the I None
groups I None
in I None
any I None
of I None
the I None
tests I None
in I None
the I None
changes I None
from I None
preoperative I None
value I None
to I None
postoperative I None
value I None
. I None
<eof> I None

<s> O None
The I None
results I None
indicate I None
that I None
hypotension I Disease
induced I None
by I None
labetalol I Chemical
with I None
isoflurane I Chemical
has I None
no I None
significant I None
harmful I None
effects I None
on I None
mental I None
functions I None
compared I None
to I None
normotensive I None
anaesthesia I None
. I None
<eof> I None

<s> O None
Auditory I None
disturbance I None
associated I None
with I None
interscalene I None
brachial I None
plexus I None
block I None
. I None
<eof> I None

<s> O None
We I None
performed I None
an I None
audiometric I None
study I None
in I None
20 I None
patients I None
who I None
underwent I None
surgery I None
of I None
the I None
shoulder I None
region I None
under I None
an I None
interscalene I None
brachial I None
plexus I None
block I None
( I None
IBPB I None
) I None
. I None
<eof> I None

<s> O None
Bupivacaine I Chemical
0.75 I None
% I None
with I None
<eof> I None

<s> O None
adrenaline I Chemical
was I None
given I None
followed I None
by I None
a I None
24-hr I None
continuous I None
infusion I None
of I None
0.25 I None
% I None
bupivacaine I Chemical
. I None
<eof> I None

<s> O None
Three I None
audiometric I None
threshold I None
measurements I None
( I None
0.25 I None
- I None
18 I None
kHz I None
) I None
were I None
made I None
: I None
the I None
first I None
before I None
IBPB I None
, I None
the I None
second I None
2 I None
- I None
6 I None
h I None
after I None
surgery I None
and I None
the I None
third I None
on I None
the I None
first I None
day I None
after I None
operation I None
. I None
<eof> I None

<s> O None
In I None
four I None
patients I None
hearing I Disease
impairment O Disease
on I None
the I None
side I None
of I None
the I None
block I None
was I None
demonstrated I None
after I None
operation I None
, I None
in I None
three I None
measurements I None
on I None
the I None
day I None
of I None
surgery I None
and I None
in I None
one I None
on I None
the I None
following I None
day I None
. I None
<eof> I None

<s> O None
The I None
frequencies I None
at I None
which I None
the I None
impairment I None
occurred I None
varied I None
between I None
patients I None
; I None
in I None
one I None
only I None
low I None
frequencies I None
( I None
0.25 I None
- I None
0.5 I None
kHz I None
) I None
were I None
involved I None
. I None
<eof> I None

<s> O None
The I None
maximum I None
change I None
in I None
threshold I None
was I None
35 I None
dB I None
at I None
6 I None
kHz I None
measured I None
at I None
the I None
end I None
of I None
the I None
continuous I None
infusion I None
of I None
bupivacaine I Chemical
. I None
<eof> I None

<s> O None
This I None
patient I None
had I None
hearing I None
threshold I None
changes I None
( I None
15 I None
- I None
20 I None
dB I None
) I None
at I None
6 I None
- I None
10 I None
kHz I None
on I None
the I None
opposite I None
side I None
also I None
. I None
<eof> I None

<s> O None
IBPB I None
may I None
cause I None
transient I None
auditory I Disease
dysfunction O Disease
in I None
the I None
ipsilateral I None
ear I None
, I None
possibly I None
via I None
an I None
effect I None
on I None
sympathetic I None
innervation I None
. I None
<eof> I None

<s> O None
Midazolam I Chemical
compared I None
with I None
thiopentone I Chemical
as I None
an I None
induction I None
agent I None
. I None
<eof> I None

<s> O None
In I None
patients I None
premedicated I None
with I None
scopolamine I Chemical
+ I None
morphine I Chemical
<eof> I None

<s> O None
( I None
<eof> I None

<s> O None
+ I None
5 I None
mg I None
<eof> I None

<s> O None
nitrazepam I Chemical
the I None
evening I None
before I None
surgery I None
) I None
, I None
the I None
sleep I None
- I None
inducing I None
effect I None
of I None
midazolam I Chemical
0.15 I None
mg I None
/ I None
kg I None
i.v I None
. I None
was I None
clearly I None
slower I None
in I None
onset I None
than I None
that I None
of I None
thiopentone I Chemical
4.67 I None
mg I None
/ I None
kg I None
i.v I None
. I None
<eof> I None

<s> O None
Somewhat I None
fewer I None
cardiovascular I None
and I None
local I None
sequelae I None
were I None
found I None
in I None
the I None
midazolam I Chemical
group I None
, I None
but I None
, I None
although I None
apnoea I Disease
occurred I None
less I None
often I None
in I None
the I None
midazolam I Chemical
group I None
it I None
lasted I None
longer I None
. I None
<eof> I None

<s> O None
On I None
the I None
whole I None
, I None
the I None
differences I None
between I None
midazolam I Chemical
and I None
thiopentone I Chemical
had I None
no I None
apparent I None
clinical I None
consequences I None
. I None
<eof> I None

<s> O None
Midazolam I Chemical
is I None
a I None
new I None
alternative I None
agent I None
for I None
induction I None
in I None
combination I None
anaesthesia I None
. I None
<eof> I None

<s> O None
Cardiotoxic I Disease
and I None
possible I None
leukemogenic I None
effects I None
of I None
adriamycin I Chemical
in I None
nonhuman I None
primates I None
. I None
<eof> I None

<s> O None
10 I None
monkeys I None
( I None
macaques I None
) I None
received I None
adriamycin I Chemical
by I None
monthly I None
intravenous I None
injections I None
at I None
12 I None
mg I None
/ I None
m2 I None
( I None
1 I None
mg I None
/ I None
kg I None
) I None
. I None
<eof> I None

<s> O None
8 I None
of I None
the I None
10 I None
monkeys I None
developed I None
<eof> I None

<s> O None
congestive I Disease
heart O Disease
failure O Disease
at I None
an I None
average I None
cumulative I None
adriamycin I Chemical
dose I None
( I None
310 I None
mg I None
/ I None
m2 I None
) I None
well I None
below I None
that I None
considered I None
the I None
safe I None
upper I None
limit I None
( I None
550 I None
mg I None
/ I None
m2 I None
) I None
in I None
man I None
. I None
<eof> I None

<s> O None
Histologically I None
, I None
the I None
myocardial I Disease
lesions O Disease
resembled I None
those I None
found I None
in I None
human I None
anthracycline I Chemical
-induced I None
cardiomyopathy I Disease
. I None
<eof> I None

<s> O None
1 I None
of I None
the I None
10 I None
monkeys I None
developed I None
acute I Disease
myeloblastic O Disease
leukemia O Disease
after I None
receiving I None
324 I None
mg I None
/ I None
m2 I None
of I None
adriamycin I Chemical
; I None
the I None
10th I None
monkey I None
is I None
alive I None
and I None
well I None
26 I None
months I None
after I None
the I None
last I None
dose I None
of I None
drug I None
. I None
<eof> I None

<s> O None
Our I None
results I None
suggest I None
that I None
adriamycin I Chemical
is I None
a I None
more I None
potent I None
cardiotoxin I None
in I None
monkeys I None
than I None
in I None
man I None
, I None
and I None
that I None
leukemia I Disease
may I None
be I None
a I None
consequence I None
of I None
prolonged I None
treatment I None
with I None
this I None
drug I None
. I None
<eof> I None

<s> O None
Doxorubicin I Chemical
<eof> I None

<s> O None
cardiomyopathy I Disease
in I None
children I None
with I None
left I None
- I None
sided I None
Wilms I Disease
tumor O Disease
. I None
<eof> I None

<s> O None
Two I None
children I None
with I None
Wilms I Disease
tumor O Disease
of I None
the I None
left I None
kidney I None
experienced I None
severe I None
anthracycline I Chemical
cardiomyopathy I Disease
after I None
irradiation I None
to I None
the I None
tumor I Disease
bed I None
and I None
conventional I None
dosage I None
of I None
doxorubicin I Chemical
. I None
<eof> I None

<s> O None
The I None
cardiomyopathy I Disease
is I None
attributed I None
1 I None
) I None
to I None
the I None
fact I None
that I None
radiation I None
fields I None
for I None
left I None
<eof> I None

<s> O None
Wilms I Disease
tumor O Disease
include I None
the I None
lower I None
portion I None
of I None
the I None
heart I None
and I None
2 I None
) I None
to I None
the I None
interaction I None
of I None
doxorubicin I Chemical
and I None
irradiation I None
on I None
cardiac I None
muscle I None
. I None
<eof> I None

<s> O None
It I None
is I None
recommended I None
that I None
doxorubicin I Chemical
dosage I None
be I None
sharply I None
restricted I None
in I None
children I None
with I None
Wilms I Disease
tumor O Disease
of I None
the I None
left I None
kidney I None
who I None
receive I None
postoperative I None
irradiation I None
. I None
<eof> I None

<s> O None
Promotional I None
effects I None
of I None
testosterone I Chemical
and I None
dietary I None
fat I None
on I None
prostate I None
carcinogenesis I Disease
in I None
genetically I None
susceptible I None
rats I None
. I None
<eof> I None

<s> O None
Germfree I None
( I None
GF I None
) I None
<eof> I None

<s> O None
Lobund I None
strain I None
Wistar I None
( I None
LW I None
) I None
rats I None
, I None
fed I None
vegetable I None
diet I None
L-485 I None
, I None
have I None
developed I None
<eof> I None

<s> O None
prostate I Disease
adenocarcinomas O Disease
spontaneously I None
( I None
10 I None
% I None
incidence I None
) I None
at I None
average I None
age I None
34 I None
months I None
. I None
<eof> I None

<s> O None
Conventional I None
LW I None
rats I None
, I None
implanted I None
with I None
testosterone I Chemical
at I None
age I None
4 I None
months I None
, I None
developed I None
a I None
higher I None
incidence I None
of I None
prostate I Disease
cancer O Disease
after I None
an I None
average I None
interval I None
of I None
14 I None
months I None
: I None
24 I None
% I None
had I None
developed I None
gross I None
tumors I Disease
, I None
and I None
40 I None
% I None
when I None
it I None
included I None
microscopic I None
tumors I Disease
. I None
<eof> I None

<s> O None
Preliminary I None
results I None
indicate I None
that I None
testosterone I Chemical
-treated I None
LW I None
rats I None
that I None
were I None
fed I None
the I None
same I None
diet I None
, I None
which I None
was I None
supplemented I None
with I None
corn I None
oil I None
up I None
to I None
20 I None
% I None
fat I None
, I None
developed I None
prostate I Disease
cancer O Disease
after I None
intervals I None
of I None
6 I None
- I None
12 I None
months I None
. I None
<eof> I None

<s> O None
Aged I None
GF I None
Sprague I None
- I None
Dawley I None
( I None
SD I None
) I None
rats I None
have I None
not I None
developed I None
prostate I Disease
cancer O Disease
spontaneously I None
. I None
<eof> I None

<s> O None
Conventional I None
SD I None
rats I None
fed I None
diet I None
L-485 I None
and I None
treated I None
with I None
testosterone I Chemical
developed I None
only I None
prostatitis I Disease
. I None
<eof> I None

<s> O None
Experimental I None
designs I None
should I None
consider I None
genetic I None
susceptibility I None
as I None
a I None
basic I None
prerequisite I None
for I None
studies I None
on I None
experimental I None
prostate I Disease
cancer O Disease
. I None
<eof> I None

<s> O None
Mitomycin I Chemical
C O Chemical
associated I None
hemolytic I Disease
uremic O Disease
syndrome O Disease
. I None
<eof> I None

<s> O None
Mitomycin I Chemical
C O Chemical
associated I None
Hemolytic I Disease
Uremic O Disease
Syndrome O Disease
<eof> I None

<s> O None
( I None
HUS I Disease
) I None
is I None
a I None
potentially I None
fatal I None
but I None
uncommon I None
condition I None
that I None
is I None
not I None
yet I None
widely I None
recognised I None
. I None
<eof> I None

<s> O None
It I None
consists I None
of I None
microangiopathic I None
hemolytic I Disease
anemia O Disease
, I None
thrombocytopenia I Disease
and I None
progressive I None
renal I Disease
failure O Disease
associated I None
with I None
mitomycin I Chemical
C O Chemical
treatment I None
and I None
affects I None
about I None
10 I None
% I None
of I None
patients I None
treated I None
with I None
this I None
agent I None
. I None
<eof> I None

<s> O None
The I None
renal I Disease
failure O Disease
usually I None
develops I None
about I None
8 I None
- I None
10 I None
mth I None
after I None
start I None
of I None
mitomycin I Chemical
C O Chemical
treatment I None
and I None
the I None
mortality I None
is I None
approximately I None
60 I None
% I None
from I None
renal I Disease
failure O Disease
or I None
pulmonary I Disease
edema O Disease
. I None
<eof> I None

<s> O None
Renal I Disease
lesions O Disease
are I None
similar I None
to I None
those I None
seen I None
in I None
idiopathic I None
HUS I Disease
and I None
include I None
arteriolar I None
fibrin I None
thrombi I Disease
, I None
expanded I None
subendothelial I None
zones I None
in I None
glomerular I None
capillary I None
walls I None
, I None
ischemic I Disease
wrinkling I None
of I None
glomerular I None
basement I None
membranes I None
and I None
mesangiolysis I None
. I None
<eof> I None

<s> O None
The I None
mechanism I None
of I None
action I None
is I None
postulated I None
as I None
mitomycin I Chemical
C O Chemical
<eof> I None

<s> O None
-induced I None
endothelial I None
cell I None
damage I None
. I None
<eof> I None

<s> O None
We I None
describe I None
the I None
clinical I None
course I None
and I None
pathological I None
findings I None
in I None
a I None
65 I None
yr I None
- I None
old I None
man I None
with I None
gastric I Disease
adenocarcinoma O Disease
who I None
developed I None
renal I Disease
failure O Disease
and I None
thrombocytopenia I Disease
while I None
on I None
treatment I None
with I None
mitomycin I Chemical
C O Chemical
and I None
died I None
in I None
pulmonary I Disease
edema O Disease
. I None
<eof> I None

<s> O None
Continuous I None
ambulatory I None
ECG I None
monitoring I None
during I None
fluorouracil I Chemical
therapy I None
: I None
a I None
prospective I None
study I None
. I None
<eof> I None

<s> O None
Although I None
there I None
have I None
been I None
anecdotal I None
reports I None
of I None
cardiac I Disease
toxicity O Disease
associated I None
with I None
fluorouracil I Chemical
<eof> I None

<s> O None
( I None
5-FU I Chemical
) I None
therapy I None
, I None
this I None
phenomenon I None
has I None
not I None
been I None
studied I None
in I None
a I None
systematic I None
fashion I None
. I None
<eof> I None

<s> O None
We I None
prospectively I None
performed I None
continuous I None
ambulatory I None
ECG I None
monitoring I None
on I None
25 I None
patients I None
undergoing I None
5-FU I Chemical
infusion I None
for I None
treatment I None
of I None
solid I None
tumors I Disease
in I None
order I None
to I None
assess I None
the I None
incidence I None
of I None
ischemic I Disease
ST I None
changes I None
. I None
<eof> I None

<s> O None
Patients I None
were I None
monitored I None
for I None
23 I None
+ I None
/- I None
<eof> I None

<s> O None
4 I None
hours I None
before I None
5-FU I Chemical
infusion I None
, I None
and I None
98 I None
+ I None
/- I None
<eof> I None

<s> O None
9 I None
hours I None
during I None
5-FU I Chemical
infusion I None
. I None
<eof> I None

<s> O None
Anginal I Disease
episodes I None
were I None
rare I None
: I None
only I None
one I None
patient I None
had I None
angina I Disease
( I None
during I None
5-FU I Chemical
infusion I None
) I None
. I None
<eof> I None

<s> O None
However I None
, I None
asymptomatic I None
ST I None
changes I None
( I None
greater I None
than I None
or I None
equal I None
to I None
1 I None
mm I None
ST I None
deviation I None
) I None
were I None
common I None
: I None
six I None
of I None
25 I None
patients I None
( I None
24 I None
% I None
) I None
had I None
ST I None
changes I None
before I None
5-FU I Chemical
infusion I None
<eof> I None

<s> O None
v I None
17 I None
( I None
68 I None
% I None
) I None
during I None
5-FU I Chemical
infusion I None
( I None
P I None
less I None
than I None
.002 I None
) I None
. I None
<eof> I None

<s> O None
The I None
incidence I None
of I None
ischemic I Disease
episodes I None
per I None
patient I None
per I None
hour I None
was I None
0.05 I None
+ I None
/- I None
<eof> I None

<s> O None
0.02 I None
prior I None
to I None
5-FU I Chemical
infusion I None
v I None
0.13 I None
+ I None
/- I None
0.03 I None
during I None
5-FU I Chemical
infusion I None
( I None
P I None
less I None
than I None
.001 I None
) I None
; I None
the I None
duration I None
of I None
ECG I None
changes I None
was I None
0.6 I None
+ I None
/- I None
0.3 I None
minutes I None
per I None
patient I None
per I None
hour I None
before I None
<eof> I None

<s> O None
5-FU I Chemical
<eof> I None

<s> O None
v I None
1.9 I None
+ I None
/- I None
<eof> I None

<s> O None
0.5 I None
minutes I None
per I None
patient I None
per I None
hour I None
during I None
5-FU I Chemical
<eof> I None

<s> O None
( I None
P I None
less I None
than I None
.01 I None
) I None
. I None
<eof> I None

<s> O None
ECG I None
changes I None
were I None
more I None
common I None
among I None
patients I None
with I None
known I None
coronary I Disease
artery O Disease
disease O Disease
. I None
<eof> I None

<s> O None
There I None
were I None
two I None
cases I None
of I None
sudden I Disease
death O Disease
, I None
both I None
of I None
which I None
occurred I None
at I None
the I None
end I None
of I None
the I None
chemotherapy I None
course I None
. I None
<eof> I None

<s> O None
We I None
conclude I None
that I None
5-FU I Chemical
infusion I None
is I None
associated I None
with I None
a I None
significant I None
increase I None
in I None
silent I None
ST I None
segment I None
deviation I None
suggestive I None
of I None
ischemia I Disease
, I None
particularly I None
among I None
patients I None
with I None
coronary I Disease
artery O Disease
disease O Disease
. I None
<eof> I None

<s> O None
The I None
mechanism I None
and I None
clinical I None
significance I None
of I None
these I None
ECG I None
changes I None
remain I None
to I None
be I None
determined I None
. I None
<eof> I None

<s> O None
Lethal I None
anuria I Disease
<eof> I None

<s> O None
complicating I None
high I None
dose I None
ifosfamide I Chemical
chemotherapy I None
in I None
a I None
breast I Disease
cancer O Disease
patient I None
with I None
an I None
impaired I Disease
renal O Disease
function O Disease
. I None
<eof> I None

<s> O None
A I None
sixty I None
- I None
year I None
- I None
old I None
woman I None
with I None
advanced I None
breast I Disease
cancer O Disease
, I None
previously I None
treated I None
with I None
cisplatin I Chemical
, I None
developed I None
an I None
irreversible I None
lethal I None
renal I Disease
failure O Disease
with I None
anuria I Disease
, I None
the I None
day I None
after I None
5 I None
g I None
/ I None
m2 I None
bolus I None
ifosfamide I Chemical
. I None
<eof> I None

<s> O None
Postrenal I Disease
failure O Disease
was I None
excluded I None
by I None
echography I None
. I None
<eof> I None

<s> O None
A I None
prerenal I None
component I None
could I None
have I None
contributed I None
to I None
renal I Disease
failure O Disease
because I None
of I None
a I None
transient I None
hypotension I Disease
, I None
due I None
to I None
an I None
increasing I None
ascitis I None
, I None
occurring I None
just I None
before I None
anuria I Disease
. I None
<eof> I None

<s> O None
However I None
, I None
correction I None
of I None
the I None
hemodynamic I None
parameters I None
did I None
not I None
improve I None
renal I None
function I None
. I None
<eof> I None

<s> O None
Ifosfamide I Chemical
is I None
a I None
known I None
nephrotoxic I Disease
drug I None
with I None
demonstrated I None
tubulopathies I Disease
. I None
<eof> I None

<s> O None
We I None
strongly I None
suspect I None
that I None
this I None
lethal I None
anuria I Disease
was I None
mainly I None
due I None
to I None
ifosfamide I Chemical
, I None
occurring I None
in I None
a I None
patient I None
having I None
received I None
previous I None
cisplatin I Chemical
chemotherapy I None
and I None
with I None
poor I None
kidney I None
perfusion I None
due I None
to I None
transient I None
hypotension I Disease
. I None
<eof> I None

<s> O None
We I None
recommend I None
careful I None
use I None
of I None
ifosfamide I Chemical
in I None
patients I None
pretreated I None
with I None
nephrotoxic I Disease
chemotherapy I None
and I None
inadequate I None
renal I None
perfusion I None
. I None
<eof> I None

<s> O None
Central I None
vein I Disease
thrombosis O Disease
and I None
topical I None
dipivalyl I Chemical
epinephrine O Chemical
. I None
<eof> I None

<s> O None
A I None
report I None
is I None
given I None
on I None
an I None
83-year I None
- I None
old I None
female I None
who I None
acquired I None
central I None
vein I Disease
thrombosis O Disease
in I None
her I None
seeing I None
eye I None
one I None
day I None
after I None
having I None
started I None
topical I None
medication I None
with I None
dipivalyl I Chemical
epinephrine O Chemical
for I None
advanced I None
glaucoma I Disease
discovered I None
in I None
the I None
other I None
eye I None
. I None
<eof> I None

<s> O None
From I None
present I None
knowledge I None
about I None
the I None
effects I None
of I None
adrenergic I None
eye I None
drops I None
on I None
ocular I None
blood I None
circulation I None
, I None
it I None
is I None
difficult I None
to I None
suggest I None
an I None
association I None
between I None
the I None
two I None
events I None
, I None
which I None
may I None
be I None
coincidental I None
only I None
. I None
<eof> I None

<s> O None
Amelioration I None
of I None
bendrofluazide I Chemical
-induced I None
<eof> I None

<s> O None
hypokalemia I Disease
by I None
timolol I Chemical
. I None
<eof> I None

<s> O None
The I None
beta I None
adrenergic I None
blocking I None
drug I None
, I None
timolol I Chemical
, I None
tended I None
to I None
correct I None
the I None
hypokalemia I Disease
of I None
short I None
- I None
term I None
bendrofluazide I Chemical
treatment I None
in I None
6 I None
healthy I None
male I None
subjects I None
and I None
although I None
the I None
effect I None
was I None
small I None
it I None
was I None
significant I None
. I None
<eof> I None

<s> O None
Timolol I Chemical
also I None
reduced I None
the I None
rise I None
in I None
plasma I None
aldosterone I Chemical
and I None
urine I None
potassium I Chemical
excretion I None
following I None
bendrofluazide I Chemical
and I None
increased I None
the I None
urine I None
sodium I Chemical
/ I None
potassium I Chemical
ratio I None
. I None
<eof> I None

<s> O None
There I None
was I None
no I None
evidence I None
of I None
a I None
shift I None
of I None
potassium I Chemical
from I None
the I None
intracellular I None
to I None
the I None
extracellular I None
space I None
. I None
<eof> I None

<s> O None
A I None
cross I None
- I None
sectional I None
evaluation I None
of I None
the I None
effect I None
of I None
risperidone I Chemical
and I None
selective I None
serotonin I Chemical
reuptake I None
inhibitors I None
on I None
bone I None
mineral I None
density I None
in I None
boys I None
. I None
<eof> I None

<s> O None
OBJECTIVE I None
: I None
<eof> I None

<s> O None
The I None
aim I None
of I None
the I None
present I None
study I None
was I None
to I None
investigate I None
the I None
effect I None
of I None
risperidone I Chemical
-induced I None
<eof> I None

<s> O None
hyperprolactinemia I Disease
on I None
trabecular I None
bone I None
mineral I None
density I None
( I None
BMD I None
) I None
in I None
children I None
and I None
adolescents I None
. I None
<eof> I None

<s> O None
METHOD I None
: I None
<eof> I None

<s> O None
Medically I None
healthy I None
<eof> I None

<s> O None
7- I None
to I None
17-year I None
- I None
old I None
males I None
chronically I None
treated I None
, I None
in I None
a I None
naturalistic I None
setting I None
, I None
with I None
risperidone I Chemical
were I None
recruited I None
for I None
this I None
cross I None
- I None
sectional I None
study I None
through I None
child I None
psychiatry I None
outpatient I None
clinics I None
between I None
November I None
2005 I None
and I None
June I None
2007 I None
. I None
<eof> I None

<s> O None
Anthropometric I None
measurements I None
and I None
laboratory I None
testing I None
were I None
conducted I None
. I None
<eof> I None

<s> O None
The I None
clinical I None
diagnoses I None
were I None
based I None
on I None
chart I None
review I None
, I None
and I None
developmental I None
and I None
treatment I None
history I None
was I None
obtained I None
from I None
the I None
medical I None
record I None
. I None
<eof> I None

<s> O None
Volumetric I None
BMD I None
of I None
the I None
ultradistal I None
radius I None
was I None
measured I None
using I None
peripheral I None
quantitative I None
computed I None
tomography I None
, I None
and I None
areal I None
BMD I None
of I None
the I None
lumbar I None
spine I None
was I None
estimated I None
using I None
dual I None
- I None
energy I None
x I None
- I None
ray I None
absorptiometry I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
Hyperprolactinemia I Disease
was I None
present I None
in I None
49 I None
% I None
of I None
83 I None
boys I None
( I None
n I None
= I None
41 I None
) I None
treated I None
with I None
risperidone I Chemical
for I None
a I None
mean I None
of I None
2.9 I None
years I None
. I None
<eof> I None

<s> O None
Serum I None
testosterone I Chemical
<eof> I None

<s> O None
concentration I None
increased I None
with I None
pubertal I None
status I None
but I None
was I None
not I None
affected I None
by I None
hyperprolactinemia I Disease
. I None
<eof> I None

<s> O None
As I None
expected I None
, I None
bone I None
mineral I None
content I None
and I None
BMD I None
increased I None
with I None
sexual I None
maturity I None
. I None
<eof> I None

<s> O None
After I None
adjusting I None
for I None
the I None
stage I None
of I None
sexual I None
development I None
and I None
height I None
and I None
BMI I None
z I None
scores I None
, I None
serum I None
prolactin I None
was I None
negatively I None
associated I None
with I None
trabecular I None
volumetric I None
BMD I None
at I None
the I None
ultradistal I None
radius I None
( I None
P I None
< I None
.03 I None
) I None
. I None
<eof> I None

<s> O None
Controlling I None
for I None
relevant I None
covariates I None
, I None
we I None
also I None
found I None
treatment I None
with I None
selective I None
serotonin I Chemical
reuptake I None
inhibitors I None
( I None
SSRIs I None
) I None
to I None
be I None
associated I None
with I None
lower I None
trabecular I None
BMD I None
at I None
the I None
radius I None
( I None
P I None
= I None
.03 I None
) I None
and I None
BMD I None
z I None
score I None
at I None
the I None
lumbar I None
spine I None
( I None
P I None
< I None
.05 I None
) I None
. I None
<eof> I None

<s> O None
These I None
findings I None
became I None
more I None
marked I None
when I None
the I None
analysis I None
was I None
restricted I None
to I None
non I None
- I None
Hispanic I None
white I None
patients I None
. I None
<eof> I None

<s> O None
Of I None
13 I None
documented I None
fractures I Disease
, I None
3 I None
occurred I None
after I None
risperidone I Chemical
and I None
SSRIs I None
were I None
started I None
, I None
and I None
none I None
occurred I None
in I None
patients I None
with I None
hyperprolactinemia I Disease
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
This I None
is I None
the I None
first I None
study I None
to I None
link I None
risperidone I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
hyperprolactinemia I Disease
and I None
SSRI I None
treatment I None
to I None
lower I None
BMD I None
in I None
children I None
and I None
adolescents I None
. I None
<eof> I None

<s> O None
Future I None
research I None
should I None
evaluate I None
the I None
longitudinal I None
course I None
of I None
this I None
adverse I None
event I None
to I None
determine I None
its I None
temporal I None
stability I None
and I None
whether I None
a I None
higher I None
fracture I None
rate I None
ensues I None
. I None
<eof> I None

<s> O None
Seizures I Disease
associated I None
with I None
levofloxacin I Chemical
: I None
case I None
presentation I None
and I None
literature I None
review I None
. I None
<eof> I None

<s> O None
PURPOSE I None
: I None
<eof> I None

<s> O None
We I None
present I None
a I None
case I None
of I None
a I None
patient I None
who I None
developed I None
seizures I Disease
shortly I None
after I None
initiating I None
treatment I None
with I None
levofloxacin I Chemical
and I None
to I None
discuss I None
the I None
potential I None
drug I None
- I None
drug I None
interactions I None
related I None
to I None
the I None
inhibition I None
of I None
cytochrome I None
P450 I None
( I None
CYP I None
) I None
<eof> I None

<s> O None
1A2 I None
in I None
this I None
case I None
, I None
as I None
well I None
as I None
in I None
other I None
cases I None
, I None
of I None
levofloxacin I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
seizures I Disease
. I None
<eof> I None

<s> O None
METHODS I None
: I None
<eof> I None

<s> O None
Several I None
biomedical I None
databases I None
were I None
searched I None
including I None
MEDLINE I None
, I None
Cochrane I None
and I None
Ovid I None
. I None
<eof> I None

<s> O None
The I None
main I None
search I None
terms I None
utilized I None
were I None
case I None
report I None
and I None
levofloxacin I Chemical
. I None
<eof> I None

<s> O None
The I None
search I None
was I None
limited I None
to I None
studies I None
published I None
in I None
English I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
Six I None
cases I None
of I None
levofloxacin I Chemical
-induced I None
seizures I Disease
have I None
been I None
reported I None
in I None
the I None
literature I None
. I None
<eof> I None

<s> O None
Drug I None
- I None
drug I None
interactions I None
related I None
to I None
the I None
inhibition I None
of I None
CYP1A2 I None
by I None
levofloxacin I Chemical
are I None
likely I None
involved I None
in I None
the I None
clinical I None
outcome I None
of I None
these I None
cases I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
Clinicians I None
are I None
exhorted I None
to I None
pay I None
close I None
attention I None
when I None
initiating I None
levofloxacin I Chemical
therapy I None
in I None
patients I None
taking I None
medications I None
with I None
epileptogenic I None
properties I None
that I None
are I None
CYP1A2 I None
substrates I None
. I None
<eof> I None

<s> O None
Mice I None
lacking I None
mPGES-1 I None
are I None
resistant I None
to I None
lithium I Chemical
<eof> I None

<s> O None
-induced I None
polyuria I Disease
. I None
<eof> I None

<s> O None
Cyclooxygenase-2 I None
activity I None
is I None
required I None
for I None
the I None
development I None
of I None
lithium I Chemical
-induced I None
polyuria I Disease
. I None
<eof> I None

<s> O None
However I None
, I None
the I None
involvement I None
of I None
a I None
specific I None
, I None
terminal I None
prostaglandin I Chemical
<eof> I None

<s> O None
( I None
PG I Chemical
) I None
isomerase I None
has I None
not I None
been I None
evaluated I None
. I None
<eof> I None

<s> O None
The I None
present I None
study I None
was I None
undertaken I None
to I None
assess I None
<eof> I None

<s> O None
lithium I Chemical
-induced I None
<eof> I None

<s> O None
polyuria I Disease
in I None
mice I None
deficient I None
in I None
microsomal I None
prostaglandin I Chemical
E O Chemical
<eof> I None

<s> O None
synthase-1 I None
( I None
<eof> I None

<s> O None
mPGES-1 I None
) I None
. I None
<eof> I None

<s> O None
A I None
2-wk I None
administration I None
of I None
LiCl I Chemical
<eof> I None

<s> O None
( I None
4 I None
mmol.kg(-1).day(-1 I None
) I None
<eof> I None

<s> O None
ip I None
) I None
in I None
mPGES-1 I None
+ I None
<eof> I None

<s> O None
/+ I None
mice I None
led I None
to I None
a I None
marked I None
polyuria I Disease
with I None
hyposmotic I None
urine I None
. I None
<eof> I None

<s> O None
This I None
was I None
associated I None
with I None
elevated I None
renal I None
mPGES-1 I None
protein I None
expression I None
and I None
increased I None
urine I None
PGE(2 I Chemical
) O Chemical
excretion I None
. I None
<eof> I None

<s> O None
In I None
contrast I None
, I None
mPGES-1 I None
-/- I None
mice I None
were I None
largely I None
resistant I None
to I None
lithium I Chemical
-induced I None
polyuria I Disease
and I None
a I None
urine I None
concentrating I None
defect I None
, I None
accompanied I None
by I None
nearly I None
complete I None
blockade I None
of I None
high I None
urine I None
PGE(2 I Chemical
) O Chemical
and I None
cAMP I None
output I None
. I None
<eof> I None

<s> O None
Immunoblotting I None
, I None
immunohistochemistry I None
, I None
and I None
quantitative I None
( I None
q I None
) I None
RT I None
- I None
PCR I None
consistently I None
detected I None
a I None
significant I None
decrease I None
in I None
aquaporin-2 I None
( I None
AQP2 I None
) I None
protein I None
expression I None
in I None
both I None
the I None
renal I None
cortex I None
and I None
medulla I None
of I None
<eof> I None

<s> O None
lithium I Chemical
-treated I None
<eof> I None

<s> O None
+ I None
/+ I None
mice I None
. I None
<eof> I None

<s> O None
This I None
decrease I None
was I None
significantly I None
attenuated I None
in I None
the I None
-/- I None
mice I None
. I None
<eof> I None

<s> O None
qRT I None
- I None
PCR I None
detected I None
similar I None
patterns I None
of I None
changes I None
in I None
AQP2 I None
mRNA I None
in I None
the I None
medulla I None
but I None
not I None
in I None
the I None
cortex I None
. I None
<eof> I None

<s> O None
Similarly I None
, I None
the I None
total I None
protein I None
abundance I None
of I None
the I None
Na I Chemical
- I None
K I Chemical
-2 I None
<eof> I None

<s> O None
Cl I Chemical
<eof> I None

<s> O None
cotransporter I None
( I None
NKCC2 I None
) I None
in I None
the I None
medulla I None
but I None
not I None
in I None
the I None
cortex I None
of I None
the I None
+ I None
/+ I None
<eof> I None

<s> O None
mice I None
was I None
significantly I None
reduced I None
by I None
lithium I Chemical
treatment I None
. I None
<eof> I None

<s> O None
In I None
contrast I None
, I None
the I None
dowregulation I None
of I None
renal I None
medullary I None
NKCC2 I None
expression I None
was I None
significantly I None
attenuated I None
in I None
the I None
-/- I None
mice I None
. I None
<eof> I None

<s> O None
We I None
conclude I None
that I None
mPGES-1-derived I None
PGE(2 I Chemical
) O Chemical
mediates I None
<eof> I None

<s> O None
lithium I Chemical
-induced I None
<eof> I None

<s> O None
polyuria I Disease
likely I None
via I None
inhibition I None
of I None
AQP2 I None
and I None
NKCC2 I None
expression I None
. I None
<eof> I None

<s> O None
Identification I None
of I None
a I None
simple I None
and I None
sensitive I None
microplate I None
method I None
for I None
the I None
detection I None
of I None
oversulfated I None
chondroitin I Chemical
sulfate O Chemical
in I None
heparin I Chemical
products I None
. I None
<eof> I None

<s> O None
Heparin I Chemical
is I None
a I None
commonly I None
implemented I None
anticoagulant I None
used I None
to I None
treat I None
critically I None
ill I None
patients I None
. I None
<eof> I None

<s> O None
Recently I None
, I None
a I None
number I None
of I None
commercial I None
lots I None
of I None
heparin I Chemical
products I None
were I None
found I None
to I None
be I None
contaminated I None
with I None
an I None
oversulfated I None
chondroitin I Chemical
sulfate O Chemical
<eof> I None

<s> O None
( I None
OSCS I None
) I None
derivative I None
that I None
could I None
elicit I None
a I None
hypotensive I Disease
response I None
in I None
pigs I None
following I None
a I None
single I None
high I None
- I None
dose I None
infusion I None
. I None
<eof> I None

<s> O None
Using I None
both I None
contaminated I None
heparin I Chemical
products I None
and I None
the I None
synthetically I None
produced I None
derivative I None
<eof> I None

<s> O None
, I None
we I None
showed I None
that I None
the I None
OSCS I None
produces I None
dose I None
- I None
dependent I None
hypotension I Disease
in I None
pigs I None
. I None
<eof> I None

<s> O None
The I None
no I None
observed I None
effect I None
level I None
( I None
NOEL I None
) I None
for I None
this I None
contaminant I None
appears I None
to I None
be I None
approximately I None
1mg I None
/ I None
kg I None
, I None
corresponding I None
to I None
a I None
contamination I None
level I None
of I None
approximately I None
3 I None
% I None
. I None
<eof> I None

<s> O None
We I None
also I None
demonstrated I None
that I None
OSCS I None
can I None
be I None
identified I None
in I None
heparin I Chemical
products I None
using I None
a I None
simple I None
, I None
inexpensive I None
, I None
commercially I None
available I None
heparin I Chemical
enzyme I None
immunoassay I None
( I None
EIA I None
) I None
kit I None
that I None
has I None
a I None
limit I None
of I None
detection I None
of I None
approximately I None
0.1 I None
% I None
, I None
well I None
below I None
the I None
NOEL I None
. I None
<eof> I None

<s> O None
This I None
kit I None
may I None
provide I None
a I None
useful I None
method I None
to I None
test I None
heparin I Chemical
products I None
for I None
contamination I None
with I None
oversulfated I None
GAG I None
derivatives I None
. I None
<eof> I None

<s> O None
Doxorubicin I Chemical
<eof> I None

<s> O None
cardiomyopathy I Disease
-induced I None
<eof> I None

<s> O None
inflammation I Disease
and I None
apoptosis I None
are I None
attenuated I None
by I None
gene I None
deletion I None
of I None
the I None
kinin I None
B1 I None
receptor I None
. I None
<eof> I None

<s> O None
Clinical I None
use I None
of I None
the I None
anthracycline I Chemical
doxorubicin I Chemical
<eof> I None

<s> O None
( I None
DOX I Chemical
) I None
is I None
limited I None
by I None
its I None
cardiotoxic I Disease
effects I None
, I None
which I None
are I None
attributed I None
to I None
the I None
induction I None
of I None
apoptosis I None
. I None
<eof> I None

<s> O None
To I None
elucidate I None
the I None
possible I None
role I None
of I None
the I None
kinin I None
B1 I None
receptor I None
( I None
B1R I None
) I None
during I None
the I None
development I None
of I None
DOX I Chemical
<eof> I None

<s> O None
cardiomyopathy I Disease
, I None
we I None
studied I None
B1R I None
knockout I None
mice I None
( I None
B1R(-/- I None
) I None
) I None
by I None
investigating I None
cardiac I None
inflammation I Disease
and I None
apoptosis I None
after I None
induction I None
of I None
DOX I Chemical
-induced I None
cardiomyopathy I Disease
. I None
<eof> I None

<s> O None
DOX I Chemical
control I None
mice I None
showed I None
cardiac I Disease
dysfunction O Disease
<eof> I None

<s> O None
measured I None
by I None
pressure I None
- I None
volume I None
loops I None
in I None
vivo I None
. I None
<eof> I None

<s> O None
This I None
was I None
associated I None
with I None
a I None
reduced I None
activation I None
state I None
of I None
AKT I None
, I None
as I None
well I None
as I None
an I None
increased I None
bax I None
/ I None
bcl2 I None
ratio I None
in I None
Western I None
blots I None
, I None
indicating I None
cardiac I Disease
apoptosis O Disease
. I None
<eof> I None

<s> O None
Furthermore I None
, I None
mRNA I None
levels I None
of I None
the I None
proinflammatory I None
cytokine I None
interleukin I None
6 I None
were I None
increased I None
in I None
the I None
cardiac I None
tissue I None
. I None
<eof> I None

<s> O None
In I None
DOX I Chemical
B1R(-/- I None
) I None
mice I None
, I None
cardiac I Disease
dysfunction O Disease
was I None
improved I None
compared I None
to I None
DOX I Chemical
control I None
mice I None
, I None
which I None
was I None
associated I None
with I None
normalization I None
of I None
the I None
bax I None
/ I None
bcl-2 I None
ratio I None
and I None
interleukin I None
6 I None
, I None
as I None
well I None
as I None
AKT I None
activation I None
state I None
. I None
<eof> I None

<s> O None
These I None
findings I None
suggest I None
that I None
B1R I None
is I None
detrimental I None
in I None
DOX I Chemical
<eof> I None

<s> O None
cardiomyopathy I Disease
<eof> I None

<s> O None
in I None
that I None
it I None
mediates I None
the I None
inflammatory I None
response I None
and I None
apoptosis I None
. I None
<eof> I None

<s> O None
These I None
insights I None
might I None
have I None
useful I None
implications I None
for I None
future I None
studies I None
utilizing I None
B1R I None
antagonists I None
for I None
treatment I None
of I None
human I None
DOX I Chemical
cardiomyopathy I Disease
. I None
<eof> I None

<s> O None
Hepatotoxicity I Disease
associated I None
with I None
sulfasalazine I Chemical
in I None
inflammatory I None
arthritis I Disease
: I None
<eof> I None

<s> O None
A I None
case I None
series I None
from I None
a I None
local I None
surveillance I None
of I None
serious I None
adverse I None
events I None
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
<eof> I None

<s> O None
Spontaneous I None
reporting I None
systems I None
for I None
adverse I None
drug I None
reactions I None
( I None
ADRs I None
) I None
are I None
handicapped I None
by I None
under I None
- I None
reporting I None
and I None
limited I None
detail I None
on I None
individual I None
cases I None
. I None
<eof> I None

<s> O None
We I None
report I None
an I None
investigation I None
from I None
a I None
local I None
surveillance I None
for I None
serious I None
adverse I None
drug I None
reactions I None
associated I None
with I None
disease I None
modifying I None
anti I None
- I None
rheumatic I None
drugs I None
that I None
was I None
triggered I None
by I None
the I None
occurrence I None
of I None
liver I Disease
failure O Disease
in I None
two I None
of I None
our I None
patients I None
. I None
<eof> I None

<s> O None
METHODS I None
: I None
<eof> I None

<s> O None
Serious I None
ADR I None
reports I None
have I None
been I None
solicited I None
from I None
local I None
clinicians I None
by I None
regular I None
postcards I None
over I None
the I None
past I None
seven I None
years I None
. I None
<eof> I None

<s> O None
Patients I None
' I None
, I None
who I None
had I None
hepatotoxicity I Disease
on I None
sulfasalazine I Chemical
and I None
met I None
a I None
definition I None
of I None
a I None
serious I None
ADR I None
, I None
were I None
identified I None
. I None
<eof> I None

<s> O None
Two I None
clinicians I None
reviewed I None
structured I None
case I None
reports I None
and I None
assessed I None
causality I None
by I None
consensus I None
and I None
by I None
using I None
a I None
causality I None
assessment I None
instrument I None
. I None
<eof> I None

<s> O None
The I None
likely I None
frequency I None
of I None
hepatotoxicity I Disease
with I None
sulfasalazine I Chemical
was I None
estimated I None
by I None
making I None
a I None
series I None
of I None
conservative I None
assumptions I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
Ten I None
cases I None
were I None
identified I None
: I None
eight I None
occurred I None
during I None
surveillance I None
. I None
<eof> I None

<s> O None
Eight I None
patients I None
were I None
hospitalised I None
, I None
two I None
in I None
<eof> I None

<s> O None
hepatic I Disease
failure O Disease
- I None
one I None
died I None
after I None
a I None
liver I None
transplant I None
. I None
<eof> I None

<s> O None
All I None
but I None
one I None
event I None
occurred I None
within I None
6 I None
weeks I None
of I None
treatment I None
. I None
<eof> I None

<s> O None
Seven I None
patients I None
had I None
a I None
skin I Disease
rash O Disease
, I None
three I None
eosinophilia I Disease
and I None
one I None
interstitial I Disease
nephritis O Disease
. I None
<eof> I None

<s> O None
Five I None
patients I None
were I None
of I None
Black I None
British I None
of I None
African I None
or I None
Caribbean I None
descent I None
. I None
<eof> I None

<s> O None
Liver I None
enzymes I None
showed I None
a I None
hepatocellular I None
pattern I None
in I None
four I None
cases I None
and I None
a I None
mixed I None
pattern I None
in I None
six I None
. I None
<eof> I None

<s> O None
Drug I None
- I None
related I None
<eof> I None

<s> O None
hepatotoxicity I Disease
was I None
judged I None
probable I None
or I None
highly I None
probable I None
in I None
8 I None
patients I None
. I None
<eof> I None

<s> O None
The I None
likely I None
frequency I None
of I None
serious I None
hepatotoxicity I Disease
with I None
sulfasalazine I Chemical
was I None
estimated I None
at I None
0.4 I None
% I None
of I None
treated I None
patients I None
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
<eof> I None

<s> O None
Serious I None
hepatotoxicity I Disease
associated I None
with I None
sulfasalazine I Chemical
appears I None
to I None
be I None
under I None
- I None
appreciated I None
and I None
intensive I None
monitoring I None
and I None
vigilance I None
in I None
the I None
first I None
6 I None
weeks I None
of I None
treatment I None
is I None
especially I None
important I None
. I None
<eof> I None

<s> O None
An I None
evaluation I None
of I None
amikacin I Chemical
nephrotoxicity I Disease
in I None
the I None
hematology I None
/ I None
oncology I None
population I None
. I None
<eof> I None

<s> O None
Amikacin I Chemical
is I None
an I None
aminoglycoside I Chemical
commonly I None
used I None
to I None
provide I None
empirical I None
double I None
gram I None
- I None
negative I None
treatment I None
for I None
febrile I Disease
neutropenia O Disease
and I None
other I None
suspected I None
infections I Disease
. I None
<eof> I None

<s> O None
Strategies I None
of I None
extended I None
- I None
interval I None
and I None
conventional I None
dosing I None
have I None
been I None
utilized I None
extensively I None
in I None
the I None
general I None
medical I None
population I None
; I None
however I None
, I None
data I None
are I None
lacking I None
to I None
support I None
a I None
dosing I None
strategy I None
in I None
the I None
hematology I None
/ I None
oncology I None
population I None
. I None
<eof> I None

<s> O None
To I None
evaluate I None
amikacin I Chemical
-associated I None
nephrotoxicity I Disease
in I None
an I None
adult I None
hematology I None
/ I None
oncology I None
population I None
, I None
a I None
prospective I None
, I None
randomized I None
, I None
open I None
- I None
label I None
trial I None
was I None
conducted I None
at I None
a I None
university I None
- I None
affiliated I None
medical I None
center I None
. I None
<eof> I None

<s> O None
Forty I None
patients I None
with I None
a I None
diagnosis I None
consistent I None
with I None
a I None
hematologic I None
/ I None
oncologic I None
disorder I None
that I None
required I None
treatment I None
with I None
an I None
aminoglycoside I Chemical
were I None
randomized I None
to I None
either I None
conventional I None
or I None
extended I None
- I None
interval I None
amikacin I Chemical
. I None
<eof> I None

<s> O None
The I None
occurrence I None
of I None
nephrotoxicity I Disease
by I None
means I None
of I None
an I None
increase I None
in I None
serum I None
creatinine I Chemical
and I None
evaluation I None
of I None
efficacy I None
via I None
amikacin I Chemical
serum I None
concentrations I None
with I None
respective I None
pathogens I None
were I None
assessed I None
. I None
<eof> I None

<s> O None
The I None
occurrence I None
of I None
nephrotoxicity I Disease
was I None
similar I None
between I None
the I None
conventional I None
and I None
extended I None
- I None
interval I None
groups I None
, I None
at I None
10 I None
% I None
and I None
5 I None
% I None
, I None
respectively I None
( I None
P I None
= I None
1.00 I None
) I None
. I None
<eof> I None

<s> O None
Six I None
patients I None
in I None
the I None
conventional I None
group I None
had I None
a I None
positive I None
culture I None
, I None
compared I None
with I None
none I None
in I None
the I None
extended I None
- I None
interval I None
group I None
( I None
P I None
= I None
0.002 I None
) I None
. I None
<eof> I None

<s> O None
The I None
occurrence I None
of I None
nephrotoxicity I Disease
was I None
similar I None
between I None
the I None
two I None
dosing I None
regimens I None
, I None
but I None
the I None
distribution I None
of I None
risk I None
factors I None
was I None
variable I None
between I None
the I None
two I None
groups I None
. I None
<eof> I None

<s> O None
Efficacy I None
could I None
not I None
be I None
assessed I None
. I None
<eof> I None

<s> O None
Memory I None
function I None
and I None
serotonin I Chemical
transporter I None
promoter I None
gene I None
polymorphism I None
in I None
ecstasy I Chemical
<eof> I None

<s> O None
( I None
MDMA I Chemical
) I None
users I None
. I None
<eof> I None

<s> O None
Although I None
3,4-methylenedioxymethamphetamine I Chemical
<eof> I None

<s> O None
( I None
MDMA I Chemical
or I None
ecstasy I Chemical
) I None
has I None
been I None
shown I None
to I None
damage I None
brain I None
serotonin I Chemical
<eof> I None

<s> O None
( I None
5-HT I Chemical
) I None
neurons I None
in I None
animals I None
and I None
possibly I None
humans I None
, I None
little I None
is I None
known I None
about I None
the I None
long I None
- I None
term I None
consequences I None
of I None
MDMA I Chemical
-induced I None
5-HT I Chemical
neurotoxic I Disease
lesions O Disease
on I None
functions I None
in I None
which I None
5-HT I Chemical
is I None
involved I None
, I None
such I None
as I None
cognitive I None
function I None
. I None
<eof> I None

<s> O None
Because I None
5-HT I Chemical
transporters I None
play I None
a I None
key I None
element I None
in I None
the I None
regulation I None
of I None
synaptic I None
5-HT I Chemical
transmission I None
it I None
may I None
be I None
important I None
to I None
control I None
for I None
the I None
potential I None
covariance I None
effect I None
of I None
a I None
polymorphism I None
in I None
the I None
5-HT I Chemical
transporter I None
promoter I None
gene I None
region I None
( I None
5-HTTLPR I None
) I None
when I None
studying I None
the I None
effects I None
of I None
MDMA I Chemical
as I None
well I None
as I None
cognitive I None
functioning I None
. I None
<eof> I None

<s> O None
The I None
aim I None
of I None
the I None
study I None
was I None
to I None
investigate I None
the I None
effects I None
of I None
moderate I None
and I None
heavy I None
MDMA I Chemical
use I None
on I None
cognitive I None
function I None
, I None
as I None
well I None
as I None
the I None
effects I None
of I None
long I None
- I None
term I None
abstention I None
from I None
MDMA I Chemical
, I None
in I None
subjects I None
genotyped I None
for I None
5-HTTLPR I None
. I None
<eof> I None

<s> O None
A I None
second I None
aim I None
of I None
the I None
study I None
was I None
to I None
determine I None
whether I None
these I None
effects I None
differ I None
for I None
females I None
and I None
males I None
. I None
<eof> I None

<s> O None
Fifteen I None
moderate I None
MDMA I Chemical
users I None
( I None
< I None
55 I None
lifetime I None
tablets I None
) I None
, I None
22 I None
heavy I None
MDMA I Chemical
+ I None
users I None
<eof> I None

<s> O None
( I None
> I None
55 I None
lifetime I None
tablets I None
) I None
, I None
<eof> I None

<s> O None
16 I None
ex- I None
<eof> I None

<s> O None
MDMA I Chemical
+ I None
users I None
<eof> I None

<s> O None
( I None
last I None
tablet I None
> I None
1 I None
year I None
ago I None
) I None
and I None
13 I None
controls I None
were I None
compared I None
on I None
a I None
battery I None
of I None
neuropsychological I None
tests I None
. I None
<eof> I None

<s> O None
DNA I None
from I None
peripheral I None
nuclear I None
blood I None
cells I None
was I None
genotyped I None
for I None
5-HTTLPR I None
using I None
standard I None
polymerase I None
chain I None
reaction I None
methods I None
. I None
<eof> I None

<s> O None
A I None
significant I None
group I None
effect I None
was I None
observed I None
only I None
on I None
memory I None
function I None
tasks I None
( I None
p I None
= I None
0.04 I None
) I None
but I None
not I None
on I None
reaction I None
times I None
( I None
p I None
= I None
0.61 I None
) I None
or I None
attention I None
/ I None
executive I None
functioning I None
( I None
p I None
= I None
0.59 I None
) I None
. I None
<eof> I None

<s> O None
Heavy I None
and I None
ex- I None
<eof> I None

<s> O None
MDMA I Chemical
+ I None
users I None
performed I None
significantly I None
poorer I None
on I None
memory I None
tasks I None
than I None
controls I None
. I None
<eof> I None

<s> O None
In I None
contrast I None
, I None
no I None
evidence I None
of I None
memory I Disease
impairment O Disease
was I None
observed I None
in I None
moderate I None
MDMA I Chemical
users I None
. I None
<eof> I None

<s> O None
No I None
significant I None
effect I None
of I None
5-HTTLPR I None
or I None
gender I None
was I None
observed I None
. I None
<eof> I None

<s> O None
While I None
the I None
use I None
of I None
MDMA I Chemical
in I None
quantities I None
that I None
may I None
be I None
considered I None
" I None
moderate I None
" I None
is I None
not I None
associated I None
with I None
impaired I Disease
memory O Disease
functioning O Disease
, I None
heavy I None
use I None
of I None
MDMA I Chemical
use I None
<eof> I None

<s> O None
may I None
lead I None
to I None
long I None
lasting I None
memory I Disease
impairments O Disease
. I None
<eof> I None

<s> O None
No I None
effect I None
of I None
5-HTTLPR I None
or I None
gender I None
on I None
memory I None
function I None
or I None
MDMA I Chemical
use I None
was I None
observed I None
. I None
<eof> I None

<s> O None
Aging I None
process I None
of I None
epithelial I None
cells I None
of I None
the I None
rat I None
prostate I None
lateral I None
lobe I None
in I None
experimental I None
hyperprolactinemia I Disease
induced I None
by I None
haloperidol I Chemical
. I None
<eof> I None

<s> O None
The I None
aim I None
of I None
the I None
study I None
was I None
to I None
examine I None
the I None
influence I None
of I None
hyperprolactinemia I Disease
, I None
induced I None
by I None
haloperidol I Chemical
<eof> I None

<s> O None
( I None
HAL I Chemical
) I None
on I None
age I None
related I None
morphology I None
and I None
function I None
changes I None
of I None
epithelial I None
cells I None
in I None
rat I None
prostate I None
lateral I None
lobe I None
. I None
<eof> I None

<s> O None
The I None
study I None
was I None
performed I None
on I None
sexually I None
mature I None
male I None
rats I None
. I None
<eof> I None

<s> O None
Serum I None
concentrations I None
of I None
prolactin I None
( I None
PRL I Chemical
) I None
and I None
testosterone I Chemical
<eof> I None

<s> O None
( I None
T I Chemical
) I None
were I None
measured I None
. I None
<eof> I None

<s> O None
Tissue I None
sections I None
were I None
evaluated I None
with I None
light I None
and I None
electron I None
microscopy I None
. I None
<eof> I None

<s> O None
Immunohistochemical I None
reactions I None
for I None
Anti I None
- I None
Proliferating I None
Cell I None
Nuclear I None
Antigen I None
( I None
PCNA I None
) I None
were I None
performed I None
. I None
<eof> I None

<s> O None
In I None
rats I None
of I None
the I None
experimental I None
group I None
, I None
the I None
mean I None
concentration I None
of I None
: I None
PRL I Chemical
was I None
more I None
than I None
twice I None
higher I None
, I None
whereas I None
T I Chemical
concentration I None
was I None
almost I None
twice I None
lower I None
than I None
that I None
in I None
the I None
control I None
group I None
. I None
<eof> I None

<s> O None
Light I None
microscopy I None
visualized I None
the I None
following I None
: I None
hypertrophy I Disease
and I None
epithelium I None
hyperplasia I Disease
of I None
the I None
glandular I None
ducts I None
, I None
associated I None
with I None
increased I None
PCNA I None
expression I None
. I None
<eof> I None

<s> O None
Electron I None
microscopy I None
revealed I None
changes I None
in I None
columnar I None
epithelial I None
cells I None
, I None
concerning I None
organelles I None
, I None
engaged I None
in I None
protein I None
synthesis I None
and I None
secretion I None
. I None
<eof> I None

<s> O None
Does I None
supplemental I None
<eof> I None

<s> O None
vitamin I Chemical
C O Chemical
increase I None
cardiovascular I Disease
disease O Disease
risk I None
in I None
women I None
with I None
diabetes I Disease
? I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
<eof> I None

<s> O None
Vitamin I Chemical
C O Chemical
acts I None
as I None
a I None
potent I None
antioxidant I None
; I None
however I None
, I None
it I None
can I None
also I None
be I None
a I None
prooxidant I None
and I None
glycate I None
protein I None
under I None
certain I None
circumstances I None
in I None
vitro I None
. I None
<eof> I None

<s> O None
These I None
observations I None
led I None
us I None
to I None
hypothesize I None
that I None
a I None
high I None
intake I None
of I None
vitamin I Chemical
C O Chemical
in I None
diabetic I Disease
persons I None
might I None
promote I None
atherosclerosis I Disease
. I None
<eof> I None

<s> O None
OBJECTIVE I None
: I None
<eof> I None

<s> O None
The I None
objective I None
was I None
to I None
examine I None
the I None
relation I None
between I None
vitamin I Chemical
C O Chemical
intake I None
and I None
mortality I None
from I None
cardiovascular I Disease
disease O Disease
. I None
<eof> I None

<s> O None
DESIGN I None
: I None
<eof> I None

<s> O None
We I None
studied I None
the I None
relation I None
between I None
vitamin I Chemical
C O Chemical
intake I None
and I None
mortality I None
from I None
total I None
cardiovascular I Disease
disease O Disease
<eof> I None

<s> O None
( I None
n I None
= I None
281 I None
) I None
, I None
coronary I Disease
artery O Disease
disease O Disease
( I None
n I None
= I None
175 I None
) I None
, I None
and I None
stroke I Disease
<eof> I None

<s> O None
( I None
n I None
= I None
57 I None
) I None
in I None
1923 I None
postmenopausal I None
women I None
who I None
reported I None
being I None
diabetic I Disease
at I None
baseline I None
. I None
<eof> I None

<s> O None
Diet I None
was I None
assessed I None
with I None
a I None
food I None
- I None
frequency I None
questionnaire I None
at I None
baseline I None
, I None
and I None
subjects I None
initially I None
free I None
of I None
coronary I Disease
artery O Disease
disease O Disease
were I None
prospectively I None
followed I None
for I None
15 I None
y. I None
RESULTS I None
: I None
<eof> I None

<s> O None
After I None
adjustment I None
for I None
cardiovascular I Disease
disease O Disease
risk I None
factors I None
, I None
type I None
of I None
<eof> I None

<s> O None
diabetes I Disease
medication I None
used I None
, I None
duration I None
of I None
diabetes I Disease
, I None
and I None
intakes I None
of I None
folate I Chemical
, I None
vitamin I Chemical
E O Chemical
, I None
and I None
beta I Chemical
- O Chemical
carotene O Chemical
, I None
<eof> I None

<s> O None
the I None
adjusted I None
relative I None
risks I None
of I None
total I None
cardiovascular I Disease
disease O Disease
mortality I None
were I None
1.0 I None
, I None
0.97 I None
, I None
1.11 I None
, I None
1.47 I None
, I None
and I None
1.84 I None
( I None
P I None
for I None
trend I None
< I None
0.01 I None
) I None
across I None
quintiles I None
of I None
total I None
vitamin I Chemical
C O Chemical
intake I None
from I None
food I None
and I None
supplements I None
. I None
<eof> I None

<s> O None
Adjusted I None
relative I None
risks I None
of I None
coronary I Disease
artery O Disease
disease O Disease
were I None
1.0 I None
, I None
0.81 I None
, I None
0.99 I None
, I None
1.26 I None
, I None
and I None
1.91 I None
( I None
P I None
for I None
trend I None
= I None
0.01 I None
) I None
and I None
of I None
stroke I Disease
were I None
1.0 I None
, I None
0.52 I None
, I None
1.23 I None
, I None
2.22 I None
, I None
and I None
2.57 I None
( I None
P I None
for I None
trend I None
< I None
0.01 I None
) I None
. I None
<eof> I None

<s> O None
When I None
dietary I None
and I None
supplemental I None
vitamin I Chemical
C O Chemical
were I None
analyzed I None
separately I None
, I None
only I None
supplemental I None
vitamin I Chemical
C O Chemical
showed I None
a I None
positive I None
association I None
with I None
mortality I None
endpoints I None
. I None
<eof> I None

<s> O None
Vitamin I Chemical
C O Chemical
intake I None
was I None
unrelated I None
to I None
mortality I None
from I None
cardiovascular I Disease
disease O Disease
in I None
the I None
nondiabetic I None
subjects I None
at I None
baseline I None
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
<eof> I None

<s> O None
A I None
high I None
vitamin I Chemical
C O Chemical
intake I None
from I None
supplements I None
is I None
associated I None
with I None
an I None
increased I None
risk I None
of I None
cardiovascular I Disease
disease O Disease
mortality I None
in I None
postmenopausal I None
women I None
with I None
diabetes I Disease
. I None
<eof> I None

<s> O None
Absolute I None
and I None
attributable I None
risk I None
of I None
venous I Disease
thromboembolism O Disease
in I None
women I None
on I None
combined I None
cyproterone I Chemical
acetate O Chemical
and I None
ethinylestradiol I Chemical
. I None
<eof> I None

<s> O None
OBJECTIVE I None
: I None
<eof> I None

<s> O None
To I None
achieve I None
absolute I None
risk I None
estimates I None
of I None
venous I Disease
thromboembolism O Disease
<eof> I None

<s> O None
( I None
VTE I Disease
) I None
among I None
women I None
on I None
cyproterone I Chemical
acetate O Chemical
plus I None
ethinylestradiol I Chemical
<eof> I None

<s> O None
( I None
CPA I Chemical
/ I None
EE I Chemical
) I None
, I None
and I None
among I None
women I None
on I None
combined I Chemical
oral O Chemical
contraceptives O Chemical
<eof> I None

<s> O None
( I None
COCs I Chemical
) I None
. I None
<eof> I None

<s> O None
METHODS I None
: I None
<eof> I None

<s> O None
From I None
the I None
Danish I None
National I None
Register I None
of I None
Patients I None
( I None
NRP I None
) I None
, I None
1996 I None
to I None
1998 I None
, I None
the I None
records I None
of I None
1.1 I None
million I None
Danish I None
women I None
, I None
ages I None
15 I None
to I None
44 I None
years I None
, I None
were I None
searched I None
for I None
evidence I None
of I None
VTE I Disease
. I None
<eof> I None

<s> O None
COC I Chemical
use I None
was I None
ascertained I None
through I None
mailed I None
questionnaires I None
. I None
<eof> I None

<s> O None
Sales I None
statistics I None
of I None
COCs I Chemical
and I None
CPA I Chemical
/ I None
EE I Chemical
were I None
provided I None
through I None
Danish I None
Drug I None
Statistics I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
During I None
the I None
time I None
frame I None
of I None
the I None
study I None
, I None
330 I None
women I None
were I None
found I None
to I None
have I None
had I None
VTE I Disease
while I None
on I None
COCs I Chemical
. I None
<eof> I None

<s> O None
Of I None
these I None
women I None
, I None
67 I None
were I None
on I None
levonorgestrel I Chemical
<eof> I None

<s> O None
-containing I None
COCs I Chemical
. I None
<eof> I None

<s> O None
Eleven I None
were I None
on I None
CPA I Chemical
/ I None
EE I Chemical
. I None
<eof> I None

<s> O None
The I None
corresponding I None
absolute I None
risk I None
of I None
VTE I Disease
was I None
3.4 I None
( I None
range I None
, I None
3.1 I None
- I None
3.8 I None
) I None
per I None
10 I None
000 I None
women I None
years I None
among I None
the I None
women I None
on I None
COCs I Chemical
, I None
4.2 I None
( I None
range I None
, I None
3.2 I None
- I None
5.2 I None
) I None
per I None
10 I None
000 I None
women I None
years I None
among I None
women I None
on I None
<eof> I None

<s> O None
levonorgestrel I Chemical
-containing I None
COCs I Chemical
, I None
and I None
3.1 I None
( I None
range I None
, I None
1.3 I None
- I None
4.9 I None
) I None
per I None
10 I None
000 I None
women I None
years I None
among I None
the I None
women I None
on I None
CPA I Chemical
/ I None
EE I Chemical
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
<eof> I None

<s> O None
Our I None
results I None
suggest I None
the I None
absolute I None
risk I None
of I None
VTE I Disease
among I None
Danish I None
women I None
on I None
COCs I Chemical
is I None
similar I None
to I None
that I None
among I None
women I None
taking I None
CPA I Chemical
/ I None
EE I Chemical
. I None
<eof> I None

<s> O None
Effect I None
of I None
lindane I Chemical
on I None
hepatic I None
and I None
brain I None
cytochrome I None
P450s I None
and I None
influence I None
of I None
P450 I None
modulation I None
in I None
lindane I Chemical
induced I None
neurotoxicity I Disease
. I None
<eof> I None

<s> O None
Oral I None
administration I None
of I None
lindane I Chemical
<eof> I None

<s> O None
( I None
2.5 I None
, I None
5 I None
, I None
10 I None
and I None
15 I None
mg I None
/ I None
kg I None
, I None
body I None
weight I None
) I None
for I None
5 I None
days I None
was I None
found I None
to I None
produce I None
a I None
dose I None
- I None
dependent I None
increase I None
in I None
the I None
activity I None
of I None
P450 I None
dependent I None
7-ethoxyresorufin I None
- I None
O I None
- I None
deethylase I None
( I None
EROD I None
) I None
, I None
7-pentoxyresorufin I None
- I None
O I None
- I None
dealkylase I None
( I None
PROD I None
) I None
and I None
N I Chemical
- O Chemical
nitrosodimethylamine O Chemical
demethylase I None
( I None
NDMA I Chemical
-d I None
) I None
in I None
rat I None
brain I None
and I None
liver I None
. I None
<eof> I None

<s> O None
A I None
significant I None
increase I None
in I None
the I None
hepatic I None
and I None
brain I None
P450 I None
monooxygenases I None
was I None
also I None
observed I None
when I None
the I None
duration I None
of I None
exposure I None
of I None
low I None
dose I None
( I None
2.5 I None
mg I None
/ I None
kg I None
) I None
of I None
lindane I Chemical
was I None
increased I None
from I None
5 I None
days I None
to I None
15 I None
or I None
21 I None
days I None
. I None
<eof> I None

<s> O None
As I None
observed I None
with I None
different I None
doses I None
, I None
the I None
magnitude I None
of I None
induction I None
in I None
the I None
activity I None
of I None
P450 I None
monooxygenases I None
was I None
several I None
fold I None
higher I None
in I None
liver I None
microsomes I None
when I None
compared I None
with I None
the I None
brain I None
. I None
<eof> I None

<s> O None
Western I None
blotting I None
studies I None
have I None
indicated I None
that I None
the I None
increase I None
in I None
the I None
P450 I None
enzymes I None
could I None
be I None
due I None
to I None
the I None
increase I None
in I None
the I None
expression I None
of I None
P450 I None
1A1/1A2 I None
, I None
2B1/2B2 I None
and I None
2E1 I None
isoenzymes I None
. I None
<eof> I None

<s> O None
In I None
vitro I None
studies I None
using I None
organic I None
inhibitors I None
specific I None
for I None
individual I None
P450 I None
isoenzymes I None
and I None
antibody I None
inhibition I None
experiments I None
have I None
further I None
demonstrated I None
that I None
the I None
increase I None
in I None
the I None
activity I None
of I None
PROD I None
, I None
EROD I None
and I None
NDMA I Chemical
-d I None
are I None
due I None
to I None
the I None
increase I None
in I None
the I None
levels I None
of I None
P450 I None
2B1/2B2 I None
, I None
1A1/1A2 I None
and I None
2E1 I None
isoenzymes I None
, I None
respectively I None
. I None
<eof> I None

<s> O None
Induction I None
studies I None
have I None
further I None
shown I None
that I None
while I None
pretreatment I None
of I None
3-methylcholanthrene I Chemical
<eof> I None

<s> O None
( I None
MC I Chemical
) I None
, I None
an I None
inducer I None
of I None
P4501A1/1A2 I None
, I None
did I None
not I None
produce I None
any I None
significant I None
effect I None
in I None
the I None
incidence I None
of I None
lindane I Chemical
induced I None
convulsions I Disease
, I None
pretreatment I None
with I None
phenobarbital I Chemical
<eof> I None

<s> O None
( I None
PB I None
) I None
, I None
an I None
inducer I None
of I None
P450 I None
2B1/2B2 I None
or I None
ethanol I Chemical
, I None
an I None
inducer I None
of I None
P450 I None
2E1 I None
catalysed I None
reactions I None
, I None
significantly I None
increased I None
the I None
incidence I None
of I None
lindane I Chemical
induced I None
convulsions I Disease
. I None
<eof> I None

<s> O None
Similarly I None
, I None
when I None
the I None
P450-mediated I None
metabolism I None
of I None
lindane I Chemical
was I None
blocked I None
by I None
cobalt I Chemical
chloride O Chemical
incidence I None
of I None
convulsions I Disease
was I None
increased I None
in I None
animals I None
treated I None
with I None
<eof> I None

<s> O None
lindane I Chemical
indicating I None
that I None
lindane I Chemical
per I None
se I None
or I None
its I None
metabolites I None
formed I None
by I None
PB I None
or I None
ethanol I Chemical
inducible I None
P450 I None
isoenzymes I None
are I None
involved I None
in I None
its I None
neurobehavioral I None
toxicity I Disease
. I None
<eof> I None

<s> O None
Seizure I Disease
associated I None
with I None
sleep I Disease
deprivation O Disease
and I None
sustained I None
- I None
release I None
bupropion I Chemical
. I None
<eof> I None

<s> O None
This I None
case I None
report I None
describes I None
a I None
generalized I None
seizure I Disease
associated I None
with I None
sustained I None
- I None
release I None
bupropion I Chemical
use I None
and I None
sleep I Disease
deprivation O Disease
. I None
<eof> I None

<s> O None
The I None
subject I None
, I None
a I None
31-year I None
- I None
old I None
female I None
smoker I None
, I None
was I None
participating I None
in I None
a I None
clinical I None
trial I None
evaluating I None
an I None
investigational I None
medication I None
for I None
smoking I None
cessation I None
that I None
used I None
sustained I None
- I None
release I None
bupropion I Chemical
as I None
an I None
active I None
control I None
. I None
<eof> I None

<s> O None
After I None
5 I None
weeks I None
of I None
bupropion I Chemical
use I None
, I None
the I None
subject I None
experienced I None
a I None
generalized I None
tonic I None
clonic I None
seizure I Disease
after I None
staying I None
up I None
nearly I None
all I None
night I None
packing I None
and I None
moving I None
to I None
a I None
new I None
residence I None
. I None
<eof> I None

<s> O None
The I None
patient I None
had I None
no I None
other I None
risk I None
factors I None
for I None
seizures I Disease
. I None
<eof> I None

<s> O None
We I None
suggest I None
that I None
sleep I Disease
deprivation O Disease
may I None
add I None
to I None
the I None
risk I None
of I None
bupropion I Chemical
<eof> I None

<s> O None
-associated I None
<eof> I None

<s> O None
seizures I Disease
. I None
<eof> I None

<s> O None
Nephrotoxic I Disease
effects I None
in I None
high I None
- I None
risk I None
patients I None
undergoing I None
angiography I None
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
<eof> I None

<s> O None
The I None
use I None
of I None
iodinated I None
contrast I None
medium I None
can I None
result I None
in I None
nephropathy I Disease
. I None
<eof> I None

<s> O None
Whether I None
iso I None
- I None
osmolar I None
contrast I None
medium I None
is I None
less I None
nephrotoxic I Disease
than I None
low I None
- I None
osmolar I None
contrast I None
medium I None
in I None
high I None
- I None
risk I None
patients I None
is I None
uncertain I None
. I None
<eof> I None

<s> O None
METHODS I None
: I None
<eof> I None

<s> O None
We I None
conducted I None
a I None
randomized I None
, I None
double I None
- I None
blind I None
, I None
prospective I None
, I None
multicenter I None
study I None
comparing I None
the I None
nephrotoxic I Disease
effects I None
of I None
an I None
iso I None
- I None
osmolar I None
, I None
dimeric I None
, I None
nonionic I None
contrast I None
medium I None
, I None
iodixanol I Chemical
, I None
with I None
those I None
of I None
a I None
low I None
- I None
osmolar I None
, I None
nonionic I None
, I None
monomeric I None
contrast I None
medium I None
, I None
iohexol I Chemical
. I None
<eof> I None

<s> O None
The I None
study I None
involved I None
129 I None
patients I None
with I None
diabetes I Disease
with I None
serum I None
<eof> I None

<s> O None
creatinine I Chemical
concentrations I None
of I None
1.5 I None
to I None
3.5 I None
mg I None
per I None
deciliter I None
who I None
underwent I None
coronary I None
or I None
aortofemoral I None
angiography I None
. I None
<eof> I None

<s> O None
The I None
primary I None
end I None
point I None
was I None
the I None
peak I None
increase I None
from I None
base I None
line I None
in I None
the I None
creatinine I Chemical
concentration I None
during I None
the I None
three I None
days I None
after I None
angiography I None
. I None
<eof> I None

<s> O None
Other I None
end I None
points I None
were I None
an I None
increase I None
in I None
the I None
creatinine I Chemical
concentration I None
of I None
0.5 I None
mg I None
per I None
deciliter I None
or I None
more I None
, I None
an I None
increase I None
of I None
1.0 I None
mg I None
per I None
deciliter I None
or I None
more I None
, I None
and I None
a I None
change I None
in I None
the I None
creatinine I Chemical
concentration I None
from I None
day I None
0 I None
to I None
day I None
7 I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
The I None
creatinine I Chemical
concentration I None
increased I None
significantly I None
less I None
in I None
patients I None
who I None
received I None
iodixanol I Chemical
. I None
<eof> I None

<s> O None
From I None
day I None
0 I None
to I None
day I None
3 I None
, I None
the I None
mean I None
peak I None
increase I None
in I None
creatinine I Chemical
was I None
0.13 I None
mg I None
per I None
deciliter I None
in I None
the I None
iodixanol I Chemical
group I None
and I None
0.55 I None
mg I None
per I None
deciliter I None
in I None
the I None
iohexol I Chemical
group I None
( I None
P=0.001 I None
; I None
the I None
increase I None
with I None
iodixanol I Chemical
minus I None
the I None
increase I None
with I None
iohexol I Chemical
, I None
-0.42 I None
mg I None
per I None
deciliter I None
[ I None
95 I None
percent I None
confidence I None
interval I None
, I None
-0.73 I None
to I None
-0.22 I None
] I None
) I None
. I None
<eof> I None

<s> O None
Two I None
of I None
the I None
64 I None
patients I None
in I None
the I None
iodixanol I Chemical
group I None
( I None
3 I None
percent I None
) I None
had I None
an I None
increase I None
in I None
the I None
creatinine I Chemical
concentration I None
of I None
0.5 I None
mg I None
per I None
deciliter I None
or I None
more I None
, I None
as I None
compared I None
with I None
17 I None
of I None
the I None
65 I None
patients I None
in I None
the I None
iohexol I Chemical
group I None
( I None
26 I None
percent I None
) I None
<eof> I None

<s> O None
( I None
P=0.002 I None
; I None
odds I None
ratio I None
for I None
such I None
an I None
increase I None
in I None
the I None
iodixanol I Chemical
group I None
, I None
0.09 I None
[ I None
95 I None
percent I None
confidence I None
interval I None
, I None
0.02 I None
to I None
0.41 I None
] I None
) I None
. I None
<eof> I None

<s> O None
No I None
patient I None
receiving I None
iodixanol I Chemical
had I None
an I None
increase I None
of I None
1.0 I None
mg I None
per I None
deciliter I None
or I None
more I None
, I None
but I None
10 I None
patients I None
in I None
the I None
iohexol I Chemical
group I None
( I None
15 I None
percent I None
) I None
did I None
. I None
<eof> I None

<s> O None
The I None
mean I None
change I None
in I None
the I None
creatinine I Chemical
concentration I None
from I None
day I None
0 I None
to I None
day I None
7 I None
was I None
0.07 I None
mg I None
per I None
deciliter I None
in I None
the I None
iodixanol I Chemical
group I None
and I None
0.24 I None
mg I None
per I None
deciliter I None
in I None
the I None
iohexol I Chemical
group I None
( I None
P=0.003 I None
; I None
value I None
in I None
the I None
iodixanol I Chemical
group I None
minus I None
the I None
value I None
in I None
the I None
iohexol I Chemical
group I None
, I None
-0.17 I None
mg I None
per I None
deciliter I None
[ I None
95 I None
percent I None
confidence I None
interval I None
, I None
-0.34 I None
to I None
-0.07 I None
] I None
) I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
Nephropathy I Disease
induced I None
by I None
contrast I None
medium I None
may I None
be I None
less I None
likely I None
to I None
develop I None
in I None
high I None
- I None
risk I None
patients I None
when I None
iodixanol I Chemical
is I None
used I None
rather I None
than I None
a I None
low I None
- I None
osmolar I None
, I None
nonionic I None
contrast I None
medium I None
. I None
<eof> I None

<s> O None
Experimental I None
cranial I None
pain I Disease
elicited I None
by I None
capsaicin I Chemical
: I None
a I None
PET I None
study I None
. I None
<eof> I None

<s> O None
Using I None
a I None
positron I None
emission I None
tomography I None
( I None
PET I None
) I None
study I None
it I None
was I None
shown I None
recently I None
that I None
in I None
migraine I Disease
without I None
aura I None
certain I None
areas I None
in I None
the I None
brain I None
stem I None
were I None
activated I None
during I None
the I None
headache I Disease
state I None
, I None
but I None
not I None
in I None
the I None
headache I Disease
free I None
interval I None
. I None
<eof> I None

<s> O None
It I None
was I None
suggested I None
that I None
this I None
brain I None
stem I None
activation I None
is I None
inherent I None
to I None
the I None
migraine I Disease
attack I None
itself I None
and I None
represents I None
the I None
so I None
called I None
' I None
migraine I Disease
generator I None
' I None
. I None
<eof> I None

<s> O None
To I None
test I None
this I None
hypothesis I None
we I None
performed I None
an I None
experimental I None
pain I Disease
study I None
in I None
seven I None
healthy I None
volunteers I None
, I None
using I None
the I None
same I None
positioning I None
in I None
the I None
PET I None
scanner I None
as I None
in I None
the I None
migraine I Disease
patients I None
. I None
<eof> I None

<s> O None
A I None
small I None
amount I None
of I None
capsaicin I Chemical
was I None
administered I None
subcutaneously I None
in I None
the I None
right I None
forehead I None
to I None
evoke I None
a I None
burning I None
painful I Disease
sensation I None
in I None
the I None
first I None
division I None
of I None
the I None
trigeminal I None
nerve I None
. I None
<eof> I None

<s> O None
Increases I None
of I None
regional I None
cerebral I None
blood I None
flow I None
( I None
rCBF I None
) I None
were I None
found I None
bilaterally I None
in I None
the I None
insula I None
, I None
in I None
the I None
anterior I None
cingulate I None
cortex I None
, I None
the I None
cavernous I None
sinus I None
and I None
the I None
cerebellum I None
. I None
<eof> I None

<s> O None
Using I None
the I None
same I None
stereotactic I None
space I None
limits I None
as I None
in I None
the I None
above I None
mentioned I None
<eof> I None

<s> O None
migraine I Disease
study I None
no I None
brain I None
stem I None
activation I None
was I None
found I None
in I None
the I None
acute I None
pain I Disease
state I None
compared I None
to I None
the I None
pain I Disease
free I None
state I None
. I None
<eof> I None

<s> O None
The I None
increase I None
of I None
activation I None
in I None
the I None
region I None
of I None
the I None
cavernous I None
sinus I None
however I None
, I None
suggests I None
that I None
this I None
structure I None
is I None
more I None
likely I None
to I None
be I None
involved I None
in I None
trigeminal I None
transmitted I None
<eof> I None

<s> O None
pain I Disease
as I None
such I None
, I None
rather I None
than I None
in I None
a I None
specific I None
type I None
of I None
headache I Disease
as I None
was I None
suggested I None
for I None
cluster I Disease
headache O Disease
. I None
<eof> I None

<s> O None
Neuroleptic I Disease
malignant O Disease
syndrome O Disease
with I None
risperidone I Chemical
. I None
<eof> I None

<s> O None
Neuroleptic I Disease
malignant O Disease
syndrome O Disease
is I None
thought I None
to I None
be I None
a I None
result I None
of I None
dopamine I Chemical
D2 I None
receptor I None
blockade I None
in I None
the I None
striatum I None
of I None
the I None
basal I None
ganglia I None
. I None
<eof> I None

<s> O None
Risperidone I Chemical
, I None
a I None
benzisoxazole I Chemical
derivative I None
antipsychotic I None
, I None
has I None
high I None
serotonin I Chemical
5-HT2 I None
receptor I None
blockade I None
and I None
dose I None
- I None
related I None
D2 I None
receptor I None
blockade I None
. I None
<eof> I None

<s> O None
The I None
high I None
ratio I None
is I None
believed I None
to I None
impart I None
the I None
low I None
frequency I None
of I None
extrapyramidal I Disease
symptoms O Disease
with I None
risperidone I Chemical
at I None
low I None
dosages I None
. I None
<eof> I None

<s> O None
With I None
this I None
low I None
frequency I None
of I None
extrapyramidal I Disease
symptoms O Disease
, I None
it I None
was I None
thought I None
the I None
frequency I None
of I None
neuroleptic I Disease
malignant O Disease
syndrome O Disease
might I None
also I None
be I None
lowered I None
. I None
<eof> I None

<s> O None
A I None
73-year I None
- I None
old I None
woman I None
developed I None
neuroleptic I Disease
malignant O Disease
syndrome O Disease
after I None
monotherapy I None
with I None
risperidone I Chemical
. I None
<eof> I None

<s> O None
The I None
syndrome I None
reversed I None
after I None
discontinuing I None
risperidone I Chemical
and I None
starting I None
treatment I None
with I None
dantrolene I Chemical
and I None
bromocriptine I Chemical
. I None
<eof> I None

<s> O None
It I None
appears I None
that I None
the I None
protection I None
from I None
extrapyramidal I None
side I None
effects I None
observed I None
with I None
risperidone I Chemical
does I None
not I None
ensure I None
protection I None
from I None
neuroleptic I Disease
malignant O Disease
syndrome O Disease
. I None
<eof> I None

<s> O None
Hepatic I None
and I None
extrahepatic I None
angiotensinogen I None
gene I None
expression I None
in I None
rats I None
with I None
acute I None
nephrotic I Disease
syndrome O Disease
. I None
<eof> I None

<s> O None
Plasma I None
concentration I None
and I None
urine I None
excretion I None
of I None
the I None
renin- I None
angiotensin I Chemical
system I None
proteins I None
are I None
altered I None
in I None
rats I None
with I None
nephrotic I Disease
syndrome O Disease
<eof> I None

<s> O None
( I None
NS I Disease
) I None
. I None
<eof> I None

<s> O None
In I None
this I None
work I None
the I None
messenger I None
ribonucleic I None
acid I None
( I None
mRNA I None
) I None
levels I None
of I None
angiotensinogen I None
( I None
Ao I None
) I None
were I None
analyzed I None
with I None
the I None
slot I None
- I None
blot I None
hybridization I None
technique I None
in I None
liver I None
and I None
other I None
extrahepatic I None
tissues I None
: I None
kidney I None
, I None
heart I None
, I None
brain I None
, I None
and I None
adrenal I None
gland I None
from I None
control I None
, I None
nephrotic I Disease
, I None
and I None
pair I None
- I None
fed I None
( I None
PF I None
) I None
rats I None
. I None
<eof> I None

<s> O None
NS I Disease
was I None
induced I None
by I None
a I None
single I None
injection I None
of I None
puromycin I Chemical
amino O Chemical
- O Chemical
nucleoside O Chemical
<eof> I None

<s> O None
( I None
PAN I Chemical
) I None
. I None
<eof> I None

<s> O None
Although I None
a I None
great I None
urinary I None
excretion I None
and I None
half I None
- I None
normal I None
plasma I None
levels I None
of I None
Ao I None
were I None
observed I None
on I None
day I None
6 I None
after I None
PAN I Chemical
injection I None
, I None
when I None
NS I Disease
was I None
clearly I None
established I None
, I None
hepatic I None
Ao I None
mRNA I None
levels I None
did I None
not I None
change I None
. I None
<eof> I None

<s> O None
Furthermore I None
, I None
the I None
Ao I None
mRNA I None
levels I None
did I None
not I None
change I None
in I None
any I None
of I None
the I None
extrahepatic I None
tissues I None
studied I None
on I None
day I None
6 I None
, I None
nor I None
did I None
its I None
hepatic I None
levels I None
at I None
days I None
1 I None
, I None
3 I None
, I None
5 I None
, I None
or I None
7 I None
after I None
PAN I Chemical
injection I None
. I None
<eof> I None

<s> O None
These I None
data I None
suggest I None
that I None
the I None
hepatic I None
and I None
extrahepatic I None
Ao I None
mRNA I None
levels I None
are I None
unaltered I None
during I None
the I None
development I None
of I None
the I None
acute I None
NS I Disease
induced I None
by I None
PAN I Chemical
. I None
<eof> I None

<s> O None
Cyclophosphamide I Chemical
associated I None
<eof> I None

<s> O None
bladder I Disease
cancer O Disease
--a I None
<eof> I None

<s> O None
highly I None
aggressive I None
disease I None
: I None
analysis I None
of I None
12 I None
cases I None
. I None
<eof> I None

<s> O None
PURPOSE I None
: I None
<eof> I None

<s> O None
We I None
gained I None
knowledge I None
of I None
the I None
etiology I None
, I None
treatment I None
and I None
prevention I None
of I None
cyclophosphamide I Chemical
associated I None
urothelial I Disease
cancer O Disease
. I None
MATERIALS I None
AND I None
METHODS I None
: I None
<eof> I None

<s> O None
The I None
medical I None
records I None
of I None
6 I None
men I None
and I None
6 I None
women I None
( I None
mean I None
age I None
55 I None
years I None
) I None
with I None
cyclophosphamide I Chemical
associated I None
bladder I Disease
cancer O Disease
were I None
reviewed I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
All I None
tumors I Disease
were I None
grade I None
3 I None
or I None
4 I None
transitional I None
cell I None
carcinoma I Disease
. I None
<eof> I None

<s> O None
Of I None
the I None
5 I None
patients I None
initially I None
treated I None
with I None
endoscopic I None
resection I None
alone I None
only I None
1 I None
is I None
alive I None
without I None
disease I None
. I None
<eof> I None

<s> O None
Of I None
the I None
6 I None
patients I None
who I None
underwent I None
early I None
cystectomy I None
4 I None
were I None
alive I None
at I None
24 I None
to I None
111 I None
months I None
. I None
<eof> I None

<s> O None
The I None
remaining I None
patient I None
with I None
extensive I None
cancer I Disease
underwent I None
partial I None
cystectomy I None
for I None
palliation I None
and I None
died I None
3 I None
months I None
later I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
Cyclophosphamide I Chemical
associated I None
<eof> I None

<s> O None
bladder I Disease
tumor O Disease
is I None
an I None
aggressive I None
disease I None
. I None
<eof> I None

<s> O None
However I None
, I None
long I None
- I None
term I None
survival I None
is I None
possible I None
when I None
radical I None
cystectomy I None
is I None
performed I None
for I None
bladder I Disease
tumors O Disease
with I None
any I None
sign I None
of I None
invasion I None
and I None
for I None
recurrent I None
high I None
grade I None
disease I None
, I None
even I None
when I None
noninvasive I None
. I None
<eof> I None

<s> O None
Leg I Disease
and O Disease
back O Disease
pain O Disease
after I None
spinal I None
anaesthesia I None
involving I None
hyperbaric I None
5 I None
% I None
lignocaine I Chemical
. I None
<eof> I None

<s> O None
Fifty I None
- I None
four I None
patients I None
, I None
aged I None
27 I None
- I None
90 I None
years I None
, I None
who I None
were I None
given I None
lignocaine I Chemical
5 I None
% I None
in I None
6.8 I None
% I None
glucose I Chemical
solution I None
for I None
spinal I None
anaesthesia I None
were I None
studied I None
. I None
<eof> I None

<s> O None
Thirteen I None
of I None
these I None
patients I None
experienced I None
pain I Disease
in O Disease
the O Disease
legs O Disease
and/or O Disease
back O Disease
after I None
recovery I None
from I None
anaesthesia I None
. I None
<eof> I None

<s> O None
The I None
patients I None
affected I None
were I None
younger I None
( I None
p I None
< I None
0.05 I None
) I None
and I None
the I None
site I None
of I None
the I None
dural I None
puncture I None
was I None
higher I None
( I None
p I None
< I None
0.01 I None
) I None
than I None
those I None
individuals I None
without I None
pain I Disease
. I None
<eof> I None

<s> O None
Five I None
of I None
the I None
13 I None
patients I None
( I None
38 I None
% I None
) I None
with I None
pain I Disease
and I None
seven I None
of I None
the I None
41 I None
patients I None
( I None
17 I None
% I None
) I None
without I None
pain I Disease
admitted I None
to I None
a I None
high I None
alcohol I Chemical
intake I None
, I None
which I None
might I None
be I None
a I None
contributing I None
factor I None
. I None
<eof> I None

<s> O None
Leg I Disease
and/or O Disease
back O Disease
pain O Disease
is I None
associated I None
with I None
the I None
intrathecal I None
use I None
of I None
hyperbaric I None
5 I None
% I None
lignocaine I Chemical
. I None
<eof> I None

<s> O None
Acute I None
blood I None
pressure I None
elevations I None
with I None
caffeine I Chemical
in I None
men I None
with I None
borderline I None
systemic I None
hypertension I Disease
. I None
<eof> I None

<s> O None
Whether I None
the I None
vasoconstrictive I None
actions I None
of I None
caffeine I Chemical
are I None
enhanced I None
in I None
hypertensive I Disease
persons I None
has I None
not I None
been I None
demonstrated I None
. I None
<eof> I None

<s> O None
Thus I None
, I None
caffeine I Chemical
( I None
3.3 I None
mg I None
/ I None
kg I None
) I None
versus I None
placebo I None
was I None
tested I None
in I None
48 I None
healthy I None
men I None
( I None
aged I None
20 I None
to I None
35 I None
years I None
) I None
selected I None
after I None
screening I None
on I None
2 I None
separate I None
occasions I None
. I None
<eof> I None

<s> O None
Borderline I None
hypertensive I Disease
<eof> I None

<s> O None
men I None
( I None
n I None
= I None
24 I None
) I None
were I None
selected I None
with I None
screening I None
systolic I None
blood I None
pressure I None
( I None
BP I None
) I None
of I None
140 I None
to I None
160 I None
mm I None
Hg I None
and/or I None
diastolic I None
BP I None
90 I None
to I None
99 I None
mm I None
Hg I None
. I None
<eof> I None

<s> O None
Low I None
- I None
risk I None
controls I None
( I None
n I None
= I None
24 I None
) I None
reported I None
no I None
parental I None
history I None
of I None
hypertension I Disease
and I None
had I None
screening I None
BP I None
< I None
130/85 I None
mm I None
Hg I None
. I None
<eof> I None

<s> O None
Participants I None
were I None
then I None
tested I None
on I None
2 I None
occasions I None
after I None
12-hour I None
abstinence I None
from I None
caffeine I Chemical
in I None
each I None
of I None
2 I None
protocols I None
; I None
this I None
required I None
a I None
total I None
of I None
4 I None
laboratory I None
visits I None
. I None
<eof> I None

<s> O None
Caffeine I Chemical
-induced I None
changes I None
in I None
diastolic I None
BP I None
were I None
2 I None
to I None
3 I None
times I None
larger I None
in I None
borderline I None
subjects I None
than I None
in I None
controls I None
( I None
+ I None
8.4 I None
vs I None
+ I None
3.8 I None
mm I None
Hg I None
, I None
p I None
< I None
0.0001 I None
) I None
, I None
and I None
were I None
attributable I None
to I None
larger I None
changes I None
in I None
impedance I None
- I None
derived I None
measures I None
of I None
systemic I None
vascular I None
resistance I None
( I None
+ I None
135 I None
vs I None
+ I None
45 I None
dynes.s.cm-5 I None
, I None
p I None
< I None
0.004 I None
) I None
. I None
<eof> I None

<s> O None
These I None
findings I None
were I None
consistent I None
and I None
reached I None
significance I None
in I None
both I None
protocols I None
. I None
<eof> I None

<s> O None
The I None
percentage I None
of I None
borderline I None
subjects I None
in I None
whom I None
diastolic I None
BP I None
changes I None
exceeded I None
the I None
median I None
control I None
response I None
was I None
96 I None
% I None
. I None
<eof> I None

<s> O None
Consequently I None
, I None
whereas I None
all I None
participants I None
exhibited I None
normotensive I None
levels I None
during I None
the I None
resting I None
predrug I None
baseline I None
, I None
33 I None
% I None
of I None
borderline I None
subjects I None
achieved I None
hypertensive I Disease
BP I None
levels I None
after I None
caffeine I Chemical
ingestion I None
. I None
<eof> I None

<s> O None
Thus I None
, I None
in I None
borderline I None
hypertensive I Disease
men I None
, I None
exaggerated I None
responses I None
to I None
caffeine I Chemical
were I None
: I None
selective I None
for I None
diastolic I None
BP I None
, I None
consistent I None
with I None
greater I None
vasoconstriction I None
, I None
replicated I None
in I None
2 I None
protocols I None
, I None
and I None
representative I None
of I None
nearly I None
all I None
borderline I None
hypertensives I Disease
. I None
<eof> I None

<s> O None
We I None
suspect I None
that I None
the I None
potential I None
for I None
caffeine I Chemical
to I None
stabilize I None
high I None
resistance I None
states I None
in I None
susceptible I None
persons I None
suggests I None
that I None
its I None
use I None
may I None
facilitate I None
their I None
disease I None
progression I None
, I None
as I None
well I None
as I None
hinder I None
accurate I None
diagnosis I None
and I None
treatment I None
. I None
<eof> I None

<s> O None
Hallucinations I Disease
and I None
ifosfamide I Chemical
-induced I None
<eof> I None

<s> O None
neurotoxicity I Disease
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
<eof> I None

<s> O None
Hallucinations I Disease
as I None
a I None
symptom I None
of I None
central I None
neurotoxicity I Disease
are I None
a I None
known I None
but I None
poorly I None
described I None
side I None
effect I None
of I None
ifosfamide I Chemical
. I None
<eof> I None

<s> O None
Most I None
cases I None
of I None
ifosfamide I Chemical
-induced I None
hallucinations I Disease
have I None
been I None
reported I None
with I None
other I None
mental I None
status I None
changes I None
. I None
<eof> I None

<s> O None
METHODS I None
: I None
<eof> I None

<s> O None
The I None
authors I None
interviewed I None
six I None
persons I None
with I None
ifosfamide I Chemical
-induced I None
<eof> I None

<s> O None
hallucinations I Disease
in I None
the I None
presence I None
of I None
a I None
clear I None
sensorium I None
. I None
<eof> I None

<s> O None
All I None
patients I None
were I None
receiving I None
high I None
- I None
dose I None
ifosfamide I Chemical
as I None
part I None
of I None
their I None
bone I None
marrow I None
transplant I None
procedure I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
Hallucinations I Disease
occurred I None
only I None
when I None
the I None
patient I None
's I None
eyes I None
were I None
closed I None
and I None
, I None
in I None
all I None
but I None
one I None
case I None
, I None
were I None
reported I None
as I None
disturbing I None
or I None
frightening I None
. I None
<eof> I None

<s> O None
Underreporting I None
of I None
these I None
hallucinations I Disease
by I None
patients I None
is I None
likely I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
Hallucinations I Disease
may I None
be I None
the I None
sole I None
or I None
first I None
manifestation I None
of I None
neurotoxicity I Disease
. I None
<eof> I None

<s> O None
The I None
incidence I None
may I None
be I None
dose I None
and I None
infusion I None
- I None
time I None
related I None
. I None
<eof> I None

<s> O None
The I None
clinician I None
should I None
be I None
alerted I None
for I None
possible I None
ifosfamide I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
hallucinations I Disease
, I None
which I None
may I None
occur I None
without I None
other I None
signs I None
of I None
neurotoxicity I Disease
. I None
<eof> I None

<s> O None
" I None
Eyes I None
- I None
closed I None
" I None
hallucinatory I Disease
experiences I None
appear I None
to I None
be I None
an I None
unusual I None
feature I None
of I None
this I None
presentation I None
. I None
<eof> I None

<s> O None
Patients I None
anxious I None
about I None
this I None
experience I None
respond I None
well I None
to I None
support I None
and I None
education I None
about I None
this I None
occurrence I None
. I None
<eof> I None

<s> O None
Optimal I None
pharmacologic I None
management I None
of I None
disturbed I None
patients I None
is I None
unclear I None
. I None
<eof> I None

<s> O None
If I None
agitation I Disease
becomes I None
marked I None
, I None
high I None
- I None
potency I None
neuroleptics I None
( I None
i.e. I None
, I None
haloperidol I Chemical
) I None
may I None
be I None
effective I None
. I None
<eof> I None

<s> O None
Chlorpropamide I Chemical
-induced I None
optic I Disease
neuropathy O Disease
. I None
<eof> I None

<s> O None
A I None
65-year I None
- I None
old I None
woman I None
with I None
adult I Disease
- O Disease
onset O Disease
diabetes O Disease
treated I None
with I None
chlorpropamide I Chemical
<eof> I None

<s> O None
( I None
Diabenese I Chemical
) I None
had I None
a I None
toxic I Disease
optic O Disease
neuropathy O Disease
that I None
resolved I None
with I None
discontinuation I None
of I None
chlorpropamide I Chemical
therapy I None
. I None
<eof> I None

<s> O None
Visual I Disease
loss O Disease
occurs I None
in I None
diabetics I Disease
for I None
a I None
variety I None
of I None
reasons I None
, I None
and I None
accurate I None
diagnosis I None
is I None
necessary I None
to I None
institute I None
appropriate I None
therapy I None
. I None
<eof> I None

<s> O None
The I None
possibility I None
of I None
a I None
drug I None
- I None
induced I None
optic I Disease
neuropathy O Disease
should I None
be I None
considered I None
in I None
the I None
differential I None
diagnosis I None
of I None
visual I Disease
loss O Disease
in I None
diabetics I Disease
. I None
<eof> I None

<s> O None
Levodopa I Chemical
-induced I None
dyskinesia I Disease
and I None
thalamotomy I None
. I None
<eof> I None

<s> O None
Levodopa I Chemical
-induced I None
dyskinesia I Disease
of I None
the I None
limbs I None
in I None
thirteen I None
cases I None
of I None
Parkinsonism I Disease
, I None
which I None
was I None
choreic I None
, I None
ballistic I None
or I None
dystonic I Disease
in I None
type I None
, I None
was I None
alleviated I None
almost I None
completely I None
by I None
stereotaxic I None
surgery I None
using I None
a I None
microelectrode I None
technique I None
for I None
the I None
ventralis I None
oralis I None
anterior I None
and I None
posterior I None
nuclei I None
of I None
the I None
thalamus I None
, I None
but I None
much I None
less I None
by I None
the I None
ventralis I None
intermedius I None
nucleus I None
. I None
<eof> I None

<s> O None
Control I None
of I None
levodopa I Chemical
-induced I None
dyskinesias I Disease
by I None
thalamic I Disease
lesions O Disease
in I None
the I None
course I None
of I None
routine I None
treatment I None
of I None
Parkinsonism I Disease
is I None
discussed I None
. I None
<eof> I None

<s> O None
Factors I None
associated I None
with I None
nephrotoxicity I Disease
and I None
clinical I None
outcome I None
in I None
patients I None
receiving I None
amikacin I Chemical
. I None
<eof> I None

<s> O None
Data I None
from I None
60 I None
patients I None
treated I None
with I None
amikacin I Chemical
were I None
analyzed I None
for I None
factors I None
associated I None
with I None
nephrotoxicity I Disease
. I None
<eof> I None

<s> O None
In I None
42 I None
of I None
these I None
patients I None
, I None
data I None
were I None
examined I None
for I None
factors I None
associated I None
with I None
clinical I None
outcome I None
. I None
<eof> I None

<s> O None
Variables I None
evaluated I None
included I None
patient I None
weight I None
, I None
age I None
, I None
sex I None
, I None
serum I None
creatinine I Chemical
level I None
, I None
creatinine I Chemical
clearance I None
, I None
duration I None
of I None
therapy I None
, I None
total I None
dose I None
, I None
mean I None
daily I None
dose I None
, I None
organism I None
minimum I None
inhibitory I None
concentration I None
( I None
MIC I None
) I None
, I None
mean I None
peak I None
levels I None
, I None
mean I None
trough I None
levels I None
, I None
mean I None
area I None
under I None
the I None
serum I None
concentration I None
- I None
time I None
curve I None
( I None
AUC I None
) I None
, I None
total I None
AUC I None
, I None
mean I None
AUC I None
greater I None
than I None
MIC I None
, I None
total I None
AUC I None
greater I None
than I None
MIC I None
, I None
mean I None
Schumacher I None
's I None
intensity I None
factor I None
( I None
IF I None
) I None
, I None
<eof> I None

<s> O None
total I None
IF I None
, I None
In I None
( I None
mean I None
maximum I None
concentration I None
[ I None
Cmax]/MIC I None
) I None
. I None
<eof> I None

<s> O None
Model I None
- I None
dependent I None
pharmacokinetic I None
parameters I None
were I None
calculated I None
by I None
computer I None
based I None
on I None
a I None
one I None
- I None
compartment I None
model I None
. I None
<eof> I None

<s> O None
When I None
the I None
parameters I None
were I None
examined I None
individually I None
, I None
duration I None
of I None
therapy I None
and I None
total I None
AUC I None
correlated I None
significantly I None
( I None
P I None
less I None
than I None
.05 I None
) I None
with I None
nephrotoxicity I Disease
. I None
<eof> I None

<s> O None
In I None
contrast I None
, I None
a I None
stepwise I None
discriminant I None
function I None
analysis I None
identified I None
only I None
duration I None
of I None
therapy I None
( I None
P I None
less I None
than I None
.001 I None
) I None
as I None
an I None
important I None
factor I None
. I None
<eof> I None

<s> O None
Based I None
on I None
this I None
model I None
and I None
on I None
Bayes I None
' I None
theorem I None
, I None
the I None
predictive I None
accuracy I None
of I None
identifying I None
" I None
nephrotoxic I Disease
" I None
patients I None
increased I None
from I None
0.17 I None
to I None
0.39 I None
. I None
<eof> I None

<s> O None
When I None
examined I None
individually I None
, I None
mean I None
<eof> I None

<s> O None
IF I None
, I None
MIC I None
, I None
total I None
dose I None
, I None
mean I None
daily I None
dose I None
, I None
and I None
ln I None
( I None
mean I None
Cmax I None
/ I None
MIC I None
) I None
correlated I None
significantly I None
( I None
P I None
less I None
than I None
.05 I None
) I None
with I None
cure I None
. I None
<eof> I None

<s> O None
In I None
contrast I None
, I None
a I None
simultaneous I None
multivariable I None
analysis I None
identified I None
<eof> I None

<s> O None
IF I None
, I None
MIC I None
, I None
and I None
total I None
dose I None
according I None
to I None
one I None
model I None
and I None
ln I None
( I None
mean I None
Cmax I None
/ I None
MIC I None
) I None
according I None
to I None
a I None
second I None
statistical I None
model I None
of I None
parameters I None
selected I None
to I None
have I None
the I None
greatest I None
prospective I None
value I None
. I None
<eof> I None

<s> O None
Based I None
on I None
Bayes I None
' I None
theorem I None
and I None
the I None
first I None
model I None
, I None
the I None
predictive I None
accuracy I None
of I None
identifying I None
patients I None
not I None
cured I None
increased I None
from I None
0.19 I None
to I None
0.83 I None
. I None
<eof> I None

<s> O None
For I None
the I None
second I None
model I None
, I None
the I None
predictive I None
accuracy I None
increased I None
from I None
0.19 I None
to I None
0.50.(ABSTRACT I None
TRUNCATED I None
AT I None
250 I None
WORDS I None
) I None
<eof> I None

<s> O None
Cardiac I None
transplantation I None
: I None
improved I None
quality I None
of I None
survival I None
with I None
a I None
modified I None
immunosuppressive I None
protocol I None
. I None
<eof> I None

<s> O None
The I None
effects I None
on I None
renal I None
function I None
on I None
two I None
different I None
immunosuppressive I None
protocols I None
were I None
evaluated I None
retrospectively I None
in I None
two I None
subsequent I None
groups I None
of I None
heart I None
transplant I None
recipients I None
. I None
<eof> I None

<s> O None
In I None
group I None
I I None
, I None
cyclosporine I Chemical
was I None
given I None
before I None
the I None
procedure I None
at I None
a I None
loading I None
dose I None
of I None
17.5 I None
mg I None
/ I None
kg I None
and I None
then I None
continued I None
after I None
the I None
procedure I None
to I None
keep I None
a I None
whole I None
blood I None
level I None
about I None
1000 I None
ng I None
/ I None
ml I None
. I None
<eof> I None

<s> O None
In I None
group I None
II I None
, I None
cyclosporine I Chemical
was I None
started I None
only I None
after I None
the I None
procedure I None
at I None
a I None
lower I None
dosage I None
and I None
was I None
complemented I None
by I None
azathioprine I Chemical
, I None
which I None
was I None
used I None
for I None
the I None
first I None
postoperative I None
week I None
. I None
<eof> I None

<s> O None
Group I None
II I None
showed I None
a I None
better I None
perioperative I None
renal I None
function I None
as I None
determined I None
by I None
serum I None
blood I None
urea I Chemical
nitrogen O Chemical
and I None
serum I None
creatinine I Chemical
levels I None
. I None
<eof> I None

<s> O None
Group I None
II I None
also I None
showed I None
a I None
significant I None
decrease I None
of I None
chronic I None
nephrotoxicity I Disease
secondary I None
to I None
long I None
- I None
term I None
therapy I None
with I None
cyclosporine I Chemical
. I None
<eof> I None

<s> O None
Despite I None
this I None
improvement I None
in I None
late I None
renal I None
function I None
, I None
group I None
II I None
still I None
shows I None
a I None
slow I None
rise I None
in I None
serum I None
creatinine I Chemical
. I None
<eof> I None

<s> O None
We I None
think I None
that I None
even I None
these I None
lower I None
dosages I None
of I None
cyclosporine I Chemical
can I None
cause I None
chronic I None
nephrotoxicity I Disease
and I None
that I None
further I None
modification I None
of I None
the I None
immunosuppressive I None
regimen I None
is I None
required I None
to I None
completely I None
abolish I None
this I None
toxic I None
side I None
effect I None
. I None
<eof> I None

<s> O None
Reversible I None
cholestasis I Disease
with I None
<eof> I None

<s> O None
bile I Disease
duct O Disease
injury O Disease
following I None
azathioprine I Chemical
therapy I None
. I None
<eof> I None

<s> O None
A I None
case I None
report I None
. I None
<eof> I None

<s> O None
A I None
67-year I None
- I None
old I None
patient I None
, I None
with I None
primary I None
polymyositis I Disease
and I None
without I None
previous I None
evidence I None
of I None
liver I Disease
disease O Disease
, I None
developed I None
clinical I None
and I None
biochemical I None
features I None
of I None
severe I None
cholestasis I Disease
3 I None
months I None
after I None
initiation I None
of I None
azathioprine I Chemical
therapy I None
. I None
<eof> I None

<s> O None
Liver I None
biopsy I None
showed I None
cholestasis I Disease
with I None
both I None
cytological I None
and I None
architectural I None
alterations I None
of I None
interlobular I None
bile I None
ducts I None
. I None
<eof> I None

<s> O None
Azathioprine I Chemical
withdrawal I None
resulted I None
after I None
7 I None
weeks I None
in I None
the I None
resolution I None
of I None
clinical I None
and I None
biochemical I None
abnormalities I None
. I None
<eof> I None

<s> O None
It I None
is I None
believed I None
that I None
this I None
is I None
the I None
first I None
reported I None
case I None
of I None
reversible I None
azathioprine I Chemical
-induced I None
<eof> I None

<s> O None
cholestasis I Disease
associated I None
with I None
histological I None
evidence I None
of I None
bile I Disease
duct O Disease
injury O Disease
. I None
<eof> I None

<s> O None
Renal I None
function I None
and I None
hemodynamics I None
during I None
prolonged I None
isoflurane I Chemical
-induced I None
<eof> I None

<s> O None
hypotension I Disease
in I None
humans I None
. I None
<eof> I None

<s> O None
The I None
effect I None
of I None
isoflurane I Chemical
-induced I None
hypotension I Disease
on I None
glomerular I None
function I None
and I None
renal I None
blood I None
flow I None
was I None
investigated I None
in I None
20 I None
human I None
subjects I None
. I None
<eof> I None

<s> O None
Glomerular I None
filtration I None
rate I None
( I None
GFR I None
) I None
and I None
effective I None
renal I None
plasma I None
flow I None
( I None
ERPF I None
) I None
were I None
measured I None
by I None
inulin I None
and I None
para I Chemical
- O Chemical
aminohippurate O Chemical
<eof> I None

<s> O None
( I None
PAH I Chemical
) I None
clearance I None
, I None
respectively I None
. I None
<eof> I None

<s> O None
Anesthesia I None
was I None
maintained I None
with I None
fentanyl I Chemical
, I None
nitrous I Chemical
oxide O Chemical
, I None
oxygen I Chemical
, I None
and I None
isoflurane I Chemical
. I None
<eof> I None

<s> O None
Hypotension I Disease
was I None
induced I None
for I None
236.9 I None
+ I None
/- I None
<eof> I None

<s> O None
15.1 I None
min I None
by I None
increasing I None
the I None
isoflurane I Chemical
inspired I None
concentration I None
to I None
maintain I None
a I None
mean I None
arterial I None
pressure I None
of I None
59.8 I None
+ I None
/- I None
0.4 I None
mmHg I None
. I None
<eof> I None

<s> O None
GFR I None
and I None
ERPF I None
decreased I None
with I None
the I None
induction I None
of I None
anesthesia I None
but I None
not I None
significantly I None
more I None
during I None
hypotension I Disease
. I None
<eof> I None

<s> O None
Postoperatively I None
, I None
ERPF I None
returned I None
to I None
preoperative I None
values I None
, I None
whereas I None
GFR I None
was I None
higher I None
than I None
preoperative I None
values I None
. I None
<eof> I None

<s> O None
Renal I None
vascular I None
resistance I None
increased I None
during I None
anesthesia I None
but I None
decreased I None
when I None
hypotension I Disease
was I None
induced I None
, I None
allowing I None
the I None
maintenance I None
of I None
renal I None
blood I None
flow I None
. I None
<eof> I None

<s> O None
We I None
conclude I None
that I None
renal I None
compensatory I None
mechanisms I None
are I None
preserved I None
during I None
isoflurane I Chemical
-induced I None
hypotension I Disease
and I None
that I None
renal I None
function I None
and I None
hemodynamics I None
quickly I None
return I None
to I None
normal I None
when I None
normotension I None
is I None
resumed I None
. I None
<eof> I None

<s> O None
Debrisoquine I Chemical
phenotype I None
and I None
the I None
pharmacokinetics I None
and I None
beta-2 I None
receptor I None
pharmacodynamics I None
of I None
metoprolol I Chemical
and I None
its I None
enantiomers I None
. I None
<eof> I None

<s> O None
The I None
metabolism I None
of I None
the I None
cardioselective I None
beta I None
- I None
blocker I None
metoprolol I Chemical
is I None
under I None
genetic I None
control I None
of I None
the I None
debrisoquine I Chemical
/ I None
sparteine I Chemical
type I None
. I None
<eof> I None

<s> O None
The I None
two I None
metabolic I None
phenotypes I None
, I None
extensive I None
( I None
EM I None
) I None
and I None
poor I None
metabolizers I None
( I None
PM I None
) I None
, I None
show I None
different I None
stereoselective I None
metabolism I None
, I None
resulting I None
in I None
apparently I None
higher I None
beta-1 I None
adrenoceptor I None
antagonistic I None
potency I None
of I None
racemic I None
metoprolol I Chemical
in I None
EMs I None
. I None
<eof> I None

<s> O None
We I None
investigated I None
if I None
the I None
latter I None
also I None
applies I None
to I None
the I None
beta-2 I None
adrenoceptor I None
antagonism I None
by I None
metoprolol I Chemical
. I None
<eof> I None

<s> O None
The I None
drug I None
effect I None
studied I None
was I None
the I None
antagonism I None
by I None
metoprolol I Chemical
of I None
terbutaline I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
hypokalemia I Disease
. I None
<eof> I None

<s> O None
By I None
using I None
pharmacokinetic I None
pharmacodynamic I None
modeling I None
the I None
pharmacodynamics I None
of I None
racemic I None
metoprolol I Chemical
and I None
the I None
active I None
S I None
- I None
isomer I None
, I None
were I None
quantitated I None
in I None
EMs I None
and I None
PMs I None
in I None
terms I None
of I None
IC50 I None
values I None
, I None
representing I None
metoprolol I Chemical
plasma I None
concentrations I None
resulting I None
in I None
half I None
- I None
maximum I None
receptor I None
occupancy I None
. I None
<eof> I None

<s> O None
Six I None
EMs I None
received I None
0.5 I None
mg I None
of I None
terbutaline I Chemical
s.c I None
. I None
<eof> I None

<s> O None
on I None
two I None
different I None
occasions I None
: I None
1 I None
) I None
1 I None
hr I None
after I None
administration I None
of I None
a I None
placebo I None
and I None
2 I None
) I None
1 I None
hr I None
after I None
150 I None
mg I None
of I None
metoprolol I Chemical
p.o I None
. I None
<eof> I None

<s> O None
Five I None
PMs I None
were I None
studied I None
according I None
to I None
the I None
same I None
protocol I None
, I None
except I None
for I None
a I None
higher I None
terbutaline I Chemical
dose I None
( I None
0.75 I None
mg I None
) I None
on I None
day I None
2 I None
. I None
<eof> I None

<s> O None
Blood I None
samples I None
for I None
the I None
analysis I None
of I None
plasma I None
potassium I Chemical
, I None
terbutaline I Chemical
, I None
metoprolol I Chemical
( I None
racemic I None
, I None
R- I None
and I None
S I None
- I None
isomer I None
) I None
, I None
and I None
alpha I Chemical
- O Chemical
hydroxymetoprolol O Chemical
concentrations I None
were I None
taken I None
at I None
regular I None
time I None
intervals I None
, I None
during I None
8 I None
hr I None
after I None
metoprolol I Chemical
. I None
<eof> I None

<s> O None
In I None
PMs I None
, I None
metoprolol I Chemical
increased I None
the I None
terbutaline I Chemical
area I None
under I None
the I None
plasma I None
concentration I None
vs. I None
time I None
curve I None
( I None
+ I None
67 I None
% I None
) I None
. I None
<eof> I None

<s> O None
Higher I None
metoprolol I Chemical
/ I None
alpha I Chemical
- O Chemical
hydroxymetoprolol O Chemical
ratios I None
in I None
PMs I None
were I None
predictive I None
for I None
higher I None
R-/S I None
- I None
isomer I None
ratios I None
of I None
unchanged I None
drug I None
. I None
<eof> I None

<s> O None
There I None
was I None
a I None
difference I None
in I None
metoprolol I Chemical
potency I None
with I None
higher I None
racemic I None
metoprolol I Chemical
IC50 I None
values I None
in I None
PMs I None
( I None
72 I None
+ I None
/- I None
<eof> I None

<s> O None
7 I None
ng.ml-1 I None
) I None
than I None
EMs I None
( I None
42 I None
+ I None
/- I None
<eof> I None

<s> O None
8 I None
ng.ml-1 I None
, I None
P I None
less I None
than I None
.001).(ABSTRACT I None
TRUNCATED I None
AT I None
250 I None
WORDS I None
) I None
<eof> I None

<s> O None
Cefotetan I Chemical
-induced I None
immune I None
hemolytic I Disease
anemia O Disease
. I None
<eof> I None

<s> O None
Immune I None
hemolytic I Disease
anemia O Disease
due I None
to I None
a I None
drug I None
- I None
adsorption I None
mechanism I None
has I None
been I None
described I None
primarily I None
in I None
patients I None
receiving I None
penicillins I Chemical
and I None
first I None
- I None
generation I None
cephalosporins I Chemical
. I None
<eof> I None

<s> O None
We I None
describe I None
a I None
patient I None
who I None
developed I None
anemia I Disease
while I None
receiving I None
intravenous I None
cefotetan I Chemical
. I None
<eof> I None

<s> O None
Cefotetan I Chemical
-dependent I None
antibodies I None
were I None
detected I None
in I None
the I None
patient I None
's I None
serum I None
and I None
in I None
an I None
eluate I None
prepared I None
from I None
his I None
red I None
blood I None
cells I None
. I None
<eof> I None

<s> O None
The I None
eluate I None
also I None
reacted I None
weakly I None
with I None
red I None
blood I None
cells I None
in I None
the I None
absence I None
of I None
cefotetan I Chemical
, I None
suggesting I None
the I None
concomitant I None
formation I None
of I None
warm I None
- I None
reactive I None
autoantibodies I None
. I None
<eof> I None

<s> O None
These I None
observations I None
, I None
in I None
conjunction I None
with I None
clinical I None
and I None
laboratory I None
evidence I None
of I None
extravascular I None
hemolysis I Disease
, I None
are I None
consistent I None
with I None
drug I None
- I None
induced I None
hemolytic I Disease
anemia O Disease
, I None
possibly I None
involving I None
both I None
drug I None
- I None
adsorption I None
and I None
autoantibody I None
formation I None
mechanisms I None
. I None
<eof> I None

<s> O None
This I None
case I None
emphasizes I None
the I None
need I None
for I None
increased I None
awareness I None
of I None
hemolytic I None
reactions I None
to I None
all I None
cephalosporins I Chemical
. I None
<eof> I None

<s> O None
Acute I Disease
renal O Disease
failure O Disease
subsequent I None
to I None
the I None
administration I None
of I None
rifampicin I Chemical
. I None
<eof> I None

<s> O None
A I None
follow I None
- I None
up I None
study I None
of I None
cases I None
reported I None
earlier I None
. I None
<eof> I None

<s> O None
A I None
clinical I None
presentation I None
is I None
made I None
of I None
a I None
2 I None
- I None
3 I None
year I None
follow I None
- I None
up I None
of I None
six I None
cases I None
of I None
acute I Disease
renal O Disease
failure O Disease
that I None
have I None
been I None
reported I None
earlier I None
. I None
<eof> I None

<s> O None
The I None
patients I None
had I None
developed I None
transient I None
renal I Disease
failure O Disease
after I None
the I None
intermittent I None
administration I None
of I None
rifampicin I Chemical
. I None
<eof> I None

<s> O None
The I None
stage I None
of I None
olig- I None
anuria I Disease
lasted I None
for I None
1 I None
- I None
3 I None
weeks I None
, I None
and I None
five I None
of I None
the I None
patients I None
were I None
treated I None
by I None
hemodialysis I None
. I None
<eof> I None

<s> O None
Two I None
of I None
the I None
patients I None
died I None
due I None
to I None
unrelated I None
causes I None
during I None
the I None
follow I None
- I None
up I None
period I None
. I None
<eof> I None

<s> O None
The I None
four I None
patients I None
re I None
- I None
examined I None
were I None
clinically I None
cured I None
. I None
<eof> I None

<s> O None
Pathologic I None
findings I None
by I None
light I None
microscopy I None
and I None
immunofluorescence I None
at I None
biopsy I None
were I None
scarce I None
. I None
<eof> I None

<s> O None
Nothing I None
abnormal I None
was I None
seen I None
by I None
electron I None
microscopy I None
in I None
two I None
of I None
the I None
cases I None
studied I None
. I None
<eof> I None

<s> O None
Renal I None
function I None
was I None
normal I None
. I None
<eof> I None

<s> O None
In I None
three I None
cases I None
the I None
excretion I None
at I None
131I I None
- I None
hippuran I None
renography I None
was I None
slightly I None
slowed I None
. I None
<eof> I None

<s> O None
Although I None
in I None
the I None
acute I None
stage I None
the I None
renal I Disease
lesions O Disease
<eof> I None

<s> O None
histologically I None
appeared I None
toxic I None
, I None
evidence I None
suggestive I None
of I None
an I None
immunological I None
mechanism I None
can I None
not I None
be I None
excluded I None
. I None
<eof> I None

<s> O None
Type I Disease
B O Disease
hepatitis O Disease
after I None
needle I None
- I None
stick I None
exposure I None
: I None
prevention I None
with I None
hepatitis I Disease
B O Disease
immune I None
globulin I None
. I None
<eof> I None

<s> O None
Final I None
report I None
of I None
the I None
Veterans I None
Administration I None
Cooperative I None
Study I None
. I None
<eof> I None

<s> O None
Hepatitis I Disease
B O Disease
immune I None
globulin I None
( I None
HBIG I None
) I None
and I None
immune I None
serum I None
globulin I None
( I None
ISG I None
) I None
were I None
examined I None
in I None
a I None
randomized I None
, I None
double I None
- I None
blind I None
trial I None
to I None
assess I None
their I None
relative I None
efficacies I None
in I None
preventing I None
type I Disease
B O Disease
hepatitis O Disease
after I None
needle I None
- I None
stick I None
exposure I None
to I None
hepatitis I Chemical
B O Chemical
surface O Chemical
antigen O Chemical
<eof> I None

<s> O None
( I None
HBsAG I Chemical
) I None
-positive I None
donors I None
. I None
<eof> I None

<s> O None
Clinical I None
hepatitis I Disease
developed I None
in I None
1.4 I None
% I None
of I None
HBIG I None
and I None
in I None
5.9 I None
% I None
of I None
ISG I None
recipients I None
( I None
P I None
= I None
0.016 I None
) I None
, I None
and I None
seroconversion I None
( I None
anti I None
- I None
HBs I None
) I None
occurred I None
in I None
5.6 I None
% I None
and I None
20.7 I None
% I None
of I None
them I None
respectively I None
( I None
P I None
less I None
than I None
0.001 I None
) I None
. I None
<eof> I None

<s> O None
Mild I None
and I None
transient I None
side I None
- I None
effects I None
were I None
noted I None
in I None
3.0 I None
% I None
of I None
ISG I None
and I None
in I None
3.2 I None
% I None
of I None
HBIG I None
recipients I None
. I None
<eof> I None

<s> O None
Available I None
donor I None
sera I None
were I None
examined I None
for I None
DNA I None
polymerase I None
( I None
DNAP I None
) I None
and I None
e I None
antigen I None
and I None
antibody I None
( I None
HBeAg I Chemical
; I None
anti I None
- I None
HBE I None
) I None
. I None
<eof> I None

<s> O None
Both I None
DNAP I None
and I None
HBeAg I Chemical
showed I None
a I None
highly I None
statistically I None
significant I None
correlation I None
with I None
the I None
infectivity I None
of I None
HBsAg I Chemical
-positive I None
donors I None
. I None
<eof> I None

<s> O None
Hepatitis I Disease
B O Disease
immune I None
globulin I None
remained I None
significantly I None
superior I None
to I None
ISG I None
in I None
preventing I None
type I Disease
B O Disease
hepatitis O Disease
even I None
when I None
the I None
analysis I None
was I None
confined I None
to I None
these I None
two I None
high I None
- I None
risk I None
subgroups I None
. I None
<eof> I None

<s> O None
The I None
efficacy I None
of I None
ISG I None
in I None
preventing I None
type I Disease
B O Disease
hepatitis O Disease
can I None
not I None
be I None
ascertained I None
because I None
a I None
true I None
placebo I None
group I None
was I None
not I None
included I None
. I None
<eof> I None

<s> O None
Serotonin I Disease
syndrome O Disease
from I None
venlafaxine I Chemical
- I None
tranylcypromine I Chemical
interaction I None
. I None
<eof> I None

<s> O None
Excessive I None
stimulation I None
of I None
serotonin I Chemical
<eof> I None

<s> O None
5HT1A I None
receptors I None
causes I None
a I None
syndrome I None
of I None
serotonin I Chemical
<eof> I None

<s> O None
excess I None
that I None
consists I None
of I None
shivering I None
, I None
muscle I Disease
rigidity O Disease
, I None
salivation I Disease
, I None
confusion I Disease
, I None
agitation I Disease
and I None
hyperthermia I Disease
. I None
<eof> I None

<s> O None
The I None
most I None
common I None
cause I None
of I None
this I None
syndrome I None
is I None
an I None
interaction I None
between I None
a I None
monoamine I None
oxidase I None
inhibitor I None
( I None
MAOI I None
) I None
and I None
a I None
specific I None
serotonin I Chemical
reuptake I None
inhibitor I None
. I None
<eof> I None

<s> O None
Venlafaxine I Chemical
is I None
a I None
new I None
antidepressant I None
agent I None
that I None
inhibits I None
the I None
reuptake I None
of I None
serotonin I Chemical
and I None
norepinephrine I Chemical
. I None
<eof> I None

<s> O None
We I None
report I None
a I None
venlafaxine I Chemical
<eof> I None

<s> O None
-MAOI I None
interaction I None
that I None
resulted I None
in I None
the I None
serotonin I Disease
syndrome O Disease
in I None
a I None
23-y I None
- I None
old I None
male I None
who I None
was I None
taking I None
tranylcypromine I Chemical
for I None
depression I Disease
. I None
<eof> I None

<s> O None
He I None
had I None
been I None
well I None
until I None
the I None
morning I None
of I None
presentation I None
when I None
he I None
took I None
1/2 I None
tab I None
of I None
venlafaxine I Chemical
. I None
<eof> I None

<s> O None
Within I None
2 I None
h I None
he I None
became I None
confused I None
with I None
jerking I None
movements I None
of I None
his I None
extremities I None
, I None
tremors I Disease
and I None
rigidity I Disease
. I None
<eof> I None

<s> O None
He I None
was I None
brought I None
directly I None
to I None
a I None
hospital I None
where I None
he I None
was I None
found I None
to I None
be I None
agitated I None
and I None
confused I None
with I None
shivering I None
, I None
myoclonic I Disease
jerks O Disease
, I None
rigidity I Disease
, I None
salivation I Disease
and I None
diaphoresis I None
. I None
<eof> I None

<s> O None
His I None
pupils I None
were I None
7 I None
mm I None
and I None
sluggishly I None
reactive I None
to I None
light I None
. I None
<eof> I None

<s> O None
Vital I None
signs I None
were I None
: I None
blood I None
pressure I None
120/67 I None
mm I None
Hg I None
, I None
heart I None
rate I None
<eof> I None

<s> O None
127/min I None
, I None
respiratory I None
rate I None
28/min I None
, I None
and I None
temperature I None
97 I None
F. I None
<eof> I None

<s> O None
After I None
180 I None
mg I None
of I None
diazepam I Chemical
i.v I None
. I None
<eof> I None

<s> O None
he I None
remained I None
tremulous I None
with I None
muscle I Disease
rigidity O Disease
and I None
clenched I None
jaws I None
. I None
<eof> I None

<s> O None
He I None
was I None
intubated I None
for I None
airway I None
protection I None
and I None
because I None
of I None
hypoventilation I Disease
, I None
and I None
was I None
paralyzed I Disease
to I None
control I None
muscle I Disease
rigidity O Disease
. I None
<eof> I None

<s> O None
His I None
subsequent I None
course I None
was I None
remarkable I None
for I None
non I None
- I None
immune I None
thrombocytopenia I Disease
which I None
resolved I None
. I None
<eof> I None

<s> O None
The I None
patient I None
's I None
maximal I None
temperature I None
was I None
101.2 I None
F I None
and I None
his I None
CPK I None
remained I None
< I None
500 I None
units I None
/ I None
L I None
with I None
no I None
other I None
evidence I None
of I None
rhabdomyolysis I Disease
. I None
<eof> I None

<s> O None
His I None
mental I None
status I None
normalized I None
and I None
he I None
was I None
transferred I None
to I None
a I None
psychiatry I None
ward I None
. I None
<eof> I None

<s> O None
This I None
patient I None
survived I None
without I None
sequelae I None
due I None
to I None
the I None
aggressive I None
sedation I None
and I None
neuromuscular I None
paralysis I Disease
. I None
<eof> I None

<s> O None
Effect I None
of I None
nondopaminergic I None
drugs I None
on I None
L I Chemical
- O Chemical
dopa O Chemical
-induced I None
<eof> I None

<s> O None
dyskinesias I Disease
in I None
MPTP I Chemical
-treated I None
monkeys I None
. I None
<eof> I None

<s> O None
A I None
group I None
of I None
four I None
monkeys I None
was I None
rendered I None
<eof> I None

<s> O None
parkinsonian I Disease
with I None
the I None
toxin I None
MPTP I Chemical
. I None
<eof> I None

<s> O None
They I None
were I None
then I None
treated I None
chronically I None
with I None
L I Chemical
- O Chemical
DOPA O Chemical
/ O Chemical
benserazide O Chemical
<eof> I None

<s> O None
50/12.5 I None
mg I None
/ I None
kg I None
given I None
orally I None
daily I None
for I None
2 I None
months I None
. I None
<eof> I None

<s> O None
This I None
dose I None
produced I None
a I None
striking I None
antiparkinsonian I None
effect I None
, I None
but I None
all I None
animals I None
manifested I None
dyskinesia I Disease
. I None
<eof> I None

<s> O None
A I None
series I None
of I None
agents I None
acting I None
primarily I None
on I None
neurotransmitters I None
other I None
than I None
dopamine I Chemical
were I None
then I None
tested I None
in I None
combination I None
with I None
L I Chemical
- O Chemical
DOPA O Chemical
to I None
see I None
if I None
the I None
dyskinetic I Disease
movements I None
would I None
be I None
modified I None
. I None
<eof> I None

<s> O None
Several I None
drugs I None
, I None
including I None
clonidine I Chemical
, I None
physostigmine I Chemical
, I None
methysergide I Chemical
, I None
5-MDOT I Chemical
, I None
propranolol I Chemical
, I None
and I None
MK-801 I Chemical
, I None
markedly I None
reduced I None
the I None
dyskinetic I Disease
movements I None
but I None
at I None
the I None
cost I None
of I None
a I None
return I None
of I None
parkinsonian I Disease
symptomatology I None
. I None
<eof> I None

<s> O None
However I None
, I None
yohimbine I Chemical
and I None
meperidine I Chemical
reduced I None
predominantly I None
the I None
dyskinetic I Disease
movements I None
. I None
<eof> I None

<s> O None
Baclofen I Chemical
was I None
also I None
useful I None
in I None
one I None
monkey I None
against I None
a I None
more I None
dystonic I Disease
form I None
of I None
dyskinesia I Disease
. I None
<eof> I None

<s> O None
Atropine I Chemical
converted I None
the I None
dystonic I Disease
movements I None
into I None
chorea I Disease
. I None
<eof> I None

<s> O None
CCNU I Chemical
( I None
lomustine I Chemical
) I None
toxicity I Disease
in I None
dogs I None
: I None
a I None
retrospective I None
study I None
( I None
2002 I None
- I None
07 I None
) I None
. I None
<eof> I None

<s> O None
OBJECTIVE I None
: I None
<eof> I None

<s> O None
To I None
describe I None
the I None
incidence I None
of I None
haematological I None
, I None
renal I None
, I None
hepatic I None
and I None
gastrointestinal I None
toxicities I None
in I None
tumour I None
- I None
bearing I None
dogs I None
receiving I None
1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea I Chemical
<eof> I None

<s> O None
( I None
CCNU I Chemical
) I None
. I None
<eof> I None

<s> O None
DESIGN I None
: I None
<eof> I None

<s> O None
The I None
medical I None
records I None
of I None
206 I None
dogs I None
that I None
were I None
treated I None
with I None
CCNU I Chemical
at I None
the I None
Melbourne I None
Veterinary I None
Specialist I None
Centre I None
between I None
February I None
2002 I None
and I None
December I None
2007 I None
were I None
retrospectively I None
evaluated I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
Of I None
the I None
206 I None
dogs I None
treated I None
with I None
CCNU I Chemical
, I None
185 I None
met I None
the I None
inclusion I None
criteria I None
for I None
at I None
least I None
one I None
class I None
of I None
toxicity I Disease
. I None
<eof> I None

<s> O None
CCNU I Chemical
was I None
used I None
most I None
commonly I None
in I None
the I None
treatment I None
of I None
lymphoma I Disease
, I None
mast I Disease
cell O Disease
tumour O Disease
, I None
brain I Disease
tumour O Disease
, I None
histiocytic I Disease
tumours O Disease
and I None
epitheliotropic I Disease
lymphoma O Disease
. I None
<eof> I None

<s> O None
Throughout I None
treatment I None
, I None
56.9 I None
% I None
of I None
dogs I None
experienced I None
neutropenia I Disease
, I None
34.2 I None
% I None
experienced I None
anaemia I Disease
and I None
14.2 I None
% I None
experienced I None
thrombocytopenia I Disease
. I None
<eof> I None

<s> O None
Gastrointestinal I Disease
toxicosis O Disease
was I None
detected I None
in I None
37.8 I None
% I None
of I None
dogs I None
, I None
the I None
most I None
common I None
sign I None
of I None
which I None
was I None
vomiting I Disease
( I None
24.3 I None
% I None
) I None
. I None
<eof> I None

<s> O None
Potential I None
renal I None
toxicity I Disease
and I None
elevated I None
alanine I Chemical
transaminase I None
( I None
ALT I None
) I None
concentration I None
were I None
reported I None
in I None
12.2 I None
% I None
and I None
48.8 I None
% I None
of I None
dogs I None
, I None
respectively I None
. I None
<eof> I None

<s> O None
The I None
incidence I None
of I None
hepatic I Disease
failure O Disease
was I None
1.2 I None
% I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
CCNU I Chemical
-associated I None
<eof> I None

<s> O None
toxicity I Disease
in I None
dogs I None
is I None
common I None
, I None
but I None
is I None
usually I None
not I None
life I None
threatening I None
. I None
<eof> I None

<s> O None
Neuroactive I None
steroids I Chemical
protect I None
against I None
pilocarpine I Chemical
- I None
and I None
kainic I Chemical
acid O Chemical
-induced I None
limbic I None
<eof> I None

<s> O None
seizures I Disease
and I None
status I Disease
epilepticus O Disease
in I None
mice I None
. I None
<eof> I None

<s> O None
Several I None
structurally I None
related I None
metabolites I None
of I None
progesterone I Chemical
<eof> I None

<s> O None
( I None
3 I Chemical
alpha O Chemical
- O Chemical
hydroxy O Chemical
pregnane-20-ones O Chemical
) I None
and I None
deoxycorticosterone I Chemical
<eof> I None

<s> O None
( I None
3 I Chemical
alpha O Chemical
- O Chemical
hydroxy O Chemical
pregnane-21-diol-20-ones O Chemical
) I None
and I None
their I None
3 I None
beta I None
- I None
epimers I None
were I None
evaluated I None
for I None
protective I None
activity I None
against I None
pilocarpine I Chemical
- I None
, I None
kainic I Chemical
acid O Chemical
- I None
and I None
N I Chemical
- O Chemical
methyl O Chemical
- O Chemical
D O Chemical
- O Chemical
aspartate O Chemical
( I None
NMDA I Chemical
) I None
-induced I None
<eof> I None

<s> O None
seizures I Disease
in I None
mice I None
. I None
<eof> I None

<s> O None
Steroids I Chemical
with I None
the I None
3-hydroxy I None
group I None
in I None
the I None
alpha I None
- I None
position I None
and I None
5-H I None
in I None
the I None
alpha- I None
or I None
beta I None
- I None
configurations I None
were I None
highly I None
effective I None
in I None
protecting I None
against I None
pilocarpine I Chemical
<eof> I None

<s> O None
( I None
416 I None
mg I None
/ I None
kg I None
, I None
s.c.)-induced I None
limbic I None
motor I None
seizures I Disease
and I None
status I Disease
epilepticus O Disease
( I None
ED50 I None
values I None
, I None
7.0 I None
- I None
18.7 I None
mg I None
/ I None
kg I None
, I None
i.p I None
. I None
) I None
. I None
<eof> I None

<s> O None
The I None
corresponding I None
epimers I None
with I None
the I None
3-hydroxy I None
group I None
in I None
the I None
beta I None
- I None
position I None
were I None
also I None
effective I None
but I None
less I None
potent I None
( I None
ED50 I None
values I None
, I None
33.8 I None
- I None
63.5 I None
, I None
i.p I None
. I None
) I None
. I None
<eof> I None

<s> O None
Although I None
the I None
neuroactive I None
steroids I Chemical
were I None
considerably I None
less I None
potent I None
than I None
the I None
benzodiazepine I Chemical
clonazepam I Chemical
in I None
protecting I None
against I None
pilocarpine I Chemical
seizures I Disease
, I None
steroids I Chemical
with I None
the I None
5 I None
alpha,3 I None
alpha I None
- I None
configuration I None
had I None
comparable I None
or I None
higher I None
protective I None
index I None
values I None
( I None
TD50 I None
for I None
motor I None
impairment I None
divided I None
by I None
ED50 I None
for I None
seizure I Disease
protection I None
) I None
than I None
clonazepam I Chemical
, I None
indicating I None
that I None
some I None
neuroactive I None
steroids I Chemical
may I None
have I None
lower I None
relative I None
toxicity I Disease
. I None
<eof> I None

<s> O None
Steroids I Chemical
with I None
the I None
5 I None
alpha,3 I None
alpha- I None
or I None
5 I None
beta,3 I None
alpha I None
- I None
configurations I None
also I None
produced I None
a I None
dose I None
- I None
dependent I None
delay I None
in I None
the I None
onset I None
of I None
limbic I None
seizures I Disease
induced I None
by I None
kainic I Chemical
acid O Chemical
<eof> I None

<s> O None
( I None
32 I None
mg I None
/ I None
kg I None
, I None
s.c I None
. I None
) I None
, I None
but I None
did I None
not I None
completely I None
protect I None
against I None
the I None
seizures I Disease
. I None
<eof> I None

<s> O None
However I None
, I None
when I None
a I None
second I None
dose I None
of I None
the I None
steroid I Chemical
was I None
administered I None
1 I None
hr I None
after I None
the I None
first I None
dose I None
, I None
complete I None
protection I None
from I None
the I None
kainic I Chemical
acid O Chemical
-induced I None
limbic I None
seizures I Disease
and I None
status I Disease
epilepticus O Disease
was I None
obtained I None
. I None
<eof> I None

<s> O None
The I None
steroids I Chemical
also I None
caused I None
a I None
dose I None
- I None
dependent I None
delay I None
in I None
NMDA I Chemical
<eof> I None

<s> O None
( I None
257 I None
mg I None
/ I None
kg I None
, I None
s.c.)-induced I None
lethality I None
, I None
but I None
did I None
not I None
completely I None
protect I None
against I None
NMDA I Chemical
seizures I Disease
or I None
lethality I None
. I None
<eof> I None

<s> O None
We I None
conclude I None
that I None
neuroactive I None
<eof> I None

<s> O None
steroids I Chemical
are I None
highly I None
effective I None
in I None
protecting I None
against I None
pilocarpine I Chemical
- I None
and I None
kainic I Chemical
acid O Chemical
-induced I None
<eof> I None

<s> O None
seizures I Disease
and I None
status I Disease
epilepticus O Disease
in I None
mice I None
, I None
and I None
may I None
be I None
of I None
utility I None
in I None
the I None
treatment I None
of I None
some I None
forms I None
of I None
status I Disease
epilepticus O Disease
in I None
humans I None
. I None
<eof> I None

<s> O None
The I None
safety I None
and I None
efficacy I None
of I None
combination I None
N I Chemical
- O Chemical
butyl O Chemical
- O Chemical
deoxynojirimycin O Chemical
<eof> I None

<s> O None
( I None
SC-48334 I Chemical
) I None
and I None
zidovudine I Chemical
in I None
patients I None
with I None
HIV-1 I Disease
infection O Disease
and I None
200 I None
- I None
500 I None
CD4 I None
cells I None
/ I None
mm3 I None
. I None
<eof> I None

<s> O None
We I None
conducted I None
a I None
double I None
- I None
blind I None
, I None
randomized I None
phase I None
II I None
study I None
to I None
evaluate I None
the I None
safety I None
and I None
activity I None
of I None
combination I None
therapy I None
with I None
N I Chemical
- O Chemical
butyl O Chemical
- O Chemical
deoxynojirimycin O Chemical
<eof> I None

<s> O None
( I None
SC-48334 I Chemical
) I None
( I None
an I None
alpha I None
- I None
glucosidase I None
<eof> I None

<s> O None
I I None
inhibitor I None
) I None
and I None
zidovudine I Chemical
versus I None
zidovudine I Chemical
alone I None
. I None
<eof> I None

<s> O None
Patients I None
with I None
200 I None
to I None
500 I None
CD4 I None
cells I None
/ I None
mm3 I None
who I None
tolerated I None
< I None
or I None
= I None
12 I None
weeks I None
of I None
prior I None
zidovudine I Chemical
therapy I None
received I None
SC-48334 I Chemical
<eof> I None

<s> O None
( I None
1000 I None
mg I None
every I None
8 I None
h I None
) I None
and I None
zidovudine I Chemical
<eof> I None

<s> O None
( I None
100 I None
mg I None
every I None
8 I None
h I None
) I None
or I None
zidovudine I Chemical
and I None
placebo I None
. I None
<eof> I None

<s> O None
Sixty I None
patients I None
received I None
combination I None
therapy I None
and I None
58 I None
, I None
zidovudine I Chemical
and I None
placebo I None
. I None
<eof> I None

<s> O None
Twenty I None
- I None
three I None
patients I None
( I None
38 I None
% I None
) I None
and I None
15 I None
( I None
26 I None
% I None
) I None
, I None
in I None
the I None
combination I None
and I None
zidovudine I Chemical
groups I None
, I None
respectively I None
, I None
discontinued I None
therapy I None
( I None
p I None
= I None
0.15 I None
) I None
. I None
<eof> I None

<s> O None
The I None
mean I None
SC-48334 I Chemical
steady I None
- I None
state I None
trough I None
level I None
( I None
4.04 I None
+ I None
/- I None
<eof> I None

<s> O None
0.99 I None
micrograms I None
/ I None
ml I None
) I None
was I None
below I None
the I None
in I None
vitro I None
inhibitory I None
concentration I None
for I None
human I None
immunodeficiency I Disease
virus I None
( I None
HIV I None
) I None
. I None
<eof> I None

<s> O None
The I None
mean I None
increase I None
in I None
CD4 I None
cells I None
at I None
week I None
4 I None
was I None
73.8 I None
cells I None
/ I None
mm3 I None
and I None
52.4 I None
cells I None
/ I None
mm3 I None
for I None
the I None
combination I None
and I None
zidovudine I Chemical
groups I None
, I None
respectively I None
( I None
p I None
> I None
0.36 I None
) I None
. I None
<eof> I None

<s> O None
For I None
patients I None
with I None
prior I None
zidovudine I Chemical
therapy I None
, I None
the I None
mean I None
change I None
in I None
CD4 I None
cells I None
in I None
the I None
combination I None
and I None
zidovudine I Chemical
groups I None
was I None
63.7 I None
cells I None
/ I None
mm3 I None
and I None
4.9 I None
cells I None
/ I None
mm3 I None
at I None
week I None
8 I None
and I None
6.8 I None
cells I None
/ I None
mm3 I None
and I None
-45.1 I None
cells I None
/ I None
mm3 I None
at I None
week I None
16 I None
, I None
respectively I None
. I None
<eof> I None

<s> O None
The I None
number I None
of I None
patients I None
with I None
suppression I None
of I None
HIV I None
p24 I None
antigenemia I None
in I None
the I None
combination I None
and I None
zidovudine I Chemical
groups I None
was I None
six I None
( I None
40 I None
% I None
) I None
and I None
two I None
( I None
11 I None
% I None
) I None
at I None
week I None
4 I None
( I None
p I None
= I None
0.10 I None
) I None
and I None
five I None
( I None
45 I None
% I None
) I None
and I None
two I None
( I None
14 I None
% I None
) I None
at I None
week I None
24 I None
( I None
p I None
= I None
0.08 I None
) I None
, I None
respectively I None
. I None
Diarrhea I Disease
, I None
flatulence I Disease
, I None
abdominal I Disease
pain O Disease
, I None
and I None
weight I Disease
loss O Disease
were I None
common I None
for I None
combination I None
recipients.(ABSTRACT I None
TRUNCATED I None
AT I None
250 I None
WORDS I None
) I None
<eof> I None

<s> O None
Recent I None
preclinical I None
and I None
clinical I None
studies I None
with I None
the I None
thymidylate I None
synthase I None
inhibitor I None
N10-propargyl-5,8-dideazafolic I Chemical
acid O Chemical
<eof> I None

<s> O None
( I None
CB I Chemical
3717 O Chemical
) I None
. I None
<eof> I None

<s> O None
CB I Chemical
3717 O Chemical
, I None
N10-propargyl-5,8-dideazafolic I Chemical
acid O Chemical
, I None
is I None
a I None
tight I None
- I None
binding I None
inhibitor I None
of I None
thymidylate I None
synthase I None
( I None
TS I None
) I None
whose I None
cytotoxicity I Disease
is I None
mediated I None
solely I None
through I None
the I None
inhibition I None
of I None
this I None
enzyme I None
. I None
<eof> I None

<s> O None
Recent I None
preclinical I None
studies I None
have I None
focused I None
on I None
the I None
intracellular I None
formation I None
of I None
CB I Chemical
3717 O Chemical
polyglutamates I None
. I None
<eof> I None

<s> O None
Following I None
a I None
12-hour I None
exposure I None
of I None
L1210 I None
cells I None
to I None
50 I None
microM I None
[ I None
3H I None
] I None
CB I Chemical
3717 O Chemical
, I None
30 I None
% I None
of I None
the I None
extractable I None
radioactivity I None
could I None
be I None
accounted I None
for I None
as I None
CB I Chemical
3717 O Chemical
tetra- I None
and I None
pentaglutamate I None
, I None
as I None
determined I None
by I None
high I None
- I None
pressure I None
liquid I None
chromatography I None
( I None
HPLC I None
) I None
analyses I None
. I None
<eof> I None

<s> O None
As I None
inhibitors I None
of I None
isolated I None
L1210 I None
TS I None
, I None
CB I None
3717 I None
di- I None
, I None
tri- I None
, I None
tetra- I None
and I None
pentaglutamate I None
are I None
26- I None
, I None
87- I None
, I None
119- I None
and I None
114-fold I None
more I None
potent I None
than I None
CB I Chemical
3717 O Chemical
, I None
respectively I None
, I None
and I None
their I None
formation I None
may I None
, I None
therefore I None
, I None
be I None
an I None
important I None
determinant I None
of I None
CB I Chemical
3717 O Chemical
cytotoxicity I Disease
. I None
<eof> I None

<s> O None
In I None
early I None
clinical I None
studies I None
with I None
CB I Chemical
3717 O Chemical
, I None
activity I None
has I None
been I None
seen I None
in I None
breast I Disease
cancer O Disease
, I None
ovarian I Disease
cancer O Disease
, I None
hepatoma I Disease
, I None
and I None
mesothelioma I Disease
. I None
<eof> I None

<s> O None
Toxicities I Disease
included I None
<eof> I None

<s> O None
hepatotoxicity I Disease
, I None
malaise I Disease
, I None
and I None
dose I None
- I None
limiting I None
nephrotoxicity I Disease
. I None
<eof> I None

<s> O None
This I None
latter I None
effect I None
is I None
thought I None
to I None
be I None
due I None
to I None
drug I None
precipitation I None
within I None
the I None
renal I None
tubule I None
as I None
a I None
result I None
of I None
the I None
poor I None
solubility I None
of I None
CB I Chemical
3717 O Chemical
under I None
acidic I None
conditions I None
. I None
<eof> I None

<s> O None
In I None
an I None
attempt I None
to I None
overcome I None
this I None
problem I None
, I None
a I None
clinical I None
trial I None
of I None
CB I Chemical
3717 O Chemical
administered I None
with I None
alkaline I None
diuresis I None
is I None
under I None
way I None
. I None
<eof> I None

<s> O None
Preliminary I None
results I None
at I None
400 I None
and I None
500 I None
mg I None
/ I None
m2 I None
suggest I None
that I None
a I None
reduction I None
in I None
nephrotoxicity I Disease
may I None
have I None
been I None
achieved I None
with I None
only I None
1 I None
instance I None
of I None
renal I Disease
toxicity O Disease
in I None
10 I None
patients I None
. I None
<eof> I None

<s> O None
Hepatotoxicity I Disease
and I None
malaise I Disease
are I None
again I None
the I None
most I None
frequent I None
side I None
effects I None
. I None
<eof> I None

<s> O None
Evidence I None
of I None
antitumor I None
activity I None
has I None
been I None
seen I None
in I None
3 I None
patients I None
. I None
<eof> I None

<s> O None
Pharmacokinetic I None
investigations I None
have I None
shown I None
that I None
alkaline I None
diuresis I None
does I None
not I None
alter I None
CB I Chemical
3717 O Chemical
plasma I None
levels I None
or I None
urinary I None
excretion I None
and I None
that I None
satisfactory I None
urinary I None
alkalinization I None
can I None
be I None
readily I None
achieved I None
. I None
<eof> I None

<s> O None
Ethopropazine I Chemical
and I None
benztropine I Chemical
in I None
neuroleptic I None
- I None
induced I None
parkinsonism I Disease
. I None
<eof> I None

<s> O None
In I None
a I None
12-week I None
controlled I None
study I None
ethopropazine I Chemical
was I None
compared I None
to I None
benztropine I Chemical
in I None
the I None
treatment I None
of I None
parkinsonism I Disease
induced I None
by I None
fluphenazine I Chemical
enanthate O Chemical
in I None
60 I None
<eof> I None

<s> O None
schizophrenic I Disease
outpatients I None
. I None
<eof> I None

<s> O None
Ethopropazine I Chemical
and I None
benztropine I Chemical
were I None
found I None
to I None
be I None
equally I None
effective I None
in I None
controlling I None
parkinsonian I Disease
symptoms O Disease
and I None
were I None
as I None
efficacious I None
as I None
procyclidine I Chemical
, I None
their I None
previous I None
antiparkinsonian I None
drug I None
. I None
<eof> I None

<s> O None
However I None
, I None
benztropine I Chemical
treated I None
patients I None
had I None
a I None
significant I None
increase I None
in I None
tardive I Disease
dyskinesia O Disease
compared I None
to I None
their I None
condition I None
during I None
procyclindine I Chemical
treatment I None
, I None
and I None
significantly I None
more I None
<eof> I None

<s> O None
anxiety I Disease
and I None
depression I Disease
than I None
ethopropazine I Chemical
treated I None
patients I None
. I None
<eof> I None

<s> O None
This I None
suggests I None
that I None
benztropine I Chemical
is I None
not I None
the I None
anticholinergic I None
drug I None
of I None
choice I None
in I None
the I None
treatment I None
of I None
neuroleptic I None
- I None
induced I None
parkinsonian I Disease
symptoms O Disease
, I None
because I None
of I None
its I None
more I None
toxic I None
central I None
and I None
peripheral I None
atropinic I None
effect I None
. I None
<eof> I None

<s> O None
Effect I None
of I None
alpha I Chemical
- O Chemical
tocopherol O Chemical
and I None
deferoxamine I Chemical
on I None
methamphetamine I Chemical
-induced I None
neurotoxicity I Disease
. I None
<eof> I None

<s> O None
Methamphetamine I Chemical
( I None
MA I Chemical
) I None
-induced I None
<eof> I None

<s> O None
dopaminergic I None
neurotoxicity I Disease
is I None
believed I None
to I None
be I None
associated I None
with I None
the I None
increased I None
formation I None
of I None
free I None
radicals I None
. I None
<eof> I None

<s> O None
This I None
study I None
examined I None
the I None
effect I None
of I None
alpha I Chemical
- O Chemical
tocopherol O Chemical
<eof> I None

<s> O None
( I None
alpha I Chemical
- O Chemical
TC O Chemical
) I None
, I None
a I None
scavenger I None
of I None
reactive I None
oxygen I Chemical
species I None
, I None
and I None
deferoxamine I Chemical
<eof> I None

<s> O None
( I None
DFO I Chemical
) I None
, I None
an I None
iron I Chemical
chelator I None
, I None
on I None
the I None
MA I Chemical
-induced I None
neurotoxicity I Disease
. I None
<eof> I None

<s> O None
Male I None
rats I None
were I None
treated I None
with I None
MA I Chemical
<eof> I None

<s> O None
( I None
10 I None
mg I None
/ I None
kg I None
, I None
every I None
2 I None
h I None
for I None
four I None
injections I None
) I None
. I None
<eof> I None

<s> O None
The I None
rat I None
received I None
either I None
alpha I Chemical
- O Chemical
TC O Chemical
<eof> I None

<s> O None
( I None
20 I None
mg I None
/ I None
kg I None
) I None
<eof> I None

<s> O None
intraperitoneally I None
for I None
3 I None
days I None
and I None
30 I None
min I None
prior I None
to I None
MA I Chemical
administration I None
or I None
DFO I Chemical
<eof> I None

<s> O None
( I None
50 I None
mg I None
/ I None
kg I None
) I None
subcutaneously I None
30 I None
min I None
before I None
MA I Chemical
administration I None
. I None
<eof> I None

<s> O None
The I None
concentrations I None
of I None
dopamine I Chemical
<eof> I None

<s> O None
( I None
DA I Chemical
) I None
, I None
<eof> I None

<s> O None
serotonin I Chemical
and I None
their I None
metabolites I None
decreased I None
significantly I None
after I None
MA I Chemical
administration I None
, I None
which I None
was I None
inhibited I None
by I None
the I None
alpha I Chemical
- O Chemical
TC O Chemical
and I None
DFO I Chemical
pretreatment I None
. I None
<eof> I None

<s> O None
alpha I Chemical
- O Chemical
TC O Chemical
and I None
DFO I Chemical
attenuated I None
the I None
MA I Chemical
-induced I None
<eof> I None

<s> O None
hyperthermia I Disease
as I None
well I None
as I None
the I None
alterations I None
in I None
the I None
locomotor I None
activity I None
. I None
<eof> I None

<s> O None
The I None
level I None
of I None
lipid I None
peroxidation I None
was I None
higher I None
and I None
the I None
reduced I None
glutathione I Chemical
concentration I None
was I None
lower I None
in I None
the I None
MA I Chemical
-treated I None
rats I None
. I None
<eof> I None

<s> O None
These I None
changes I None
were I None
significantly I None
attenuated I None
by I None
alpha I Chemical
- O Chemical
TC O Chemical
and I None
DFO I Chemical
. I None
<eof> I None

<s> O None
This I None
suggests I None
that I None
alpha I Chemical
- O Chemical
TC O Chemical
and I None
DFO I Chemical
ameliorate I None
the I None
MA I Chemical
-induced I None
neuronal I Disease
damage O Disease
by I None
decreasing I None
the I None
level I None
of I None
oxidative I None
stress I None
. I None
<eof> I None

<s> O None
Use I None
of I None
dexamethasone I Chemical
with I None
mesna I Chemical
for I None
the I None
prevention I None
of I None
ifosfamide I Chemical
<eof> I None

<s> O None
-induced I None
hemorrhagic I None
cystitis I None
. I None
<eof> I None

<s> O None
AIM I None
: I None
Hemorrhagic I None
cystitis I None
( I None
HC I Disease
) I None
is I None
a I None
limiting I None
side I None
- I None
effect I None
of I None
chemotherapy I None
with I None
ifosfamide I Chemical
<eof> I None

<s> O None
( I None
IFS I Chemical
) I None
. I None
<eof> I None

<s> O None
In I None
the I None
study I None
presented I None
here I None
, I None
we I None
investigated I None
the I None
use I None
of I None
dexamethasone I Chemical
in I None
combination I None
with I None
mesna I Chemical
for I None
the I None
prevention I None
of I None
IFS I Chemical
-induced I None
HC I Disease
. I None
<eof> I None

<s> O None
METHODS I None
: I None
<eof> I None

<s> O None
Male I None
Wistar I None
rats I None
( I None
150 I None
- I None
200 I None
g I None
; I None
6 I None
rats I None
per I None
group I None
) I None
were I None
treated I None
with I None
saline I None
or I None
mesna I Chemical
5 I None
min I None
( I None
i.p I None
. I None
) I None
<eof> I None

<s> O None
before I None
and I None
2 I None
and I None
6 I None
h I None
after I None
( I None
v.o I None
. I None
) I None
<eof> I None

<s> O None
administration I None
of I None
IFS I Chemical
. I None
<eof> I None

<s> O None
One I None
, I None
two I None
or I None
three I None
doses I None
of I None
<eof> I None

<s> O None
mesna I Chemical
were I None
replaced I None
with I None
dexamethasone I Chemical
alone I None
or I None
with I None
dexamethasone I Chemical
plus I None
mesna I Chemical
. I None
<eof> I None

<s> O None
Cystitis I Disease
was I None
evaluated I None
24 I None
h I None
after I None
its I None
induction I None
by I None
the I None
changes I None
in I None
bladder I None
wet I None
weight I None
and I None
by I None
macroscopic I None
and I None
microscopic I None
analysis I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
The I None
replacement I None
of I None
the I None
last I None
dose I None
or I None
the I None
last I None
two I None
doses I None
of I None
mesna I Chemical
with I None
<eof> I None

<s> O None
dexamethasone I Chemical
reduced I None
the I None
increase I None
in I None
bladder I None
wet I None
weight I None
induced I None
by I None
IFS I Chemical
by I None
84.79 I None
% I None
and I None
89.13 I None
% I None
, I None
respectively I None
. I None
<eof> I None

<s> O None
In I None
addition I None
, I None
it I None
almost I None
abolished I None
the I None
macroscopic I None
and I None
microscopic I None
alterations I None
induced I None
by I None
IFS I Chemical
. I None
<eof> I None

<s> O None
Moreover I None
, I None
the I None
addition I None
of I None
dexamethasone I Chemical
to I None
the I None
last I None
two I None
doses I None
of I None
mesna I Chemical
was I None
more I None
efficient I None
than I None
three I None
doses I None
of I None
mesna I Chemical
alone I None
when I None
evaluated I None
microscopically I None
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
<eof> I None

<s> O None
Dexamethasone I Chemical
in I None
combination I None
with I None
mesna I Chemical
was I None
efficient I None
in I None
blocking I None
IFS I Chemical
-induced I None
<eof> I None

<s> O None
HC I Disease
. I None
<eof> I None

<s> O None
However I None
, I None
the I None
replacement I None
of I None
last I None
two I None
doses I None
of I None
mesna I Chemical
with I None
saline I None
or I None
all I None
of I None
the I None
mesna I Chemical
doses I None
with I None
dexamethasone I Chemical
did I None
not I None
prevent I None
HC I Disease
. I None
<eof> I None

<s> O None
Behavioral I None
effects I None
of I None
MK-801 I Chemical
on I None
reserpine I Chemical
-treated I None
mice I None
. I None
<eof> I None

<s> O None
The I None
effects I None
of I None
dizocilpine I Chemical
<eof> I None

<s> O None
( I None
MK-801 I Chemical
) I None
, I None
a I None
noncompetitive I None
N I Chemical
- O Chemical
methyl O Chemical
- O Chemical
D O Chemical
- O Chemical
aspartate O Chemical
<eof> I None

<s> O None
( I None
NMDA I Chemical
) I None
receptor I None
antagonist I None
, I None
were I None
studied I None
on I None
dopamine I Chemical
-related I None
behaviors I None
induced I None
by I None
reserpine I Chemical
treatments I None
. I None
<eof> I None

<s> O None
This I None
study I None
focuses I None
on I None
behavioral I None
syndromes I None
that I None
may I None
used I None
as I None
models I None
for I None
Parkinson I Disease
's O Disease
disease O Disease
, I None
or I None
tardive I Disease
dyskinesia O Disease
, I None
and I None
its I None
response I None
after I None
glutamatergic I None
blockage I None
. I None
<eof> I None

<s> O None
Reserpine I Chemical
( I None
1 I None
mg I None
/ I None
kg I None
) I None
, I None
administered I None
once I None
every I None
other I None
day I None
for I None
4 I None
days I None
, I None
produced I None
increases I None
in I None
orofacial I Disease
dyskinesia O Disease
, I None
tongue I None
protrusion I None
and I None
vacuous I None
chewing I None
in I None
mice I None
, I None
which I None
are I None
signs I None
indicative I None
of I None
tardive I Disease
dyskinesia O Disease
. I None
<eof> I None

<s> O None
Reserpine I Chemical
also I None
produced I None
<eof> I None

<s> O None
tremor I Disease
and I None
catalepsy I Disease
, I None
which I None
are I None
signs I None
suggestive I None
of I None
Parkinson I Disease
's O Disease
disease O Disease
. I None
<eof> I None

<s> O None
MK-801 I Chemical
( I None
0.1 I None
mg I None
/ I None
kg I None
) I None
, I None
administered I None
30 I None
min I None
before I None
the I None
observation I None
test I None
, I None
prevented I None
the I None
vacuous I None
chewing I None
movements I None
, I None
tongue I None
protrusions I None
and I None
catalepsy I Disease
induced I None
by I None
reserpine I Chemical
. I None
<eof> I None

<s> O None
However I None
, I None
MK-801 I Chemical
injection I None
produced I None
a I None
significant I None
increase I None
of I None
tremor I Disease
in I None
reserpine I Chemical
-treated I None
mice I None
. I None
<eof> I None

<s> O None
Reserpine I Chemical
( I None
1 I None
mg I None
/ I None
kg I None
) I None
, I None
administered I None
90 I None
min I None
before I None
the I None
test I None
and I None
followed I None
by I None
apomophine I Chemical
injection I None
( I None
0.1 I None
mg I None
/ I None
kg I None
) I None
5 I None
min I None
before I None
the I None
test I None
, I None
did I None
not I None
produce I None
oral I Disease
dyskinesia O Disease
in I None
mice I None
. I None
<eof> I None

<s> O None
On I None
the I None
other I None
hand I None
, I None
reserpine I Chemical
induced I None
increases I None
in I None
tremor I Disease
and I None
catalepsy I Disease
compared I None
to I None
control I None
mice I None
. I None
<eof> I None

<s> O None
MK-801 I Chemical
( I None
0.1 I None
mg I None
/ I None
kg I None
) I None
administration I None
attenuated I None
the I None
catalepsy I Disease
and I None
tremor I Disease
induced I None
by I None
reserpine I Chemical
. I None
<eof> I None

<s> O None
Pretreatment I None
with I None
reserpine I Chemical
<eof> I None

<s> O None
( I None
1 I None
mg I None
/ I None
kg I None
) I None
<eof> I None

<s> O None
24 I None
h I None
before I None
the I None
observation I None
test I None
produced I None
increases I None
in I None
vacuous I None
chewing I None
movements I None
and I None
tongue I None
protrusion I None
, I None
as I None
well I None
as I None
increases I None
in I None
tremor I Disease
and I None
catalepsy I Disease
, I None
whereas I None
MK-801 I Chemical
<eof> I None

<s> O None
( I None
0.1 I None
mg I None
/ I None
kg I None
) I None
injection I None
90 I None
min I None
before I None
the I None
test I None
reversed I None
the I None
effects I None
of I None
reserpine I Chemical
. I None
<eof> I None

<s> O None
These I None
results I None
show I None
that I None
reserpine I Chemical
produces I None
different I None
and I None
abnormal I Disease
movements O Disease
, I None
which I None
are I None
related I None
to I None
dose I None
and I None
schedule I None
employed I None
and I None
can I None
be I None
considered I None
as I None
parkinsonian I Disease
-like I None
and I None
tardive I Disease
dsykinesia O Disease
signs I None
. I None
<eof> I None

<s> O None
The I None
glutamatergic I None
blockage I None
produced I None
by I None
NMDA I Chemical
can I None
restore I None
these I None
signs I None
, I None
such I None
as I None
vacuous I None
chewing I None
movements I None
, I None
tongue I None
protrusions I None
, I None
catalepsy I Disease
and I None
tremor I Disease
according I None
to I None
the I None
employed I None
model I None
. I None
<eof> I None

<s> O None
Effect I None
of I None
glyceryl I Chemical
trinitrate O Chemical
on I None
the I None
sphincter I None
of I None
Oddi I None
spasm I None
evoked I None
by I None
prostigmine I Chemical
- I None
morphine I Chemical
administration I None
. I None
<eof> I None

<s> O None
OBJECTIVE I None
: I None
<eof> I None

<s> O None
In I None
this I None
study I None
the I None
effect I None
of I None
glyceryl I Chemical
trinitrate O Chemical
on I None
the I None
prostigmine I Chemical
- I None
morphine I Chemical
-induced I None
sphincter I None
of I None
Oddi I None
spasm I None
was I None
evaluated I None
in I None
nine I None
female I None
patients I None
with I None
sphincter I Disease
of O Disease
Oddi O Disease
dyskinesia O Disease
. I None
<eof> I None

<s> O None
METHOD I None
: I None
<eof> I None

<s> O None
Sphincter I None
of I None
Oddi I None
spasm I None
was I None
induced I None
by I None
prostigmine I Chemical
- I None
morphine I Chemical
administration I None
( I None
0.5 I None
mg I None
prostigmine I Chemical
intramuscularly I None
and I None
<eof> I None

<s> O None
10 I None
mg I None
<eof> I None

<s> O None
morphine I Chemical
subcutaneously I None
) I None
and I None
visualized I None
by I None
quantitative I None
hepatobiliary I None
scintigraphy I None
. I None
<eof> I None

<s> O None
The I None
entire I None
procedure I None
was I None
repeated I None
during I None
glyceryl I Chemical
trinitrate O Chemical
infusion I None
<eof> I None

<s> O None
( I None
Nitrolingual I Chemical
1 I None
microg I None
/ I None
kg I None
/ I None
min I None
for I None
120 I None
min I None
) I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
Prostigmine I Chemical
- I None
morphine I Chemical
provocation I None
caused I None
significant I None
increases I None
in I None
the I None
time I None
to I None
peak I None
activity I None
( I None
Tmax I None
) I None
over I None
the I None
hepatic I None
hilum I None
( I None
HH I None
: I None
34.33 I None
+ I None
/- I None
<eof> I None

<s> O None
5.05 I None
vs. I None
22.77 I None
+ I None
/- I None
3.26 I None
) I None
and I None
the I None
common I None
bile I None
duct I None
( I None
CBD I None
: I None
60.44 I None
+ I None
/- I None
5.99 I None
vs. I None
40.0 I None
+ I None
/- I None
2.88 I None
) I None
and I None
in I None
the I None
half I None
- I None
time I None
of I None
excretion I None
( I None
T1/2 I None
) I None
over I None
the I None
liver I None
parenchyma I None
( I None
LP I None
: I None
120.04 I None
+ I None
/- I None
16.01 I None
vs. I None
27.37 I None
+ I None
/- I None
2.19 I None
) I None
, I None
HH I None
( I None
117.61 I None
+ I None
/- I None
14.71 I None
vs. I None
31.85 I None
+ I None
/- I None
3.99 I None
) I None
and I None
CBD I None
( I None
158.11 I None
+ I None
/- I None
<eof> I None

<s> O None
9.18 I None
vs. I None
40.1 I None
+ I None
/- I None
<eof> I None

<s> O None
6.24 I None
) I None
, I None
<eof> I None

<s> O None
indicating I None
a I None
complete I None
spasm I Disease
at I None
the I None
level I None
of I None
the I None
sphincter I None
of I None
Oddi I None
. I None
<eof> I None

<s> O None
Glyceryl I Chemical
trinitrate O Chemical
infusion I None
completely I None
normalized I None
the I None
prostigmine I Chemical
- I None
morphine I Chemical
-induced I None
alterations I None
in I None
these I None
quantitative I None
parameters I None
( I None
TmaX I None
over I None
the I None
LP I None
: I None
11.33 I None
+ I None
/- I None
<eof> I None

<s> O None
1.13 I None
; I None
over I None
the I None
HH I None
: I None
18.88 I None
+ I None
/- I None
1.48 I None
; I None
and I None
over I None
the I None
CBD I None
: I None
36.22 I None
+ I None
/- I None
<eof> I None

<s> O None
1.92 I None
; I None
and I None
T1/2 I None
over I None
the I None
LP I None
: I None
28.21 I None
+ I None
/- I None
<eof> I None

<s> O None
1.83 I None
; I None
over I None
the I None
HH I None
: I None
33.42 I None
+ I None
/- I None
3.10 I None
; I None
and I None
over I None
the I None
CBD I None
: I None
41.66 I None
+ I None
/- I None
6.33 I None
) I None
, I None
suggesting I None
an I None
effective I None
sphincter I None
- I None
relaxing I None
effect I None
of I None
glyceryl I Chemical
trinitrate O Chemical
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
<eof> I None

<s> O None
These I None
results I None
provide I None
the I None
first I None
evidence I None
of I None
the I None
effectiveness I None
of I None
glyceryl I Chemical
trinitrate O Chemical
on I None
the I None
morphine I Chemical
-induced I None
sphincter I None
of I None
Oddi I None
spasm I None
in I None
humans I None
. I None
<eof> I None

<s> O None
Since I None
glyceryl I Chemical
trinitrate O Chemical
is I None
able I None
to I None
overcome I None
even I None
the I None
drastic I None
effect I None
of I None
morphine I Chemical
, I None
it I None
might I None
be I None
of I None
relevance I None
in I None
the I None
treatment I None
of I None
sphincter I Disease
of O Disease
Oddi O Disease
dyskinesia O Disease
. I None
<eof> I None

<s> O None
Effects I None
of I None
acute I None
steroid I Chemical
administration I None
on I None
ventilatory I None
and I None
peripheral I None
muscles I None
in I None
rats I None
. I None
<eof> I None

<s> O None
Occasional I None
case I None
reports I None
have I None
shown I None
that I None
acute I None
myopathy I Disease
may I None
occur I None
in I None
patients I None
treated I None
with I None
massive I None
doses I None
of I None
corticosteroids I Chemical
. I None
<eof> I None

<s> O None
The I None
mechanism I None
of I None
this I None
myopathy I Disease
is I None
poorly I None
understood I None
. I None
<eof> I None

<s> O None
Therefore I None
, I None
60 I None
male I None
rats I None
were I None
randomly I None
assigned I None
to I None
receive I None
daily I None
injection I None
of I None
saline I None
( I None
C I None
) I None
, I None
methylprednisolone I Chemical
<eof> I None

<s> O None
( I None
M I Chemical
) I None
, I None
or I None
triamcinolone I Chemical
( I None
T I Chemical
) I None
80 I None
mg I None
/ I None
kg I None
/ I None
<eof> I None

<s> O None
d I None
for I None
5 I None
d. I None
Nutritional I None
intake I None
, I None
measured I None
daily I None
in I None
15 I None
animals I None
, I None
showed I None
a I None
significant I None
reduction I Disease
of O Disease
food O Disease
intake O Disease
in I None
the I None
steroid I Chemical
-treated I None
groups I None
( I None
-50 I None
and I None
-79 I None
% I None
in I None
M I Chemical
and I None
T I Chemical
, I None
respectively I None
) I None
. I None
<eof> I None

<s> O None
This I None
was I None
associated I None
with I None
a I None
similar I None
loss I Disease
in O Disease
body O Disease
weight O Disease
. I None
<eof> I None

<s> O None
In I None
the I None
45 I None
remaining I None
animals I None
, I None
diaphragm I None
contractility I None
and I None
histopathologic I None
features I None
of I None
several I None
muscles I None
were I None
studied I None
. I None
<eof> I None

<s> O None
Weights I None
of I None
respiratory I None
and I None
peripheral I None
muscles I None
were I None
similarly I None
decreased I None
after I None
steroid I Chemical
treatment I None
. I None
<eof> I None

<s> O None
Maximal I None
twitches I None
of I None
the I None
diaphragm I None
were I None
lower I None
in I None
the I None
C I None
group I None
( I None
653 I None
+ I None
/- I None
<eof> I None

<s> O None
174 I None
g I None
/ I None
cm(2 I None
) I None
) I None
than I None
in I None
the I None
M I Chemical
group I None
( I None
837 I None
+ I None
/- I None
171 I None
g I None
/ I None
cm(2 I None
) I None
; I None
p I None
< I None
0.05 I None
) I None
and I None
the I None
T I Chemical
group I None
( I None
765 I None
+ I None
/- I None
<eof> I None

<s> O None
145 I None
g I None
/ I None
cm(2 I None
) I None
, I None
NS I None
) I None
. I None
<eof> I None

<s> O None
Half I None
- I None
relaxation I None
time I None
was I None
prolonged I None
in I None
both I None
steroid I Chemical
groups I None
, I None
and I None
time I None
to I None
peak I None
tension I None
was I None
longer I None
with I None
M I Chemical
, I None
whereas I None
tetanic I Disease
tensions I None
were I None
similar I None
. I None
<eof> I None

<s> O None
Steroid I Chemical
treatment I None
also I None
induced I None
a I None
leftward I None
shift I None
of I None
the I None
force I None
- I None
frequency I None
curve I None
at I None
25 I None
and I None
50 I None
Hz I None
when I None
compared I None
with I None
saline I None
treatment I None
( I None
p I None
< I None
0.05 I None
) I None
. I None
<eof> I None

<s> O None
ATPase I None
staining I None
of I None
the I None
diaphragm I None
, I None
scalenus I None
medius I None
, I None
and I None
gastrocnemius I None
showed I None
type I None
IIb I None
fiber I None
<eof> I None

<s> O None
atrophy I Disease
in I None
the I None
steroid I Chemical
groups I None
and I None
also I None
diaphragmatic I None
type I None
IIa I None
<eof> I None

<s> O None
atrophy I Disease
with I None
T I Chemical
, I None
whereas I None
histologic I None
examinations I None
revealed I None
a I None
normal I None
muscular I None
pattern I None
with I None
absence I None
of I None
necrosis I Disease
. I None
<eof> I None

<s> O None
Finally I None
, I None
a I None
pair I None
- I None
fed I None
( I None
PF I None
) I None
study I None
, I None
performed I None
in I None
18 I None
rats I None
( I None
C I None
, I None
T I Chemical
, I None
and I None
PF I None
) I None
, I None
showed I None
that I None
muscle I Disease
atrophy O Disease
was I None
considerably I None
less I None
pronounced I None
in I None
PF I None
animals I None
than I None
in I None
T I Chemical
-treated I None
animals I None
. I None
<eof> I None

<s> O None
We I None
conclude I None
that I None
( I None
1 I None
) I None
short I None
- I None
term I None
treatment I None
with I None
massive I None
doses I None
of I None
steroids I Chemical
induced I None
severe I None
respiratory I None
and I None
limb I None
muscle I None
wasting I None
; I None
<eof> I None

<s> O None
( I None
2 I None
) I None
both I None
types I None
of I None
steroids I Chemical
induced I None
predominantly I None
type I None
IIb I None
atrophy I Disease
, I None
resulting I None
in I None
the I None
expected I None
alterations I None
in I None
diaphragm I None
contractile I None
properties I None
; I None
( I None
3 I None
) I None
neither I None
steroid I Chemical
caused I None
muscle I None
<eof> I None

<s> O None
necrosis I Disease
; I None
( I None
4 I None
) I None
type I None
IIb I None
<eof> I None

<s> O None
atrophy I Disease
was I None
not I None
caused I None
by I None
acute I None
nutritional I None
deprivation I None
alone I None
. I None
<eof> I None

<s> O None
Refractory I None
cardiogenic I Disease
shock O Disease
and I None
complete I None
heart I Disease
block O Disease
after I None
verapamil I Chemical
SR I None
and I None
metoprolol I Chemical
treatment I None
. I None
<eof> I None

<s> O None
A I None
case I None
report I None
. I None
<eof> I None

<s> O None
A I None
seventy I None
- I None
eight I None
- I None
year I None
- I None
old I None
woman I None
presented I None
with I None
complete I None
heart I Disease
block O Disease
and I None
refractory I None
hypotension I Disease
two I None
days I None
after I None
a I None
therapeutic I None
dose I None
of I None
sustained I None
- I None
release I None
verapamil I Chemical
with I None
concomitant I None
use I None
of I None
metoprolol I Chemical
. I None
<eof> I None

<s> O None
The I None
patient I None
continued I None
to I None
remain I None
hypotensive I Disease
with I None
complete I None
heart I Disease
block O Disease
, I None
even I None
with I None
multiple I None
uses I None
of I None
intravenous I None
atropine I Chemical
as I None
well I None
as I None
high I None
doses I None
of I None
pressor I None
agents I None
such I None
as I None
dopamine I Chemical
and I None
dobutamine I Chemical
. I None
<eof> I None

<s> O None
However I None
, I None
shortly I None
after I None
the I None
use I None
of I None
intravenous I None
calcium I Chemical
chloride O Chemical
, I None
the I None
refractory I None
hypotension I Disease
and I None
complete I None
heart I Disease
block O Disease
resolved I None
. I None
<eof> I None

<s> O None
A I None
phase I None
I I None
clinical I None
study I None
of I None
the I None
antipurine I Chemical
antifolate I None
lometrexol I Chemical
<eof> I None

<s> O None
( I None
DDATHF I Chemical
) I None
given I None
with I None
oral I None
folic I Chemical
acid O Chemical
. I None
<eof> I None

<s> O None
Lometrexol I Chemical
is I None
an I None
antifolate I None
which I None
inhibits I None
glycinamide I Chemical
ribonucleotide O Chemical
formyltransferase I None
( I None
GARFT I None
) I None
, I None
an I None
enzyme I None
essential I None
for I None
de I None
novo I None
purine I Chemical
synthesis I None
. I None
<eof> I None

<s> O None
Extensive I None
experimental I None
and I None
limited I None
clinical I None
data I None
have I None
shown I None
that I None
lometrexol I Chemical
has I None
activity I None
against I None
tumours I Disease
which I None
are I None
refractory I None
to I None
other I None
drugs I None
, I None
notably I None
methotrexate I Chemical
. I None
<eof> I None

<s> O None
However I None
, I None
the I None
initial I None
clinical I None
development I None
of I None
lometrexol I Chemical
was I None
curtailed I None
because I None
of I None
severe I None
and I None
cumulative I None
antiproliferative I None
toxicities I Disease
. I None
<eof> I None

<s> O None
Preclinical I None
murine I None
studies I None
demonstrated I None
that I None
the I None
toxicity I Disease
of I None
lometrexol I Chemical
can I None
be I None
prevented I None
by I None
low I None
dose I None
folic I Chemical
acid O Chemical
administration I None
, I None
i.e. I None
for I None
7 I None
days I None
prior I None
to I None
and I None
7 I None
days I None
following I None
a I None
single I None
bolus I None
dose I None
. I None
<eof> I None

<s> O None
This I None
observation I None
prompted I None
a I None
Phase I None
I I None
clinical I None
study I None
of I None
lometrexol I Chemical
given I None
with I None
folic I Chemical
acid O Chemical
supplementation I None
which I None
has I None
confirmed I None
that I None
the I None
toxicity I Disease
of I None
lometrexol I Chemical
can I None
be I None
markedly I None
reduced I None
by I None
folic I Chemical
acid O Chemical
supplementation I None
. I None
<eof> I None

<s> O None
Thrombocytopenia I Disease
and I None
mucositis I Disease
were I None
the I None
major I None
toxicities I Disease
. I None
<eof> I None

<s> O None
There I None
was I None
no I None
clear I None
relationship I None
between I None
clinical I None
toxicity I Disease
and I None
the I None
extent I None
of I None
plasma I None
folate I Chemical
elevation I None
. I None
<eof> I None

<s> O None
Associated I None
studies I None
demonstrated I None
that I None
lometrexol I Chemical
plasma I None
pharmacokinetics I None
were I None
not I None
altered I None
by I None
folic I Chemical
acid O Chemical
administration I None
indicating I None
that I None
supplementation I None
is I None
unlikely I None
to I None
reduce I None
toxicity I Disease
by I None
enhancing I None
lometrexol I Chemical
plasma I None
clearance I None
. I None
<eof> I None

<s> O None
The I None
work I None
described I None
in I None
this I None
report I None
has I None
identified I None
for I None
the I None
first I None
time I None
a I None
clinically I None
acceptable I None
schedule I None
for I None
the I None
administration I None
of I None
a I None
GARFT I None
inhibitor I None
. I None
<eof> I None

<s> O None
This I None
information I None
will I None
facilitate I None
the I None
future I None
evaluation I None
of I None
this I None
class I None
of I None
compounds I None
in I None
cancer I Disease
therapy I None
. I None
<eof> I None

<s> O None
Involvement I None
of I None
the I None
mu I None
- I None
opiate I None
receptor I None
in I None
peripheral I None
analgesia I Disease
. I None
<eof> I None

<s> O None
The I None
intradermal I None
injection I None
of I None
mu I None
( I None
morphine I Chemical
, I None
Tyr I Chemical
- O Chemical
D O Chemical
- O Chemical
Ala O Chemical
- O Chemical
Gly O Chemical
- O Chemical
NMe O Chemical
- O Chemical
Phe O Chemical
- O Chemical
Gly O Chemical
- O Chemical
ol O Chemical
and I None
morphiceptin I Chemical
) I None
, I None
kappa I None
( I None
trans-3,4-dichloro I Chemical
- O Chemical
N O Chemical
- O Chemical
methyl O Chemical
- O Chemical
N[2-(1-pyrrolidinyl O Chemical
) O Chemical
cyclohexyl]benzeneactemide O Chemical
) I None
and I None
delta I None
( I None
[ I Chemical
D O Chemical
- O Chemical
Pen2.5]-enkephalin O Chemical
and I None
[ I Chemical
D O Chemical
- O Chemical
Ser2]-[Leu]enkephalin O Chemical
- O Chemical
Thr O Chemical
) I None
selective I None
opioid I None
- I None
agonists I None
, I None
by I None
themselves I None
, I None
did I None
not I None
significantly I None
affect I None
the I None
mechanical I None
nociceptive I None
threshold I None
in I None
the I None
hindpaw I None
of I None
the I None
rat I None
. I None
<eof> I None

<s> O None
Intradermal I None
injection I None
of I None
mu I None
, I None
but I None
not I None
delta I None
or I None
kappa I None
opioid I None
- I None
agonists I None
, I None
however I None
, I None
produced I None
dose I None
- I None
dependent I None
inhibition I None
of I None
prostaglandin I Chemical
E2 O Chemical
-induced I None
<eof> I None

<s> O None
hyperalgesia I Disease
. I None
<eof> I None

<s> O None
The I None
analgesic I None
effect I None
of I None
the I None
mu I None
- I None
agonist I None
morphine I Chemical
was I None
dose I None
- I None
dependently I None
antagonized I None
by I None
naloxone I Chemical
and I None
prevented I None
by I None
co I None
- I None
injection I None
of I None
pertussis I None
toxin I None
. I None
<eof> I None

<s> O None
Morphine I Chemical
did I None
not I None
, I None
however I None
, I None
alter I None
the I None
hyperalgesia I Disease
induced I None
by I None
8-bromo I Chemical
cyclic O Chemical
adenosine O Chemical
monophosphate O Chemical
. I None
<eof> I None

<s> O None
We I None
conclude I None
that I None
the I None
analgesic I None
action I None
of I None
opioids I None
on I None
the I None
peripheral I None
terminals I None
of I None
primary I None
afferents I None
is I None
via I None
a I None
binding I None
site I None
with I None
characteristics I None
of I None
the I None
mu I None
- I None
opioid I None
receptor I None
and I None
that I None
this I None
action I None
is I None
mediated I None
by I None
inhibition I None
of I None
the I None
cyclic I Chemical
adenosine O Chemical
monophosphate O Chemical
second I None
messenger I None
system I None
. I None
<eof> I None

<s> O None
Adequate I None
timing I None
of I None
ribavirin I Chemical
reduction I None
in I None
patients I None
with I None
hemolysis I Disease
during I None
combination I None
therapy I None
of I None
interferon I Chemical
and I None
ribavirin I Chemical
for I None
chronic I Disease
hepatitis O Disease
C O Disease
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
<eof> I None

<s> O None
Hemolytic I Disease
anemia O Disease
is I None
one I None
of I None
the I None
major I None
adverse I None
events I None
of I None
the I None
combination I None
therapy I None
of I None
interferon I Chemical
and I None
ribavirin I Chemical
. I None
<eof> I None

<s> O None
Because I None
of I None
ribavirin I Chemical
-related I None
hemolytic I Disease
anemia O Disease
, I None
dose I None
reduction I None
is I None
a I None
common I None
event I None
in I None
this I None
therapy I None
. I None
<eof> I None

<s> O None
In I None
this I None
clinical I None
retrospective I None
cohort I None
study I None
we I None
have I None
examined I None
the I None
suitable I None
timing I None
of I None
ribavirin I Chemical
reduction I None
in I None
patients I None
with I None
hemolysis I Disease
during I None
combination I None
therapy I None
. I None
<eof> I None

<s> O None
METHODS I None
: I None
<eof> I None

<s> O None
Thirty I None
- I None
seven I None
of I None
160 I None
patients I None
who I None
had I None
HCV I None
- I None
genotype I None
1b I None
, I None
had I None
high I None
virus I None
load I None
, I None
and I None
received I None
24-week I None
combination I None
therapy I None
developed I None
anemia I Disease
with I None
hemoglobin I None
level I None
< I None
10 I None
g I None
/ I None
dl I None
or I None
anemia I Disease
-related I None
signs I None
during I None
therapy I None
. I None
<eof> I None

<s> O None
After I None
that I None
, I None
these I None
37 I None
patients I None
were I None
reduced I None
one I None
tablet I None
of I None
ribavirin I Chemical
<eof> I None

<s> O None
( I None
200 I None
mg I None
) I None
per I None
day I None
. I None
<eof> I None

<s> O None
After I None
reduction I None
of I None
ribavirin I Chemical
, I None
27 I None
of I None
37 I None
patients I None
could I None
continue I None
combination I None
therapy I None
for I None
a I None
total I None
of I None
24 I None
weeks I None
( I None
group I None
A I None
) I None
. I None
<eof> I None

<s> O None
However I None
, I None
10 I None
of I None
37 I None
patients I None
with I None
reduction I None
of I None
ribavirin I Chemical
could I None
not I None
continue I None
combination I None
therapy I None
because I None
their I None
< I None
8.5 I None
g I None
/ I None
dl I None
hemoglobin I None
values I None
decreased I None
to I None
or I None
anemia I Disease
-related I None
severe I None
side I None
effects I None
occurred I None
( I None
group I None
B I None
) I None
. I None
<eof> I None

<s> O None
We I None
assessed I None
the I None
final I None
efficacy I None
and I None
safety I None
after I None
reduction I None
of I None
ribavirin I Chemical
in I None
groups I None
A I None
and I None
B. I None
RESULTS I None
: I None
<eof> I None

<s> O None
A I None
sustained I None
virological I None
response I None
( I None
SVR I None
) I None
was I None
29.6 I None
% I None
( I None
8/27 I None
) I None
in I None
group I None
A I None
and I None
10 I None
% I None
( I None
1/10 I None
) I None
in I None
group I None
B I None
, I None
respectively I None
. I None
<eof> I None

<s> O None
A I None
34.4 I None
% I None
( I None
12/27 I None
) I None
of I None
SVR I None
+ I None
biological I None
response I None
in I None
group I None
A I None
was I None
higher I None
than I None
10 I None
% I None
( I None
1/10 I None
) I None
in I None
group I None
B I None
( I None
P I None
= I None
0.051 I None
) I None
, I None
with I None
slight I None
significance I None
. I None
<eof> I None

<s> O None
With I None
respect I None
to I None
hemoglobin I None
level I None
at I None
the I None
time I None
of I None
ribavirin I Chemical
reduction I None
, I None
a I None
rate I None
of I None
continuation I None
of I None
therapy I None
in I None
patients I None
with I None
> I None
or I None
= I None
10 I None
g I None
/ I None
dl I None
hemoglobin I None
was I None
higher I None
than I None
that I None
in I None
patients I None
with I None
< I None
10 I None
g I None
/ I None
dl I None
( I None
P I None
= I None
0.036 I None
) I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
Reduction I None
of I None
ribavirin I Chemical
at I None
hemoglobin I None
level I None
> I None
or I None
= I None
10 I None
g I None
/ I None
dl I None
is I None
suitable I None
in I None
terms I None
of I None
efficacy I None
and I None
side I None
effects I None
. I None
<eof> I None

<s> O None
Increased I None
expression I None
and I None
apical I None
targeting I None
of I None
renal I None
ENaC I None
subunits I None
in I None
puromycin I Chemical
aminonucleoside O Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
nephrotic I Disease
syndrome O Disease
in I None
rats I None
. I None
<eof> I None

<s> O None
Nephrotic I Disease
syndrome O Disease
is I None
often I None
accompanied I None
by I None
sodium I Chemical
retention I None
and I None
generalized I None
edema I Disease
. I None
<eof> I None

<s> O None
However I None
, I None
the I None
molecular I None
basis I None
for I None
the I None
decreased I None
renal I None
sodium I Chemical
excretion I None
remains I None
undefined I None
. I None
<eof> I None

<s> O None
We I None
hypothesized I None
that I None
epithelial I None
Na I Chemical
channel I None
( I None
ENaC I None
) I None
subunit I None
dysregulation I None
may I None
be I None
responsible I None
for I None
the I None
increased I None
sodium I Chemical
retention I None
. I None
<eof> I None

<s> O None
An I None
experimental I None
group I None
of I None
rats I None
was I None
treated I None
with I None
puromycin I Chemical
aminonucleoside O Chemical
<eof> I None

<s> O None
( I None
PAN I Chemical
; I None
180 I None
mg I None
/ I None
kg I None
iv I None
) I None
, I None
whereas I None
the I None
control I None
group I None
received I None
only I None
vehicle I None
. I None
<eof> I None

<s> O None
After I None
7 I None
days I None
, I None
PAN I Chemical
treatment I None
induced I None
significant I None
proteinuria I Disease
, I None
hypoalbuminemia I Disease
, I None
decreased I None
urinary I None
sodium I Chemical
excretion I None
, I None
and I None
extensive I None
ascites I Disease
. I None
<eof> I None

<s> O None
The I None
protein I None
abundance I None
of I None
alpha I None
- I None
ENaC I None
and I None
beta I None
- I None
ENaC I None
was I None
increased I None
in I None
the I None
inner I None
stripe I None
of I None
the I None
outer I None
medulla I None
( I None
ISOM I None
) I None
and I None
in I None
the I None
inner I None
medulla I None
( I None
IM I None
) I None
but I None
was I None
not I None
altered I None
in I None
the I None
cortex I None
. I None
<eof> I None

<s> O None
gamma I None
- I None
ENaC I None
abundance I None
was I None
increased I None
in I None
the I None
cortex I None
, I None
ISOM I None
, I None
and I None
IM I None
. I None
<eof> I None

<s> O None
Immunoperoxidase I None
brightfield- I None
and I None
laser I None
- I None
scanning I None
confocal I None
fluorescence I None
microscopy I None
demonstrated I None
increased I None
targeting I None
of I None
alpha I None
- I None
ENaC I None
, I None
beta I None
- I None
ENaC I None
, I None
and I None
gamma I None
- I None
ENaC I None
subunits I None
to I None
the I None
apical I None
plasma I None
membrane I None
in I None
the I None
distal I None
convoluted I None
tubule I None
( I None
DCT2 I None
) I None
, I None
connecting I None
tubule I None
, I None
and I None
cortical I None
and I None
medullary I None
collecting I None
duct I None
segments I None
. I None
<eof> I None

<s> O None
Immunoelectron I None
microscopy I None
further I None
revealed I None
an I None
increased I None
labeling I None
of I None
alpha I None
- I None
ENaC I None
in I None
the I None
apical I None
plasma I None
membrane I None
of I None
cortical I None
collecting I None
duct I None
principal I None
cells I None
of I None
PAN I Chemical
<eof> I None

<s> O None
-treated I None
rats I None
, I None
indicating I None
enhanced I None
apical I None
targeting I None
of I None
alpha I None
- I None
ENaC I None
subunits I None
. I None
<eof> I None

<s> O None
In I None
contrast I None
, I None
the I None
protein I None
abundances I None
of I None
Na I Chemical
( I None
+ I None
) I None
/ I None
H I Chemical
( I None
+ I None
) I None
exchanger I None
type I None
3 I None
( I None
NHE3 I None
) I None
, I None
Na I Chemical
( I None
+ I None
) I None
- I None
K I Chemical
( I None
+ I None
<eof> I None

<s> O None
) I None
-2 I None
Cl I Chemical
( I None
- I None
) I None
cotransporter I None
( I None
BSC-1 I None
) I None
, I None
and I None
thiazide I Chemical
-sensitive I None
Na I Chemical
( I None
+ I None
) I None
- I None
Cl I Chemical
( I None
- I None
) I None
cotransporter I None
( I None
TSC I None
) I None
were I None
decreased I None
. I None
<eof> I None

<s> O None
Moreover I None
, I None
the I None
abundance I None
of I None
the I None
alpha(1)-subunit I None
of I None
the I None
Na I Chemical
- I None
K I Chemical
-ATPase I None
was I None
decreased I None
in I None
the I None
cortex I None
and I None
ISOM I None
, I None
but I None
it I None
remained I None
unchanged I None
in I None
the I None
IM I None
. I None
<eof> I None

<s> O None
In I None
conclusion I None
, I None
the I None
increased I None
or I None
sustained I None
expression I None
of I None
ENaC I None
subunits I None
combined I None
with I None
increased I None
apical I None
targeting I None
in I None
the I None
DCT2 I None
, I None
connecting I None
tubule I None
, I None
and I None
collecting I None
duct I None
are I None
likely I None
to I None
play I None
a I None
role I None
in I None
the I None
sodium I Chemical
retention I None
associated I None
with I None
PAN I Chemical
-induced I None
nephrotic I Disease
syndrome O Disease
. I None
<eof> I None

<s> O None
The I None
decreased I None
abundance I None
of I None
NHE3 I None
, I None
BSC-1 I None
, I None
TSC I None
, I None
and I None
Na I Chemical
- I None
K I Chemical
<eof> I None

<s> O None
-ATPase I None
may I None
play I None
a I None
compensatory I None
role I None
to I None
promote I None
sodium I Chemical
excretion I None
. I None
<eof> I None

<s> O None
Does I None
hormone I None
therapy I None
for I None
the I None
treatment I None
of I None
breast I Disease
cancer O Disease
have I None
a I None
detrimental I None
effect I None
on I None
memory I None
and I None
cognition I None
? I None
<eof> I None

<s> O None
A I None
pilot I None
study I None
. I None
<eof> I None

<s> O None
This I None
pilot I None
study I None
examines I None
whether I None
hormone I None
therapy I None
for I None
breast I Disease
cancer O Disease
<eof> I None

<s> O None
affects I None
cognition I None
. I None
<eof> I None

<s> O None
Patients I None
participating I None
in I None
a I None
randomised I None
trial I None
of I None
anastrozole I Chemical
, I None
tamoxifen I Chemical
alone I None
or I None
combined I None
( I None
ATAC I None
) I None
<eof> I None

<s> O None
( I None
n=94 I None
) I None
and I None
a I None
group I None
of I None
women I None
without I None
breast I Disease
cancer O Disease
<eof> I None

<s> O None
( I None
n=35 I None
) I None
completed I None
a I None
battery I None
of I None
neuropsychological I None
measures I None
. I None
<eof> I None

<s> O None
Compared I None
with I None
the I None
control I None
group I None
, I None
the I None
patients I None
were I None
impaired I None
on I None
a I None
processing I None
speed I None
task I None
( I None
p=0.032 I None
) I None
and I None
on I None
a I None
measure I None
of I None
immediate I None
verbal I None
memory I None
( I None
p=0.026 I None
) I None
after I None
controlling I None
for I None
the I None
use I None
of I None
hormone I None
replacement I None
therapy I None
in I None
both I None
groups I None
. I None
<eof> I None

<s> O None
Patient I None
group I None
performance I None
was I None
not I None
significantly I None
related I None
to I None
length I None
of I None
treatment I None
or I None
measures I None
of I None
psychological I None
morbidity I None
. I None
<eof> I None

<s> O None
The I None
results I None
showed I None
specific I None
impairments I None
in I None
processing I None
speed I None
and I None
verbal I None
memory I None
in I None
women I None
receiving I None
hormonal I None
therapy I None
for I None
the I None
treatment I None
of I None
breast I Disease
cancer O Disease
. I None
<eof> I None

<s> O None
Verbal I None
memory I None
may I None
be I None
especially I None
sensitive I None
to I None
changes I None
in I None
oestrogen I Chemical
levels I None
, I None
a I None
finding I None
commonly I None
reported I None
in I None
studies I None
of I None
hormone I None
replacement I None
therapy I None
in I None
healthy I None
women I None
. I None
<eof> I None

<s> O None
In I None
view I None
of I None
the I None
increased I None
use I None
of I None
hormone I None
therapies I None
in I None
an I None
adjuvant I None
and I None
preventative I None
setting I None
their I None
impact I None
on I None
cognitive I None
functioning I None
should I None
be I None
investigated I None
more I None
thoroughly I None
. I None
<eof> I None

<s> O None
Association I None
of I None
nitric I Chemical
oxide O Chemical
production I None
and I None
apoptosis I None
in I None
a I None
model I None
of I None
experimental I None
nephropathy I Disease
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
<eof> I None

<s> O None
In I None
recent I None
studies I None
increased I None
amounts I None
of I None
nitric I Chemical
oxide O Chemical
<eof> I None

<s> O None
( I None
NO I Chemical
) I None
and I None
apoptosis I None
have I None
been I None
implicated I None
in I None
various I None
pathological I None
conditions I None
in I None
the I None
kidney I None
. I None
<eof> I None

<s> O None
We I None
have I None
studied I None
the I None
role I None
of I None
NO I Chemical
and I None
its I None
association I None
with I None
apoptosis I None
in I None
an I None
experimental I None
model I None
of I None
nephrotic I Disease
syndrome O Disease
induced I None
by I None
a I None
single I None
injection I None
of I None
adriamycin I Chemical
<eof> I None

<s> O None
( I None
ADR I Chemical
) I None
. I None
<eof> I None

<s> O None
METHODS I None
: I None
<eof> I None

<s> O None
The I None
alteration I None
in I None
the I None
NO I Chemical
pathway I None
was I None
assessed I None
by I None
measuring I None
nitrite I Chemical
levels I None
in I None
serum I None
/ I None
urine I None
and I None
by I None
evaluating I None
the I None
changes I None
in I None
vascular I None
reactivity I None
of I None
the I None
isolated I None
perfused I None
rat I None
kidney I None
( I None
IPRK I None
) I None
system I None
. I None
<eof> I None

<s> O None
Rats I None
were I None
stratified I None
into I None
control I None
groups I None
and I None
ADR I Chemical
-induced I None
nephropathy I Disease
groups I None
. I None
<eof> I None

<s> O None
These I None
two I None
groups I None
were I None
then I None
divided I None
into I None
: I None
group I None
1 I None
, I None
animals I None
receiving I None
saline I None
; I None
and I None
group I None
2 I None
, I None
animals I None
receiving I None
aminoguanidine I Chemical
<eof> I None

<s> O None
( I None
AG I Chemical
) I None
which I None
is I None
a I None
specific I None
inhibitor I None
of I None
inducible- I None
NO I Chemical
synthase I None
. I None
<eof> I None

<s> O None
On I None
day I None
21 I None
, I None
rats I None
were I None
sacrificed I None
after I None
obtaining I None
material I None
for I None
biochemical I None
analysis I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
Histopathological I None
examination I None
of I None
the I None
kidneys I None
of I None
rats I None
treated I None
with I None
<eof> I None

<s> O None
ADR I Chemical
revealed I None
focal I None
areas I None
of I None
mesangial I Disease
proliferation O Disease
and I None
mild I None
tubulointerstitial I Disease
inflammation O Disease
. I None
<eof> I None

<s> O None
They I None
also I None
had I None
significantly I None
higher I None
levels I None
of I None
proteinuria I Disease
compared I None
with I None
control I None
and I None
treatment I None
groups I None
( I None
P I None
< I None
0.05 I None
) I None
. I None
<eof> I None

<s> O None
Urine I None
nitrite I Chemical
levels I None
were I None
significantly I None
increased I None
in I None
the I None
ADR I Chemical
- I None
nephropathy I Disease
group I None
( I None
P I None
< I None
0.05 I None
) I None
. I None
<eof> I None

<s> O None
In I None
the I None
IPRK I None
phenylephrine I Chemical
and I None
acetylcholine I Chemical
related I None
responses I None
were I None
significantly I None
impaired I None
in I None
the I None
ADR I Chemical
- I None
nephropathy I Disease
group I None
. I None
<eof> I None

<s> O None
Apoptosis I None
was I None
not I None
detected I None
in I None
controls I None
. I None
<eof> I None

<s> O None
However I None
, I None
in I None
the I None
ADR I Chemical
- I None
nephropathy I Disease
group I None
, I None
numerous I None
apoptotic I None
cells I None
were I None
identified I None
in I None
the I None
tubulointerstitial I None
areas I None
. I None
<eof> I None

<s> O None
Double I None
staining I None
revealed I None
numerous I None
interstitial I None
apoptotic I None
cells I None
to I None
stain I None
for I None
ED1 I None
, I None
a I None
marker I None
for I None
monocytes I None
/ I None
macrophages I None
. I None
<eof> I None

<s> O None
Treatment I None
with I None
AG I Chemical
prevented I None
the I None
impairment I None
of I None
renal I None
vascular I None
bed I None
responses I None
and I None
reduced I None
both I None
urine I None
nitrite I Chemical
levels I None
and I None
apoptosis I None
to I None
control I None
levels I None
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
<eof> I None

<s> O None
We I None
suggest I None
that I None
interactions I None
between I None
NO I Chemical
and I None
apoptosis I None
are I None
important I None
in I None
the I None
pathogenesis I None
of I None
the I None
ADR I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
nephrosis I Disease
. I None
<eof> I None

<s> O None
The I None
attenuating I None
effect I None
of I None
carteolol I Chemical
hydrochloride O Chemical
, I None
a I None
beta I None
- I None
adrenoceptor I None
antagonist I None
, I None
on I None
neuroleptic I None
- I None
induced I None
catalepsy I Disease
in I None
rats I None
. I None
<eof> I None

<s> O None
It I None
is I None
known I None
that I None
beta I None
- I None
adrenoceptor I None
antagonists I None
are I None
effective I None
in I None
the I None
treatment I None
of I None
akathisia I Disease
, I None
one I None
of I None
the I None
extrapyramidal I None
side I None
effects I None
that I None
occur I None
during I None
neuroleptic I None
treatment I None
. I None
<eof> I None

<s> O None
Neuroleptic I None
- I None
induced I None
catalepsy I Disease
, I None
a I None
model I None
of I None
neuroleptic I None
- I None
induced I None
extrapyramidal I None
side I None
effects I None
, I None
was I None
considered I None
suitable I None
as I None
a I None
model I None
for I None
predicting I None
neuroleptic I None
- I None
induced I None
akathisia I Disease
in I None
humans I None
, I None
although I None
neuroleptic I None
- I None
induced I None
catalepsy I Disease
was I None
not I None
considered I None
a I None
specific I None
test I None
for I None
neuroleptic I None
- I None
induced I None
akathisia I Disease
. I None
<eof> I None

<s> O None
Therefore I None
, I None
the I None
effects I None
of I None
carteolol I Chemical
, I None
a I None
beta I None
- I None
adrenoceptor I None
antagonist I None
, I None
on I None
haloperidol I Chemical
-induced I None
catalepsy I Disease
in I None
rats I None
were I None
behaviorally I None
studied I None
and I None
compared I None
with I None
those I None
of I None
propranolol I Chemical
and I None
biperiden I Chemical
, I None
a I None
muscarinic I None
receptor I None
antagonist I None
. I None
<eof> I None

<s> O None
Carteolol I Chemical
, I None
as I None
well I None
as I None
propranolol I Chemical
and I None
biperiden I Chemical
, I None
inhibited I None
the I None
haloperidol I Chemical
-induced I None
catalepsy I Disease
. I None
<eof> I None

<s> O None
The I None
inhibitory I None
effect I None
of I None
carteolol I Chemical
was I None
almost I None
comparable I None
to I None
that I None
of I None
propranolol I Chemical
, I None
but I None
was I None
weaker I None
than I None
that I None
of I None
biperiden I Chemical
. I None
<eof> I None

<s> O None
Carteolol I Chemical
did I None
not I None
evoke I None
postsynaptic I None
dopamine I Chemical
<eof> I None

<s> O None
receptor I None
- I None
stimulating I None
behavioral I None
signs I None
such I None
as I None
stereotypy I None
and I None
hyperlocomotion I Disease
in I None
rats I None
. I None
<eof> I None

<s> O None
Carteolol I Chemical
did I None
not I None
antagonize I None
the I None
inhibitory I None
effects I None
of I None
haloperidol I Chemical
on I None
apomorphine I Chemical
-induced I None
stereotypy I None
and I None
locomotor I None
activity I None
in I None
rats I None
. I None
<eof> I None

<s> O None
In I None
addition I None
, I None
carteolol I Chemical
did I None
not I None
evoke I None
5-HT1A I None
receptor I None
- I None
stimulating I None
behavioral I None
signs I None
such I None
as I None
flat I None
body I None
posture I None
and I None
forepaw I None
treading I None
and I None
did I None
not I None
inhibit I None
<eof> I None

<s> O None
5-hydroxytryptophan I Chemical
-induced I None
<eof> I None

<s> O None
head I None
twitch I None
in I None
rats I None
. I None
<eof> I None

<s> O None
Finally I None
, I None
carteolol I Chemical
did I None
not I None
inhibit I None
physostigmine I Chemical
-induced I None
lethality I None
in I None
rats I None
. I None
<eof> I None

<s> O None
These I None
results I None
strongly I None
suggest I None
that I None
carteolol I Chemical
improves I None
haloperidol I Chemical
-induced I None
catalepsy I Disease
via I None
its I None
beta I None
- I None
adrenoceptor I None
antagonistic I None
activity I None
and I None
is I None
expected I None
to I None
be I None
effective I None
in I None
the I None
treatment I None
of I None
akathisia I Disease
without I None
attenuating I None
neuroleptic I None
- I None
induced I None
antipsychotic I None
effects I None
due I None
to I None
its I None
postsynaptic I None
dopamine I Chemical
receptor I None
antagonistic I None
activity I None
. I None
<eof> I None

<s> O None
Penicillamine I Chemical
-induced I None
rapidly I None
progressive I None
glomerulonephritis I Disease
in I None
a I None
patient I None
with I None
rheumatoid I Disease
arthritis O Disease
. I None
<eof> I None

<s> O None
A I None
67-year I None
- I None
old I None
woman I None
with I None
rheumatoid I Disease
arthritis O Disease
presented I None
rapidly I None
progressive I None
glomerulonephritis I Disease
<eof> I None

<s> O None
( I None
RPGN I Disease
) I None
after I None
5 I None
months I None
of I None
D I Chemical
- O Chemical
penicillamine O Chemical
<eof> I None

<s> O None
( I None
250 I None
mg I None
/ I None
day I None
) I None
treatment I None
. I None
<eof> I None

<s> O None
Light I None
microscopy I None
study I None
showed I None
severe I None
glomerulonephritis I Disease
with I None
crescent I None
formation I None
in I None
60 I None
% I None
of I None
the I None
glomeruli I None
and I None
infiltration I None
of I None
inflammatory I None
cells I None
in I None
the I None
wall I None
of I None
an I None
arteriole I None
. I None
<eof> I None

<s> O None
Immunofluorescence I None
revealed I None
scanty I None
granular I None
IgG I None
, I None
IgA I None
and I None
C3 I None
deposits I None
along I None
the I None
capillary I None
walls I None
and I None
mesangium I None
. I None
<eof> I None

<s> O None
The I None
patient I None
was I None
treated I None
with I None
steroid I Chemical
pulse I None
, I None
plasmapheresis I None
, I None
cyclophosphamide I Chemical
and I None
antiplatelet I Chemical
agents O Chemical
. I None
<eof> I None

<s> O None
A I None
complete I None
recovery I None
of I None
renal I None
function I None
was I None
achieved I None
in I None
a I None
few I None
weeks I None
. I None
<eof> I None

<s> O None
This I None
new I None
case I None
of I None
RPGN I Disease
in I None
the I None
course I None
of I None
D I Chemical
- O Chemical
penicillamine O Chemical
treatment I None
emphasizes I None
the I None
need I None
for I None
frequent I None
monitoring I None
of I None
renal I None
function I None
and I None
evaluation I None
of I None
urinary I None
sediment I None
and I None
proteinuria I Disease
in I None
these I None
patients I None
. I None
<eof> I None

<s> O None
The I None
prompt I None
discontinuation I None
of I None
D I Chemical
- O Chemical
penicillamine O Chemical
and I None
vigorous I None
treatment I None
measures I None
could I None
allow I None
for I None
a I None
good I None
prognosis I None
as I None
in I None
this I None
case I None
. I None
<eof> I None

<s> O None
Nature I None
, I None
time I None
course I None
and I None
dose I None
dependence I None
of I None
zidovudine I Chemical
-related I None
side I None
effects I None
: I None
results I None
from I None
the I None
Multicenter I None
Canadian I None
Azidothymidine I Chemical
Trial I None
. I None
<eof> I None

<s> O None
To I None
characterize I None
the I None
nature I None
, I None
time I None
course I None
and I None
dose I None
dependency I None
of I None
zidovudine I Chemical
-related I None
side I None
effects I None
, I None
we I None
undertook I None
a I None
multicenter I None
, I None
prospective I None
, I None
dose I None
- I None
range I None
finding I None
study I None
. I None
<eof> I None

<s> O None
Our I None
study I None
group I None
consisted I None
of I None
74 I None
HIV I None
- I None
positive I None
homosexual I None
men I None
belonging I None
to I None
groups I None
II I None
B I None
, I None
III I None
and I None
IV I None
C2 I None
from I None
the I None
Centers I None
for I None
Disease I None
Control I None
( I None
CDC I None
) I None
classification I None
of I None
HIV I Disease
disease O Disease
. I None
<eof> I None

<s> O None
Following I None
a I None
3-week I None
observation I None
period I None
, I None
volunteers I None
were I None
treated I None
with I None
zidovudine I Chemical
<eof> I None

<s> O None
600 I None
mg I None
/ I None
day I None
for I None
18 I None
weeks I None
, I None
900 I None
mg I None
/ I None
day I None
for I None
9 I None
weeks I None
and I None
1200 I None
mg I None
/ I None
day I None
for I None
9 I None
weeks I None
, I None
followed I None
by I None
a I None
washout I None
period I None
of I None
6 I None
weeks I None
<eof> I None

<s> O None
after I None
which I None
they I None
were I None
re I None
- I None
started I None
on I None
1200 I None
mg I None
/ I None
day I None
or I None
the I None
highest I None
tolerated I None
dose I None
at I None
8-hourly I None
intervals I None
. I None
<eof> I None

<s> O None
Subjects I None
were I None
randomly I None
assigned I None
to I None
4-hourly I None
or I None
8-hourly I None
regimens I None
within I None
CDC I None
groups I None
while I None
taking I None
600 I None
and I None
1200 I None
mg I None
/ I None
day I None
. I None
<eof> I None

<s> O None
Clinical I None
and I None
laboratory I None
evaluations I None
were I None
performed I None
at I None
3-week I None
intervals I None
. I None
<eof> I None

<s> O None
Symptomatic I None
adverse I None
effects I None
were I None
present I None
in I None
96 I None
% I None
of I None
subjects I None
, I None
most I None
commonly I None
nausea I Disease
( I None
64 I None
% I None
) I None
, I None
fatigue I Disease
( I None
55 I None
% I None
) I None
and I None
headache I Disease
( I None
49 I None
% I None
) I None
. I None
<eof> I None

<s> O None
These I None
were I None
generally I None
self I None
- I None
limited I None
, I None
reappearing I None
briefly I None
at I None
each I None
dose I None
increment I None
. I None
<eof> I None

<s> O None
A I None
decrease I None
in I None
hemoglobin I None
occurred I None
shortly I None
after I None
initiation I None
of I None
therapy I None
. I None
<eof> I None

<s> O None
This I None
was I None
not I None
dose I None
dependent I None
and I None
reversed I None
rapidly I None
upon I None
discontinuation I None
of I None
treatment I None
. I None
<eof> I None

<s> O None
A I None
red I None
blood I None
cell I None
count I None
decrease I None
, I None
a I None
mean I None
cell I None
volume I None
increase I None
and I None
a I None
granulocyte I None
count I None
decrease I None
developed I None
early I None
in I None
a I None
dose I None
- I None
independent I None
fashion I None
, I None
reverting I None
at I None
least I None
partially I None
during I None
the I None
washout I None
phase I None
. I None
<eof> I None

<s> O None
The I None
decrease I None
in I None
reticulocyte I None
count I None
was I None
dose I None
related I None
between I None
600 I None
and I None
900 I None
mg I None
/ I None
day I None
with I None
no I None
further I None
change I None
when I None
the I None
dose I None
was I None
escalated I None
to I None
1200 I None
mg I None
/ I None
day I None
. I None
<eof> I None

<s> O None
Bone I None
marrow I None
changes I None
occurred I None
rapidly I None
as I None
demonstrated I None
by I None
megaloblastosis I Disease
in I None
95 I None
% I None
of I None
65 I None
specimens I None
at I None
week I None
18.(ABSTRACT I None
TRUNCATED I None
AT I None
250 I None
WORDS I None
) I None
<eof> I None

<s> O None
Bilateral I Disease
optic O Disease
neuropathy O Disease
due I None
to I None
combined I None
ethambutol I Chemical
and I None
isoniazid I Chemical
treatment I None
. I None
<eof> I None

<s> O None
The I None
case I None
of I None
a I None
40-year I None
- I None
old I None
patient I None
who I None
underwent I None
an I None
unsuccessful I None
cadaver I None
kidney I None
transplantation I None
and I None
was I None
treated I None
with I None
ethambutol I Chemical
and I None
isoniazid I Chemical
is I None
reported I None
. I None
<eof> I None

<s> O None
A I None
bilateral I Disease
retrobulbar O Disease
neuropathy O Disease
with I None
an I None
unusual I None
central I None
bitemporal I None
hemianopic I None
scotoma I Disease
was I None
found I None
. I None
<eof> I None

<s> O None
Ethambutol I Chemical
was I None
stopped I None
and I None
only I None
small I None
improvement I None
of I None
the I None
visual I None
acuity I None
followed I None
. I None
<eof> I None

<s> O None
Isoniazid I Chemical
was I None
discontinued I None
later I None
, I None
followed I None
by I None
a I None
dramatic I None
improvement I None
in I None
the I None
visual I None
acuity I None
. I None
<eof> I None

<s> O None
The I None
hazards I None
of I None
optic I None
nerve I None
toxicity I Disease
due I None
to I None
ethambutol I Chemical
are I None
known I None
. I None
<eof> I None

<s> O None
We I None
emphasize I None
the I None
potential I None
danger I None
in I None
the I None
use I None
of I None
ethambutol I Chemical
and I None
isoniazid I Chemical
. I None
<eof> I None

<s> O None
Progestational I None
agents I None
and I None
blood I Disease
coagulation O Disease
. I None
<eof> I None

<s> O None
VII I None
. I None
<eof> I None

<s> O None
Thromboembolic I Disease
and I None
other I None
complications I None
of I None
oral I Chemical
contraceptive O Chemical
therapy I None
in I None
relationship I None
to I None
pretreatment I None
levels I None
of I None
blood I Disease
coagulation O Disease
factors I None
: I None
summary I None
report I None
of I None
a I None
ten I None
- I None
year I None
study I None
. I None
<eof> I None

<s> O None
During I None
a I None
ten I None
- I None
year I None
period I None
, I None
348 I None
women I None
were I None
studied I None
for I None
a I None
total I None
of I None
5,877 I None
patient I None
months I None
in I None
four I None
separate I None
studies I None
relating I None
oral I Chemical
contraceptives O Chemical
to I None
changes I None
in I None
hematologic I None
parameters I None
. I None
<eof> I None

<s> O None
Significant I None
increases I None
in I None
certain I None
factors I None
of I None
the I None
blood I Disease
coagulation O Disease
and I None
fibrinolysin I None
systems I None
( I None
factors I None
I I None
, I None
II I None
, I None
VII I None
, I None
VIII I None
, I None
IX I None
, I None
and I None
X I None
and I None
plasminogen I None
) I None
were I None
observed I None
in I None
the I None
treated I None
groups I None
. I None
<eof> I None

<s> O None
Severe I None
complications I None
developed I None
in I None
four I None
patients I None
. I None
<eof> I None

<s> O None
All I None
four I None
had I None
an I None
abnormal I None
blood I Disease
coagulation O Disease
profile I None
, I None
suggesting I None
" I None
hypercoagulability I Disease
" I None
before I None
initiation I None
of I None
therapy I None
. I None
<eof> I None

<s> O None
Some I None
of I None
these I None
findings I None
represented I None
the I None
most I None
extreme I None
abnormalities I None
seen I None
in I None
the I None
entire I None
group I None
of I None
patients I None
; I None
some I None
increased I None
further I None
during I None
therapy I None
. I None
<eof> I None

<s> O None
One I None
of I None
these I None
patients I None
developed I None
a I None
myocardial I Disease
infarction O Disease
before I None
receiving I None
any I None
medication I None
, I None
shortly I None
after I None
the I None
base I None
- I None
line I None
values I None
were I None
obtained I None
. I None
<eof> I None

<s> O None
One I None
patient I None
developed I None
retinopathy I Disease
<eof> I None

<s> O None
19 I None
months I None
after I None
she I None
began I None
therapy I None
, I None
and I None
another I None
developed I None
<eof> I None

<s> O None
thrombophlebitis I Disease
after I None
27 I None
months I None
of I None
therapy I None
. I None
<eof> I None

<s> O None
The I None
fourth I None
patient I None
developed I None
thrombophlebitis I Disease
<eof> I None

<s> O None
14 I None
days I None
after I None
initiation I None
of I None
contraceptive I None
therapy I None
. I None
<eof> I None

<s> O None
All I None
four I None
patients I None
were I None
of I None
the I None
A I None
or I None
AB I None
blood I None
group I None
. I None
<eof> I None

<s> O None
Previous I None
studies I None
suggested I None
the I None
possiblility I None
of I None
increased I None
propensity I None
for I None
thromboembolic I Disease
episodes O Disease
in I None
patients I None
possessing I None
the I None
A I None
antigen I None
. I None
<eof> I None

<s> O None
It I None
appears I None
from I None
these I None
data I None
that I None
hematologic I None
work I None
- I None
ups I None
may I None
be I None
useful I None
in I None
women I None
who I None
are I None
about I None
to I None
start I None
long I None
- I None
term I None
oral I Chemical
contraceptive O Chemical
therapy I None
. I None
<eof> I None

<s> O None
Cardiac I Disease
arrest O Disease
in I None
a I None
child I None
with I None
cerebral I Disease
palsy O Disease
undergoing I None
sevoflurane I Chemical
induction I None
of I None
anesthesia I None
after I None
preoperative I None
clonidine I Chemical
. I None
<eof> I None

<s> O None
Clonidine I Chemical
is I None
a I None
frequently I None
administered I None
alpha2-adrenergic I None
agonist I None
which I None
can I None
decrease I None
heart I None
rate I None
and I None
blood I None
pressure I None
. I None
<eof> I None

<s> O None
We I None
present I None
a I None
case I None
of I None
a I None
5-year I None
- I None
old I None
child I None
with I None
cerebral I Disease
palsy O Disease
and I None
seizure I Disease
disorder O Disease
, I None
receiving I None
clonidine I Chemical
for I None
restlessness I Disease
, I None
who I None
presented I None
for I None
placement I None
of I None
a I None
baclofen I Chemical
pump I None
. I None
<eof> I None

<s> O None
Without I None
the I None
knowledge I None
of I None
the I None
medical I None
personnel I None
, I None
the I None
patient I None
's I None
mother I None
administered I None
three I None
doses I None
of I None
clonidine I Chemical
during I None
the I None
evening I None
before I None
and I None
morning I None
of I None
surgery I None
to I None
reduce I None
anxiety I Disease
. I None
<eof> I None

<s> O None
During I None
induction I None
of I None
anesthesia I None
, I None
the I None
patient I None
developed I None
bradycardia I Disease
and I None
hypotension I Disease
requiring I None
cardiac I None
resuscitation I None
. I None
<eof> I None

<s> O None
There I None
are I None
no I None
previous I None
reports I None
of I None
clonidine I Chemical
<eof> I None

<s> O None
-associated I None
<eof> I None

<s> O None
cardiac I Disease
arrest O Disease
in I None
a I None
child I None
undergoing I None
induction I None
of I None
anesthesia I None
. I None
<eof> I None

<s> O None
Effects I None
of I None
UMB24 I Chemical
and I None
<eof> I None

<s> O None
( I None
+ I None
/-)- I None
SM I Chemical
21 O Chemical
, I None
putative I None
sigma2-preferring I None
antagonists I None
, I None
on I None
behavioral I None
toxic I None
and I None
stimulant I None
effects I None
of I None
cocaine I Chemical
in I None
mice I None
. I None
<eof> I None

<s> O None
Earlier I None
studies I None
have I None
demonstrated I None
that I None
antagonism I None
of I None
sigma1 I None
receptors I None
attenuates I None
the I None
convulsive I Disease
, I None
lethal I None
, I None
locomotor I None
stimulatory I None
and I None
rewarding I None
actions I None
of I None
cocaine I Chemical
in I None
mice I None
. I None
<eof> I None

<s> O None
In I None
contrast I None
, I None
the I None
contribution I None
of I None
sigma2 I None
receptors I None
is I None
unclear I None
because I None
experimental I None
tools I None
to I None
selectively I None
target I None
this I None
subtype I None
are I None
unavailable I None
. I None
<eof> I None

<s> O None
To I None
begin I None
addressing I None
this I None
need I None
, I None
we I None
characterized I None
UMB24 I Chemical
<eof> I None

<s> O None
( I None
1-(2-phenethyl)-4-(2-pyridyl)-piperazine I Chemical
) I None
and I None
<eof> I None

<s> O None
( I None
+ I None
/-)- I None
<eof> I None

<s> O None
SM I Chemical
21 O Chemical
<eof> I None

<s> O None
( I None
3alpha I Chemical
- O Chemical
tropanyl-2-(4-chorophenoxy)butyrate O Chemical
) I None
in I None
receptor I None
binding I None
and I None
behavioral I None
studies I None
. I None
<eof> I None

<s> O None
Receptor I None
binding I None
studies I None
confirmed I None
that I None
UMB24 I Chemical
and I None
<eof> I None

<s> O None
( I None
+ I None
/-)- I None
SM I Chemical
21 O Chemical
display I None
preferential I None
affinity I None
for I None
sigma2 I None
over I None
sigma1 I None
receptors I None
. I None
<eof> I None

<s> O None
In I None
behavioral I None
studies I None
, I None
pretreatment I None
of I None
Swiss I None
Webster I None
mice I None
with I None
UMB24 I Chemical
or I None
<eof> I None

<s> O None
( I None
+ I None
<eof> I None

<s> O None
/-)- I None
SM I Chemical
21 O Chemical
significantly I None
attenuated I None
cocaine I Chemical
-induced I None
convulsions I Disease
and I None
locomotor I None
activity I None
, I None
but I None
not I None
lethality I None
. I None
<eof> I None

<s> O None
When I None
administered I None
alone I None
, I None
( I None
+ I None
/-)- I None
<eof> I None

<s> O None
SM I Chemical
21 O Chemical
produced I None
no I None
significant I None
effects I None
compared I None
to I None
control I None
injections I None
of I None
saline I None
, I None
but I None
UMB24 I Chemical
had I None
locomotor I None
depressant I None
actions I None
. I None
<eof> I None

<s> O None
Together I None
, I None
the I None
data I None
suggest I None
that I None
sigma2 I None
receptor I None
antagonists I None
have I None
the I None
potential I None
to I None
attenuate I None
some I None
of I None
the I None
behavioral I None
effects I None
of I None
cocaine I Chemical
, I None
and I None
further I None
development I None
of I None
more I None
selective I None
, I None
high I None
affinity I None
ligands I None
are I None
warranted I None
. I None
<eof> I None

<s> O None
Methimazole I Chemical
-induced I None
cholestatic I Disease
jaundice O Disease
. I None
<eof> I None

<s> O None
Methimazole I Chemical
is I None
a I None
widely I None
used I None
and I None
generally I None
well I None
- I None
tolerated I None
antithyroid I None
agent I None
. I None
<eof> I None

<s> O None
A I None
43-year I None
- I None
old I None
woman I None
had I None
severe I None
jaundice I Disease
and I None
itching I Disease
1 I None
month I None
after I None
receiving I None
methimazole I Chemical
<eof> I None

<s> O None
( I None
10 I None
mg I None
tid I None
) I None
and I None
propranolol I Chemical
( I None
20 I None
mg I None
tid I None
) I None
for I None
treatment I None
of I None
hyperthyroidism I Disease
. I None
<eof> I None

<s> O None
The I None
patient I None
continued I None
treatment I None
for I None
another I None
4 I None
days I None
after I None
the I None
appearance I None
of I None
jaundice I Disease
until I None
she I None
finished I None
both I None
medications I None
. I None
<eof> I None

<s> O None
When I None
seen I None
at I None
the I None
emergency I None
department I None
2 I None
weeks I None
later I None
, I None
she I None
still I None
had I None
severe I None
icterus I Disease
, I None
pruritus I Disease
, I None
and I None
hyperbilirubinemia I Disease
, I None
formed I None
mainly I None
of I None
the I None
conjugated I None
fraction I None
. I None
<eof> I None

<s> O None
Methimazole I Chemical
-induced I None
<eof> I None

<s> O None
cholestasis I Disease
was I None
diagnosed I None
, I None
and I None
propranolol I Chemical
therapy I None
was I None
resumed I None
. I None
<eof> I None

<s> O None
Over I None
the I None
following I None
9 I None
days I None
, I None
the I None
symptoms I None
improved I None
and I None
plasma I None
bilirubin I Chemical
levels I None
were I None
normal I None
after I None
12 I None
weeks I None
without I None
methimazole I Chemical
. I None
<eof> I None

<s> O None
In I None
rare I None
cases I None
within I None
the I None
first I None
few I None
weeks I None
of I None
therapy I None
, I None
this I None
drug I None
can I None
cause I None
severe I None
and I None
reversible I None
cholestatic I Disease
jaundice O Disease
. I None
<eof> I None

<s> O None
Physicians I None
and I None
patients I None
should I None
be I None
aware I None
of I None
this I None
adverse I None
effect I None
so I None
that I None
, I None
upon I None
occurrence I None
, I None
they I None
can I None
discontinue I None
methimazole I Chemical
therapy I None
and I None
avoid I None
unnecessary I None
invasive I None
procedures I None
. I None
<eof> I None

<s> O None
Ciprofloxacin I Chemical
-induced I None
acute I None
interstitial I Disease
nephritis O Disease
and I None
autoimmune I Disease
hemolytic O Disease
anemia O Disease
. I None
<eof> I None

<s> O None
Ciprofloxacin I Chemical
has I None
been I None
associated I None
with I None
several I None
side I None
effects I None
including I None
interstitial I Disease
nephritis O Disease
and I None
hemolytic I Disease
anemia O Disease
. I None
<eof> I None

<s> O None
The I None
combination I None
of I None
both I None
side I None
effects I None
is I None
extremely I None
rare I None
. I None
<eof> I None

<s> O None
In I None
this I None
report I None
, I None
we I None
describe I None
a I None
case I None
of I None
ciprofloxacin I Chemical
-induced I None
interstitial I Disease
nephritis O Disease
and I None
autoimmune I Disease
hemolytic O Disease
anemia O Disease
. I None
<eof> I None

<s> O None
Hemolytic I Disease
anemia O Disease
improved I None
after I None
stopping I None
the I None
drug I None
and I None
initiation I None
of I None
steroid I Chemical
therapy I None
. I None
<eof> I None

<s> O None
Unfortunately I None
, I None
acute I None
interstitial I Disease
nephritis O Disease
was I None
irreversible I None
and I None
the I None
patient I None
developed I None
end I Disease
- O Disease
stage O Disease
renal O Disease
disease O Disease
. I None
<eof> I None

<s> O None
Contribution I None
of I None
sodium I Chemical
valproate O Chemical
to I None
the I None
syndrome I Disease
of O Disease
inappropriate O Disease
secretion O Disease
of O Disease
antidiuretic O Disease
hormone O Disease
. I None
<eof> I None

<s> O None
We I None
report I None
the I None
case I None
of I None
a I None
62-year I None
- I None
old I None
man I None
who I None
was I None
administered I None
sodium I Chemical
valproate O Chemical
<eof> I None

<s> O None
( I None
VPA I Chemical
) I None
and I None
who I None
subsequently I None
developed I None
the I None
syndrome I Disease
of O Disease
inappropriate O Disease
secretion O Disease
of O Disease
antidiuretic O Disease
hormone O Disease
<eof> I None

<s> O None
( I None
SIADH I Disease
) I None
. I None
<eof> I None

<s> O None
He I None
had I None
been I None
taking I None
VPA I Chemical
for I None
treatment I None
of I None
idiopathic I None
generalized I None
<eof> I None

<s> O None
tonic I Disease
- O Disease
clonic O Disease
convulsions O Disease
since I None
he I None
was I None
56 I None
years I None
old I None
. I None
<eof> I None

<s> O None
After I None
substituting I None
VPA I Chemical
with I None
zonisamide I Chemical
, I None
the I None
serum I None
sodium I Chemical
level I None
returned I None
to I None
normal I None
. I None
<eof> I None

<s> O None
We I None
consider I None
this I None
episode I None
of I None
SIADH I Disease
to I None
be I None
the I None
result I None
of I None
a I None
combination I None
of I None
factors I None
including I None
a I None
weakness I Disease
of O Disease
the O Disease
central O Disease
nervous O Disease
system O Disease
and I None
the I None
long I None
- I None
term I None
administration I None
of I None
VPA I Chemical
. I None
<eof> I None

<s> O None
Vasopressin I Chemical
in I None
the I None
treatment I None
of I None
milrinone I Chemical
-induced I None
hypotension I Disease
in I None
severe I None
heart I Disease
failure O Disease
. I None
<eof> I None

<s> O None
The I None
use I None
of I None
phosphodiesterase I None
inhibitors I None
such I None
as I None
milrinone I Chemical
in I None
the I None
treatment I None
of I None
severe I None
heart I Disease
failure O Disease
is I None
frequently I None
restricted I None
because I None
they I None
cause I None
vasodilation I None
and I None
hypotension I Disease
. I None
<eof> I None

<s> O None
In I None
patients I None
with I None
decompensated I None
heart I Disease
failure O Disease
with I None
hypotension I Disease
after I None
treatment I None
with I None
milrinone I Chemical
, I None
low I None
doses I None
of I None
<eof> I None

<s> O None
vasopressin I Chemical
restored I None
blood I None
pressure I None
without I None
inhibiting I None
the I None
inotropic I None
effect I None
of I None
milrinone I Chemical
. I None
<eof> I None

<s> O None
Halogenated I None
anesthetics I None
form I None
liver I None
adducts I None
and I None
antigens I None
that I None
cross I None
- I None
react I None
with I None
halothane I Chemical
-induced I None
antibodies I None
. I None
<eof> I None

<s> O None
Two I None
halogenated I None
anesthetics I None
, I None
enflurane I Chemical
and I None
isoflurane I Chemical
, I None
have I None
been I None
associated I None
with I None
an I None
allergic I None
- I None
type I None
hepatic I Disease
injury O Disease
both I None
alone I None
and I None
following I None
previous I None
exposure I None
to I None
halothane I Chemical
. I None
<eof> I None

<s> O None
Halothane I Chemical
<eof> I None

<s> O None
hepatitis I Disease
appears I None
to I None
involve I None
an I None
aberrant I None
immune I None
response I None
. I None
<eof> I None

<s> O None
An I None
antibody I None
response I None
to I None
a I None
protein I None
- I None
bound I None
biotransformation I None
product I None
( I None
trifluoroacetyl I Chemical
adduct I None
) I None
has I None
been I None
detected I None
on I None
halothane I Chemical
hepatitis I Disease
patients I None
. I None
<eof> I None

<s> O None
This I None
study I None
was I None
performed I None
to I None
determine I None
cross I None
- I None
reactivity I None
between I None
enflurane I Chemical
and I None
isoflurane I Chemical
with I None
the I None
hypersensitivity I Disease
induced I None
by I None
halothane I Chemical
. I None
<eof> I None

<s> O None
The I None
subcellular I None
and I None
lobular I None
production I None
of I None
hepatic I None
neoantigens I None
recognized I None
by I None
halothane I Chemical
-induced I None
antibodies I None
following I None
enflurane I Chemical
and I None
isoflurane I Chemical
, I None
and I None
the I None
biochemical I None
nature I None
of I None
these I None
neoantigens I None
was I None
investigated I None
in I None
two I None
animal I None
models I None
. I None
<eof> I None

<s> O None
Enflurane I Chemical
administration I None
resulted I None
in I None
neoantigens I None
detected I None
in I None
both I None
the I None
microsomal I None
and I None
cytosolic I None
fraction I None
of I None
liver I None
homogenates I None
and I None
in I None
the I None
centrilobular I None
region I None
of I None
the I None
liver I None
. I None
<eof> I None

<s> O None
In I None
the I None
same I None
liver I None
, I None
biochemical I None
analysis I None
detected I None
fluorinated I None
liver I None
adducts I None
that I None
were I None
up I None
to I None
20-fold I None
greater I None
in I None
guinea I None
pigs I None
than I None
in I None
rats I None
. I None
<eof> I None

<s> O None
This I None
supports I None
and I None
extends I None
previous I None
evidence I None
for I None
a I None
mechanism I None
by I None
which I None
enflurane I Chemical
and/or I None
isoflurane I Chemical
could I None
produce I None
a I None
hypersensitivity I Disease
condition I None
similar I None
to I None
that I None
of I None
halothane I Chemical
<eof> I None

<s> O None
hepatitis I Disease
either I None
alone I None
or I None
subsequent I None
to I None
halothane I Chemical
administration I None
. I None
<eof> I None

<s> O None
The I None
guinea I None
pig I None
would I None
appear I None
to I None
be I None
a I None
useful I None
model I None
for I None
further I None
investigations I None
of I None
the I None
immunological I None
response I None
to I None
these I None
antigens I None
. I None
<eof> I None

<s> O None
Induction I None
by I None
paracetamol I Chemical
of I None
bladder I None
and I None
liver I None
tumours I None
in I None
the I None
rat I None
. I None
<eof> I None

<s> O None
Effects I None
on I None
hepatocyte I None
fine I None
structure I None
. I None
<eof> I None

<s> O None
Groups I None
of I None
male I None
and I None
female I None
inbred I None
Leeds I None
strain I None
rats I None
were I None
fed I None
diets I None
containing I None
either I None
0.5 I None
% I None
or I None
1.0 I None
% I None
paracetamol I Chemical
by I None
weight I None
for I None
up I None
to I None
18 I None
months I None
. I None
<eof> I None

<s> O None
At I None
the I None
1.0 I None
% I None
dosage I None
level I None
, I None
20 I None
% I None
of I None
rats I None
of I None
both I None
sexes I None
developed I None
neoplastic I None
nodules I None
of I None
the I None
liver I None
, I None
a I None
statistically I None
significant I None
incidence I None
. I None
<eof> I None

<s> O None
These I None
rats I None
also I None
showed I None
gross I None
enlargement I None
of I None
their I None
livers I None
and I None
an I None
increase I None
in I None
foci I None
of I None
cellular I None
alteration I None
, I None
the I None
latter I None
also I None
being I None
observed I None
in I None
the I None
low I None
dosage I None
male I None
rats I None
. I None
<eof> I None

<s> O None
Papillomas I Disease
of I None
the I None
transitional I None
epithelium I None
of I None
the I None
bladder I None
developed I None
in I None
all I None
paracetamol I Chemical
-treated I None
groups I None
, I None
and I None
three I None
rats I None
bore I None
bladder I Disease
carcinomas O Disease
. I None
<eof> I None

<s> O None
However I None
, I None
significant I None
yields I None
of I None
bladder I Disease
tumours O Disease
were I None
only I None
obtained I None
from I None
low I None
dosage I None
females I None
and I None
high I None
dosage I None
males I None
. I None
<eof> I None

<s> O None
Additionally I None
, I None
20 I None
to I None
25 I None
% I None
of I None
paracetamol I Chemical
-treated I None
rats I None
developed I None
hyperplasia I Disease
of I None
the I None
bladder I None
epithelium I None
, I None
which I None
was I None
not I None
coincident I None
with I None
the I None
presence I None
of I None
bladder I Disease
calculi O Disease
. I None
<eof> I None

<s> O None
A I None
low I None
yield I None
of I None
tumours I Disease
at I None
various I None
other I None
sites I None
also I None
arose I None
following I None
paracetamol I Chemical
feeding I None
. I None
<eof> I None

<s> O None
An I None
electron I None
microscope I None
study I None
of I None
the I None
livers I None
of I None
<eof> I None

<s> O None
paracetamol I Chemical
-treated I None
rats I None
revealed I None
ultrastructural I None
changes I None
in I None
the I None
hepatocytes I None
that I None
resemble I None
those I None
that I None
result I None
from I None
exposure I None
to I None
a I None
variety I None
of I None
known I None
hepatocarcinogens I Disease
. I None
<eof> I None

<s> O None
Rat I None
extraocular I None
muscle I None
regeneration I None
. I None
<eof> I None

<s> O None
Repair I None
of I None
local I None
anesthetic I None
- I None
induced I None
damage I None
. I None
<eof> I None

<s> O None
Local I None
anesthetics I None
that I None
are I None
commonly I None
used I None
in I None
ophthalmic I None
surgery I None
( I None
0.75 I None
% I None
bupivacaine I Chemical
hydrochloride O Chemical
, I None
2.0 I None
% I None
mepivacaine I Chemical
hydrochloride O Chemical
, I None
and I None
2.0 I None
% I None
<eof> I None

<s> O None
lidocaine I Chemical
hydrochloride O Chemical
plus I None
1:100,000 I None
epinephrine I Chemical
) I None
were I None
injected I None
into I None
the I None
retrobulbar I None
area I None
of I None
rat I None
eyes I None
. I None
<eof> I None

<s> O None
Controls I None
were I None
injected I None
with I None
physiological I None
saline I None
. I None
<eof> I None

<s> O None
All I None
three I None
anesthetics I None
produced I None
massive I None
degeneration I None
of I None
the I None
extraocular I None
muscles I None
. I None
<eof> I None

<s> O None
Muscle I Disease
degeneration O Disease
is I None
followed I None
by I None
regeneration I None
of I None
the I None
damaged I None
muscle I None
fibers I None
. I None
<eof> I None

<s> O None
In I None
addition I None
to I None
muscle I Disease
damage O Disease
, I None
severe I None
damage I None
was I None
also I None
seen I None
in I None
harderian I None
glands I None
, I None
especially I None
after I None
exposure I None
to I None
mepivacaine I Chemical
and I None
lidocaine I Chemical
plus I None
epinephrine I Chemical
. I None
<eof> I None

<s> O None
With I None
these I None
findings I None
in I None
rats I None
, I None
it I None
is I None
hypothesized I None
that I None
the I None
temporary I None
diplopia I Disease
sometimes I None
seen I None
in I None
patients I None
after I None
ophthalmic I None
surgery I None
might I None
be I None
due I None
to I None
anesthetic I None
- I None
induced I None
damage I None
to I None
the I None
extraocular I None
muscles I None
. I None
<eof> I None

<s> O None
Reversal I None
of I None
neuroleptic I None
- I None
induced I None
catalepsy I Disease
by I None
novel I None
aryl I Chemical
- O Chemical
piperazine O Chemical
anxiolytic I None
drugs I None
. I None
<eof> I None

<s> O None
The I None
novel I None
anxiolytic I None
drug I None
, I None
buspirone I Chemical
, I None
reverses I None
catalepsy I Disease
<eof> I None

<s> O None
induced I None
by I None
haloperidol I Chemical
. I None
<eof> I None

<s> O None
A I None
series I None
of I None
aryl I Chemical
- O Chemical
piperazine O Chemical
analogues I None
of I None
buspirone I Chemical
and I None
other I None
5-hydroxytryptaminergic I Chemical
agonists O Chemical
were I None
tested I None
for I None
their I None
ability I None
to I None
reverse I None
haloperidol I Chemical
induced I None
catalepsy I Disease
. I None
<eof> I None

<s> O None
Those I None
drugs I None
with I None
strong I None
affinity I None
for I None
5-hydroxytryptamine I Chemical
1a I None
receptors I None
were I None
able I None
to I None
reverse I None
catalepsy I Disease
. I None
<eof> I None

<s> O None
Drugs I None
with I None
affinity I None
for I None
other I None
5-HT I Chemical
receptors I None
or I None
weak I None
affinity I None
were I None
ineffective I None
. I None
<eof> I None

<s> O None
However I None
, I None
inhibition I None
of I None
postsynaptic I None
5-HT I Chemical
receptors I None
neither I None
inhibited I None
nor I None
potentiated I None
reversal I None
of I None
catalepsy I Disease
and I None
leaves I None
open I None
the I None
question I None
as I None
to I None
the I None
site I None
or I None
mechanism I None
for I None
this I None
effect I None
. I None
<eof> I None

<s> O None
Diazepam I Chemical
facilitates I None
reflex I None
bradycardia I Disease
in I None
conscious I None
rats I None
. I None
<eof> I None

<s> O None
The I None
effects I None
of I None
diazepam I Chemical
on I None
cardiovascular I None
function I None
were I None
assessed I None
in I None
conscious I None
rats I None
. I None
<eof> I None

<s> O None
Intravenous I None
administration I None
of I None
diazepam I Chemical
<eof> I None

<s> O None
( I None
1 I None
- I None
30 I None
mg I None
kg-1 I None
) I None
produced I None
a I None
dose I None
- I None
dependent I None
decrease I None
in I None
both I None
the I None
mean I None
arterial I None
pressure I None
and I None
the I None
heart I None
rate I None
. I None
<eof> I None

<s> O None
Also I None
, I None
reflex I None
bradycardia I Disease
was I None
produced I None
in I None
rats I None
by I None
intravenous I None
infusion I None
of I None
adrenaline I Chemical
( I None
1.25 I None
- I None
2.5 I None
micrograms I None
kg-1 I None
) I None
. I None
<eof> I None

<s> O None
Intravenous I None
pretreatment I None
of I None
the I None
rats I None
with I None
diazepam I Chemical
, I None
although I None
causing I None
no I None
change I None
in I None
the I None
adrenaline I Chemical
-induced I None
pressor I None
effect I None
, I None
did I None
enhance I None
the I None
adrenaline I Chemical
-induced I None
reflex I None
bradycardia I Disease
. I None
<eof> I None

<s> O None
However I None
, I None
the I None
diazepam I Chemical
enhancement I None
of I None
adrenaline I Chemical
-induced I None
reflex I None
bradycardia I Disease
was I None
antagonized I None
by I None
pretreatment I None
of I None
rats I None
with I None
an I None
intravenous I None
dose I None
of I None
picrotoxin I Chemical
<eof> I None

<s> O None
( I None
an I None
agent I None
blocks I None
chloride I Chemical
channels I None
by I None
binding I None
to I None
sites I None
associated I None
with I None
the I None
benzodiazepine I Chemical
- I None
GABA I Chemical
- I None
chloride I Chemical
channel I None
macromolecular I None
complex I None
) I None
. I None
<eof> I None

<s> O None
The I None
data I None
indicate I None
that I None
diazepam I Chemical
acts I None
through I None
the I None
benzodiazepine I Chemical
- I None
GABA I Chemical
- I None
chloride I Chemical
channel I None
macromolecular I None
complex I None
within I None
the I None
central I None
nervous I None
system I None
to I None
facilitate I None
reflex I None
bradycardia I Disease
mediated I None
through I None
baroreceptor I None
reflexes I None
in I None
response I None
to I None
an I None
acute I None
increase I None
in I None
arterial I None
pressure I None
. I None
<eof> I None

<s> O None
Chronic I None
carbamazepine I Chemical
inhibits I None
the I None
development I None
of I None
local I None
anesthetic I None
seizures I Disease
kindled I None
by I None
cocaine I Chemical
and I None
lidocaine I Chemical
. I None
<eof> I None

<s> O None
The I None
effects I None
of I None
carbamazepine I Chemical
<eof> I None

<s> O None
( I None
CBZ I Chemical
) I None
treatment I None
on I None
local I None
anesthetic I None
- I None
kindled I None
<eof> I None

<s> O None
seizures I Disease
and I None
lethality I None
were I None
evaluated I None
in I None
different I None
stages I None
of I None
the I None
kindling I None
process I None
and I None
under I None
different I None
methods I None
of I None
CBZ I Chemical
administration I None
. I None
<eof> I None

<s> O None
Chronic I None
oral I None
CBZ I Chemical
inhibited I None
the I None
development I None
of I None
both I None
lidocaine I Chemical
- I None
and I None
cocaine I Chemical
-induced I None
seizures I Disease
, I None
but I None
had I None
little I None
effect I None
on I None
the I None
fully I None
developed I None
local I None
anesthetic I None
seizures I Disease
. I None
<eof> I None

<s> O None
Chronic I None
CBZ I Chemical
also I None
decreased I None
the I None
incidence I None
of I None
seizure I Disease
<eof> I None

<s> O None
-related I None
mortality I None
in I None
the I None
cocaine I Chemical
-injected I None
rats I None
. I None
<eof> I None

<s> O None
Acute I None
CBZ I Chemical
over I None
a I None
range I None
of I None
doses I None
( I None
15 I None
- I None
50 I None
mg I None
/ I None
kg I None
) I None
had I None
no I None
effect I None
on I None
completed I None
lidocaine I Chemical
-kindled I None
or I None
acute I None
cocaine I Chemical
-induced I None
seizures I Disease
. I None
<eof> I None

<s> O None
Repeated I None
i.p I None
. I None
injection I None
of I None
CBZ I Chemical
<eof> I None

<s> O None
( I None
15 I None
mg I None
/ I None
kg I None
) I None
also I None
was I None
without I None
effect I None
on I None
the I None
development I None
of I None
lidocaine I Chemical
- I None
or I None
cocaine I Chemical
<eof> I None

<s> O None
-kindled I None
<eof> I None

<s> O None
seizures I Disease
. I None
<eof> I None

<s> O None
The I None
differential I None
effects I None
of I None
CBZ I Chemical
depending I None
upon I None
stage I None
of I None
seizure I Disease
development I None
suggest I None
that I None
distinct I None
mechanisms I None
underlie I None
the I None
development I None
versus I None
maintenance I None
of I None
local I None
anesthetic I None
- I None
kindled I None
seizures I Disease
. I None
<eof> I None

<s> O None
The I None
effectiveness I None
of I None
chronic I None
but I None
not I None
repeated I None
, I None
intermittent I None
injections I None
of I None
CBZ I Chemical
suggests I None
that I None
different I None
biochemical I None
consequences I None
result I None
from I None
the I None
different I None
treatment I None
regimens I None
. I None
<eof> I None

<s> O None
The I None
possible I None
utility I None
of I None
chronic I None
CBZ I Chemical
in I None
preventing I None
the I None
development I None
of I None
toxic I None
side I None
effects I None
in I None
human I None
cocaine I Chemical
users I None
is I None
suggested I None
by I None
these I None
data I None
, I None
but I None
remains I None
to I None
be I None
directly I None
evaluated I None
. I None
<eof> I None

<s> O None
D I Chemical
- O Chemical
penicillamine O Chemical
in I None
the I None
treatment I None
of I None
localized I Disease
scleroderma O Disease
. I None
<eof> I None

<s> O None
Localized I Disease
scleroderma O Disease
has I None
no I None
recognized I None
internal I None
organ I None
involvement I None
but I None
may I None
be I None
disfiguring I None
and I None
disabling I None
when I None
the I None
cutaneous I None
lesions I None
are I None
extensive I None
or I None
affect I None
children I None
. I None
<eof> I None

<s> O None
There I None
is I None
no I None
accepted I None
or I None
proven I None
treatment I None
for I None
localized I Disease
scleroderma O Disease
. I None
<eof> I None

<s> O None
Case I None
reports I None
of I None
11 I None
patients I None
with I None
severe I None
, I None
extensive I None
localized I Disease
scleroderma O Disease
who I None
were I None
treated I None
with I None
<eof> I None

<s> O None
D I Chemical
- O Chemical
penicillamine O Chemical
are I None
summarized I None
in I None
this I None
article I None
. I None
<eof> I None

<s> O None
This I None
drug I None
was I None
judged I None
to I None
have I None
a I None
favorable I None
effect I None
on I None
the I None
disease I None
course I None
in I None
7 I None
( I None
64 I None
% I None
) I None
of I None
11 I None
patients I None
. I None
<eof> I None

<s> O None
Improvement I None
began I None
within I None
3 I None
to I None
6 I None
months I None
and I None
consisted I None
of I None
cessation I None
of I None
active I None
cutaneous I None
lesions I None
in I None
all I None
7 I None
patients I None
, I None
skin I None
softening I None
in I None
5 I None
, I None
and I None
more I None
normal I None
growth I None
of I None
the I None
affected I None
limb I None
in I None
2 I None
of I None
3 I None
children I None
. I None
<eof> I None

<s> O None
Joint I None
stiffness I None
and I None
contractures I Disease
also I None
improved I None
. I None
<eof> I None

<s> O None
The I None
dose I None
of I None
D I Chemical
- O Chemical
penicillamine O Chemical
associated I None
with I None
a I None
favorable I None
response I None
was I None
as I None
low I None
as I None
2 I None
to I None
5 I None
mg I None
/ I None
kg I None
per I None
day I None
given I None
over I None
a I None
period I None
ranging I None
from I None
15 I None
to I None
53 I None
months I None
. I None
<eof> I None

<s> O None
D I Chemical
- O Chemical
Penicillamine O Chemical
caused I None
<eof> I None

<s> O None
nephrotic I Disease
syndrome O Disease
in I None
1 I None
patient I None
and I None
milder I None
reversible I None
proteinuria I Disease
in I None
3 I None
other I None
patients I None
; I None
none I None
developed I None
renal I Disease
insufficiency O Disease
. I None
<eof> I None

<s> O None
These I None
data I None
suggest I None
that I None
D I Chemical
- O Chemical
penicillamine O Chemical
may I None
be I None
effective I None
in I None
severe I None
cases I None
of I None
localized I Disease
scleroderma O Disease
. I None
<eof> I None

<s> O None
Preservation I None
of I None
renal I None
blood I None
flow I None
during I None
hypotension I Disease
induced I None
with I None
fenoldopam I Chemical
in I None
dogs I None
. I None
<eof> I None

<s> O None
The I None
introduction I None
of I None
drugs I None
that I None
could I None
induce I None
hypotension I Disease
with I None
different I None
pharmacological I None
actions I None
would I None
be I None
advantageous I None
because I None
side I None
effects I None
unique I None
to I None
a I None
specific I None
drug I None
could I None
be I None
minimized I None
by I None
selecting I None
appropriate I None
therapy I None
. I None
<eof> I None

<s> O None
Specific I None
<eof> I None

<s> O None
dopamine I Chemical
-1 I None
, I None
<eof> I None

<s> O None
( I None
DA I Chemical
1 I None
) I None
and I None
dopamine I Chemical
-2 I None
( I None
DA I Chemical
2 I None
) I None
receptor I None
agonists I None
are I None
now I None
under I None
clinical I None
investigation I None
. I None
<eof> I None

<s> O None
Fenoldopam I Chemical
mesylate O Chemical
is I None
a I None
specific I None
DA1 I None
receptor I None
agonist I None
that I None
lowers I None
blood I None
pressure I None
by I None
vasodilatation I None
. I None
<eof> I None

<s> O None
The I None
hypothesis I None
that I None
fenoldopam I Chemical
could I None
be I None
used I None
to I None
induce I None
hypotension I Disease
and I None
preserve I None
blood I None
flow I None
to I None
the I None
kidney I None
was I None
tested I None
. I None
<eof> I None

<s> O None
Systemic I None
aortic I None
blood I None
pressure I None
and I None
renal I None
blood I None
flow I None
were I None
measured I None
continuously I None
with I None
a I None
carotid I None
arterial I None
catheter I None
and I None
an I None
electromagnetic I None
flow I None
probe I None
respectively I None
, I None
in I None
order I None
to I None
compare I None
the I None
cardiovascular I None
and I None
renal I None
vascular I None
effects I None
of I None
fenoldopam I Chemical
and I None
sodium I Chemical
<eof> I None

<s> O None
nitroprusside I Chemical
in I None
ten I None
dogs I None
under I None
halothane I Chemical
general I None
anaesthesia I None
. I None
<eof> I None

<s> O None
Mean I None
arterial I None
pressure I None
was I None
decreased I None
30 I None
+ I None
/- I None
<eof> I None

<s> O None
8 I None
per I None
cent I None
from I None
control I None
with I None
infusion I None
of I None
fenoldopam I Chemical
( I None
3.4 I None
+ I None
/- I None
<eof> I None

<s> O None
2.0 I None
micrograms.kg-1.min-1 I None
) I None
and I None
34 I None
+ I None
/- I None
4 I None
per I None
cent I None
with I None
infusion I None
of I None
sodium I Chemical
nitroprusside I Chemical
<eof> I None

<s> O None
( I None
5.9 I None
micrograms.kg-1.min-1 I None
) I None
( I None
NS I None
) I None
. I None
<eof> I None

<s> O None
Renal I None
blood I None
flow I None
( I None
RBF I None
) I None
increased I None
during I None
fenoldopam I Chemical
-induced I None
<eof> I None

<s> O None
hypotension I Disease
11 I None
+ I None
/- I None
7 I None
per I None
cent I None
and I None
decreased I None
21 I None
+ I None
/- I None
<eof> I None

<s> O None
8 I None
per I None
cent I None
during I None
sodium I Chemical
<eof> I None

<s> O None
nitroprusside I Chemical
-induced I None
<eof> I None

<s> O None
hypotension I Disease
( I None
P I None
less I None
than I None
0.01 I None
) I None
. I None
<eof> I None

<s> O None
Sodium I None
nitroprusside I Chemical
is I None
a I None
non I None
- I None
selective I None
arteriolar I None
and I None
venous I None
vasodilator I None
that I None
can I None
produce I None
redistribution I None
of I None
blood I None
flow I None
away I None
from I None
the I None
kidney I None
during I None
induced I None
hypotension I Disease
. I None
<eof> I None

<s> O None
Fenoldopam I None
is I None
a I None
selective I None
dopamine I Chemical
-1 I None
( I None
DA1 I None
) I None
receptor I None
agonist I None
that I None
causes I None
vasodilatation I None
to I None
the I None
kidney I None
and I None
other I None
organs I None
with I None
DA1 I None
receptors I None
and I None
preserves I None
blood I None
flow I None
to I None
the I None
kidney I None
during I None
induced I None
hypotension I Disease
. I None
<eof> I None

<s> O None
Antiarrhythmic I None
effects I None
of I None
optical I None
isomers I None
of I None
cibenzoline I Chemical
on I None
canine I None
ventricular I Disease
arrhythmias O Disease
. I None
<eof> I None

<s> O None
Antiarrhythmic I None
effects I None
of I None
( I None
+ I None
) I None
- I None
cibenzoline I Chemical
and I None
( I None
-)- I None
cibenzoline I Chemical
were I None
examined I None
using I None
two I None
canine I None
ventricular I Disease
arrhythmia O Disease
models I None
. I None
<eof> I None

<s> O None
Digitalis I Chemical
<eof> I None

<s> O None
arrhythmia I Disease
, I None
which I None
is I None
suppressed I None
by I None
Na I Chemical
channel I None
blockers I None
, I None
was I None
induced I None
by I None
intermittent I None
intravenous I None
( I None
i.v I None
. I None
) I None
<eof> I None

<s> O None
injection I None
of I None
ouabain I Chemical
in I None
pentobarbital I Chemical
-anesthetized I None
dogs I None
. I None
<eof> I None

<s> O None
Adrenaline I Disease
arrhythmia O Disease
, I None
which I None
is I None
suppressed I None
by I None
Ca I Chemical
channel I None
blockers I None
, I None
was I None
induced I None
by I None
adrenaline I Chemical
infusion I None
in I None
<eof> I None

<s> O None
halothane I Chemical
-anesthetized I None
dogs I None
. I None
<eof> I None

<s> O None
Ten I None
and I None
5 I None
mg I None
/ I None
kg I None
i.v I None
. I None
<eof> I None

<s> O None
( I None
+ I None
) I None
- I None
cibenzoline I Chemical
suppressed I None
<eof> I None

<s> O None
digitalis I Chemical
- I None
and I None
adrenaline I Chemical
-induced I None
arrhythmias I Disease
, I None
respectively I None
. I None
<eof> I None

<s> O None
The I None
minimum I None
effective I None
plasma I None
concentrations I None
of I None
( I None
+ I None
) I None
- I None
cibenzoline I Chemical
for I None
digitalis I Chemical
- I None
and I None
adrenaline I Chemical
-induced I None
<eof> I None

<s> O None
arrhythmias I Disease
were I None
1.4 I None
+ I None
/- I None
0.4 I None
and I None
2.0 I None
+ I None
/- I None
<eof> I None

<s> O None
0.6 I None
micrograms I None
/ I None
ml I None
, I None
respectively I None
( I None
mean I None
+ I None
/- I None
SD I None
, I None
n I None
= I None
6 I None
) I None
. I None
<eof> I None

<s> O None
A I None
lower I None
dose I None
of I None
1 I None
mg I None
/ I None
kg I None
i.v I None
. I None
of I None
( I None
-)- I None
cibenzoline I Chemical
suppressed I None
the I None
digitalis I Chemical
-induced I None
arrhythmia I Disease
, I None
whereas I None
5 I None
mg I None
/ I None
kg I None
i.v I None
. I None
was I None
needed I None
to I None
suppress I None
adrenaline I Chemical
<eof> I None

<s> O None
-induced I None
arrhythmias I Disease
. I None
<eof> I None

<s> O None
The I None
minimum I None
effective I None
plasma I None
concentrations I None
of I None
( I None
-)- I None
cibenzoline I Chemical
for I None
digitalis I Chemical
- I None
and I None
adrenaline I Chemical
-induced I None
<eof> I None

<s> O None
arrhythmia I Disease
were I None
0.06 I None
+ I None
/- I None
<eof> I None

<s> O None
0.04 I None
and I None
0.7 I None
+ I None
/- I None
<eof> I None

<s> O None
0.1 I None
micrograms I None
/ I None
ml I None
, I None
respectively I None
( I None
mean I None
+ I None
/- I None
SD I None
, I None
n I None
= I None
6 I None
) I None
. I None
<eof> I None

<s> O None
The I None
stronger I None
antiarrhythmic I None
effect I None
of I None
( I None
-)- I None
cibenzoline I Chemical
indicates I None
that I None
( I None
-)-isomer I None
may I None
have I None
an I None
effect I None
nearly I None
5 I None
- I None
20 I None
times I None
stronger I None
in I None
suppressing I None
Na I Chemical
channels I None
, I None
but I None
effects I None
of I None
both I None
drugs I None
on I None
Ca I Chemical
channels I None
may I None
be I None
almost I None
equipotent I None
. I None
<eof> I None

<s> O None
Effect I None
of I None
Hibiscus I Chemical
rosa O Chemical
sinensis O Chemical
on I None
reserpine I Chemical
-induced I None
neurobehavioral I None
and I None
biochemical I None
alterations I None
in I None
rats I None
. I None
<eof> I None

<s> O None
Effect I None
of I None
methanolic I None
extract I None
of I None
Hibiscus I Chemical
rosa O Chemical
sinensis O Chemical
<eof> I None

<s> O None
( I None
100 I None
- I None
300 I None
mg I None
/ I None
kg I None
) I None
was I None
studied I None
on I None
reserpine I Chemical
-induced I None
orofacial I None
dyskinesia I Disease
and I None
neurochemical I None
alterations I None
. I None
<eof> I None

<s> O None
The I None
rats I None
were I None
treated I None
with I None
intraperitoneal I None
reserpine I Chemical
<eof> I None

<s> O None
( I None
1 I None
mg I None
/ I None
kg I None
, I None
ip I None
) I None
for I None
3 I None
days I None
every I None
other I None
day I None
. I None
<eof> I None

<s> O None
On I None
day I None
5 I None
, I None
vacuous I None
chewing I None
movements I None
and I None
tongue I None
protrusions I None
were I None
counted I None
for I None
5 I None
min I None
. I None
<eof> I None

<s> O None
Reserpine I Chemical
treated I None
rats I None
significantly I None
developed I None
vacuous I None
chewing I None
movements I None
and I None
tongue I None
protrusions I None
however I None
, I None
coadministration I None
of I None
Hibiscus I Chemical
rosa O Chemical
sinensis O Chemical
roots I None
extract I None
( I None
100 I None
, I None
200 I None
and I None
300 I None
mg I None
/ I None
kg I None
, I None
per I None
orally I None
) I None
attenuated I None
the I None
effects I None
. I None
<eof> I None

<s> O None
Biochemical I None
analysis I None
of I None
brain I None
revealed I None
that I None
the I None
reserpine I Chemical
treatment I None
significantly I None
increased I None
lipid I None
peroxidation I None
and I None
decreased I None
levels I None
of I None
superoxide I Chemical
dismutase I None
( I None
SOD I None
) I None
, I None
catalase I None
( I None
CAT I None
) I None
and I None
glutathione I Chemical
reductase I None
( I None
GSH I None
) I None
, I None
an I None
index I None
of I None
oxidative I None
stress I None
process I None
. I None
<eof> I None

<s> O None
Coadministration I None
of I None
extract I None
significantly I None
reduced I None
the I None
lipid I None
peroxidation I None
and I None
reversed I None
the I None
decrease I None
in I None
brain I None
SOD I None
, I None
CAT I None
and I None
GSH I None
levels I None
. I None
<eof> I None

<s> O None
The I None
results I None
of I None
the I None
present I None
study I None
suggested I None
that I None
Hibiscus I Chemical
rosa O Chemical
sinensis O Chemical
had I None
a I None
protective I None
role I None
against I None
reserpine I Chemical
-induced I None
orofacial I None
dyskinesia I Disease
and I None
oxidative I None
stress I None
. I None
<eof> I None

<s> O None
Comparison I None
of I None
aqueous I None
and I None
gellan I None
ophthalmic I None
timolol I Chemical
with I None
placebo I None
on I None
the I None
24-hour I None
heart I None
rate I None
response I None
in I None
patients I None
on I None
treatment I None
for I None
glaucoma I Disease
. I None
<eof> I None

<s> O None
PURPOSE I None
: I None
<eof> I None

<s> O None
Topical I None
beta I None
- I None
blocker I None
treatment I None
is I None
routine I None
therapy I None
in I None
the I None
management I None
of I None
patients I None
with I None
glaucoma I Disease
. I None
<eof> I None

<s> O None
Therapy I None
results I None
in I None
systemic I None
absorption I None
, I None
however I None
, I None
the I None
degree I None
of I None
reduction I None
of I None
resting I None
and I None
peak I None
heart I None
rate I None
has I None
not I None
been I None
quantified I None
. I None
<eof> I None

<s> O None
DESIGN I None
: I None
<eof> I None

<s> O None
This I None
trial I None
evaluated I None
the I None
effect I None
of I None
placebo I None
, I None
0.5 I None
% I None
aqueous I None
timolol I Chemical
<eof> I None

<s> O None
( I None
timolol I Chemical
solution I None
) I None
and I None
a I None
0.5 I None
% I None
timolol I Chemical
suspension I None
that I None
forms I None
a I None
gel I None
on I None
application I None
to I None
the I None
conjunctiva I None
( I None
timolol I Chemical
gellan I None
) I None
on I None
the I None
24-hour I None
heart I None
rate I None
in I None
patients I None
currently I None
being I None
treated I None
for I None
glaucoma I Disease
to I None
quantify I None
the I None
reduction I None
in I None
mean I None
heart I None
rate I None
. I None
<eof> I None

<s> O None
METHODS I None
: I None
<eof> I None

<s> O None
Forty I None
- I None
three I None
Caucasian I None
patients I None
with I None
primary I None
open I Disease
- O Disease
angle O Disease
glaucoma O Disease
or I None
ocular I Disease
hypertension O Disease
with I None
a I None
mean I None
( I None
+ I None
/-SD I None
) I None
age I None
of I None
63 I None
( I None
+ I None
/-8 I None
) I None
years I None
were I None
randomized I None
and I None
crossed I None
over I None
in I None
a I None
double I None
- I None
masked I None
manner I None
to I None
14 I None
days I None
of I None
treatment I None
with I None
placebo I None
( I None
morning I None
and I None
evening I None
in I None
both I None
eyes I None
) I None
, I None
timolol I Chemical
solution I None
( I None
morning I None
and I None
evening I None
in I None
both I None
eyes I None
) I None
, I None
or I None
timolol I Chemical
gellan I None
( I None
morning I None
in I None
both I None
eyes I None
with I None
placebo I None
in I None
the I None
evening I None
) I None
. I None
<eof> I None

<s> O None
On I None
the I None
13th I None
day I None
of I None
each I None
period I None
, I None
heart I None
rate I None
was I None
recorded I None
continuously I None
during I None
a I None
typical I None
, I None
ambulant I None
24-hour I None
period I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
Both I None
timolol I Chemical
solution I None
and I None
timolol I Chemical
gellan I None
reduced I None
the I None
mean I None
24-hour I None
heart I None
rate I None
compared I None
with I None
placebo I None
( I None
P I None
< I None
or I None
= I None
.001 I None
) I None
, I None
and I None
this I None
reduction I None
was I None
most I None
pronounced I None
during I None
the I None
daytime I None
( I None
-7.5 I None
% I None
change I None
in I None
mean I None
heart I None
rate I None
, I None
-5.7 I None
beats I None
/ I None
min I None
) I None
. I None
<eof> I None

<s> O None
Timolol I Chemical
gellan I None
showed I None
a I None
numerically I None
but I None
not I None
significantly I None
smaller I None
reduction I None
in I None
24-hour I None
heart I None
rate I None
, I None
compared I None
with I None
timolol I Chemical
solution I None
. I None
<eof> I None

<s> O None
During I None
the I None
night I None
, I None
the I None
mean I None
12-hour I None
heart I None
rate I None
on I None
placebo I None
and I None
timolol I Chemical
gellan I None
were I None
both I None
significantly I None
less I None
than I None
on I None
timolol I Chemical
solution I None
; I None
the I None
difference I None
between I None
solution I None
and I None
gellan I None
treatments I None
was I None
statistically I None
significant I None
( I None
P I None
= I None
.01 I None
) I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
Both I None
timolol I Chemical
solution I None
and I None
timolol I Chemical
gellan I None
decrease I None
the I None
mean I None
24-hour I None
heart I None
rate I None
compared I None
with I None
placebo I None
. I None
<eof> I None

<s> O None
This I None
response I None
was I None
most I None
pronounced I None
during I None
the I None
active I None
daytime I None
period I None
. I None
<eof> I None

<s> O None
These I None
data I None
quantify I None
the I None
modest I None
bradycardia I Disease
associated I None
with I None
ophthalmic I None
beta I None
- I None
blocker I None
therapy I None
in I None
a I None
typical I None
patient I None
population I None
on I None
therapy I None
for I None
glaucoma I Disease
. I None
<eof> I None

<s> O None
Although I None
exercise I None
performance I None
was I None
not I None
assessed I None
in I None
this I None
trial I None
, I None
reductions I None
of I None
this I None
magnitude I None
should I None
not I None
have I None
substantial I None
clinical I None
consequences I None
. I None
<eof> I None

<s> O None
5 I Chemical
flourouracil O Chemical
-induced I None
apical I Disease
ballooning O Disease
syndrome O Disease
: I None
a I None
case I None
report I None
. I None
<eof> I None

<s> O None
The I None
apical I Disease
ballooning O Disease
syndrome O Disease
<eof> I None

<s> O None
( I None
ABS I Disease
) I None
is I None
a I None
recently I None
described I None
stress I None
- I None
mediated I None
acute I Disease
cardiac O Disease
syndrome O Disease
characterized I None
by I None
transient I None
wall I None
- I None
motion I None
abnormalities I None
involving I None
the I None
apex I None
and I None
midventricle I None
with I None
hyperkinesis I Disease
of I None
the I None
basal I None
left I None
ventricular I None
( I None
LV I None
) I None
segments I None
without I None
obstructive I None
epicardial I Disease
coronary O Disease
disease O Disease
. I None
<eof> I None

<s> O None
Cardiotoxicity I Disease
is I None
not I None
an I None
uncommon I None
adverse I None
effect I None
of I None
chemotherapeutic I None
agents I None
. I None
<eof> I None

<s> O None
However I None
, I None
there I None
are I None
no I None
reports I None
of I None
ABS I Disease
secondary I None
to I None
chemotherapeutic I None
agents I None
. I None
<eof> I None

<s> O None
We I None
describe I None
the I None
case I None
of I None
a I None
woman I None
who I None
developed I None
the I None
syndrome I None
after I None
chemotherapy I None
for I None
metastatic I None
cancer I Disease
. I None
<eof> I None

<s> O None
A I None
79-year I None
- I None
old I None
woman I None
presented I None
with I None
typical I None
ischemic I Disease
chest I Disease
pain O Disease
, I None
elevated I None
cardiac I None
enzymes I None
with I None
significant I None
ST I None
- I None
segment I None
abnormalities I None
on I None
her I None
electrocardiogram I None
. I None
<eof> I None

<s> O None
She I None
underwent I None
recent I None
chemotherapy I None
with I None
fluorouracil I Chemical
for I None
metastatic I None
colorectal I Disease
cancer O Disease
. I None
<eof> I None

<s> O None
Echocardiography I None
revealed I None
a I None
wall I None
- I None
motion I None
abnormality I None
involving I None
the I None
apical I None
and I None
periapical I None
segments I None
which I None
appeared I None
akinetic I Disease
. I None
<eof> I None

<s> O None
Coronary I None
angiography I None
revealed I None
no I None
obstructive I None
coronary I None
lesions I None
. I None
<eof> I None

<s> O None
The I None
patient I None
was I None
stabilized I None
with I None
medical I None
therapy I None
. I None
<eof> I None

<s> O None
Four I None
weeks I None
later I None
she I None
remained I None
completely I None
asymptomatic I None
. I None
<eof> I None

<s> O None
Echocardiogram I None
revealed I None
a I None
normal I None
ejection I None
fraction I None
and I None
a I None
resolution I None
of I None
the I None
apical I None
akinesis I Disease
. I None
<eof> I None

<s> O None
Pathogenetic I None
mechanisms I None
of I None
cardiac I Disease
complications O Disease
in I None
cancer I Disease
patients I None
undergoing I None
chemotherapy I None
include I None
coronary I Disease
vasospasm O Disease
, I None
endothelial I None
damage I None
and I None
consequent I None
thrombus I Disease
formation I None
. I None
<eof> I None

<s> O None
In I None
our I None
patient I None
, I None
both I None
supraphysiologic I None
levels I None
of I None
plasma I None
catecholamines I Chemical
and I None
stress I None
related I None
neuropeptides I None
caused I None
by I None
cancer I Disease
diagnosis I None
as I None
well I None
as I None
chemotherapy I None
may I None
have I None
contributed I None
the I None
development I None
of I None
ABS I Disease
. I None
<eof> I None

<s> O None
Reduction I None
of I None
pain I Disease
during I None
induction I None
with I None
target I None
- I None
controlled I None
propofol I Chemical
and I None
remifentanil I Chemical
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
<eof> I None

<s> O None
Pain I Disease
on I None
injection I None
of I None
propofol I Chemical
is I None
unpleasant I None
. I None
<eof> I None

<s> O None
We I None
hypothesized I None
that I None
propofol I Chemical
infusion I None
<eof> I None

<s> O None
pain I Disease
might I None
be I None
prevented I None
by I None
infusing I None
remifentanil I Chemical
before I None
starting I None
the I None
propofol I Chemical
infusion I None
in I None
a I None
clinical I None
setting I None
where I None
target I None
- I None
controlled I None
infusions I None
( I None
TCI I None
) I None
of I None
both I None
drugs I None
were I None
used I None
. I None
<eof> I None

<s> O None
A I None
prospective I None
, I None
randomized I None
, I None
double I None
- I None
blind I None
, I None
placebo I None
- I None
controlled I None
trial I None
was I None
performed I None
to I None
determine I None
the I None
effect I None
- I None
site I None
concentration I None
( I None
Ce I None
) I None
of I None
remifentanil I Chemical
to I None
prevent I None
the I None
pain I Disease
without I None
producing I None
complications I None
. I None
<eof> I None

<s> O None
METHODS I None
: I None
<eof> I None

<s> O None
A I None
total I None
of I None
128 I None
patients I None
undergoing I None
general I None
surgery I None
were I None
randomly I None
allocated I None
to I None
receive I None
normal I None
saline I None
( I None
control I None
) I None
or I None
remifentanil I Chemical
to I None
a I None
target I None
Ce I None
of I None
2 I None
ng I None
ml(-1 I None
) I None
<eof> I None

<s> O None
( I None
R2 I None
) I None
, I None
4 I None
ng I None
ml(-1 I None
) I None
( I None
R4 I None
) I None
, I None
or I None
6 I None
ng I None
ml(-1 I None
) I None
( I None
R6 I None
) I None
administered I None
via I None
TCI I None
. I None
<eof> I None

<s> O None
After I None
the I None
target I None
Ce I None
was I None
achieved I None
, I None
the I None
infusion I None
of I None
propofol I Chemical
was I None
started I None
. I None
<eof> I None

<s> O None
Remifentanil I Chemical
-related I None
complications I None
were I None
assessed I None
during I None
the I None
remifentanil I Chemical
infusion I None
, I None
and I None
pain I Disease
caused I None
by I None
propofol I Chemical
was I None
evaluated I None
using I None
a I None
four I None
- I None
point I None
scale I None
during I None
the I None
propofol I Chemical
infusion I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
The I None
incidence I None
of I None
pain I Disease
was I None
significantly I None
lower I None
in I None
Groups I None
R4 I None
and I None
R6 I None
than I None
in I None
the I None
control I None
and I None
R2 I None
groups I None
( I None
12/32 I None
and I None
6/31 I None
vs I None
26/31 I None
and I None
25/32 I None
, I None
respectively I None
, I None
P<0.001 I None
) I None
. I None
<eof> I None

<s> O None
Pain I Disease
was I None
less I None
severe I None
in I None
Groups I None
R4 I None
and I None
R6 I None
than I None
in I None
the I None
control I None
and I None
R2 I None
groups I None
( I None
P<0.001 I None
) I None
. I None
<eof> I None

<s> O None
However I None
, I None
both I None
incidence I None
and I None
severity I None
of I None
pain I Disease
were I None
not I None
different I None
between I None
Groups I None
R4 I None
and I None
R6 I None
. I None
<eof> I None

<s> O None
No I None
significant I None
complications I None
were I None
observed I None
during I None
the I None
study I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
During I None
induction I None
of I None
anaesthesia I None
with I None
TCI I None
of I None
propofol I Chemical
and I None
remifentanil I Chemical
, I None
a I None
significant I None
reduction I None
in I None
propofol I Chemical
infusion I None
<eof> I None

<s> O None
pain I Disease
was I None
achieved I None
without I None
significant I None
complications I None
by I None
prior I None
administration I None
of I None
remifentanil I Chemical
at I None
a I None
target I None
Ce I None
of I None
4 I None
ng I None
ml(-1 I None
) I None
. I None
<eof> I None

<s> O None
Prenatal I None
exposure I None
to I None
fluoxetine I Chemical
induces I None
fetal I None
pulmonary I None
hypertension I None
in I None
the I None
rat I None
. I None
<eof> I None

<s> O None
RATIONALE I None
: I None
<eof> I None

<s> O None
Fluoxetine I Chemical
is I None
a I None
selective I None
serotonin I Chemical
reuptake I None
inhibitor I None
antidepressant I None
widely I None
used I None
by I None
pregnant I None
women I None
. I None
<eof> I None

<s> O None
Epidemiological I None
data I None
suggest I None
that I None
fluoxetine I Chemical
exposure I None
prenatally I None
increases I None
the I None
prevalence I None
of I None
persistent I None
pulmonary I Disease
hypertension O Disease
syndrome O Disease
of I None
the I None
newborn I None
. I None
<eof> I None

<s> O None
The I None
mechanism I None
responsible I None
for I None
this I None
effect I None
is I None
unclear I None
and I None
paradoxical I None
, I None
considering I None
the I None
current I None
evidence I None
of I None
a I None
pulmonary I Disease
hypertension O Disease
protective I None
fluoxetine I Chemical
effect I None
in I None
adult I None
rodents I None
. I None
<eof> I None

<s> O None
OBJECTIVES I None
: I None
<eof> I None

<s> O None
To I None
evaluate I None
the I None
fluoxetine I Chemical
effect I None
on I None
fetal I None
rat I None
pulmonary I None
vascular I None
smooth I None
muscle I None
mechanical I None
properties I None
and I None
cell I None
proliferation I None
rate I None
. I None
<eof> I None

<s> O None
METHODS I None
: I None
<eof> I None

<s> O None
Pregnant I None
rats I None
were I None
treated I None
with I None
fluoxetine I Chemical
<eof> I None

<s> O None
( I None
10 I None
mg I None
/ I None
kg I None
) I None
from I None
Day I None
11 I None
through I None
Day I None
21 I None
of I None
gestation I None
. I None
<eof> I None

<s> O None
MEASUREMENTS I None
AND I None
MAIN I None
RESULTS I None
: I None
<eof> I None

<s> O None
Fetuses I None
were I None
delivered I None
by I None
cesarean I None
section I None
. I None
<eof> I None

<s> O None
As I None
compared I None
with I None
controls I None
, I None
fluoxetine I Chemical
exposure I None
resulted I None
in I None
fetal I None
pulmonary I None
hypertension I None
as I None
evidenced I None
by I None
an I None
increase I None
in I None
the I None
weight I None
ratio I None
of I None
the I None
right I None
ventricle I None
to I None
the I None
left I None
ventricle I None
plus I None
septum I None
( I None
P I None
= I None
0.02 I None
) I None
and I None
by I None
an I None
increase I None
in I None
pulmonary I None
arterial I None
medial I None
thickness I None
( I None
P I None
< I None
0.01 I None
) I None
. I None
<eof> I None

<s> O None
Postnatal I None
mortality I None
was I None
increased I None
among I None
experimental I None
animals I None
, I None
and I None
arterial I None
oxygen I Chemical
saturation I None
was I None
96 I None
+ I None
/- I None
<eof> I None

<s> O None
1 I None
% I None
in I None
1-day I None
- I None
old I None
control I None
animals I None
and I None
significantly I None
lower I None
( I None
P I None
< I None
0.01 I None
) I None
in I None
fluoxetine I Chemical
-exposed I None
pups I None
( I None
79 I None
+ I None
/- I None
2 I None
% I None
) I None
. I None
<eof> I None

<s> O None
In I None
vitro I None
, I None
fluoxetine I Chemical
induced I None
pulmonary I None
arterial I None
muscle I None
contraction I None
in I None
fetal I None
, I None
but I None
not I None
adult I None
, I None
animals I None
( I None
P I None
< I None
0.01 I None
) I None
and I None
reduced I None
serotonin I Chemical
-induced I None
contraction I None
at I None
both I None
ages I None
( I None
P I None
< I None
0.01 I None
) I None
. I None
<eof> I None

<s> O None
After I None
in I None
utero I None
exposure I None
to I None
a I None
low I None
fluoxetine I Chemical
concentration I None
the I None
pulmonary I None
arterial I None
smooth I None
muscle I None
cell I None
proliferation I None
rate I None
was I None
significantly I None
increased I None
in I None
fetal I None
, I None
but I None
not I None
adult I None
, I None
cells I None
( I None
P I None
< I None
0.01 I None
) I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
In I None
contrast I None
to I None
the I None
adult I None
, I None
fluoxetine I Chemical
exposure I None
in I None
utero I None
induces I None
pulmonary I Disease
hypertension O Disease
in I None
the I None
fetal I None
rat I None
as I None
a I None
result I None
of I None
a I None
developmentally I None
regulated I None
increase I None
in I None
pulmonary I None
vascular I None
smooth I None
muscle I None
proliferation I None
. I None
<eof> I None

<s> O None
Syncope I Disease
and I None
QT I Disease
prolongation O Disease
among I None
patients I None
treated I None
with I None
methadone I Chemical
for I None
heroin I Chemical
dependence I None
in I None
the I None
city I None
of I None
Copenhagen I None
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
<eof> I None

<s> O None
Methadone I Chemical
is I None
prescribed I None
to I None
heroin I Chemical
addicts I None
to I None
decrease I None
illicit I None
opioid I None
use I None
. I None
<eof> I None

<s> O None
Prolongation I None
of I None
the I None
QT I None
interval I None
in I None
the I None
ECG I None
of I None
patients I None
with I None
torsade I Disease
de O Disease
pointes O Disease
<eof> I None

<s> O None
( I None
TdP I Disease
) I None
has I None
been I None
reported I None
in I None
methadone I Chemical
users I None
. I None
<eof> I None

<s> O None
As I None
heroin I Chemical
addicts I None
sometimes I None
faint I None
while I None
using I None
illicit I None
drugs I None
, I None
doctors I None
might I None
attribute I None
too I None
many I None
episodes I None
of I None
syncope I Disease
to I None
illicit I None
drug I None
use I None
and I None
thereby I None
underestimate I None
the I None
incidence I None
of I None
TdP I Disease
in I None
this I None
special I None
population I None
, I None
and I None
the I None
high I None
mortality I None
in I None
this I None
population I None
may I None
, I None
in I None
part I None
, I None
be I None
caused I None
by I None
the I None
proarrhythmic I None
effect I None
of I None
methadone I Chemical
. I None
<eof> I None

<s> O None
METHODS I None
: I None
<eof> I None

<s> O None
In I None
this I None
cross I None
- I None
sectional I None
study I None
interview I None
, I None
ECGs I None
and I None
blood I None
samples I None
were I None
collected I None
in I None
a I None
population I None
of I None
adult I None
heroin I Chemical
addicts I None
treated I None
with I None
methadone I Chemical
or I None
buprenorphine I Chemical
on I None
a I None
daily I None
basis I None
. I None
<eof> I None

<s> O None
Of I None
the I None
patients I None
at I None
the I None
Drug I None
Addiction I None
Service I None
in I None
the I None
municipal I None
of I None
Copenhagen I None
, I None
450 I None
( I None
approximately I None
52 I None
% I None
) I None
were I None
included I None
. I None
<eof> I None

<s> O None
The I None
QT I None
interval I None
was I None
estimated I None
from I None
12 I None
lead I None
ECGs I None
. I None
<eof> I None

<s> O None
All I None
participants I None
were I None
interviewed I None
about I None
any I None
experience I None
of I None
syncope I Disease
. I None
<eof> I None

<s> O None
The I None
association I None
between I None
opioid I None
dose I None
and I None
QT I None
, I None
and I None
methadone I Chemical
dose I None
and I None
reporting I None
of I None
syncope I Disease
was I None
assessed I None
using I None
multivariate I None
linear I None
regression I None
and I None
logistic I None
regression I None
, I None
respectively I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
Methadone I Chemical
dose I None
was I None
associated I None
with I None
longer I None
QT I None
interval I None
of I None
0.140 I None
ms I None
/ I None
mg I None
( I None
p I None
= I None
0.002 I None
) I None
. I None
<eof> I None

<s> O None
No I None
association I None
between I None
buprenorphine I Chemical
and I None
QTc I None
was I None
found I None
. I None
<eof> I None

<s> O None
Among I None
the I None
subjects I None
treated I None
with I None
methadone I Chemical
, I None
28 I None
% I None
men I None
and I None
32 I None
% I None
women I None
had I None
prolonged I Disease
QTc O Disease
interval O Disease
. I None
<eof> I None

<s> O None
None I None
of I None
the I None
subjects I None
treated I None
with I None
buprenorphine I Chemical
had I None
QTc I None
interval I None
> I None
0.440 I None
s((1/2 I None
) I None
) I None
. I None
<eof> I None

<s> O None
A I None
50 I None
mg I None
higher I None
methadone I Chemical
dose I None
was I None
associated I None
with I None
a I None
1.2 I None
( I None
95 I None
% I None
CI I None
1.1 I None
to I None
1.4 I None
) I None
times I None
higher I None
odds I None
for I None
syncope I Disease
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
Methadone I Chemical
is I None
associated I None
with I None
QT I Disease
prolongation O Disease
and I None
higher I None
reporting I None
of I None
syncope I Disease
in I None
a I None
population I None
of I None
heroin I Chemical
addicts I None
. I None
<eof> I None

<s> O None
Peripheral I Disease
neuropathy O Disease
caused I None
by I None
high I None
- I None
dose I None
cytosine I Chemical
arabinoside O Chemical
treatment I None
in I None
a I None
patient I None
with I None
acute I Disease
myeloid O Disease
leukemia O Disease
. I None
<eof> I None

<s> O None
The I None
central I None
nervous I None
system I None
<eof> I None

<s> O None
toxicity I Disease
of I None
high I None
- I None
dose I None
cytosine I Chemical
arabinoside O Chemical
is I None
well I None
recognized I None
, I None
but I None
the I None
toxicity I Disease
of I None
cytosine I Chemical
arabinoside O Chemical
<eof> I None

<s> O None
in I None
the I None
peripheral I None
nervous I None
system I None
has I None
been I None
infrequently I None
reported I None
. I None
<eof> I None

<s> O None
A I None
49-year I None
- I None
old I None
Japanese I None
man I None
was I None
diagnosed I None
with I None
acute I Disease
myeloid O Disease
leukemia O Disease
. I None
<eof> I None

<s> O None
After I None
he I None
achieved I None
complete I None
remission I None
, I None
he I None
received I None
high I None
- I None
dose I None
cytosine I Chemical
arabinoside O Chemical
treatment I None
( I None
2 I None
g I None
/ I None
m2 I None
twice I None
a I None
day I None
for I None
5 I None
days I None
; I None
total I None
, I None
20 I None
g I None
/ I None
m2 I None
) I None
as I None
consolidation I None
therapy I None
. I None
<eof> I None

<s> O None
The I None
first I None
course I None
of I None
high I None
- I None
dose I None
cytosine I Chemical
arabinoside O Chemical
resulted I None
in I None
no I None
unusual I None
symptoms I None
, I None
but I None
on I None
day I None
21 I None
of I None
the I None
second I None
course I None
of I None
treatment I None
, I None
the I None
patient I None
complained I None
of I None
numbness I Disease
in I None
his I None
right I None
foot I None
. I None
<eof> I None

<s> O None
Electromyogram I None
and I None
nerve I None
- I None
conduction I None
studies I None
showed I None
<eof> I None

<s> O None
peripheral I Disease
neuropathy O Disease
in I None
both I None
peroneal I None
nerves I None
. I None
<eof> I None

<s> O None
This I None
neuropathy I Disease
was I None
gradually I None
resolving I None
; I None
however I None
, I None
after I None
the I None
patient I None
received I None
allogeneic I None
bone I None
marrow I None
transplantation I None
, I None
the I None
symptoms I None
worsened I None
, I None
with I None
the I None
development I None
of I None
graft I Disease
- O Disease
versus O Disease
- O Disease
host O Disease
disease O Disease
, I None
and I None
the I None
symptoms I None
subsequently I None
responded I None
to I None
methylprednisolone I Chemical
. I None
<eof> I None

<s> O None
Although I None
the I None
mechanisms I None
of I None
peripheral I Disease
neuropathy O Disease
are I None
still I None
unclear I None
, I None
high I None
- I None
dose I None
cytosine I Chemical
arabinoside O Chemical
is I None
a I None
therapy I None
that I None
is I None
potentially I None
toxic I None
to I None
the I None
peripheral I None
nervous I None
system I None
, I None
and I None
auto I None
/ I None
alloimmunity I None
may I None
play I None
an I None
important I None
role I None
in I None
these I None
mechanisms I None
. I None
<eof> I None

<s> O None
Atorvastatin I Chemical
prevented I None
and I None
reversed I None
<eof> I None

<s> O None
dexamethasone I Chemical
-induced I None
<eof> I None

<s> O None
hypertension I Disease
in I None
the I None
rat I None
. I None
<eof> I None

<s> O None
To I None
assess I None
the I None
antioxidant I None
effects I None
of I None
atorvastatin I Chemical
<eof> I None

<s> O None
( I None
atorva I Chemical
) I None
on I None
dexamethasone I Chemical
<eof> I None

<s> O None
( I None
dex I Chemical
) I None
-induced I None
<eof> I None

<s> O None
hypertension I Disease
, I None
60 I None
male I None
Sprague I None
- I None
Dawley I None
rats I None
were I None
treated I None
with I None
atorva I Chemical
30 I None
mg I None
/ I None
kg I None
/ I None
day I None
or I None
tap I None
water I None
for I None
15 I None
days I None
. I None
<eof> I None

<s> O None
Dex I Chemical
increased I None
systolic I None
blood I None
pressure I None
( I None
SBP I None
) I None
from I None
109 I None
+ I None
/- I None
<eof> I None

<s> O None
1.8 I None
to I None
135 I None
+ I None
/- I None
<eof> I None

<s> O None
0.6 I None
mmHg I None
and I None
plasma I None
superoxide I Chemical
<eof> I None

<s> O None
( I None
5711 I None
+ I None
/- I None
<eof> I None

<s> O None
284.9 I None
saline I None
, I None
7931 I None
+ I None
/- I None
<eof> I None

<s> O None
392.8 I None
U I None
/ I None
ml I None
dex I Chemical
, I None
P I None
< I None
0.001 I None
) I None
. I None
<eof> I None

<s> O None
In I None
this I None
prevention I None
study I None
, I None
SBP I None
in I None
the I None
atorva I Chemical
+ I None
dex I Chemical
group I None
was I None
increased I None
from I None
115 I None
+ I None
/- I None
0.4 I None
to I None
124 I None
+ I None
/- I None
<eof> I None

<s> O None
1.5 I None
mmHg I None
, I None
but I None
this I None
was I None
significantly I None
lower I None
than I None
in I None
the I None
dex I Chemical
-only I None
group I None
( I None
P I None
' I None
< I None
0.05 I None
) I None
. I None
<eof> I None

<s> O None
Atorva I Chemical
reversed I None
<eof> I None

<s> O None
dex I Chemical
-induced I None
<eof> I None

<s> O None
hypertension I Disease
( I None
129 I None
+ I None
/- I None
0.6 I None
<eof> I None

<s> O None
mmHg I None
, I None
vs. I None
135 I None
+ I None
<eof> I None

<s> O None
/- I None
0.6 I None
mmHg I None
P I None
' I None
< I None
0.05 I None
) I None
and I None
decreased I None
plasma I None
<eof> I None

<s> O None
superoxide I Chemical
( I None
7931 I None
+ I None
/- I None
392.8 I None
dex I Chemical
, I None
1187 I None
+ I None
/- I None
<eof> I None

<s> O None
441.2 I None
<eof> I None

<s> O None
atorva I Chemical
+ I None
dex I Chemical
, I None
P I None
< I None
0.0001 I None
) I None
. I None
<eof> I None

<s> O None
Plasma I None
nitrate I Chemical
/ I None
nitrite I Chemical
( I None
NOx I None
) I None
was I None
decreased I None
in I None
dex I Chemical
-treated I None
rats I None
compared I None
to I None
saline I None
- I None
treated I None
rats I None
( I None
11.2 I None
+ I None
/- I None
<eof> I None

<s> O None
1.08 I None
microm I None
, I None
15.3 I None
+ I None
/- I None
<eof> I None

<s> O None
1.17 I None
microm I None
, I None
respectively I None
, I None
P I None
< I None
0.05 I None
) I None
. I None
<eof> I None

<s> O None
Atorva I Chemical
affected I None
neither I None
plasma I None
NOx I None
nor I None
thymus I None
weight I None
. I None
<eof> I None

<s> O None
Thus I None
, I None
atorvastatin I Chemical
prevented I None
and I None
reversed I None
<eof> I None

<s> O None
dexamethasone I Chemical
-induced I None
<eof> I None

<s> O None
hypertension I Disease
in I None
the I None
rat I None
. I None
<eof> I None

<s> O None
Two I None
prodrugs I None
of I None
potent I None
and I None
selective I None
GluR5 I None
<eof> I None

<s> O None
kainate I Chemical
receptor I None
antagonists I None
actives I None
in I None
three I None
animal I None
models I None
of I None
pain I Disease
. I None
<eof> I None

<s> O None
Amino I None
acids I None
5 I None
and I None
7 I None
, I None
two I None
potent I None
and I None
selective I None
competitive I None
GluR5 I None
KA I Chemical
<eof> I None

<s> O None
receptor I None
antagonists I None
, I None
exhibited I None
high I None
GluR5 I None
receptor I None
affinity I None
over I None
other I None
glutamate I Chemical
receptors I None
. I None
<eof> I None

<s> O None
Their I None
ester I None
prodrugs I None
6 I None
and I None
8 I None
were I None
orally I None
active I None
in I None
three I None
models I None
of I None
pain I Disease
: I None
reversal I None
of I None
formalin I Chemical
<eof> I None

<s> O None
-induced I None
paw I None
licking I None
, I None
carrageenan I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
thermal I Disease
hyperalgesia O Disease
, I None
and I None
capsaicin I Chemical
-induced I None
mechanical I Disease
hyperalgesia O Disease
. I None
<eof> I None

<s> O None
Sirolimus I Chemical
and I None
mycophenolate I Chemical
mofetil O Chemical
for I None
calcineurin I None
- I None
free I None
immunosuppression I None
in I None
renal I None
transplant I None
recipients I None
. I None
<eof> I None

<s> O None
Calcineurin I None
inhibitors I None
, I None
such I None
as I None
cyclosporine I Chemical
and I None
tacrolimus I Chemical
, I None
have I None
been I None
available I None
for I None
almost I None
20 I None
years I None
. I None
<eof> I None

<s> O None
Although I None
these I None
drugs I None
are I None
highly I None
effective I None
and I None
represent I None
the I None
mainstay I None
of I None
transplant I None
immunosuppression I None
, I None
they I None
are I None
associated I None
with I None
acute I None
and I None
chronic I None
nephrotoxicity I Disease
. I None
<eof> I None

<s> O None
Acute I None
nephrotoxicity I Disease
, I None
which I None
occurs I None
in I None
the I None
early I None
period I None
after I None
transplantation I None
, I None
leads I None
to I None
a I None
higher I None
rate I None
of I None
dialysis I None
, I None
and I None
chronic I None
<eof> I None

<s> O None
nephrotoxicity I Disease
may I None
eventually I None
result I None
in I None
graft I None
loss I None
. I None
<eof> I None

<s> O None
Acute I None
and I None
chronic I None
nephrotoxicity I Disease
is I None
becoming I None
more I None
common I None
as I None
the I None
use I None
of I None
marginal I None
kidneys I None
for I None
transplantation I None
increases I None
. I None
<eof> I None

<s> O None
Two I None
recently I None
available I None
immunosuppressive I None
agents I None
, I None
mycophenolate I Chemical
mofetil O Chemical
and I None
sirolimus I Chemical
<eof> I None

<s> O None
( I None
rapamycin I Chemical
) I None
, I None
have I None
no I None
nephrotoxicity I Disease
. I None
<eof> I None

<s> O None
The I None
use I None
of I None
these I None
drugs I None
in I None
combination I None
with I None
other I None
agents I None
has I None
led I None
to I None
the I None
development I None
of I None
new I None
paradigms I None
of I None
immunosuppressive I None
therapy I None
. I None
<eof> I None

<s> O None
This I None
paper I None
reviews I None
the I None
results I None
of I None
clinical I None
trials I None
that I None
have I None
investigated I None
these I None
new I None
approaches I None
to I None
immunosuppression I None
in I None
renal I None
transplant I None
recipients I None
. I None
<eof> I None

<s> O None
Erythropoietin I None
restores I None
the I None
anemia I Disease
-induced I None
reduction I None
in I None
cyclophosphamide I Chemical
cytotoxicity I Disease
in I None
rat I None
tumors I Disease
. I None
<eof> I None

<s> O None
The I None
aim I None
of I None
this I None
study I None
was I None
to I None
examine I None
the I None
impact I None
of I None
anemia I Disease
prevention I None
by I None
recombinant I None
human I None
erythropoietin I None
( I None
rHuEPO I None
) I None
treatment I None
on I None
the I None
cytotoxicity I Disease
of I None
cyclophosphamide I Chemical
in I None
solid I None
experimental I None
tumors I Disease
. I None
<eof> I None

<s> O None
Anemia I Disease
was I None
induced I None
using I None
a I None
single I None
dose I None
of I None
carboplatin I Chemical
<eof> I None

<s> O None
( I None
50 I None
mg I None
/ I None
kg I None
i.v I None
. I None
) I None
<eof> I None

<s> O None
resulting I None
in I None
a I None
long I None
- I None
lasting I None
reduction I None
( I None
30 I None
% I None
) I None
of I None
the I None
hemoglobin I None
concentration I None
. I None
<eof> I None

<s> O None
In I None
a I None
second I None
group I None
, I None
the I None
development I None
of I None
anemia I Disease
was I None
prevented I None
by I None
rHuEPO I None
( I None
1000 I None
IU I None
/ I None
kg I None
) I None
administered I None
s.c I None
. I None
<eof> I None

<s> O None
three I None
times I None
/ I None
week I None
starting I None
7 I None
days I None
before I None
carboplatin I Chemical
application I None
. I None
<eof> I None

<s> O None
Four I None
days I None
after I None
carboplatin I Chemical
treatment I None
, I None
tumors I Disease
<eof> I None

<s> O None
( I None
DS- I None
sarcoma I Disease
of I None
the I None
rat I None
) I None
were I None
implanted I None
s.c I None
. I None
<eof> I None

<s> O None
onto I None
the I None
hind I None
food I None
dorsum I None
. I None
<eof> I None

<s> O None
Neither I None
carboplatin I Chemical
nor I None
rHuEPO I None
treatment I None
influenced I None
tumor I Disease
growth I None
rate I None
per I None
se I None
. I None
<eof> I None

<s> O None
When I None
tumors I Disease
were I None
treated I None
with I None
a I None
single I None
dose I None
of I None
cyclophosphamide I Chemical
<eof> I None

<s> O None
( I None
60 I None
mg I None
/ I None
kg I None
i.p I None
. I None
) I None
<eof> I None

<s> O None
5 I None
days I None
after I None
implantation I None
, I None
a I None
growth I None
delay I None
with I None
a I None
subsequent I None
regrowth I None
of I None
the I None
tumors I Disease
was I None
observed I None
. I None
<eof> I None

<s> O None
In I None
the I None
anemia I Disease
group I None
, I None
the I None
growth I None
delay I None
was I None
significantly I None
shorter I None
compared I None
with I None
nonanemic I None
controls I None
( I None
13.3 I None
days I None
versus I None
8.6 I None
days I None
) I None
. I None
<eof> I None

<s> O None
In I None
the I None
group I None
where I None
anemia I Disease
was I None
prevented I None
by I None
rHuEPO I None
treatment I None
, I None
growth I None
delay I None
was I None
comparable I None
with I None
that I None
of I None
nonanemic I None
controls I None
( I None
13.3 I None
days I None
) I None
. I None
<eof> I None

<s> O None
These I None
results I None
suggest I None
that I None
chemotherapy I None
- I None
induced I None
anemia I Disease
reduces I None
cytotoxicity I Disease
of I None
cyclophosphamide I Chemical
in I None
tumors I Disease
, I None
whereas I None
correction I None
of I None
anemia I Disease
by I None
rHuEPO I None
treatment I None
( I None
epoetin I None
alpha I None
) I None
increases I None
the I None
sensitivity I None
, I None
probably I None
as I None
a I None
result I None
of I None
an I None
improved I None
oxygen I Chemical
supply I None
to I None
tumor I Disease
tissue I None
. I None
<eof> I None

<s> O None
The I None
role I None
of I None
nitrergic I None
system I None
in I None
lidocaine I Chemical
-induced I None
convulsion I Disease
in I None
the I None
mouse I None
. I None
<eof> I None

<s> O None
The I None
effects I None
of I None
N I Chemical
- O Chemical
nitro O Chemical
- O Chemical
L O Chemical
- O Chemical
arginine O Chemical
- O Chemical
methyl O Chemical
ester O Chemical
<eof> I None

<s> O None
( I None
L I Chemical
- O Chemical
NAME O Chemical
) I None
a I None
nitric I Chemical
oxide O Chemical
<eof> I None

<s> O None
( I None
NO I Chemical
) I None
synthase I None
inhibitor I None
and I None
L I Chemical
- O Chemical
arginine O Chemical
, I None
a I None
NO I Chemical
precursor I None
, I None
were I None
investigated I None
on I None
lidocaine I Chemical
-induced I None
<eof> I None

<s> O None
convulsions I Disease
. I None
<eof> I None

<s> O None
In I None
the I None
first I None
experiment I None
, I None
four I None
groups I None
of I None
mice I None
received I None
physiological I None
saline I None
( I None
0.9 I None
% I None
) I None
, I None
L I Chemical
- O Chemical
arginine O Chemical
<eof> I None

<s> O None
( I None
300 I None
mg I None
/ I None
kg I None
, I None
i.p I None
. I None
) I None
, I None
L I Chemical
- O Chemical
NAME O Chemical
<eof> I None

<s> O None
( I None
100 I None
mg I None
/ I None
kg I None
, I None
i.p I None
. I None
) I None
and I None
diazepam I Chemical
<eof> I None

<s> O None
( I None
2 I None
mg I None
/ I None
kg I None
) I None
, I None
respectively I None
. I None
<eof> I None

<s> O None
Thirty I None
minutes I None
after I None
these I None
injections I None
, I None
all I None
mice I None
received I None
lidocaine I Chemical
<eof> I None

<s> O None
( I None
50 I None
mg I None
/ I None
kg I None
, I None
i.p I None
. I None
) I None
. I None
<eof> I None

<s> O None
In I None
the I None
second I None
experiment I None
, I None
four I None
groups I None
of I None
mice I None
received I None
similar I None
treatment I None
in I None
the I None
first I None
experiment I None
, I None
and I None
30 I None
min I None
after I None
these I None
injections I None
, I None
all I None
mice I None
received I None
a I None
higher I None
dose I None
of I None
lidocaine I Chemical
<eof> I None

<s> O None
( I None
80 I None
mg I None
/ I None
kg I None
) I None
. I None
<eof> I None

<s> O None
L I Chemical
- O Chemical
NAME O Chemical
( I None
100 I None
mg I None
/ I None
kg I None
, I None
i.p I None
. I None
) I None
and I None
diazepam I Chemical
<eof> I None

<s> O None
( I None
2 I None
mg I None
/ I None
kg I None
) I None
significantly I None
decreased I None
the I None
incidence I None
of I None
lidocaine I Chemical
<eof> I None

<s> O None
( I None
50 I None
mg I None
/ I None
kg)-induced I None
convulsions I Disease
. I None
<eof> I None

<s> O None
In I None
contrast I None
, I None
the I None
L I Chemical
- O Chemical
arginine O Chemical
treatment I None
increased I None
the I None
incidence I None
of I None
lidocaine I Chemical
<eof> I None

<s> O None
( I None
80 I None
mg I None
/ I None
kg I None
, I None
i.p.)-induced I None
<eof> I None

<s> O None
convulsions I Disease
significantly I None
. I None
<eof> I None

<s> O None
These I None
results I None
may I None
suggest I None
that I None
NO I Chemical
is I None
a I None
proconvulsant I None
mediator I None
in I None
lidocaine I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
convulsions I Disease
. I None
<eof> I None

<s> O None
Effect I None
of I None
intravenous I None
metoprolol I Chemical
or I None
intravenous I None
metoprolol I Chemical
plus I None
glucagon I None
on I None
dobutamine I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
myocardial I Disease
ischemia O Disease
. I None
<eof> I None

<s> O None
STUDY I None
OBJECTIVE I None
: I None
<eof> I None

<s> O None
To I None
determine I None
the I None
effect I None
of I None
metoprolol I Chemical
on I None
dobutamine I Chemical
stress I None
testing I None
with I None
technetium-99 I Chemical
m O Chemical
sestamibi O Chemical
single I None
- I None
photon I None
emission I None
computed I None
tomography I None
imaging I None
and I None
ST I None
- I None
segment I None
monitoring I None
, I None
and I None
to I None
assess I None
the I None
impact I None
of I None
intravenous I None
glucagon I None
on I None
metoprolol I Chemical
's I None
effects I None
. I None
<eof> I None

<s> O None
DESIGN I None
: I None
<eof> I None

<s> O None
Randomized I None
, I None
double I None
- I None
blind I None
, I None
placebo I None
- I None
controlled I None
trial I None
. I None
<eof> I None

<s> O None
SETTING I None
: I None
<eof> I None

<s> O None
Community I None
hospital I None
. I None
<eof> I None

<s> O None
PATIENTS I None
: I None
<eof> I None

<s> O None
Twenty I None
- I None
two I None
patients I None
with I None
known I None
reversible I None
perfusion I None
defects I None
. I None
<eof> I None

<s> O None
INTERVENTION I None
: I None
<eof> I None

<s> O None
Patients I None
underwent I None
dobutamine I Chemical
stress I None
tests I None
per I None
standard I None
protocol I None
. I None
<eof> I None

<s> O None
Before I None
dobutamine I Chemical
was I None
begun I None
, I None
no I None
therapy I None
was I None
given I None
during I None
the I None
first I None
visit I None
, I None
and I None
patients I None
were I None
randomized I None
on I None
subsequent I None
visits I None
to I None
receive I None
metoprolol I Chemical
or I None
metoprolol I Chemical
plus I None
glucagon I None
1 I None
mg I None
. I None
<eof> I None

<s> O None
Metoprolol I Chemical
was I None
dosed I None
to I None
achieve I None
a I None
resting I None
predobutamine I Chemical
heart I None
rate I None
below I None
65 I None
beats I None
/ I None
minute I None
or I None
a I None
total I None
intravenous I None
dose I None
of I None
20 I None
mg I None
. I None
<eof> I None

<s> O None
MEASUREMENTS I None
AND I None
MAIN I None
RESULTS I None
: I None
<eof> I None

<s> O None
Metoprolol I Chemical
reduced I None
maximum I None
heart I None
rate I None
31 I None
% I None
, I None
summed I None
stress I None
scores I None
29 I None
% I None
, I None
and I None
summed I None
difference I None
scores I None
43 I None
% I None
versus I None
control I None
. I None
<eof> I None

<s> O None
Metoprolol I Chemical
plus I None
glucagon I None
also I None
reduced I None
the I None
maximum I None
heart I None
rate I None
29 I None
% I None
versus I None
control I None
. I None
<eof> I None

<s> O None
Summed I None
stress I None
and I None
summed I None
difference I None
scores I None
were I None
not I None
significantly I None
reduced I None
, I None
although I None
they I None
were I None
18 I None
% I None
and I None
30 I None
% I None
lower I None
, I None
respectively I None
, I None
than I None
control I None
. I None
<eof> I None

<s> O None
No I None
significant I None
differences I None
were I None
found I None
in I None
any I None
parameter I None
between I None
metoprolol I Chemical
and I None
metoprolol I Chemical
-glucagon I None
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
<eof> I None

<s> O None
During I None
dobutamine I Chemical
stress I None
testing I None
, I None
metoprolol I Chemical
attenuates I None
or I None
eliminates I None
evidence I None
of I None
myocardial I Disease
ischemia O Disease
. I None
<eof> I None

<s> O None
Glucagon I None
1 I None
mg I None
, I None
although I None
somewhat I None
effective I None
, I None
does I None
not I None
correct I None
this I None
effect I None
to I None
the I None
extent I None
that I None
it I None
can I None
be I None
administered I None
clinically I None
. I None
<eof> I None

<s> O None
Prednisolone I Chemical
-induced I None
<eof> I None

<s> O None
muscle I Disease
dysfunction O Disease
is I None
caused I None
more I None
by I None
atrophy I Disease
than I None
by I None
altered I None
acetylcholine I Chemical
receptor I None
expression I None
. I None
<eof> I None

<s> O None
Large I None
doses I None
of I None
glucocorticoids I None
can I None
alter I None
muscle I None
physiology I None
and I None
susceptibility I None
to I None
neuromuscular I None
blocking I None
drugs I None
by I None
mechanisms I None
not I None
clearly I None
understood I None
. I None
<eof> I None

<s> O None
We I None
investigated I None
the I None
effects I None
of I None
moderate I None
and I None
large I None
doses I None
of I None
prednisolone I Chemical
on I None
muscle I None
function I None
and I None
pharmacology I None
, I None
and I None
their I None
relationship I None
to I None
changes I None
in I None
muscle I None
size I None
and I None
acetylcholine I Chemical
receptor I None
( I None
AChR I None
) I None
expression I None
. I None
<eof> I None

<s> O None
With I None
institutional I None
approval I None
, I None
35 I None
Sprague I None
- I None
Dawley I None
rats I None
were I None
randomly I None
allocated I None
to I None
receive I None
daily I None
subcutaneous I None
doses I None
of I None
10 I None
mg I None
/ I None
kg I None
prednisolone I Chemical
<eof> I None

<s> O None
( I None
P10 I None
group I None
) I None
, I None
100 I None
mg I None
/ I None
kg I None
prednisolone I Chemical
<eof> I None

<s> O None
( I None
P100 I None
group I None
) I None
, I None
or I None
an I None
equal I None
volume I None
of I None
saline I None
( I None
S I None
group I None
) I None
for I None
7 I None
days I None
. I None
<eof> I None

<s> O None
A I None
fourth I None
group I None
of I None
rats I None
was I None
pair I None
fed I None
( I None
food I None
restricted I None
) I None
with I None
the I None
P100 I None
rats I None
for I None
7 I None
days I None
( I None
FR I None
group I None
) I None
. I None
<eof> I None

<s> O None
On I None
Day I None
8 I None
, I None
the I None
nerve I None
- I None
evoked I None
peak I None
twitch I None
tensions I None
, I None
tetanic I Disease
tensions I None
, I None
and I None
fatigability I None
, I None
and I None
the I None
dose I None
- I None
response I None
curves I None
of I None
d I Chemical
- O Chemical
tubocurarine O Chemical
in I None
the I None
tibialis I None
cranialis I None
muscle I None
were I None
measured I None
in I None
vivo I None
and I None
related I None
to I None
muscle I None
mass I None
or I None
expression I None
of I None
AChRs I None
. I None
<eof> I None

<s> O None
Rate I None
of I None
body I None
weight I None
gain I None
was I None
depressed I None
in I None
the I None
P100 I None
, I None
FR I None
, I None
and I None
P10 I None
groups I None
compared I None
with I None
the I None
S I None
group I None
. I None
<eof> I None

<s> O None
Tibialis I None
muscle I None
mass I None
was I None
smaller I None
in I None
the I None
P100 I None
group I None
than I None
in I None
the I None
P10 I None
or I None
S I None
groups I None
. I None
<eof> I None

<s> O None
The I None
evoked I None
peak I None
twitch I None
and I None
tetanic I Disease
tensions I None
were I None
less I None
in I None
the I None
P100 I None
group I None
than I None
in I None
the I None
P10 I None
or I None
S I None
groups I None
, I None
however I None
, I None
tension I None
per I None
milligram I None
of I None
muscle I None
mass I None
was I None
greater I None
in I None
the I None
P100 I None
group I None
than I None
in I None
the I None
S I None
group I None
. I None
<eof> I None

<s> O None
The I None
50 I None
% I None
effective I None
dose I None
of I None
d I Chemical
- O Chemical
tubocurarine O Chemical
<eof> I None

<s> O None
( I None
microg I None
/ I None
kg I None
) I None
in I None
the I None
tibialis I None
muscle I None
was I None
smaller I None
in I None
the I None
P10 I None
( I None
33.6 I None
+ I None
/- I None
5.4 I None
) I None
than I None
in I None
the I None
S I None
( I None
61.9 I None
+ I None
/- I None
5.0 I None
) I None
or I None
the I None
P100 I None
( I None
71.3 I None
+ I None
/- I None
<eof> I None

<s> O None
9.6 I None
) I None
groups I None
. I None
<eof> I None

<s> O None
AChR I None
expression I None
was I None
less I None
in I None
the I None
P10 I None
group I None
than I None
in I None
the I None
S I None
group I None
. I None
<eof> I None

<s> O None
The I None
evoked I None
tensions I None
correlated I None
with I None
muscle I None
mass I None
( I None
r(2 I None
) I None
= I None
0.32 I None
, I None
P I None
< I None
0.001 I None
) I None
, I None
however I None
, I None
not I None
with I None
expression I None
of I None
AChR. I None
The I None
50 I None
% I None
effective I None
dose I None
of I None
d I Chemical
- O Chemical
tubocurarine O Chemical
did I None
not I None
correlate I None
with I None
muscle I None
mass I None
or I None
AChR I None
expression I None
. I None
<eof> I None

<s> O None
Our I None
results I None
suggest I None
that I None
the I None
neuromuscular I Disease
dysfunction O Disease
after I None
prednisolone I Chemical
is I None
dose I None
- I None
dependent I None
, I None
and I None
derives I None
primarily I None
from I None
muscle I Disease
atrophy O Disease
and I None
derives I None
less I None
so I None
from I None
changes I None
in I None
AChR I None
expression I None
. I None
<eof> I None

<s> O None
IMPLICATIONS I None
: I None
<eof> I None

<s> O None
The I None
mechanisms I None
by I None
which I None
chronic I None
glucocorticoid I None
therapy I None
alters I None
neuromuscular I None
physiology I None
and I None
pharmacology I None
are I None
unclear I None
. I None
<eof> I None

<s> O None
We I None
suggest I None
that I None
the I None
observed I None
effects I None
are I None
dose I None
- I None
dependent I None
and I None
derive I None
primarily I None
from I None
muscle I Disease
atrophy O Disease
and I None
derive I None
less I None
from I None
changes I None
in I None
acetylcholine I Chemical
receptor I None
expression I None
. I None
<eof> I None

<s> O None
Rapid I None
reversal I None
of I None
life I None
- I None
threatening I None
diltiazem I Chemical
-induced I None
<eof> I None

<s> O None
tetany I Disease
with I None
calcium I Chemical
chloride O Chemical
. I None
<eof> I None

<s> O None
We I None
describe I None
a I None
patient I None
who I None
developed I None
tetany I Disease
with I None
sudden I None
respiratory I Disease
arrest O Disease
after I None
the I None
infusion I None
of I None
intravenous I None
diltiazem I Chemical
. I None
<eof> I None

<s> O None
The I None
administration I None
of I None
calcium I Chemical
chloride O Chemical
rapidly I None
resolved I None
the I None
patient I None
's I None
tetany I Disease
with I None
prompt I None
recovery I None
of I None
respiratory I None
function I None
, I None
averting I None
the I None
need I None
for I None
more I None
aggressive I None
airway I None
management I None
and I None
ventilatory I None
support I None
. I None
<eof> I None

<s> O None
The I None
emergency I None
physician I None
should I None
be I None
aware I None
that I None
life I None
- I None
threatening I None
tetany I Disease
may I None
accompany I None
the I None
administration I None
of I None
intravenous I None
diltiazem I Chemical
and I None
that I None
calcium I Chemical
chloride O Chemical
may I None
be I None
a I None
rapid I None
and I None
effective I None
remedy I None
. I None
<eof> I None

<s> O None
Effects I None
of I None
nonsteroidal I None
anti I None
- I None
inflammatory I None
drugs I None
on I None
hemostasis I None
in I None
patients I None
with I None
aneurysmal I Disease
subarachnoid O Disease
hemorrhage O Disease
. I None
<eof> I None

<s> O None
Platelet I None
function I None
is I None
impaired I None
by I None
nonsteroidal I None
anti I None
- I None
inflammatory I None
drugs I None
( I None
NSAIDs I None
) I None
with I None
prominent I None
anti I None
- I None
inflammatory I None
properties I None
. I None
<eof> I None

<s> O None
Their I None
safety I None
in I None
patients I None
undergoing I None
intracranial I None
surgery I None
is I None
under I None
debate I None
. I None
<eof> I None

<s> O None
Patients I None
with I None
aneurysmal I Disease
subarachnoid O Disease
hemorrhage O Disease
<eof> I None

<s> O None
( I None
SAH I Disease
) I None
were I None
randomized I None
to I None
receive I None
either I None
ketoprofen I Chemical
, I None
100 I None
mg I None
, I None
three I None
times I None
a I None
day I None
( I None
ketoprofen I Chemical
group I None
, I None
n I None
= I None
9 I None
) I None
or I None
a I None
weak I None
NSAID I None
, I None
acetaminophen I Chemical
, I None
1 I None
g I None
, I None
three I None
times I None
a I None
day I None
( I None
acetaminophen I Chemical
group I None
, I None
n I None
= I None
9 I None
) I None
starting I None
immediately I None
after I None
the I None
diagnosis I None
of I None
aneurysmal I Disease
<eof> I None

<s> O None
SAH I Disease
. I None
<eof> I None

<s> O None
Treatment I None
was I None
continued I None
for I None
3 I None
days I None
postoperatively I None
. I None
<eof> I None

<s> O None
Test I None
blood I None
samples I None
were I None
taken I None
before I None
treatment I None
and I None
surgery I None
as I None
well I None
as I None
on I None
the I None
first I None
, I None
third I None
, I None
and I None
fifth I None
postoperative I None
mornings I None
. I None
<eof> I None

<s> O None
Maximal I None
platelet I Disease
aggregation O Disease
<eof> I None

<s> O None
induced I None
by I None
6 I None
microM I None
of I None
adenosine I Chemical
diphosphate O Chemical
decreased I None
after I None
administration I None
of I None
ketoprofen I Chemical
. I None
<eof> I None

<s> O None
Aggregation I None
was I None
lower I None
( I None
P I None
< I None
.05 I None
) I None
in I None
the I None
ketoprofen I Chemical
group I None
than I None
in I None
the I None
acetaminophen I Chemical
group I None
just I None
before I None
surgery I None
and I None
on I None
the I None
third I None
postoperative I None
day I None
. I None
<eof> I None

<s> O None
In I None
contrast I None
, I None
maximal I None
platelet I Disease
aggregation O Disease
increased I None
in I None
the I None
acetaminophen I Chemical
group I None
on I None
the I None
third I None
postoperative I None
day I None
as I None
compared I None
with I None
the I None
pretreatment I None
platelet I Disease
aggregation O Disease
results I None
( I None
P I None
< I None
.05 I None
) I None
. I None
<eof> I None

<s> O None
One I None
patient I None
in I None
the I None
ketoprofen I Chemical
group I None
developed I None
a I None
postoperative I None
intracranial I None
hematoma I Disease
. I None
<eof> I None

<s> O None
Coagulation I None
( I None
prothrombin I None
time I None
[ I None
PT I None
] I None
, I None
activated I None
partial I None
thromboplastin I None
time I None
[ I None
APPT I None
] I None
, I None
fibrinogen I None
concentration I None
, I None
and I None
antithrombin I None
III I None
[ I None
AT I None
III I None
] I None
) I None
was I None
comparable I None
between I None
the I None
two I None
groups I None
. I None
<eof> I None

<s> O None
Ketoprofen I Chemical
but I None
not I None
acetaminophen I Chemical
impaired I None
platelet I None
function I None
in I None
patients I None
with I None
SAH I Disease
. I None
<eof> I None

<s> O None
If I None
ketoprofen I Chemical
is I None
used I None
before I None
surgery I None
on I None
cerebral I None
artery I Disease
aneurysms O Disease
, I None
it I None
may I None
pose I None
an I None
additional I None
risk I None
factor I None
for I None
hemorrhage I Disease
. I None
<eof> I None

<s> O None
Value I None
of I None
methylprednisolone I Chemical
in I None
prevention I None
of I None
the I None
arthralgia I Disease
- I None
myalgia I Disease
syndrome I None
associated I None
with I None
the I None
total I None
dose I None
infusion I None
of I None
iron I Chemical
dextran O Chemical
: I None
a I None
double I None
blind I None
randomized I None
trial I None
. I None
<eof> I None

<s> O None
The I None
safety I None
and I None
efficacy I None
of I None
total I None
dose I None
infusion I None
( I None
TDI I None
) I None
of I None
iron I Chemical
dextran O Chemical
has I None
been I None
well I None
documented I None
. I None
<eof> I None

<s> O None
In I None
40 I None
% I None
of I None
treated I None
patients I None
, I None
an I None
arthralgia I Disease
- I None
myalgia I Disease
syndrome I None
develops I None
. I None
<eof> I None

<s> O None
The I None
purpose I None
of I None
this I None
randomized I None
, I None
double I None
- I None
blind I None
, I None
prospective I None
study I None
was I None
to I None
investigate I None
whether I None
intravenous I None
( I None
i.v I None
. I None
) I None
<eof> I None

<s> O None
administration I None
of I None
methylprednisolone I Chemical
<eof> I None

<s> O None
( I None
MP I Chemical
) I None
prevents I None
this I None
complication I None
. I None
<eof> I None

<s> O None
Sixty I None
- I None
five I None
patients I None
, I None
34 I None
women I None
and I None
31 I None
men I None
, I None
ages I None
36 I None
to I None
80 I None
years I None
, I None
received I None
either I None
normal I None
saline I None
before I None
and I None
after I None
TDI I None
( I None
group I None
1 I None
) I None
, I None
125 I None
mg I None
i.v I None
. I None
<eof> I None

<s> O None
MP I Chemical
before I None
and I None
saline I None
after I None
TDI I None
( I None
group I None
2 I None
) I None
, I None
or I None
125 I None
mg I None
i.v I None
. I None
<eof> I None

<s> O None
MP I Chemical
before I None
and I None
after I None
TDI I None
( I None
group I None
3 I None
) I None
. I None
<eof> I None

<s> O None
Patients I None
were I None
observed I None
for I None
72 I None
hours I None
and I None
reactions I None
were I None
recorded I None
and I None
graded I None
according I None
to I None
severity I None
. I None
<eof> I None

<s> O None
Fifty I None
- I None
eight I None
percent I None
of I None
group I None
1 I None
patients I None
, I None
33 I None
% I None
of I None
group I None
2 I None
, I None
and I None
26 I None
% I None
of I None
group I None
3 I None
had I None
reactions I None
to I None
TDI I None
. I None
<eof> I None

<s> O None
The I None
severity I None
of I None
reactions I None
( I None
minimal I None
, I None
mild I None
, I None
and I None
moderate I None
, I None
respectively I None
) I None
was I None
as I None
follows I None
: I None
group I None
1 I None
- I None
-6 I None
, I None
6 I None
, I None
and I None
2 I None
; I None
group I None
2 I None
- I None
-1 I None
, I None
5 I None
, I None
and I None
0 I None
; I None
group I None
3 I None
- I None
-5 I None
, I None
1 I None
, I None
and I None
0 I None
. I None
<eof> I None

<s> O None
Data I None
were I None
analyzed I None
by I None
the I None
two I None
- I None
sided I None
Fisher I None
's I None
exact I None
test I None
using I None
95 I None
% I None
confidence I None
intervals I None
with I None
the I None
approximation I None
of I None
Woolf I None
. I None
<eof> I None

<s> O None
These I None
data I None
demonstrate I None
that I None
administration I None
of I None
MP I Chemical
before I None
and I None
after I None
TDI I None
reduces I None
the I None
frequency I None
and I None
severity I None
of I None
the I None
arthralgia I Disease
- I None
myalgia I Disease
syndrome I None
. I None
<eof> I None

<s> O None
We I None
conclude I None
that I None
125 I None
mg I None
i.v I None
. I None
<eof> I None

<s> O None
MP I Chemical
should I None
be I None
given I None
routinely I None
before I None
and I None
after I None
TDI I None
of I None
iron I Chemical
dextran O Chemical
. I None
<eof> I None

<s> O None
Long I None
- I None
term I None
effects I None
of I None
vincristine I Chemical
on I None
the I None
peripheral I None
nervous I None
system I None
. I None
<eof> I None

<s> O None
Forty I None
patients I None
with I None
Non I Disease
- O Disease
Hodgkin O Disease
's O Disease
Lymphoma O Disease
treated I None
with I None
vincristine I Chemical
between I None
1984 I None
and I None
1990 I None
( I None
cumulative I None
dose I None
12 I None
mg I None
in I None
18 I None
- I None
24 I None
weeks I None
) I None
were I None
investigated I None
in I None
order I None
to I None
evaluate I None
the I None
long I None
term I None
effects I None
of I None
vincristine I Chemical
on I None
the I None
peripheral I None
nervous I None
system I None
. I None
<eof> I None

<s> O None
The I None
patients I None
were I None
interviewed I None
with I None
emphasis I None
on I None
neuropathic I Disease
symptoms O Disease
. I None
<eof> I None

<s> O None
Physical I None
and I None
quantitative I None
sensory I None
examination I None
with I None
determination I None
of I None
vibratory I None
perception I None
and I None
thermal I None
discrimination I None
thresholds I None
were I None
performed I None
, I None
four I None
to I None
77 I None
months I None
( I None
median I None
34 I None
months I None
) I None
after I None
vincristine I Chemical
treatment I None
. I None
<eof> I None

<s> O None
Twenty I None
- I None
seven I None
patients I None
reported I None
neuropathic I Disease
symptoms O Disease
. I None
<eof> I None

<s> O None
In I None
13 I None
of I None
these I None
27 I None
patients I None
symptoms I None
were I None
still I None
present I None
at I None
the I None
time I None
of I None
examination I None
. I None
<eof> I None

<s> O None
In I None
these I None
patients I None
sensory I None
signs I None
and I None
symptoms I None
predominated I None
. I None
<eof> I None

<s> O None
In I None
the I None
other I None
14 I None
patients I None
symptoms I None
had I None
been I None
present I None
in I None
the I None
past I None
. I None
<eof> I None

<s> O None
Symptoms I None
persisted I None
maximally I None
40 I None
months I None
since I None
cessation I None
of I None
therapy I None
. I None
<eof> I None

<s> O None
There I None
was I None
no I None
age I None
difference I None
between I None
patients I None
with I None
and I None
without I None
complaints I None
at I None
the I None
time I None
of I None
examination I None
. I None
<eof> I None

<s> O None
Normal I None
reflexes I None
were I None
found I None
in I None
two I None
third I None
of I None
patients I None
. I None
<eof> I None

<s> O None
Neuropathic I None
complaints I None
were I None
not I None
very I None
troublesome I None
on I None
the I None
long I None
term I None
. I None
<eof> I None

<s> O None
It I None
is I None
concluded I None
that I None
with I None
the I None
above I None
mentioned I None
vincristine I Chemical
<eof> I None

<s> O None
dose I None
schedule I None
signs I None
and I None
symptoms I None
of I None
vincristine I Chemical
<eof> I None

<s> O None
neuropathy I Disease
are I None
reversible I None
for I None
a I None
great I None
deal I None
and I None
prognosis I None
is I None
fairly I None
good I None
. I None
<eof> I None

<s> O None
A I None
case I None
of I None
polymyositis I Disease
in I None
a I None
patient I None
with I None
primary I Disease
biliary O Disease
cirrhosis O Disease
treated I None
with I None
D I Chemical
- O Chemical
penicillamine O Chemical
. I None
<eof> I None

<s> O None
Although I None
D I Chemical
- O Chemical
penicillamine O Chemical
has I None
been I None
used I None
for I None
many I None
rheumatologic I Disease
diseases O Disease
, I None
toxicity I Disease
limits I None
its I None
usefulness I None
in I None
many I None
patients I None
. I None
<eof> I None

<s> O None
Polymyositis I Disease
/ I None
dermatomyositis I Disease
can I None
develop I None
as I None
one I None
of I None
the I None
autoimmune I None
complications I None
of I None
D I Chemical
- O Chemical
penicillamine O Chemical
treatment I None
, I None
but I None
its I None
exact I None
pathogenesis I None
remains I None
unclear I None
. I None
<eof> I None

<s> O None
We I None
report I None
a I None
patient I None
with I None
primary I Disease
biliary O Disease
cirrhosis O Disease
, I None
who I None
developed I None
polymyositis I Disease
while I None
receiving I None
D I Chemical
- O Chemical
penicillamine O Chemical
therapy I None
. I None
<eof> I None

<s> O None
We I None
described I None
the I None
special I None
clinical I None
course I None
of I None
the I None
patient I None
. I None
<eof> I None

<s> O None
Patients I None
receiving I None
D I Chemical
- O Chemical
penicillamine O Chemical
therapy I None
should I None
be I None
followed I None
carefully I None
for I None
the I None
development I None
of I None
autoimmune I None
complications I None
like I None
polymyositis I Disease
/ I None
dermatomyositis I Disease
. I None
<eof> I None

<s> O None
Photodistributed I None
<eof> I None

<s> O None
nifedipine I Chemical
-induced I None
facial I None
telangiectasia I Disease
. I None
<eof> I None

<s> O None
Five I None
months I None
after I None
starting I None
nifedipine I Chemical
<eof> I None

<s> O None
( I None
Adalat I Chemical
) I None
, I None
two I None
patients I None
developed I None
photodistributed I None
facial I None
telangiectasia I Disease
, I None
which I None
became I None
more I None
noticeable I None
with I None
time I None
. I None
<eof> I None

<s> O None
Neither I None
patient I None
complained I None
of I None
photosensitivity I None
or I None
flushing I Disease
. I None
<eof> I None

<s> O None
Both I None
patients I None
reported I None
a I None
significant I None
cosmetic I None
improvement I None
after I None
discontinuing I None
the I None
drug I None
. I None
<eof> I None

<s> O None
One I None
commenced I None
the I None
closely I None
related I None
drug I None
amlodipine I Chemical
3 I None
years I None
later I None
, I None
with I None
recurrence I None
of I None
telangiectasia I Disease
. I None
<eof> I None

<s> O None
The I None
photodistribution I None
of I None
the I None
telangiectasia I Disease
suggests I None
a I None
significant I None
drug I None
/ I None
light I None
interaction I None
. I None
<eof> I None

<s> O None
Nephrotoxicity I Disease
of I None
cyclosporin I Chemical
A O Chemical
and I None
FK506 I Chemical
: I None
inhibition I None
of I None
calcineurin I None
phosphatase I None
. I None
<eof> I None

<s> O None
Cyclosporin I Chemical
A O Chemical
<eof> I None

<s> O None
( I None
CsA I Chemical
; I None
50 I None
mg I None
/ I None
kg I None
) I None
and I None
Fujimycine I Chemical
<eof> I None

<s> O None
( I None
FK506 I Chemical
; I None
5 I None
mg I None
/ I None
kg I None
) I None
, I None
but I None
not I None
the I None
related I None
macrolide I Chemical
immunosuppressant I None
rapamycin I Chemical
<eof> I None

<s> O None
( I None
5 I None
mg I None
/ I None
kg I None
) I None
, I None
caused I None
a I None
reduction I None
of I None
glomerular I None
filtration I None
rate I None
, I None
degenerative I None
changes I None
of I None
proximal I None
tubular I None
epithelium I None
, I None
and I None
hypertrophy I Disease
of I None
the I None
juxtaglomerular I None
apparatus I None
in I None
male I None
Wistar I None
rats I None
when I None
given I None
for I None
10 I None
days I None
. I None
<eof> I None

<s> O None
The I None
molecular I None
mechanisms I None
of I None
CsA I Chemical
and I None
FK506 I Chemical
toxicity I Disease
were I None
investigated I None
. I None
<eof> I None

<s> O None
Cyclophilin I None
A I None
and I None
FK506 I Chemical
-binding I None
protein I None
, I None
the I None
main I None
intracytoplasmic I None
receptors I None
for I None
CsA I Chemical
and I None
FK506 I Chemical
, I None
respectively I None
, I None
were I None
each I None
detected I None
in I None
renal I None
tissue I None
extract I None
. I None
<eof> I None

<s> O None
In I None
the I None
kidney I None
, I None
high I None
levels I None
of I None
immunoreactive I None
and I None
enzymatically I None
active I None
calcineurin I None
were I None
found I None
which I None
were I None
inhibited I None
by I None
the I None
immunosuppressants I None
CsA I Chemical
and I None
FK506 I Chemical
, I None
but I None
not I None
by I None
rapamycin I Chemical
. I None
<eof> I None

<s> O None
Finally I None
, I None
specific I None
immunophilin I None
- I None
drug I None
- I None
calcineurin I None
complexes I None
formed I None
only I None
in I None
the I None
presence I None
of I None
CsA I Chemical
and I None
FK506 I Chemical
, I None
but I None
not I None
rapamycin I Chemical
. I None
<eof> I None

<s> O None
These I None
results I None
suggest I None
that I None
the I None
nephrotoxic I Disease
effects I None
of I None
CsA I Chemical
and I None
FK506 I Chemical
is I None
likely I None
mediated I None
through I None
binding I None
to I None
renal I None
immunophilin I None
and I None
inhibiting I None
calcineurin I None
phosphatase I None
. I None
<eof> I None

<s> O None
Massive I None
cerebral I Disease
edema O Disease
associated I None
with I None
fulminant I None
hepatic I Disease
failure O Disease
in I None
acetaminophen I Chemical
overdose I Disease
: I None
possible I None
role I None
of I None
cranial I None
decompression I None
. I None
<eof> I None

<s> O None
Cerebral I Disease
edema O Disease
may I None
complicate I None
the I None
course I None
of I None
fulminant I Disease
hepatic O Disease
failure O Disease
. I None
<eof> I None

<s> O None
Response I None
to I None
conventional I None
therapy I None
has I None
been I None
disappointing I None
. I None
<eof> I None

<s> O None
We I None
present I None
a I None
patient I None
with I None
fatal I None
acetaminophen I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
fulminant I Disease
hepatic O Disease
failure O Disease
, I None
with I None
signs I None
and I None
symptoms I None
of I None
cerebral I Disease
edema O Disease
, I None
unresponsive I None
to I None
conventional I None
medical I None
therapy I None
. I None
<eof> I None

<s> O None
Cranial I None
decompression I None
was I None
carried I None
out I None
. I None
<eof> I None

<s> O None
A I None
justification I None
of I None
the I None
need I None
for I None
further I None
evaluation I None
of I None
cranial I None
decompression I None
in I None
such I None
patients I None
is I None
presented I None
. I None
<eof> I None

<s> O None
Gentamicin I Chemical
<eof> I None

<s> O None
nephropathy I Disease
in I None
a I None
neonate I None
. I None
<eof> I None

<s> O None
The I None
clinical I None
and I None
autopsy I None
findings I None
in I None
a I None
premature I None
baby I None
who I None
died I None
of I None
acute I Disease
renal O Disease
failure O Disease
after I None
therapy I None
with I None
gentamicin I Chemical
<eof> I None

<s> O None
( I None
5 I None
mg I None
/ I None
kg I None
/ I None
day I None
) I None
and I None
penicillin I Chemical
are I None
presented I None
. I None
<eof> I None

<s> O None
The I None
serum I None
gentamicin I Chemical
concentration I None
had I None
reached I None
toxic I None
levels I None
when I None
anuria I Disease
developed I None
. I None
<eof> I None

<s> O None
Numerous I None
periodic I Chemical
acid O Chemical
<eof> I None

<s> O None
Schiff I None
( I None
PAS I None
) I None
<eof> I None

<s> O None
positive I None
, I None
diastase I None
resistant I None
cytoplasmic I None
inclusion I None
bodies I None
which I None
appeared I None
as I None
myelin I None
figures I None
in I None
cytosegresomes I None
under I None
the I None
electron I None
microscope I None
were I None
identified I None
in I None
the I None
proximal I None
convoluted I None
tubules I None
. I None
<eof> I None

<s> O None
The I None
pathological I None
changes I None
induced I None
by I None
gentamicin I Chemical
in I None
the I None
human I None
neonatal I None
kidneys I None
have I None
not I None
been I None
previously I None
reported I None
. I None
<eof> I None

<s> O None
Anti- I None
carcinogenic I Disease
action I None
of I None
phenobarbital I Chemical
given I None
simultaneously I None
with I None
diethylnitrosamine I Chemical
in I None
the I None
rat I None
. I None
<eof> I None

<s> O None
The I None
present I None
work I None
has I None
been I None
planned I None
in I None
order I None
to I None
elucidate I None
the I None
effect I None
of I None
phenobarbital I Chemical
<eof> I None

<s> O None
( I None
PB I Chemical
: I None
15 I None
mg I None
per I None
rat I None
of I None
ingested I None
dose I None
) I None
on I None
carcinogenesis I Disease
when I None
it I None
is I None
administered I None
simultaneously I None
with I None
diethylnitrosamine I Chemical
<eof> I None

<s> O None
( I None
DEN I Chemical
: I None
10 I None
mg I None
/ I None
kg I None
/ I None
day I None
) I None
. I None
<eof> I None

<s> O None
Wistar I None
rats I None
( I None
180 I None
g I None
) I None
were I None
treated I None
by I None
DEN I Chemical
alone I None
or I None
by I None
DEN I Chemical
+ I None
PB I Chemical
during I None
2 I None
, I None
4 I None
and I None
6 I None
weeks I None
according I None
to I None
our I None
schedule I None
for I None
hepatocarcinogenesis I Disease
. I None
<eof> I None

<s> O None
After I None
the I None
end I None
of I None
the I None
treatment I None
, I None
the I None
number I None
and I None
the I None
size I None
of I None
induced I None
PAS I None
positive I None
preneoplastic I Disease
foci O Disease
was I None
significantly I None
reduced I None
when I None
PB I Chemical
was I None
given I None
simultaneously I None
with I None
DEN I Chemical
for I None
4 I None
and I None
6 I None
weeks I None
. I None
<eof> I None

<s> O None
The I None
mitotic I None
inhibition I None
and I None
the I None
production I None
of I None
micronuclei I None
normally I None
observed I None
after I None
partial I None
hepatectomy I None
in I None
<eof> I None

<s> O None
DEN I Chemical
treated I None
rats I None
were I None
also I None
significantly I None
decreased I None
in I None
DEN I Chemical
+ I None
<eof> I None

<s> O None
PB I Chemical
treated I None
rats I None
. I None
<eof> I None

<s> O None
When I None
the I None
treatment I None
last I None
only I None
2 I None
weeks I None
, I None
the I None
presence I None
of I None
PB I Chemical
did I None
not I None
change I None
significantly I None
the I None
last I None
parameters I None
. I None
<eof> I None

<s> O None
In I None
DEN I Chemical
+ I None
PB I Chemical
treated I None
rats I None
, I None
the I None
survival I None
was I None
prolonged I None
and I None
the I None
tumor I Disease
incidence I None
decreased I None
as I None
compared I None
with I None
the I None
results I None
obtained I None
by I None
DEN I Chemical
alone I None
. I None
<eof> I None

<s> O None
It I None
is I None
concluded I None
that I None
PB I Chemical
, I None
which I None
promotes I None
carcinogenesis I Disease
when I None
administered I None
after I None
the I None
DEN I Chemical
treatment I None
, I None
reduces I None
the I None
carcinogen I None
effect I None
when I None
given I None
simultaneously I None
with I None
DEN I Chemical
. I None
<eof> I None

<s> O None
This I None
' I None
anti I None
- I None
carcinogen I None
' I None
effect I None
acts I None
on I None
the I None
initiation I None
as I None
well I None
as I None
on I None
the I None
promotion I None
of I None
the I None
precancerous I Disease
lesions O Disease
. I None
<eof> I None

<s> O None
Biochemical I None
investigations I None
are I None
in I None
progress I None
to I None
obtain I None
more I None
information I None
about I None
this I None
' I None
paradoxical I None
' I None
PB I Chemical
effect I None
. I None
<eof> I None

<s> O None
Post I None
- I None
operative I None
rigidity I Disease
after I None
fentanyl I Chemical
administration I None
. I None
<eof> I None

<s> O None
A I None
case I None
of I None
thoraco I None
- I None
abdominal I None
rigidity I Disease
leading I None
to I None
respiratory I Disease
failure O Disease
is I None
described I None
in I None
the I None
post I None
- I None
operative I None
period I None
in I None
an I None
elderly I None
patient I None
who I None
received I None
a I None
moderate I None
dose I None
of I None
fentanyl I Chemical
. I None
<eof> I None

<s> O None
This I None
was I None
successfully I None
reversed I None
by I None
naloxone I Chemical
. I None
<eof> I None

<s> O None
The I None
mechanisms I None
possibly I None
implicated I None
in I None
this I None
accident I None
are I None
discussed I None
. I None
<eof> I None

<s> O None
Postpartum I None
<eof> I None

<s> O None
psychosis I Disease
induced I None
by I None
bromocriptine I Chemical
. I None
<eof> I None

<s> O None
Two I None
multigravida I None
patients I None
with I None
no I None
prior I None
psychiatric I Disease
<eof> I None

<s> O None
history I None
were I None
seen I None
with I None
postpartum I None
psychosis I Disease
, I None
having I None
received I None
bromocriptine I Chemical
for I None
inhibition I Disease
of O Disease
lactation O Disease
. I None
<eof> I None

<s> O None
Bromocriptine I Chemical
given I None
in I None
high I None
doses I None
has I None
been I None
associated I None
with I None
psychosis I Disease
in I None
patients I None
receiving I None
the I None
drug I None
for I None
Parkinson I Disease
's O Disease
disease O Disease
. I None
<eof> I None

<s> O None
These I None
cases I None
demonstrate I None
that I None
bromocriptine I Chemical
may I None
cause I None
psychosis I Disease
even I None
when I None
given I None
in I None
low I None
doses I None
. I None
<eof> I None

<s> O None
A I None
prospective I None
study I None
on I None
the I None
dose I None
dependency I None
of I None
cardiotoxicity I Disease
induced I None
by I None
mitomycin I Chemical
C O Chemical
. I None
<eof> I None

<s> O None
Since I None
1975 I None
mitomycin I Chemical
C O Chemical
<eof> I None

<s> O None
( I None
MMC I Chemical
) I None
has I None
been I None
suggested I None
to I None
be I None
cardiotoxic I Disease
, I None
especially I None
when I None
combined I None
with I None
or I None
given I None
following I None
doxorubicin I Chemical
. I None
<eof> I None

<s> O None
Data I None
on I None
dose I None
dependency I None
or I None
incidence I None
concerning I None
this I None
side I None
effect I None
were I None
not I None
known I None
. I None
<eof> I None

<s> O None
We I None
have I None
initiated I None
a I None
prospective I None
study I None
to I None
obtain I None
some I None
more I None
data I None
on I None
these I None
subjects I None
. I None
<eof> I None

<s> O None
Forty I None
- I None
four I None
<eof> I None

<s> O None
MMC I Chemical
<eof> I None

<s> O None
-treated I None
patients I None
were I None
studied I None
, I None
37 I None
of I None
them I None
could I None
be I None
evaluated I None
. I None
<eof> I None

<s> O None
All I None
patients I None
were I None
studied I None
by I None
repeated I None
physical I None
examinations I None
, I None
chest I None
X I None
- I None
rays I None
, I None
electro- I None
and I None
echocardiography I None
and I None
radionuclide I None
left I None
ventricular I None
ejection I None
fraction I None
( I None
EF I None
) I None
determinations I None
. I None
<eof> I None

<s> O None
The I None
results I None
were I None
evaluated I None
per I None
cumulative I None
dose I None
level I None
. I None
<eof> I None

<s> O None
One I None
of I None
the I None
patients I None
developed I None
cardiac I Disease
failure O Disease
after I None
30 I None
mg I None
m-2 I None
MMC I Chemical
and I None
only I None
150 I None
mg I None
m-2 I None
<eof> I None

<s> O None
doxorubicin I Chemical
. I None
<eof> I None

<s> O None
The I None
cardiac I Disease
failure O Disease
was I None
predicted I None
by I None
a I None
drop I None
in I None
EF I None
determined I None
during I None
a I None
cold I None
pressor I None
test I None
. I None
<eof> I None

<s> O None
None I None
of I None
the I None
other I None
patients I None
developed I None
clinical I None
cardiotoxicity I Disease
, I None
nor I None
did I None
the I None
studied I None
parameters I None
change I None
. I None
<eof> I None

<s> O None
The I None
literature I None
on I None
this I None
subject I None
was I None
also I None
reviewed I None
. I None
<eof> I None

<s> O None
Based I None
on I None
the I None
combined I None
data I None
from I None
the I None
present I None
study I None
and I None
the I None
literature I None
, I None
we I None
suggest I None
that I None
MMC I Chemical
-related I None
cardiotoxicity I Disease
is I None
dose I None
dependent I None
, I None
occurring I None
at I None
cumulative I None
dose I None
levels I None
of I None
30 I None
mg I None
m-2 I None
or I None
more I None
, I None
mainly I None
in I None
patients I None
also I None
( I None
previously I None
or I None
simultaneously I None
) I None
treated I None
with I None
doxorubicin I Chemical
. I None
<eof> I None

<s> O None
The I None
incidence I None
is I None
likely I None
to I None
be I None
less I None
than I None
10 I None
% I None
even I None
for I None
this I None
risk I None
group I None
. I None
<eof> I None

<s> O None
Phlorizin I Chemical
-induced I None
glycosuria I Disease
does I None
not I None
prevent I None
<eof> I None

<s> O None
gentamicin I Chemical
nephrotoxicity I Disease
in I None
rats I None
. I None
<eof> I None

<s> O None
Because I None
rats I None
with I None
streptozotocin I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
diabetes I Disease
mellitus O Disease
<eof> I None

<s> O None
( I None
DM I Disease
) I None
have I None
a I None
high I None
solute I None
diuresis I None
( I None
glycosuria I Disease
of I None
10 I None
to I None
12 I None
g I None
/ I None
day I None
) I None
, I None
we I None
have I None
suggested I None
that I None
this I None
may I None
in I None
part I None
be I None
responsible I None
for I None
their I None
resistance I None
to I None
gentamicin I Chemical
-induced I None
acute I Disease
renal O Disease
failure O Disease
<eof> I None

<s> O None
( I None
ARF I Disease
) I None
. I None
<eof> I None

<s> O None
The I None
protection I None
from I None
gentamicin I Chemical
nephrotoxicity I Disease
was I None
studied I None
in I None
non- I None
diabetic I Disease
rats I None
with I None
chronic I None
solute I None
diuresis I None
induced I None
by I None
blockage I None
of I None
tubular I None
glucose I Chemical
reabsorption I None
with I None
phlorizin I Chemical
<eof> I None

<s> O None
( I None
P I Chemical
) I None
. I None
<eof> I None

<s> O None
DM I Disease
rats I None
with I None
mild I None
glycosuria I Disease
( I None
similar I None
in I None
degree I None
to I None
that I None
of I None
the I None
P I Chemical
treated I None
animals I None
) I None
were I None
also I None
studied I None
. I None
<eof> I None

<s> O None
Unanesthetized I None
adult I None
female I None
, I None
Sprague I None
- I None
Dawley I None
rats I None
were I None
divided I None
in I None
four I None
groups I None
and I None
studied I None
for I None
15 I None
days I None
. I None
<eof> I None

<s> O None
Group I None
1 I None
( I None
P I Chemical
alone I None
) I None
received I None
P I Chemical
, I None
360 I None
mg I None
/ I None
day I None
, I None
for I None
15 I None
days I None
; I None
Group I None
II I None
( I None
P I Chemical
+ I None
gentamicin I Chemical
) I None
; I None
Group I None
III I None
( I None
gentamicin I Chemical
alone I None
) I None
and I None
Group I None
IV I None
( I None
mild I None
DM I Disease
+ I None
gentamicin I Chemical
) I None
. I None
<eof> I None

<s> O None
Nephrotoxic I Disease
doses I None
( I None
40 I None
mg I None
/ I None
kg I None
body I None
wt I None
/ I None
day I None
) I None
of I None
<eof> I None

<s> O None
gentamicin I Chemical
were I None
injected I None
during I None
the I None
last I None
nine I None
days I None
of I None
study I None
to I None
the I None
animals I None
of I None
groups I None
II I None
to I None
IV I None
. I None
<eof> I None

<s> O None
In I None
Group I None
I I None
, I None
P I Chemical
induced I None
a I None
moderate I None
and I None
stable I None
glycosuria I Disease
( I None
3.9 I None
+ I None
/- I None
<eof> I None

<s> O None
0.1 I None
g I None
/ I None
day I None
, I None
SE I None
) I None
, I None
and I None
no I None
functional I None
or I None
morphologic I None
evidence I None
of I None
renal I Disease
dysfunction O Disease
<eof> I None

<s> O None
( I None
baseline I None
CCr I None
2.1 I None
+ I None
/- I None
<eof> I None

<s> O None
0.1 I None
ml I None
/ I None
min I None
, I None
undetectable I None
lysozymuria I None
) I None
or I None
damage I None
( I None
tubular I Disease
necrosis O Disease
score I None
[ I None
maximum I None
4 I None
] I None
, I None
zero I None
) I None
. I None
<eof> I None

<s> O None
In I None
Group I None
II I None
, I None
P I Chemical
did I None
not I None
prevent I None
gentamicin I Chemical
- I None
ARF I Disease
<eof> I None

<s> O None
( I None
maximal I None
decrease I None
in I None
CCr I None
at I None
day I None
9.89 I None
% I None
, I None
P I Chemical
less I None
than I None
0.001 I None
; I None
peak I None
lysozymuria I None
, I None
1863 I None
+ I None
/- I None
<eof> I None

<s> O None
321 I None
micrograms I None
/ I None
day I None
; I None
and I None
tubular I Disease
necrosis O Disease
score I None
, I None
3.9 I None
+ I None
/- I None
0.1 I None
) I None
. I None
<eof> I None

<s> O None
These I None
values I None
were I None
not I None
different I None
from I None
those I None
of I None
Group I None
III I None
: I None
maximal I None
decrease I None
in I None
CCr I None
73 I None
% I None
( I None
P I Chemical
less I None
than I None
0.001 I None
) I None
; I None
lysozymuria I None
, I None
2147 I None
+ I None
/- I None
701 I None
micrograms I None
/ I None
day I None
; I None
tubular I Disease
necrosis O Disease
score I None
, I None
3.8 I None
+ I None
/- I None
0.1.(ABSTRACT I None
TRUNCATED I None
AT I None
250 I None
WORDS I None
) I None
<eof> I None

<s> O None
Tiapride I Chemical
in I None
levodopa I Chemical
-induced I None
involuntary I Disease
movements O Disease
. I None
<eof> I None

<s> O None
Tiapride I Chemical
, I None
a I None
substituted I None
benzamide I Chemical
derivative I None
closely I None
related I None
to I None
metoclopramide I Chemical
, I None
reduced I None
<eof> I None

<s> O None
levodopa I Chemical
-induced I None
<eof> I None

<s> O None
peak I None
dose I None
involuntary I Disease
movements O Disease
in I None
16 I None
patients I None
with I None
idiopathic I Disease
Parkinson O Disease
's O Disease
disease O Disease
. I None
<eof> I None

<s> O None
However I None
, I None
an I None
unacceptable I None
increase I None
in I None
disability I None
from I None
Parkinsonism I Disease
with I None
aggravation I None
of I None
end I None
- I None
of I None
- I None
dose I None
akinesia I Disease
led I None
to I None
its I None
cessation I None
in I None
14 I None
patients I None
. I None
<eof> I None

<s> O None
Tiapride I Chemical
had I None
no I None
effect I None
on I None
<eof> I None

<s> O None
levodopa I Chemical
-induced I None
early I None
morning I None
of I None
" I None
off I None
- I None
period I None
" I None
segmental I None
dystonia I Disease
. I None
<eof> I None

<s> O None
These I None
results I None
fail I None
to I None
support I None
the I None
notion I None
that I None
levodopa I Chemical
-induced I None
dyskinesias I Disease
are I None
caused I None
by I None
overstimulation I None
of I None
a I None
separate I None
group I None
of I None
dopamine I Chemical
receptors I None
. I None
<eof> I None

<s> O None
Effects I None
of I None
the I None
hippocampal I None
deep I None
brain I None
stimulation I None
on I None
cortical I None
epileptic I Disease
discharges I None
in I None
penicillin I Chemical
- I None
induced I None
epilepsy I Disease
model I None
in I None
rats I None
. I None
<eof> I None

<s> O None
AIM I None
: I None
Experimental I None
and I None
clinical I None
studies I None
have I None
revealed I None
that I None
hippocampal I None
DBS I None
can I None
control I None
epileptic I Disease
activity I None
, I None
but I None
the I None
mechanism I None
of I None
action I None
is I None
obscure I None
and I None
optimal I None
stimulation I None
parameters I None
are I None
not I None
clearly I None
defined I None
. I None
<eof> I None

<s> O None
The I None
aim I None
was I None
to I None
evaluate I None
the I None
effects I None
of I None
high I None
frequency I None
hippocampal I None
stimulation I None
on I None
cortical I None
epileptic I Disease
activity I None
in I None
penicillin I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
epilepsy I Disease
model I None
. I None
<eof> I None

<s> O None
MATERIAL I None
AND I None
METHODS I None
: I None
Twenty I None
- I None
five I None
Sprague I None
- I None
Dawley I None
rats I None
were I None
implanted I None
DBS I None
electrodes I None
. I None
<eof> I None

<s> O None
In I None
group-1 I None
( I None
n=10 I None
) I None
hippocampal I None
DBS I None
was I None
off I None
and I None
in I None
the I None
group-2 I None
( I None
n=10 I None
) I None
hippocampal I None
DBS I None
was I None
on I None
( I None
185 I None
Hz I None
, I None
0.5V I None
, I None
1V I None
, I None
2V I None
, I None
and I None
5V I None
for I None
60 I None
sec I None
) I None
following I None
penicillin I Chemical
G O Chemical
injection I None
intracortically I None
. I None
<eof> I None

<s> O None
In I None
the I None
control I None
group I None
hippocampal I None
DBS I None
was I None
on I None
following I None
8 I None
l I None
saline I None
injection I None
intracortically I None
. I None
<eof> I None

<s> O None
EEG I None
recordings I None
were I None
obtained I None
before I None
and I None
15 I None
minutes I None
following I None
penicillin I Chemical
- O Chemical
G O Chemical
injection I None
, I None
and I None
at I None
10th I None
minutes I None
following I None
each I None
stimulus I None
for I None
analysis I None
in I None
terms I None
of I None
frequency I None
, I None
amplitude I None
, I None
and I None
power I None
spectrum I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
High I None
frequency I None
hippocampal I None
DBS I None
suppressed I None
the I None
acute I None
penicillin I Chemical
-induced I None
cortical I None
epileptic I Disease
activity I None
independent I None
from I None
stimulus I None
intensity I None
. I None
<eof> I None

<s> O None
In I None
the I None
control I None
group I None
, I None
hippocampal I None
stimulation I None
alone I None
lead I None
only I None
to I None
diffuse I None
slowing I None
of I None
cerebral I None
bioelectrical I None
activity I None
at I None
5V I None
stimulation I None
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
<eof> I None

<s> O None
Our I None
results I None
revealed I None
that I None
continuous I None
high I None
frequency I None
stimulation I None
of I None
the I None
hippocampus I None
suppressed I None
acute I None
cortical I None
epileptic I Disease
activity I None
effectively I None
without I None
causing I None
secondary I None
epileptic I Disease
discharges I None
. I None
<eof> I None

<s> O None
These I None
results I None
are I None
important I None
in I None
terms I None
of I None
defining I None
the I None
optimal I None
parameters I None
of I None
hippocampal I None
DBS I None
in I None
patients I None
with I None
epilepsy I Disease
. I None
<eof> I None

<s> O None
Neural I None
correlates I None
of I None
S I Chemical
- O Chemical
ketamine O Chemical
induced I None
<eof> I None

<s> O None
psychosis I Disease
during I None
overt I None
continuous I None
verbal I None
fluency I None
. I None
<eof> I None

<s> O None
The I None
glutamatergic I None
N I Chemical
- O Chemical
methyl O Chemical
- O Chemical
D O Chemical
- O Chemical
aspartate O Chemical
<eof> I None

<s> O None
( I None
NMDA I Chemical
) I None
receptor I None
has I None
been I None
implicated I None
in I None
the I None
pathophysiology I None
of I None
schizophrenia I Disease
. I None
<eof> I None

<s> O None
Administered I None
to I None
healthy I None
volunteers I None
, I None
a I None
subanesthetic I None
dose I None
of I None
the I None
non I None
- I None
competitive I None
NMDA I Chemical
receptor I None
antagonist I None
ketamine I Chemical
leads I None
to I None
psychopathological I None
symptoms I None
similar I None
to I None
those I None
observed I None
in I None
schizophrenia I Disease
. I None
<eof> I None

<s> O None
In I None
patients I None
with I None
schizophrenia I Disease
, I None
ketamine I Chemical
exacerbates I None
the I None
core I None
symptoms I None
of I None
illness I None
, I None
supporting I None
the I None
hypothesis I None
of I None
a I None
glutamatergic I Disease
dysfunction O Disease
. I None
<eof> I None

<s> O None
In I None
a I None
counterbalanced I None
, I None
placebo I None
- I None
controlled I None
, I None
double I None
- I None
blind I None
study I None
design I None
, I None
healthy I None
subjects I None
were I None
administered I None
a I None
continuous I None
subanesthetic I None
S I Chemical
- O Chemical
ketamine O Chemical
infusion I None
while I None
differences I None
in I None
BOLD I None
responses I None
measured I None
with I None
fMRI I None
were I None
detected I None
. I None
<eof> I None

<s> O None
During I None
the I None
scanning I None
period I None
, I None
subjects I None
performed I None
continuous I None
overt I None
verbal I None
fluency I None
tasks I None
( I None
phonological I None
, I None
lexical I None
and I None
semantic I None
) I None
. I None
<eof> I None

<s> O None
Ketamine I Chemical
<eof> I None

<s> O None
-induced I None
psychopathological I None
symptoms I None
were I None
assessed I None
with I None
the I None
Positive I None
and I None
Negative I None
Syndrome I None
Scale I None
( I None
PANSS I None
) I None
. I None
<eof> I None

<s> O None
Ketamine I Chemical
elicited I None
<eof> I None

<s> O None
psychosis I Disease
like I None
psychopathology I None
. I None
<eof> I None

<s> O None
Post I None
- I None
hoc I None
t I None
- I None
tests I None
revealed I None
significant I None
differences I None
between I None
placebo I None
and I None
ketamine I Chemical
for I None
the I None
amounts I None
of I None
words I None
generated I None
during I None
lexical I None
and I None
semantic I None
verbal I None
fluency I None
, I None
while I None
the I None
phonological I None
domain I None
remained I None
unaffected I None
. I None
<eof> I None

<s> O None
Ketamine I Chemical
led I None
to I None
enhanced I None
cortical I None
activations I None
in I None
supramarginal I None
and I None
frontal I None
brain I None
regions I None
for I None
phonological I None
and I None
lexical I None
verbal I None
fluency I None
, I None
but I None
not I None
for I None
semantic I None
verbal I None
fluency I None
. I None
<eof> I None

<s> O None
Ketamine I Chemical
induces I None
activation I None
changes I None
in I None
healthy I None
subjects I None
similar I None
to I None
those I None
observed I None
in I None
patients I None
with I None
schizophrenia I Disease
, I None
particularly I None
in I None
frontal I None
and I None
temporal I None
brain I None
regions I None
. I None
<eof> I None

<s> O None
Our I None
results I None
provide I None
further I None
support I None
for I None
the I None
hypothesis I None
of I None
an I None
NMDA I Chemical
receptor I None
dysfunction I None
in I None
the I None
pathophysiology I None
of I None
schizophrenia I Disease
. I None
<eof> I None

<s> O None
Dopamine I Chemical
is I None
not I None
essential I None
for I None
the I None
development I None
of I None
methamphetamine I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
neurotoxicity I Disease
. I None
<eof> I None

<s> O None
It I None
is I None
widely I None
believed I None
that I None
dopamine I Chemical
<eof> I None

<s> O None
( I None
DA I Chemical
) I None
mediates I None
methamphetamine I Chemical
<eof> I None

<s> O None
( I None
METH I Chemical
) I None
-induced I None
<eof> I None

<s> O None
toxicity I Disease
to I None
brain I None
dopaminergic I None
neurons I None
, I None
because I None
drugs I None
that I None
interfere I None
with I None
DA I Chemical
neurotransmission I None
decrease I None
toxicity I Disease
, I None
<eof> I None

<s> O None
whereas I None
drugs I None
that I None
increase I None
DA I Chemical
neurotransmission I None
enhance I None
<eof> I None

<s> O None
toxicity I Disease
. I None
<eof> I None

<s> O None
However I None
, I None
temperature I None
effects I None
of I None
drugs I None
that I None
have I None
been I None
used I None
to I None
manipulate I None
brain I None
DA I Chemical
<eof> I None

<s> O None
neurotransmission I None
confound I None
interpretation I None
of I None
the I None
data I None
. I None
<eof> I None

<s> O None
Here I None
we I None
show I None
that I None
the I None
recently I None
reported I None
ability I None
of I None
L I Chemical
- O Chemical
dihydroxyphenylalanine O Chemical
to I None
reverse I None
the I None
protective I None
effect I None
of I None
alpha I Chemical
- O Chemical
methyl O Chemical
- O Chemical
para O Chemical
- O Chemical
tyrosine O Chemical
on I None
METH I Chemical
-induced I None
DA I Chemical
<eof> I None

<s> O None
neurotoxicity I Disease
is I None
also I None
confounded I None
by I None
drug I None
effects I None
on I None
body I None
temperature I None
. I None
<eof> I None

<s> O None
Further I None
, I None
we I None
show I None
that I None
mice I None
genetically I None
engineered I None
to I None
be I None
deficient I None
in I None
brain I None
DA I Chemical
develop I None
METH I Chemical
<eof> I None

<s> O None
neurotoxicity I Disease
, I None
as I None
long I None
as I None
the I None
thermic I None
effects I None
of I None
METH I Chemical
are I None
preserved I None
. I None
<eof> I None

<s> O None
In I None
addition I None
, I None
we I None
demonstrate I None
that I None
mice I None
genetically I None
engineered I None
to I None
have I None
unilateral I None
brain I None
DA I Chemical
<eof> I None

<s> O None
deficits I None
develop I None
<eof> I None

<s> O None
METH I Chemical
-induced I None
<eof> I None

<s> O None
dopaminergic I Disease
deficits O Disease
<eof> I None

<s> O None
that I None
are I None
of I None
comparable I None
magnitude I None
on I None
both I None
sides I None
of I None
the I None
brain I None
. I None
<eof> I None

<s> O None
Taken I None
together I None
, I None
these I None
findings I None
demonstrate I None
that I None
DA I Chemical
is I None
not I None
essential I None
for I None
the I None
development I None
of I None
METH I Chemical
-induced I None
dopaminergic I None
neurotoxicity I Disease
and I None
suggest I None
that I None
mechanisms I None
independent I None
of I None
DA I Chemical
warrant I None
more I None
intense I None
investigation I None
. I None
<eof> I None

<s> O None
Brainstem I Disease
dysgenesis O Disease
in I None
an I None
infant I None
prenatally I None
exposed I None
to I None
cocaine I Chemical
. I None
<eof> I None

<s> O None
Many I None
authors I None
described I None
the I None
effects I None
on I None
the I None
fetus I None
of I None
maternal I None
cocaine I Disease
abuse O Disease
during I None
pregnancy I None
. I None
<eof> I None

<s> O None
Vasoconstriction I None
appears I None
to I None
be I None
the I None
common I None
mechanism I None
of I None
action I None
leading I None
to I None
a I None
wide I None
range I None
of I None
fetal I Disease
anomalies O Disease
. I None
<eof> I None

<s> O None
We I None
report I None
on I None
an I None
infant I None
with I None
multiple I Disease
cranial O Disease
- O Disease
nerve O Disease
involvement O Disease
attributable I None
to I None
brainstem I Disease
dysgenesis O Disease
, I None
born I None
to I None
a I None
cocaine I Disease
- O Disease
addicted O Disease
mother I None
. I None
<eof> I None

<s> O None
The I None
protective I None
role I None
of I None
Nrf2 I None
in I None
streptozotocin I Chemical
-induced I None
diabetic I Disease
nephropathy O Disease
. I None
<eof> I None

<s> O None
OBJECTIVE I None
: I None
<eof> I None

<s> O None
Diabetic I Disease
nephropathy O Disease
is I None
one I None
of I None
the I None
major I None
causes I None
of I None
renal I Disease
failure O Disease
, I None
which I None
is I None
accompanied I None
by I None
the I None
production I None
of I None
reactive I None
oxygen I Chemical
species I None
( I None
ROS I None
) I None
. I None
<eof> I None

<s> O None
Nrf2 I None
is I None
the I None
primary I None
transcription I None
factor I None
that I None
controls I None
the I None
antioxidant I None
response I None
essential I None
for I None
maintaining I None
cellular I None
redox I None
homeostasis I None
. I None
<eof> I None

<s> O None
Here I None
, I None
we I None
report I None
our I None
findings I None
demonstrating I None
a I None
protective I None
role I None
of I None
Nrf2 I None
against I None
diabetic I Disease
nephropathy O Disease
. I None
<eof> I None

<s> O None
RESEARCH I None
DESIGN I None
AND I None
METHODS I None
<eof> I None

<s> O None
: I None
We I None
explore I None
the I None
protective I None
role I None
of I None
Nrf2 I None
against I None
diabetic I Disease
nephropathy O Disease
using I None
human I None
kidney I None
biopsy I None
tissues I None
from I None
diabetic I Disease
nephropathy O Disease
patients I None
, I None
a I None
streptozotocin I Chemical
-induced I None
diabetic I Disease
nephropathy O Disease
model I None
in I None
Nrf2(-/- I None
) I None
mice I None
, I None
and I None
cultured I None
human I None
mesangial I None
cells I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
The I None
glomeruli I None
of I None
human I None
diabetic I Disease
nephropathy O Disease
patients I None
were I None
under I None
oxidative I None
stress I None
and I None
had I None
elevated I None
Nrf2 I None
levels I None
. I None
<eof> I None

<s> O None
In I None
the I None
animal I None
study I None
, I None
Nrf2 I None
was I None
demonstrated I None
to I None
be I None
crucial I None
in I None
ameliorating I None
<eof> I None

<s> O None
streptozotocin I Chemical
-induced I None
<eof> I None

<s> O None
renal I Disease
damage O Disease
. I None
<eof> I None

<s> O None
This I None
is I None
evident I None
by I None
Nrf2(-/- I None
) I None
mice I None
having I None
higher I None
ROS I None
production I None
and I None
suffering I None
from I None
greater I None
oxidative I None
DNA I None
damage I None
and I None
renal I Disease
injury O Disease
compared I None
with I None
Nrf2(+/+ I None
) I None
mice I None
. I None
<eof> I None

<s> O None
Mechanistic I None
studies I None
in I None
both I None
in I None
vivo I None
and I None
in I None
vitro I None
systems I None
showed I None
that I None
the I None
Nrf2-mediated I None
protection I None
against I None
diabetic I Disease
nephropathy O Disease
is I None
, I None
at I None
least I None
, I None
partially I None
through I None
inhibition I None
of I None
transforming I None
growth I None
factor I None
- I None
beta1 I None
( I None
TGF I None
- I None
beta1 I None
) I None
and I None
reduction I None
of I None
extracellular I None
matrix I None
production I None
. I None
<eof> I None

<s> O None
In I None
human I None
renal I None
mesangial I None
cells I None
, I None
high I None
glucose I Chemical
induced I None
ROS I None
production I None
and I None
activated I None
expression I None
of I None
Nrf2 I None
and I None
its I None
downstream I None
genes I None
. I None
<eof> I None

<s> O None
Furthermore I None
, I None
activation I None
or I None
overexpression I None
of I None
Nrf2 I None
inhibited I None
the I None
promoter I None
activity I None
of I None
TGF I None
- I None
beta1 I None
in I None
a I None
dose I None
- I None
dependent I None
manner I None
, I None
whereas I None
knockdown I None
of I None
Nrf2 I None
by I None
siRNA I None
enhanced I None
TGF I None
- I None
beta1 I None
transcription I None
and I None
fibronectin I None
production I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
This I None
work I None
clearly I None
indicates I None
a I None
protective I None
role I None
of I None
Nrf2 I None
in I None
diabetic I Disease
nephropathy O Disease
, I None
suggesting I None
that I None
dietary I None
or I None
therapeutic I None
activation I None
of I None
Nrf2 I None
could I None
be I None
used I None
as I None
a I None
strategy I None
to I None
prevent I None
or I None
slow I None
down I None
the I None
progression I None
of I None
diabetic I Disease
nephropathy O Disease
. I None
<eof> I None

<s> O None
High I None
- I None
dose I None
<eof> I None

<s> O None
tranexamic I Chemical
Acid O Chemical
is I None
associated I None
with I None
nonischemic I None
clinical I None
seizures I Disease
in I None
cardiac I None
surgical I None
patients I None
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
<eof> I None

<s> O None
In I None
2 I None
separate I None
centers I None
, I None
we I None
observed I None
a I None
notable I None
increase I None
in I None
the I None
incidence I None
of I None
postoperative I None
convulsive I Disease
<eof> I None

<s> O None
seizures I Disease
from I None
1.3 I None
% I None
to I None
3.8 I None
% I None
in I None
patients I None
having I None
undergone I None
major I None
cardiac I None
surgical I None
procedures I None
. I None
<eof> I None

<s> O None
These I None
events I None
were I None
temporally I None
coincident I None
with I None
the I None
initial I None
use I None
of I None
high I None
- I None
dose I None
tranexamic I Chemical
acid O Chemical
<eof> I None

<s> O None
( I None
TXA I Chemical
) I None
therapy I None
after I None
withdrawal I None
of I None
aprotinin I None
from I None
general I None
clinical I None
usage I None
. I None
<eof> I None

<s> O None
The I None
purpose I None
of I None
this I None
review I None
was I None
to I None
perform I None
a I None
retrospective I None
analysis I None
to I None
examine I None
whether I None
there I None
was I None
a I None
relation I None
between I None
TXA I Chemical
usage I None
and I None
seizures I Disease
after I None
cardiac I None
surgery I None
. I None
<eof> I None

<s> O None
METHODS I None
: I None
<eof> I None

<s> O None
An I None
in I None
- I None
depth I None
chart I None
review I None
was I None
undertaken I None
in I None
all I None
24 I None
patients I None
who I None
developed I None
perioperative I None
seizures I Disease
. I None
<eof> I None

<s> O None
Electroencephalographic I None
activity I None
was I None
recorded I None
in I None
11 I None
of I None
these I None
patients I None
, I None
and I None
all I None
patients I None
had I None
a I None
formal I None
neurological I None
evaluation I None
and I None
brain I None
imaging I None
studies I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
Twenty I None
- I None
one I None
of I None
the I None
24 I None
patients I None
did I None
not I None
have I None
evidence I None
of I None
new I None
cerebral I Disease
ischemic O Disease
injury O Disease
, I None
but I None
seizures I Disease
were I None
likely I None
due I None
to I None
ischemic I Disease
brain O Disease
injury O Disease
in I None
3 I None
patients I None
. I None
<eof> I None

<s> O None
All I None
patients I None
with I None
seizures I Disease
did I None
not I None
have I None
permanent I None
neurological I Disease
abnormalities O Disease
. I None
<eof> I None

<s> O None
All I None
24 I None
patients I None
with I None
seizures I Disease
received I None
high I None
doses I None
of I None
TXA I Chemical
<eof> I None

<s> O None
intraoperatively I None
ranging I None
from I None
61 I None
to I None
259 I None
mg I None
/ I None
kg I None
, I None
had I None
a I None
mean I None
age I None
of I None
69.9 I None
years I None
, I None
and I None
21 I None
of I None
24 I None
had I None
undergone I None
open I None
chamber I None
rather I None
than I None
coronary I None
bypass I None
procedures I None
. I None
<eof> I None

<s> O None
All I None
but I None
one I None
patient I None
were I None
managed I None
using I None
cardiopulmonary I None
bypass I None
. I None
<eof> I None

<s> O None
No I None
evidence I None
of I None
brain I Disease
ischemic O Disease
, I None
metabolic I None
, I None
or I None
<eof> I None

<s> O None
hyperthermia I Disease
-induced I None
causes I None
for I None
their I None
seizures I Disease
was I None
apparent I None
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
<eof> I None

<s> O None
Our I None
results I None
suggest I None
that I None
use I None
of I None
high I None
- I None
dose I None
TXA I Chemical
in I None
older I None
patients I None
in I None
conjunction I None
with I None
cardiopulmonary I None
bypass I None
and I None
open I None
- I None
chamber I None
cardiac I None
surgery I None
is I None
associated I None
with I None
clinical I None
seizures I Disease
in I None
susceptible I None
patients I None
. I None
<eof> I None

<s> O None
Recurrent I None
dysosmia I Disease
induced I None
by I None
pyrazinamide I Chemical
. I None
<eof> I None

<s> O None
Pyrazinamide I Chemical
can I None
have I None
adverse I None
effects I None
such I None
as I None
hepatic I Disease
toxicity O Disease
, I None
hyperuricemia I Disease
or I None
digestive I None
disorders I None
. I None
<eof> I None

<s> O None
In I None
rare I None
cases I None
, I None
alterations I None
in I None
taste I None
and I None
smell I None
function I None
have I None
been I None
reported I None
for I None
pyrazinamide I Chemical
when I None
combined I None
with I None
other I None
drugs I None
. I None
<eof> I None

<s> O None
We I None
report I None
a I None
case I None
of I None
reversible I None
olfactory I Disease
disorder O Disease
related I None
to I None
pyrazinamide I Chemical
in I None
a I None
woman I None
, I None
with I None
a I None
positive I None
rechallenge I None
. I None
<eof> I None

<s> O None
The I None
patient I None
presented I None
every I None
day I None
a I None
sensation I None
of I None
smelling I None
something I None
burning I None
15 I None
min I None
after I None
drug I None
intake I None
. I None
<eof> I None

<s> O None
Dysosmia I Disease
disappeared I None
completely I None
after I None
pyrazinamide I Chemical
withdrawal I None
and I None
recurred I None
after I None
its I None
rechallenge I None
. I None
<eof> I None

<s> O None
The I None
case I None
was I None
reported I None
to I None
the I None
Tunisian I None
Centre I None
of I None
Pharmacovigilance I None
. I None
<eof> I None

<s> O None
Longitudinal I None
assessment I None
of I None
air I None
conduction I None
audiograms I None
in I None
a I None
phase I None
III I None
clinical I None
trial I None
of I None
difluoromethylornithine I Chemical
and I None
sulindac I Chemical
for I None
prevention I None
of I None
sporadic I None
colorectal I Disease
adenomas O Disease
. I None
<eof> I None

<s> O None
A I None
phase I None
III I None
clinical I None
trial I None
assessed I None
the I None
recurrence I None
of I None
adenomatous I Disease
polyps O Disease
after I None
treatment I None
for I None
36 I None
months I None
with I None
difluoromethylornithine I Chemical
<eof> I None

<s> O None
( I None
DFMO I Chemical
) I None
plus I None
sulindac I Chemical
or I None
matched I None
placebos I None
. I None
<eof> I None

<s> O None
Temporary I None
hearing I Disease
loss O Disease
is I None
a I None
known I None
toxicity I Disease
of I None
treatment I None
with I None
DFMO I Chemical
, I None
thus I None
a I None
comprehensive I None
approach I None
was I None
developed I None
to I None
analyze I None
serial I None
air I None
conduction I None
audiograms I None
. I None
<eof> I None

<s> O None
The I None
generalized I None
estimating I None
equation I None
method I None
estimated I None
the I None
mean I None
difference I None
between I None
treatment I None
arms I None
with I None
regard I None
to I None
change I None
in I None
air I None
conduction I None
pure I None
tone I None
thresholds I None
while I None
accounting I None
for I None
within I None
- I None
subject I None
correlation I None
due I None
to I None
repeated I None
measurements I None
at I None
frequencies I None
. I None
<eof> I None

<s> O None
Based I None
on I None
290 I None
subjects I None
, I None
there I None
was I None
an I None
average I None
difference I None
of I None
0.50 I None
dB I None
between I None
subjects I None
treated I None
with I None
DFMO I Chemical
plus I None
sulindac I Chemical
compared I None
with I None
those I None
treated I None
with I None
placebo I None
( I None
95 I None
% I None
confidence I None
interval I None
, I None
-0.64 I None
to I None
1.63 I None
dB I None
; I None
P I None
= I None
0.39 I None
) I None
, I None
adjusted I None
for I None
baseline I None
values I None
, I None
age I None
, I None
and I None
frequencies I None
. I None
<eof> I None

<s> O None
In I None
the I None
normal I None
speech I None
range I None
of I None
500 I None
to I None
3,000 I None
Hz I None
, I None
an I None
estimated I None
difference I None
of I None
0.99 I None
dB I None
( I None
-0.17 I None
to I None
2.14 I None
dB I None
; I None
P I None
= I None
0.09 I None
) I None
was I None
detected I None
. I None
<eof> I None

<s> O None
Dose I None
intensity I None
did I None
not I None
add I None
information I None
to I None
models I None
. I None
<eof> I None

<s> O None
There I None
were I None
14 I None
of I None
151 I None
( I None
9.3 I None
% I None
) I None
in I None
the I None
DFMO I Chemical
plus I None
sulindac I Chemical
group I None
and I None
4 I None
of I None
139 I None
( I None
2.9 I None
% I None
) I None
in I None
the I None
placebo I None
group I None
who I None
experienced I None
at I None
least I None
15 I None
dB I None
hearing I None
reduction I None
from I None
baseline I None
in I None
2 I None
or I None
more I None
consecutive I None
frequencies I None
across I None
the I None
entire I None
range I None
tested I None
( I None
P I None
= I None
0.02 I None
) I None
. I None
<eof> I None

<s> O None
Follow I None
- I None
up I None
air I None
conduction I None
done I None
at I None
least I None
6 I None
months I None
after I None
end I None
of I None
treatment I None
showed I None
an I None
adjusted I None
mean I None
difference I None
in I None
hearing I None
thresholds I None
of I None
1.08 I None
dB I None
( I None
-0.81 I None
to I None
2.96 I None
dB I None
; I None
P I None
= I None
0.26 I None
) I None
between I None
treatment I None
arms I None
. I None
<eof> I None

<s> O None
There I None
was I None
no I None
significant I None
difference I None
in I None
the I None
proportion I None
of I None
subjects I None
in I None
the I None
DFMO I Chemical
plus I None
sulindac I Chemical
group I None
who I None
experienced I None
clinically I None
significant I None
hearing I Disease
loss O Disease
compared I None
with I None
the I None
placebo I None
group I None
. I None
<eof> I None

<s> O None
The I None
estimated I None
attributable I None
risk I None
of I None
ototoxicity I Disease
from I None
exposure I None
to I None
the I None
drug I None
is I None
8.4 I None
% I None
( I None
95 I None
% I None
confidence I None
interval I None
, I None
-2.0 I None
% I None
to I None
18.8 I None
% I None
; I None
P I None
= I None
0.12 I None
) I None
. I None
<eof> I None

<s> O None
There I None
is I None
a I None
< I None
2 I None
dB I None
difference I None
in I None
mean I None
threshold I None
for I None
patients I None
treated I None
with I None
DFMO I Chemical
plus I None
sulindac I Chemical
compared I None
with I None
those I None
treated I None
with I None
placebo I None
. I None
<eof> I None

<s> O None
Increased I None
mental I Disease
slowing O Disease
<eof> I None

<s> O None
associated I None
with I None
the I None
APOE I None
epsilon4 I None
allele I None
after I None
trihexyphenidyl I Chemical
oral I None
anticholinergic I None
challenge I None
in I None
healthy I None
elderly I None
. I None
<eof> I None

<s> O None
OBJECTIVES I None
: I None
<eof> I None

<s> O None
The I None
objectives I None
of I None
this I None
study I None
were I None
to I None
examine I None
the I None
relationship I None
between I None
APOE I None
epsilon4 I None
and I None
subjective I None
effects I None
of I None
trihexyphenidyl I Chemical
on I None
measures I None
reflecting I None
sedation I None
and I None
confusion I Disease
and I None
to I None
investigate I None
the I None
relationship I None
between I None
trihexyphenidyl I Chemical
<eof> I None

<s> O None
-induced I None
subjective I None
effects I None
and I None
objective I None
memory I None
performance I None
. I None
<eof> I None

<s> O None
METHODS I None
: I None
<eof> I None

<s> O None
This I None
study I None
comprised I None
24 I None
cognitively I None
intact I None
, I None
health I None
elderly I None
adults I None
( I None
12 I None
APOE I None
epsilon4 I None
carriers I None
) I None
at I None
an I None
outpatient I None
geriatric I None
psychiatry I None
research I None
clinic I None
. I None
<eof> I None

<s> O None
This I None
was I None
a I None
randomized I None
, I None
double I None
blind I None
, I None
placebo I None
- I None
controlled I None
, I None
three I None
- I None
way I None
, I None
crossover I None
experimental I None
design I None
. I None
<eof> I None

<s> O None
All I None
participants I None
received I None
1.0 I None
mg I None
or I None
2.0 I None
mg I None
trihexyphenidyl I Chemical
or I None
placebo I None
administered I None
in I None
counterbalanced I None
sequences I None
over I None
a I None
period I None
of I None
three I None
consecutive I None
weeks I None
. I None
<eof> I None

<s> O None
Bond I None
and I None
Lader I None
's I None
visual I None
analog I None
scales I None
and I None
alternate I None
versions I None
of I None
the I None
Buschke I None
Selective I None
Reminding I None
Test I None
were I None
administered I None
in I None
a I None
repeated I None
measures I None
design I None
at I None
baseline I None
, I None
1 I None
, I None
2.5 I None
, I None
and I None
5 I None
hours I None
postdrug I None
administration I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
A I None
2.0-mg I None
oral I None
dose I None
of I None
<eof> I None

<s> O None
trihexyphenidyl I Chemical
resulted I None
in I None
increased I None
subjective I None
ratings I None
of I None
mental I Disease
slowness O Disease
in I None
carriers I None
of I None
the I None
APOE I None
epsilon4 I None
allele I None
only I None
. I None
<eof> I None

<s> O None
Drug I None
effects I None
as I None
determined I None
by I None
difference I None
scores I None
between I None
2.0 I None
mg I None
trihexyphenidyl I Chemical
and I None
placebo I None
on I None
ratings I None
of I None
mental I Disease
slowness O Disease
significantly I None
correlated I None
with I None
total I None
and I None
delayed I None
recall I None
on I None
the I None
Buschke I None
Selective I None
Reminding I None
Test I None
in I None
carriers I None
of I None
the I None
APOE I None
epsilon4 I None
allele I None
only I None
. I None
<eof> I None

<s> O None
However I None
, I None
no I None
significant I None
effects I None
were I None
found I None
with I None
other I None
visual I None
analog I None
scales I None
reflecting I None
subjective I None
sedation I None
and I None
clear I None
- I None
headedness I None
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
<eof> I None

<s> O None
The I None
epsilon4 I None
allele I None
in I None
healthy I None
elderly I None
was I None
associated I None
with I None
increased I None
subjective I None
mental I Disease
slowing O Disease
after I None
trihexyphenidyl I Chemical
anticholinergic I None
challenge I None
. I None
<eof> I None

<s> O None
Behavioral I None
effects I None
of I None
pubertal I None
anabolic I None
androgenic I None
<eof> I None

<s> O None
steroid I Chemical
exposure I None
in I None
male I None
rats I None
with I None
low I None
serotonin I Chemical
. I None
<eof> I None

<s> O None
The I None
goal I None
of I None
this I None
study I None
was I None
to I None
assess I None
the I None
interactive I None
effects I None
of I None
chronic I None
anabolic I None
androgenic I None
steroid I Chemical
<eof> I None

<s> O None
( I None
AAS I None
) I None
exposure I None
and I None
brain I None
serotonin I Chemical
<eof> I None

<s> O None
( I None
5-hydroxytryptamine I Chemical
, I None
5-HT I Chemical
) I None
depletion I None
on I None
behavior I None
of I None
pubertal I None
male I None
rats I None
. I None
<eof> I None

<s> O None
Serotonin I Chemical
was I None
depleted I None
beginning I None
on I None
postnatal I None
day I None
26 I None
with I None
parachlorophenylalanine I Chemical
<eof> I None

<s> O None
( I None
PCPA I Chemical
100 I None
mg I None
/ I None
kg I None
, I None
every I None
other I None
day I None
) I None
; I None
<eof> I None

<s> O None
controls I None
received I None
saline I None
. I None
<eof> I None

<s> O None
At I None
puberty I None
( I None
P40 I None
) I None
, I None
half I None
the I None
PCPA I Chemical
-treated I None
rats I None
and I None
half I None
the I None
saline I None
- I None
treated I None
rats I None
began I None
treatment I None
with I None
testosterone I Chemical
<eof> I None

<s> O None
( I None
T I Chemical
, I None
5 I None
mg I None
/ I None
kg I None
, I None
5 I None
days I None
/ I None
week I None
) I None
. I None
<eof> I None

<s> O None
Behavioral I None
measures I None
included I None
locomotion I None
, I None
irritability I Disease
, I None
copulation I None
, I None
partner I None
preference I None
, I None
and I None
aggression I Disease
. I None
<eof> I None

<s> O None
Animals I None
were I None
tested I None
for I None
aggression I Disease
in I None
their I None
home I None
cage I None
, I None
both I None
with I None
and I None
without I None
physical I None
provocation I None
( I None
mild I None
tail I None
pinch I None
) I None
. I None
<eof> I None

<s> O None
Brain I None
levels I None
of I None
5-HT I Chemical
and I None
its I None
metabolite I None
, I None
5-hydroxyindoleacetic I Chemical
acid O Chemical
<eof> I None

<s> O None
( I None
5-HIAA I Chemical
) I None
, I None
were I None
determined I None
using I None
HPLC I None
. I None
<eof> I None

<s> O None
PCPA I Chemical
significantly I None
and I None
substantially I None
depleted I None
<eof> I None

<s> O None
5-HT I Chemical
and I None
5-HIAA I Chemical
in I None
all I None
brain I None
regions I None
examined I None
. I None
<eof> I None

<s> O None
Chronic I None
T I Chemical
treatment I None
significantly I None
decreased I None
<eof> I None

<s> O None
5-HT I Chemical
and I None
5-HIAA I Chemical
in I None
certain I None
brain I None
areas I None
, I None
but I None
to I None
a I None
much I None
lesser I None
extent I None
than I None
PCPA I Chemical
. I None
<eof> I None

<s> O None
Chronic I None
exposure I None
to I None
PCPA I Chemical
alone I None
significantly I None
decreased I None
locomotor I None
activity I None
and I None
increased I None
irritability I Disease
but I None
had I None
no I None
effect I None
on I None
sexual I None
behavior I None
, I None
partner I None
preference I None
, I None
or I None
aggression I Disease
. I None
<eof> I None

<s> O None
T I Chemical
alone I None
had I None
no I None
effect I None
on I None
locomotion I None
, I None
irritability I Disease
, I None
or I None
sexual I None
behavior I None
but I None
increased I None
partner I None
preference I None
and I None
aggression I Disease
. I None
<eof> I None

<s> O None
The I None
most I None
striking I None
effect I None
of I None
combining I None
T I Chemical
+ I None
PCPA I Chemical
was I None
a I None
significant I None
increase I None
in I None
attack I None
frequency I None
as I None
well I None
as I None
a I None
significant I None
decrease I None
in I None
the I None
latency I None
to I None
attack I None
, I None
particularly I None
following I None
physical I None
provocation I None
. I None
<eof> I None

<s> O None
Based I None
on I None
these I None
data I None
, I None
it I None
can I None
be I None
speculated I None
that I None
pubertal I None
AAS I None
users I None
with I None
low I None
central I None
5-HT I Chemical
may I None
be I None
especially I None
prone I None
to I None
exhibit I None
aggressive I Disease
behavior O Disease
. I None
<eof> I None

<s> O None
Intracavitary I None
chemotherapy I None
( I None
paclitaxel I Chemical
/ I None
carboplatin I Chemical
liquid I None
crystalline I None
cubic I None
phases I None
) I None
for I None
recurrent I None
<eof> I None

<s> O None
glioblastoma I Disease
-- I None
clinical I None
observations I None
. I None
<eof> I None

<s> O None
Human I None
malignant I None
<eof> I None

<s> O None
brain I Disease
tumors O Disease
have I None
a I None
poor I None
prognosis I None
in I None
spite I None
of I None
surgery I None
and I None
radiation I None
therapy I None
. I None
<eof> I None

<s> O None
Cubic I None
phases I None
consist I None
of I None
curved I None
biocontinuous I None
lipid I None
bilayers I None
, I None
separating I None
two I None
congruent I None
networks I None
of I None
water I None
channels I None
. I None
<eof> I None

<s> O None
Used I None
as I None
a I None
host I None
for I None
cytotoxic I None
drugs I None
, I None
the I None
gel I None
- I None
like I None
matrix I None
can I None
easily I None
be I None
applied I None
to I None
the I None
walls I None
of I None
a I None
surgical I None
resection I None
cavity I None
. I None
<eof> I None

<s> O None
For I None
human I None
glioblastoma I Disease
recurrences I None
, I None
the I None
feasibility I None
, I None
safety I None
, I None
and I None
short I None
- I None
term I None
effects I None
of I None
a I None
surgical I None
intracavitary I None
application I None
of I None
paclitaxel I Chemical
and I None
carboplatin I Chemical
encapsulated I None
by I None
liquid I None
crystalline I None
cubic I None
phases I None
are I None
examined I None
in I None
a I None
pilot I None
study I None
. I None
<eof> I None

<s> O None
A I None
total I None
of I None
12 I None
patients I None
with I None
a I None
recurrence I None
of I None
a I None
glioblastoma I Disease
multiforme I None
underwent I None
re I None
- I None
resection I None
and I None
received I None
an I None
intracavitary I None
application I None
of I None
paclitaxel I Chemical
and I None
carboplatin I Chemical
cubic I None
phases I None
in I None
different I None
dosages I None
. I None
<eof> I None

<s> O None
Six I None
of I None
the I None
patients I None
received I None
more I None
than I None
15 I None
mg I None
paclitaxel I Chemical
and I None
suffered I None
from I None
moderate I None
to I None
severe I None
brain I Disease
edema O Disease
, I None
while I None
the I None
remaining I None
patients I None
received I None
only I None
a I None
total I None
of I None
15 I None
mg I None
paclitaxel I Chemical
. I None
<eof> I None

<s> O None
In I None
the I None
latter I None
group I None
, I None
brain I Disease
edema O Disease
was I None
markedly I None
reduced I None
and I None
dealt I None
medically I None
. I None
<eof> I None

<s> O None
Intracavitary I None
chemotherapy I None
in I None
recurrent I None
<eof> I None

<s> O None
glioblastoma I Disease
using I None
cubic I None
phases I None
is I None
feasible I None
and I None
safe I None
, I None
yet I None
the I None
clinical I None
benefit I None
remains I None
to I None
be I None
examined I None
in I None
a I None
clinical I None
phase I None
II I None
study I None
. I None
<eof> I None

<s> O None
Methylphenidate I Chemical
-induced I None
obsessive I Disease
- O Disease
compulsive O Disease
symptoms O Disease
in I None
an I None
elderly I None
man I None
. I None
<eof> I None

<s> O None
An I None
82-year I None
- I None
old I None
man I None
with I None
treatment I Disease
- O Disease
resistant O Disease
depression O Disease
and I None
early I None
Alzheimer I Disease
's O Disease
disease O Disease
was I None
started I None
on I None
methylphenidate I Chemical
. I None
<eof> I None

<s> O None
Significant I None
<eof> I None

<s> O None
obsessive I Disease
- O Disease
compulsive O Disease
behavior O Disease
ensued I None
but I None
diminished I None
over I None
several I None
weeks I None
when I None
methylphenidate I Chemical
was I None
replaced I None
by I None
fluvoxamine I Chemical
. I None
<eof> I None

<s> O None
The I None
patient I None
had I None
no I None
prior I None
psychiatric I Disease
history I None
, I None
but I None
he I None
had I None
a I None
sister I None
with I None
obsessive I Disease
- O Disease
compulsive O Disease
disorder O Disease
. I None
<eof> I None

<s> O None
It I None
appears I None
that I None
methylphenidate I Chemical
precipitated I None
the I None
patient I None
's I None
pathological I None
behavior I None
. I None
<eof> I None

<s> O None
Cardiac I Disease
arrest O Disease
after I None
intravenous I None
metoclopramide I Chemical
- I None
a I None
case I None
of I None
five I None
repeated I None
injections I None
of I None
metoclopramide I Chemical
causing I None
five I None
episodes I None
of I None
cardiac I Disease
arrest O Disease
. I None
<eof> I None

<s> O None
We I None
describe I None
a I None
patient I None
where I None
intravenous I None
injection I None
of I None
metoclopramide I Chemical
was I None
immediately I None
followed I None
by I None
asystole I Disease
repeatedly I None
. I None
<eof> I None

<s> O None
The I None
patient I None
received I None
metoclopramide I Chemical
10 I None
mg I None
i.v I None
. I None
<eof> I None

<s> O None
five I None
times I None
during I None
48 I None
h. I None
After I None
interviewing I None
the I None
attending I None
nurses I None
and I None
reviewing I None
the I None
written I None
documentation I None
, I None
it I None
is I None
clear I None
that I None
every I None
administration I None
of I None
metoclopramide I Chemical
was I None
immediately I None
( I None
within I None
s I None
) I None
followed I None
by I None
asystole I Disease
. I None
<eof> I None

<s> O None
The I None
asystole I Disease
lasted I None
15 I None
- I None
30 I None
s I None
on I None
four I None
occasions I None
, I None
on I None
one I None
occasion I None
it I None
lasted I None
2 I None
min I None
. I None
<eof> I None

<s> O None
The I None
patient I None
received I None
atropine I Chemical
<eof> I None

<s> O None
0.5 I None
- I None
1 I None
mg I None
and I None
chest I None
compressions I None
, I None
before I None
sinus I None
rhythm I None
again I None
took I None
over I None
. I None
<eof> I None

<s> O None
We I None
interpret I None
this I None
as I None
episodes I None
of I None
cardiac I Disease
arrest O Disease
caused I None
by I None
metoclopramide I Chemical
. I None
<eof> I None

<s> O None
The I None
rapid I None
injection I None
via I None
the I None
central I None
venous I None
route I None
and I None
the I None
concomitant I None
tapering I None
of I None
dopamine I Chemical
infusion I None
might I None
have I None
contributed I None
in I None
precipitating I None
the I None
adverse I None
drug I None
reaction I None
. I None
<eof> I None

<s> O None
Severe I None
immune I None
hemolytic I Disease
anemia O Disease
<eof> I None

<s> O None
associated I None
with I None
prophylactic I None
use I None
of I None
cefotetan I Chemical
in I None
obstetric I None
and I None
gynecologic I None
procedures I None
. I None
<eof> I None

<s> O None
Second- I None
and I None
<eof> I None

<s> O None
third I None
- I None
generation I None
cephalosporins I Chemical
, I None
especially I None
cefotetan I Chemical
, I None
are I None
increasingly I None
associated I None
with I None
severe I None
, I None
sometimes I None
fatal I None
immune I None
hemolytic I Disease
anemia O Disease
. I None
<eof> I None

<s> O None
We I None
noticed I None
that I None
10 I None
of I None
our I None
35 I None
cases I None
of I None
cefotetan I Chemical
-induced I None
<eof> I None

<s> O None
hemolytic I Disease
anemias O Disease
were I None
in I None
patients I None
who I None
had I None
received I None
cefotetan I Chemical
prophylactically I None
for I None
obstetric I None
and I None
gynecologic I None
procedures I None
. I None
<eof> I None

<s> O None
Eight I None
of I None
these I None
cases I None
of I None
severe I None
immune I None
hemolytic I Disease
anemia O Disease
are I None
described I None
. I None
<eof> I None

<s> O None
Cauda I Disease
equina O Disease
syndrome O Disease
after I None
spinal I None
anaesthesia I None
with I None
hyperbaric I None
5 I None
% I None
lignocaine I Chemical
: I None
a I None
review I None
of I None
six I None
cases I None
of I None
cauda I Disease
equina O Disease
syndrome O Disease
reported I None
to I None
the I None
Swedish I None
Pharmaceutical I None
Insurance I None
1993 I None
- I None
1997 I None
. I None
<eof> I None

<s> O None
Six I None
cases I None
of I None
cauda I Disease
equina O Disease
syndrome O Disease
with I None
varying I None
severity I None
were I None
reported I None
to I None
the I None
Swedish I None
Pharmaceutical I None
Insurance I None
during I None
the I None
period I None
1993 I None
- I None
1997 I None
. I None
<eof> I None

<s> O None
All I None
were I None
associated I None
with I None
spinal I None
anaesthesia I None
using I None
hyperbaric I None
5 I None
% I None
lignocaine I Chemical
. I None
<eof> I None

<s> O None
Five I None
cases I None
had I None
single I None
- I None
shot I None
spinal I None
anaesthesia I None
and I None
one I None
had I None
a I None
repeat I None
spinal I None
anaesthetic I None
due I None
to I None
inadequate I None
block I None
. I None
<eof> I None

<s> O None
The I None
dose I None
of I None
hyperbaric I None
5 I None
% I None
lignocaine I Chemical
<eof> I None

<s> O None
administered I None
ranged I None
from I None
60 I None
to I None
120 I None
mg I None
. I None
<eof> I None

<s> O None
Three I None
of I None
the I None
cases I None
were I None
most I None
likely I None
caused I None
by I None
direct I None
neurotoxicity I Disease
of I None
hyperbaric I None
5 I None
% I None
lignocaine I Chemical
. I None
<eof> I None

<s> O None
In I None
the I None
other I None
3 I None
cases I None
, I None
direct I None
neurotoxicity I Disease
was I None
also I None
probable I None
, I None
but I None
unfortunately I None
radiological I None
investigations I None
were I None
not I None
done I None
to I None
definitely I None
exclude I None
a I None
compressive I None
aetiology I None
. I None
<eof> I None

<s> O None
All I None
cases I None
sustained I None
permanent I None
neurological I Disease
deficits O Disease
. I None
<eof> I None

<s> O None
We I None
recommend I None
that I None
hyperbaric I None
lignocaine I Chemical
should I None
be I None
administered I None
in I None
concentrations I None
not I None
greater I None
than I None
2 I None
% I None
and I None
at I None
a I None
total I None
dose I None
preferably I None
not I None
exceeding I None
60 I None
mg I None
. I None
<eof> I None

<s> O None
Cortical I None
motor I None
overactivation I None
in I None
parkinsonian I Disease
patients I None
with I None
L I Chemical
- O Chemical
dopa O Chemical
-induced I None
peak I None
- I None
dose I None
dyskinesia I Disease
. I None
<eof> I None

<s> O None
We I None
have I None
studied I None
the I None
regional I None
cerebral I None
blood I None
flow I None
( I None
rCBF I None
) I None
changes I None
induced I None
by I None
the I None
execution I None
of I None
a I None
finger I None
- I None
to I None
- I None
thumb I None
opposition I None
motor I None
task I None
in I None
the I None
supplementary I None
and I None
primary I None
motor I None
cortex I None
of I None
two I None
groups I None
of I None
parkinsonian I Disease
patients I None
on I None
L I Chemical
- O Chemical
dopa O Chemical
medication I None
, I None
the I None
first I None
one I None
without I None
<eof> I None

<s> O None
L I Chemical
- O Chemical
dopa O Chemical
induced I None
dyskinesia I Disease
<eof> I None

<s> O None
( I None
n I None
= I None
23 I None
) I None
and I None
the I None
other I None
with I None
moderate I None
peak I None
- I None
dose I None
dyskinesia I Disease
<eof> I None

<s> O None
( I None
n I None
= I None
15 I None
) I None
, I None
and I None
of I None
a I None
group I None
of I None
14 I None
normal I None
subjects I None
. I None
<eof> I None

<s> O None
Single I None
photon I None
emission I None
tomography I None
with I None
i.v I None
. I None
<eof> I None

<s> O None
133Xe I None
was I None
used I None
to I None
measure I None
the I None
rCBF I None
changes I None
. I None
<eof> I None

<s> O None
The I None
dyskinetic I Disease
parkinsonian I Disease
patients I None
exhibited I None
a I None
pattern I None
of I None
response I None
which I None
was I None
markedly I None
different I None
from I None
those I None
of I None
the I None
normal I None
subjects I None
and I None
non- I None
dyskinetic I Disease
parkinsonian I Disease
patients I None
, I None
with I None
a I None
significant I None
overactivation I None
in I None
the I None
supplementary I None
motor I None
area I None
and I None
the I None
ipsi- I None
and I None
contralateral I None
primary I None
motor I None
areas I None
. I None
<eof> I None

<s> O None
These I None
results I None
are I None
compatible I None
with I None
the I None
hypothesis I None
that I None
an I None
hyperkinetic I Disease
abnormal I Disease
involuntary O Disease
movement O Disease
, I None
like I None
L I Chemical
- O Chemical
dopa O Chemical
-induced I None
peak I None
dose I None
dyskinesia I Disease
, I None
is I None
due I None
to I None
a I None
disinhibition I None
of I None
the I None
primary I None
and I None
associated I None
motor I None
cortex I None
secondary I None
to I None
an I None
excessive I None
outflow I None
of I None
the I None
pallidothalamocortical I None
motor I None
loop I None
. I None
<eof> I None

<s> O None
Dexamethasone I Chemical
-induced I None
ocular I Disease
hypertension O Disease
in I None
perfusion I None
- I None
cultured I None
human I None
eyes I None
. I None
<eof> I None

<s> O None
PURPOSE I None
: I None
<eof> I None

<s> O None
Glucocorticoid I None
administration I None
can I None
lead I None
to I None
the I None
development I None
of I None
ocular I Disease
hypertension O Disease
and I None
corticosteroid I Disease
glaucoma O Disease
in I None
a I None
subset I None
of I None
the I None
population I None
through I None
a I None
decrease I None
in I None
the I None
aqueous I None
humor I None
outflow I None
facility I None
. I None
<eof> I None

<s> O None
The I None
purpose I None
of I None
this I None
study I None
was I None
to I None
determine I None
whether I None
glucocorticoid I None
treatment I None
can I None
directly I None
affect I None
the I None
outflow I None
facility I None
of I None
isolated I None
, I None
perfusion I None
- I None
cultured I None
human I None
eyes I None
. I None
<eof> I None

<s> O None
METHODS I None
: I None
<eof> I None

<s> O None
The I None
anterior I None
segments I None
of I None
human I None
donor I None
eyes I None
from I None
regional I None
eye I None
banks I None
were I None
placed I None
in I None
a I None
constant I None
flow I None
, I None
variable I None
pressure I None
perfusion I None
culture I None
system I None
. I None
<eof> I None

<s> O None
Paired I None
eyes I None
were I None
perfused I None
in I None
serum I None
- I None
free I None
media I None
with I None
or I None
without I None
10(-7 I None
) I None
M I None
dexamethasone I Chemical
for I None
12 I None
days I None
. I None
<eof> I None

<s> O None
Intraocular I None
pressure I None
was I None
monitored I None
daily I None
. I None
<eof> I None

<s> O None
After I None
incubation I None
, I None
the I None
eyes I None
were I None
morphologically I None
characterized I None
by I None
light I None
microscopy I None
, I None
transmission I None
and I None
scanning I None
electron I None
microscopy I None
, I None
and I None
scanning I None
laser I None
confocal I None
microscopy I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
A I None
significant I None
increase I None
in I None
intraocular I None
pressure I None
developed I None
in I None
13 I None
of I None
the I None
44 I None
pairs I None
of I None
eyes I None
perfused I None
with I None
dexamethasone I Chemical
with I None
an I None
average I None
pressure I None
rise I None
of I None
17.5 I None
+ I None
/- I None
<eof> I None

<s> O None
3.8 I None
mm I None
Hg I None
after I None
12 I None
days I None
of I None
dexamethasone I Chemical
exposure I None
. I None
<eof> I None

<s> O None
The I None
contralateral I None
control I None
eyes I None
, I None
which I None
did I None
not I None
receive I None
dexamethasone I Chemical
, I None
maintained I None
a I None
stable I None
intraocular I None
pressure I None
during I None
the I None
same I None
period I None
. I None
<eof> I None

<s> O None
The I None
outflow I None
pathway I None
of I None
the I None
untreated I None
eyes I None
appeared I None
morphologically I None
normal I None
. I None
<eof> I None

<s> O None
In I None
contrast I None
, I None
the I None
dexamethasone I Chemical
-treated I None
hypertensive I Disease
eyes O Disease
had I None
thickened I None
trabecular I None
beams I None
, I None
decreased I None
intertrabecular I None
spaces I None
, I None
thickened I None
juxtacanalicular I None
tissue I None
, I None
activated I None
trabecular I None
meshwork I None
cells I None
, I None
and I None
increased I None
amounts I None
of I None
amorphogranular I None
extracellular I None
material I None
, I None
especially I None
in I None
the I None
juxtacanalicular I None
tissue I None
and I None
beneath I None
the I None
endothelial I None
lining I None
of I None
the I None
canal I None
of I None
Schlemm I None
. I None
<eof> I None

<s> O None
The I None
dexamethasone I Chemical
-treated I None
nonresponder I None
eyes I None
appeared I None
to I None
be I None
morphologically I None
similar I None
to I None
the I None
untreated I None
eyes I None
, I None
although I None
several I None
subtle I None
dexamethasone I Chemical
-induced I None
morphologic I None
changes I None
were I None
evident I None
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
<eof> I None

<s> O None
Dexamethasone I Chemical
treatment I None
of I None
isolated I None
, I None
perfusion I None
- I None
cultured I None
human I None
eyes I None
led I None
to I None
the I None
generation I None
of I None
ocular I Disease
hypertension O Disease
in I None
approximately I None
30 I None
% I None
of I None
the I None
dexamethasone I Chemical
-treated I None
eyes I None
. I None
<eof> I None

<s> O None
Steroid I Chemical
treatment I None
resulted I None
in I None
morphologic I None
changes I None
in I None
the I None
trabecular I None
meshwork I None
similar I None
to I None
those I None
reported I None
for I None
corticosteroid I Disease
glaucoma O Disease
and I None
open I Disease
angle O Disease
glaucoma O Disease
. I None
<eof> I None

<s> O None
This I None
system I None
may I None
provide I None
an I None
acute I None
model I None
in I None
which I None
to I None
study I None
the I None
pathogenic I None
mechanisms I None
involved I None
in I None
steroid I Disease
glaucoma O Disease
and I None
primary I Disease
open O Disease
angle O Disease
glaucoma O Disease
. I None
<eof> I None

<s> O None
Cognitive I Disease
deterioration O Disease
from I None
long I None
- I None
term I None
abuse I None
of I None
dextromethorphan I Chemical
: I None
a I None
case I None
report I None
. I None
<eof> I None

<s> O None
Dextromethorphan I Chemical
( I None
DM I Chemical
) I None
, I None
the I None
dextrorotatory I None
isomer I None
of I None
3-hydroxy I Chemical
- O Chemical
N O Chemical
- O Chemical
methylmorphinan O Chemical
, I None
is I None
the I None
main I None
ingredient I None
in I None
a I None
number I None
of I None
widely I None
available I None
, I None
over I None
- I None
the I None
- I None
counter I None
antitussives I None
. I None
<eof> I None

<s> O None
Initial I None
studies I None
( I None
Bornstein I None
1968 I None
) I None
showed I None
that I None
it I None
possessed I None
no I None
respiratory I None
suppressant I None
effects I None
and I None
no I None
addiction I None
liability I None
. I None
<eof> I None

<s> O None
Subsequently I None
, I None
however I None
, I None
several I None
articles I None
reporting I None
abuse I None
of I None
this I None
drug I None
have I None
appeared I None
in I None
the I None
literature I None
. I None
<eof> I None

<s> O None
The I None
drug I None
is I None
known I None
to I None
cause I None
a I None
variety I None
of I None
acute I None
toxic I None
effects I None
, I None
ranging I None
from I None
nausea I Disease
, I None
restlessness I Disease
, I None
insomnia I Disease
, I None
ataxia I Disease
, I None
slurred I None
speech I None
and I None
nystagmus I Disease
to I None
mood I None
changes I None
, I None
perceptual I None
alterations I None
, I None
inattention I None
, I None
disorientation I None
and I None
aggressive I Disease
behavior O Disease
( I None
Rammer I None
et I None
al I None
1988 I None
; I None
Katona I None
and I None
Watson I None
1986 I None
; I None
Isbell I None
and I None
Fraser I None
1953 I None
; I None
Devlin I None
et I None
al I None
1985 I None
; I None
McCarthy I None
1971 I None
; I None
Dodds I None
and I None
Revai I None
1967 I None
; I None
Degkwitz I None
1964 I None
; I None
Hildebrand I None
et I None
al I None
1989 I None
) I None
. I None
<eof> I None

<s> O None
There I None
have I None
also I None
been I None
two I None
reported I None
fatalities I None
from I None
DM I Chemical
<eof> I None

<s> O None
overdoses I None
( I None
Fleming I None
1986 I None
) I None
. I None
<eof> I None

<s> O None
However I None
, I None
there I None
are I None
no I None
reports I None
describing I None
the I None
effects I None
of I None
chronic I None
abuse I None
. I None
<eof> I None

<s> O None
This I None
report I None
describes I None
a I None
case I None
of I None
cognitive I Disease
deterioration O Disease
resulting I None
from I None
prolonged I None
use I None
of I None
DM I Chemical
. I None
<eof> I None

<s> O None
Long I None
- I None
term I None
lithium I Chemical
treatment I None
and I None
the I None
kidney I None
. I None
<eof> I None

<s> O None
Interim I None
report I None
on I None
fifty I None
patients I None
. I None
<eof> I None

<s> O None
This I None
is I None
a I None
report I None
on I None
the I None
first I None
part I None
of I None
our I None
study I None
of I None
the I None
effects I None
of I None
long I None
- I None
term I None
lithium I Chemical
treatment I None
on I None
the I None
kidney I None
. I None
<eof> I None

<s> O None
Creatinine I Chemical
clearance I None
, I None
maximum I None
urinary I None
osmolality I None
and I None
24 I None
hour I None
urine I None
volume I None
have I None
been I None
tested I None
in I None
50 I None
affectively I None
ill I None
patients I None
who I None
have I None
been I None
on I None
long I None
- I None
term I None
lithium I Chemical
for I None
more I None
than I None
one I None
year I None
. I None
<eof> I None

<s> O None
These I None
findings I None
have I None
been I None
compared I None
with I None
norms I None
and I None
with I None
values I None
of I None
the I None
same I None
tests I None
from I None
screening I None
prior I None
to I None
lithium I Chemical
, I None
available I None
for I None
most I None
of I None
our I None
patients I None
. I None
<eof> I None

<s> O None
No I None
evidence I None
was I None
found I None
for I None
any I None
reduction I None
of I None
glomerular I None
filtration I None
during I None
lithium I Chemical
treatment I None
. I None
<eof> I None

<s> O None
Low I None
clearance I None
values I None
found I None
in I None
several I None
patients I None
could I None
be I None
accounted I None
for I None
by I None
their I None
age I None
and I None
their I None
pre- I None
lithium I Chemical
values I None
. I None
<eof> I None

<s> O None
Urinary I None
concentration I None
defect I None
appeared I None
frequent I None
but I None
the I None
extent I None
of I None
the I None
impairment I None
is I None
difficult I None
to I None
assess I None
because I None
of I None
the I None
uncertainty I None
about I None
the I None
norms I None
applicable I None
to I None
this I None
group I None
of I None
patients I None
. I None
<eof> I None

<s> O None
The I None
concentration I None
defect I None
appeared I None
reversible I None
, I None
at I None
least I None
in I None
part I None
. I None
<eof> I None

<s> O None
Polyuria I Disease
above I None
<eof> I None

<s> O None
3 I None
litres/24 I None
<eof> I None

<s> O None
hours I None
was I None
found I None
in I None
10 I None
% I None
of I None
patients I None
. I None
<eof> I None

<s> O None
An I None
attempt I None
is I None
made I None
to I None
draw I None
practical I None
conclusions I None
from I None
the I None
preliminary I None
findings I None
. I None
<eof> I None

<s> O None
Complete I None
<eof> I None

<s> O None
heart I Disease
block O Disease
following I None
a I None
single I None
dose I None
of I None
trazodone I Chemical
. I None
<eof> I None

<s> O None
Forty I None
minutes I None
after I None
receiving I None
a I None
single I None
starting I None
dose I None
of I None
trazodone I Chemical
, I None
a I None
patient I None
developed I None
complete I None
heart I Disease
block O Disease
. I None
<eof> I None

<s> O None
The I None
case I None
illustrates I None
that I None
, I None
despite I None
the I None
results I None
of I None
earlier I None
studies I None
, I None
trazodone I Chemical
's I None
effect I None
on I None
cardiac I None
conduction I None
may I None
be I None
severe I None
in I None
individuals I None
at I None
risk I None
for I None
conduction I None
delay I None
. I None
<eof> I None

<s> O None
Quinidine I Chemical
phenylethylbarbiturate O Chemical
-induced I None
fulminant I None
hepatitis I Disease
in I None
a I None
pregnant I None
woman I None
. I None
<eof> I None

<s> O None
A I None
case I None
report I None
. I None
<eof> I None

<s> O None
We I None
report I None
the I None
case I None
of I None
a I None
19-year I None
- I None
old I None
Laotian I None
patient I None
affected I None
by I None
fulminant I None
hepatitis I Disease
during I None
the I None
third I None
trimester I None
of I None
her I None
pregnancy I None
after I None
a I None
1-month I None
administration I None
of I None
quinidine I Chemical
phenylethylbarbiturate O Chemical
. I None
<eof> I None

<s> O None
After I None
delivery I None
, I None
the I None
patient I None
underwent I None
orthotopic I None
liver I None
transplantation I None
. I None
<eof> I None

<s> O None
The I None
patient I None
was I None
in I None
good I None
condition I None
16 I None
months I None
after I None
liver I None
transplantation I None
. I None
<eof> I None

<s> O None
Quinidine I Chemical
itself I None
or I None
phenylethylbarbiturate I Chemical
may I None
be I None
responsible I None
for I None
fulminant I None
hepatitis I Disease
in I None
this I None
patient I None
. I None
<eof> I None

<s> O None
The I None
epidemiology I None
of I None
the I None
acute I None
flank I Disease
pain O Disease
syndrome I None
from I None
suprofen I Chemical
. I None
<eof> I None

<s> O None
Suprofen I Chemical
, I None
a I None
new I None
nonsteroidal I None
anti I None
- I None
inflammatory I None
drug I None
, I None
was I None
marketed I None
in I None
early I None
1986 I None
as I None
an I None
analgesic I None
agent I None
. I None
<eof> I None

<s> O None
Until I None
physicians I None
began I None
reporting I None
an I None
unusual I None
acute I None
flank I Disease
pain O Disease
syndrome I None
to I None
the I None
spontaneous I None
reporting I None
system I None
, I None
700,000 I None
persons I None
used I None
the I None
drug I None
in I None
the I None
United I None
States I None
. I None
<eof> I None

<s> O None
Through I None
August I None
1986 I None
, I None
a I None
total I None
of I None
163 I None
cases I None
of I None
this I None
syndrome I None
were I None
reported I None
. I None
<eof> I None

<s> O None
To I None
elucidate I None
the I None
epidemiology I None
of I None
the I None
syndrome I None
, I None
a I None
case I None
- I None
control I None
study I None
was I None
performed I None
, I None
comparing I None
62 I None
of I None
the I None
case I None
patients I None
who I None
had I None
been I None
reported I None
to I None
the I None
spontaneous I None
reporting I None
system I None
to I None
185 I None
suprofen I Chemical
-exposed I None
control I None
subjects I None
who I None
did I None
not I None
have I None
the I None
syndrome I None
. I None
<eof> I None

<s> O None
Case I None
patients I None
were I None
more I None
likely I None
to I None
be I None
men I None
( I None
odds I None
ratio I None
, I None
3.8 I None
; I None
95 I None
% I None
confidence I None
interval I None
, I None
1.2 I None
- I None
12.1 I None
) I None
, I None
suffer I None
from I None
hay I Disease
fever O Disease
and I None
asthma I Disease
<eof> I None

<s> O None
( I None
odds I None
ratio I None
, I None
3.4 I None
; I None
95 I None
% I None
confidence I None
interval I None
, I None
1.0 I None
- I None
11.9 I None
) I None
; I None
to I None
participate I None
in I None
regular I None
exercise I None
( I None
odds I None
ratio I None
, I None
5.9 I None
; I None
95 I None
% I None
confidence I None
interval I None
, I None
1.1 I None
- I None
30.7 I None
) I None
, I None
especially I None
in I None
the I None
use I None
of I None
Nautilus I None
equipment I None
( I None
p I None
= I None
0.02 I None
) I None
; I None
and I None
to I None
use I None
alcohol I Chemical
<eof> I None

<s> O None
( I None
odds I None
ratio I None
, I None
4.4 I None
; I None
95 I None
% I None
confidence I None
interval I None
, I None
1.1 I None
- I None
17.5 I None
) I None
. I None
<eof> I None

<s> O None
Possible I None
risk I None
factors I None
included I None
young I None
age I None
, I None
concurrent I None
use I None
of I None
other I None
analgesic I None
agents I None
( I None
especially I None
ibuprofen I Chemical
) I None
, I None
preexisting I None
renal I Disease
disease O Disease
, I None
a I None
history I None
of I None
kidney I Disease
stones O Disease
, I None
a I None
history I None
of I None
gout I Disease
, I None
a I None
recent I None
increase I None
in I None
activity I None
, I None
a I None
recent I None
increase I None
in I None
sun I None
exposure I None
, I None
and I None
residence I None
in I None
the I None
Sunbelt I None
. I None
<eof> I None

<s> O None
These I None
were I None
findings I None
that I None
were I None
suggestive I None
but I None
did I None
not I None
reach I None
conventional I None
statistical I None
significance I None
. I None
<eof> I None

<s> O None
These I None
findings I None
are I None
consistent I None
with I None
the I None
postulated I None
mechanism I None
for I None
this I None
unusual I None
syndrome I None
: I None
acute I None
diffuse I None
crystallization I None
of I None
uric I Chemical
acid O Chemical
in I None
renal I None
tubules I None
. I None
<eof> I None

<s> O None
Hemolytic I Disease
- O Disease
uremic O Disease
syndrome O Disease
associated I None
with I None
ingestion I None
of I None
quinine I Chemical
. I None
<eof> I None

<s> O None
Hemolytic I Disease
- O Disease
uremic O Disease
syndrome O Disease
following I None
quinine I Chemical
ingestion I None
is I None
a I None
newly I None
described I None
phenomenon I None
, I None
with I None
just I None
two I None
previous I None
descriptions I None
of I None
4 I None
cases I None
in I None
the I None
literature I None
. I None
<eof> I None

<s> O None
We I None
describe I None
a I None
5th I None
case I None
. I None
<eof> I None

<s> O None
The I None
reaction I None
may I None
be I None
mediated I None
by I None
the I None
presence I None
of I None
antibodies I None
reactive I None
against I None
platelets I None
in I None
the I None
presence I None
of I None
quinine I Chemical
. I None
<eof> I None

<s> O None
Treatment I None
has I None
included I None
use I None
of I None
plasma I None
exchange I None
, I None
prednisone I Chemical
, I None
aspirin I Chemical
, I None
and I None
dipyridamole I Chemical
. I None
<eof> I None

<s> O None
The I None
patients I None
have I None
all I None
regained I None
some I None
degree I None
of I None
renal I None
function I None
. I None
<eof> I None

<s> O None
However I None
, I None
it I None
is I None
unclear I None
whether I None
pharmacological I None
treatment I None
or I None
spontaneous I None
resolution I None
is I None
responsible I None
for I None
the I None
improvement I None
. I None
<eof> I None

<s> O None
Quinine I Chemical
-associated I None
<eof> I None

<s> O None
hemolytic I Disease
- O Disease
uremic O Disease
syndrome O Disease
probably I None
occurs I None
more I None
often I None
than I None
is I None
recognized I None
. I None
<eof> I None

<s> O None
It I None
is I None
important I None
to I None
recognize I None
this I None
reaction I None
when I None
it I None
occurs I None
and I None
to I None
avoid I None
further I None
quinine I Chemical
exposure I None
, I None
since I None
the I None
reaction I None
seems I None
to I None
be I None
recurrent I None
. I None
<eof> I None

<s> O None
Pyeloureteral I None
filling I None
defects I None
associated I None
with I None
systemic I None
anticoagulation I None
: I None
a I None
case I None
report I None
. I None
<eof> I None

<s> O None
The I None
etiology I None
of I None
pyeloureteritis I Disease
cystica O Disease
has I None
long I None
been I None
attributed I None
to I None
chronic I None
infection I Disease
and I None
inflammation I Disease
. I None
<eof> I None

<s> O None
A I None
case I None
is I None
presented I None
that I None
is I None
unique I None
in I None
that I None
the I None
acute I None
onset I None
and I None
the I None
rapid I None
resolution I None
of I None
pyeloureteral I None
filling I None
defects I None
in I None
this I None
patient I None
were I None
documented I None
by I None
radiography I None
. I None
<eof> I None

<s> O None
There I None
is I None
no I None
evidence I None
of I None
antecedent I None
or I None
concurrent I None
infection I Disease
in I None
this I None
patient I None
. I None
<eof> I None

<s> O None
The I None
disease I None
occurred I None
subsequent I None
to I None
the I None
initiation I None
of I None
heparin I Chemical
therapy I None
for I None
suspected I None
pelvic I None
thrombophlebitis I Disease
and I None
cleared I None
rapidly I None
subsequent I None
to I None
its I None
discontinuation I None
. I None
<eof> I None

<s> O None
The I None
rate I None
of I None
resolution I None
of I None
the I None
radiographic I None
findings I None
may I None
be I None
helpful I None
in I None
distinguishing I None
between I None
true I None
pyeloureteritis I Disease
cystica O Disease
and I None
submucosal I Disease
hemorrhage O Disease
. I None
<eof> I None

<s> O None
Changes I None
in I None
peroxisomes I None
in I None
preneoplastic I None
liver I None
and I None
hepatoma I Disease
of I None
mice I None
induced I None
by I None
alpha I Chemical
- O Chemical
benzene O Chemical
hexachloride O Chemical
. I None
<eof> I None

<s> O None
Peroxisomes I None
in I None
hepatomas I Disease
and I None
hyperplastic I None
preneoplastic I None
liver I Disease
lesions O Disease
induced I None
in I None
mice I None
by I None
500 I None
ppm I None
<eof> I None

<s> O None
alpha I Chemical
- O Chemical
benzene O Chemical
hexachloride O Chemical
were I None
examined I None
histochemically I None
and I None
electron I None
microscopically I None
. I None
<eof> I None

<s> O None
Although I None
most I None
of I None
the I None
hepatomas I Disease
were I None
well I None
- I None
differentiated I None
tumors I Disease
and I None
contained I None
a I None
considerable I None
number I None
of I None
peroxisomes I None
, I None
the I None
tumor I Disease
cells I None
did I None
not I None
respond I None
to I None
ethyl I Chemical
- O Chemical
alpha O Chemical
- O Chemical
p O Chemical
- O Chemical
chlorophenoxyisobutyrate O Chemical
with I None
proliferation I None
of I None
peroxisomes I None
. I None
<eof> I None

<s> O None
At I None
the I None
16th I None
week I None
of I None
carcinogen I None
feeding I None
, I None
hyperplastic I None
nodules I None
appeared I None
and I None
advanced I None
to I None
further I None
stages I None
. I None
<eof> I None

<s> O None
A I None
majority I None
of I None
the I None
nodules I None
showed I None
a I None
considerable I None
number I None
of I None
peroxisomes I None
and I None
the I None
inductive I None
proliferation I None
of I None
peroxisomes I None
. I None
<eof> I None

<s> O None
Within I None
the I None
nodules I None
, I None
foci I None
of I None
proliferation I None
of I None
the I None
cells I None
that I None
showed I None
no I None
inducibility I None
of I None
proliferation I None
of I None
peroxisomes I None
appeared I None
. I None
<eof> I None

<s> O None
These I None
cells I None
proliferated I None
further I None
, I None
replacing I None
the I None
most I None
part I None
of I None
the I None
nodules I None
, I None
and I None
with I None
this I None
process I None
hepatomas I Disease
appeared I None
to I None
have I None
been I None
formed I None
. I None
<eof> I None

<s> O None
No I None
abnormal I None
matrical I None
inclusions I None
of I None
peroxisomes I None
were I None
formed I None
in I None
the I None
cells I None
of I None
hyperplastic I None
nodules I None
by I None
ethyl I Chemical
- O Chemical
alpha O Chemical
- O Chemical
p O Chemical
- O Chemical
chlorophenoxyisobutyrate O Chemical
unlike I None
in I None
the I None
case I None
of I None
rats I None
. I None
<eof> I None

<s> O None
Quinidine I Chemical
hepatitis I Disease
. I None
<eof> I None

<s> O None
Long I None
- I None
term I None
administration I None
of I None
quinidine I Chemical
was I None
associated I None
with I None
persistent I None
elevation I None
of I None
serum I None
concentrations I None
of I None
SGOT I None
, I None
lactic I Chemical
acid O Chemical
dehydrogenase I None
, I None
and I None
alkaline I None
phosphatase I None
. I None
<eof> I None

<s> O None
Liver I None
biopsy I None
showed I None
active I None
hepatitis I Disease
. I None
<eof> I None

<s> O None
Discontinuance I None
of I None
quinidine I Chemical
therapy I None
led I None
to I None
normalization I None
of I None
liver I None
function I None
tests I None
. I None
<eof> I None

<s> O None
A I None
challenge I None
dose I None
of I None
<eof> I None

<s> O None
quinidine I Chemical
caused I None
clinical I None
symptoms I None
and I None
abrupt I None
elevation I None
of I None
SGOT I None
, I None
alkaline I None
phosphatase I None
, I None
and I None
lactic I Chemical
acid O Chemical
dehydrogenase I None
values I None
. I None
<eof> I None

<s> O None
We I None
concluded I None
that I None
this I None
patient I None
had I None
quinidine I Chemical
hepatotoxicity I Disease
and I None
believe I None
that I None
this I None
is I None
the I None
first I None
case I None
reported I None
with I None
liver I None
biopsy I None
documentation I None
. I None
<eof> I None

<s> O None
This I None
report I None
also I None
suggests I None
that I None
, I None
even I None
after I None
long I None
- I None
term I None
administration I None
, I None
the I None
hepatic I Disease
toxicity O Disease
is I None
reversible I None
. I None
<eof> I None

<s> O None
Cholesteryl I Chemical
hemisuccinate O Chemical
treatment I None
protects I None
rodents I None
from I None
the I None
toxic I None
effects I None
of I None
acetaminophen I Chemical
, I None
adriamycin I Chemical
, I None
carbon I Chemical
tetrachloride O Chemical
, I None
chloroform I Chemical
and I None
galactosamine I Chemical
. I None
<eof> I None

<s> O None
In I None
addition I None
to I None
its I None
use I None
as I None
a I None
stabilizer I None
/ I None
rigidifier I None
of I None
membranes I None
, I None
cholesteryl I Chemical
hemisuccinate O Chemical
, I None
tris I Chemical
salt O Chemical
<eof> I None

<s> O None
( I None
CS I Chemical
) I None
administration I None
has I None
also I None
been I None
shown I None
to I None
protect I None
rats I None
from I None
the I None
hepatotoxic I Disease
effects I None
of I None
carbon I Chemical
tetrachloride O Chemical
<eof> I None

<s> O None
( I None
CCl4 I Chemical
) I None
. I None
<eof> I None

<s> O None
To I None
further I None
our I None
understanding I None
of I None
the I None
mechanism I None
of I None
CS I Chemical
cytoprotection I None
, I None
we I None
examined I None
in I None
rats I None
and I None
mice I None
the I None
protective I None
abilities I None
of I None
CS I Chemical
and I None
the I None
non I None
- I None
hydrolyzable I None
ether I None
form I None
of I None
CS I Chemical
, I None
gamma I Chemical
- O Chemical
cholesteryloxybutyric O Chemical
acid O Chemical
, I None
tris I Chemical
salt O Chemical
<eof> I None

<s> O None
( I None
CSE I Chemical
) I None
against I None
acetaminophen I Chemical
- I None
, I None
adriamycin I Chemical
- I None
, I None
carbon I Chemical
tetrachloride O Chemical
- I None
, I None
chloroform I Chemical
- I None
and I None
galactosamine I Chemical
-induced I None
toxicity I Disease
. I None
<eof> I None

<s> O None
The I None
results I None
of I None
these I None
studies I None
demonstrated I None
that I None
CS I Chemical
-mediated I None
protection I None
is I None
not I None
selective I None
for I None
a I None
particular I None
species I None
, I None
organ I None
system I None
or I None
toxic I None
chemical I None
. I None
<eof> I None

<s> O None
A I None
24-h I None
pretreatment I None
of I None
both I None
rats I None
and I None
mice I None
with I None
a I None
single I None
dose I None
of I None
CS I Chemical
<eof> I None

<s> O None
( I None
100mg I None
/ I None
kg I None
, I None
i.p I None
. I None
) I None
, I None
resulted I None
in I None
significant I None
protection I None
against I None
the I None
hepatotoxic I Disease
effects I None
of I None
CCl4 I Chemical
, I None
CHCl3 I Chemical
, I None
acetaminophen I Chemical
and I None
galactosamine I Chemical
and I None
against I None
the I None
lethal I None
( I None
and I None
presumably I None
cardiotoxic I Disease
) I None
effect I None
of I None
adriamycin I Chemical
administration I None
. I None
<eof> I None

<s> O None
Maximal I None
CS I Chemical
<eof> I None

<s> O None
-mediated I None
protection I None
was I None
observed I None
in I None
experimental I None
animals I None
pretreated I None
24 I None
h I None
prior I None
to I None
the I None
toxic I None
insult I None
. I None
<eof> I None

<s> O None
These I None
data I None
suggest I None
that I None
CS I Chemical
intervenes I None
in I None
a I None
critical I None
cellular I None
event I None
that I None
is I None
an I None
important I None
common I None
pathway I None
to I None
toxic I None
cell I None
death I None
. I None
<eof> I None

<s> O None
The I None
mechanism I None
of I None
CS I Chemical
protection I None
does I None
not I None
appear I None
to I None
be I None
dependent I None
on I None
the I None
inhibition I None
of I None
chemical I None
bioactivation I None
to I None
a I None
toxic I None
reactive I None
intermediate I None
( I None
in I None
light I None
of I None
the I None
protection I None
observed I None
against I None
galactosamine I Chemical
hepatotoxicity I Disease
) I None
. I None
<eof> I None

<s> O None
However I None
, I None
based I None
on I None
the I None
data I None
presented I None
, I None
we I None
can I None
not I None
exclude I None
the I None
possibility I None
that I None
CS I Chemical
administration I None
inhibits I None
chemical I None
bioactivation I None
. I None
<eof> I None

<s> O None
Our I None
findings I None
do I None
suggest I None
that I None
CS I Chemical
-mediated I None
protection I None
is I None
dependent I None
on I None
the I None
action I None
of I None
the I None
intact I None
anionic I None
CS I Chemical
molecule I None
( I None
non I None
- I None
hydrolyzable I None
CSE I Chemical
was I None
as I None
protective I None
as I None
CS I Chemical
) I None
, I None
whose I None
mechanism I None
has I None
yet I None
to I None
be I None
defined I None
. I None
<eof> I None

<s> O None
DSMM I None
XI I None
study I None
: I None
dose I None
definition I None
for I None
intravenous I None
cyclophosphamide I Chemical
in I None
combination I None
with I None
<eof> I None

<s> O None
bortezomib I Chemical
/ I None
dexamethasone I Chemical
for I None
remission I None
induction I None
in I None
patients I None
with I None
newly I None
diagnosed I None
myeloma I Disease
. I None
<eof> I None

<s> O None
A I None
clinical I None
trial I None
was I None
initiated I None
to I None
evaluate I None
the I None
recommended I None
dose I None
of I None
cyclophosphamide I Chemical
in I None
combination I None
with I None
bortezomib I Chemical
and I None
dexamethasone I Chemical
as I None
induction I None
treatment I None
before I None
stem I None
cell I None
transplantation I None
for I None
younger I None
patients I None
with I None
newly I None
diagnosed I None
multiple I Disease
myeloma O Disease
<eof> I None

<s> O None
( I None
MM I Disease
) I None
. I None
<eof> I None

<s> O None
Thirty I None
patients I None
were I None
treated I None
with I None
three I None
21-day I None
cycles I None
of I None
bortezomib I Chemical
1.3 I None
mg I None
/ I None
m(2 I None
) I None
on I None
days I None
1 I None
, I None
4 I None
, I None
8 I None
, I None
and I None
11 I None
plus I None
<eof> I None

<s> O None
dexamethasone I Chemical
40 I None
mg I None
on I None
the I None
day I None
of I None
bortezomib I Chemical
injection I None
and I None
the I None
day I None
after I None
plus I None
cyclophosphamide I Chemical
at I None
900 I None
, I None
1,200 I None
, I None
or I None
1,500 I None
mg I None
/ I None
m(2 I None
) I None
on I None
day I None
1 I None
. I None
<eof> I None

<s> O None
The I None
maximum I None
tolerated I None
dose I None
of I None
cyclophosphamide I Chemical
was I None
defined I None
as I None
900 I None
mg I None
/ I None
m(2 I None
) I None
. I None
<eof> I None

<s> O None
At I None
this I None
dose I None
level I None
, I None
92 I None
% I None
of I None
patients I None
achieved I None
at I None
least I None
a I None
partial I None
response I None
. I None
<eof> I None

<s> O None
The I None
overall I None
response I None
rate I None
[ I None
complete I None
response I None
( I None
CR I None
) I None
plus I None
partial I None
response I None
( I None
PR I None
) I None
] I None
across I None
all I None
dose I None
levels I None
was I None
77 I None
% I None
, I None
with I None
a I None
10 I None
% I None
CR I None
rate I None
. I None
<eof> I None

<s> O None
No I None
patient I None
experienced I None
progressive I None
disease I None
. I None
<eof> I None

<s> O None
The I None
most I None
frequent I None
adverse I None
events I None
were I None
hematological I None
and I None
gastrointestinal I None
toxicities I None
as I None
well I None
as I None
neuropathy I Disease
. I None
<eof> I None

<s> O None
The I None
results I None
suggest I None
that I None
bortezomib I Chemical
in I None
combination I None
with I None
cyclophosphamide I Chemical
at I None
900 I None
mg I None
/ I None
m(2 I None
) I None
and I None
dexamethasone I Chemical
is I None
an I None
effective I None
induction I None
treatment I None
for I None
patients I None
with I None
newly I None
diagnosed I None
MM I Disease
that I None
warrants I None
further I None
investigation I None
. I None
<eof> I None

<s> O None
Results I None
of I None
a I None
comparative I None
, I None
phase I None
III I None
, I None
12-week I None
, I None
multicenter I None
, I None
prospective I None
, I None
randomized I None
, I None
double I None
- I None
blind I None
assessment I None
of I None
the I None
efficacy I None
and I None
tolerability I None
of I None
a I None
fixed I None
- I None
dose I None
combination I None
of I None
telmisartan I Chemical
and I None
amlodipine I Chemical
versus I None
amlodipine I Chemical
monotherapy I None
in I None
Indian I None
adults I None
with I None
stage I None
II I None
hypertension I Disease
. I None
<eof> I None

<s> O None
OBJECTIVE I None
: I None
<eof> I None

<s> O None
The I None
aim I None
of I None
this I None
study I None
was I None
to I None
evaluate I None
the I None
efficacy I None
and I None
tolerability I None
of I None
a I None
new I None
fixed I None
- I None
dose I None
combination I None
( I None
FDC I None
) I None
of I None
<eof> I None

<s> O None
telmisartan I Chemical
40 I None
mg I None
+ I None
amlodipine I Chemical
5 I None
mg I None
( I None
T+A I None
) I None
compared I None
with I None
amlodipine I Chemical
5-mg I None
monotherapy I None
<eof> I None

<s> O None
( I None
A I None
) I None
in I None
adult I None
Indian I None
patients I None
with I None
stage I None
II I None
hypertension I Disease
. I None
<eof> I None

<s> O None
METHODS I None
: I None
<eof> I None

<s> O None
This I None
comparative I None
, I None
Phase I None
III I None
, I None
12-week I None
, I None
multicenter I None
, I None
prospective I None
, I None
randomized I None
, I None
double I None
- I None
blind I None
study I None
was I None
conducted I None
in I None
Indian I None
patients I None
aged I None
18 I None
to I None
65 I None
years I None
with I None
established I None
stage I None
II I None
hypertension I Disease
. I None
<eof> I None

<s> O None
Patients I None
were I None
treated I None
with I None
oral I None
FDC I None
of I None
T+A I None
or I None
A I None
QD I None
before I None
breakfast I None
for I None
12 I None
weeks I None
; I None
blood I None
pressure I None
( I None
BP I None
) I None
and I None
heart I None
rate I None
were I None
measured I None
in I None
the I None
sitting I None
position I None
. I None
<eof> I None

<s> O None
Primary I None
efficacy I None
end I None
points I None
were I None
reduction I None
in I None
clinical I None
systolic I None
BP I None
( I None
SBP)/ I None
diastolic I None
BP I None
( I None
DBP I None
) I None
from I None
baseline I None
to I None
study I None
end I None
and I None
number I None
of I None
responders I None
( I None
ie I None
, I None
patients I None
who I None
achieved I None
target I None
SBP/ I None
DBP I None
< I None
130/<80 I None
mm I None
Hg I None
) I None
at I None
end I None
of I None
study I None
. I None
<eof> I None

<s> O None
Tolerability I None
was I None
assessed I None
by I None
treatment I None
- I None
emergent I None
adverse I None
events I None
, I None
identified I None
using I None
physical I None
examination I None
, I None
laboratory I None
analysis I None
, I None
and I None
electrocardiography I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
A I None
total I None
of I None
210 I None
patients I None
were I None
enrolled I None
in I None
the I None
study I None
; I None
203 I None
patients I None
( I None
143 I None
men I None
, I None
60 I None
women I None
) I None
completed I None
the I None
study I None
while I None
7 I None
were I None
lost I None
to I None
follow I None
- I None
up I None
( I None
4 I None
patients I None
in I None
the I None
T+A I None
group I None
and I None
3 I None
in I None
the I None
A I None
group I None
) I None
and I None
considered I None
with I None
- I None
drawn I None
. I None
<eof> I None

<s> O None
At I None
study I None
end I None
, I None
statistically I None
significant I None
percentage I None
reductions I None
from I None
baseline I None
within I None
groups I None
and I None
between I None
groups I None
were I None
observed I None
in I None
SBP I None
( I None
T+A I None
[ I None
-27.4 I None
% I None
] I None
; I None
A I None
[ I None
-16.6 I None
% I None
] I None
) I None
and I None
DBP I None
( I None
T+A I None
[ I None
-20.1 I None
% I None
] I None
; I None
A I None
[ I None
-13.3 I None
% I None
] I None
) I None
( I None
all I None
, I None
P I None
< I None
0.05 I None
) I None
. I None
<eof> I None

<s> O None
Response I None
rates I None
were I None
87.3 I None
% I None
( I None
89/102 I None
) I None
in I None
the I None
T+A I None
group I None
and I None
69.3 I None
% I None
( I None
70/101 I None
) I None
in I None
the I None
A I None
group I None
( I None
P I None
< I None
0.05 I None
) I None
. I None
<eof> I None

<s> O None
The I None
prevalences I None
of I None
adverse I None
events I None
were I None
not I None
significantly I None
different I None
between I None
the I None
2 I None
treatment I None
groups I None
( I None
T+A I None
, I None
16.0 I None
% I None
[ I None
17/106 I None
] I None
; I None
A I None
, I None
15.4 I None
% I None
[ I None
16/104 I None
] I None
) I None
. I None
<eof> I None

<s> O None
Peripheral I None
edema I Disease
was I None
reported I None
in I None
8.5 I None
% I None
patients I None
( I None
9/106 I None
) I None
in I None
the I None
T+A I None
group I None
compared I None
with I None
13.5 I None
% I None
( I None
14/104 I None
) I None
in I None
the I None
A I None
group I None
, I None
and I None
cough I Disease
was I None
reported I None
in I None
3.8 I None
% I None
patients I None
( I None
4/106 I None
) I None
in I None
the I None
T+A I None
group I None
and I None
1.0 I None
% I None
( I None
1/104 I None
) I None
patients I None
in I None
the I None
A I None
group I None
; I None
these I None
differences I None
did I None
not I None
reach I None
statistical I None
significance I None
. I None
<eof> I None

<s> O None
The I None
incidences I None
of I None
headache I Disease
, I None
dizziness I Disease
, I None
and I None
diarrhea I Disease
were I None
similar I None
between I None
the I None
2 I None
groups I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
Among I None
these I None
Indian I None
patients I None
with I None
stage I None
II I None
hypertension I Disease
, I None
the I None
FDC I None
of I None
T+A I None
was I None
found I None
to I None
be I None
significantly I None
more I None
effective I None
, I None
with I None
regard I None
to I None
BP I None
reductions I None
, I None
than I None
A I None
, I None
and I None
both I None
treatments I None
were I None
well I None
tolerated I None
. I None
<eof> I None

<s> O None
Cutaneous I Disease
leucocytoclastic O Disease
vasculitis O Disease
associated I None
with I None
oxacillin I Chemical
. I None
<eof> I None

<s> O None
A I None
67-year I None
- I None
old I None
man I None
who I None
was I None
treated I None
with I None
oxacillin I Chemical
for I None
one I None
week I None
because I None
of I None
Staphylococcus I None
aureus I None
bacteremia I None
, I None
developed I None
<eof> I None

<s> O None
renal I Disease
failure O Disease
and I None
diffuse I None
, I None
symmetric I None
, I None
palpable I None
purpuric I Disease
lesions O Disease
on I None
his I None
feet I None
. I None
<eof> I None

<s> O None
Necrotic I None
blisters I None
were I None
noted I None
on I None
his I None
fingers I None
. I None
<eof> I None

<s> O None
Skin I None
biopsies I None
showed I None
findings I None
diagnostic I None
of I None
leucocytoclastic I Disease
vasculitis O Disease
. I None
<eof> I None

<s> O None
Oxacillin I Chemical
was I None
discontinued I None
and I None
patient I None
was I None
treated I None
with I None
corticosteroids I Chemical
. I None
<eof> I None

<s> O None
The I None
rash I Disease
disappeared I None
after I None
three I None
weeks I None
and I None
renal I None
function I None
returned I None
to I None
normal I None
. I None
<eof> I None

<s> O None
Leucocytoclastic I Disease
vasculitis O Disease
presents I None
as I None
palpable I None
purpura I Disease
of I None
the I None
lower I None
extremities I None
often I None
accompanied I None
by I None
abdominal I Disease
pain O Disease
, I None
arthralgia I Disease
, I None
and I None
renal I Disease
involvement O Disease
. I None
<eof> I None

<s> O None
Etiologic I None
factors I None
or I None
associated I None
disorders I None
include I None
infections I Disease
, I None
medications I None
, I None
collagen I Disease
vascular O Disease
disease O Disease
and I None
neoplasia I Disease
. I None
<eof> I None

<s> O None
However I None
, I None
in I None
half I None
of I None
the I None
cases I None
no I None
etiologic I None
factor I None
is I None
identified I None
. I None
<eof> I None

<s> O None
Usually I None
it I None
is I None
a I None
self I None
- I None
limited I None
disorder I None
, I None
but I None
corticosteroid I Chemical
therapy I None
may I None
be I None
needed I None
in I None
life I None
- I None
threatening I None
cases I None
since I None
early I None
treatment I None
with I None
corticosteroids I Chemical
in I None
severe I None
cases I None
can I None
prevent I None
complications I None
. I None
<eof> I None

<s> O None
Oxacillin I Chemical
should I None
be I None
included I None
among I None
the I None
drugs I None
that I None
can I None
cause I None
leucocytoclastic I Disease
vasculitis O Disease
. I None
<eof> I None

<s> O None
Naloxazone I Chemical
pretreatment I None
modifies I None
cardiorespiratory I None
, I None
temperature I None
, I None
and I None
behavioral I None
effects I None
of I None
morphine I Chemical
. I None
<eof> I None

<s> O None
Behavioral I None
and I None
cardiorespiratory I None
responses I None
to I None
a I None
lethal I None
dose I None
of I None
morphine I Chemical
were I None
evaluated I None
in I None
rats I None
pretreated I None
with I None
saline I None
or I None
naloxazone I Chemical
, I None
an I None
antagonist I None
of I None
high I None
- I None
affinity I None
mu I None
1 I None
opioid I None
receptors I None
. I None
<eof> I None

<s> O None
Pretreatment I None
with I None
naloxazone I Chemical
significantly I None
blocked I None
<eof> I None

<s> O None
morphine I Chemical
analgesia I Disease
, I None
catalepsy I Disease
and I None
hypothermia I Disease
at I None
a I None
dose I None
which I None
completely I None
eliminated I None
high I None
- I None
affinity I None
binding I None
in I None
brain I None
membranes I None
. I None
<eof> I None

<s> O None
Moreover I None
, I None
naloxazone I Chemical
significantly I None
attenuated I None
the I None
morphine I Chemical
-induced I None
hypotension I Disease
and I None
respiratory I Disease
depression O Disease
, I None
whereas I None
morphine I Chemical
-induced I None
<eof> I None

<s> O None
bradycardia I Disease
was I None
less I None
affected I None
. I None
<eof> I None

<s> O None
Results I None
indicate I None
that I None
subpopulations I None
of I None
mu I None
receptors I None
may I None
mediate I None
selective I None
behavioral I None
and I None
cardiorespiratory I None
responses I None
to I None
morphine I Chemical
. I None
<eof> I None

<s> O None
Dexrazoxane I Chemical
protects I None
against I None
myelosuppression I Disease
from I None
the I None
DNA I None
cleavage I None
- I None
enhancing I None
drugs I None
etoposide I Chemical
and I None
daunorubicin I Chemical
but I None
not I None
doxorubicin I Chemical
. I None
<eof> I None

<s> O None
PURPOSE I None
: I None
<eof> I None

<s> O None
The I None
anthracyclines I Chemical
<eof> I None

<s> O None
daunorubicin I Chemical
and I None
doxorubicin I Chemical
and I None
the I None
epipodophyllotoxin I Chemical
<eof> I None

<s> O None
etoposide I Chemical
are I None
potent I None
DNA I None
cleavage I None
- I None
enhancing I None
drugs I None
that I None
are I None
widely I None
used I None
in I None
clinical I None
oncology I None
; I None
however I None
, I None
myelosuppression I Disease
and I None
cardiac I Disease
toxicity O Disease
limit I None
their I None
use I None
. I None
<eof> I None

<s> O None
Dexrazoxane I Chemical
<eof> I None

<s> O None
( I None
ICRF-187 I Chemical
) I None
is I None
recommended I None
for I None
protection I None
against I None
anthracycline I Chemical
-induced I None
cardiotoxicity I Disease
. I None
<eof> I None

<s> O None
EXPERIMENTAL I None
DESIGN I None
: I None
<eof> I None

<s> O None
Because I None
of I None
their I None
widespread I None
use I None
, I None
the I None
hematologic I Disease
toxicity O Disease
following I None
coadministration I None
of I None
dexrazoxane I Chemical
and I None
these I None
three I None
structurally I None
different I None
DNA I None
cleavage I None
enhancers I None
was I None
investigated I None
: I None
Sensitivity I None
of I None
human I None
and I None
murine I None
blood I None
progenitor I None
cells I None
to I None
etoposide I Chemical
, I None
daunorubicin I Chemical
, I None
and I None
doxorubicin I Chemical
+ I None
/- I None
<eof> I None

<s> O None
dexrazoxane I Chemical
was I None
determined I None
in I None
granulocyte I None
- I None
macrophage I None
colony I None
forming I None
assays I None
. I None
<eof> I None

<s> O None
Likewise I None
, I None
in I None
vivo I None
, I None
B6D2F1 I None
mice I None
were I None
treated I None
with I None
etoposide I Chemical
, I None
daunorubicin I Chemical
, I None
and I None
doxorubicin I Chemical
, I None
with I None
or I None
without I None
dexrazoxane I Chemical
over I None
a I None
wide I None
range I None
of I None
doses I None
: I None
posttreatment I None
, I None
a I None
full I None
hematologic I None
evaluation I None
was I None
done I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
Nontoxic I None
doses I None
of I None
dexrazoxane I Chemical
reduced I None
<eof> I None

<s> O None
myelosuppression I Disease
and I None
weight I Disease
loss O Disease
from I None
daunorubicin I Chemical
and I None
etoposide I Chemical
in I None
mice I None
and I None
antagonized I None
their I None
antiproliferative I None
effects I None
in I None
the I None
colony I None
assay I None
; I None
however I None
, I None
dexrazoxane I Chemical
neither I None
reduced I None
<eof> I None

<s> O None
myelosuppression I Disease
, I None
weight I Disease
loss O Disease
, I None
nor I None
the I None
in I None
vitro I None
cytotoxicity I Disease
from I None
doxorubicin I Chemical
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
<eof> I None

<s> O None
Although I None
our I None
findings I None
support I None
the I None
observation I None
that I None
dexrazoxane I Chemical
reduces I None
neither I None
hematologic I None
activity I None
nor I None
antitumor I None
activity I None
from I None
doxorubicin I Chemical
clinically I None
, I None
the I None
potent I None
antagonism I None
of I None
daunorubicin I Chemical
activity I None
raises I None
concern I None
; I None
a I None
possible I None
interference I None
with I None
anticancer I None
efficacy I None
certainly I None
would I None
call I None
for I None
renewed I None
attention I None
. I None
<eof> I None

<s> O None
Our I None
data I None
also I None
suggest I None
that I None
significant I None
etoposide I Chemical
<eof> I None

<s> O None
dose I None
escalation I None
is I None
perhaps I None
possible I None
by I None
the I None
use I None
of I None
dexrazoxane I Chemical
. I None
<eof> I None

<s> O None
Clinical I None
trials I None
in I None
patients I None
with I None
brain I None
metastases I Disease
combining I None
dexrazoxane I Chemical
and I None
high I None
doses I None
of I None
etoposide I Chemical
is I None
ongoing I None
with I None
the I None
aim I None
of I None
improving I None
efficacy I None
without I None
aggravating I None
hematologic I Disease
toxicity O Disease
. I None
<eof> I None

<s> O None
If I None
successful I None
, I None
this I None
represents I None
an I None
exciting I None
mechanism I None
for I None
pharmacologic I None
regulation I None
of I None
side I None
effects I None
from I None
cytotoxic I None
chemotherapy I None
. I None
<eof> I None

<s> O None
Effects I None
of I None
the I None
novel I None
compound I None
aniracetam I Chemical
<eof> I None

<s> O None
( I None
Ro I Chemical
13 O Chemical
- O Chemical
5057 O Chemical
) I None
upon I None
impaired I None
learning I None
and I None
memory I None
in I None
rodents I None
. I None
<eof> I None

<s> O None
The I None
effect I None
of I None
aniracetam I Chemical
<eof> I None

<s> O None
( I None
Ro I Chemical
13 O Chemical
- O Chemical
5057 O Chemical
, I None
1-anisoyl-2-pyrrolidinone I Chemical
) I None
was I None
studied I None
on I None
various I None
forms I None
of I None
experimentally I None
impaired I Disease
cognitive O Disease
functions O Disease
( I None
learning I None
and I None
memory I None
) I None
in I None
rodents I None
and I None
produced I None
the I None
following I None
effects I None
: I None
( I None
1 I None
) I None
almost I None
complete I None
prevention I None
of I None
the I None
incapacity I None
to I None
learn I None
a I None
discrete I None
escape I None
response I None
in I None
rats I None
exposed I None
to I None
sublethal I None
hypercapnia I Disease
immediately I None
before I None
the I None
acquisition I None
session I None
; I None
( I None
2 I None
) I None
partial I None
( I None
rats I None
) I None
or I None
complete I None
( I None
mice I None
) I None
prevention I None
of I None
the I None
scopolamine I Chemical
-induced I None
short I None
- I None
term I None
amnesia I Disease
for I None
a I None
passive I None
avoidance I None
task I None
; I None
( I None
3 I None
) I None
complete I None
protection I None
against I None
amnesia I Disease
for I None
a I None
passive I None
avoidance I None
task I None
in I None
rats I None
submitted I None
to I None
electroconvulsive I None
shock I None
immediately I None
after I None
avoidance I None
acquisition I None
; I None
( I None
4 I None
) I None
prevention I None
of I None
the I None
long I None
- I None
term I None
retention- I None
or I None
retrieval I None
- I None
deficit I None
for I None
a I None
passive I None
avoidance I None
task I None
induced I None
in I None
rats I None
and I None
mice I None
by I None
chloramphenicol I Chemical
or I None
cycloheximide I Chemical
administered I None
immediately I None
after I None
acquisition I None
; I None
( I None
5 I None
) I None
reversal I None
, I None
when I None
administered I None
as I None
late I None
as I None
1 I None
h I None
before I None
the I None
retention I None
test I None
, I None
of I None
the I None
deficit I None
in I None
retention I None
or I None
retrieval I None
of I None
a I None
passive I None
avoidance I None
task I None
induced I None
by I None
cycloheximide I Chemical
injected I None
2 I None
days I None
previously I None
; I None
( I None
6 I None
) I None
prevention I None
of I None
the I None
deficit I None
in I None
the I None
retrieval I None
of I None
an I None
active I None
avoidance I None
task I None
induced I None
in I None
mice I None
by I None
subconvulsant I None
electroshock I None
or I None
hypercapnia I Disease
applied I None
immediately I None
before I None
retrieval I None
testing I None
( I None
24 I None
h I None
after I None
acquisition I None
) I None
. I None
<eof> I None

<s> O None
These I None
improvements I None
or I None
normalizations I None
of I None
impaired I Disease
cognitive O Disease
functions O Disease
were I None
seen I None
at I None
oral I None
aniracetam I Chemical
doses I None
of I None
10 I None
- I None
100 I None
mg I None
/ I None
kg I None
. I None
<eof> I None

<s> O None
Generally I None
, I None
the I None
dose I None
- I None
response I None
curves I None
were I None
bell I None
- I None
shaped I None
. I None
<eof> I None

<s> O None
The I None
mechanisms I None
underlying I None
the I None
activity I None
of I None
aniracetam I Chemical
and I None
its I None
' I None
therapeutic I None
window I None
' I None
are I None
unknown I None
. I None
<eof> I None

<s> O None
Piracetam I Chemical
, I None
another I None
pyrrolidinone I Chemical
derivative I None
was I None
used I None
for I None
comparison I None
. I None
<eof> I None

<s> O None
It I None
was I None
active I None
only I None
in I None
six I None
of I None
nine I None
tests I None
and I None
had I None
about I None
one I None
- I None
tenth I None
the I None
potency I None
of I None
aniracetam I Chemical
. I None
<eof> I None

<s> O None
The I None
results I None
indicate I None
that I None
aniracetam I Chemical
improves I None
cognitive I None
functions I None
which I None
are I None
impaired I None
by I None
different I None
procedure I None
and I None
in I None
different I None
phases I None
of I None
the I None
learning I None
and I None
memory I None
process I None
. I None
<eof> I None

<s> O None
Nicotine I Chemical
potentiation I None
of I None
morphine I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
catalepsy I Disease
in I None
mice I None
. I None
<eof> I None

<s> O None
In I None
the I None
present I None
study I None
, I None
effects I None
of I None
nicotine I Chemical
on I None
catalepsy I Disease
induced I None
by I None
morphine I Chemical
in I None
mice I None
have I None
been I None
investigated I None
. I None
<eof> I None

<s> O None
Morphine I Chemical
but I None
not I None
nicotine I Chemical
induced I None
a I None
dose I None
- I None
dependent I None
catalepsy I Disease
. I None
<eof> I None

<s> O None
The I None
response I None
of I None
morphine I Chemical
was I None
potentiated I None
by I None
nicotine I Chemical
. I None
<eof> I None

<s> O None
Intraperitoneal I None
administration I None
of I None
atropine I Chemical
, I None
naloxone I Chemical
, I None
mecamylamine I Chemical
, I None
and I None
hexamethonium I Chemical
to I None
mice I None
reduced I None
catalepsy I Disease
<eof> I None

<s> O None
induced I None
by I None
a I None
combination I None
of I None
morphine I Chemical
with I None
nicotine I Chemical
. I None
<eof> I None

<s> O None
Intracerebroventricular I None
injection I None
of I None
atropine I Chemical
, I None
hexamethonium I Chemical
, I None
and I None
naloxone I Chemical
also I None
decreased I None
<eof> I None

<s> O None
catalepsy I Disease
induced I None
by I None
morphine I Chemical
plus I None
nicotine I Chemical
. I None
<eof> I None

<s> O None
Intraperitoneal I None
administration I None
of I None
atropine I Chemical
, I None
but I None
not I None
intraperitoneal I None
or I None
intracerebroventricular I None
injection I None
of I None
hexamethonium I Chemical
, I None
decreased I None
the I None
effect I None
of I None
a I None
single I None
dose I None
of I None
morphine I Chemical
. I None
<eof> I None

<s> O None
It I None
was I None
concluded I None
that I None
morphine I Chemical
<eof> I None

<s> O None
catalepsy I Disease
can I None
be I None
elicited I None
by I None
opioid I None
and I None
cholinergic I None
receptors I None
, I None
and I None
the I None
potentiation I None
of I None
morphine I Chemical
induced I None
by I None
nicotine I Chemical
may I None
also I None
be I None
mediated I None
through I None
cholinergic I None
receptor I None
mechanisms I None
. I None
<eof> I None

<s> O None
Reduced I None
cardiotoxicity I Disease
and I None
preserved I None
antitumor I None
efficacy I None
of I None
liposome I None
- I None
encapsulated I None
doxorubicin I Chemical
and I None
cyclophosphamide I Chemical
compared I None
with I None
conventional I None
doxorubicin I Chemical
and I None
cyclophosphamide I Chemical
in I None
a I None
randomized I None
, I None
multicenter I None
trial I None
of I None
metastatic I None
breast I Disease
cancer O Disease
. I None
<eof> I None

<s> O None
PURPOSE I None
: I None
<eof> I None

<s> O None
To I None
determine I None
whether I None
Myocet I Chemical
<eof> I None

<s> O None
( I None
liposome I None
- I None
encapsulated I None
doxorubicin I Chemical
; I None
The I None
Liposome I None
Company I None
, I None
Elan I None
Corporation I None
, I None
Princeton I None
, I None
NJ I None
) I None
in I None
combination I None
with I None
cyclophosphamide I Chemical
significantly I None
reduces I None
doxorubicin I Chemical
<eof> I None

<s> O None
cardiotoxicity I Disease
while I None
providing I None
comparable I None
antitumor I None
efficacy I None
in I None
first I None
- I None
line I None
treatment I None
of I None
metastatic I None
breast I Disease
cancer O Disease
<eof> I None

<s> O None
( I None
MBC I Disease
) I None
. I None
<eof> I None

<s> O None
PATIENTS I None
AND I None
METHODS I None
: I None
<eof> I None

<s> O None
Two I None
hundred I None
ninety I None
- I None
seven I None
patients I None
with I None
MBC I Disease
<eof> I None

<s> O None
and I None
no I None
prior I None
chemotherapy I None
for I None
metastatic I None
disease I None
were I None
randomized I None
to I None
receive I None
either I None
60 I None
mg I None
/ I None
m(2 I None
) I None
of I None
Myocet I Chemical
<eof> I None

<s> O None
( I None
M I None
) I None
or I None
conventional I None
doxorubicin I Chemical
( I None
A I None
) I None
, I None
in I None
combination I None
with I None
600 I None
mg I None
/ I None
m(2 I None
) I None
of I None
cyclophosphamide I Chemical
( I None
C I None
) I None
, I None
every I None
3 I None
weeks I None
until I None
disease I None
progression I None
or I None
unacceptable I None
toxicity I Disease
. I None
<eof> I None

<s> O None
Cardiotoxicity I Disease
was I None
defined I None
by I None
reductions I None
in I None
left I None
- I None
ventricular I None
ejection I None
fraction I None
, I None
assessed I None
by I None
serial I None
multigated I None
radionuclide I None
angiography I None
scans I None
, I None
or I None
congestive I Disease
heart O Disease
failure O Disease
<eof> I None

<s> O None
( I None
CHF I Disease
) I None
. I None
<eof> I None

<s> O None
Antitumor I None
efficacy I None
was I None
assessed I None
by I None
objective I None
tumor I Disease
response I None
rates I None
( I None
World I None
Health I None
Organization I None
criteria I None
) I None
, I None
time I None
to I None
progression I None
, I None
and I None
survival I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
Six I None
percent I None
of I None
MC I None
patients I None
versus I None
21 I None
% I None
( I None
including I None
five I None
cases I None
of I None
CHF I Disease
) I None
of I None
AC I None
patients I None
developed I None
<eof> I None

<s> O None
cardiotoxicity I Disease
( I None
P I None
= I None
.0002 I None
) I None
. I None
<eof> I None

<s> O None
Median I None
cumulative I None
doxorubicin I Chemical
dose I None
at I None
onset I None
was I None
more I None
than I None
2,220 I None
mg I None
/ I None
m(2 I None
) I None
for I None
MC I None
versus I None
480 I None
mg I None
/ I None
m(2 I None
) I None
for I None
AC I None
( I None
P I None
= I None
.0001 I None
, I None
hazard I None
ratio I None
, I None
5.04 I None
) I None
. I None
<eof> I None

<s> O None
MC I None
patients I None
also I None
experienced I None
less I None
grade I None
4 I None
neutropenia I Disease
. I None
<eof> I None

<s> O None
Antitumor I None
efficacy I None
of I None
MC I None
versus I None
AC I None
was I None
comparable I None
: I None
<eof> I None

<s> O None
objective I None
response I None
rates I None
, I None
43 I None
% I None
versus I None
43 I None
% I None
; I None
median I None
time I None
to I None
progression I None
, I None
5.1 I None
% I None
versus I None
5.5 I None
months I None
; I None
median I None
time I None
to I None
treatment I None
failure I None
, I None
4.6 I None
versus I None
4.4 I None
months I None
; I None
and I None
median I None
survival I None
, I None
19 I None
versus I None
16 I None
months I None
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
<eof> I None

<s> O None
Myocet I Chemical
improves I None
the I None
therapeutic I None
index I None
of I None
doxorubicin I Chemical
by I None
significantly I None
reducing I None
cardiotoxicity I Disease
and I None
grade I None
4 I None
neutropenia I Disease
and I None
provides I None
comparable I None
antitumor I None
efficacy I None
, I None
when I None
used I None
in I None
combination I None
with I None
cyclophosphamide I Chemical
as I None
first I None
- I None
line I None
therapy I None
for I None
MBC I Disease
. I None
<eof> I None

<s> O None
Protective I None
effect I None
of I None
a I None
specific I None
platelet I None
- I None
activating I None
factor I None
antagonist I None
, I None
BN I Chemical
52021 O Chemical
, I None
on I None
bupivacaine I Chemical
-induced I None
<eof> I None

<s> O None
cardiovascular I Disease
impairments O Disease
in I None
rats I None
. I None
<eof> I None

<s> O None
Administration I None
of I None
the I None
local I None
anaesthetic I None
bupivacaine I Chemical
<eof> I None

<s> O None
( I None
1.5 I None
or I None
2 I None
mg I None
/ I None
kg I None
, I None
i.v I None
. I None
) I None
<eof> I None

<s> O None
to I None
rats I None
elicited I None
a I None
marked I None
decrease I None
of I None
mean I None
arterial I None
blood I None
pressure I None
( I None
MBP I None
) I None
and I None
heart I None
rate I None
( I None
HR I None
) I None
leading I None
to I None
death I None
( I None
in I None
67 I None
% I None
or I None
90 I None
% I None
of I None
animals I None
respectively I None
) I None
. I None
<eof> I None

<s> O None
Intravenous I None
injection I None
of I None
the I None
specific I None
platelet I None
- I None
activating I None
factor I None
( I None
PAF I None
) I None
antagonist I None
BN I Chemical
52021 O Chemical
<eof> I None

<s> O None
( I None
10 I None
mg I None
/ I None
kg I None
) I None
, I None
30 I None
min I None
before I None
bupivacaine I Chemical
administration I None
( I None
2 I None
mg I None
/ I None
kg I None
i.v I None
. I None
) I None
<eof> I None

<s> O None
suppressed I None
both I None
the I None
decrease I None
of I None
MBP I None
and I None
HR I None
. I None
<eof> I None

<s> O None
In I None
contrast I None
, I None
doses I None
of I None
1 I None
mg I None
/ I None
kg I None
<eof> I None

<s> O None
BN I Chemical
52021 O Chemical
given I None
30 I None
min I None
before I None
or I None
10 I None
mg I None
/ I None
kg I None
administered I None
5 I None
min I None
before I None
i.v I None
. I None
<eof> I None

<s> O None
injection I None
of I None
bupivacaine I Chemical
were I None
ineffective I None
. I None
<eof> I None

<s> O None
When I None
BN I Chemical
52021 O Chemical
( I None
20 I None
mg I None
/ I None
kg I None
i.v I None
. I None
) I None
was I None
injected I None
immediately I None
after I None
bupivacaine I Chemical
<eof> I None

<s> O None
( I None
2 I None
mg I None
/ I None
kg I None
) I None
, I None
<eof> I None

<s> O None
a I None
partial I None
reversion I None
of I None
the I None
decrease I None
of I None
MBP I None
and I None
HR I None
was I None
observed I None
, I None
whereas I None
the I None
dose I None
of I None
10 I None
mg I None
/ I None
kg I None
was I None
ineffective I None
. I None
<eof> I None

<s> O None
A I None
partial I None
recovery I None
of I None
bupivacaine I Chemical
-induced I None
ECG I None
alterations I None
was I None
observed I None
after I None
pretreatment I None
of I None
the I None
rats I None
with I None
BN I Chemical
52021 O Chemical
. I None
<eof> I None

<s> O None
Since I None
the I None
administration I None
of I None
BN I Chemical
52021 O Chemical
, I None
at I None
all I None
doses I None
studied I None
, I None
did I None
not I None
alter I None
MBP I None
and I None
HR I None
at I None
the I None
doses I None
used I None
, I None
the I None
bulk I None
of I None
these I None
results I None
clearly I None
demonstrate I None
a I None
protective I None
action I None
of I None
BN I Chemical
52021 O Chemical
, I None
a I None
specific I None
antagonist I None
of I None
PAF I None
, I None
against I None
<eof> I None

<s> O None
bupivacaine I Chemical
-induced I None
<eof> I None

<s> O None
cardiovascular I Disease
toxicity O Disease
. I None
<eof> I None

<s> O None
Thus I None
, I None
consistent I None
with I None
its I None
direct I None
effect I None
on I None
heart I None
, I None
PAF I None
appears I None
to I None
be I None
implicated I None
in I None
bupivacaine I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
cardiovascular I Disease
alterations O Disease
. I None
<eof> I None

<s> O None
Benzylacyclouridine I Chemical
reverses I None
<eof> I None

<s> O None
azidothymidine I Chemical
-induced I None
<eof> I None

<s> O None
marrow I Disease
suppression O Disease
without I None
impairment I None
of I None
anti I None
- I None
human I None
immunodeficiency I Disease
virus I None
activity I None
. I None
<eof> I None

<s> O None
Increased I None
extracellular I None
concentrations I None
of I None
uridine I Chemical
<eof> I None

<s> O None
( I None
Urd I Chemical
) I None
have I None
been I None
reported I None
to I None
reduce I None
, I None
in I None
vitro I None
, I None
azidothymidine I Chemical
( I None
AZT I Chemical
) I None
-induced I None
inhibition I None
of I None
human I None
granulocyte I None
- I None
macrophage I None
progenitor I None
cells I None
without I None
impairment I None
of I None
its I None
antihuman I None
immunodeficiency I Disease
virus I None
( I None
HIV I None
) I None
activity I None
. I None
<eof> I None

<s> O None
Because I None
of I None
the I None
clinical I None
toxicities I Disease
associated I None
with I None
chronic I None
Urd I Chemical
administration I None
, I None
the I None
ability I None
of I None
benzylacyclouridine I Chemical
<eof> I None

<s> O None
( I None
BAU I Chemical
) I None
to I None
effect I None
, I None
in I None
vivo I None
, I None
AZT I Chemical
-induced I None
anemia I Disease
and I None
leukopenia I Disease
was I None
assessed I None
. I None
<eof> I None

<s> O None
This I None
agent I None
inhibits I None
Urd I Chemical
catabolism I None
and I None
, I None
in I None
vivo I None
, I None
increases I None
the I None
plasma I None
concentration I None
of I None
Urd I Chemical
in I None
a I None
dose I None
- I None
dependent I None
manner I None
, I None
without I None
Urd I Chemical
<eof> I None

<s> O None
-related I None
<eof> I None

<s> O None
toxicity I Disease
. I None
<eof> I None

<s> O None
In I None
mice I None
rendered I None
<eof> I None

<s> O None
anemic I Disease
and I None
leukopenic I Disease
by I None
the I None
administration I None
of I None
AZT I Chemical
for I None
28 I None
days I None
in I None
drinking I None
water I None
( I None
1.5 I None
mg I None
/ I None
mL I None
) I None
, I None
the I None
continued I None
administration I None
of I None
AZT I Chemical
plus I None
<eof> I None

<s> O None
daily I None
BAU I Chemical
<eof> I None

<s> O None
( I None
300 I None
mg I None
/ I None
kg I None
, I None
orally I None
) I None
partially I None
reversed I None
<eof> I None

<s> O None
AZT I Chemical
-induced I None
anemia I Disease
and I None
leukopenia I Disease
( I None
P I None
less I None
than I None
.05 I None
) I None
, I None
increased I None
peripheral I None
reticulocytes I None
( I None
to I None
4.9 I None
% I None
, I None
P I None
less I None
than I None
.01 I None
) I None
, I None
increased I None
cellularity I None
in I None
the I None
marrow I None
, I None
and I None
improved I None
<eof> I None

<s> O None
megaloblastosis I Disease
. I None
<eof> I None

<s> O None
When I None
coadministered I None
with I None
AZT I Chemical
from I None
the I None
onset I None
of I None
drug I None
administration I None
, I None
BAU I Chemical
reduced I None
AZT I Chemical
<eof> I None

<s> O None
-induced I None
marrow I Disease
toxicity O Disease
. I None
<eof> I None

<s> O None
In I None
vitro I None
, I None
at I None
a I None
concentration I None
of I None
100 I None
mumol I None
/ I None
L I None
, I None
BAU I Chemical
possesses I None
minimal I None
anti I None
- I None
HIV I None
activity I None
and I None
has I None
no I None
effect I None
on I None
the I None
ability I None
of I None
AZT I Chemical
to I None
reverse I None
the I None
HIV I None
- I None
induced I None
cytopathic I None
effect I None
in I None
MT4 I None
cells I None
. I None
<eof> I None

<s> O None
The I None
clinical I None
and I None
biochemical I None
implications I None
of I None
these I None
findings I None
are I None
discussed I None
. I None
<eof> I None

<s> O None
Cyclophosphamide I Chemical
-induced I None
cystitis I Disease
in I None
freely I None
- I None
moving I None
conscious I None
rats I None
: I None
behavioral I None
approach I None
to I None
a I None
new I None
model I None
of I None
visceral I Disease
pain O Disease
. I None
<eof> I None

<s> O None
PURPOSE I None
: I None
To I None
develop I None
a I None
model I None
of I None
visceral I Disease
pain O Disease
in I None
rats I None
using I None
a I None
behavioral I None
approach I None
. I None
<eof> I None

<s> O None
Cyclophosphamide I Chemical
<eof> I None

<s> O None
( I None
CP I Chemical
) I None
, I None
an I None
antitumoral I None
agent I None
known I None
to I None
produce I None
toxic I None
effects I None
on I None
the I None
bladder I None
wall I None
through I None
its I None
main I None
toxic I None
metabolite I None
acrolein I Chemical
, I None
was I None
used I None
to I None
induce I None
cystitis I Disease
. I None
<eof> I None

<s> O None
MATERIALS I None
AND I None
METHODS I None
: I None
<eof> I None

<s> O None
CP I Chemical
was I None
administered I None
at I None
doses I None
of I None
50 I None
, I None
100 I None
and I None
200 I None
mg./kg I None
. I None
<eof> I None

<s> O None
i.p I None
. I None
<eof> I None

<s> O None
to I None
male I None
rats I None
, I None
and I None
their I None
behavior I None
observed I None
and I None
scored I None
. I None
<eof> I None

<s> O None
The I None
effects I None
of I None
morphine I Chemical
<eof> I None

<s> O None
( I None
0.5 I None
to I None
4 I None
mg./kg I None
. I None
i.v I None
. I None
) I None
on I None
<eof> I None

<s> O None
CP I Chemical
-induced I None
behavioral I None
modifications I None
were I None
tested I None
administered I None
alone I None
and I None
after I None
naloxone I Chemical
<eof> I None

<s> O None
( I None
1 I None
mg./kg I None
. I None
s.c I None
. I None
) I None
. I None
<eof> I None

<s> O None
In I None
addition I None
, I None
90 I None
minutes I None
after I None
CP I Chemical
injection I None
, I None
that I None
is I None
, I None
at I None
the I None
time I None
of I None
administration I None
of I None
morphine I Chemical
, I None
the I None
bladder I None
was I None
removed I None
in I None
some I None
rats I None
for I None
histological I None
examination I None
. I None
<eof> I None

<s> O None
Finally I None
, I None
to I None
show I None
that I None
the I None
bladder I None
is I None
essential I None
for I None
the I None
CP I Chemical
-induced I None
behavioral I None
modifications I None
, I None
female I None
rats I None
also I None
received I None
CP I Chemical
at I None
doses I None
of I None
200 I None
mg./kg I None
. I None
<eof> I None

<s> O None
i.p I None
. I None
<eof> I None

<s> O None
and I None
of I None
20 I None
mg I None
. I None
by I None
the I None
intravesical I None
route I None
, I None
and I None
acrolein I Chemical
at I None
doses I None
of I None
0.5 I None
mg I None
. I None
by I None
the I None
intravesical I None
route I None
and I None
of I None
5 I None
mg./kg I None
. I None
i.v I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
CP I Chemical
dose I None
- I None
relatedly I None
induced I None
marked I None
behavioral I None
modifications I None
in I None
male I None
rats I None
: I None
breathing I None
rate I None
decrease I None
, I None
closing I None
of I None
the I None
eyes I None
and I None
occurrence I None
of I None
specific I None
postures I None
. I None
<eof> I None

<s> O None
Morphine I Chemical
<eof> I None

<s> O None
dose I None
- I None
dependently I None
reversed I None
these I None
behavioral I Disease
disorders O Disease
. I None
<eof> I None

<s> O None
A I None
dose I None
of I None
0.5 I None
mg./kg I None
. I None
produced I None
a I None
reduction I None
of I None
almost I None
50 I None
% I None
of I None
the I None
behavioral I None
score I None
induced I None
by I None
CP I Chemical
200 I None
mg./kg I None
. I None
<eof> I None

<s> O None
This I None
effect I None
was I None
completely I None
prevented I None
by I None
pretreatment I None
with I None
naloxone I Chemical
. I None
<eof> I None

<s> O None
At I None
the I None
time I None
of I None
administration I None
of I None
morphine I Chemical
, I None
histological I None
modifications I None
of I None
the I None
bladder I None
wall I None
, I None
such I None
as I None
chorionic I None
and I None
muscle I None
layer I None
edema I Disease
, I None
were I None
observed I None
. I None
<eof> I None

<s> O None
In I None
female I None
rats I None
, I None
CP I Chemical
200 I None
mg./kg I None
. I None
i.p I None
. I None
produced I None
the I None
same I None
marked I None
behavioral I None
modifications I None
as I None
those I None
observed I None
in I None
male I None
rats I None
. I None
<eof> I None

<s> O None
Administered I None
at I None
the I None
dose I None
of I None
20 I None
mg I None
. I None
<eof> I None

<s> O None
intravesically I None
, I None
CP I Chemical
did I None
not I None
produce I None
any I None
behavioral I None
effects I None
, I None
whereas I None
<eof> I None

<s> O None
acrolein I Chemical
at I None
0.5 I None
mg I None
. I None
<eof> I None

<s> O None
intravesically I None
induced I None
behavioral I None
modifications I None
identical I None
to I None
those I None
under I None
CP I Chemical
200 I None
mg./kg I None
. I None
i.p I None
. I None
<eof> I None

<s> O None
, I None
with I None
the I None
same I None
maximal I None
levels I None
. I None
<eof> I None

<s> O None
Conversely I None
, I None
acrolein I Chemical
5 I None
mg./kg I None
. I None
i.v I None
. I None
<eof> I None

<s> O None
did I None
not I None
produce I None
any I None
behavioral I None
effects I None
at I None
all I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
Overall I None
, I None
these I None
results I None
indicate I None
that I None
this I None
experimental I None
model I None
of I None
CP I Chemical
-induced I None
<eof> I None

<s> O None
cystitis I Disease
may I None
be I None
an I None
interesting I None
new I None
behavioral I None
model I None
of I None
inflammatory I None
visceral I Disease
pain O Disease
, I None
allowing I None
a I None
better I None
understanding I None
of I None
these I None
painful I Disease
syndromes O Disease
and I None
thus I None
a I None
better I None
therapeutic I None
approach I None
to I None
them I None
. I None
<eof> I None

<s> O None
Hyperalgesia I Disease
and I None
myoclonus I Disease
in I None
terminal I None
cancer I Disease
patients I None
treated I None
with I None
continuous I None
intravenous I None
morphine I Chemical
. I None
<eof> I None

<s> O None
Eight I None
<eof> I None

<s> O None
cancer I Disease
patients I None
in I None
the I None
terminal I None
stages I None
of I None
the I None
disease I None
treated I None
with I None
high I None
doses I None
of I None
intravenous I None
morphine I Chemical
developed I None
<eof> I None

<s> O None
hyperalgesia I Disease
. I None
<eof> I None

<s> O None
All I None
cases I None
were I None
retrospectively I None
sampled I None
from I None
three I None
different I None
hospitals I None
in I None
Copenhagen I None
. I None
<eof> I None

<s> O None
Five I None
patients I None
developed I None
universal I None
hyperalgesia I Disease
and I None
hyperesthesia I Disease
which I None
in I None
2 I None
cases I None
were I None
accompanied I None
by I None
myoclonus I Disease
. I None
<eof> I None

<s> O None
In I None
3 I None
patients I None
a I None
pre I None
- I None
existing I None
neuralgia I Disease
increased I None
to I None
excruciating I None
intensity I None
and I None
in I None
2 I None
of I None
these I None
cases I None
myoclonus I Disease
occurred I None
simultaneously I None
. I None
<eof> I None

<s> O None
Although I None
only I None
few I None
clinical I None
descriptions I None
of I None
the I None
relationship I None
between I None
hyperalgesia I Disease
/ I None
myoclonus I Disease
and I None
high I None
doses I None
of I None
morphine I Chemical
are I None
available I None
, I None
experimental I None
support I None
from I None
animal I None
studies I None
indicates I None
that I None
morphine I Chemical
, I None
or I None
its I None
metabolites I None
, I None
plays I None
a I None
causative I None
role I None
for I None
the I None
observed I None
behavioural I None
syndrome I None
. I None
<eof> I None

<s> O None
The I None
possible I None
mechanisms I None
are I None
discussed I None
and I None
treatment I None
proposals I None
given I None
suggesting I None
the I None
use I None
of I None
more I None
efficacious I None
opioids I None
with I None
less I None
excitatory I None
potency I None
in I None
these I None
situations I None
. I None
<eof> I None

<s> O None
A I None
prospective I None
study I None
of I None
adverse I None
reactions I None
associated I None
with I None
vancomycin I Chemical
therapy I None
. I None
<eof> I None

<s> O None
A I None
prospective I None
evaluation I None
of I None
the I None
efficacy I None
and I None
safety I None
of I None
vancomycin I Chemical
was I None
conducted I None
in I None
54 I None
consecutive I None
patients I None
over I None
a I None
16-month I None
period I None
. I None
<eof> I None

<s> O None
Vancomycin I Chemical
was I None
curative I None
in I None
95 I None
% I None
of I None
43 I None
patients I None
with I None
proven I None
infection I Disease
. I None
<eof> I None

<s> O None
Drugs I None
were I None
ceased I None
in I None
six I None
patients I None
because I None
of I None
adverse I None
reactions I None
; I None
in I None
three I None
of I None
these I None
vancomycin I Chemical
was I None
considered I None
the I None
likely I None
cause I None
. I None
<eof> I None

<s> O None
Reactions I None
included I None
<eof> I None

<s> O None
thrombophlebitis I Disease
( I None
20 I None
of I None
54 I None
patients I None
) I None
, I None
rash I Disease
( I None
4 I None
of I None
54 I None
) I None
, I None
nephrotoxicity I Disease
<eof> I None

<s> O None
( I None
4 I None
of I None
50 I None
) I None
, I None
proteinuria I Disease
( I None
1 I None
of I None
50 I None
) I None
and I None
ototoxicity I Disease
<eof> I None

<s> O None
( I None
1 I None
of I None
11 I None
patients I None
tested I None
by I None
audiometry I None
) I None
. I None
<eof> I None

<s> O None
Thrombophlebitis I Disease
occurred I None
only I None
with I None
infusion I None
through I None
peripheral I None
cannulae I None
; I None
nephrotoxicity I Disease
and I None
ototoxicity I Disease
were I None
confined I None
to I None
patients I None
receiving I None
an I None
aminoglycoside I Chemical
plus I None
vancomycin I Chemical
. I None
<eof> I None

<s> O None
We I None
conclude I None
that I None
vancomycin I Chemical
, I None
administered I None
appropriately I None
, I None
constitutes I None
safe I None
, I None
effective I None
therapy I None
for I None
infections I Disease
caused I None
by I None
susceptible I None
bacteria I None
. I None
<eof> I None

<s> O None
Blockade I None
of I None
both I None
D-1 I None
and I None
D-2 I None
dopamine I Chemical
receptors I None
may I None
induce I None
catalepsy I Disease
in I None
mice I None
. I None
<eof> I None

<s> O None
1 I None
. I None
<eof> I None

<s> O None
The I None
catalepsy I Disease
induced I None
by I None
dopamine I Chemical
antagonists I None
has I None
been I None
tested I None
and I None
the I None
possible I None
dopamine I Chemical
subtypes I None
involved I None
in I None
catalepsy I Disease
was I None
determined I None
. I None
<eof> I None

<s> O None
2 I None
. I None
<eof> I None

<s> O None
Dopamine I Chemical
antagonist I None
fluphenazine I Chemical
, I None
D-1 I None
antagonist I None
SCH I Chemical
23390 O Chemical
or I None
D-2 I None
antagonist I None
sulpiride I Chemical
induced I None
catalepsy I Disease
. I None
<eof> I None

<s> O None
The I None
effect I None
of I None
fluphenazine I Chemical
and I None
sulpiride I Chemical
was I None
dose I None
- I None
dependent I None
. I None
<eof> I None

<s> O None
Combination I None
of I None
SCH I Chemical
23390 O Chemical
with I None
sulpiride I Chemical
did I None
not I None
induce I None
catalepsy I Disease
potentiation I None
. I None
<eof> I None

<s> O None
3 I None
. I None
D-1 I None
agonist I None
<eof> I None

<s> O None
SKF I Chemical
38393 O Chemical
or I None
D-2 I None
agonist I None
<eof> I None

<s> O None
quinpirole I Chemical
decreased I None
the I None
catalepsy I Disease
induced I None
by I None
fluphenazine I Chemical
, I None
SCH I Chemical
23390 O Chemical
or I None
sulpiride I Chemical
. I None
<eof> I None

<s> O None
4 I None
. I None
<eof> I None

<s> O None
Combination I None
of I None
SKF I Chemical
38393 O Chemical
with I None
quinpirole I Chemical
did I None
not I None
cause I None
potentiated I None
inhibitory I None
effect I None
on I None
catalepsy I Disease
induced I None
by I None
dopamine I Chemical
antagonists I None
. I None
<eof> I None

<s> O None
5 I None
. I None
<eof> I None

<s> O None
The I None
data I None
may I None
indicate I None
that I None
although I None
D-2 I None
receptor I None
blockade I None
is I None
involved I None
in I None
catalepsy I Disease
, I None
the I None
D-1 I None
receptor I None
may I None
plan I None
a I None
role I None
. I None
<eof> I None

<s> O None
Dextran I Chemical
- I None
etodolac I Chemical
conjugates I None
: I None
synthesis I None
, I None
in I None
vitro I None
and I None
in I None
vivo I None
evaluation I None
. I None
<eof> I None

<s> O None
Etodolac I Chemical
( I None
E I Chemical
) I None
, I None
is I None
a I None
non I None
- I None
narcotic I None
analgesic I None
and I None
antiinflammatory I None
drug I None
. I None
<eof> I None

<s> O None
A I None
biodegradable I None
polymer I None
dextran I Chemical
has I None
been I None
utilized I None
as I None
a I None
carrier I None
for I None
synthesis I None
of I None
etodolac I Chemical
- I None
dextran I Chemical
conjugates I None
( I None
ED I None
) I None
to I None
improve I None
its I None
aqueous I None
solubility I None
and I None
reduce I None
gastrointestinal I None
side I None
effects I None
. I None
<eof> I None

<s> O None
An I None
activated I None
moiety I None
, I None
i.e. I None
N I Chemical
- O Chemical
acylimidazole O Chemical
derivative I None
of I None
etodolac I Chemical
<eof> I None

<s> O None
( I None
EAI I Chemical
) I None
, I None
was I None
condensed I None
with I None
the I None
polysaccharide I None
polymer I None
dextran I Chemical
of I None
different I None
molecular I None
weights I None
( I None
40000 I None
, I None
60000 I None
, I None
110000 I None
and I None
200000 I None
) I None
. I None
<eof> I None

<s> O None
IR I None
spectral I None
data I None
confirmed I None
formation I None
of I None
ester I None
bonding I None
in I None
the I None
conjugates I None
. I None
<eof> I None

<s> O None
Etodolac I Chemical
contents I None
were I None
evaluated I None
by I None
UV I None
- I None
spectrophotometric I None
analysis I None
. I None
<eof> I None

<s> O None
The I None
molecular I None
weights I None
were I None
determined I None
by I None
measuring I None
viscosity I None
using I None
the I None
Mark I None
- I None
Howink I None
- I None
Sakurada I None
equation I None
. I None
<eof> I None

<s> O None
In I None
vitro I None
hydrolysis I None
of I None
ED I None
was I None
done I None
in I None
aqueous I None
buffers I None
( I None
pH I None
1.2 I None
, I None
7.4 I None
, I None
9 I None
) I None
and I None
in I None
80 I None
% I None
( I None
v I None
/ I None
v I None
) I None
human I None
plasma I None
( I None
pH I None
7.4 I None
) I None
. I None
<eof> I None

<s> O None
At I None
pH I None
9 I None
, I None
a I None
higher I None
rate I None
of I None
etodolac I Chemical
release I None
from I None
ED I None
was I None
observed I None
as I None
compared I None
to I None
aqueous I None
buffer I None
of I None
pH I None
7.4 I None
and I None
80 I None
% I None
human I None
plasma I None
( I None
pH I None
7.4 I None
) I None
, I None
following I None
first I None
- I None
order I None
kinetics I None
. I None
<eof> I None

<s> O None
In I None
vivo I None
investigations I None
were I None
performed I None
in I None
animals I None
. I None
<eof> I None

<s> O None
Acute I None
analgesic I None
and I None
antiinflammatory I None
activities I None
were I None
ascertained I None
using I None
acetic I Chemical
acid O Chemical
induced I None
writhing I Disease
model I None
( I None
mice I None
) I None
and I None
carrageenan I Chemical
-induced I None
rat I None
paw I None
edema I Disease
model I None
, I None
respectively I None
. I None
<eof> I None

<s> O None
In I None
comparison I None
to I None
control I None
, I None
E I Chemical
and I None
ED1-ED4 I None
showed I None
highly I None
significant I None
analgesic I None
and I None
antiinflammatory I None
activities I None
( I None
p I None
< I None
0.001 I None
) I None
. I None
<eof> I None

<s> O None
Biological I None
evaluation I None
suggested I None
that I None
conjugates I None
( I None
ED1-ED4 I None
) I None
retained I None
comparable I None
analgesic I None
and I None
antiinflammatory I None
activities I None
with I None
remarkably I None
reduced I None
ulcerogenicity I None
as I None
compared I None
to I None
their I None
parent I None
drug-- I None
etodolac I Chemical
. I None
<eof> I None

<s> O None
Hypersensitivity I Disease
<eof> I None

<s> O None
myocarditis I Disease
complicating I None
hypertrophic I Disease
cardiomyopathy O Disease
heart I None
. I None
<eof> I None

<s> O None
The I None
present I None
report I None
describes I None
a I None
case I None
of I None
eosinophilic I None
myocarditis I None
complicating I None
hypertrophic I Disease
cardiomyopathy O Disease
. I None
<eof> I None

<s> O None
The I None
47-year I None
- I None
old I None
female I None
patient I None
, I None
known I None
to I None
have I None
hypertrophic I Disease
cardiomyopathy O Disease
, I None
was I None
admitted I None
with I None
biventricular I Disease
failure O Disease
and I None
managed I None
aggressively I None
with I None
dobutamine I Chemical
infusion I None
and I None
other I None
drugs I None
while I None
being I None
assessed I None
for I None
heart I None
transplantation I None
. I None
<eof> I None

<s> O None
On I None
transthoracic I None
echocardiogram I None
, I None
she I None
had I None
moderate I None
left I Disease
ventricular O Disease
dysfunction O Disease
with I None
regional I None
variability I None
and I None
moderate I None
mitral I Disease
regurgitation O Disease
. I None
<eof> I None

<s> O None
The I None
recipient I None
's I None
heart I None
showed I None
the I None
features I None
of I None
apical I None
hypertrophic I Disease
cardiomyopathy O Disease
and I None
myocarditis I Disease
with I None
abundant I None
eosinophils I None
. I None
<eof> I None

<s> O None
Myocarditis I Disease
is I None
rare I None
and I None
eosinophilic I None
myocarditis I None
is I None
rarer I None
. I None
<eof> I None

<s> O None
It I None
is I None
likely I None
that I None
the I None
hypersensitivity I Disease
<eof> I None

<s> O None
( I None
eosinophilic I Disease
) I None
<eof> I None

<s> O None
myocarditis I Disease
was I None
related I None
to I None
dobutamine I Chemical
infusion I None
therapy I None
. I None
<eof> I None

<s> O None
Eosinophilic I None
myocarditis I None
has I None
been I None
reported I None
with I None
an I None
incidence I None
of I None
2.4 I None
% I None
to I None
7.2 I None
% I None
in I None
explanted I None
hearts I None
and I None
may I None
be I None
related I None
to I None
multidrug I None
therapy I None
. I None
<eof> I None

<s> O None
All- I Chemical
trans O Chemical
- O Chemical
retinoic O Chemical
acid O Chemical
-induced I None
erythema I Disease
nodosum O Disease
in I None
patients I None
with I None
acute I Disease
promyelocytic O Disease
leukemia O Disease
. I None
<eof> I None

<s> O None
Erythema I Disease
nodosum O Disease
associated I None
with I None
all- I Chemical
trans O Chemical
- O Chemical
retinoic O Chemical
acid O Chemical
<eof> I None

<s> O None
( I None
ATRA I Chemical
) I None
for I None
acute I Disease
promyelocytic O Disease
leukemia O Disease
<eof> I None

<s> O None
( I None
APL I Disease
) I None
is I None
very I None
rare I None
. I None
<eof> I None

<s> O None
We I None
describe I None
four I None
patients I None
with I None
classic I None
APL I Disease
who I None
developed I None
erythema I Disease
nodosum O Disease
during I None
ATRA I Chemical
therapy I None
. I None
<eof> I None

<s> O None
Fever I Disease
and I None
subsequent I None
multiple I None
painful I Disease
erythematous I Disease
nodules O Disease
over I None
extremities I None
developed I None
on I None
D11 I None
, I None
D16 I None
, I None
D17 I None
, I None
and I None
D19 I None
, I None
respectively I None
, I None
after I None
ATRA I Chemical
therapy I None
. I None
<eof> I None

<s> O None
The I None
skin I None
biopsy I None
taken I None
from I None
each I None
patient I None
was I None
consistent I None
with I None
erythema I Disease
nodosum O Disease
. I None
<eof> I None

<s> O None
All I None
patients I None
received I None
short I None
course I None
of I None
steroids I Chemical
. I None
<eof> I None

<s> O None
Fever I Disease
subsided I None
rapidly I None
and I None
the I None
skin I None
lesions I None
regressed I None
completely I None
. I None
<eof> I None

<s> O None
All I None
patients I None
achieved I None
complete I None
remission I None
without I None
withdrawal I None
of I None
ATRA I Chemical
. I None
<eof> I None

<s> O None
ATRA I Chemical
seemed I None
to I None
be I None
the I None
most I None
possible I None
etiology I None
of I None
erythema I Disease
nodosum O Disease
in I None
our I None
patients I None
. I None
<eof> I None

<s> O None
Short I None
- I None
term I None
use I None
of I None
steroid I Chemical
is I None
very I None
effective I None
in I None
<eof> I None

<s> O None
ATRA I Chemical
-induced I None
<eof> I None

<s> O None
erythema I Disease
nodosum O Disease
. I None
<eof> I None

<s> O None
Delayed I None
- I None
onset I None
<eof> I None

<s> O None
heparin I Chemical
-induced I None
thrombocytopenia I Disease
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
<eof> I None

<s> O None
Heparin I Chemical
-induced I None
<eof> I None

<s> O None
thrombocytopenia I Disease
presents I None
5 I None
to I None
12 I None
days I None
after I None
heparin I Chemical
exposure I None
, I None
with I None
or I None
without I None
arterial I None
or I None
venous I None
thromboemboli I None
. I None
<eof> I None

<s> O None
Delayed I None
recognition I None
and I None
treatment I None
of I None
<eof> I None

<s> O None
heparin I Chemical
-induced I None
<eof> I None

<s> O None
thrombocytopenia I Disease
contribute I None
to I None
poor I None
patient I None
outcomes I None
. I None
<eof> I None

<s> O None
OBJECTIVE I None
: I None
<eof> I None

<s> O None
To I None
describe I None
and I None
increase I None
awareness I None
of I None
a I None
clinical I None
scenario I None
in I None
which I None
the I None
onset I None
or I None
manifestations I None
of I None
heparin I Chemical
-induced I None
<eof> I None

<s> O None
thrombocytopenia I Disease
are I None
delayed I None
. I None
<eof> I None

<s> O None
DESIGN I None
: I None
<eof> I None

<s> O None
Retrospective I None
case I None
series I None
. I None
<eof> I None

<s> O None
SETTING I None
: I None
<eof> I None

<s> O None
Three I None
large I None
urban I None
hospitals I None
( I None
with I None
active I None
cardiovascular I None
surgery I None
programs I None
) I None
. I None
<eof> I None

<s> O None
PATIENTS I None
: I None
14 I None
patients I None
seen I None
over I None
a I None
3-year I None
period I None
in I None
whom I None
heparin I Chemical
-induced I None
<eof> I None

<s> O None
thrombocytopenia I Disease
became I None
apparent I None
on I None
delayed I None
presentation I None
with I None
thromboembolic I Disease
complications I None
. I None
<eof> I None

<s> O None
MEASUREMENTS I None
: I None
Platelet I None
counts I None
, I None
onset I None
of I None
objectively I None
determined I None
thromboembolism I Disease
, I None
results I None
of I None
heparin I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
platelet I None
factor I None
4 I None
antibody I None
tests I None
, I None
and I None
outcomes I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
Patients I None
went I None
home I None
after I None
hospitalizations I None
that I None
had I None
included I None
heparin I Chemical
exposure I None
-- I None
in I None
most I None
cases I None
, I None
with I None
no I None
thrombocytopenia I Disease
recognized I None
-- I None
only I None
to I None
return I None
to I None
the I None
hospital I None
( I None
median I None
, I None
day I None
14 I None
) I None
with I None
thromboembolic I Disease
complications I None
. I None
<eof> I None

<s> O None
Thromboemboli I Disease
were I None
venous I None
( I None
12 I None
patients I None
, I None
7 I None
with I None
pulmonary I Disease
emboli O Disease
) I None
or I None
arterial I None
( I None
4 I None
patients I None
) I None
or I None
both I None
. I None
<eof> I None

<s> O None
Platelet I None
counts I None
were I None
mildly I None
decreased I None
in I None
all I None
but I None
2 I None
patients I None
on I None
second I None
presentation I None
. I None
<eof> I None

<s> O None
On I None
readmission I None
, I None
11 I None
patients I None
received I None
therapeutic I None
heparin I Chemical
, I None
which I None
worsened I None
the I None
patients I None
' I None
clinical I None
condition I None
and I None
, I None
in I None
all I None
11 I None
cases I None
, I None
decreased I None
the I None
platelet I None
count I None
( I None
mean I None
at I None
readmission I None
, I None
143 I None
x I None
10(9 I None
) I None
cells I None
/ I None
L I None
; I None
mean I None
nadir I None
after I None
heparin I Chemical
re I None
- I None
exposure I None
, I None
39 I None
x I None
10(9 I None
) I None
cells I None
/ I None
L I None
) I None
. I None
<eof> I None

<s> O None
Results I None
of I None
serologic I None
tests I None
for I None
heparin I Chemical
-induced I None
antibodies I None
were I None
positive I None
in I None
all I None
patients I None
. I None
<eof> I None

<s> O None
Subsequent I None
treatments I None
included I None
alternative I None
anticoagulants I None
( I None
11 I None
patients I None
) I None
, I None
thrombolytic I None
drugs I None
( I None
3 I None
patients I None
) I None
, I None
inferior I None
vena I None
cava I None
filters I None
( I None
3 I None
patients I None
) I None
and I None
, I None
eventually I None
, I None
warfarin I Chemical
<eof> I None

<s> O None
( I None
11 I None
patients I None
) I None
. I None
<eof> I None

<s> O None
Three I None
patients I None
died I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
Delayed I None
- I None
onset I None
<eof> I None

<s> O None
heparin I Chemical
-induced I None
<eof> I None

<s> O None
thrombocytopenia I Disease
is I None
increasingly I None
being I None
recognized I None
. I None
<eof> I None

<s> O None
To I None
avoid I None
disastrous I None
outcomes I None
, I None
physicians I None
must I None
consider I None
<eof> I None

<s> O None
heparin I Chemical
-induced I None
<eof> I None

<s> O None
thrombocytopenia I Disease
<eof> I None

<s> O None
whenever I None
a I None
recently I None
hospitalized I None
patient I None
returns I None
with I None
thromboembolism I Disease
; I None
therapy I None
with I None
alternative I None
anticoagulants I None
, I None
not I None
heparin I Chemical
, I None
should I None
be I None
initiated I None
. I None
<eof> I None

<s> O None
Valsartan I Chemical
, I None
a I None
new I None
angiotensin I Chemical
II O Chemical
antagonist I None
for I None
the I None
treatment I None
of I None
essential I None
hypertension I Disease
: I None
a I None
comparative I None
study I None
of I None
the I None
efficacy I None
and I None
safety I None
against I None
amlodipine I Chemical
. I None
<eof> I None

<s> O None
OBJECTIVE I None
: I None
<eof> I None

<s> O None
To I None
compare I None
the I None
antihypertensive I None
efficacy I None
of I None
a I None
new I None
angiotensin I Chemical
II O Chemical
antagonist I None
, I None
valsartan I Chemical
, I None
with I None
a I None
reference I None
therapy I None
, I None
amlodipine I Chemical
. I None
<eof> I None

<s> O None
METHODS I None
: I None
<eof> I None

<s> O None
One I None
hundred I None
sixty I None
- I None
eight I None
adult I None
outpatients I None
with I None
mild I None
to I None
moderate I None
hypertension I Disease
were I None
randomly I None
allocated I None
in I None
double I None
- I None
blind I None
fashion I None
and I None
equal I None
number I None
to I None
receive I None
80 I None
mg I None
valsartan I Chemical
or I None
5 I None
mg I None
amlodipine I Chemical
for I None
12 I None
weeks I None
. I None
<eof> I None

<s> O None
After I None
8 I None
weeks I None
of I None
therapy I None
, I None
in I None
patients I None
whose I None
blood I None
pressure I None
remained I None
uncontrolled I None
, I None
5 I None
mg I None
amlodipine I Chemical
was I None
added I None
to I None
the I None
initial I None
therapy I None
. I None
<eof> I None

<s> O None
Patients I None
were I None
assessed I None
at I None
4 I None
, I None
8 I None
, I None
and I None
12 I None
weeks I None
. I None
<eof> I None

<s> O None
The I None
primary I None
efficacy I None
variable I None
was I None
change I None
from I None
baseline I None
in I None
mean I None
sitting I None
diastolic I None
blood I None
pressure I None
at I None
8 I None
weeks I None
. I None
<eof> I None

<s> O None
Secondary I None
variables I None
included I None
change I None
in I None
sitting I None
systolic I None
blood I None
pressure I None
and I None
responder I None
rates I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
Both I None
valsartan I Chemical
and I None
amlodipine I Chemical
were I None
effective I None
at I None
lowering I None
blood I None
pressure I None
at I None
4 I None
, I None
8 I None
, I None
and I None
12 I None
weeks I None
. I None
<eof> I None

<s> O None
Similar I None
decreases I None
were I None
observed I None
in I None
both I None
groups I None
, I None
with I None
no I None
statistically I None
significant I None
differences I None
between I None
the I None
groups I None
for I None
any I None
variable I None
analyzed I None
. I None
<eof> I None

<s> O None
For I None
the I None
primary I None
variable I None
the I None
difference I None
was I None
0.5 I None
mm I None
Hg I None
in I None
favor I None
of I None
valsartan I Chemical
<eof> I None

<s> O None
( I None
p I None
= I None
0.68 I None
; I None
95 I None
% I None
confidence I None
interval I None
, I None
-2.7 I None
to I None
1.7 I None
) I None
. I None
<eof> I None

<s> O None
Responder I None
rates I None
at I None
8 I None
weeks I None
were I None
66.7 I None
% I None
for I None
valsartan I Chemical
and I None
60.2 I None
% I None
for I None
amlodipine I Chemical
<eof> I None

<s> O None
( I None
p I None
= I None
0.39 I None
) I None
. I None
<eof> I None

<s> O None
Both I None
treatments I None
were I None
well I None
tolerated I None
. I None
<eof> I None

<s> O None
The I None
incidence I None
of I None
drug I None
- I None
related I None
dependent I None
edema I Disease
was I None
somewhat I None
higher I None
in I None
the I None
amlodipine I Chemical
group I None
, I None
particularly I None
at I None
a I None
dose I None
of I None
10 I None
mg I None
per I None
day I None
( I None
2.4 I None
% I None
for I None
80 I None
mg I None
valsartan I Chemical
; I None
3.6 I None
% I None
for I None
5 I None
mg I None
amlodipine I Chemical
; I None
0 I None
% I None
for I None
valsartan I Chemical
plus I None
5 I None
mg I None
amlodipine I Chemical
; I None
14.3 I None
% I None
for I None
10 I None
mg I None
amlodipine I Chemical
) I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
The I None
data I None
show I None
that I None
valsartan I Chemical
is I None
at I None
least I None
as I None
effective I None
as I None
amlodipine I Chemical
in I None
the I None
treatment I None
of I None
mild I None
to I None
moderate I None
hypertension I Disease
. I None
<eof> I None

<s> O None
The I None
results I None
also I None
show I None
valsartan I Chemical
to I None
be I None
well I None
tolerated I None
and I None
suggest I None
that I None
it I None
is I None
not I None
associated I None
with I None
side I None
effects I None
characteristic I None
of I None
this I None
comparator I None
class I None
, I None
dihydropyridine I Chemical
calcium I Chemical
antagonists I None
. I None
<eof> I None

<s> O None
KF17837 I Chemical
: I None
a I None
novel I None
selective I None
adenosine I Chemical
A2A I None
receptor I None
antagonist I None
with I None
anticataleptic I None
activity I None
. I None
<eof> I None

<s> O None
KF17837 I Chemical
is I None
a I None
novel I None
selective I None
adenosine I Chemical
A2A I None
receptor I None
antagonist I None
. I None
<eof> I None

<s> O None
Oral I None
administration I None
of I None
KF17837 I Chemical
<eof> I None

<s> O None
( I None
2.5 I None
, I None
10.0 I None
and I None
30.0 I None
mg I None
/ I None
kg I None
) I None
<eof> I None

<s> O None
significantly I None
ameliorated I None
the I None
cataleptic I Disease
responses I None
induced I None
by I None
intracerebroventricular I None
administration I None
of I None
an I None
adenosine I Chemical
A2A I None
receptor I None
agonist I None
, I None
CGS I Chemical
21680 O Chemical
( I None
10 I None
micrograms I None
) I None
, I None
in I None
a I None
dose I None
- I None
dependent I None
manner I None
. I None
<eof> I None

<s> O None
KF17837 I Chemical
also I None
reduced I None
the I None
catalepsy I Disease
induced I None
by I None
haloperidol I Chemical
<eof> I None

<s> O None
( I None
1 I None
mg I None
/ I None
kg I None
i.p I None
. I None
) I None
<eof> I None

<s> O None
and I None
by I None
reserpine I Chemical
<eof> I None

<s> O None
( I None
5 I None
mg I None
/ I None
kg I None
i.p I None
. I None
) I None
. I None
<eof> I None

<s> O None
These I None
anticataleptic I None
effects I None
were I None
exhibited I None
dose I None
dependently I None
at I None
doses I None
from I None
0.625 I None
and I None
2.5 I None
mg I None
/ I None
kg I None
p.o I None
. I None
, I None
respectively I None
. I None
<eof> I None

<s> O None
Moreover I None
, I None
KF17837 I Chemical
<eof> I None

<s> O None
( I None
0.625 I None
mg I None
/ I None
kg I None
p.o I None
. I None
) I None
<eof> I None

<s> O None
potentiated I None
the I None
anticataleptic I None
effects I None
of I None
a I None
subthreshold I None
dose I None
of I None
L-3,4-dihydroxyphenylalanine I Chemical
<eof> I None

<s> O None
( I None
L I Chemical
- O Chemical
DOPA O Chemical
; I None
25 I None
mg I None
/ I None
kg I None
i.p I None
. I None
) I None
plus I None
benserazide I Chemical
( I None
6.25 I None
mg I None
/ I None
kg I None
i.p I None
. I None
) I None
. I None
<eof> I None

<s> O None
These I None
results I None
suggested I None
that I None
KF17837 I Chemical
is I None
a I None
centrally I None
active I None
adenosine I Chemical
A2A I None
receptor I None
antagonist I None
and I None
that I None
the I None
dopaminergic I None
function I None
of I None
the I None
nigrostriatal I None
pathway I None
is I None
potentiated I None
by I None
adenosine I Chemical
<eof> I None

<s> O None
A2A I None
receptor I None
antagonists I None
. I None
<eof> I None

<s> O None
Furthermore I None
, I None
KF17837 I Chemical
may I None
be I None
a I None
useful I None
drug I None
in I None
the I None
treatment I None
of I None
parkinsonism I Disease
. I None
<eof> I None

<s> O None
Some I None
central I None
effects I None
of I None
repeated I None
treatment I None
with I None
fluvoxamine I Chemical
. I None
<eof> I None

<s> O None
We I None
investigated I None
the I None
effect I None
of I None
repeated I None
treatment I None
with I None
fluvoxamine I Chemical
, I None
a I None
selective I None
serotonin I Chemical
uptake I None
inhibitor I None
, I None
on I None
behavioral I None
effects I None
of I None
dopaminomimetics I None
and I None
methoxamine I Chemical
and I None
on I None
the I None
animal I None
behavior I None
in I None
the I None
" I None
behavioral I None
despair I None
" I None
test I None
. I None
<eof> I None

<s> O None
A I None
repeated I None
treatment I None
with I None
fluvoxamine I Chemical
<eof> I None

<s> O None
( I None
twice I None
daily I None
for I None
14 I None
days I None
) I None
potentiated I None
in I None
mice I None
and I None
in I None
rats I None
( I None
weaker I None
) I None
the I None
amphetamine I Chemical
-induced I None
hyperactivity I Disease
. I None
<eof> I None

<s> O None
The I None
hyperactivity I Disease
induced I None
by I None
nomifensine I Chemical
in I None
mice I None
remained I None
unaffected I None
by I None
fluvoxamine I Chemical
. I None
<eof> I None

<s> O None
The I None
stimulation I None
of I None
locomotor I None
activity I None
by I None
intracerebroventricularly I None
administered I None
methoxamine I Chemical
was I None
not I None
affected I None
by I None
repeated I None
treatment I None
with I None
fluvoxamine I Chemical
. I None
<eof> I None

<s> O None
Given I None
three I None
times I None
fluvoxamine I Chemical
had I None
no I None
effect I None
on I None
the I None
immobilization I None
time I None
in I None
the I None
" I None
behavioral I None
despair I None
" I None
test I None
in I None
rats I None
. I None
<eof> I None

<s> O None
The I None
results I None
indicate I None
that I None
fluvoxamine I Chemical
given I None
repeatedly I None
acts I None
differently I None
than I None
citalopram I Chemical
, I None
another I None
selective I None
serotonin I Chemical
uptake I None
inhibitor I None
, I None
and I None
differs I None
also I None
from I None
other I None
antidepressant I None
drugs I None
. I None
<eof> I None

<s> O None
Severe I None
congestive I Disease
heart O Disease
failure O Disease
patient I None
on I None
<eof> I None

<s> O None
amiodarone I Chemical
<eof> I None

<s> O None
presenting I None
with I None
myxedemic I None
coma I None
: I None
a I None
case I None
report I None
. I None
<eof> I None

<s> O None
This I None
is I None
a I None
case I None
report I None
of I None
myxedema I None
coma I None
secondary I None
to I None
amiodarone I Chemical
-induced I None
hypothyroidism I Disease
in I None
a I None
patient I None
with I None
severe I None
congestive I Disease
heart O Disease
failure O Disease
<eof> I None

<s> O None
( I None
CHF I Disease
) I None
. I None
<eof> I None

<s> O None
To I None
our I None
knowledge I None
and I None
after I None
reviewing I None
the I None
literature I None
there I None
is I None
one I None
case I None
report I None
of I None
myxedema I None
coma I None
during I None
long I None
term I None
amiodarone I Chemical
therapy I None
. I None
<eof> I None

<s> O None
Myxedema I None
coma I None
is I None
a I None
life I None
threatening I None
condition I None
that I None
carries I None
a I None
mortality I None
reaching I None
as I None
high I None
as I None
20 I None
% I None
with I None
treatment I None
. I None
<eof> I None

<s> O None
The I None
condition I None
is I None
treated I None
with I None
intravenous I None
thyroxine I Chemical
<eof> I None

<s> O None
( I None
T4 I Chemical
) I None
or I None
intravenous I None
tri I Chemical
- O Chemical
iodo O Chemical
- O Chemical
thyronine O Chemical
<eof> I None

<s> O None
( I None
T3 I Chemical
) I None
. I None
<eof> I None

<s> O None
Patients I None
with I None
CHF I Disease
on I None
amiodarone I Chemical
may I None
suffer I None
serious I None
morbidity I None
and I None
mortality I None
from I None
hypothyroidism I Disease
, I None
and I None
thus I None
may I None
deserve I None
closer I None
follow I None
up I None
for I None
thyroid I None
stimulating I None
hormone I None
( I None
TSH I None
) I None
levels I None
. I None
<eof> I None

<s> O None
This I None
case I None
report I None
carries I None
an I None
important I None
clinical I None
application I None
given I None
the I None
frequent I None
usage I None
of I None
amiodarone I Chemical
among I None
CHF I Disease
patients I None
. I None
<eof> I None

<s> O None
The I None
myriad I None
clinical I None
presentation I None
of I None
myxedema I None
coma I None
and I None
its I None
serious I None
morbidity I None
and I None
mortality I None
stresses I None
the I None
need I None
to I None
suspect I None
this I None
clinical I None
syndrome I None
among I None
CHF I Disease
patients I None
presenting I None
with I None
hypotension I Disease
, I None
weakness I Disease
or I None
other I None
unexplained I None
symptoms I None
. I None
<eof> I None

<s> O None
Fear I None
- I None
potentiated I None
startle I Disease
, I None
but I None
not I None
light I None
- I None
enhanced I None
startle I Disease
, I None
is I None
enhanced I None
by I None
anxiogenic I None
drugs I None
. I None
<eof> I None

<s> O None
RATIONALE I None
AND I None
OBJECTIVES I None
: I None
<eof> I None

<s> O None
The I None
light I None
- I None
enhanced I None
startle I Disease
paradigm I None
( I None
LES I None
) I None
is I None
suggested I None
to I None
model I None
anxiety I Disease
, I None
because I None
of I None
the I None
non I None
- I None
specific I None
cue I None
and I None
the I None
long I None
- I None
term I None
effect I None
. I None
<eof> I None

<s> O None
In I None
contrast I None
, I None
the I None
fear I None
- I None
potentiated I None
startle I Disease
<eof> I None

<s> O None
( I None
FPS I None
) I None
is I None
suggested I None
to I None
model I None
conditioned I None
fear I None
. I None
<eof> I None

<s> O None
However I None
, I None
the I None
pharmacological I None
profiles I None
of I None
these I None
two I None
paradigms I None
are I None
very I None
similar I None
. I None
<eof> I None

<s> O None
The I None
present I None
study I None
investigated I None
the I None
effects I None
of I None
putative I None
anxiogenic I None
drugs I None
on I None
LES I None
and I None
FPS I None
and I None
aimed I None
at I None
determining I None
the I None
sensitivity I None
of I None
LES I None
for I None
anxiogenic I None
drugs I None
and I None
to I None
potentially I None
showing I None
a I None
pharmacological I None
differentiation I None
between I None
these I None
two I None
paradigms I None
. I None
<eof> I None

<s> O None
METHODS I None
: I None
<eof> I None

<s> O None
Male I None
Wistar I None
rats I None
received I None
each I None
dose I None
of I None
the I None
alpha(2)-adrenoceptor I None
antagonist I None
yohimbine I Chemical
( I None
0.25 I None
- I None
1.0mg I None
/ I None
kg I None
) I None
, I None
the I None
5-HT I Chemical
( I None
<eof> I None

<s> O None
2C I None
) I None
receptor I None
agonist I None
m I Chemical
- O Chemical
chlorophenylpiperazine O Chemical
<eof> I None

<s> O None
( I None
mCPP I Chemical
, I None
0.5 I None
- I None
2.0mg I None
/ I None
kg I None
) I None
or I None
the I None
GABA I Chemical
( I None
A I None
) I None
inverse I None
receptor I None
agonist I None
pentylenetetrazole I Chemical
<eof> I None

<s> O None
( I None
PTZ I Chemical
, I None
3 I None
- I None
30mg I None
/ I None
kg I None
) I None
and I None
were I None
subsequently I None
tested I None
in I None
either I None
LES I None
or I None
FPS I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
None I None
of I None
the I None
drugs I None
enhanced I None
LES I None
, I None
whereas I None
mCPP I Chemical
increased I None
percentage I None
FPS I None
and I None
<eof> I None

<s> O None
yohimbine I Chemical
increased I None
absolute I None
FPS I None
values I None
. I None
<eof> I None

<s> O None
Furthermore I None
, I None
yohimbine I Chemical
increased I None
baseline I None
startle I Disease
amplitude I None
in I None
the I None
LES I None
, I None
while I None
mCPP I Chemical
suppressed I None
baseline I None
startle I Disease
in I None
both I None
the I None
LES I None
and I None
FPS I None
and I None
PTZ I Chemical
suppressed I None
baseline I None
startle I Disease
in I None
the I None
FPS I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
In I None
contrast I None
to I None
findings I None
in I None
the I None
FPS I None
paradigm I None
, I None
none I None
of I None
the I None
drugs I None
were I None
able I None
to I None
exacerbate I None
the I None
LES I None
response I None
. I None
<eof> I None

<s> O None
Thus I None
, I None
a I None
clear I None
pharmacological I None
differentiation I None
was I None
found I None
between I None
LES I None
and I None
FPS I None
. I None
<eof> I None

<s> O None
Proteinase I None
3-antineutrophil I None
cytoplasmic I None
antibody-(PR3-ANCA I None
) I None
positive I None
necrotizing I None
glomerulonephritis I Disease
after I None
restarting I None
sulphasalazine I Chemical
treatment I None
. I None
<eof> I None

<s> O None
A I None
59-year I None
- I None
old I None
woman I None
with I None
ulcerative I Disease
colitis O Disease
developed I None
<eof> I None

<s> O None
red I Disease
eyes O Disease
, I None
pleural I Disease
effusion O Disease
, I None
eosinophilia I Disease
and I None
urinary I Disease
abnormalities O Disease
after I None
restarting I None
of I None
sulphasalazine I Chemical
treatment I None
. I None
<eof> I None

<s> O None
Light I None
microscopy I None
of I None
a I None
kidney I None
biopsy I None
revealed I None
segmental I Disease
necrotizing O Disease
glomerulonephritis O Disease
without I None
deposition I None
of I None
immunoglobulin I None
or I None
complement I None
. I None
<eof> I None

<s> O None
Proteinase I None
3-antineutrophil I None
cytoplasmic I None
antibody I None
( I None
PR3-ANCA I None
) I None
<eof> I None

<s> O None
titer I None
was I None
elevated I None
at I None
183 I None
ELISA I None
units I None
( I None
EU I None
) I None
in I None
sera I None
( I None
normal I None
range I None
less I None
than I None
10 I None
EU I None
) I None
, I None
myeloperoxidase I None
- I None
ANCA I None
was I None
negative I None
. I None
<eof> I None

<s> O None
PR3-ANCA I None
titer I None
was I None
250 I None
and I None
1,070 I None
EU I None
in I None
pleural I Disease
effusions O Disease
on I None
right I None
and I None
left I None
side I None
, I None
respectively I None
. I None
<eof> I None

<s> O None
Although I None
cessation I None
of I None
sulphasalazine I Chemical
treatment I None
resulted I None
in I None
improvements I None
in I None
fever I Disease
, I None
red I Disease
eyes O Disease
, I None
chest I Disease
pain O Disease
, I None
titer I None
of I None
C I None
- I None
reactive I None
protein I None
and I None
volume I None
of I None
the I None
pleural I Disease
effusions O Disease
, I None
we I None
initiated I None
steroid I Chemical
therapy I None
, I None
because I None
PR3-ANCA I None
titer I None
rose I None
to I None
320 I None
EU I None
, I None
eosinophil I None
count I None
increased I None
to I None
1,100 I None
cells I None
/ I None
microl I None
, I None
and I None
the I None
pleural I Disease
effusion O Disease
remained I None
. I None
<eof> I None

<s> O None
One I None
month I None
after I None
steroid I Chemical
therapy I None
, I None
the I None
pleural I Disease
effusion O Disease
disappeared I None
, I None
and I None
PR3-ANCA I None
titer I None
normalized I None
3 I None
months I None
later I None
. I None
<eof> I None

<s> O None
This I None
case I None
suggests I None
that I None
sulphasalazine I Chemical
can I None
induce I None
PR3-ANCA I None
- I None
positive I None
necrotizing I None
glomerulonephritis I Disease
. I None
<eof> I None

<s> O None
Is I None
phenytoin I Chemical
administration I None
safe I None
in I None
a I None
hypothermic I Disease
child I None
? I None
<eof> I None

<s> O None
A I None
male I None
neonate I None
with I None
a I None
Chiari I Disease
malformation O Disease
and I None
a I None
leaking I None
myelomeningocoele I None
underwent I None
ventriculoperitoneal I None
shunt I None
insertion I None
followed I None
by I None
repair I None
of I None
myelomeningocoele I None
. I None
<eof> I None

<s> O None
During I None
anaesthesia I None
and I None
surgery I None
, I None
he I None
inadvertently I None
became I None
moderately I None
hypothermic I Disease
. I None
<eof> I None

<s> O None
Intravenous I None
phenytoin I Chemical
was I None
administered I None
during I None
the I None
later I None
part I None
of I None
the I None
surgery I None
for I None
seizure I Disease
prophylaxis I None
. I None
<eof> I None

<s> O None
Following I None
phenytoin I Chemical
administration I None
, I None
the I None
patient I None
developed I None
acute I None
severe I None
bradycardia I Disease
, I None
refractory I None
to I None
atropine I Chemical
and I None
adrenaline I Chemical
. I None
<eof> I None

<s> O None
The I None
cardiac I None
depressant I None
actions I None
of I None
phenytoin I Chemical
and I None
hypothermia I Disease
can I None
be I None
additive I None
. I None
<eof> I None

<s> O None
Administration I None
of I None
phenytoin I Chemical
in I None
the I None
presence I None
of I None
hypothermia I Disease
may I None
lead I None
to I None
an I None
adverse I None
cardiac I None
event I None
in I None
children I None
. I None
<eof> I None

<s> O None
As I None
phenytoin I Chemical
is I None
a I None
commonly I None
used I None
drug I None
, I None
clinicians I None
need I None
to I None
be I None
aware I None
of I None
this I None
interaction I None
. I None
<eof> I None

<s> O None
Amisulpride I Chemical
related I None
<eof> I None

<s> O None
tic I Disease
- O Disease
like O Disease
symptoms O Disease
in I None
an I None
adolescent I None
schizophrenic I Disease
. I None
<eof> I None

<s> O None
Tic I Disease
disorders O Disease
can I None
be I None
effectively I None
treated I None
by I None
atypical I None
antipsychotics I None
such I None
as I None
risperidone I Chemical
, I None
olanzapine I Chemical
and I None
ziprasidone I Chemical
. I None
<eof> I None

<s> O None
However I None
, I None
there I None
are I None
two I None
case I None
reports I None
that I None
show I None
tic I Disease
- O Disease
like O Disease
symptoms O Disease
, I None
including I None
motor I None
and I None
phonic I None
variants I None
, I None
occurring I None
during I None
treatment I None
with I None
quetiapine I Chemical
or I None
clozapine I Chemical
. I None
<eof> I None

<s> O None
We I None
present I None
a I None
15-year I None
- I None
old I None
girl I None
schizophrenic I Disease
who I None
developed I None
frequent I None
involuntary I Disease
eye O Disease
- O Disease
blinking O Disease
movements O Disease
after I None
5 I None
months I None
of I None
amisulpride I Chemical
treatment I None
( I None
1000 I None
mg I None
per I None
day I None
) I None
. I None
<eof> I None

<s> O None
The I None
tic I Disease
- O Disease
like O Disease
symptoms O Disease
resolved I None
completely I None
after I None
we I None
reduced I None
the I None
dose I None
of I None
amisulpride I Chemical
down I None
to I None
800 I None
mg I None
per I None
day I None
. I None
<eof> I None

<s> O None
However I None
, I None
her I None
psychosis I Disease
recurred I None
after I None
the I None
dose I None
reduction I None
. I None
<eof> I None

<s> O None
We I None
then I None
placed I None
her I None
on I None
an I None
additional I None
100 I None
mg I None
per I None
day I None
of I None
quetiapine I Chemical
. I None
<eof> I None

<s> O None
She I None
has I None
been I None
in I None
complete I None
remission I None
under I None
the I None
combined I None
medications I None
for I None
more I None
than I None
one I None
year I None
and I None
maintains I None
a I None
fair I None
role I None
function I None
. I None
<eof> I None

<s> O None
No I None
more I None
<eof> I None

<s> O None
tic I Disease
- O Disease
like O Disease
symptoms O Disease
or I None
other I None
side I None
effects I None
have I None
been I None
reported I None
. I None
<eof> I None

<s> O None
Together I None
with I None
previously I None
reported I None
cases I None
, I None
our I None
patient I None
suggests I None
that I None
tic I Disease
- O Disease
like O Disease
symptoms O Disease
might I None
occur I None
in I None
certain I None
vulnerable I None
individuals I None
during I None
treatment I None
with I None
atypical I None
antipsychotics I None
such I None
as I None
quetiapine I Chemical
, I None
clozapine I Chemical
, I None
or I None
amisulpride I Chemical
. I None
<eof> I None

<s> O None
Comparison I None
of I None
developmental I None
toxicology I None
of I None
aspirin I Chemical
<eof> I None

<s> O None
( I None
acetylsalicylic I Chemical
acid O Chemical
) I None
in I None
rats I None
using I None
selected I None
dosing I None
paradigms I None
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
<eof> I None

<s> O None
Analysis I None
of I None
the I None
literature I None
for I None
nonsteroidal I None
anti I None
- I None
inflammatory I None
drugs I None
( I None
NSAIDs I None
) I None
suggests I None
that I None
a I None
low I None
incidence I None
of I None
developmental I Disease
anomalies O Disease
occurs I None
in I None
rats I None
given I None
NSAIDs I None
on I None
specific I None
days I None
during I None
organogenesis I None
. I None
<eof> I None

<s> O None
Aspirin I Chemical
<eof> I None

<s> O None
( I None
acetylsalicylic I Chemical
acid O Chemical
[ I None
ASA I Chemical
] I None
) I None
, I None
an I None
irreversible I None
cyclooxygenase I None
1 I None
and I None
2 I None
inhibitor I None
, I None
induces I None
developmental I Disease
anomalies O Disease
when I None
administered I None
to I None
Wistar I None
rats I None
on I None
gestational I None
day I None
( I None
GD I None
) I None
<eof> I None

<s> O None
9 I None
, I None
10 I None
, I None
or I None
11 I None
( I None
Kimmel I None
CA I None
, I None
Wilson I None
JG I None
, I None
Schumacher I None
HJ I None
. I None
<eof> I None

<s> O None
Teratology I None
4:15 I None
- I None
24 I None
, I None
1971 I None
) I None
. I None
<eof> I None

<s> O None
There I None
are I None
no I None
published I None
ASA I Chemical
studies I None
using I None
the I None
multiple I None
dosing I None
paradigm I None
of I None
GDs I None
6 I None
to I None
17 I None
. I None
<eof> I None

<s> O None
Objectives I None
of I None
the I None
current I None
study I None
were I None
to I None
compare I None
results I None
between I None
Sprague I None
- I None
Dawley I None
( I None
SD I None
) I None
and I None
Wistar I None
strains I None
when I None
ASA I Chemical
is I None
administered I None
on I None
GD I None
9 I None
, I None
10 I None
, I None
or I None
11 I None
; I None
to I None
compare I None
the I None
malformation I None
patterns I None
following I None
single I None
and I None
multiple I None
dosings I None
during I None
organogenesis I None
in I None
SD I None
rats I None
; I None
and I None
to I None
test I None
the I None
hypothesis I None
that I None
maternal I None
gastrointestinal I Disease
toxicity O Disease
confounds I None
the I None
detection I None
of I None
low I None
incidence I None
malformations I Disease
with I None
ASA I Chemical
when I None
a I None
multiple I None
dosing I None
paradigm I None
is I None
used I None
. I None
<eof> I None

<s> O None
METHODS I None
: I None
<eof> I None

<s> O None
ASA I Chemical
was I None
administered I None
as I None
a I None
single I None
dose I None
on I None
GD I None
9 I None
( I None
0 I None
, I None
250 I None
, I None
500 I None
, I None
or I None
625 I None
mg I None
/ I None
kg I None
) I None
, I None
10 I None
( I None
0 I None
, I None
500 I None
, I None
625 I None
, I None
or I None
750 I None
mg I None
/ I None
kg I None
) I None
, I None
or I None
11 I None
( I None
0 I None
, I None
500 I None
, I None
750 I None
, I None
or I None
1000 I None
mg I None
/ I None
kg I None
) I None
and I None
from I None
GD I None
6 I None
to I None
GD I None
17 I None
( I None
0 I None
, I None
50 I None
, I None
125 I None
, I None
or I None
250 I None
mg I None
/ I None
kg I None
a I None
day I None
) I None
<eof> I None

<s> O None
in I None
the I None
multiple I None
dose I None
study I None
to I None
SD I None
rats I None
. I None
<eof> I None

<s> O None
Animals I None
were I None
killed I None
on I None
GD I None
21 I None
, I None
and I None
fetuses I None
were I None
examined I None
viscerally I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
The I None
literature I None
evaluation I None
suggested I None
that I None
NSAIDs I None
induce I None
ventricular I Disease
septal O Disease
defects O Disease
<eof> I None

<s> O None
( I None
VSDs I Disease
) I None
and I None
midline I Disease
defects O Disease
<eof> I None

<s> O None
( I None
MDs I Disease
) I None
in I None
rats I None
and I None
diaphragmatic I Disease
hernia O Disease
<eof> I None

<s> O None
( I None
DH I Disease
) I None
, I None
MDs I Disease
, I None
and I None
VSDs I Disease
in I None
rabbits I None
( I None
Cook I None
JC I None
et I None
al I None
. I None
, I None
2003 I None
) I None
; I None
hence I None
, I None
the I None
present I None
study I None
focused I None
on I None
these I None
malformations I Disease
, I None
even I None
though I None
ASA I Chemical
induces I None
several I None
other I None
low I None
- I None
incidence I None
malformations I Disease
. I None
<eof> I None

<s> O None
In I None
single I None
dose I None
studies I None
, I None
DH I Disease
, I None
MD I Disease
, I None
and I None
VSD I Disease
were I None
induced I None
on I None
GDs I None
9 I None
and I None
10 I None
. I None
<eof> I None

<s> O None
VSD I Disease
also I None
was I None
noted I None
following I None
treatment I None
on I None
GD I None
11 I None
. I None
<eof> I None

<s> O None
In I None
contrast I None
, I None
DH I Disease
and I None
MD I Disease
were I None
noted I None
in I None
the I None
multiple I None
dose I None
study I None
design I None
only I None
in I None
the I None
high I None
- I None
dose I None
group I None
, I None
and I None
VSD I Disease
was I None
noted I None
across I None
all I None
dose I None
groups I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
High I None
concordance I None
in I None
major I None
developmental I Disease
anomalies O Disease
between I None
Wistar I None
and I None
SD I None
rats I None
were I None
noted I None
with I None
the I None
exception I None
of I None
VSD I Disease
in I None
the I None
SD I None
rats I None
and I None
hydrocephalus I Disease
in I None
the I None
Wistar I None
rats I None
. I None
<eof> I None

<s> O None
Variations I None
and I None
malformations I Disease
were I None
similar I None
when I None
ASA I Chemical
was I None
administered I None
as I None
a I None
single I None
dose I None
or I None
during I None
the I None
period I None
of I None
organogenesis I None
( I None
GDs I None
6 I None
to I None
17 I None
) I None
. I None
<eof> I None

<s> O None
It I None
was I None
also I None
evident I None
that I None
, I None
by I None
titrating I None
the I None
dose I None
to I None
achieve I None
a I None
maximum I None
tolerated I None
dose I None
, I None
malformations I Disease
that I None
normally I None
occur I None
at I None
low I None
incidence I None
, I None
as I None
reported I None
from I None
previous I None
single I None
dose I None
studies I None
, I None
could I None
also I None
be I None
induced I None
with I None
ASA I Chemical
given I None
at I None
multiple I None
doses I None
. I None
<eof> I None

<s> O None
Torsade I Disease
de O Disease
pointes O Disease
induced I None
by I None
metoclopramide I Chemical
in I None
an I None
elderly I None
woman I None
with I None
preexisting I None
complete I None
left I Disease
bundle O Disease
branch O Disease
block O Disease
. I None
<eof> I None

<s> O None
There I None
is I None
a I None
growing I None
list I None
of I None
drugs I None
implicated I None
in I None
acquired I None
long I Disease
QT O Disease
syndrome O Disease
and I None
torsade I Disease
de O Disease
pointes O Disease
. I None
<eof> I None

<s> O None
However I None
, I None
the I None
torsadogenic I None
potential I None
of I None
metoclopramide I Chemical
, I None
a I None
commonly I None
used I None
antiemetic I None
and I None
prokinetic I None
drug I None
, I None
has I None
not I None
been I None
reported I None
in I None
the I None
literature I None
, I None
despite I None
its I None
chemical I None
similarity I None
to I None
procainamide I Chemical
. I None
<eof> I None

<s> O None
We I None
report I None
on I None
a I None
92-year I None
- I None
old I None
woman I None
with I None
preexisting I None
complete I None
left I Disease
bundle O Disease
branch O Disease
block O Disease
who I None
developed I None
torsade I Disease
de O Disease
pointes O Disease
after I None
intravenous I None
and I None
oral I None
administration I None
of I None
metoclopramide I Chemical
. I None
<eof> I None

<s> O None
This I None
patient I None
also I None
developed I None
torsade I Disease
de O Disease
pointes O Disease
when I None
cisapride I Chemical
and I None
erythromycin I Chemical
were I None
given I None
simultaneously I None
. I None
<eof> I None

<s> O None
These I None
two I None
episodes I None
were I None
suppressed I None
successfully I None
after I None
discontinuing I None
the I None
offending I None
drugs I None
and I None
administering I None
class I None
IB I None
drugs I None
. I None
<eof> I None

<s> O None
This I None
is I None
the I None
first I None
documentation I None
that I None
metoclopramide I Chemical
provokes I None
torsade I Disease
de O Disease
pointes O Disease
clinically I None
. I None
<eof> I None

<s> O None
Metoclopramide I Chemical
should I None
be I None
used I None
cautiously I None
in I None
patients I None
with I None
a I None
risk I None
of I None
torsade I Disease
de O Disease
pointes O Disease
. I None
<eof> I None

<s> O None
Apomorphine I Chemical
: I None
an I None
underutilized I None
therapy I None
for I None
Parkinson I Disease
's O Disease
disease O Disease
. I None
<eof> I None

<s> O None
Apomorphine I Chemical
was I None
the I None
first I None
dopaminergic I None
drug I None
ever I None
used I None
to I None
treat I None
symptoms I None
of I None
Parkinson I Disease
's O Disease
disease O Disease
. I None
<eof> I None

<s> O None
While I None
powerful I None
antiparkinsonian I None
effects I None
had I None
been I None
observed I None
as I None
early I None
as I None
1951 I None
, I None
the I None
potential I None
of I None
treating I None
fluctuating I None
Parkinson I Disease
's O Disease
disease O Disease
by I None
subcutaneous I None
administration I None
of I None
apomorphine I Chemical
has I None
only I None
recently I None
become I None
the I None
subject I None
of I None
systematic I None
study I None
. I None
<eof> I None

<s> O None
A I None
number I None
of I None
small I None
scale I None
clinical I None
trials I None
have I None
unequivocally I None
shown I None
that I None
intermittent I None
subcutaneous I None
apomorphine I Chemical
injections I None
produce I None
antiparkinsonian I None
benefit I None
close I None
if I None
not I None
identical I None
to I None
that I None
seen I None
with I None
levodopa I Chemical
and I None
that I None
apomorphine I Chemical
rescue I None
injections I None
can I None
reliably I None
revert I None
off I None
- I None
periods I None
even I None
in I None
patients I None
with I None
complex I None
on I None
- I None
off I None
motor I None
swings I None
. I None
<eof> I None

<s> O None
Continuous I None
subcutaneous I None
apomorphine I Chemical
infusions I None
can I None
reduce I None
daily I None
off I None
- I None
time I None
by I None
more I None
than I None
50 I None
% I None
in I None
this I None
group I None
of I None
patients I None
, I None
which I None
appears I None
to I None
be I None
a I None
stronger I None
effect I None
than I None
that I None
generally I None
seen I None
with I None
add I None
- I None
on I None
therapy I None
with I None
oral I None
dopamine I Chemical
agonists I None
or I None
COMT I None
inhibitors I None
. I None
<eof> I None

<s> O None
Extended I None
follow I None
- I None
up I None
studies I None
of I None
up I None
to I None
8 I None
years I None
have I None
demonstrated I None
long I None
- I None
term I None
persistence I None
of I None
apomorphine I Chemical
efficacy I None
. I None
<eof> I None

<s> O None
In I None
addition I None
, I None
there I None
is I None
convincing I None
clinical I None
evidence I None
that I None
monotherapy I None
with I None
continuous I None
subcutaneous I None
apomorphine I Chemical
infusions I None
is I None
associated I None
with I None
marked I None
reductions I None
of I None
preexisting I None
levodopa I Chemical
-induced I None
<eof> I None

<s> O None
dyskinesias I Disease
. I None
<eof> I None

<s> O None
The I None
main I None
side I None
effects I None
of I None
subcutaneous I None
apomorphine I Chemical
treatment I None
are I None
related I None
to I None
cutaneous I None
tolerability I None
problems I None
, I None
whereas I None
sedation I None
and I None
psychiatric I Disease
complications I None
play I None
a I None
lesser I None
role I None
. I None
<eof> I None

<s> O None
Given I None
the I None
marked I None
degree I None
of I None
efficacy I None
of I None
subcutaneous I None
apomorphine I Chemical
treatment I None
in I None
fluctuating I None
Parkinson I Disease
's O Disease
disease O Disease
, I None
this I None
approach I None
seems I None
to I None
deserve I None
more I None
widespread I None
clinical I None
use I None
. I None
<eof> I None

<s> O None
Fatal I None
excited I None
<eof> I None

<s> O None
delirium I Disease
following I None
cocaine I Chemical
use I None
: I None
epidemiologic I None
findings I None
provide I None
new I None
evidence I None
for I None
mechanisms I None
of I None
cocaine I Chemical
toxicity I Disease
. I None
<eof> I None

<s> O None
We I None
describe I None
an I None
outbreak I None
of I None
deaths I None
from I None
cocaine I Chemical
-induced I None
excited I None
delirium I Disease
<eof> I None

<s> O None
( I None
EDDs I Disease
) I None
in I None
Dade I None
County I None
, I None
Florida I None
between I None
1979 I None
and I None
1990 I None
. I None
<eof> I None

<s> O None
From I None
a I None
registry I None
of I None
all I None
cocaine I Chemical
-related I None
deaths I None
in I None
Dade I None
County I None
, I None
Florida I None
, I None
from I None
1969 I None
- I None
1990 I None
, I None
58 I None
EDDs I Disease
were I None
compared I None
with I None
125 I None
victims I None
of I None
accidental I None
cocaine I Chemical
<eof> I None

<s> O None
overdose I Disease
without I None
excited I None
delirium I Disease
. I None
<eof> I None

<s> O None
Compared I None
with I None
controls I None
, I None
EDDs I Disease
were I None
more I None
frequently I None
black I None
, I None
male I None
, I None
and I None
younger I None
. I None
<eof> I None

<s> O None
They I None
were I None
less I None
likely I None
to I None
have I None
a I None
low I None
body I None
mass I None
index I None
, I None
and I None
more I None
likely I None
to I None
have I None
died I None
in I None
police I None
custody I None
, I None
to I None
have I None
received I None
medical I None
treatment I None
immediately I None
before I None
death I None
, I None
to I None
have I None
survived I None
for I None
a I None
longer I None
period I None
, I None
to I None
have I None
developed I None
hyperthermia I Disease
, I None
and I None
to I None
have I None
died I None
in I None
summer I None
months I None
. I None
<eof> I None

<s> O None
EDDs I Disease
had I None
concentrations I None
of I None
cocaine I Chemical
and I None
benzoylecgonine I Chemical
in I None
autopsy I None
blood I None
that I None
were I None
similar I None
to I None
those I None
for I None
controls I None
. I None
<eof> I None

<s> O None
The I None
epidemiologic I None
findings I None
are I None
most I None
consistent I None
with I None
the I None
hypothesis I None
that I None
chronic I None
cocaine I Chemical
use I None
disrupts I None
dopaminergic I None
function I None
and I None
, I None
when I None
coupled I None
with I None
recent I None
cocaine I Chemical
use I None
, I None
may I None
precipitate I None
agitation I Disease
, I None
delirium I Disease
, I None
aberrant I None
thermoregulation I None
, I None
rhabdomyolysis I Disease
, I None
and I None
sudden I Disease
death O Disease
. I None
<eof> I None

<s> O None
Heparin I Chemical
-induced I None
thrombocytopenia I Disease
, I None
thrombosis I Disease
, I None
and I None
hemorrhage I Disease
. I None
<eof> I None

<s> O None
Sixty I None
- I None
two I None
patients I None
with I None
a I None
heparin I Chemical
-induced I None
thrombocytopenia I Disease
are I None
reported I None
. I None
<eof> I None

<s> O None
Clinical I None
manifestations I None
of I None
this I None
disorder I None
include I None
hemorrhage I Disease
or I None
, I None
more I None
frequently I None
, I None
thromboembolic I Disease
events I None
in I None
patients I None
receiving I None
heparin I Chemical
. I None
<eof> I None

<s> O None
Laboratory I None
testing I None
has I None
revealed I None
a I Disease
falling O Disease
platelet O Disease
count O Disease
, I None
increased I None
resistance I None
to I None
heparin I Chemical
, I None
and I None
aggregation I None
of I None
platelets I None
by I None
the I None
patient I None
's I None
plasma I None
when I None
heparin I Chemical
is I None
added I None
. I None
<eof> I None

<s> O None
Immunologic I None
testing I None
has I None
demonstrated I None
the I None
presence I None
of I None
a I None
heparin I Chemical
-dependent I None
platelet I None
membrane I None
antibody I None
. I None
<eof> I None

<s> O None
The I None
20 I None
deaths I None
, I None
52 I None
hemorrhagic I None
and I None
thromboembolic I None
complications I None
, I None
and I None
21 I None
surgical I None
procedures I None
to I None
manage I None
the I None
complications I None
confirm I None
the I None
seriousness I None
of I None
the I None
disorder I None
. I None
<eof> I None

<s> O None
Specific I None
risk I None
factors I None
have I None
not I None
been I None
identified I None
; I None
therefore I None
, I None
all I None
patients I None
receiving I None
heparin I Chemical
should I None
be I None
monitored I None
. I None
<eof> I None

<s> O None
If I None
the I None
platelet I None
count I None
falls I None
to I None
less I None
than I None
100,000/mm3 I None
, I None
while I None
the I None
patient I None
is I None
receiving I None
heparin I Chemical
, I None
platelet I Disease
aggregation O Disease
testing I None
, I None
using I None
the I None
patient I None
's I None
plasma I None
, I None
is I None
indicated I None
. I None
<eof> I None

<s> O None
Management I None
consists I None
of I None
cessation I None
of I None
heparin I Chemical
, I None
platelet I None
anti I None
- I None
aggregating I None
agents I None
, I None
and I None
alternate I None
forms I None
of I None
anticoagulation I None
when I None
indicated I None
. I None
<eof> I None

<s> O None
Cardiac I Disease
toxicity O Disease
of I None
5-fluorouracil I Chemical
. I None
<eof> I None

<s> O None
Report I None
of I None
a I None
case I None
of I None
spontaneous I None
angina I Disease
. I None
<eof> I None

<s> O None
We I None
report I None
a I None
case I None
of I None
a I None
patient I None
with I None
colon I Disease
carcinoma O Disease
and I None
liver I None
metastasis I Disease
who I None
presented I None
chest I Disease
pain O Disease
after I None
5-fluorouracil I Chemical
<eof> I None

<s> O None
( I None
5-FU I Chemical
) I None
administration I None
. I None
<eof> I None

<s> O None
Clinical I None
electrocardiographic I None
evolution I None
was I None
similar I None
to I None
that I None
observed I None
in I None
Prinzmetal I Disease
's O Disease
angina O Disease
, I None
and I None
chest I Disease
pain O Disease
promptly I None
resolved I None
with I None
nifedipine I Chemical
. I None
<eof> I None

<s> O None
These I None
data I None
suggest I None
that I None
coronary I Disease
spasm O Disease
may I None
be I None
the I None
cause I None
of I None
cardiotoxicity I Disease
due I None
to I None
5-FU I Chemical
, I None
and I None
that I None
calcium I Chemical
antagonists I None
may I None
probably I None
be I None
used I None
in I None
the I None
prevention I None
or I None
treatment I None
of I None
5-FU I Chemical
cardiotoxicity I Disease
. I None
<eof> I None

<s> O None
Toxicity I Disease
due I None
to I None
remission I None
inducing I None
drugs I None
in I None
rheumatoid I Disease
arthritis O Disease
. I None
<eof> I None

<s> O None
Association I None
with I None
HLA I None
- I None
B35 I None
and I None
Cw4 I None
antigens I None
. I None
<eof> I None

<s> O None
Twenty I None
- I None
five I None
patients I None
with I None
rheumatoid I Disease
arthritis O Disease
<eof> I None

<s> O None
( I None
RA I Disease
) I None
who I None
developed I None
toxicity I Disease
while I None
taking I None
remission I None
inducing I None
drugs I None
and I None
30 I None
without I None
toxicity I Disease
were I None
studied I None
for I None
possible I None
associations I None
with I None
class I None
I I None
and I None
II I None
HLA I None
antigens I None
. I None
<eof> I None

<s> O None
A I None
strong I None
association I None
has I None
been I None
found I None
between I None
nephritis I Disease
and I None
dermatitis I Disease
due I None
to I None
Tiopronin I Chemical
( I None
a I None
D I Chemical
- O Chemical
Penicillamine O Chemical
like I None
compound I None
) I None
and I None
class I None
I I None
antigens I None
B35-Cw4 I None
, I None
and I None
between I None
dermatitis I Disease
due I None
to I None
gold I Chemical
thiosulphate I Chemical
and I None
B35 I None
. I None
<eof> I None

<s> O None
Compared I None
to I None
healthy I None
controls I None
a I None
lower I None
DR5 I None
frequency I None
was I None
observed I None
in I None
patients I None
with I None
RA I Disease
except I None
for I None
the I None
Tiopronin I Chemical
related I None
nephritis I Disease
group I None
. I None
<eof> I None

<s> O None
Transient I None
hemiparesis I Disease
: I None
a I None
rare I None
manifestation I None
of I None
diphenylhydantoin I Chemical
toxicity I Disease
. I None
<eof> I None

<s> O None
Report I None
of I None
two I None
cases I None
. I None
<eof> I None

<s> O None
Among I None
the I None
common I None
side I None
effects I None
of I None
diphenylhydantoin I Chemical
<eof> I None

<s> O None
( I None
DPH I Chemical
) I None
<eof> I None

<s> O None
overdose I Disease
, I None
the I None
most I None
frequently I None
encountered I None
neurological I None
signs I None
are I None
those I None
of I None
cerebellar I Disease
dysfunction O Disease
. I None
<eof> I None

<s> O None
Very I None
rarely I None
, I None
the I None
toxic I None
neurological I None
manifestations I None
of I None
this I None
drug I None
are I None
of I None
cerebral I None
origin I None
. I None
<eof> I None

<s> O None
Two I None
patients I None
are I None
presented I None
who I None
suffered I None
progressive I None
hemiparesis I Disease
due I None
to I None
DPH I Chemical
overdose I Disease
. I None
<eof> I None

<s> O None
Both I None
had I None
brain I None
surgery I None
before I None
DPH I Chemical
treatment I None
. I None
<eof> I None

<s> O None
It I None
is I None
assumed I None
that I None
patients I None
with I None
some I None
cerebral I Disease
damage O Disease
are I None
liable I None
to I None
manifest I None
DPH I Chemical
<eof> I None

<s> O None
toxicity I Disease
as I None
focal I None
neurological I None
signs I None
. I None
<eof> I None

<s> O None
Nerve I None
growth I None
factor I None
and I None
prostaglandins I Chemical
in I None
the I None
urine I None
of I None
female I None
patients I None
with I None
overactive I Disease
bladder O Disease
. I None
<eof> I None

<s> O None
PURPOSE I None
: I None
<eof> I None

<s> O None
NGF I None
and I None
PGs I Chemical
in I None
the I None
bladder I None
can I None
be I None
affected I None
by I None
pathological I None
changes I None
in I None
the I None
bladder I None
and I None
these I None
changes I None
can I None
be I None
detected I None
in I None
urine I None
. I None
<eof> I None

<s> O None
We I None
investigated I None
changes I None
in I None
urinary I None
NGF I None
and I None
PGs I Chemical
in I None
women I None
with I None
OAB I Disease
. I None
<eof> I None

<s> O None
MATERIALS I None
AND I None
METHODS I None
: I None
<eof> I None

<s> O None
The I None
study I None
groups I None
included I None
65 I None
women I None
with I None
OAB I Disease
and I None
20 I None
without I None
bladder I None
symptoms I None
who I None
served I None
as I None
controls I None
. I None
<eof> I None

<s> O None
Evaluation I None
included I None
patient I None
history I None
, I None
urinalysis I None
, I None
a I None
voiding I None
diary I None
and I None
urodynamic I None
studies I None
. I None
<eof> I None

<s> O None
Urine I None
samples I None
were I None
collected I None
. I None
<eof> I None

<s> O None
NGF I None
, I None
PGE2 I Chemical
, I None
PGF2alpha I Chemical
and I None
PGI2 I Chemical
were I None
measured I None
using I None
enzyme I None
- I None
linked I None
immunosorbent I None
assay I None
and I None
compared I None
between I None
the I None
groups I None
. I None
<eof> I None

<s> O None
In I None
addition I None
, I None
correlations I None
between I None
urinary I None
NGF I None
and I None
PG I Chemical
, I None
and I None
urodynamic I None
parameters I None
in I None
patients I None
with I None
OAB I Disease
were I None
examined I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
Urinary I None
NGF I None
, I None
PGE2 I Chemical
and I None
PGF2alpha I Chemical
were I None
significantly I None
increased I None
in I None
patients I None
with I None
OAB I Disease
compared I None
with I None
controls I None
( I None
p I None
< I None
0.05 I None
) I None
. I None
<eof> I None

<s> O None
However I None
, I None
urinary I None
PGI2 I Chemical
was I None
not I None
different I None
between I None
controls I None
and I None
patients I None
with I None
OAB I Disease
. I None
<eof> I None

<s> O None
In I None
patients I None
with I None
OAB I Disease
urinary I None
PGE2 I Chemical
positively I None
correlated I None
with I None
volume I None
at I None
first I None
desire I None
to I None
void I None
and I None
maximum I None
cystometric I None
capacity I None
( I None
p I None
< I None
0.05 I None
) I None
. I None
<eof> I None

<s> O None
Urinary I None
NGF I None
, I None
PGF2alpha I Chemical
and I None
PGI2 I Chemical
did I None
not I None
correlate I None
with I None
urodynamic I None
parameters I None
in I None
patients I None
with I None
OAB I Disease
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
NGF I None
and I None
PGs I Chemical
have I None
important I None
roles I None
in I None
the I None
development I None
of I None
OAB I Disease
symptoms I None
in I None
female I None
patients I None
. I None
<eof> I None

<s> O None
Urinary I None
levels I None
of I None
these I None
factors I None
may I None
be I None
used I None
as I None
markers I None
to I None
evaluate I None
OAB I Disease
symptoms I None
. I None
<eof> I None

<s> O None
Acute I None
low I Disease
back O Disease
pain O Disease
during I None
intravenous I None
administration I None
of I None
amiodarone I Chemical
: I None
a I None
report I None
of I None
two I None
cases I None
. I None
<eof> I None

<s> O None
Amiodarone I Chemical
represents I None
an I None
effective I None
antiarrhythmic I None
drug I None
for I None
cardioversion I None
of I None
recent I None
- I None
onset I None
atrial I Disease
fibrillation O Disease
<eof> I None

<s> O None
( I None
AF I Disease
) I None
and I None
maintenance I None
of I None
sinus I None
rhythm I None
. I None
<eof> I None

<s> O None
We I None
briefly I None
describe I None
two I None
patients I None
suffering I None
from I None
recent I None
- I None
onset I None
atrial I Disease
fibrillation O Disease
, I None
who I None
experienced I None
an I None
acute I None
devastating I None
low I Disease
back O Disease
pain O Disease
a I None
few I None
minutes I None
after I None
initiation I None
of I None
intravenous I None
amiodarone I Chemical
loading I None
. I None
<eof> I None

<s> O None
Notably I None
, I None
this I None
side I None
effect I None
has I None
not I None
been I None
ever I None
reported I None
in I None
the I None
medical I None
literature I None
. I None
<eof> I None

<s> O None
Clinicians I None
should I None
be I None
aware I None
of I None
this I None
reaction I None
since I None
prompt I None
termination I None
of I None
parenteral I None
administration I None
leads I None
to I None
complete I None
resolution I None
. I None
<eof> I None

<s> O None
Postoperative I Disease
myalgia O Disease
after I None
succinylcholine I Chemical
: I None
no I None
evidence I None
for I None
an I None
inflammatory I None
origin I None
. I None
<eof> I None

<s> O None
A I None
common I None
side I None
effect I None
associated I None
with I None
succinylcholine I Chemical
is I None
postoperative I Disease
myalgia O Disease
. I None
<eof> I None

<s> O None
The I None
pathogenesis I None
of I None
this I None
myalgia I Disease
is I None
still I None
unclear I None
; I None
inflammation I Disease
has I None
been I None
suggested I None
but I None
without I None
convincing I None
evidence I None
. I None
<eof> I None

<s> O None
We I None
designed I None
the I None
present I None
study I None
to I None
investigate I None
whether I None
an I None
inflammatory I None
reaction I None
contributes I None
to I None
this I None
myalgia I Disease
. I None
<eof> I None

<s> O None
The I None
incidence I None
and I None
severity I None
of I None
succinylcholine I Chemical
-associated I None
myalgia I Disease
was I None
determined I None
in I None
64 I None
patients I None
pretreated I None
with I None
saline I None
or I None
dexamethasone I Chemical
before I None
succinylcholine I Chemical
<eof> I None

<s> O None
( I None
n I None
= I None
32 I None
for I None
each I None
) I None
. I None
<eof> I None

<s> O None
Incidence I None
and I None
severity I None
of I None
myalgia I Disease
did I None
not I None
differ I None
significantly I None
between I None
the I None
two I None
groups I None
: I None
15 I None
patients I None
in I None
the I None
dexamethasone I Chemical
group I None
complained I None
of I None
myalgia I Disease
compared I None
with I None
18 I None
patients I None
in I None
the I None
saline I None
group I None
, I None
and I None
severe I None
myalgia I Disease
was I None
reported I None
by I None
five I None
patients I None
and I None
three I None
patients I None
, I None
respectively I None
( I None
not I None
significant I None
) I None
. I None
<eof> I None

<s> O None
At I None
48 I None
h I None
after I None
surgery I None
, I None
12 I None
patients I None
in I None
both I None
groups I None
still I None
suffered I None
from I None
myalgia I Disease
<eof> I None

<s> O None
( I None
not I None
significant I None
) I None
. I None
<eof> I None

<s> O None
In I None
addition I None
, I None
interleukin-6 I None
( I None
IL-6 I None
) I None
as I None
an I None
early I None
marker I None
of I None
inflammation I Disease
was I None
assessed I None
in I None
a I None
subgroup I None
of I None
10 I None
patients I None
pretreated I None
with I None
saline I None
. I None
<eof> I None

<s> O None
We I None
found I None
an I None
increase I None
of I None
IL-6 I None
for I None
only I None
three I None
patients I None
, I None
but I None
only I None
one I None
patient I None
reported I None
myalgia I Disease
; I None
no I None
relationship I None
between I None
myalgia I Disease
and I None
the I None
increase I None
of I None
IL-6 I None
was I None
found I None
. I None
<eof> I None

<s> O None
In I None
conclusion I None
, I None
there I None
is I None
no I None
evidence I None
for I None
an I None
inflammatory I None
origin I None
of I None
succinylcholine I Chemical
-associated I None
myalgia I Disease
. I None
<eof> I None

<s> O None
IMPLICATIONS I None
: I None
<eof> I None

<s> O None
Administration I None
of I None
dexamethasone I Chemical
before I None
succinylcholine I Chemical
was I None
not I None
effective I None
in I None
decreasing I None
the I None
incidence I None
or I None
the I None
severity I None
of I None
succinylcholine I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
postoperative I Disease
myalgia O Disease
. I None
<eof> I None

<s> O None
Furthermore I None
, I None
there I None
was I None
no I None
significant I None
relationship I None
between I None
postoperative I Disease
myalgia O Disease
and I None
time I None
course I None
of I None
interleukin-6 I None
concentrations I None
, I None
a I None
marker I None
of I None
inflammation I Disease
. I None
<eof> I None

<s> O None
Pretreatment I None
with I None
dexamethasone I Chemical
is I None
not I None
justified I None
to I None
prevent I None
postoperative I Disease
myalgia O Disease
after I None
succinylcholine I Chemical
. I None
<eof> I None

<s> O None
Levodopa I Chemical
-induced I None
oromandibular I None
dystonia I Disease
in I None
progressive I Disease
supranuclear O Disease
palsy O Disease
. I None
<eof> I None

<s> O None
Levodopa I Chemical
-induced I None
<eof> I None

<s> O None
dyskinesias I Disease
have I None
been I None
reported I None
in I None
Parkinson I Disease
's O Disease
disease O Disease
and I None
multiple I Disease
system O Disease
atrophy O Disease
. I None
<eof> I None

<s> O None
Cranial I None
dystonias I Disease
are I None
rare I None
in I None
patients I None
with I None
progressive I Disease
supranuclear O Disease
palsy O Disease
<eof> I None

<s> O None
( I None
PSP I Disease
) I None
. I None
<eof> I None

<s> O None
In I None
this I None
report I None
we I None
describe I None
an I None
unusual I None
case I None
of I None
reversible I None
levodopa I Chemical
-induced I None
Oromandibular I Disease
dystonia O Disease
<eof> I None

<s> O None
( I None
OMD I Disease
) I None
in I None
a I None
PSP I Disease
patient I None
to I None
highlight I None
the I None
importance I None
of I None
recognizing I None
this I None
drug I None
related I None
complication I None
in I None
the I None
management I None
of I None
PSP I Disease
, I None
and I None
discuss I None
the I None
possible I None
underlying I None
pathophysiology I None
. I None
<eof> I None

<s> O None
Protective I None
effect I None
of I None
edaravone I Chemical
against I None
streptomycin I Chemical
-induced I None
vestibulotoxicity I Disease
in I None
the I None
guinea I None
pig I None
. I None
<eof> I None

<s> O None
This I None
study I None
investigated I None
alleviation I None
of I None
streptomycin I Chemical
-induced I None
<eof> I None

<s> O None
vestibulotoxicity I Disease
by I None
edaravone I Chemical
in I None
guinea I None
pigs I None
. I None
<eof> I None

<s> O None
Edaravone I Chemical
, I None
a I None
free I None
radical I None
scavenger I None
, I None
has I None
potent I None
free I None
radical I None
quenching I None
action I None
and I None
is I None
used I None
in I None
clinical I None
practice I None
to I None
treat I None
cerebral I Disease
infarction O Disease
. I None
<eof> I None

<s> O None
Streptomycin I Chemical
was I None
administered I None
to I None
the I None
inner I None
ear I None
by I None
osmotic I None
pump I None
for I None
24 I None
h I None
, I None
and I None
edaravone I Chemical
( I None
n=8 I None
) I None
or I None
saline I None
( I None
n=6 I None
) I None
was I None
intraperitoneally I None
injected I None
once I None
a I None
day I None
for I None
7 I None
days I None
. I None
<eof> I None

<s> O None
We I None
observed I None
horizontal I None
vestibulo I None
- I None
ocular I None
reflex I None
as I None
a I None
marker I None
of I None
postoperative I None
vestibular I None
function I None
. I None
<eof> I None

<s> O None
Animals I None
injected I None
with I None
saline I None
showed I None
statistically I None
smaller I None
gains I None
than I None
those I None
injected I None
with I None
edaravone I Chemical
. I None
<eof> I None

<s> O None
These I None
results I None
suggest I None
that I None
edaravone I Chemical
suppresses I None
<eof> I None

<s> O None
streptomycin I Chemical
-induced I None
<eof> I None

<s> O None
vestibulotoxicity I Disease
. I None
<eof> I None

<s> O None
Ketamine I Chemical
in I None
war I None
/ I None
tropical I None
surgery I None
( I None
a I None
final I None
tribute I None
to I None
the I None
racemic I None
mixture I None
) I None
. I None
<eof> I None

<s> O None
A I None
technique I None
of I None
continuous I None
intravenous I None
anaesthesia I None
with I None
ketamine I Chemical
was I None
used I None
successfully I None
during I None
the I None
Somalia I None
civil I None
war I None
in I None
1994 I None
and I None
in I None
north I None
Uganda I None
in I None
1999 I None
for I None
64 I None
operations I None
in I None
62 I None
patients I None
, I None
aged I None
from I None
6 I None
weeks I None
to I None
70 I None
years I None
, I None
undergoing I None
limb I None
and I None
abdominal I None
surgery I None
including I None
caesarian I None
sections I None
and I None
interventions I None
in I None
neonates I None
. I None
<eof> I None

<s> O None
Operations I None
lasting I None
up I None
to I None
2h I None
could I None
be I None
performed I None
in I None
the I None
absence I None
of I None
sophisticated I None
equipment I None
such I None
as I None
pulse I None
oximeters I None
or I None
ventilators I None
in I None
patients I None
on I None
spontaneous I None
ventilation I None
breathing I None
air/ I None
oxygen I Chemical
only I None
. I None
<eof> I None

<s> O None
After I None
premedication I None
with I None
diazepam I Chemical
, I None
glycopyrrolate I Chemical
and I None
local I None
anaesthesia I None
, I None
and I None
induction I None
with I None
standard I None
doses I None
of I None
ketamine I Chemical
, I None
a I None
maintenance I None
dose I None
of I None
10 I None
- I None
20 I None
microg I None
/ I None
kg I None
/ I None
min I None
of I None
ketamine I Chemical
proved I None
safe I None
and I None
effective I None
. I None
<eof> I None

<s> O None
Emphasis I None
was I None
placed I None
on I None
bedside I None
clinical I None
monitoring I None
, I None
relying I None
heavily I None
on I None
the I None
heart I None
rate I None
. I None
<eof> I None

<s> O None
Diazepam I Chemical
, I None
unless I None
contraindicated I None
or I None
risky I None
, I None
remains I None
the I None
only I None
necessary I None
complementary I None
drug I None
to I None
ketamine I Chemical
as I None
it I None
buffers I None
its I None
cardiovascular I None
response I None
and I None
decreases I None
the I None
duration I None
and I None
intensity I None
of I None
operative I None
and I None
postoperative I None
hallucinations I Disease
. I None
<eof> I None

<s> O None
Local I None
anaesthetic I None
blocks I None
were I None
useful I None
in I None
decreasing I None
the I None
requirement I None
for I None
postoperative I None
analgesia I Disease
. I None
<eof> I None

<s> O None
An I None
antisialogue I None
was I None
usually I None
unnecessary I None
in I None
operations I None
lasting I None
up I None
to I None
2 I None
h I None
, I None
glycopyrrolate I Chemical
being I None
the I None
best I None
choice I None
for I None
its I None
lowest I None
psychotropic I None
and I None
chronotropic I None
effects I None
, I None
especially I None
in I None
a I None
hot I None
climate I None
. I None
<eof> I None

<s> O None
Experience I None
in I None
war I None
/ I None
tropical I None
settings I None
suggests I None
this I None
technique I None
could I None
be I None
useful I None
in I None
civilian I None
contexts I None
such I None
as I None
outdoor I None
life I None
- I None
saving I None
emergency I None
surgery I None
or I None
in I None
mass I None
casualties I None
where I None
, I None
e.g. I None
amputation I None
and I None
rapid I None
extrication I None
were I None
required I None
. I None
<eof> I None

<s> O None
Steroid I Chemical
structure I None
and I None
pharmacological I None
properties I None
determine I None
the I None
anti- I None
amnesic I Disease
effects I None
of I None
pregnenolone I Chemical
sulphate O Chemical
in I None
the I None
passive I None
avoidance I None
task I None
in I None
rats I None
. I None
<eof> I None

<s> O None
Pregnenolone I Chemical
sulphate O Chemical
<eof> I None

<s> O None
( I None
PREGS I Chemical
) I None
has I None
generated I None
interest I None
as I None
one I None
of I None
the I None
most I None
potent I None
memory I None
- I None
enhancing I None
neurosteroids I None
to I None
be I None
examined I None
in I None
rodent I None
learning I None
studies I None
, I None
with I None
particular I None
importance I None
in I None
the I None
ageing I None
process I None
. I None
<eof> I None

<s> O None
The I None
mechanism I None
by I None
which I None
this I None
endogenous I None
steroid I Chemical
enhances I None
memory I None
formation I None
is I None
hypothesized I None
to I None
involve I None
actions I None
on I None
glutamatergic I None
and I None
GABAergic I None
systems I None
. I None
<eof> I None

<s> O None
This I None
hypothesis I None
stems I None
from I None
findings I None
that I None
PREGS I Chemical
is I None
a I None
potent I None
positive I None
modulator I None
of I None
N I Chemical
- O Chemical
methyl O Chemical
- O Chemical
d O Chemical
- O Chemical
aspartate O Chemical
receptors I None
( I None
NMDARs I None
) I None
and I None
a I None
negative I None
modulator I None
of I None
gamma I Chemical
- O Chemical
aminobutyric O Chemical
acid O Chemical
( I None
A I None
) I None
receptors I None
( I None
GABA I Chemical
( I None
A)Rs I None
) I None
. I None
<eof> I None

<s> O None
Moreover I None
, I None
PREGS I Chemical
is I None
able I None
to I None
reverse I None
the I None
amnesic I Disease
-like I None
effects I None
of I None
NMDAR I None
and I None
GABA I Chemical
( I None
A)R I None
ligands I None
. I None
<eof> I None

<s> O None
To I None
investigate I None
this I None
hypothesis I None
, I None
the I None
present I None
study I None
in I None
rats I None
examined I None
the I None
memory I None
- I None
altering I None
abilities I None
of I None
structural I None
analogs I None
of I None
PREGS I Chemical
, I None
which I None
differ I None
in I None
their I None
modulation I None
of I None
NMDAR I None
and/or I None
GABA I Chemical
<eof> I None

<s> O None
( I None
A)R I None
function I None
. I None
<eof> I None

<s> O None
The I None
analogs I None
tested I None
were I None
: I None
11-ketopregnenolone I Chemical
sulphate O Chemical
<eof> I None

<s> O None
( I None
an I None
agent I None
that I None
is I None
inactive I None
at I None
GABA I Chemical
<eof> I None

<s> O None
( I None
A)Rs I None
and I None
NMDARs I None
) I None
, I None
epipregnanolone I Chemical
( O Chemical
[ O Chemical
3beta O Chemical
- O Chemical
hydroxy-5beta O Chemical
- O Chemical
pregnan-20-one O Chemical
] O Chemical
sulphate O Chemical
, I None
an I None
inhibitor I None
of I None
both I None
GABA I Chemical
( I None
A)Rs I None
and I None
NMDARs I None
) I None
, I None
and I None
a I None
newly I None
synthesized I None
( I None
- I None
) I None
PREGS I Chemical
enantiomer I None
( I None
which I None
is I None
identical I None
to I None
PREGS I Chemical
in I None
effects I None
on I None
GABA I Chemical
<eof> I None

<s> O None
( I None
A)Rs I None
and I None
NMDARs I None
) I None
. I None
<eof> I None

<s> O None
The I None
memory I None
- I None
enhancing I None
effects I None
of I None
PREGS I Chemical
and I None
its I None
analogs I None
were I None
tested I None
in I None
the I None
passive I None
avoidance I None
task I None
using I None
the I None
model I None
of I None
scopolamine I Chemical
<eof> I None

<s> O None
-induced I None
amnesia I Disease
. I None
<eof> I None

<s> O None
Both I None
PREGS I Chemical
and I None
its I None
( I None
- I None
) I None
enantiomer I None
blocked I None
the I None
effects I None
of I None
scopolamine I Chemical
. I None
<eof> I None

<s> O None
The I None
results I None
show I None
that I None
, I None
unlike I None
PREGS I Chemical
, I None
11-ketopregnenolone I Chemical
sulphate O Chemical
and I None
epipregnanolone I Chemical
sulphate O Chemical
failed I None
to I None
block I None
the I None
effect I None
of I None
scopolamine I Chemical
, I None
suggesting I None
that I None
altering I None
the I None
modulation I None
of I None
NMDA I Chemical
receptors I None
diminishes I None
the I None
memory I None
- I None
enhancing I None
effects I None
of I None
PREGS I Chemical
. I None
<eof> I None

<s> O None
Moreover I None
, I None
enantioselectivity I None
was I None
demonstrated I None
by I None
the I None
ability I None
of I None
natural I None
PREGS I Chemical
to I None
be I None
an I None
order I None
of I None
magnitude I None
more I None
effective I None
than I None
its I None
synthetic I None
enantiomer I None
in I None
reversing I None
scopolamine I Chemical
<eof> I None

<s> O None
-induced I None
amnesia I Disease
. I None
<eof> I None

<s> O None
These I None
results I None
identify I None
a I None
novel I None
neuropharmacological I None
site I None
for I None
the I None
modulation I None
of I None
memory I None
processes I None
by I None
neuroactive I None
steroids I Chemical
. I None
<eof> I None

<s> O None
Preliminary I None
efficacy I None
assessment I None
of I None
intrathecal I None
injection I None
of I None
an I None
American I None
formulation I None
of I None
adenosine I Chemical
in I None
humans I None
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
<eof> I None

<s> O None
Preclinical I None
studies I None
of I None
intrathecal I None
adenosine I Chemical
suggest I None
it I None
may I None
be I None
effective I None
in I None
the I None
treatment I None
of I None
acute I None
and I None
chronic I None
pain I None
in I None
humans I None
, I None
and I None
preliminary I None
studies I None
in I None
volunteers I None
and I None
patients I None
with I None
a I None
Swedish I None
formulation I None
of I None
adenosine I Chemical
suggests I None
it I None
may I None
be I None
effective I None
in I None
hypersensitivity I Disease
states I None
but I None
not I None
with I None
acute I None
noxious I None
stimulation I None
. I None
<eof> I None

<s> O None
The I None
purpose I None
of I None
this I None
study I None
was I None
to I None
screen I None
for I None
efficacy I None
of I None
a I None
different I None
formulation I None
of I None
adenosine I Chemical
marketed I None
in I None
the I None
US I None
, I None
using I None
both I None
acute I None
noxious I None
stimulation I None
and I None
capsaicin I Chemical
-evoked I None
mechanical I None
hypersensitivity I Disease
. I None
<eof> I None

<s> O None
METHODS I None
: I None
<eof> I None

<s> O None
Following I None
Food I None
and I None
Drug I None
Administration I None
and I None
institutional I None
review I None
board I None
approval I None
and I None
written I None
informed I None
consent I None
, I None
65 I None
volunteers I None
were I None
studied I None
in I None
two I None
trials I None
: I None
an I None
open I None
- I None
label I None
, I None
dose I None
- I None
escalating I None
trial I None
with I None
intrathecal I None
adenosine I Chemical
doses I None
of I None
0.25 I None
- I None
2.0 I None
mg I None
and I None
a I None
double I None
- I None
blind I None
, I None
placebo I None
- I None
controlled I None
trial I None
of I None
adenosine I Chemical
, I None
2 I None
mg I None
. I None
<eof> I None

<s> O None
Cerebrospinal I None
fluid I None
was I None
obtained I None
for I None
pharmacokinetic I None
analysis I None
, I None
and I None
pain I Disease
ratings I None
in I None
response I None
to I None
acute I None
heat I None
stimuli I None
and I None
areas I None
of I None
mechanical I Disease
hyperalgesia O Disease
and I None
allodynia I Disease
after I None
intradermal I None
capsaicin I Chemical
injection I None
were I None
determined I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
Adenosine I Chemical
produced I None
no I None
effect I None
on I None
pain I Disease
report I None
to I None
acute I None
noxious I None
thermal I None
or I None
chemical I None
stimulation I None
but I None
reduced I None
mechanical I Disease
hyperalgesia O Disease
and I None
allodynia I Disease
from I None
intradermal I None
capsaicin I Chemical
injection I None
for I None
at I None
least I None
24 I None
h. I None
<eof> I None

<s> O None
In I None
contrast I None
, I None
residence I None
time I None
of I None
adenosine I Chemical
in I None
cerebrospinal I None
fluid I None
was I None
short I None
( I None
< I None
4 I None
h I None
) I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
These I None
results I None
show I None
selective I None
inhibition I None
by I None
intrathecal I None
adenosine I Chemical
of I None
hypersensitivity I Disease
, I None
presumed I None
to I None
reflect I None
central I None
sensitization I None
in I None
humans I None
after I None
peripheral I None
capsaicin I Chemical
injection I None
. I None
<eof> I None

<s> O None
The I None
long I None
- I None
lasting I None
effect I None
is I None
consistent I None
with I None
that I None
observed I None
in I None
preliminary I None
reports I None
of I None
patients I None
with I None
chronic I None
neuropathic I Disease
pain O Disease
and I None
is I None
not I None
due I None
to I None
prolonged I None
residence I None
of I None
adenosine I Chemical
in I None
cerebrospinal I None
fluid I None
. I None
<eof> I None

<s> O None
Effect I None
of I None
lithium I Chemical
maintenance I None
therapy I None
on I None
thyroid I None
and I None
parathyroid I None
function I None
. I None
<eof> I None

<s> O None
OBJECTIVES I None
: I None
<eof> I None

<s> O None
To I None
assess I None
changes I None
induced I None
by I None
lithium I Chemical
maintenance I None
therapy I None
on I None
the I None
incidence I None
of I None
thyroid I None
, I None
parathyroid I None
and I None
ion I None
alterations I None
. I None
<eof> I None

<s> O None
These I None
were I None
evaluated I None
with I None
respect I None
to I None
the I None
duration I None
of I None
lithium I Chemical
therapy I None
, I None
age I None
, I None
sex I None
, I None
and I None
family I None
history I None
( I None
whether I None
or I None
not I None
the I None
patient I None
had I None
a I None
first I None
- I None
degree I None
relative I None
with I None
thyroid I Disease
disease O Disease
) I None
. I None
<eof> I None

<s> O None
DESIGN I None
: I None
Prospective I None
study I None
. I None
<eof> I None

<s> O None
SETTING I None
: I None
<eof> I None

<s> O None
Affective I None
Disorders I None
Clinic I None
at I None
St. I None
Mary I None
's I None
Hospital I None
, I None
Montreal I None
. I None
<eof> I None

<s> O None
PATIENTS I None
: I None
<eof> I None

<s> O None
One I None
hundred I None
and I None
one I None
patients I None
( I None
28 I None
men I None
and I None
73 I None
women I None
) I None
with I None
bipolar I Disease
disorder O Disease
receiving I None
lithium I Chemical
maintenance I None
therapy I None
ranging I None
from I None
1 I None
year I None
's I None
to I None
32 I None
years I None
' I None
duration I None
. I None
<eof> I None

<s> O None
The I None
control I None
group I None
consisted I None
of I None
82 I None
patients I None
with I None
no I None
psychiatric I Disease
or I None
endocrinological I None
diagnoses I None
from I None
the I None
hospital I None
's I None
out I None
- I None
patient I None
clinics I None
. I None
<eof> I None

<s> O None
OUTCOME I None
MEASURES I None
: I None
<eof> I None

<s> O None
Laboratory I None
analyses I None
of I None
calcium I Chemical
, I None
magnesium I Chemical
and I None
thyroid I None
- I None
stimulating I None
hormone I None
levels I None
performed I None
before I None
beginning I None
lithium I Chemical
therapy I None
and I None
at I None
biannual I None
follow I None
- I None
up I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
Hypothyroidism I Disease
developed I None
in I None
40 I None
patients I None
, I None
excluding I None
8 I None
patients I None
who I None
were I None
hypothyroid I Disease
at I None
baseline I None
. I None
<eof> I None

<s> O None
All I None
patients I None
having I None
first I None
- I None
degree I None
relatives I None
affected I None
by I None
<eof> I None

<s> O None
thyroid I Disease
illness O Disease
had I None
accelerated I None
onset I None
of I None
hypothyroidism I Disease
<eof> I None

<s> O None
( I None
3.7 I None
years I None
after I None
onset I None
of I None
lithium I Chemical
therapy I None
) I None
compared I None
with I None
patients I None
without I None
a I None
family I None
history I None
( I None
8.6 I None
years I None
after I None
onset I None
of I None
lithium I Chemical
therapy I None
) I None
. I None
<eof> I None

<s> O None
Women I None
over I None
60 I None
years I None
of I None
age I None
were I None
more I None
often I None
affected I None
by I None
hypothyroidism I Disease
than I None
women I None
under I None
60 I None
years I None
of I None
age I None
( I None
34.6 I None
% I None
versus I None
31.9 I None
% I None
) I None
. I None
<eof> I None

<s> O None
Magnesium I Chemical
levels I None
in I None
patients I None
on I None
lithium I Chemical
treatment I None
were I None
unchanged I None
from I None
baseline I None
levels I None
. I None
<eof> I None

<s> O None
After I None
lithium I Chemical
treatment I None
, I None
calcium I Chemical
levels I None
were I None
higher I None
than I None
either I None
baseline I None
levels I None
or I None
control I None
levels I None
. I None
<eof> I None

<s> O None
Thus I None
, I None
lithium I Chemical
treatment I None
counteracted I None
the I None
decrease I None
in I None
plasma I None
calcium I Chemical
levels I None
associated I None
with I None
aging I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
Familial I None
thyroid I Disease
illness O Disease
is I None
a I None
risk I None
factor I None
for I None
hypothyroidism I Disease
and I None
hypercalcemia I Disease
during I None
lithium I Chemical
therapy I None
. I None
<eof> I None

<s> O None
Systemic I None
toxicity I Disease
following I None
administration I None
of I None
sirolimus I Chemical
( I None
formerly I None
rapamycin I Chemical
) I None
for I None
psoriasis I Disease
: I None
association I None
of I None
capillary I Disease
leak O Disease
syndrome O Disease
with I None
apoptosis I None
of I None
lesional I None
lymphocytes I None
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
<eof> I None

<s> O None
Sirolimus I Chemical
( I None
formerly I None
rapamycin I Chemical
) I None
is I None
an I None
immunosuppressive I None
agent I None
that I None
interferes I None
with I None
T I None
- I None
cell I None
activation I None
. I None
<eof> I None

<s> O None
After I None
2 I None
individuals I None
with I None
psoriasis I Disease
developed I None
a I None
capillary I Disease
leak O Disease
syndrome O Disease
following I None
treatment I None
with I None
oral I None
sirolimus I Chemical
<eof> I None

<s> O None
lesional I None
skin I None
cells I None
and I None
activated I None
peripheral I None
blood I None
cells I None
were I None
analyzed I None
for I None
induction I None
of I None
apoptosis I None
. I None
<eof> I None

<s> O None
OBSERVATIONS I None
: I None
<eof> I None

<s> O None
A I None
keratome I None
skin I None
specimen I None
from I None
1 I None
patient I None
with I None
sirolimus I Chemical
-induced I None
<eof> I None

<s> O None
capillary I Disease
leak O Disease
syndrome O Disease
had I None
a I None
2.3-fold I None
increase I None
in I None
percentage I None
of I None
apoptotic I None
cells I None
( I None
to I None
48 I None
% I None
) I None
compared I None
with I None
an I None
unaffected I None
sirolimus I Chemical
-treated I None
patient I None
with I None
psoriasis I Disease
<eof> I None

<s> O None
( I None
21 I None
% I None
) I None
. I None
<eof> I None

<s> O None
Activated I None
peripheral I None
blood I None
T I None
cells I None
from I None
patients I None
with I None
psoriasis I Disease
tended I None
to I None
exhibit I None
greater I None
spontaneous I None
or I None
dexamethasone I Chemical
-induced I None
apoptosis I None
than I None
did I None
normal I None
T I None
cells I None
, I None
particularly I None
in I None
the I None
presence I None
of I None
sirolimus I Chemical
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
Severe I None
adverse I None
effects I None
of I None
sirolimus I Chemical
include I None
fever I Disease
, I None
anemia I Disease
, I None
and I None
capillary I Disease
leak O Disease
syndrome O Disease
. I None
<eof> I None

<s> O None
These I None
symptoms I None
may I None
be I None
the I None
result I None
of I None
drug I None
- I None
induced I None
apoptosis I None
of I None
lesional I None
leukocytes I None
, I None
especially I None
activated I None
T I None
lymphocytes I None
, I None
and I None
possibly I None
release I None
of I None
inflammatory I None
mediators I None
. I None
<eof> I None

<s> O None
Because I None
patients I None
with I None
severe I None
psoriasis I Disease
may I None
develop I None
capillary I Disease
leak O Disease
from I None
various I None
systemic I None
therapies I None
, I None
clinical I None
monitoring I None
is I None
advisable I None
for I None
patients I None
with I None
inflammatory I Disease
diseases O Disease
who I None
are I None
treated I None
with I None
immune I None
modulators I None
. I None
<eof> I None

<s> O None
Contribution I None
of I None
the I None
glycine I Chemical
site I None
of I None
NMDA I Chemical
receptors I None
in I None
rostral I None
and I None
intermediate I None
- I None
caudal I None
parts I None
of I None
the I None
striatum I None
to I None
the I None
regulation I None
of I None
muscle I None
tone I None
in I None
rats I None
. I None
<eof> I None

<s> O None
The I None
aim I None
of I None
the I None
present I None
study I None
was I None
to I None
assess I None
the I None
contribution I None
of I None
the I None
glycine I Chemical
site I None
of I None
NMDA I Chemical
receptors I None
in I None
the I None
striatum I None
to I None
the I None
regulation I None
of I None
muscle I None
tone I None
. I None
<eof> I None

<s> O None
Muscle I None
tone I None
was I None
examined I None
using I None
a I None
combined I None
mechanoand I None
electromyographic I None
method I None
, I None
which I None
measured I None
simultaneously I None
the I None
muscle I None
resistance I None
( I None
MMG I None
) I None
of I None
the I None
rat I None
's I None
hind I None
foot I None
to I None
passive I None
extension I None
and I None
flexion I None
in I None
the I None
ankle I None
joint I None
and I None
the I None
electromyographic I None
activity I None
( I None
EMG I None
) I None
of I None
the I None
antagonistic I None
muscles I None
of I None
that I None
joint I None
: I None
gastrocnemius I None
and I None
tibialis I None
anterior I None
. I None
<eof> I None

<s> O None
Muscle I Disease
rigidity O Disease
was I None
induced I None
by I None
haloperidol I Chemical
( I None
2.5 I None
mg I None
/ I None
kg I None
i.p I None
. I None
) I None
. I None
<eof> I None

<s> O None
5,7-dichlorokynurenic I Chemical
acid O Chemical
<eof> I None

<s> O None
( I None
5,7-DCKA I Chemical
) I None
, I None
a I None
selective I None
glycine I Chemical
site I None
antagonist I None
, I None
injected I None
in I None
doses I None
of I None
2.5 I None
and I None
4.5 I None
microg/0.5 I None
microl I None
bilaterally I None
, I None
into I None
the I None
rostral I None
region I None
of I None
the I None
striatum I None
, I None
decreased I None
both I None
the I None
haloperidol I Chemical
-induced I None
<eof> I None

<s> O None
muscle I Disease
rigidity O Disease
( I None
MMG I None
) I None
and I None
the I None
enhanced I None
electromyographic I None
activity I None
( I None
EMG I None
) I None
. I None
<eof> I None

<s> O None
5,7-DCKA I Chemical
injected I None
bilaterally I None
in I None
a I None
dose I None
of I None
4.5 I None
microg/0.5 I None
microl I None
into I None
the I None
intermediate I None
- I None
caudal I None
region I None
of I None
the I None
striatum I None
of I None
rats I None
not I None
pretreated I None
with I None
haloperidol I Chemical
<eof> I None

<s> O None
had I None
no I None
effect I None
on I None
the I None
muscle I None
tone I None
. I None
<eof> I None

<s> O None
The I None
present I None
results I None
suggest I None
that I None
blockade I None
of I None
the I None
glycine I Chemical
site I None
of I None
NMDA I Chemical
receptors I None
in I None
the I None
rostral I None
part I None
of I None
the I None
striatum I None
may I None
be I None
mainly I None
responsible I None
for I None
the I None
antiparkinsonian I None
action I None
of I None
this I None
drug I None
. I None
<eof> I None

<s> O None
Efficacy I None
and I None
tolerability I None
of I None
lovastatin I Chemical
in I None
3390 I None
women I None
with I None
moderate I None
hypercholesterolemia I Disease
. I None
<eof> I None

<s> O None
OBJECTIVE I None
: I None
<eof> I None

<s> O None
To I None
evaluate I None
the I None
efficacy I None
and I None
safety I None
of I None
lovastatin I Chemical
in I None
women I None
with I None
moderate I None
hypercholesterolemia I Disease
. I None
<eof> I None

<s> O None
DESIGN I None
: I None
<eof> I None

<s> O None
The I None
Expanded I None
Clinical I None
Evaluation I None
of I None
Lovastatin I Chemical
<eof> I None

<s> O None
( I None
EXCEL I None
) I None
Study I None
, I None
a I None
multicenter I None
, I None
double I None
- I None
blind I None
, I None
diet- I None
and I None
placebo I None
- I None
controlled I None
trial I None
, I None
in I None
which I None
participants I None
were I None
randomly I None
assigned I None
to I None
receive I None
placebo I None
or I None
lovastatin I Chemical
at I None
doses I None
of I None
20 I None
or I None
40 I None
mg I None
once I None
daily I None
, I None
or I None
20 I None
or I None
40 I None
mg I None
twice I None
daily I None
for I None
48 I None
weeks I None
. I None
<eof> I None

<s> O None
SETTING I None
: I None
<eof> I None

<s> O None
Ambulatory I None
patients I None
recruited I None
by I None
362 I None
participating I None
centers I None
throughout I None
the I None
United I None
States I None
. I None
<eof> I None

<s> O None
PATIENTS I None
: I None
Women I None
( I None
n I None
= I None
3390 I None
) I None
from I None
the I None
total I None
cohort I None
of I None
8245 I None
volunteers I None
. I None
<eof> I None

<s> O None
MEASUREMENTS I None
: I None
Plasma I None
total I None
, I None
low I None
- I None
density I None
lipoprotein I None
( I None
LDL I None
) I None
, I None
and I None
high I None
- I None
density I None
lipoprotein I None
( I None
HDL I None
) I None
cholesterol I Chemical
, I None
and I None
triglycerides I Chemical
; I None
and I None
laboratory I None
and I None
clinical I None
evidence I None
of I None
adverse I None
events I None
monitored I None
periodically I None
throughout I None
the I None
study I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
Among I None
women I None
, I None
lovastatin I Chemical
<eof> I None

<s> O None
( I None
20 I None
to I None
80 I None
mg I None
/ I None
d I None
<eof> I None

<s> O None
) I None
produced I None
sustained I None
( I None
12- I None
to I None
48-week I None
) I None
, I None
dose I None
- I None
related I None
changes I None
( I None
P I None
< I None
0.001 I None
) I None
: I None
decreases I None
in I None
LDL I None
cholesterol I Chemical
<eof> I None

<s> O None
( I None
24 I None
% I None
to I None
40 I None
% I None
) I None
and I None
triglycerides I Chemical
( I None
9 I None
% I None
to I None
18 I None
% I None
) I None
, I None
and I None
increases I None
in I None
HDL I None
cholesterol I Chemical
( I None
6.7 I None
% I None
to I None
8.6 I None
% I None
) I None
. I None
<eof> I None

<s> O None
Depending I None
on I None
the I None
dose I None
, I None
from I None
82 I None
% I None
to I None
95 I None
% I None
of I None
lovastatin I Chemical
-treated I None
women I None
achieved I None
the I None
National I None
Cholesterol I Chemical
Education I None
Program I None
goal I None
of I None
LDL I None
cholesterol I Chemical
levels I None
less I None
than I None
4.14 I None
mmol I None
/ I None
L I None
( I None
160 I None
mg I None
/ I None
dL I None
) I None
, I None
and I None
40 I None
% I None
to I None
87 I None
% I None
achieved I None
the I None
goal I None
of I None
3.36 I None
mmol I None
/ I None
<eof> I None

<s> O None
L I None
( I None
130 I None
mg I None
/ I None
dL I None
) I None
. I None
<eof> I None

<s> O None
Successive I None
transaminase I None
elevations I None
greater I None
than I None
three I None
times I None
the I None
upper I None
limit I None
of I None
normal I None
occurred I None
in I None
0.1 I None
% I None
of I None
women I None
and I None
were I None
dose I None
dependent I None
above I None
the I None
20-mg I None
dose I None
. I None
<eof> I None

<s> O None
Myopathy I Disease
, I None
defined I None
as I None
muscle I None
symptoms I None
with I None
creatine I Chemical
<eof> I None

<s> O None
kinase I None
elevations I None
greater I None
than I None
10 I None
times I None
the I None
upper I None
limit I None
of I None
normal I None
, I None
was I None
rare I None
and I None
associated I None
with I None
the I None
highest I None
recommended I None
daily I None
dose I None
of I None
lovastatin I Chemical
<eof> I None

<s> O None
( I None
80 I None
mg I None
) I None
. I None
<eof> I None

<s> O None
Estrogen I None
- I None
replacement I None
therapy I None
appeared I None
to I None
have I None
no I None
effect I None
on I None
either I None
the I None
efficacy I None
or I None
safety I None
profile I None
of I None
lovastatin I Chemical
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
<eof> I None

<s> O None
Lovastatin I Chemical
is I None
highly I None
effective I None
and I None
generally I None
well I None
tolerated I None
as I None
therapy I None
for I None
primary I None
hypercholesterolemia I Disease
in I None
women I None
. I None
<eof> I None

<s> O None
REM I Disease
sleep O Disease
deprivation O Disease
changes I None
behavioral I None
response I None
to I None
catecholaminergic I None
and I None
serotonergic I None
receptor I None
activation I None
in I None
rats I None
. I None
<eof> I None

<s> O None
The I None
effects I None
of I None
REM I Disease
sleep O Disease
deprivation O Disease
<eof> I None

<s> O None
( I None
REMD I Disease
) I None
on I None
apomorphine I Chemical
-induced I None
aggressiveness I Disease
and I None
quipazine I Chemical
-induced I None
<eof> I None

<s> O None
head I Disease
twitches O Disease
in I None
rats I None
were I None
determined I None
. I None
<eof> I None

<s> O None
Forty I None
- I None
eight I None
hr I None
of I None
REMD I Disease
increased I None
<eof> I None

<s> O None
apomorphine I Chemical
-induced I None
aggressiveness I Disease
, I None
and I None
reduced I None
( I None
immediately I None
after I None
completing I None
of I None
REMD I Disease
) I None
or I None
increased I None
( I None
96 I None
hr I None
after I None
completing I None
of I None
REMD I Disease
) I None
<eof> I None

<s> O None
quipazine I Chemical
-induced I None
head I Disease
twitches O Disease
. I None
<eof> I None

<s> O None
Results I None
are I None
discussed I None
in I None
terms I None
of I None
similarity I None
to I None
pharmacological I None
effects I None
of I None
other I None
antidepressive I None
treatments I None
. I None
<eof> I None

<s> O None
Extrapyramidal I None
side I None
effects I None
and I None
oral I None
haloperidol I Chemical
: I None
an I None
analysis I None
of I None
explanatory I None
patient I None
and I None
treatment I None
characteristics I None
. I None
<eof> I None

<s> O None
The I None
incidence I None
of I None
extrapyramidal I None
side I None
effects I None
( I None
EPS I None
) I None
was I None
evaluated I None
in I None
98 I None
patients I None
treated I None
with I None
haloperidol I Chemical
. I None
<eof> I None

<s> O None
The I None
incidence I None
of I None
parkinsonism I Disease
was I None
higher I None
at I None
higher I None
doses I None
of I None
haloperidol I Chemical
and I None
in I None
younger I None
patients I None
. I None
<eof> I None

<s> O None
Prophylactic I None
antiparkinsonian I None
medication I None
was I None
effective I None
in I None
younger I None
but I None
not I None
in I None
older I None
patients I None
. I None
<eof> I None

<s> O None
However I None
, I None
these I None
medications I None
were I None
more I None
effective I None
in I None
both I None
young I None
and I None
old I None
patients I None
when I None
given I None
after I None
parkinsonism I Disease
developed I None
. I None
<eof> I None

<s> O None
Akathisia I Disease
was I None
controlled I None
by I None
the I None
benzodiazepine I Chemical
lorazepam I Chemical
in I None
14 I None
out I None
of I None
16 I None
patients I None
, I None
while I None
prophylactic I None
antiparkinsonians I None
were I None
ineffective I None
. I None
<eof> I None

<s> O None
The I None
present I None
study I None
points I None
to I None
patient I None
characteristics I None
that I None
may I None
be I None
of I None
significance I None
in I None
the I None
development I None
of I None
EPS I None
due I None
to I None
haloperidol I Chemical
. I None
<eof> I None

<s> O None
Hepatic I Disease
veno O Disease
- O Disease
occlusive O Disease
disease O Disease
caused I None
by I None
6-thioguanine I Chemical
. I None
<eof> I None

<s> O None
Clinically I None
reversible I None
veno I Disease
- O Disease
occlusive O Disease
disease O Disease
of O Disease
the O Disease
liver O Disease
developed I None
in I None
a I None
23-year I None
- I None
old I None
man I None
with I None
acute I Disease
lymphocytic O Disease
leukemia O Disease
after I None
10 I None
months I None
of I None
maintenance I None
therapy I None
with I None
6-thioguanine I Chemical
. I None
<eof> I None

<s> O None
Serial I None
liver I None
biopsies I None
showed I None
the I None
development I None
and I None
resolution I None
of I None
intense I None
sinusoidal I None
engorgement I None
. I None
<eof> I None

<s> O None
Although I None
this I None
disease I None
was I None
clinically I None
reversible I None
, I None
some I None
subintimal I None
<eof> I None

<s> O None
fibrosis I Disease
about I None
the I None
terminal I None
hepatic I None
veins I None
persisted I None
. I None
<eof> I None

<s> O None
This I None
case I None
presented I None
a I None
unique I None
opportunity I None
to I None
observe I None
the I None
histologic I None
features I None
of I None
clinically I None
reversible I None
hepatic I Disease
veno O Disease
- O Disease
occlusive O Disease
disease O Disease
over I None
time I None
, I None
and I None
may I None
be I None
the I None
first I None
case I None
of I None
veno I None
- I None
occlusive I None
related I None
solely I None
to I None
6-thioguanine I Chemical
. I None
<eof> I None

<s> O None
Treatment I None
of I None
ifosfamide I Chemical
-induced I None
urothelial I Disease
toxicity O Disease
by I None
oral I None
administration I None
of I None
sodium I Chemical
2-mercaptoethane O Chemical
sulphonate O Chemical
<eof> I None

<s> O None
( I None
MESNA I Chemical
) I None
to I None
patients I None
with I None
inoperable I None
lung I Disease
cancer O Disease
. I None
<eof> I None

<s> O None
The I None
protective I None
effect I None
of I None
oral I None
administration I None
of I None
the I None
thiol I Chemical
compound I None
sodium I Chemical
2-mercaptoethane O Chemical
sulphonate O Chemical
<eof> I None

<s> O None
( I None
MESNA I Chemical
) I None
against I None
urothelial I Disease
toxicity O Disease
induced I None
by I None
ifosfamide I Chemical
<eof> I None

<s> O None
( I None
IF I Chemical
) I None
was I None
tested I None
in I None
a I None
group I None
of I None
45 I None
patients I None
with I None
inoperable I None
lung I Disease
cancer O Disease
under I None
treatment I None
with I None
IF I Chemical
<eof> I None

<s> O None
( I None
2250 I None
mg I None
/ I None
m2 I None
on I None
days I None
2 I None
- I None
5 I None
) I None
as I None
part I None
of I None
a I None
polychemotherapy I None
regimen I None
repeated I None
in I None
a I None
4-week I None
cycle I None
. I None
<eof> I None

<s> O None
MESNA I Chemical
was I None
given I None
orally I None
on I None
the I None
days I None
of I None
treatment I None
with I None
IF I Chemical
in I None
3 I None
doses I None
of I None
840 I None
mg I None
/ I None
m2 I None
, I None
each I None
administered I None
at I None
0 I None
hr I None
(= I None
injection I None
of I None
IF I Chemical
) I None
, I None
4 I None
hr I None
and I None
8 I None
hr I None
p.i I None
. I None
<eof> I None

<s> O None
Out I None
of I None
a I None
total I None
of I None
88 I None
courses I None
of I None
this I None
treatment I None
we I None
observed I None
10 I None
episodes I None
of I None
asymptomatic I None
microscopic I None
haematuria I Disease
and I None
no I None
episodes I None
of I None
gross I None
haematuria I Disease
. I None
<eof> I None

<s> O None
In I None
this I None
group I None
of I None
45 I None
patients I None
under I None
protection I None
with I None
MESNA I Chemical
there I None
were I None
5 I None
complete I None
remissions I None
and I None
9 I None
partial I None
remissions I None
( I None
total I None
31 I None
% I None
) I None
. I None
<eof> I None

<s> O None
A I None
further I None
group I None
of I None
25 I None
patients I None
under I None
polychemotherapy I None
with I None
IF I Chemical
were I None
treated I None
by I None
conventional I None
prophylactic I None
measures I None
( I None
raised I None
fluid I None
intake I None
and I None
forced I None
diuresis I None
) I None
. I None
<eof> I None

<s> O None
In I None
this I None
group I None
there I None
were I None
1 I None
complete I None
and I None
5 I None
partial I None
remissions I None
( I None
total I None
24 I None
% I None
) I None
, I None
but I None
nearly I None
all I None
patients I None
developed I None
either I None
gross I None
haematuria I Disease
and/or I None
symptoms I None
of I None
bladder I Disease
irritation O Disease
<eof> I None

<s> O None
( I None
cystitis I Disease
and I None
pollakisuria I Disease
) I None
. I None
<eof> I None

<s> O None
There I None
were I None
no I None
appreciable I None
differences I None
between I None
the I None
MESNA I Chemical
series I None
and I None
the I None
conventional I None
prophylaxis I None
series I None
with I None
respect I None
to I None
either I None
haematological I None
or I None
systemic I None
toxicity I Disease
of I None
the I None
cytostatic I None
treatment I None
. I None
<eof> I None

<s> O None
Our I None
results I None
support I None
the I None
view I None
that I None
MESNA I Chemical
, I None
given I None
orally I None
in I None
conjunction I None
with I None
combined I None
cytostatic I None
regimens I None
which I None
include I None
IF I Chemical
, I None
simplifies I None
the I None
treatment I None
and I None
provides I None
optimum I None
protection I None
for I None
the I None
urinary I None
epithelium I None
. I None
<eof> I None

<s> O None
Protection I None
with I None
oral I None
MESNA I Chemical
is I None
particularly I None
suitable I None
for I None
outpatients I None
. I None
<eof> I None

<s> O None
Time I None
course I None
alterations I None
of I None
QTC I None
interval I None
due I None
to I None
hypaque I Chemical
76 O Chemical
. I None
<eof> I None

<s> O None
Sequential I None
measurement I None
of I None
QT I None
interval I None
during I None
left I None
ventricular I None
angiography I None
was I None
made I None
30 I None
seconds I None
and I None
one I None
, I None
three I None
, I None
five I None
and I None
ten I None
minutes I None
after I None
injection I None
of I None
hypaque I Chemical
76 O Chemical
. I None
<eof> I None

<s> O None
The I None
subjects I None
were I None
ten I None
patients I None
found I None
to I None
have I None
normal I None
left I None
ventricles I None
and I None
coronary I None
arteries I None
. I None
<eof> I None

<s> O None
Significant I None
QTC I Disease
prolongation O Disease
occurred I None
in I None
30 I None
seconds I None
to I None
one I None
minute I None
in I None
association I None
with I None
marked I None
hypotension I Disease
and I None
elevation I None
of I None
cardiac I None
output I None
. I None
<eof> I None

<s> O None
Production I None
of I None
autochthonous I None
prostate I Disease
cancer O Disease
in I None
Lobund I None
- I None
Wistar I None
rats I None
by I None
treatments I None
with I None
N I Chemical
- O Chemical
nitroso O Chemical
- O Chemical
N O Chemical
- O Chemical
methylurea O Chemical
and I None
testosterone I Chemical
. I None
<eof> I None

<s> O None
More I None
than I None
50 I None
% I None
of I None
Lobund I None
- I None
Wistar I None
( I None
L I None
- I None
W I None
) I None
<eof> I None

<s> O None
strain I None
rats I None
developed I None
large I None
, I None
palpable I None
prostate I Disease
adenocarcinomas O Disease
<eof> I None

<s> O None
( I None
PAs I Disease
) I None
following I None
treatments I None
with I None
N I Chemical
- O Chemical
nitroso O Chemical
- O Chemical
N O Chemical
- O Chemical
methylurea O Chemical
<eof> I None

<s> O None
( I None
CAS I None
: I None
684 I None
- I None
93 I None
- I None
5 I None
) I None
and I None
testosterone I Chemical
propionate O Chemical
<eof> I None

<s> O None
[ I None
( I None
TP I Chemical
) I None
CAS I None
: I None
57 I None
- I None
85 I None
- I None
2 I None
] I None
, I None
and I None
most I None
of I None
the I None
tumor I Disease
-bearing I None
rats I None
manifested I None
metastatic I None
lesions I None
. I None
<eof> I None

<s> O None
The I None
incubation I None
periods I None
averaged I None
10.6 I None
months I None
. I None
<eof> I None

<s> O None
Within I None
the I None
same I None
timeframe I None
, I None
no I None
L I None
- I None
W I None
rat I None
developed I None
a I None
similar I None
palpable I None
PA I Disease
when I None
treated I None
only I None
with I None
TP I Chemical
. I None
<eof> I None

<s> O None
In I None
L I None
- I None
W I None
rats I None
, I None
TP I Chemical
acted I None
as I None
a I None
tumor I Disease
enhancement I None
agent I None
, I None
with I None
primary I None
emphasis I None
on I None
the I None
development I None
of I None
prostate I Disease
cancer O Disease
. I None
<eof> I None

<s> O None
A I None
dystonia I Disease
-like I None
syndrome I None
after I None
neuropeptide I None
( I None
MSH I Chemical
/ I None
ACTH I Chemical
) I None
stimulation I None
of I None
the I None
rat I None
locus I None
ceruleus I None
. I None
<eof> I None

<s> O None
The I None
movement I Disease
disorder O Disease
investigated I None
in I None
these I None
studies I None
has I None
some I None
features I None
in I None
common I None
with I None
human I None
idiopathic I None
dystonia I Disease
, I None
and I None
information I None
obtained I None
in I None
these I None
studies I None
may I None
be I None
of I None
potential I None
clinical I None
benefit I None
. I None
<eof> I None

<s> O None
The I None
present I None
experimental I None
results I None
indicated I None
that I None
peptidergic I None
stimulation I None
of I None
the I None
LC I None
resulted I None
in I None
a I None
NE I None
- I None
mediated I None
inhibition I None
of I None
cerebellar I None
Purkinje I None
cells I None
located I None
at I None
terminals I None
of I None
the I None
ceruleo I None
- I None
cerebellar I None
pathway I None
. I None
<eof> I None

<s> O None
However I None
, I None
it I None
is I None
not I None
certain I None
as I None
to I None
the I None
following I None
: I None
( I None
a I None
) I None
what I None
receptors I None
were I None
stimulated I None
by I None
the I None
ACTH I Chemical
N I None
- I None
terminal I None
fragments I None
at I None
the I None
LC I None
that I None
resulted I None
in I None
this I None
disorder I None
; I None
( I None
b I None
) I None
whether I None
NE I None
, I None
released I None
onto I None
Purkinje I None
cell I None
synapses I None
located I None
at I None
terminals I None
of I None
the I None
ceruleo I None
- I None
cerebellar I None
pathway I None
, I None
did I None
indeed I None
cause I None
the I None
long I None
- I None
term I None
depression I Disease
at I None
Purkinje I None
cell I None
synapses I None
( I None
previously I None
described I None
by I None
others I None
) I None
that I None
resulted I None
in I None
the I None
long I None
duration I None
of I None
the I None
movement I Disease
disorder O Disease
; I None
( I None
c I None
) I None
whether I None
the I None
inhibition I None
of I None
inhibitory I None
Purkinje I None
cells I None
resulted I None
in I None
disinhibition I None
or I None
increased I None
excitability I None
of I None
the I None
unilateral I None
cerebellar I None
fastigial I None
or I None
interpositus I None
nuclei I None
, I None
the I None
output I None
targets I None
of I None
the I None
Purkinje I None
cell I None
axons I None
, I None
that I None
may I None
have I None
been I None
an I None
important I None
contributing I None
factor I None
to I None
this I None
disorder I None
. I None
<eof> I None

<s> O None
These I None
questions I None
are I None
currently I None
being I None
investigated I None
. I None
<eof> I None

<s> O None
Dexmedetomidine I Chemical
, I None
acting I None
through I None
central I None
alpha-2 I None
adrenoceptors I None
, I None
prevents I None
opiate I None
- I None
induced I None
muscle I Disease
rigidity O Disease
in I None
the I None
rat I None
. I None
<eof> I None

<s> O None
The I None
highly I None
- I None
selective I None
alpha-2 I None
adrenergic I None
agonist I None
dexmedetomidine I Chemical
<eof> I None

<s> O None
( I None
D I Chemical
- O Chemical
MED O Chemical
) I None
is I None
capable I None
of I None
inducing I None
muscle I Disease
flaccidity O Disease
and I None
anesthesia I None
in I None
rats I None
and I None
dogs I None
. I None
<eof> I None

<s> O None
Intense I None
generalized I None
muscle I Disease
rigidity O Disease
is I None
an I None
undesirable I None
side I None
effect I None
of I None
potent I None
opiate I None
agonists I None
. I None
<eof> I None

<s> O None
Although I None
the I None
neurochemistry I None
of I None
opiate I None
- I None
induced I None
rigidity I Disease
has I None
yet I None
to I None
be I None
fully I None
elucidated I None
, I None
recent I None
work I None
suggests I None
a I None
role I None
for I None
a I None
central I None
adrenergic I None
mechanism I None
. I None
<eof> I None

<s> O None
In I None
the I None
present I None
study I None
, I None
the I None
authors I None
determined I None
if I None
treatment I None
with I None
D I Chemical
- O Chemical
MED O Chemical
prevents I None
the I None
muscle I Disease
rigidity O Disease
caused I None
by I None
high I None
- I None
dose I None
alfentanil I Chemical
anesthesia I None
in I None
the I None
rat I None
. I None
<eof> I None

<s> O None
Animals I None
( I None
n I None
= I None
42 I None
) I None
were I None
treated I None
intraperitoneally I None
with I None
one I None
of I None
the I None
following I None
six I None
regimens I None
: I None
1 I None
) I None
L I None
- I None
MED I None
( I None
the I None
inactive I None
L I None
- I None
isomer I None
of I None
medetomidine I Chemical
) I None
, I None
30 I None
micrograms I None
/ I None
kg I None
; I None
2 I None
) I None
D I Chemical
- O Chemical
MED O Chemical
, I None
10 I None
micrograms I None
/ I None
kg I None
; I None
3 I None
) I None
D I Chemical
- O Chemical
MED O Chemical
, I None
30 I None
micrograms I None
/ I None
kg I None
; I None
4 I None
) I None
D I Chemical
- O Chemical
MED O Chemical
[ I None
30 I None
micrograms I None
/ I None
kg I None
] I None
and I None
the I None
central I None
- I None
acting I None
alpha-2 I None
antagonist I None
, I None
idazoxan I Chemical
<eof> I None

<s> O None
[ I None
10 I None
mg I None
/ I None
kg I None
] I None
; I None
5 I None
) I None
D I Chemical
- O Chemical
MED O Chemical
<eof> I None

<s> O None
[ I None
30 I None
micrograms I None
/ I None
kg I None
] I None
and I None
the I None
peripheral I None
- I None
acting I None
alpha-2 I None
antagonist I None
DG-5128 I Chemical
<eof> I None

<s> O None
[ I None
10 I None
mg I None
/ I None
kg I None
] I None
, I None
or I None
; I None
6 I None
) I None
saline I None
. I None
<eof> I None

<s> O None
Baseline I None
electromyographic I None
activity I None
was I None
recorded I None
from I None
the I None
gastrocnemius I None
muscle I None
before I None
and I None
after I None
drug I None
treatment I None
. I None
<eof> I None

<s> O None
Each I None
rat I None
was I None
then I None
injected I None
with I None
alfentanil I Chemical
<eof> I None

<s> O None
( I None
ALF I Chemical
, I None
0.5 I None
mg I None
/ I None
kg I None
sc I None
) I None
. I None
<eof> I None

<s> O None
ALF I Chemical
injection I None
resulted I None
in I None
a I None
marked I None
increase I None
in I None
hindlimb I None
EMG I None
activity I None
in I None
the I None
L I None
- I None
MED I None
treatment I None
group I None
which I None
was I None
indistinguishable I None
from I None
that I None
seen I None
in I None
animals I None
treated I None
with I None
saline I None
. I None
<eof> I None

<s> O None
In I None
contrast I None
, I None
D I Chemical
- O Chemical
MED O Chemical
prevented I None
<eof> I None

<s> O None
alfentanil I Chemical
-induced I None
muscle I Disease
rigidity O Disease
in I None
a I None
dose I None
- I None
dependent I None
fashion I None
. I None
<eof> I None

<s> O None
The I None
small I None
EMG I None
values I None
obtained I None
in I None
the I None
high I None
- I None
dose I None
D I Chemical
- O Chemical
MED O Chemical
group I None
were I None
comparable I None
with I None
those I None
recorded I None
in I None
earlier I None
studies I None
from I None
control I None
animals I None
not I None
given I None
any I None
opiate I None
. I None
<eof> I None

<s> O None
The I None
high I None
- I None
dose I None
D I Chemical
- O Chemical
MED O Chemical
animals I None
were I None
flaccid I None
, I None
akinetic I Disease
, I None
and I None
lacked I None
a I None
startle I Disease
response I None
during I None
the I None
entire I None
experimental I None
period.(ABSTRACT I None
TRUNCATED I None
AT I None
250 I None
WORDS I None
) I None
<eof> I None

<s> O None
Seizure I Disease
activity I None
with I None
imipenem I Chemical
therapy I None
: I None
incidence I None
and I None
risk I None
factors I None
. I None
<eof> I None

<s> O None
Two I None
elderly I None
patients I None
with I None
a I None
history I None
of I None
either I None
cerebral I Disease
vascular O Disease
accident O Disease
<eof> I None

<s> O None
( I None
CVA I Disease
) I None
or I None
head I Disease
trauma O Disease
and I None
no I None
evidence I None
of I None
renal I Disease
disease O Disease
developed I None
<eof> I None

<s> O None
seizures I Disease
while I None
receiving I None
maximum I None
doses I None
of I None
imipenem I Chemical
/ O Chemical
cilastatin O Chemical
. I None
<eof> I None

<s> O None
Neither I None
patient I None
had I None
reported I None
previous I None
seizures I Disease
or I None
seizure I Disease
-like I None
activity I None
nor I None
was I None
receiving I None
anticonvulsant I None
agents I None
. I None
<eof> I None

<s> O None
All I None
seizures I Disease
were I None
controlled I None
with I None
therapeutic I None
doses I None
of I None
phenytoin I Chemical
. I None
<eof> I None

<s> O None
Both I None
patients I None
had I None
received I None
maximum I None
doses I None
of I None
other I None
beta I Chemical
- O Chemical
lactam O Chemical
antibiotics I None
without I None
evidence I None
of I None
seizure I Disease
activity I None
. I None
<eof> I None

<s> O None
The I None
ability I None
of I None
insulin I None
treatment I None
to I None
reverse I None
or I None
prevent I None
the I None
changes I None
in I None
urinary I None
bladder I None
function I None
caused I None
by I None
streptozotocin I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
diabetes I Disease
mellitus O Disease
. I None
<eof> I None

<s> O None
1 I None
. I None
<eof> I None

<s> O None
The I None
effects I None
of I None
insulin I None
treatment I None
on I None
in I None
vivo I None
and I None
in I None
vitro I None
urinary I None
bladder I None
function I None
in I None
streptozotocin I Chemical
- I None
diabetic I Disease
rats I None
were I None
investigated I None
. I None
<eof> I None

<s> O None
2 I None
. I None
<eof> I None

<s> O None
Diabetes I Disease
of I None
2 I None
months I None
duration I None
resulted I None
in I None
decreases I None
in I None
body I None
weight I None
and I None
increases I None
in I None
fluid I None
consumption I None
, I None
urine I None
volume I None
, I None
frequency I None
of I None
micturition I None
, I None
and I None
average I None
volume I None
per I None
micturition I None
; I None
effects I None
which I None
were I None
prevented I None
by I None
insulin I None
treatment I None
. I None
<eof> I None

<s> O None
3 I None
. I None
<eof> I None

<s> O None
Insulin I None
treatment I None
also I None
prevented I None
the I None
increases I None
in I None
contractile I None
responses I None
of I None
bladder I None
body I None
strips I None
from I None
diabetic I Disease
rats I None
to I None
nerve I None
stimulation I None
, I None
ATP I Chemical
, I None
and I None
bethanechol I Chemical
. I None
<eof> I None

<s> O None
4 I None
. I None
<eof> I None

<s> O None
Diabetes I Disease
of I None
4 I None
months I None
duration I None
also I None
resulted I None
in I None
decreases I None
in I None
body I None
weight I None
, I None
and I None
increases I None
in I None
fluid I None
consumption I None
, I None
urine I None
volume I None
, I None
frequency I None
of I None
micturition I None
, I None
and I None
average I None
volume I None
per I None
micturition I None
, I None
effects I None
which I None
were I None
reversed I None
by I None
insulin I None
treatment I None
for I None
the I None
final I None
2 I None
months I None
of I None
the I None
study I None
. I None
<eof> I None

<s> O None
5 I None
. I None
<eof> I None

<s> O None
Insulin I None
treatment I None
reversed I None
the I None
increases I None
in I None
contractile I None
responses I None
of I None
bladder I None
body I None
strips I None
from I None
diabetic I Disease
rats I None
to I None
nerve I None
stimulation I None
, I None
ATP I Chemical
, I None
and I None
bethanechol I Chemical
. I None
<eof> I None

<s> O None
6 I None
. I None
<eof> I None

<s> O None
The I None
data I None
indicate I None
that I None
the I None
effects I None
of I None
streptozotocin I Chemical
-induced I None
diabetes I Disease
on I None
urinary I None
bladder I None
function I None
are I None
both I None
prevented I None
and I None
reversed I None
by I None
insulin I None
treatment I None
. I None
<eof> I None

<s> O None
Delayed I None
institution I None
of I None
hypertension I Disease
during I None
focal I None
cerebral I Disease
ischemia O Disease
: I None
effect I None
on I None
brain I Disease
edema O Disease
. I None
<eof> I None

<s> O None
The I None
effect I None
of I None
induced I None
hypertension I Disease
instituted I None
after I None
a I None
2-h I None
delay I None
following I None
middle I Disease
cerebral O Disease
artery O Disease
occlusion O Disease
<eof> I None

<s> O None
( I None
MCAO I Disease
) I None
on I None
brain I Disease
edema O Disease
formation I None
and I None
histochemical I None
injury I None
was I None
studied I None
. I None
<eof> I None

<s> O None
Under I None
isoflurane I Chemical
anesthesia I None
, I None
the I None
MCA I None
of I None
14 I None
spontaneously I None
hypertensive I Disease
rats I None
was I None
occluded I None
. I None
<eof> I None

<s> O None
In I None
the I None
control I None
group I None
( I None
n I None
= I None
7 I None
) I None
, I None
the I None
mean I None
arterial I None
pressure I None
( I None
MAP I None
) I None
was I None
not I None
manipulated I None
. I None
<eof> I None

<s> O None
In I None
the I None
hypertensive I Disease
group I None
( I None
n I None
= I None
7 I None
) I None
, I None
the I None
MAP I None
was I None
elevated I None
by I None
25 I None
- I None
30 I None
mm I None
Hg I None
beginning I None
2 I None
h I None
after I None
MCAO I Disease
. I None
<eof> I None

<s> O None
Four I None
hours I None
after I None
<eof> I None

<s> O None
MCAO I Disease
, I None
the I None
rats I None
were I None
killed I None
and I None
the I None
brains I None
harvested I None
. I None
<eof> I None

<s> O None
The I None
brains I None
were I None
sectioned I None
along I None
coronal I None
planes I None
spanning I None
the I None
distribution I None
of I None
ischemia I Disease
produced I None
by I None
MCAO I Disease
. I None
<eof> I None

<s> O None
Specific I None
gravity I None
( I None
SG I None
) I None
was I None
determined I None
in I None
the I None
subcortex I None
and I None
in I None
two I None
sites I None
in I None
the I None
cortex I None
( I None
core I None
and I None
periphery I None
of I None
the I None
ischemic I Disease
territory I None
) I None
. I None
<eof> I None

<s> O None
The I None
extent I None
of I None
neuronal I Disease
injury O Disease
was I None
determined I None
by I None
2,3,5-triphenyltetrazolium I Chemical
staining I None
. I None
<eof> I None

<s> O None
In I None
the I None
ischemic I Disease
core I None
, I None
there I None
was I None
no I None
difference I None
in I None
SG I None
in I None
the I None
subcortex I None
and I None
cortex I None
in I None
the I None
two I None
groups I None
. I None
<eof> I None

<s> O None
In I None
the I None
periphery I None
of I None
the I None
ischemic I Disease
territory I None
, I None
SG I None
in I None
the I None
cortex I None
was I None
greater I None
( I None
less I None
edema I Disease
accumulation I None
) I None
in I None
the I None
hypertensive I Disease
group I None
( I None
1.041 I None
+ I None
/- I None
0.001 I None
vs I None
1.039 I None
+ I None
/- I None
0.001 I None
, I None
P I None
less I None
than I None
0.05 I None
) I None
. I None
<eof> I None

<s> O None
The I None
area I None
of I None
histochemical I None
injury I None
( I None
as I None
a I None
percent I None
of I None
the I None
cross I None
- I None
sectional I None
area I None
of I None
the I None
hemisphere I None
) I None
was I None
less I None
in I None
the I None
hypertensive I Disease
group I None
( I None
33 I None
+ I None
/- I None
3 I None
% I None
vs I None
21 I None
+ I None
/- I None
<eof> I None

<s> O None
2 I None
% I None
, I None
P I None
less I None
than I None
0.05 I None
) I None
. I None
<eof> I None

<s> O None
The I None
data I None
indicate I None
that I None
phenylephrine I Chemical
-induced I None
hypertension I Disease
instituted I None
2 I None
h I None
after I None
MCAO I Disease
does I None
not I None
aggravate I None
edema I Disease
in I None
the I None
ischemic I Disease
core I None
, I None
that I None
it I None
improves I None
edema I Disease
in I None
the I None
periphery I None
of I None
the I None
ischemic I Disease
territory I None
, I None
and I None
that I None
it I None
reduces I None
the I None
area I None
of I None
histochemical I None
neuronal I Disease
dysfunction O Disease
. I None
<eof> I None

<s> O None
Amiodarone I Chemical
pulmonary I Disease
toxicity O Disease
. I None
<eof> I None

<s> O None
Amiodarone I Chemical
is I None
an I None
effective I None
antiarrhythmic I None
agent I None
whose I None
utility I None
is I None
limited I None
by I None
many I None
side I None
- I None
effects I None
, I None
the I None
most I None
problematic I None
being I None
pneumonitis I Disease
. I None
<eof> I None

<s> O None
The I None
pulmonary I Disease
toxicity O Disease
of I None
amiodarone I Chemical
is I None
thought I None
to I None
result I None
from I None
direct I None
injury I None
related I None
to I None
the I None
intracellular I None
accumulation I None
of I None
phospholipid I None
and I None
T I None
cell I None
- I None
mediated I None
hypersensitivity I None
pneumonitis I None
. I None
<eof> I None

<s> O None
The I None
clinical I None
and I None
radiographic I None
features I None
of I None
amiodarone I Chemical
-induced I None
<eof> I None

<s> O None
pulmonary I Disease
toxicity O Disease
are I None
characteristic I None
but I None
nonspecific I None
. I None
<eof> I None

<s> O None
The I None
diagnosis I None
depends I None
on I None
exclusion I None
of I None
other I None
entities I None
, I None
such I None
as I None
heart I Disease
failure O Disease
, I None
infection I Disease
, I None
and I None
malignancy I Disease
. I None
<eof> I None

<s> O None
While I None
withdrawal I None
of I None
amiodarone I Chemical
leads I None
to I None
clinical I None
improvement I None
in I None
majority I None
of I None
cases I None
, I None
this I None
is I None
not I None
always I None
possible I None
or I None
advisable I None
. I None
<eof> I None

<s> O None
Dose I None
reduction I None
or I None
concomitant I None
steroid I Chemical
therapy I None
may I None
have I None
a I None
role I None
in I None
selected I None
patients I None
. I None
<eof> I None

<s> O None
Light I None
chain I None
proteinuria I Disease
and I None
cellular I None
mediated I None
immunity I None
in I None
<eof> I None

<s> O None
rifampin I Chemical
treated I None
patients I None
with I None
tuberculosis I Disease
. I None
<eof> I None

<s> O None
Light I None
chain I None
<eof> I None

<s> O None
proteinuria I Disease
was I None
found I None
in I None
9 I None
of I None
17 I None
<eof> I None

<s> O None
tuberculosis I Disease
patients I None
treated I None
with I None
rifampin I Chemical
. I None
<eof> I None

<s> O None
Concomitant I None
assay I None
of I None
cellular I None
mediated I None
immunity I None
in I None
these I None
patients I None
using I None
skin I None
test I None
antigen I None
and I None
a I None
lymphokine I None
in I None
vitro I None
test I None
provided I None
results I None
that I None
were I None
different I None
. I None
<eof> I None

<s> O None
Response I None
to I None
Varidase I None
skin I None
test I None
antigen I None
was I None
negative I None
for I None
all I None
eight I None
tuberculosis I Disease
patients I None
tested I None
, I None
but I None
there I None
occurred I None
a I None
hyper I None
- I None
responsiveness I None
of I None
the I None
lymphocytes I None
of I None
these I None
eight I None
patients I None
to I None
phytomitogen I None
( I None
PHA I None
- I None
P I None
) I None
. I None
<eof> I None

<s> O None
as I None
well I None
as I None
of I None
those I None
of I None
seven I None
other I None
tuberculous I Disease
patients I None
. I None
<eof> I None

<s> O None
This I None
last I None
finding I None
may I None
be I None
related I None
to I None
time I None
of I None
testing I None
and/or I None
endogenous I None
serum I None
binding I None
of I None
rifampin I Chemical
which I None
could I None
have I None
inhibited I None
mitogen I None
activity I None
for I None
the I None
lymphocyte I None
. I None
<eof> I None

<s> O None
Initial I None
potassium I Chemical
loss I None
and I None
hypokalaemia I Disease
during I None
chlorthalidone I Chemical
administration I None
in I None
patients I None
with I None
essential I None
hypertension I Disease
: I None
the I None
influence I None
of I None
dietary I None
sodium I Chemical
restriction I None
. I None
<eof> I None

<s> O None
To I None
investigate I None
the I None
initial I None
potassium I Chemical
loss I None
and I None
development I None
of I None
hypokalaemia I Disease
during I None
the I None
administration I None
of I None
an I None
oral I None
diuretic I None
, I None
metabolic I None
balance I None
studies I None
were I None
performed I None
in I None
ten I None
patients I None
with I None
essential I None
hypertension I Disease
who I None
had I None
shown I None
hypokalaemia I Disease
under I None
prior I None
oral I None
diuretic I None
treatment I None
. I None
<eof> I None

<s> O None
Chlorthalidone I Chemical
( I None
50 I None
mg I None
daily I None
) I None
was I None
given I None
for I None
14 I None
days I None
. I None
<eof> I None

<s> O None
Six I None
patients I None
received I None
a I None
normal- I None
sodium I Chemical
diet I None
and I None
four I None
a I None
low- I None
sodium I Chemical
( I None
17 I None
mmol I None
/ I None
day I None
) I None
diet I None
. I None
<eof> I None

<s> O None
All I None
patients I None
had I None
a I None
normal I None
initial I None
total I None
body I None
potassium I Chemical
<eof> I None

<s> O None
( I None
40 I None
K I None
) I None
. I None
<eof> I None

<s> O None
The I None
electrolyte I None
balances I None
, I None
weight I None
, I None
bromide I None
space I None
, I None
plasma I None
renin I None
activity I None
, I None
and I None
aldosterone I Chemical
secretion I None
rate I None
were I None
measured I None
. I None
<eof> I None

<s> O None
In I None
both I None
groups I None
a I None
potassium I Chemical
deficit I None
developed I None
, I None
with I None
proportionally I None
larger I None
losses I None
from I None
the I None
extracellular I None
than I None
from I None
the I None
intracellular I None
compartment I None
. I None
<eof> I None

<s> O None
In I None
the I None
normal- I None
sodium I Chemical
group I None
the I None
highest I None
mean I None
potassium I Chemical
deficit I None
was I None
176 I None
mmol I None
on I None
day I None
9 I None
, I None
after I None
which I None
some I None
potassium I Chemical
was I None
regained I None
; I None
in I None
the I None
low- I None
sodium I Chemical
group I None
the I None
highest I None
deficit I None
was I None
276 I None
mmol I None
on I None
day I None
13 I None
. I None
<eof> I None

<s> O None
The I None
normal- I None
sodium I Chemical
group I None
showed I None
an I None
immediate I None
but I None
temporary I None
rise I None
of I None
the I None
renin I None
and I None
aldosterone I Chemical
levels I None
; I None
in I None
the I None
low- I None
sodium I Chemical
group I None
renin I None
and I None
aldosterone I Chemical
increased I None
more I None
slowly I None
but I None
remained I None
elevated I None
. I None
<eof> I None

<s> O None
It I None
is I None
concluded I None
that I None
dietary I None
sodium I Chemical
restriction I None
increases I None
diuretic I None
- I None
induced I None
potassium I Chemical
loss I None
, I None
presumably I None
by I None
an I None
increased I None
activity I None
of I None
the I None
renin- I None
angiotensin I Chemical
- I None
aldosterone I Chemical
system I None
, I None
while I None
sodium I Chemical
delivery I None
to I None
the I None
distal I None
renal I None
tubules I None
remains I None
sufficiently I None
high I None
to I None
allow I None
increased I None
potassium I Chemical
secretion I None
. I None
<eof> I None

<s> O None
Dynamic I None
response I None
of I None
blood I None
vessel I None
in I None
acute I Disease
renal O Disease
failure O Disease
. I None
<eof> I None

<s> O None
In I None
this I None
study I None
we I None
postulated I None
that I None
during I None
acute I Disease
renal O Disease
failure O Disease
induced I None
by I None
gentamicin I Chemical
the I None
transient I None
or I None
dynamic I None
response I None
of I None
blood I None
vessels I None
could I None
be I None
affected I None
, I None
and I None
that I None
antioxidants I None
can I None
prevent I None
the I None
changes I None
in I None
dynamic I None
responses I None
of I None
blood I None
vessels I None
. I None
<eof> I None

<s> O None
The I None
new I None
approach I None
to I None
ex I None
vivo I None
blood I None
vessel I None
experiments I None
in I None
which I None
not I None
only I None
the I None
end I None
points I None
of I None
vessels I None
response I None
within I None
the I None
time I None
interval I None
is I None
considered I None
, I None
but I None
also I None
dynamics I None
of I None
this I None
response I None
, I None
was I None
used I None
in I None
this I None
paper I None
. I None
<eof> I None

<s> O None
Our I None
results I None
confirm I None
the I None
alteration I None
in I None
dynamic I None
response I None
of I None
blood I None
vessels I None
during I None
the I None
change I None
of I None
pressure I None
in I None
gentamicin I Chemical
<eof> I None

<s> O None
-treated I None
animals I None
. I None
<eof> I None

<s> O None
The I None
beneficial I None
effects I None
of I None
vitamin I Chemical
C O Chemical
administration I None
to I None
gentamicin I Chemical
<eof> I None

<s> O None
-treated I None
animals I None
are I None
also I None
confirmed I None
through I None
: I None
lower I None
level I None
of I None
blood I None
urea I Chemical
and I None
creatinine I Chemical
and I None
higher I None
level I None
of I None
potassium I Chemical
. I None
<eof> I None

<s> O None
The I None
pressure I None
dynamic I None
responses I None
of I None
isolated I None
blood I None
vessels I None
show I None
a I None
faster I None
pressure I None
change I None
in I None
gentamicin I Chemical
<eof> I None

<s> O None
-treated I None
animals I None
( I None
8.07 I None
+ I None
/- I None
<eof> I None

<s> O None
1.7 I None
s I None
vs. I None
5.64 I None
+ I None
/- I None
<eof> I None

<s> O None
0.18 I None
s I None
) I None
. I None
<eof> I None

<s> O None
Vitamin I Chemical
C O Chemical
administration I None
induced I None
slowdown I None
of I None
pressure I None
change I None
back I None
to I None
the I None
control I None
values I None
. I None
<eof> I None

<s> O None
The I None
pressure I None
dynamic I None
properties I None
, I None
quantitatively I None
defined I None
by I None
comparative I None
pressure I None
dynamic I None
and I None
total I None
pressure I None
dynamic I None
, I None
confirm I None
the I None
alteration I None
in I None
dynamic I None
response I None
of I None
blood I None
vessels I None
during I None
the I None
change I None
of I None
pressure I None
in I None
gentamicin I Chemical
-treated I None
animals I None
and I None
beneficial I None
effects I None
of I None
vitamin I Chemical
C O Chemical
administration I None
. I None
<eof> I None

<s> O None
The I None
hemodynamics I None
of I None
oxytocin I Chemical
and I None
other I None
vasoactive I None
agents I None
during I None
neuraxial I None
anesthesia I None
for I None
cesarean I None
delivery I None
: I None
findings I None
in I None
six I None
cases I None
. I None
<eof> I None

<s> O None
Oxytocin I Chemical
is I None
a I None
commonly I None
used I None
uterotonic I None
that I None
can I None
cause I None
significant I None
and I None
even I None
fatal I None
hypotension I Disease
, I None
particularly I None
when I None
given I None
as I None
a I None
bolus I None
. I None
<eof> I None

<s> O None
The I None
resulting I None
hypotension I Disease
can I None
be I None
produced I None
by I None
a I None
decrease I None
in I None
systemic I None
vascular I None
resistance I None
or I None
cardiac I None
output I None
through I None
a I None
decrease I None
in I None
venous I None
return I None
. I None
<eof> I None

<s> O None
Parturients I None
with I None
normal I None
volume I None
status I None
, I None
heart I None
valves I None
and I None
pulmonary I None
vasculature I None
most I None
often I None
respond I None
to I None
this I None
hypotension I Disease
with I None
a I None
compensatory I None
increase I None
in I None
heart I None
rate I None
and I None
stroke I Disease
volume I None
. I None
<eof> I None

<s> O None
Oxytocin I Chemical
-induced I None
<eof> I None

<s> O None
hypotension I Disease
at I None
cesarean I None
delivery I None
may I None
be I None
incorrectly I None
attributed I None
to I None
blood I Disease
loss O Disease
. I None
<eof> I None

<s> O None
Pulse I None
power I None
analysis I None
( I None
also I None
called I None
" I None
pulse I None
contour I None
analysis I None
" I None
) I None
of I None
an I None
arterial I None
pressure I None
wave I None
form I None
allows I None
continuous I None
evaluation I None
of I None
systemic I None
vascular I None
resistance I None
and I None
cardiac I None
output I None
in I None
real I None
time I None
, I None
thereby I None
elucidating I None
the I None
causative I None
factors I None
behind I None
changes I None
in I None
blood I None
pressure I None
. I None
<eof> I None

<s> O None
Pulse I None
power I None
analysis I None
was I None
conducted I None
in I None
six I None
cases I None
of I None
cesarean I None
delivery I None
performed I None
under I None
neuraxial I None
anesthesia I None
. I None
<eof> I None

<s> O None
Hypotension I Disease
in I None
response I None
to I None
<eof> I None

<s> O None
oxytocin I Chemical
was I None
associated I None
with I None
a I None
decrease I None
in I None
systemic I None
vascular I None
resistance I None
and I None
a I None
compensatory I None
increase I None
in I None
stroke I Disease
volume I None
, I None
heart I None
rate I None
and I None
cardiac I None
output I None
. I None
<eof> I None

<s> O None
Pulse I None
power I None
analysis I None
may I None
be I None
helpful I None
in I None
determining I None
the I None
etiology I None
of I None
and I None
treating I None
hypotension I Disease
during I None
cesarean I None
delivery I None
under I None
neuraxial I None
anesthesia I None
. I None
<eof> I None

<s> O None
Exaggerated I None
expression I None
of I None
inflammatory I None
mediators I None
in I None
vasoactive I None
intestinal I None
polypeptide I None
knockout I None
<eof> I None

<s> O None
( I None
VIP-/- I None
) I None
mice I None
with I None
cyclophosphamide I Chemical
<eof> I None

<s> O None
( I None
CYP I Chemical
) I None
-induced I None
cystitis I Disease
. I None
<eof> I None

<s> O None
Vasoactive I None
intestinal I None
polypeptide I None
( I None
VIP I None
) I None
is I None
an I None
immunomodulatory I None
neuropeptide I None
distributed I None
in I None
micturition I None
pathways I None
. I None
<eof> I None

<s> O None
VIP(-/- I None
) I None
mice I None
exhibit I None
altered I None
bladder I None
function I None
and I None
neurochemical I None
properties I None
in I None
micturition I None
pathways I None
after I None
cyclophosphamide I Chemical
<eof> I None

<s> O None
( I None
CYP I Chemical
) I None
-induced I None
cystitis I Disease
. I None
<eof> I None

<s> O None
Given I None
VIP I None
's I None
role I None
as I None
an I None
anti I None
- I None
inflammatory I None
mediator I None
, I None
we I None
hypothesized I None
that I None
VIP(-/- I None
) I None
mice I None
would I None
exhibit I None
enhanced I None
inflammatory I None
mediator I None
expression I None
after I None
cystitis I Disease
. I None
<eof> I None

<s> O None
A I None
mouse I None
inflammatory I None
cytokine I None
and I None
receptor I None
RT2 I None
profiler I None
array I None
was I None
used I None
to I None
determine I None
regulated I None
transcripts I None
in I None
the I None
urinary I None
bladder I None
of I None
wild I None
type I None
( I None
WT I None
) I None
and I None
VIP(-/- I None
) I None
mice I None
with I None
or I None
without I None
<eof> I None

<s> O None
CYP I Chemical
-induced I None
<eof> I None

<s> O None
cystitis I Disease
<eof> I None

<s> O None
( I None
150 I None
mg I None
/ I None
kg I None
; I None
i.p I None
. I None
; I None
48 I None
h I None
) I None
. I None
<eof> I None

<s> O None
Four I None
binary I None
comparisons I None
were I None
made I None
: I None
WT I None
control I None
versus I None
CYP I Chemical
treatment I None
( I None
48 I None
h I None
) I None
, I None
VIP(-/- I None
) I None
control I None
versus I None
CYP I Chemical
treatment I None
( I None
48 I None
h I None
) I None
, I None
WT I None
control I None
versus I None
VIP(-/- I None
) I None
control I None
, I None
and I None
WT I None
with I None
CYP I Chemical
treatment I None
( I None
48 I None
h I None
) I None
versus I None
VIP(-/- I None
) I None
with I None
CYP I Chemical
treatment I None
( I None
48 I None
h I None
) I None
. I None
<eof> I None

<s> O None
The I None
genes I None
presented I None
represent I None
( I None
1 I None
) I None
greater I None
than I None
1.5-fold I None
change I None
in I None
either I None
direction I None
and I None
( I None
2 I None
) I None
the I None
p I None
value I None
is I None
less I None
than I None
0.05 I None
for I None
the I None
comparison I None
being I None
made I None
. I None
<eof> I None

<s> O None
Several I None
regulated I None
genes I None
were I None
validated I None
using I None
enzyme I None
- I None
linked I None
immunoassays I None
including I None
IL-1beta I None
and I None
CXCL1 I None
. I None
<eof> I None

<s> O None
CYP I Chemical
treatment I None
significantly I None
( I None
p I None
< I None
or I None
= I None
0.001 I None
) I None
increased I None
expression I None
of I None
CXCL1 I None
and I None
IL-1beta I None
in I None
the I None
urinary I None
bladder I None
of I None
WT I None
and I None
VIP(-/- I None
) I None
mice I None
, I None
but I None
expression I None
in I None
VIP(-/- I None
) I None
mice I None
with I None
CYP I Chemical
treatment I None
was I None
significantly I None
( I None
p I None
< I None
or I None
= I None
0.001 I None
) I None
greater I None
( I None
4.2- I None
to I None
13-fold I None
increase I None
) I None
than I None
that I None
observed I None
in I None
WT I None
urinary I None
bladder I None
( I None
3.6- I None
to I None
5-fold I None
increase I None
) I None
. I None
<eof> I None

<s> O None
The I None
data I None
suggest I None
that I None
in I None
VIP(-/- I None
) I None
mice I None
with I None
bladder I Disease
inflammation O Disease
, I None
inflammatory I None
mediators I None
are I None
increased I None
above I None
that I None
observed I None
in I None
WT I None
with I None
CYP I Chemical
. I None
<eof> I None

<s> O None
This I None
shift I None
in I None
balance I None
may I None
contribute I None
to I None
increased I None
bladder I Disease
dysfunction O Disease
in I None
VIP(-/- I None
) I None
mice I None
with I None
bladder I Disease
inflammation O Disease
and I None
altered I None
neurochemical I None
expression I None
in I None
micturition I None
pathways I None
. I None
<eof> I None

<s> O None
Intraocular I None
pressure I None
in I None
patients I None
with I None
uveitis I Disease
treated I None
with I None
fluocinolone I Chemical
acetonide O Chemical
implants I None
. I None
<eof> I None

<s> O None
OBJECTIVE I None
: I None
<eof> I None

<s> O None
To I None
report I None
the I None
incidence I None
and I None
management I None
of I None
elevated I Disease
intraocular O Disease
pressure O Disease
<eof> I None

<s> O None
( I None
IOP I None
) I None
in I None
patients I None
with I None
uveitis I Disease
treated I None
with I None
the I None
fluocinolone I Chemical
acetonide O Chemical
<eof> I None

<s> O None
( I None
FA I Chemical
) I None
intravitreal I None
implant I None
. I None
<eof> I None

<s> O None
DESIGN I None
: I None
<eof> I None

<s> O None
Pooled I None
data I None
from I None
3 I None
multicenter I None
, I None
double I None
- I None
masked I None
, I None
randomized I None
, I None
controlled I None
, I None
phase I None
2b/3 I None
clinical I None
trials I None
evaluating I None
the I None
safety I None
and I None
efficacy I None
of I None
the I None
0.59-mg I None
or I None
2.1-mg I None
FA I Chemical
intravitreal I None
implant I None
or I None
standard I None
therapy I None
were I None
analyzed I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
During I None
the I None
3-year I None
follow I None
- I None
up I None
, I None
71.0 I None
% I None
of I None
implanted I None
eyes I None
had I None
an I None
IOP I None
increase I None
of I None
10 I None
mm I None
Hg I None
or I None
more I None
than I None
baseline I None
and I None
55.1 I None
% I None
, I None
24.7 I None
% I None
, I None
and I None
6.2 I None
% I None
of I None
eyes I None
reached I None
an I None
IOP I None
of I None
30 I None
mm I None
Hg I None
or I None
more I None
, I None
40 I None
mm I None
Hg I None
or I None
more I None
, I None
and I None
50 I None
mm I None
Hg I None
or I None
more I None
, I None
respectively I None
. I None
<eof> I None

<s> O None
Topical I None
IOP I None
- I None
lowering I None
medication I None
was I None
administered I None
in I None
74.8 I None
% I None
of I None
implanted I None
eyes I None
, I None
and I None
IOP I None
- I None
lowering I None
surgeries I None
, I None
most I None
of I None
which I None
were I None
trabeculectomies I None
( I None
76.2 I None
% I None
) I None
, I None
were I None
performed I None
on I None
36.6 I None
% I None
of I None
implanted I None
eyes I None
. I None
<eof> I None

<s> O None
Intraocular I None
pressure I None
- I None
lowering I None
surgeries I None
were I None
considered I None
a I None
success I None
( I None
postoperative I None
IOP I None
of I None
6 I None
- I None
21 I None
mm I None
Hg I None
with I None
or I None
without I None
additional I None
IOP I None
- I None
lowering I None
medication I None
) I None
in I None
85.1 I None
% I None
of I None
eyes I None
at I None
1 I None
year I None
. I None
<eof> I None

<s> O None
The I None
rate I None
of I None
hypotony I Disease
<eof> I None

<s> O None
( I None
IOP I None
< I None
/= I None
5 I None
mm I None
Hg I None
) I None
following I None
IOP I None
- I None
lowering I None
surgery I None
( I None
42.5 I None
% I None
) I None
was I None
not I None
different I None
from I None
that I None
of I None
implanted I None
eyes I None
not I None
subjected I None
to I None
surgery I None
( I None
35.4 I None
% I None
) I None
<eof> I None

<s> O None
( I None
P I None
= I None
.09 I None
) I None
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
<eof> I None

<s> O None
Elevated I None
IOP I None
is I None
a I None
significant I None
complication I None
with I None
the I None
FA I None
intravitreal I None
implant I None
but I None
may I None
be I None
controlled I None
with I None
medication I None
and I None
surgery I None
. I None
<eof> I None

<s> O None
Pallidal I None
stimulation I None
: I None
an I None
alternative I None
to I None
pallidotomy I None
? I None
<eof> I None

<s> O None
A I None
resurgence I None
of I None
interest I None
in I None
the I None
surgical I None
treatment I None
of I None
Parkinson I Disease
's O Disease
disease O Disease
<eof> I None

<s> O None
( I None
PD I Disease
) I None
came I None
with I None
the I None
rediscovery I None
of I None
posteroventral I None
pallidotomy I None
by I None
Laitinen I None
in I None
1985 I None
. I None
<eof> I None

<s> O None
Laitinen I None
's I None
procedure I None
improved I None
most I None
symptoms I None
in I None
drug I None
- I None
resistant I None
PD I Disease
, I None
which I None
engendered I None
wide I None
interest I None
in I None
the I None
neurosurgical I None
community I None
. I None
<eof> I None

<s> O None
Another I None
lesioning I None
procedure I None
, I None
ventrolateral I None
thalamotomy I None
, I None
has I None
become I None
a I None
powerful I None
alternative I None
to I None
stimulate I None
the I None
nucleus I None
ventralis I None
intermedius I None
, I None
producing I None
high I None
long I None
- I None
term I None
success I None
rates I None
and I None
low I None
morbidity I None
rates I None
. I None
<eof> I None

<s> O None
Pallidal I None
stimulation I None
has I None
not I None
met I None
with I None
the I None
same I None
success I None
. I None
<eof> I None

<s> O None
According I None
to I None
the I None
literature I None
pallidotomy I None
improves I None
the I None
" I None
on I None
" I None
symptoms I None
of I None
PD I Disease
, I None
such I None
as I None
dyskinesias I Disease
, I None
as I None
well I None
as I None
the I None
" I None
off I None
" I None
symptoms I None
, I None
such I None
as I None
rigidity I Disease
, I None
bradykinesia I Disease
, I None
and I None
on I None
- I None
off I None
fluctuations I None
. I None
<eof> I None

<s> O None
Pallidal I None
stimulation I None
improves I None
<eof> I None

<s> O None
bradykinesia I Disease
and I None
rigidity I Disease
to I None
a I None
minor I None
extent I None
; I None
however I None
, I None
its I None
strength I None
seems I None
to I None
be I None
in I None
improving I None
levodopa I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
dyskinesias I Disease
. I None
<eof> I None

<s> O None
Stimulation I None
often I None
produces I None
an I None
improvement I None
in I None
the I None
hyper- I Disease
or O Disease
dyskinetic O Disease
upper I None
limbs I None
, I None
but I None
increases I None
the I None
" I None
freezing I None
" I None
phenomenon I None
in I None
the I None
lower I None
limbs I None
at I None
the I None
same I None
time I None
. I None
<eof> I None

<s> O None
Considering I None
the I None
small I None
increase I None
in I None
the I None
patient I None
's I None
independence I None
, I None
the I None
high I None
costs I None
of I None
bilateral I None
implants I None
, I None
and I None
the I None
difficulty I None
most I None
patients I None
experience I None
in I None
handling I None
the I None
devices I None
, I None
the I None
question I None
arises I None
as I None
to I None
whether I None
bilateral I None
pallidal I None
stimulation I None
is I None
a I None
real I None
alternative I None
to I None
pallidotomy I None
. I None
<eof> I None

<s> O None
Case I None
report I None
: I None
Dexatrim I Chemical
<eof> I None

<s> O None
( I None
Phenylpropanolamine I Chemical
) I None
as I None
a I None
cause I None
of I None
myocardial I Disease
infarction O Disease
. I None
<eof> I None

<s> O None
Phenylpropanolamine I Chemical
<eof> I None

<s> O None
( I None
PPA I Chemical
) I None
is I None
a I None
sympathetic I None
amine I Chemical
used I None
in I None
over I None
- I None
the I None
- I None
counter I None
cold I None
remedies I None
and I None
weight I None
- I None
control I None
preparations I None
worldwide I None
. I None
<eof> I None

<s> O None
Its I None
use I None
has I None
been I None
associated I None
with I None
hypertensive I Disease
episodes I None
and I None
hemorrhagic I None
strokes I None
in I None
younger I None
women I None
. I None
<eof> I None

<s> O None
Several I None
reports I None
have I None
linked I None
the I None
abuse I None
of I None
PPA I Chemical
with I None
myocardial I Disease
injury O Disease
, I None
especially I None
when I None
overdose I Disease
is I None
involved I None
. I None
<eof> I None

<s> O None
We I None
report I None
here I None
the I None
first I None
case I None
of I None
Dexatrim I Chemical
<eof> I None

<s> O None
( I None
PPA I Chemical
) I None
-induced I None
<eof> I None

<s> O None
myocardial I Disease
injury O Disease
in I None
a I None
young I None
woman I None
who I None
was I None
using I None
it I None
at I None
recommended I None
doses I None
for I None
weight I None
control I None
. I None
<eof> I None

<s> O None
In I None
addition I None
, I None
we I None
review I None
the I None
7 I None
other I None
cases I None
of I None
PPA I Chemical
related I None
myocardial I Disease
injury O Disease
<eof> I None

<s> O None
that I None
have I None
been I None
reported I None
so I None
far I None
. I None
<eof> I None

<s> O None
Physicians I None
and I None
patients I None
should I None
be I None
alert I None
to I None
the I None
potential I None
cardiac I None
risk I None
associated I None
with I None
the I None
use I None
of I None
PPA I Chemical
, I None
even I None
at I None
doses I None
generally I None
considered I None
to I None
be I None
safe I None
. I None
<eof> I None

<s> O None
Risperidone I Chemical
-associated I None
, I None
benign I None
transient I None
visual I Disease
disturbances O Disease
in I None
schizophrenic I Disease
patients I None
with I None
a I None
past I None
history I None
of I None
LSD I Chemical
abuse I None
. I None
<eof> I None

<s> O None
Two I None
<eof> I None

<s> O None
schizophrenic I Disease
patients I None
, I None
who I None
had I None
a I None
prior I None
history I None
of I None
LSD I Chemical
abuse I None
<eof> I None

<s> O None
and I None
who I None
had I None
previously I None
developed I None
<eof> I None

<s> O None
EPS I Disease
with I None
classic I None
antipsychotics I None
, I None
were I None
successfully I None
treated I None
with I None
risperidone I Chemical
. I None
<eof> I None

<s> O None
They I None
both I None
reported I None
short I None
episodes I None
of I None
transient I None
visual I Disease
disturbances O Disease
, I None
which I None
appeared I None
immediately I None
after I None
starting I None
treatment I None
with I None
risperidone I Chemical
. I None
<eof> I None

<s> O None
This I None
imagery I None
resembled I None
visual I Disease
disturbances O Disease
previously I None
experienced I None
as I None
" I None
flashbacks I None
" I None
related I None
to I None
prior I None
LSD I Chemical
consumption I None
. I None
<eof> I None

<s> O None
Risperidone I Chemical
administration I None
was I None
continued I None
and I None
the I None
visual I Disease
disturbances O Disease
gradually I None
wore I None
off I None
. I None
<eof> I None

<s> O None
During I None
a I None
six I None
- I None
month I None
follow I None
- I None
up I None
period I None
, I None
there I None
was I None
no I None
recurrence I None
of I None
visual I Disease
disturbances O Disease
. I None
<eof> I None

<s> O None
This I None
phenomenon I None
may I None
be I None
interpreted I None
as I None
a I None
benign I None
, I None
short I None
- I None
term I None
and I None
self I None
- I None
limiting I None
side I None
effect I None
which I None
does I None
not I None
contraindicate I None
the I None
use I None
of I None
risperidone I Chemical
or I None
interfere I None
with I None
treatment I None
. I None
<eof> I None

<s> O None
Conclusions I None
based I None
on I None
two I None
case I None
reports I None
should I None
be I None
taken I None
with I None
appropriate I None
caution I None
. I None
<eof> I None

<s> O None
Activation I None
of I None
poly(ADP I Chemical
- O Chemical
ribose O Chemical
) O Chemical
polymerase I None
contributes I None
to I None
development I None
of I None
doxorubicin I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
heart I Disease
failure O Disease
. I None
<eof> I None

<s> O None
Activation I None
of I None
the I None
nuclear I None
enzyme I None
<eof> I None

<s> O None
poly(ADP I Chemical
- O Chemical
ribose O Chemical
) O Chemical
polymerase I None
( I None
PARP I None
) I None
by I None
oxidant I None
- I None
mediated I None
DNA I None
damage I None
is I None
an I None
important I None
pathway I None
of I None
cell I None
dysfunction I None
and I None
tissue I None
injury I None
in I None
conditions I None
associated I None
with I None
oxidative I None
stress I None
. I None
<eof> I None

<s> O None
Increased I None
oxidative I None
stress I None
is I None
a I None
major I None
factor I None
implicated I None
in I None
the I None
cardiotoxicity I Disease
of I None
doxorubicin I Chemical
<eof> I None

<s> O None
( I None
DOX I Chemical
) I None
, I None
a I None
widely I None
used I None
antitumor I None
anthracycline I Chemical
antibiotic I None
. I None
<eof> I None

<s> O None
Thus I None
, I None
we I None
hypothesized I None
that I None
the I None
activation I None
of I None
PARP I None
may I None
contribute I None
to I None
the I None
DOX I Chemical
-induced I None
cardiotoxicity I Disease
. I None
<eof> I None

<s> O None
Using I None
a I None
dual I None
approach I None
of I None
PARP-1 I None
suppression I None
, I None
by I None
genetic I None
deletion I None
or I None
pharmacological I None
inhibition I None
with I None
the I None
phenanthridinone I None
PARP I None
inhibitor I None
PJ34 I Chemical
, I None
we I None
now I None
demonstrate I None
the I None
role I None
of I None
PARP I None
in I None
the I None
development I None
of I None
cardiac I Disease
dysfunction O Disease
induced I None
by I None
DOX I Chemical
. I None
<eof> I None

<s> O None
PARP-1+/+ I None
and I None
PARP-1-/- I None
mice I None
received I None
a I None
single I None
injection I None
of I None
DOX I Chemical
<eof> I None

<s> O None
( I None
25 I None
mg I None
/ I None
kg I None
i.p I None
) I None
. I None
<eof> I None

<s> O None
Five I None
days I None
after I None
DOX I Chemical
administration I None
, I None
left I None
ventricular I None
performance I None
was I None
significantly I None
depressed I None
in I None
PARP-1+/+ I None
mice I None
, I None
but I None
only I None
to I None
a I None
smaller I None
extent I None
in I None
PARP-1-/- I None
ones I None
. I None
<eof> I None

<s> O None
Similar I None
experiments I None
were I None
conducted I None
in I None
BALB I None
/ I None
<eof> I None

<s> O None
c I None
mice I None
treated I None
with I None
PJ34 I Chemical
or I None
vehicle I None
. I None
<eof> I None

<s> O None
Treatment I None
with I None
a I None
PJ34 I Chemical
significantly I None
improved I None
<eof> I None

<s> O None
cardiac I Disease
dysfunction O Disease
and I None
increased I None
the I None
survival I None
of I None
the I None
animals I None
. I None
<eof> I None

<s> O None
In I None
addition I None
PJ34 I Chemical
significantly I None
reduced I None
the I None
DOX I Chemical
-induced I None
increase I None
in I None
the I None
serum I None
lactate I Chemical
dehydrogenase I None
and I None
creatine I Chemical
kinase I None
activities I None
but I None
not I None
metalloproteinase I None
activation I None
in I None
the I None
heart I None
. I None
<eof> I None

<s> O None
Thus I None
, I None
PARP I None
activation I None
contributes I None
to I None
the I None
cardiotoxicity I Disease
of I None
DOX I Chemical
. I None
<eof> I None

<s> O None
PARP I None
inhibitors I None
may I None
exert I None
protective I None
effects I None
against I None
the I None
development I None
of I None
severe I None
cardiac I Disease
complications O Disease
associated I None
with I None
the I None
DOX I Chemical
treatment I None
. I None
<eof> I None

<s> O None
Fluconazole I Chemical
-induced I None
torsade I Disease
de O Disease
pointes O Disease
. I None
<eof> I None

<s> O None
OBJECTIVE I None
: I None
<eof> I None

<s> O None
To I None
present I None
a I None
case I None
of I None
fluconazole I Chemical
-associated I None
torsade I Disease
de O Disease
pointes O Disease
<eof> I None

<s> O None
( I None
TDP I Disease
) I None
and I None
discuss I None
fluconazole I Chemical
's I None
role I None
in I None
causing I None
TDP I Disease
. I None
<eof> I None

<s> O None
CASE I None
SUMMARY I None
: I None
<eof> I None

<s> O None
A I None
68-year I None
- I None
old I None
white I None
woman I None
with I None
Candida I None
glabrata I None
isolated I None
from I None
a I None
presacral I None
abscess I None
developed I None
TDP I Disease
<eof> I None

<s> O None
eight I None
days I None
after I None
commencing I None
oral I None
fluconazole I Chemical
<eof> I None

<s> O None
The I None
patient I None
had I None
no I None
other I None
risk I None
factors I None
for I None
TDP I Disease
, I None
including I None
coronary I Disease
artery O Disease
disease O Disease
, I None
cardiomyopathy I Disease
, I None
congestive I Disease
heart O Disease
failure O Disease
, I None
and I None
electrolyte I None
abnormalities I None
<eof> I None

<s> O None
There I None
was I None
a I None
temporal I None
association I None
between I None
the I None
initiation I None
of I None
fluconazole I Chemical
and I None
TDP I Disease
. I None
<eof> I None

<s> O None
The I None
TDP I Disease
resolved I None
when I None
fluconazole I Chemical
was I None
discontinued I None
; I None
however I None
, I None
the I None
patient I None
continued I None
to I None
have I None
premature I Disease
ventricular O Disease
contractions O Disease
and I None
nonsustained I None
ventricular I Disease
tachycardia O Disease
<eof> I None

<s> O None
( I None
NSVT I Disease
) I None
until I None
six I None
days I None
after I None
drug I None
cessation I None
<eof> I None

<s> O None
DISCUSSION I None
: I None
<eof> I None

<s> O None
Use I None
of I None
the I None
Naranjo I None
probability I None
scale I None
indicates I None
a I None
probable I None
relationship I None
between I None
the I None
use I None
of I None
fluconazole I Chemical
and I None
the I None
development I None
of I None
TDP I Disease
. I None
<eof> I None

<s> O None
The I None
possible I None
mechanism I None
is I None
depression I Disease
of I None
rapidly I None
activating I None
delayed I None
rectifier I None
potassium I Chemical
currents I None
. I None
<eof> I None

<s> O None
In I None
our I None
patient I None
, I None
there I None
was I None
no I None
other I None
etiology I None
identified I None
that I None
could I None
explain I None
QT I Disease
prolongation O Disease
or I None
TDP I Disease
<eof> I None

<s> O None
The I None
complete I None
disappearance I None
of I None
NSVT I Disease
and I None
premature I Disease
ventricular O Disease
contractions O Disease
followed I None
by I None
normalization I None
of I None
QT I None
interval I None
after I None
the I None
drug I None
was I None
stopped I None
strongly I None
suggests I None
<eof> I None

<s> O None
fluconazole I Chemical
as I None
the I None
etiology I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
Clinicians I None
should I None
be I None
aware I None
that I None
fluconazole I Chemical
, I None
even I None
at I None
low I None
doses I None
, I None
may I None
cause I None
prolongation I Disease
of O Disease
the O Disease
QT O Disease
interval O Disease
, I None
leading I None
to I None
TDP I Disease
. I None
<eof> I None

<s> O None
Serial I None
electrocardiographic I None
monitoring I None
may I None
be I None
considered I None
when I None
fluconazole I Chemical
is I None
administered I None
in I None
patients I None
who I None
are I None
at I None
risk I None
for I None
ventricular I Disease
arrhythmias O Disease
. I None
<eof> I None

<s> O None
High I None
- I None
dose I None
<eof> I None

<s> O None
methylprednisolone I Chemical
may I None
do I None
more I None
harm I None
for I None
spinal I Disease
cord O Disease
injury O Disease
. I None
<eof> I None

<s> O None
Because I None
of I None
the I None
National I None
Acute I None
Spinal I Disease
Cord O Disease
Injury O Disease
<eof> I None

<s> O None
Studies I None
( I None
NASCIS I None
) I None
, I None
high I None
- I None
dose I None
<eof> I None

<s> O None
methylprednisolone I Chemical
became I None
the I None
standard I None
of I None
care I None
for I None
the I None
acute I None
spinal I Disease
cord O Disease
injury O Disease
. I None
<eof> I None

<s> O None
In I None
the I None
NASCIS I None
, I None
there I None
was I None
no I None
mention I None
regarding I None
the I None
possibility I None
of I None
acute I None
corticosteroid I Chemical
myopathy I Disease
that I None
high I None
- I None
dose I None
methylprednisolone I Chemical
may I None
cause I None
. I None
<eof> I None

<s> O None
The I None
dosage I None
of I None
methylprednisolone I Chemical
recommended I None
by I None
the I None
NASCIS I None
3 I None
is I None
the I None
highest I None
dose I None
of I None
steroids I Chemical
ever I None
being I None
used I None
during I None
a I None
2-day I None
period I None
for I None
any I None
clinical I None
condition I None
. I None
<eof> I None

<s> O None
We I None
hypothesize I None
that I None
it I None
may I None
cause I None
some I None
damage I Disease
to O Disease
the O Disease
muscle O Disease
of I None
spinal I Disease
cord O Disease
injury O Disease
patients I None
. I None
<eof> I None

<s> O None
Further I None
, I None
steroid I Chemical
myopathy I Disease
recovers I None
naturally I None
and I None
the I None
neurological I None
improvement I None
shown I None
in I None
the I None
NASCIS I None
may I None
be I None
just I None
a I None
recording I None
of I None
this I None
natural I None
motor I None
recovery I None
from I None
the I None
steroid I Chemical
myopathy I Disease
, I None
instead I None
of I None
any I None
protection I None
that I None
methylprednisolone I Chemical
offers I None
to I None
the I None
spinal I Disease
cord O Disease
injury O Disease
. I None
<eof> I None

<s> O None
To I None
our I None
knowledge I None
, I None
this I None
is I None
the I None
first I None
discussion I None
considering I None
the I None
possibility I None
that I None
the I None
methylprednisolone I Chemical
recommended I None
by I None
NASCIS I None
may I None
cause I None
acute I None
corticosteroid I Chemical
myopathy I Disease
. I None
<eof> I None

<s> O None
Probing I None
peripheral I None
and I None
central I None
cholinergic I None
system I None
responses I None
. I None
<eof> I None

<s> O None
OBJECTIVE I None
: I None
<eof> I None

<s> O None
The I None
pharmacological I None
response I None
to I None
drugs I None
that I None
act I None
on I None
the I None
cholinergic I None
system I None
of I None
the I None
iris I None
has I None
been I None
used I None
to I None
predict I None
deficits I None
in I None
central I None
cholinergic I None
functioning I None
due I None
to I None
diseases I None
such I None
as I None
Alzheimer I Disease
's O Disease
disease O Disease
, I None
yet I None
correlations I None
between I None
central I None
and I None
peripheral I None
responses I None
have I None
not I None
been I None
properly I None
studied I None
. I None
<eof> I None

<s> O None
This I None
study I None
assessed I None
the I None
effect I None
of I None
normal I None
aging I None
on I None
( I None
1 I None
) I None
the I None
tropicamide I Chemical
-induced I None
increase I None
in I None
pupil I None
diameter I None
, I None
and I None
( I None
2 I None
) I None
the I None
reversal I None
of I None
this I None
effect I None
with I None
pilocarpine I Chemical
. I None
<eof> I None

<s> O None
Scopolamine I Chemical
was I None
used I None
as I None
a I None
positive I None
control I None
to I None
detect I None
age I None
- I None
dependent I None
changes I None
in I None
central I None
cholinergic I None
functioning I None
in I None
the I None
elderly I None
. I None
<eof> I None

<s> O None
DESIGN I None
: I None
<eof> I None

<s> O None
Randomized I None
double I None
- I None
blind I None
controlled I None
trial I None
. I None
<eof> I None

<s> O None
PARTICIPANTS I None
: I None
Ten I None
healthy I None
elderly I None
( I None
mean I None
age I None
70 I None
) I None
and I None
9 I None
young I None
( I None
mean I None
age I None
33 I None
) I None
volunteers I None
. I None
<eof> I None

<s> O None
INTERVENTIONS I None
: I None
<eof> I None

<s> O None
Pupil I None
diameter I None
was I None
monitored I None
using I None
a I None
computerized I None
infrared I None
pupillometer I None
over I None
4 I None
hours I None
. I None
<eof> I None

<s> O None
The I None
study I None
involved I None
4 I None
sessions I None
. I None
<eof> I None

<s> O None
In I None
1 I None
session I None
, I None
tropicamide I Chemical
( I None
20 I None
microL I None
, I None
0.01 I None
% I None
) I None
was I None
administered I None
to I None
one I None
eye I None
and I None
placebo I None
to I None
the I None
other I None
. I None
<eof> I None

<s> O None
In I None
another I None
session I None
, I None
tropicamide I Chemical
( I None
20 I None
microL I None
, I None
0.01 I None
% I None
) I None
was I None
administered I None
to I None
both I None
eyes I None
, I None
followed I None
23 I None
minutes I None
later I None
by I None
the I None
application I None
of I None
pilocarpine I Chemical
<eof> I None

<s> O None
( I None
20 I None
microL I None
, I None
0.1 I None
% I None
) I None
to I None
one I None
eye I None
and I None
placebo I None
to I None
the I None
other I None
. I None
<eof> I None

<s> O None
All I None
eye I None
drops I None
were I None
given I None
in I None
a I None
randomized I None
order I None
. I None
<eof> I None

<s> O None
In I None
2 I None
separate I None
sessions I None
, I None
a I None
single I None
dose I None
of I None
scopolamine I Chemical
<eof> I None

<s> O None
( I None
0.5 I None
mg I None
, I None
intravenously I None
) I None
or I None
placebo I None
was I None
administered I None
, I None
and I None
the I None
effects I None
on I None
word I None
recall I None
were I None
measured I None
using I None
the I None
Buschke I None
Selective I None
Reminding I None
Test I None
over I None
2 I None
hours I None
. I None
<eof> I None

<s> O None
OUTCOME I None
MEASURES I None
: I None
<eof> I None

<s> O None
Pupil I None
size I None
at I None
time I None
points I None
after I None
administration I None
of I None
tropicamide I Chemical
and I None
pilocarpine I Chemical
; I None
scopolamine I Chemical
-induced I None
impairment I Disease
in O Disease
word O Disease
recall O Disease
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
There I None
was I None
no I None
significant I None
difference I None
between I None
elderly I None
and I None
young I None
volunteers I None
in I None
pupillary I None
response I None
to I None
tropicamide I Chemical
at I None
any I None
time I None
point I None
( I None
p I None
> I None
0.05 I None
) I None
. I None
<eof> I None

<s> O None
The I None
elderly I None
group I None
had I None
a I None
significantly I None
greater I None
pilocarpine I Chemical
-induced I None
net I None
decrease I None
in I None
pupil I None
size I None
85 I None
, I None
125 I None
, I None
165 I None
and I None
215 I None
minutes I None
after I None
administration I None
, I None
compared I None
with I None
the I None
young I None
group I None
( I None
p I None
< I None
0.05 I None
) I None
. I None
<eof> I None

<s> O None
Compared I None
with I None
the I None
young I None
group I None
, I None
the I None
elderly I None
group I None
had I None
greater I None
scopolamine I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
impairment I Disease
in O Disease
word O Disease
recall O Disease
60 I None
, I None
90 I None
and I None
120 I None
minutes I None
after I None
administration I None
( I None
p I None
< I None
0.05 I None
) I None
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
<eof> I None

<s> O None
There I None
is I None
an I None
age I None
- I None
related I None
pupillary I None
response I None
to I None
pilocarpine I Chemical
that I None
is I None
not I None
found I None
with I None
tropicamide I Chemical
. I None
<eof> I None

<s> O None
Thus I None
, I None
pilocarpine I Chemical
may I None
be I None
useful I None
to I None
assess I None
variations I None
in I None
central I None
cholinergic I None
function I None
in I None
elderly I None
patients I None
. I None
<eof> I None

<s> O None
Acetazolamide I Chemical
-induced I None
Gerstmann I Disease
syndrome O Disease
. I None
<eof> I None

<s> O None
Acute I None
confusion I Disease
induced I None
by I None
acetazolamide I Chemical
is I None
a I None
well I None
known I None
adverse I None
drug I None
reaction I None
in I None
patients I None
with I None
renal I Disease
impairment O Disease
. I None
<eof> I None

<s> O None
We I None
report I None
a I None
case I None
of I None
acetazolamide I Chemical
-induced I None
Gerstmann I Disease
syndrome O Disease
in I None
a I None
patient I None
with I None
normal I None
renal I None
function I None
, I None
to I None
highlight I None
predisposing I None
factors I None
that I None
are I None
frequently I None
overlooked I None
. I None
<eof> I None

<s> O None
Hypomania I Disease
-like I None
syndrome I None
induced I None
by I None
olanzapine I Chemical
. I None
<eof> I None

<s> O None
We I None
report I None
a I None
female I None
patient I None
with I None
a I None
diagnosis I None
of I None
a I None
not I None
otherwise I None
specified I None
psychotic I Disease
disorder O Disease
( I None
DSM I None
- I None
IV I None
) I None
who I None
developed I None
hypomania I Disease
shortly I None
after I None
the I None
introduction I None
of I None
olanzapine I Chemical
treatment I None
. I None
<eof> I None

<s> O None
Neutrophil I None
superoxide I Chemical
and I None
hydrogen I Chemical
peroxide O Chemical
production I None
in I None
patients I None
with I None
acute I Disease
liver O Disease
failure O Disease
. I None
<eof> I None

<s> O None
Defects I None
in I None
superoxide I Chemical
and I None
hydrogen I Chemical
peroxide O Chemical
production I None
may I None
be I None
implicated I None
in I None
the I None
high I None
incidence I None
of I None
bacterial I Disease
infections O Disease
in I None
patients I None
with I None
acute I Disease
liver O Disease
failure O Disease
<eof> I None

<s> O None
( I None
ALF I Disease
) I None
. I None
<eof> I None

<s> O None
In I None
the I None
present I None
study I None
, I None
oxygen I Chemical
radical I None
production I None
in I None
patients I None
with I None
ALF I Disease
due I None
to I None
paracetamol I Chemical
<eof> I None

<s> O None
overdose I Disease
was I None
compared I None
with I None
that I None
of I None
healthy I None
volunteers I None
. I None
<eof> I None

<s> O None
Neutrophils I None
from I None
14 I None
ALF I Disease
patients I None
were I None
stimulated I None
via I None
the I None
complement I None
receptors I None
using I None
zymosan I None
opsonized I None
with I None
ALF I Disease
or I None
control I None
serum I None
. I None
<eof> I None

<s> O None
Superoxide I Chemical
and I None
hydrogen I Chemical
peroxide O Chemical
production I None
by I None
ALF I Disease
neutrophils I None
stimulated I None
with I None
zymosan I None
opsonized I None
with I None
ALF I Disease
serum I None
was I None
significantly I None
reduced I None
compared I None
with I None
the I None
control I None
subjects I None
( I None
P I None
< I None
0.01 I None
) I None
. I None
<eof> I None

<s> O None
This I None
defect I None
persisted I None
when I None
zymosan I None
opsonized I None
by I None
control I None
serum I None
was I None
used I None
( I None
P I None
< I None
0.05 I None
) I None
. I None
<eof> I None

<s> O None
Superoxide I Chemical
and I None
hydrogen I Chemical
peroxide O Chemical
production I None
in I None
neutrophils I None
stimulated I None
with I None
formyl I Chemical
- O Chemical
methionyl O Chemical
- O Chemical
leucyl O Chemical
- O Chemical
phenylalanine O Chemical
<eof> I None

<s> O None
( I None
fMLP I Chemical
) I None
from I None
a I None
further I None
18 I None
ALF I Disease
<eof> I None

<s> O None
patients I None
was I None
unaffected I None
compared I None
with I None
control I None
neutrophils I None
. I None
<eof> I None

<s> O None
Serum I None
C3 I None
complement I None
levels I None
were I None
significantly I None
reduced I None
in I None
ALF I Disease
patients I None
compared I None
with I None
control I None
subjects I None
( I None
P I None
< I None
0.0005 I None
) I None
. I None
<eof> I None

<s> O None
These I None
results I None
demonstrate I None
a I None
neutrophil I None
defect I None
in I None
ALF I Disease
due I None
to I None
paracetamol I Chemical
overdose I Disease
, I None
that I None
is I None
complement I None
dependent I None
but I None
independent I None
of I None
serum I None
complement I None
, I None
possibly I None
connected I None
to I None
the I None
complement I None
receptor I None
. I None
<eof> I None

<s> O None
Absence I None
of I None
effect I None
of I None
sertraline I Chemical
on I None
time I None
- I None
based I None
sensitization I None
of I None
cognitive I Disease
impairment O Disease
with I None
haloperidol I Chemical
. I None
<eof> I None

<s> O None
This I None
double I None
- I None
blind I None
, I None
randomized I None
, I None
placebo I None
- I None
controlled I None
study I None
evaluated I None
the I None
effects I None
of I None
haloperidol I Chemical
alone I None
and I None
haloperidol I Chemical
plus I None
sertraline I Chemical
on I None
cognitive I None
and I None
psychomotor I None
function I None
in I None
24 I None
healthy I None
male I None
subjects I None
. I None
<eof> I None

<s> O None
METHOD I None
: I None
<eof> I None

<s> O None
All I None
subjects I None
received I None
placebo I None
on I None
Day I None
1 I None
and I None
haloperidol I Chemical
2 I None
mg I None
on I None
Days I None
2 I None
and I None
25 I None
. I None
<eof> I None

<s> O None
From I None
Days I None
9 I None
to I None
25 I None
, I None
subjects I None
were I None
randomly I None
assigned I None
to I None
either I None
sertraline I Chemical
<eof> I None

<s> O None
( I None
12 I None
subjects I None
) I None
or I None
placebo I None
( I None
12 I None
subjects I None
) I None
; I None
the I None
sertraline I Chemical
dose I None
was I None
titrated I None
from I None
50 I None
to I None
200 I None
mg I None
/ I None
day I None
from I None
Days I None
9 I None
to I None
16 I None
, I None
and I None
remained I None
at I None
200 I None
mg I None
/ I None
day I None
for I None
the I None
final I None
10 I None
days I None
of I None
the I None
drug I None
administration I None
period I None
. I None
<eof> I None

<s> O None
Cognitive I None
function I None
testing I None
was I None
performed I None
before I None
dosing I None
and I None
over I None
a I None
24-hour I None
period I None
after I None
dosing I None
on I None
Days I None
1 I None
, I None
2 I None
, I None
and I None
25 I None
. I None
RESULTS I None
: I None
<eof> I None

<s> O None
Impairment I Disease
of O Disease
cognitive O Disease
function O Disease
was I None
observed I None
6 I None
to I None
8 I None
hours I None
after I None
administration I None
of I None
haloperidol I Chemical
on I None
Day I None
2 I None
but I None
was I None
not I None
evident I None
23 I None
hours I None
after I None
dosing I None
. I None
<eof> I None

<s> O None
When I None
single I None
- I None
dose I None
haloperidol I Chemical
was I None
given I None
again I None
25 I None
days I None
later I None
, I None
greater I None
impairment I None
with I None
earlier I None
onset I None
was I None
noted I None
in I None
several I None
tests I None
in I None
both I None
treatment I None
groups I None
, I None
suggesting I None
enhancement I None
of I None
this I None
effect I None
. I None
<eof> I None

<s> O None
There I None
was I None
no I None
indication I None
that I None
sertraline I Chemical
exacerbated I None
the I None
impairment I None
produced I None
by I None
haloperidol I Chemical
since I None
an I None
equivalent I None
effect I None
also I None
occurred I None
in I None
the I None
placebo I None
group I None
. I None
<eof> I None

<s> O None
Three I None
subjects I None
( I None
2 I None
on I None
sertraline I Chemical
and I None
1 I None
on I None
placebo I None
) I None
withdrew I None
from I None
the I None
study I None
because I None
of I None
side I None
effects I None
. I None
<eof> I None

<s> O None
Ten I None
subjects I None
in I None
each I None
group I None
reported I None
side I None
effects I None
related I None
to I None
treatment I None
. I None
<eof> I None

<s> O None
The I None
side I None
effect I None
profiles I None
of I None
sertraline I Chemical
and I None
of I None
placebo I None
were I None
similar I None
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
<eof> I None

<s> O None
Haloperidol I Chemical
produced I None
a I None
clear I None
profile I None
of I None
cognitive I Disease
impairment O Disease
<eof> I None

<s> O None
that I None
was I None
not I None
worsened I None
by I None
concomitant I None
sertraline I Chemical
administration I None
. I None
<eof> I None

<s> O None
Ciprofloxacin I Chemical
-induced I None
nephrotoxicity I Disease
in I None
patients I None
with I None
cancer I Disease
. I None
<eof> I None

<s> O None
Nephrotoxicity I Disease
associated I None
with I None
ciprofloxacin I Chemical
is I None
uncommon I None
. I None
<eof> I None

<s> O None
Five I None
patients I None
with I None
cancer I Disease
who I None
developed I None
acute I Disease
renal O Disease
failure O Disease
that I None
followed I None
treatment I None
with I None
ciprofloxacin I Chemical
are I None
described I None
and I None
an I None
additional I None
15 I None
cases I None
reported I None
in I None
the I None
literature I None
are I None
reviewed I None
. I None
<eof> I None

<s> O None
Other I None
than I None
elevation I None
of I None
serum I None
creatinine I Chemical
levels I None
, I None
characteristic I None
clinical I None
manifestations I None
and I None
abnormal I None
laboratory I None
findings I None
are I None
not I None
frequently I None
present I None
. I None
<eof> I None

<s> O None
Allergic I None
interstitial I Disease
nephritis O Disease
is I None
believed I None
to I None
be I None
the I None
underlying I None
pathological I None
- I None
process I None
. I None
<eof> I None

<s> O None
Definitive I None
diagnosis I None
requires I None
performance I None
of I None
renal I None
biopsy I None
, I None
although I None
this I None
is I None
not I None
always I None
feasible I None
. I None
<eof> I None

<s> O None
An I None
improvement I None
in I None
renal I None
function I None
that I None
followed I None
the I None
discontinuation I None
of I None
the I None
offending I None
antibiotic I None
supports I None
the I None
presumptive I None
diagnosis I None
of I None
ciprofloxacin I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
acute I Disease
renal O Disease
failure O Disease
. I None
<eof> I None

<s> O None
Case I None
report I None
: I None
pentamidine I Chemical
and I None
polymorphic I None
ventricular I Disease
tachycardia O Disease
revisited I None
. I None
<eof> I None

<s> O None
Pentamidine I Chemical
isethionate O Chemical
has I None
been I None
associated I None
with I None
ventricular I Disease
tachyarrhythmias O Disease
, I None
including I None
torsade I Disease
de O Disease
pointes O Disease
. I None
<eof> I None

<s> O None
This I None
article I None
reports I None
two I None
cases I None
of I None
this I None
complication I None
and I None
reviews I None
all I None
reported I None
cases I None
to I None
date I None
. I None
<eof> I None

<s> O None
Pentamidine I Chemical
-induced I None
<eof> I None

<s> O None
torsade I Disease
de O Disease
pointes O Disease
may I None
be I None
related I None
to I None
serum I None
magnesium I Chemical
levels I None
and I None
<eof> I None

<s> O None
hypomagnesemia I Disease
may I None
synergistically I None
induce I None
torsade I None
. I None
<eof> I None

<s> O None
Torsade I Disease
de O Disease
pointes O Disease
occurred I None
after I None
an I None
average I None
of I None
10 I None
days I None
of I None
treatment I None
with I None
pentamidine I Chemical
. I None
<eof> I None

<s> O None
In I None
these I None
patients I None
, I None
no I None
other I None
acute I None
side I None
effects I None
of I None
pentamidine I Chemical
were I None
observed I None
. I None
<eof> I None

<s> O None
Torsade I Disease
de O Disease
pointes O Disease
can I None
be I None
treated I None
when I None
recognized I None
early I None
, I None
possibly I None
without I None
discontinuation I None
of I None
pentamidine I Chemical
. I None
<eof> I None

<s> O None
When I None
QTc I Disease
interval O Disease
prolongation O Disease
is I None
observed I None
, I None
early I None
magnesium I Chemical
supplementation I None
is I None
advocated I None
. I None
<eof> I None

<s> O None
Time I None
dependence I None
of I None
plasma I None
malondialdehyde I Chemical
, I None
oxypurines I Chemical
, I None
and I None
nucleosides I Chemical
during I None
incomplete I None
cerebral I Disease
ischemia O Disease
in I None
the I None
rat I None
. I None
<eof> I None

<s> O None
Incomplete I None
cerebral I Disease
ischemia O Disease
<eof> I None

<s> O None
( I None
30 I None
min I None
) I None
was I None
induced I None
in I None
the I None
rat I None
by I None
bilaterally I None
clamping I None
the I None
common I None
carotid I None
arteries I None
. I None
<eof> I None

<s> O None
Peripheral I None
venous I None
blood I None
samples I None
were I None
withdrawn I None
from I None
the I None
femoral I None
vein I None
four I None
times I None
( I None
once I None
every I None
5 I None
min I None
) I None
before I None
<eof> I None

<s> O None
ischemia I Disease
( I None
0 I None
time I None
) I None
and I None
5 I None
, I None
15 I None
, I None
and I None
30 I None
min I None
after I None
ischemia I Disease
. I None
<eof> I None

<s> O None
Plasma I None
extracts I None
were I None
analyzed I None
by I None
a I None
highly I None
sensitive I None
high I None
- I None
performance I None
liquid I None
chromatographic I None
method I None
for I None
the I None
direct I None
determination I None
of I None
malondialdehyde I Chemical
, I None
oxypurines I Chemical
, I None
and I None
nucleosides I Chemical
. I None
<eof> I None

<s> O None
During I None
ischemia I Disease
, I None
a I None
time I None
- I None
dependent I None
increase I None
of I None
plasma I None
oxypurines I Chemical
and I None
nucleosides I Chemical
was I None
observed I None
. I None
<eof> I None

<s> O None
Plasma I None
malondialdehyde I Chemical
, I None
which I None
was I None
present I None
in I None
minimal I None
amount I None
at I None
zero I None
time I None
( I None
0.058 I None
mumol I None
/ I None
liter I None
plasma I None
; I None
SD I None
0.015 I None
) I None
, I None
increased I None
after I None
5 I None
min I None
of I None
ischemia I Disease
, I None
resulting I None
in I None
a I None
fivefold I None
increase I None
after I None
30 I None
min I None
of I None
carotid I None
occlusion I None
( I None
0.298 I None
mumol I None
/ I None
liter I None
plasma I None
; I None
SD I None
0.078 I None
) I None
. I None
<eof> I None

<s> O None
Increased I None
plasma I None
<eof> I None

<s> O None
malondialdehyde I Chemical
was I None
also I None
recorded I None
in I None
two I None
other I None
groups I None
of I None
animals I None
subjected I None
to I None
the I None
same I None
experimental I None
model I None
, I None
one I None
receiving I None
20 I None
mg I None
/ I None
kg I None
b.w I None
. I None
of I None
the I None
cyclooxygenase I None
inhibitor I None
acetylsalicylate I Chemical
intravenously I None
immediately I None
before I None
ischemia I Disease
, I None
the I None
other I None
receiving I None
650 I None
micrograms I None
/ I None
kg I None
b.w I None
. I None
of I None
the I None
hypotensive I Disease
drug I None
nitroprusside I Chemical
at I None
a I None
flow I None
rate I None
of I None
103 I None
microliters I None
/ I None
min I None
intravenously I None
during I None
ischemia I Disease
, I None
although I None
in I None
this I None
latter I None
group I None
malondialdehyde I Chemical
was I None
significantly I None
higher I None
. I None
<eof> I None

<s> O None
The I None
present I None
data I None
indicate I None
that I None
the I None
determination I None
of I None
malondialdehyde I Chemical
, I None
oxypurines I Chemical
, I None
and I None
nucleosides I Chemical
in I None
peripheral I None
blood I None
, I None
may I None
be I None
used I None
to I None
monitor I None
the I None
metabolic I None
alterations I None
of I None
tissues I None
occurring I None
during I None
ischemic I Disease
phenomena.(ABSTRACT I None
TRUNCATED I None
AT I None
250 I None
WORDS I None
) I None
<eof> I None

<s> O None
Cholinergic I None
toxicity I Disease
resulting I None
from I None
ocular I None
instillation I None
of I None
echothiophate I Chemical
iodide O Chemical
eye I None
drops I None
. I None
<eof> I None

<s> O None
A I None
patient I None
developed I None
a I None
severe I None
cholinergic I None
syndrome I None
from I None
the I None
use I None
of I None
echothiophate I Chemical
iodide O Chemical
ophthalmic I None
drops I None
, I None
presented I None
with I None
profound I None
muscle I Disease
weakness O Disease
and I None
was I None
initially I None
given I None
the I None
diagnosis I None
of I None
myasthenia I Disease
gravis O Disease
. I None
<eof> I None

<s> O None
Red I None
blood I None
cell I None
and I None
serum I None
cholinesterase I None
levels I None
were I None
severely I None
depressed I None
and I None
symptoms I None
resolved I None
spontaneously I None
following I None
discontinuation I None
of I None
the I None
eye I None
drops I None
. I None
<eof> I None

<s> O None
Acute I Disease
renal O Disease
failure O Disease
in I None
high I None
dose I None
carboplatin I Chemical
chemotherapy I None
. I None
<eof> I None

<s> O None
Carboplatin I Chemical
has I None
been I None
reported I None
to I None
cause I None
acute I Disease
renal O Disease
failure O Disease
when I None
administered I None
in I None
high I None
doses I None
to I None
adult I None
patients I None
. I None
<eof> I None

<s> O None
We I None
report I None
a I None
4 I None
1/2-year I None
- I None
old I None
girl I None
who I None
was I None
treated I None
with I None
high I None
- I None
dose I None
carboplatin I Chemical
for I None
metastatic I None
parameningeal I None
embryonal I Disease
rhabdomyosarcoma O Disease
. I None
<eof> I None

<s> O None
Acute I Disease
renal O Disease
failure O Disease
developed I None
followed I None
by I None
a I None
slow I None
partial I None
recovery I None
of I None
renal I None
function I None
. I None
<eof> I None

<s> O None
Possible I None
contributing I None
factors I None
are I None
discussed I None
. I None
<eof> I None

<s> O None
Endometrial I Disease
carcinoma O Disease
after I None
Hodgkin I Disease
disease O Disease
in I None
childhood I None
. I None
<eof> I None

<s> O None
A I None
34-year I None
- I None
old I None
patient I None
developed I None
metastic I None
endometrial I Disease
carcinoma O Disease
after I None
Hodgkin I Disease
disease O Disease
in I None
childhood I None
. I None
<eof> I None

<s> O None
She I None
had I None
ovarian I Disease
failure O Disease
after I None
abdominal I None
irradiation I None
and I None
chemotherapy I None
for I None
Hodgkin I Disease
disease O Disease
, I None
and I None
received I None
exogenous I None
estrogens I Chemical
, I None
a I None
treatment I None
implicated I None
in I None
the I None
development I None
of I None
endometrial I Disease
cancer O Disease
in I None
menopausal I None
women I None
. I None
<eof> I None

<s> O None
Young I None
women I None
on I None
replacement I None
estrogens I Chemical
for I None
ovarian I Disease
failure O Disease
after I None
<eof> I None

<s> O None
cancer I Disease
therapy I None
may I None
also I None
have I None
increased I None
risk I None
of I None
endometrial I Disease
carcinoma O Disease
and I None
should I None
be I None
examined I None
periodically I None
. I None
<eof> I None

<s> O None
Induction I None
of I None
the I None
obstructive I Disease
sleep O Disease
apnea O Disease
syndrome O Disease
in I None
a I None
woman I None
by I None
exogenous I None
androgen I Chemical
administration I None
. I None
<eof> I None

<s> O None
We I None
documented I None
airway I None
occlusion I None
during I None
sleep I None
and I None
an I None
abnormally I None
high I None
supraglottic I None
resistance I None
while I None
awake I None
in I None
a I None
54-yr I None
- I None
old I None
woman I None
who I None
had I None
developed I None
physical I None
changes I None
and I None
the I None
syndrome I Disease
of O Disease
obstructive O Disease
sleep O Disease
apnea O Disease
while I None
being I None
administered I None
exogenous I None
androgens I Chemical
. I None
<eof> I None

<s> O None
When I None
the I None
androgens I Chemical
were I None
withdrawn I None
, I None
the I None
patient I None
's I None
physical I None
changes I None
, I None
symptoms I None
, I None
sleep I None
study I None
, I None
and I None
supraglottic I None
resistance I None
all I None
returned I None
to I None
normal I None
. I None
<eof> I None

<s> O None
A I None
rechallenge I None
with I None
androgen I Chemical
produced I None
symptoms I None
of I None
obstructive I Disease
sleep O Disease
apnea O Disease
that I None
abated I None
upon I None
withdrawal I None
of I None
the I None
hormone I None
. I None
<eof> I None

<s> O None
Previous I None
reports I None
have I None
favored I None
a I None
role I None
of I None
androgens I Chemical
in I None
the I None
pathogenesis I None
of I None
sleep I Disease
apnea O Disease
. I None
<eof> I None

<s> O None
Our I None
report I None
provides I None
direct I None
evidence I None
for I None
this I None
role I None
. I None
<eof> I None

<s> O None
Structural I None
and I None
functional I None
measurements I None
indicate I None
that I None
androgens I Chemical
exert I None
a I None
permissive I None
or I None
necessary I None
action I None
on I None
the I None
structural I None
configuration I None
of I None
the I None
oropharynx I None
that I None
predisposes I None
to I None
obstruction I None
during I None
sleep I None
. I None
<eof> I None

<s> O None
Development I None
of I None
the I None
obstructive I Disease
sleep O Disease
apnea O Disease
syndrome O Disease
must I None
be I None
considered I None
a I None
possible I None
side I None
effect I None
of I None
androgen I Chemical
therapy I None
. I None
<eof> I None

<s> O None
Effect I None
of I None
captopril I Chemical
on I None
pre I None
- I None
existing I None
and I None
aminonucleoside I Chemical
-induced I None
<eof> I None

<s> O None
proteinuria I Disease
in I None
spontaneously I None
hypertensive I Disease
rats I None
. I None
<eof> I None

<s> O None
Proteinuria I Disease
is I None
a I None
side I None
effect I None
of I None
captopril I Chemical
treatment I None
in I None
hypertensive I Disease
patients I None
. I None
<eof> I None

<s> O None
The I None
possibility I None
of I None
reproducing I None
the I None
same I None
renal I Disease
abnormality O Disease
with I None
captopril I Chemical
was I None
examined I None
in I None
SHR I None
. I None
<eof> I None

<s> O None
Oral I None
administration I None
of I None
captopril I Chemical
at I None
100 I None
mg I None
/ I None
kg I None
for I None
14 I None
days I None
failed I None
to I None
aggravate I None
proteinuria I Disease
pre I None
- I None
existing I None
in I None
SHR I None
. I None
<eof> I None

<s> O None
Also I None
, I None
captopril I Chemical
treatment I None
failed I None
to I None
potentiate I None
or I None
facilitate I None
development I None
of I None
massive I None
proteinuria I Disease
invoked I None
by I None
puromycin I Chemical
aminonucleoside O Chemical
in I None
SHR I None
. I None
<eof> I None

<s> O None
Captopril I Chemical
had I None
little I None
or I None
no I None
demonstrable I None
effects I None
on I None
serum I None
electrolyte I None
concentrations I None
, I None
excretion I None
of I None
urine I None
, I None
sodium I Chemical
and I None
potassium I Chemical
, I None
endogenous I None
creatinine I Chemical
clearance I None
, I None
body I None
weight I None
, I None
and I None
food I None
and I None
water I None
consumption I None
. I None
<eof> I None

<s> O None
However I None
, I None
ketone I Chemical
bodies I None
were I None
consistently I None
present I None
in I None
urine I None
and I None
several I None
lethalities I None
occurred I None
during I None
multiple I None
dosing I None
of I None
captopril I Chemical
in I None
SHR I None
. I None
<eof> I None

<s> O None
Epileptogenic I None
properties I None
of I None
enflurane I Chemical
and I None
their I None
clinical I None
interpretation I None
. I None
<eof> I None

<s> O None
Three I None
cases I None
of I None
EEG I None
changes I None
induced I None
by I None
single I None
exposure I None
to I None
enflurane I Chemical
anesthesia I None
are I None
reported I None
. I None
<eof> I None

<s> O None
In I None
one I None
patient I None
, I None
enflurane I Chemical
administered I None
during I None
a I None
donor I None
nephrectomy I None
resulted I None
in I None
unexpected I None
partial I None
motor I None
seizures I Disease
. I None
<eof> I None

<s> O None
Until I None
the I None
cause I None
of I None
the I None
seizures I Disease
was I None
correctly I None
identified I None
, I None
the I None
patient I None
was I None
inappropriately I None
treated I None
with I None
anticonvulsants I None
. I None
<eof> I None

<s> O None
Two I None
other I None
patients I None
suffered I None
from I None
partial I None
, I None
complex I None
and I None
generalized I None
seizures I Disease
uncontrolled I None
by I None
medication I None
. I None
<eof> I None

<s> O None
Epileptic I Disease
foci I None
delineated I None
and I None
activated I None
by I None
enflurane I Chemical
were I None
surgically I None
ablated I None
and I None
the I None
patients I None
are I None
now I None
seizure I Disease
-free I None
. I None
<eof> I None

<s> O None
Previous I None
exposures I None
to I None
enflurane I Chemical
have I None
to I None
be I None
disclosed I None
to I None
avoid I None
mistakes I None
in I None
clinical I None
interpretation I None
of I None
the I None
EEG I None
. I None
<eof> I None

<s> O None
On I None
the I None
other I None
hand I None
, I None
enflurane I Chemical
may I None
prove I None
to I None
be I None
a I None
safe I None
fast I None
acting I None
activator I None
of I None
epileptic I Disease
foci I None
during I None
corticography I None
or I None
depth I None
electrode I None
intraoperative I None
recordings I None
. I None
<eof> I None

<s> O None
Reversible I None
cerebral I Disease
lesions O Disease
associated I None
with I None
tiazofurin I Chemical
usage I None
: I None
MR I None
demonstration I None
. I None
<eof> I None

<s> O None
Tiazofurin I Chemical
is I None
an I None
experimental I None
chemotherapeutic I None
agent I None
currently I None
undergoing I None
clinical I None
evaluation I None
. I None
<eof> I None

<s> O None
We I None
report I None
our I None
results I None
with I None
magnetic I None
resonance I None
( I None
MR I None
) I None
in I None
demonstrating I None
reversible I None
cerebral I Disease
abnormalities O Disease
concurrent I None
with I None
the I None
use I None
of I None
this I None
drug I None
. I None
<eof> I None

<s> O None
The I None
abnormalities I None
on I None
MR I None
were I None
correlated I None
with I None
findings I None
on I None
CT I None
as I None
well I None
as I None
with I None
cerebral I None
angiography I None
. I None
<eof> I None

<s> O None
The I None
utility I None
of I None
MR I None
in I None
the I None
evaluation I None
of I None
patients I None
receiving I None
this I None
new I None
agent I None
is I None
illustrated I None
. I None
<eof> I None

<s> O None
Antagonism I None
of I None
diazepam I Chemical
<eof> I None

<s> O None
-induced I None
sedative I None
effects I None
by I None
Ro15 I Chemical
- O Chemical
1788 O Chemical
in I None
patients I None
after I None
surgery I None
under I None
lumbar I None
epidural I None
block I None
. I None
<eof> I None

<s> O None
A I None
double I None
- I None
blind I None
placebo I None
- I None
controlled I None
investigation I None
of I None
efficacy I None
and I None
safety I None
. I None
<eof> I None

<s> O None
The I None
aim I None
of I None
this I None
study I None
was I None
to I None
assess I None
the I None
efficacy I None
of I None
Ro15 I Chemical
- O Chemical
1788 O Chemical
and I None
a I None
placebo I None
in I None
reversing I None
<eof> I None

<s> O None
diazepam I Chemical
-induced I None
effects I None
after I None
surgery I None
under I None
epidural I None
block I None
, I None
and I None
to I None
evaluate I None
the I None
local I None
tolerance I None
and I None
general I None
safety I None
of I None
Ro15 I Chemical
- O Chemical
1788 O Chemical
. I None
<eof> I None

<s> O None
Fifty I None
- I None
seven I None
patients I None
were I None
sedated I None
with I None
diazepam I Chemical
for I None
surgery I None
under I None
epidural I None
anaesthesia I None
. I None
<eof> I None

<s> O None
Antagonism I None
of I None
diazepam I Chemical
<eof> I None

<s> O None
-induced I None
effects I None
by I None
Ro15 I Chemical
- O Chemical
1788 O Chemical
was I None
investigated I None
postoperatively I None
in I None
a I None
double I None
- I None
blind I None
placebo I None
- I None
controlled I None
trial I None
. I None
<eof> I None

<s> O None
The I None
patient I None
's I None
subjective I None
assessment I None
of I None
mood I None
rating I None
, I None
an I None
objective I None
test I None
of I None
performance I None
, I None
a I None
test I None
for I None
amnesia I Disease
, I None
and I None
vital I None
signs I None
were I None
recorded I None
for I None
up I None
to I None
300 I None
min I None
after I None
administration I None
of I None
the I None
trial I None
drug I None
. I None
<eof> I None

<s> O None
No I None
significant I None
differences I None
between I None
the I None
two I None
groups I None
were I None
observed I None
for I None
mood I None
rating I None
, I None
amnesia I Disease
, I None
or I None
vital I None
signs I None
. I None
<eof> I None

<s> O None
The I None
Ro15 I Chemical
- O Chemical
1788 O Chemical
group I None
showed I None
a I None
significant I None
improvement I None
in I None
the I None
performance I None
test I None
up I None
to I None
120 I None
min I None
after I None
administration I None
of I None
the I None
drug I None
. I None
<eof> I None

<s> O None
There I None
was I None
no I None
evidence I None
of I None
reaction I None
at I None
the I None
injection I None
site I None
. I None
<eof> I None

<s> O None
Enhanced I None
stimulus I None
- I None
induced I None
neurotransmitter I None
overflow I None
in I None
epinephrine I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
hypertensive I Disease
rats I None
is I None
not I None
mediated I None
by I None
prejunctional I None
beta I None
- I None
adrenoceptor I None
activation I None
. I None
<eof> I None

<s> O None
The I None
present I None
study I None
examines I None
the I None
effect I None
of I None
6-day I None
epinephrine I Chemical
treatment I None
( I None
100 I None
micrograms I None
/ I None
kg I None
per I None
h I None
, I None
s.c I None
. I None
) I None
<eof> I None

<s> O None
on I None
stimulus I None
- I None
induced I None
( I None
1 I None
Hz I None
) I None
endogenous I None
neurotransmitter I None
overflow I None
from I None
the I None
isolated I None
perfused I None
kidney I None
of I None
vehicle- I None
and I None
epinephrine I Chemical
-treated I None
rats I None
. I None
<eof> I None

<s> O None
Renal I None
catecholamine I Chemical
stores I None
and I None
stimulus I None
- I None
induced I None
overflow I None
in I None
the I None
vehicle I None
- I None
treated I None
group I None
consisted I None
of I None
norepinephrine I Chemical
only I None
. I None
<eof> I None

<s> O None
However I None
, I None
epinephrine I Chemical
treatment I None
resulted I None
in I None
the I None
incorporation I None
of I None
epinephrine I Chemical
into I None
renal I None
catecholamine I Chemical
stores I None
such I None
that I None
approximately I None
40 I None
% I None
of I None
the I None
catecholamine I Chemical
present I None
was I None
<eof> I None

<s> O None
epinephrine I Chemical
while I None
the I None
norepinephrine I Chemical
content I None
was I None
reduced I None
by I None
a I None
similar I None
degree I None
. I None
<eof> I None

<s> O None
Total I None
tissue I None
catecholamine I Chemical
content I None
of I None
the I None
kidney I None
on I None
a I None
molar I None
basis I None
was I None
unchanged I None
. I None
<eof> I None

<s> O None
Stimulus I None
- I None
induced I None
fractional I None
overflow I None
of I None
neurotransmitter I None
from I None
the I None
epinephrine I Chemical
<eof> I None

<s> O None
-treated I None
kidneys I None
was I None
approximately I None
twice I None
normal I None
and I None
consisted I None
of I None
both I None
norepinephrine I Chemical
and I None
epinephrine I Chemical
in I None
proportions I None
similar I None
to I None
those I None
found I None
in I None
the I None
kidney I None
. I None
<eof> I None

<s> O None
This I None
difference I None
in I None
fractional I None
overflow I None
between I None
groups I None
was I None
not I None
affected I None
by I None
neuronal I None
and I None
extraneuronal I None
uptake I None
blockade I None
. I None
<eof> I None

<s> O None
Propranolol I Chemical
had I None
no I None
effect I None
on I None
stimulus I None
- I None
induced I None
overflow I None
in I None
either I None
group I None
. I None
<eof> I None

<s> O None
Phentolamine I Chemical
increased I None
stimulus I None
- I None
induced I None
overflow I None
in I None
both I None
groups I None
although I None
the I None
increment I None
in I None
overflow I None
was I None
greater I None
in I None
the I None
epinephrine I Chemical
-treated I None
group I None
. I None
<eof> I None

<s> O None
In I None
conclusion I None
, I None
chronic I None
epinephrine I Chemical
treatment I None
results I None
in I None
enhanced I None
fractional I None
neurotransmitter I None
overflow I None
. I None
<eof> I None

<s> O None
However I None
, I None
neither I None
alterations I None
in I None
prejunctional I None
beta I None
- I None
adrenoceptor I None
influences I None
nor I None
alterations I None
in I None
neuronal I None
and I None
extraneuronal I None
uptake I None
mechanisms I None
appear I None
to I None
be I None
responsible I None
for I None
this I None
alteration I None
. I None
<eof> I None

<s> O None
Furthermore I None
, I None
data I None
obtained I None
with I None
phentolamine I Chemical
alone I None
do I None
not I None
suggest I None
alpha I None
- I None
adrenoceptor I None
desensitization I None
as I None
the I None
cause I None
of I None
the I None
enhanced I None
neurotransmitter I None
overflow I None
after I None
epinephrine I Chemical
treatment I None
. I None
<eof> I None

<s> O None
Ocular I None
manifestations I None
of I None
juvenile I Disease
rheumatoid O Disease
arthritis O Disease
. I None
<eof> I None

<s> O None
We I None
followed I None
210 I None
cases I None
of I None
juvenile I Disease
rheumatoid O Disease
arthritis O Disease
closely I None
for I None
eleven I None
years I None
. I None
<eof> I None

<s> O None
Thirty I None
- I None
six I None
of I None
the I None
210 I None
patients I None
( I None
17.2 I None
% I None
) I None
developed I None
iridocyclitis I Disease
. I None
<eof> I None

<s> O None
Iridocyclitis I Disease
was I None
seen I None
most I None
frequently I None
in I None
young I None
female I None
patients I None
( I None
0 I None
to I None
4 I None
years I None
) I None
with I None
the I None
monoarticular I None
or I None
pauciatricular I None
form I None
of I None
the I None
arthritis I Disease
. I None
<eof> I None

<s> O None
However I None
, I None
30 I None
% I None
of I None
the I None
patients I None
developed I None
uveitis I Disease
after I None
16 I None
years I None
of I None
age I None
. I None
<eof> I None

<s> O None
Although I None
61 I None
% I None
of I None
patients I None
had I None
a I None
noncontributory I None
ocular I None
history I None
on I None
entry I None
, I None
42 I None
% I None
had I None
active I None
uveitis I Disease
on I None
entry I None
. I None
<eof> I None

<s> O None
Our I None
approach I None
was I None
effective I None
in I None
detecting I None
uveitis I Disease
in I None
new I None
cases I None
and I None
exacerbations I None
of I None
uveitis I Disease
in I None
established I None
cases I None
. I None
<eof> I None

<s> O None
Forty I None
- I None
four I None
percent I None
of I None
patients I None
with I None
uveitis I Disease
had I None
one I None
or I None
more I None
identifiable I None
signs I None
or I None
symptoms I None
, I None
such I None
as I None
red I None
eye I None
, I None
ocular I Disease
pain O Disease
, I None
decreased I Disease
visual O Disease
acuity O Disease
, I None
or I None
photophobia I Disease
, I None
in I None
order I None
of I None
decreasing I None
frequency I None
. I None
<eof> I None

<s> O None
Even I None
after I None
early I None
detection I None
and I None
prompt I None
treatment I None
, I None
41 I None
% I None
of I None
cases I None
of I None
uveitis I Disease
did I None
not I None
respond I None
to I None
more I None
than I None
six I None
months I None
of I None
intensive I None
topical I None
treatment I None
with I None
corticosteroids I Chemical
and I None
mydriatics I None
. I None
<eof> I None

<s> O None
Despite I None
this I None
, I None
there I None
was I None
a I None
dramatic I None
decrease I None
in I None
the I None
50 I None
% I None
incidence I None
of I None
blinding I None
complications I None
of I None
uveitis I Disease
cited I None
in I None
earlier I None
studies I None
. I None
<eof> I None

<s> O None
Cataract I Disease
and I None
band I Disease
keratopathy O Disease
occurred I None
in I None
only I None
22 I None
and I None
13 I None
% I None
of I None
our I None
group I None
, I None
respectively I None
. I None
<eof> I None

<s> O None
We I None
used I None
chloroquine I Chemical
or I None
hydroxychloroquine I Chemical
in I None
173 I None
of I None
210 I None
cases I None
and I None
found I None
only I None
one I None
case I None
of I None
chorioretinopathy I Disease
attributable I None
to I None
these I None
drugs I None
. I None
<eof> I None

<s> O None
Systemically I None
administered I None
corticosteroids I Chemical
were I None
used I None
in I None
75 I None
of I None
210 I None
cases I None
; I None
a I None
significant I None
number I None
of I None
posterior I None
subcapsular I None
cataracts I Disease
was I None
found I None
. I None
<eof> I None

<s> O None
Typical I None
keratoconjunctivitis I Disease
sicca I None
developed I None
in I None
three I None
of I None
the I None
uveitis I Disease
cases I None
. I None
<eof> I None

<s> O None
This I None
association I None
with I None
uveitis I Disease
and I None
JRA I None
was I None
not I None
noted I None
previously I None
. I None
<eof> I None

<s> O None
Surgical I None
treatment I None
of I None
cataracts I Disease
, I None
band I Disease
keratopathy O Disease
, I None
and I None
glaucoma I Disease
achieved I None
uniformly I None
discouraging I None
results I None
. I None
<eof> I None

<s> O None
Water I Disease
intoxication O Disease
associated I None
with I None
oxytocin I Chemical
administration I None
during I None
saline I None
- I None
induced I None
abortion I Disease
. I None
<eof> I None

<s> O None
Four I None
cases I None
of I None
water I Disease
intoxication O Disease
in I None
connection I None
with I None
oxytocin I Chemical
administration I None
during I None
saline I None
- I None
induced I None
abortions I Disease
are I None
described I None
. I None
<eof> I None

<s> O None
The I None
mechanism I None
of I None
water I Disease
intoxication O Disease
is I None
discussed I None
in I None
regard I None
to I None
these I None
cases I None
. I None
<eof> I None

<s> O None
Oxytocin I Chemical
administration I None
during I None
midtrimester I None
- I None
induced I None
abortions I Disease
is I None
advocated I None
only I None
if I None
it I None
can I None
be I None
carried I None
out I None
under I None
careful I None
observations I None
of I None
an I None
alert I None
nursing I None
staff I None
, I None
aware I None
of I None
the I None
symptoms I None
of I None
water I Disease
intoxication O Disease
and I None
instructed I None
to I None
watch I None
the I None
diuresis I None
and I None
report I None
such I None
early I None
signs I None
of I None
the I None
syndrome I None
as I None
asthenia I Disease
, I None
muscular I None
irritability I Disease
, I None
or I None
headaches I Disease
. I None
<eof> I None

<s> O None
The I None
oxytocin I Chemical
should I None
be I None
given I None
only I None
in I None
Ringers I None
lactate I Chemical
or I None
, I None
alternately I None
, I None
in I None
Ringers I None
lactate I Chemical
and I None
a I None
5 I None
per I None
cent I None
dextrose I Chemical
and I None
water I None
solutions I None
. I None
<eof> I None

<s> O None
The I None
urinary I None
output I None
should I None
be I None
monitored I None
and I None
the I None
oxytocin I Chemical
administration I None
discontinued I None
and I None
the I None
serum I None
electrolytes I None
checked I None
if I None
the I None
urinary I None
output I None
decreases I None
. I None
<eof> I None

<s> O None
The I None
oxytocin I Chemical
should I None
not I None
be I None
administered I None
in I None
excess I None
of I None
36 I None
hours I None
. I None
<eof> I None

<s> O None
If I None
the I None
patient I None
has I None
not I None
aborted I None
by I None
then I None
the I None
oxytocin I Chemical
should I None
be I None
discontinued I None
for I None
10 I None
to I None
12 I None
hours I None
in I None
order I None
to I None
perform I None
electrolyte I None
determinations I None
and I None
correct I None
any I None
electrolyte I None
imbalance I None
. I None
<eof> I None

